The role of the tumour microenvironment in the phenotype of pituitary adenomas by Marques, Pedro Miguel Pereira de S
The role of the tumour microenvironment 
in the phenotype of pituitary adenomas 
Thesis presented by: 
Pedro Miguel Pereira de Sousa Marques, MD 
Thesis submitted in partial fulfillment of the requirements of the Degree of: 
Doctor of Philosophy (PhD) 
Under the supervision of: 
Prof. Márta Korbonits, MD, PhD 
Prof. Frances Balkwill, PhD 
Centre for Endocrinology,  
William Harvey Research Institute,  
Barts and the London School of Medicine and Dentistry, 
Queen Mary University of London 
London, UK, January 2020 
1 
Statement of originality 
I, Pedro Miguel Pereira de Sousa Marques, confirm that the research included within this thesis is 
my own work or that where it has been carried out in collaboration with, or supported by others, 
that this is duly acknowledged below and my contribution indicated. Previously published material 
is also acknowledged below. 
I attest that I have exercised reasonable care to ensure that the work is original, and does not to 
the best of my knowledge break any UK law, infringe any third party’s copyright or other 
Intellectual Property Right, or contain any confidential material. 
I accept that the College has the right to use plagiarism detection software to check the electronic 
version of the thesis. 
I confirm that this thesis has not been previously submitted for the award of a degree by this or 
any other university. 
The copyright of this thesis rests with the author and no quotation from it or information derived 
from it may be published without the prior written consent of the author. 
Signature: 
Date: 16/01/2020 
2 
 
Details of publication 
 
Publications containing the data presented in this thesis: 
 
Marques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, Dorward D, Grieve J, Mendoza N, 
Muquit S, Grossman A, Balkwill F, Korbonits M. Chemokines modulate the tumour 
microenvironment in pituitary neuroendocrine tumours. Acta Neuropathol Commun 2019 Nov 8; 
7(1):172. doi: 10.1186/s40478-019-0830-3. 
 
Marques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, Dorward N, Grieve J, Mendoza N, 
Muquit S, Grossman A, Balkwill F, Korbonits M. Pituitary tumour-fibroblast derived cytokines 
influence tumour aggressiveness. Endocr Relat Cancer 2019 Oct 1. doi: 10.1530/ERC-19-0327. 
[Epub ahead of print] 
 
Marques P, Caimari F, Hernández-Ramírez LC, Collier D, Iacovazzo D, Ronaldson A, Magid K, Lim C, 
Stals K, Ellard S, Grossman A, Korbonits M. Significant benefits of AIP testing and clinical screening 
in familial isolated and young-onset pituitary tumors. [In revision] 
 
Marques P, Magalhães D, Caimari F, Hernández-Ramírez LC, Collier D, Lim C, Stals K, Ellard S, Druce 
M, Akker S, Waterhouse, Drake W, Grossman A, Korbonits M. MEN1 and AIP mutation-positive 
pituitary neuroendocrine tumours (PitNETs): remarkable phenotypic differences in patients with 
distinct forms of familial PitNETs. [In preparation]  
 
 
 
Publications in the field of pituitary adenomas: 
 
Marques P, Grossman A, Balkwill F, Korbonits M. The role of the tumour microenvironment in 
pituitary tumours. [In preparation] 
 
Barry S, Carlsen E, Marques P, Stiles C, Gadaleta E, Berney D, Roncaroli F, Chelala C, Solomou A, 
Herincs M, Caimari F, Grossman A, Crnogorac-Jurcevic T, Haworth O, Gaston-Massuet C, Korbonits 
M. Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary 
tumors. Oncogene 2019 Mar 12. doi: 10.1038/s41388-019-0779-5. 
3 
 
Marques P, Collier D, Barkan A, Korbonits M. Coexisting pituitary and non-pituitary gigantism in 
the same family. Clin Endocrinol (Oxf). 2018; 89(6):887-888. doi: 10.1111/cen.13852.  
 
Marques P, Barry S, Ronaldson A, Ogilvie A, Storr H, Goadsby P, Powell M, Dang M, Chahal H, 
Evanson J, Kumar A, Grieve J, Korbonits K. Emergence of pituitary adenoma in a child during 
surveillance - Clinical challenges and the family members’ view in an AIP mutation positive family. 
Int J Endocrinol. 2018. Apr 4; 2018: 8581626. doi: 10.1155/2018/8581626. eCollection 2018. 
 
Marques P, Spencer R, Morrison P, Carr I, Dang M, Bonthron D, Hunter S, Korbonits M. Cantú 
syndrome with coexisting familial pituitary adenoma. Endocrine. 2018; 59(3): 677-684. doi: 
10.1007/s12020-017-1497-9. 
 
Marques P, Korbonits M. Genetic aspects of pituitary adenomas. Endocrinol Metab Clin North Am 
2017; 46(2):335-374. doi:10.1016/j.ecl.2017.01.004.   
 
 
Publications in other fields during the period of my PhD: 
 
Marques P, Stelmachowska-Banas M, Collier D, Wernig F, Korbonits M. Pachydermoperiostosis 
mimicking the acral abnormalities of acromegaly. Endocrine 2020 Jan 8. doi: 10.1007/s12020-019-
02168-5. [Epub ahead of print] 
 
Marques P, Korbonits M. Pseudoacromegaly. Front Neuroendocrinol. 2019; 52:113-143. doi: 
10.1016/j.yfrne.2018.11.001. 
 
Marques P, Tufton N, Bhattacharya S, Caulfield M, Akker S. Hypertension due to a 
deoxycorticosterone-secreting adrenal tumour diagnosed during pregnancy. Endocrinol Diabetes 
Metab Case Rep 2019. pii: EDM180164. doi: 10.1530/EDM-18-0164. 
 
Dahlqvist P, Spencer R, Marques P, Dang M, Glad C, Johannsson G, Korbonits M. 
Pseudoacromegaly - a differential diagnostic problem for acromegaly with a genetic solution. J 
Endocr Soc 2017;1(8):1104-1109. doi: 10.1210/js.2017-00164. 
 
 
4 
 
Abstract  
 
Non-neoplastic cells in the tumour microenvironment (TME) influence tumoural aggressiveness 
and oncogenic mechanisms. Little is known about the TME in pituitary adenomas (PAs). This work 
aimed to characterise the TME of PAs and its effects in tumour aggressiveness and oncogenic 
mechanisms, focusing on the cytokine network, infiltrating immune cells and PA-associated 
fibroblasts (TAFs). 
 
To study the cytokine secretion of tumour/non-tumoural cells, cytokine bead arrays were 
performed on culture supernatants. PA-infiltrating immune cells, angiogenesis, epithelial-to-
mesenchymal transition (EMT) and matrix metalloproteinases were assessed by 
immunohistochemistry. In vitro pituitary tumour–macrophage/TAF interactions were assessed by 
conditioned medium (CM) of GH3 (pituitary tumour) and RAW264.7 (macrophage) cell lines, as 
well as primary TAFs, in terms of morphology, migration, invasion and EMT activation.  
 
IL-8, CCL2, CCL3, CCL4, CXCL10, CCL22 and CXCL1 were the main PA-derived cytokines, which 
facilitate macrophage, neutrophil and T lymphocyte recruitment. More FOXP3+ T cells, lower 
CD8:CD4 or CD8:FOXP3 ratios and deleterious immune phenotype (CD68hiCD4hiFOXP3hiCD20hi) 
correlated with tumour proliferation, whereas M2:M1 ratio correlated with microvessel density 
and area. Invasive PAs had higher TAF-derived IL-6 levels, whereas TAFs from PA with more vessels 
and increased proliferation secreted more CCL2, both inhibited by pasireotide. GH3 cell-CM 
increased macrophage chemotaxis, while macrophage-CM/TAF-CM changed morphology, 
migration, invasion and EMT in GH3 cells. These data support that different TME elements affect 
PA tumourigenesis and aggressiveness. 
 
Data from different in vitro cell models suggest that AIP deficiency may not lead to differential 
cytokine secretion, and thus unlike to play a crucial role in the cytokine secretory function. The 
clinical study revealed that AIPmut and MEN1mut PA phenotypes are variable, including highly 
aggressive but also indolent cases such as prospectively-diagnosed AIPmut PAs, which are less 
aggressive and associated with more favourable clinical outcomes comparing to clinically-
presenting AIPmut PAs, highlighting the benefits of AIP genetic and clinical screenings. 
 
5 
 
Table of contents 
  
Statement of originality ......................................................................................................... 1 
Details of publication ............................................................................................................. 2 
Abstract ................................................................................................................................. 4 
Table of contents ................................................................................................................... 5 
List of figures ....................................................................................................................... 13 
List of tables ........................................................................................................................ 18 
List of abbreviations ............................................................................................................. 21 
Acknowledgments ............................................................................................................... 23 
Details of collaboration ........................................................................................................ 24 
General aims of the study .................................................................................................... 25 
Chapter 1: Introduction ........................................................................................................ 26 
1.1  The pituitary gland .............................................................................................................. 26 
Anatomy ................................................................................................................................. 26 
Structure ................................................................................................................................ 27 
Function and regulation ......................................................................................................... 28 
1.2  Pituitary adenomas ............................................................................................................. 29 
Definition and epidemiology .................................................................................................. 29 
Histopathological and clinical classifications ......................................................................... 29 
Aggressiveness of pituitary adenomas .................................................................................. 31 
Pituitary tumourigenesis ........................................................................................................ 32 
1.3  Familial pituitary adenomas (due to germline alterations) ................................................ 34 
Syndromes predisposing to pituitary adenomas ................................................................... 35 
Multiple Endocrine Neoplasia type 1 (MEN1) ....................................................................... 35 
Multiple Endocrine Neoplasia type 4 (MEN4) ....................................................................... 37 
6 
Carney complex (CNC) ........................................................................................................... 37 
Phaeochromocytoma/Paraganglioma and Pituitary Adenoma syndrome ............................ 38 
DICER1 syndrome ................................................................................................................... 38 
Familial Isolated Pituitary Adenomas (FIPA) .......................................................................... 39 
AIP mutation-positive FIPA .................................................................................................... 39 
CABLES1 mutation-positive FIPA ............................................................................................ 45 
CDH23 mutation-positive FIPA .............................................................................................. 45 
FIPA with undetermined genetic cause ................................................................................. 46 
1.4  Tumour microenvironment (TME) ...................................................................................... 47 
1.5  The cytokine network in pituitary adenomas ..................................................................... 48 
Cytokines: structure, receptors, pathways, biological functions and role in cancer ............. 48 
Chemokines: structure, receptors, pathways, biological functions and role in cancer ......... 51 
Cytokine-chemokine network in the normal pituitary .......................................................... 53 
Cytokine-chemokine network in the neoplastic pituitary ..................................................... 56 
1.6  Non-tumoural cells in the TME of pituitary adenomas....................................................... 63 
Immune cells in pituitary adenomas ...................................................................................... 63 
Stromal/mesenchymal cells in pituitary adenomas............................................................... 69 
Endothelial cells and angiogenesis in pituitary adenomas .................................................... 72 
1.7  Extracellular matrix and remodelling enzymes in pituitary adenomas .............................. 73 
1.8  Epithelial-to-mesenchymal transition (EMT) in pituitary adenomas .................................. 75 
EMT in cancer ......................................................................................................................... 75 
EMT in pituitary adenomas .................................................................................................... 77 
Chapter 2: Materials and methods ....................................................................................... 79 
Materials .................................................................................................................................... 79 
Human pituitary adenoma samples ....................................................................................... 79 
Human PA and skin fibroblasts .............................................................................................. 79 
7 
 
Cell lines ................................................................................................................................. 79 
Methods ..................................................................................................................................... 80 
Primary cell culture of pituitary adenomas ........................................................................... 80 
Primary cell culture of fibroblasts .......................................................................................... 81 
Cell lines culture ..................................................................................................................... 81 
Preparation of cell culture conditioned medium for in vitro experiments and supernatants for 
cytokine multiplex array ........................................................................................................ 82 
Cytokine multiplex arrays ...................................................................................................... 83 
Enzyme-linked immunosorbent assay (ELISA) ....................................................................... 84 
Cell morphology analysis ....................................................................................................... 85 
Invasion assay ........................................................................................................................ 85 
Transwell migration assay ...................................................................................................... 85 
Wound healing migration assay ............................................................................................. 86 
Immunocytochemistry ........................................................................................................... 86 
Flow cytometry ...................................................................................................................... 86 
RNA extraction ....................................................................................................................... 87 
Reverse transcription ............................................................................................................. 87 
Real-time quantitative polymerase chain reaction (RT-qPCR) .............................................. 88 
Ventana immunohistochemistry ........................................................................................... 88 
Immunohistochemical analysis .............................................................................................. 89 
RNAscope ............................................................................................................................... 90 
Affymetrix microarray analysis and xCell deconvolution ...................................................... 91 
DNA extraction ....................................................................................................................... 92 
Polymerase chain reaction and DNA sequencing .................................................................. 93 
Serum inflammation-based scores ........................................................................................ 94 
Clinical databases – International FIPA Consortium .............................................................. 94 
Statistical analysis .................................................................................................................. 94 
8 
 
Chapter 3: The cytokine network and immune cells in the tumour microenvironment of pituitary 
adenomas ............................................................................................................................ 95 
Introduction ............................................................................................................................... 95 
Aims ........................................................................................................................................... 96 
Overall aim ............................................................................................................................. 96 
Specific aims ........................................................................................................................... 96 
Results ........................................................................................................................................ 96 
The cytokine network in human pituitary adenomas ............................................................ 96 
Infiltrating immune cells in human pituitary adenomas...................................................... 113 
Recruitment of immune cells into the TME of pituitary adenomas .................................... 116 
The role of infiltrating immune cells in the PA phenotype and aggressiveness .................. 120 
In vitro studies investigating interactions between macrophages and pituitary tumour cells
 ............................................................................................................................................. 124 
Circulating immune cells and inflammation-based scores in patients with PAs ................. 137 
Discussion ................................................................................................................................ 142 
Conclusions .............................................................................................................................. 148 
Chapter 4: Fibroblasts in the tumour microenvironment of pituitary adenomas .................. 149 
Introduction ............................................................................................................................. 149 
Aims ......................................................................................................................................... 150 
Overall aim ........................................................................................................................... 150 
Specific aims ......................................................................................................................... 150 
Results ...................................................................................................................................... 151 
Detection and in vitro isolation of PA-derived tumour-associated fibroblasts ................... 151 
The role of TAF cytokine secretome in the phenotype and aggressiveness of PAs............. 152 
In vitro studies investigating the interactions between fibroblasts and pituitary tumour cells
 ............................................................................................................................................. 159 
Somatostatin analogue effect in TAF cytokine secretome .................................................. 161 
9 
 
Discussion ................................................................................................................................ 166 
Conclusions .............................................................................................................................. 169 
Chapter 5: Other tumour microenvironment-related oncogenic mechanisms in pituitary 
adenomas .......................................................................................................................... 170 
Introduction ............................................................................................................................. 170 
Aims ......................................................................................................................................... 174 
Overall aim ........................................................................................................................... 174 
Specific aims ......................................................................................................................... 174 
Results ...................................................................................................................................... 174 
Angiogenesis in human pituitary adenomas ........................................................................ 174 
ECM-remodeling matrix metalloproteinases in human pituitary adenomas ...................... 182 
Epithelial-to-mesenchymal transition in human pituitary adenomas ................................. 189 
Neural cell adhesion molecule in human pituitary adenomas ............................................ 195 
Discussion ................................................................................................................................ 199 
Conclusions .............................................................................................................................. 206 
Chapter 6: The effect of AIP deficiency in the pituitary tumour cytokine secretome ............. 208 
Introduction ............................................................................................................................. 208 
Aims ......................................................................................................................................... 209 
Overall aim ........................................................................................................................... 209 
Specific aims ......................................................................................................................... 209 
Results ...................................................................................................................................... 209 
The role of AIP deficiency in the cytokine secretome of GH3 cells ..................................... 211 
The role of AIP deficiency in the cytokine secretome of a human AIPmut somatotrophinoma
 ............................................................................................................................................. 215 
The role of AIP deficiency in the cytokine secretome of AIPmut somatotrophinoma TAFs 216 
The role of AIP deficiency in the cytokine secretome of skin fibroblasts from AIPmut subjects
 ............................................................................................................................................. 218 
10 
 
AIP mutation-positive fibroblasts cytokine secretome response to pasireotide ................ 220 
Discussion ................................................................................................................................ 225 
Conclusions .............................................................................................................................. 229 
Chapter 7: Characterisation of AIP mutation-positive pituitary adenomas and screening for AIP 
mutations: benefits of the genetic and clinical screening of AIP mutation carriers ............... 230 
Introduction ............................................................................................................................. 230 
Aims ......................................................................................................................................... 230 
Overall aim ........................................................................................................................... 230 
Specific aims ......................................................................................................................... 231 
Methods ................................................................................................................................... 231 
Study population .................................................................................................................. 231 
AIP genetic testing and clinical screening ............................................................................ 232 
Definition of AIP mutation-positive (AIPmut) and AIP mutation-negative (AIPneg) subgroups
 ............................................................................................................................................. 232 
Study groups and clinical parameters .................................................................................. 232 
Results ...................................................................................................................................... 233 
General characterisation of the study population ............................................................... 233 
Comparative analysis between AIPmut and AIPneg PAs ..................................................... 236 
Comparisons of AIPmut vs AIPneg patients by tumour type ............................................... 237 
Prospectively-diagnosed vs clinically-presenting AIPmut PAs ............................................. 241 
AIP mutations in the study population and genotype-phenotype correlation ................... 244 
Discussion ................................................................................................................................ 249 
Conclusions .............................................................................................................................. 256 
Chapter 8: Characterisation of MEN1 mutation-positive pituitary adenomas and comparison 
with AIP mutation-positive ones: remarkable phenotypic differences in patients with distinct 
forms of familial pituitary adenomas .................................................................................. 257 
Introduction ............................................................................................................................. 257 
11 
 
Aims ......................................................................................................................................... 257 
General ................................................................................................................................. 257 
Specific ................................................................................................................................. 258 
Methods ................................................................................................................................... 258 
Study population .................................................................................................................. 258 
MEN1 and AIP genetic analysis ............................................................................................ 258 
Definition of MEN1mut and AIPmut PA subgroups ............................................................. 259 
Definitions of MEN1-related diseases and the study clinical parameters ........................... 259 
Results ...................................................................................................................................... 259 
General characterisation of the MEN1mut cohort .............................................................. 259 
MEN1mut PAs characterisation and comparative subanalysis by PA type ......................... 261 
AIPmut PAs characterisation and comparative subanalysis by PA type .............................. 265 
Comparative analysis MEN1mut vs AIPmut PAs .................................................................. 267 
Discussion ................................................................................................................................ 270 
Conclusions .............................................................................................................................. 275 
Chapter 9: General conclusions and future research directions ............................................ 276 
The role of the TME in the phenotype of PAs ...................................................................... 276 
The role of AIP deficiency in the pituitary tumour cytokine secretome .............................. 279 
Phenotype of AIPmut and MEN1mut familial PAs and the benefits of genetic/clinical 
screening .............................................................................................................................. 280 
Reference list ..................................................................................................................... 282 
Appendix 1: Supplemental tables with genes with altered expression in sporadic pituitary 
adenomas, and the corresponding literature references ..................................................... 329 
Appendix 2: Supplemental table with primary antibodies and respective dilutions used for 
immunohistochemical (IHC) and immunofluorescence (IF) studies ...................................... 341 
Appendix 3: Supplemental table with primers used in RT-qPCR experiments ....................... 342 
12 
 
Appendix 4: Supplemental table with correlation between clinico-pathological and biochemical 
features and infiltrating immune cells among NFPAs and somatotrophinomas .................... 343 
Appendix 5: Supplemental tables with cytokine array data from cell lines ........................... 349 
Appendix 6: Supplemental tables with pre-operative haematological parameters and serum 
inflammation-based scores (NLR, LMR and PLR) and pituitary function and PA-derived cytokine 
secretome ......................................................................................................................... 353 
Appendix 7: Supplemental table with cytokine bead array data from TAFs untreated (baseline) 
and after pasireotide treatment, as well as from normal untreated skin fibroblasts ............. 363 
Appendix 8: Supplemental table with correlation between TAF-derived cytokine secretome and 
pituitary hormone levels among NFPAs and somatotrophinomas ........................................ 365 
Appendix 9: Supplemental tables with correlations between hormonal, cytokine and infiltrating 
immune cell data and TME-related oncogenic mechanisms in PAs ....................................... 368 
Appendix 10: Supplemental tables summarising the pro-tumoural and anti-tumoural effects of 
CX3CL1 in different cancers ................................................................................................ 380 
Appendix 11: Abstracts presented in scientific meetings ..................................................... 383 
Appendix 12: Manuscripts .................................................................................................. 386 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
List of figures  
Figure 1.1: Anatomy surrounding the pituitary gland ................................................................... 27 
Figure 1.2: Pituitary adenomas due to a genetic origin ................................................................. 35 
Figure 1.3: An approach to genetic testing in a patient with a pituitary adenoma ....................... 41 
Figure 1.4: AIP protein structure (A) and interaction partners (B) ................................................ 42 
Figure 1.5: Distribution of PA types in AIPneg FIPA kindreds ........................................................ 46 
Figure 1.6: The tumour microenvironment ................................................................................... 47 
Figure 1.7: Relationship between cytokines, inflammation and cancer ........................................ 51 
Figure 1.8: Chemokine general structures and classes .................................................................. 52 
Figure 1.9: Cytokine network role in different tumourigenic mechanisms in PAs ........................ 56 
Figure 1.10: M1 and M2 macrophages .......................................................................................... 65 
Figure 1.11: EMT in cancer and its signalling pathways. ............................................................... 75 
Figure 2.1: Appearances of a PA on MRI, a PA fragment before culturing and a PA primary culture
 ....................................................................................................................................................... 80 
Figure 2.2: Overview of the multiplexing cytokine bead-based immunoassays ........................... 84 
Figure 2.3: RNAscope assay procedure .......................................................................................... 90 
Figure 2.4: xCell study design......................................................................................................... 92 
Figure 3.1: Cytokine secretome differences between NFPAs and somatotrophinomas ............. 101 
Figure 3.2: Somatotrophinoma secretome according to pre-operative SSA or granulation pattern
 ..................................................................................................................................................... 102 
Figure 3.3: Cytokine secretome of PAs according to gender ....................................................... 105 
Figure 3.4: Cytokine secretome of PAs according to headache, visual impairment or 
hypopituitarism at diagnosis ........................................................................................................ 106 
Figure 3.5: NFPAs and somatotrophinomas secretome according to Ki-67 and cavernous sinus 
invasion ........................................................................................................................................ 108 
Figure 3.6: Cytokine secretome NFPAs and somatotrophinomas according to different clinical 
features ........................................................................................................................................ 110 
14 
 
Figure 3.7: Cytokine secretome of somatotrophinomas with normal PRL or hyperprolactinaemia
 ..................................................................................................................................................... 111 
Figure 3.8: Correlation between cytokine secretome from somatotrophinomas and serum 
hormones ..................................................................................................................................... 111 
Figure 3.9: Immunohistochemical analysis of immune cells in PAs and NPs .............................. 114 
Figure 3.10: M2- and M1-like macrophages and macrophage-polarising cytokines in PAs ........ 114 
Figure 3.11: xCell scores in PAs and NPs ...................................................................................... 115 
Figure 3.12: Cytokine secretome of PAs and infiltrating immune cells ....................................... 117 
Figure 3.13: Cytokine secretome of PAs and infiltrating CD4+ T cells, Tregs and B cells ............ 118 
Figure 3.14: IL8-CXCR2 and CCL2-CCR5 mRNA expression in PAs ............................................... 119 
Figure 3.15: Correlation between PA tissue infiltrating and circulating immune cell subpopulations
 ..................................................................................................................................................... 120 
Figure 3.16: Immune cell infiltrates in PAs and Ki-67 and cavernous sinus invasion .................. 122 
Figure 3.17: M2 and M1 macrophages and angiogenesis in PAs ................................................ 122 
Figure 3.18: In vitro cell model using GH3 cells and RAW 264.7 macrophages .......................... 124 
Figure 3.19: GH3-CM effect on macrophage chemotaxis and their chemokine receptor expression
 ..................................................................................................................................................... 125 
Figure 3.20: GH3-CM effect on macrophage morphology .......................................................... 126 
Figure 3.21: CX3CL1 dose-response optimisation for migration and morphological studies ..... 127 
Figure 3.22: GH3-CM effect on macrophage cytokine secretome .............................................. 128 
Figure 3.23: GH3-CM effect on macrophage cytokine gene expression ..................................... 129 
Figure 3.24: GH3-CM effect on macrophage polarisation ........................................................... 130 
Figure 3.25: Macrophage-CM effect on GH3 cells morphology .................................................. 132 
Figure 3.26: Macrophage-CM effect on GH3 cell invasion and migration................................... 133 
Figure 3.27: Macrophage-CM effect on GH3 cell migration assessed by wound healing assay . 133 
Figure 3.28: Macrophage-CM inducing EMT in GH3 cells assessed by immunocytochemistry .. 134 
Figure 3.29: Macrophage-CM inducing EMT in GH3 cells assessed by RT-qPCR ......................... 135 
15 
 
Figure 3.30: Macrophage-CM effect on GH3 cell cytokine secretome ........................................ 135 
Figure 3.31: Macrophage-CM effect on GH3 cell cytokine expression ....................................... 136 
Figure 3.32: Correlation between serum inflammation-based scores and PA-derived cytokines
 ..................................................................................................................................................... 141 
Figure 3.33: The tumour microenvironment of PAs .................................................................... 142 
Figure 4.1: Somatostatin and SSA affinity for the different somatostatin receptors .................. 150 
Figure 4.2: TAFs in PAs and their in vitro isolation ...................................................................... 152 
Figure 4.3: TAF cytokine secretome according to cavernous sinus invasion (A) or Ki-67 (B) ...... 154 
Figure 4.4: TAF cytokine secretome according to gender ........................................................... 154 
Figure 4.5: Correlation between TAF-derived FGF-2 levels and E-cadherin immunoreactivity in PAs
 ..................................................................................................................................................... 157 
Figure 4.6: Correlation between PA-infiltrating macrophages and TAF-derived FGF-2 .............. 157 
Figure 4.7: TAF cytokine secretome and M2:M1 macrophage ratio ........................................... 158 
Figure 4.8: TAF-CM effect on GH3 cell invasion and migration ................................................... 159 
Figure 4.9: TAF-CM effect on GH3 cell morphology .................................................................... 160 
Figure 4.10: TAF-CM inducing EMT activation in GH3 cells ......................................................... 161 
Figure 4.11: SST expression profile in TAFs ................................................................................. 162 
Figure 4.12: SST expression profile in TAFs according to PA subtype, Ki-67 or cavernous sinus 
invasion ........................................................................................................................................ 163 
Figure 4.13: TAF cytokine secretome at baseline and after pasireotide treatment .................... 163 
Figure 4.14: Cytokines decreased in more than half of pasireotide-treated TAFs ...................... 164 
Figure 4.15: Cytokines decreased in less than half of pasireotide-treated TAFs ......................... 165 
Figure 4.16: SST expression profile in TAFs at baseline and after pasireotide treatment ........... 165 
Figure 5.1: TME-related oncogenic mechanisms ......................................................................... 170 
Figure 5.2: MMPs main sources within the TME and their role in the modulation of the TME .. 171 
Figure 5.3: Molecular mechanisms of NCAM action in neuronal tissues .................................... 172 
Figure 5.4: RNA expression levels of NCAM in different malignancies ....................................... 173 
16 
 
Figure 5.5: Angiogenesis in PAs and in NPs ................................................................................. 175 
Figure 5.6: Angiogenesis in NFPAs and somatotrophinomas ...................................................... 177 
Figure 5.7: Correlation between serum IGF-1 levels and vessel perimeter and Feret’s diameter in 
PAs ............................................................................................................................................... 178 
Figure 5.8: Serum pituitary hormone levels and vessel parameters in PAs ................................ 178 
Figure 5.9: PA-derived cytokines and vessel parameters in PAs ................................................. 179 
Figure 5.10: PA-infiltrating immune cells and angiogenesis in PAs ............................................. 180 
Figure 5.11: MMP-9 and MMP-14 expression in PAs and in NPs ................................................ 182 
Figure 5.12: Expression of MMP-9 and MMP-14 in NFPAs and somatotrophinomas ................. 185 
Figure 5.13: Serum IGF-1 and MMP-9 expression ....................................................................... 186 
Figure 5.14: PA-derived cytokines and MMP-9 expression in somatotrophinomas ................... 187 
Figure 5.15: EMT in human AIPmut and AIPneg somatotrophinomas ........................................ 189 
Figure 5.16: E-cadherin expression in PAs and in NPs ................................................................. 190 
Figure 5.17: Correlation between E-cadherin and ZEB1 immunoreactivity in PAs ..................... 191 
Figure 5.18: Expression of E-cadherin and ZEB1 in NFPAs and somatotrophinomas .................. 192 
Figure 5.19: Serum GH and IGF-1 and E-cadherin expression in somatotrophinomas ............... 193 
Figure 5.20: PA-derived VEGF-A and FGF-2 and E-cadherin/ZEB1 expression in PAs ................. 194 
Figure 5.21: NCAM expression in PAs and in NPs ........................................................................ 195 
Figure 5.22: NCAM expression in NFPAs and in somatotrophinomas ......................................... 197 
Figure 5.23: Serum pituitary hormones and NCAM expression in PAs ....................................... 197 
Figure 5.24: PA-derived cytokines and NCAM expression in somatotrophinomas ..................... 198 
Figure 5.25: Modulation of oncogenic mechanisms in PAs by different TME components ........ 199 
Figure 6.1: Increased macrophage infiltrates and chemotaxis in AIP mutation-positive tumours
 ..................................................................................................................................................... 210 
Figure 6.2: GH3-Aip-KD cells have 80% reduced levels of AIP comparing to GH3-NT cells ......... 211 
Figure 6.3: CX3CL1 in GH3-Aip-KD vs GH3-NT cells ..................................................................... 212 
Figure 6.4: CX3CL1 cleavage-related proteases expression in GH3-NT and GH3-Aip-KD cells .... 212 
17 
 
Figure 6.5: Effect of AIP mutation or AIP knockdown in CX3CL1 expression .............................. 213 
Figure 6.6: Effect of AIP knockdown in CCL17 expression in GH3 cells ....................................... 215 
Figure 6.7: AIPmut PA-associated TAFs had no loss of heterozygosity at the AIP locus ............. 217 
Figure 6.8: AIPmut kindred with subjects carrying AIP mutation in homozygosity and in 
heterozygosity.............................................................................................................................. 218 
Figure 6.9: SST expression profile in human skin fibroblasts ...................................................... 221 
Figure 6.10: AIPmut skin fibroblasts cytokine secretome responsiveness to pasireotide .......... 223 
Figure 6.11: Cytokines decreased in all pasireotide-treated skin fibroblasts .............................. 224 
Figure 6.12: Cytokines responding inconsistently to pasireotide among the skin fibroblast 
subgroups..................................................................................................................................... 224 
Figure 6.13: CX3CL1 structure and its location to the membrane and cleavage ......................... 226 
Figure 7.1: Distribution of AIPmut vs AIPneg PAs according to age at onset (A) and clinical diagnosis 
(B) ................................................................................................................................................. 235 
Figure 7.2: Clinical diagnosis according to age of onset among AIPmut (A) and AIPneg (B) PA 
patients ........................................................................................................................................ 237 
Figure 7.3: Heterogeneous clinical phenotype and management of patients with AIPmut PAs, and 
the benefits of their early detection by genetic and clinical screening ....................................... 250 
Figure 8.1: Main MEN1-related manifestations among the cohort of 99 MEN1 patients .......... 260 
Figure 8.2: Current age among the cohort of 99 MEN1 patients according to main manifestations
 ..................................................................................................................................................... 260 
Figure 8.3: Age at PA diagnosis among 70 MEN1 patients with PAs according to different 
combination of MEN1 manifestations ......................................................................................... 262 
 
 
 
 
 
18 
 
List of tables  
Table 1.1: Classification of pituitary adenomas according to 2017 WHO classification ................ 31 
Table 1.2: Classification of cytokines ............................................................................................. 50 
Table 1.3: Cytokines and their receptors in normal and neoplastic pituitary ............................... 55 
Table 3.1: Baseline features of the 24 studied patients with PAs ................................................. 97 
Table 3.2: Cytokine secretome from the 24 human PA-derived supernatants ............................. 98 
Table 3.3: Detectable cytokine levels in the supernatant of 24 human PA primary cultures ..... 100 
Table 3.4: Cytokine secretome of PAs according to Ki-67 and cavernous sinus invasion ........... 103 
Table 3.5: Cytokine secretome of PAs according to Trouillas grade classification system .......... 103 
Table 3.6: Ki-67 and cavernous sinus invasion among cytokine-secreting PAs ........................... 104 
Table 3.7: Trouillas grade classification among cytokine-secreting PAs...................................... 104 
Table 3.8: Cytokine secretome of PAs and age or number of pituitary deficiencies at diagnosis..105 
Table 3.9: Headache, visual damage and hypopituitarism at diagnosis among cytokine-secreting 
PAs ............................................................................................................................................... 107 
Table 3.10: Ki-67 and cavernous sinus invasion in cytokine-secreting NFPAs and 
somatotrophinomas .................................................................................................................... 109 
Table 3.11: Correlation between cytokine secretome of NFPAs and serum hormonal levels .... 112 
Table 3.12: Correlation between infiltrating immune cells in PAs .............................................. 115 
Table 3.13: Immune cells and cell ratios among NFPA types, and between NFPAs vs 
somatotrophinomas .................................................................................................................... 116 
Table 3.14: Pre-operative haematological parameters and scores of the 24 patients with PAs 137 
Table 3.15: Haematological parameters/scores and Ki-67/cavernous sinus invasion ................ 138 
Table 3.16: Haematological parameters/scores and Trouillas grade classification..................... 138 
Table 3.17: Haematological parameters and headache, visual damage or hypopituitarism at 
diagnosis ...................................................................................................................................... 139 
Table 3.18: Haematological parameters and age at diagnosis, number of pituitary deficiencies and 
treatments ................................................................................................................................... 140 
19 
 
Table 4.1: Baseline features of the 16 patients with PAs from whom TAFs were isolated ......... 152 
Table 4.2: PA-derived TAF cytokine secretome ........................................................................... 153 
Table 4.3: TAF secretome according to headache, visual impairment or hypopituitarism at 
diagnosis ...................................................................................................................................... 155 
Table 4.4: TAF cytokine secretome and PA angiogenesis and EMT ............................................. 156 
Table 4.5: TAF cytokine secretome and PA-infiltrating immune cells ......................................... 158 
Table 4.6: Quantification of the TAF cytokine secretome responses to pasireotide .................. 164 
Table 5.1: Angiogenesis and clinical features in PAs ................................................................... 176 
Table 5.2: MMP-9 and MMP-14 expression and clinical features in PAs .................................... 183 
Table 5.3: Positive/negative MMP-9 and MMP-14 expression and clinical features in PAs ....... 184 
Table 5.4: Positive/negative MMP-9 and MMP-14 expression and PA-infiltrating immune cells..188 
Table 5.5: E-cadherin and ZEB1 expression and clinical features in PAs ..................................... 192 
Table 5.6: NCAM expression and clinical features in PAs ............................................................ 196 
Table 6.1: Cytokine secretome from an AIP mutation-positive vs 8 AIPneg somatotrophinomas
 ..................................................................................................................................................... 216 
Table 6.2: AIPmut PA-derived TAF cytokine secretome and comparison to sporadic PA-associated 
TAFs .............................................................................................................................................. 218 
Table 6.3: Cytokine secretome from AIPmut skin fibroblasts ..................................................... 219 
Table 6.4: AIPmut TAF cytokine secretome at baseline and after pasireotide treatment .......... 220 
Table 6.5: AIPmut skin fibroblasts cytokine secretome at baseline and after pasireotide treatment
 ..................................................................................................................................................... 222 
Table 7.1: Characteristics of the study population and comparative analysis of AIPmut vs AIPneg 
PAs ............................................................................................................................................... 234 
Table 7.2: AIPmut and AIPneg FIPA kindreds according to PA types ........................................... 236 
Table 7.3: Comparative analysis between AIPmut vs AIPneg somatotrophinomas .................... 239 
Table 7.4: Comparative analysis between AIPmut vs AIPneg prolactinomas and NFPAs ........... 241 
Table 7.5: Comparative analysis between prospectively-diagnosed vs clinically-presenting AIPmut 
PAs ............................................................................................................................................... 242 
20 
 
Table 7.6: Prospectively-diagnosed vs clinically-presenting AIPmut somatotrophinomas or NFPAs
 ..................................................................................................................................................... 244 
Table 7.7: List of AIP pathogenic/likely pathogenic mutations identified in our cohort ............. 246 
Table 7.8: List of non-pathogenic AIP variants identified in the study population ..................... 247 
Table 7.9: AIPmut PAs due to truncating vs non-truncating mutations or due to p.R304* vs non-
p.R304* ........................................................................................................................................ 249 
Table 8.1: List of MEN1 mutations identified in the study population ........................................ 261 
Table 8.2: Main MEN1-related manifestations order of onset in patients with MEN1mut PAs . 261 
Table 8.3: Comparative analysis between MEN1mut vs AIPmut PAs .......................................... 263 
Table 8.4: Comparative analysis by subtype among MEN1mut PAs ........................................... 265 
Table 8.5: Comparative analysis by subtype among AIPmut PAs ................................................ 266 
Table 8.6: Comparison between MEN1mut vs AIPmut prolactinomas and MEN1mut vs AIPmut 
NFPAs ........................................................................................................................................... 268 
Table 8.7: Comparative analysis between MEN1mut vs AIPmut somatotrophinomas ............... 270 
 
 
 
 
 
 
 
 
 
 
 
 
 
21 
 
List of abbreviations 
 
ACTH adrenocorticotropic hormone 
ADAM a disintegrin and metalloproteinase 
domain 
AIP aryl hydrocarbon receptor-
interacting protein 
AIPmut AIP mutation-positive 
AIPneg AIP mutation-negative 
AHR aryl hydrocarbon receptor 
α-MSH α-melanocyte-stimulating hormone 
ARG1 arginase 1 
ARNT AHR nuclear translator 
α-SMA α-smooth muscle actin 
AVP arginine-vasopressin 
BMP-4 bone morphogenetic protein-4 
CABLES1 cdk5 and ABL enzyme substrate 1 
cAMP cyclic adenosine 3´5´-
monophosphate 
CDK cyclin-dependent kinase 
CDKI cyclin-dependent kinase inhibitor 
cDNA complementary DNA 
CM conditioned medium 
CNC Carney complex 
CRH corticotrophin-releasing hormone 
CT cycle threshold 
DAB 3.3´-diaminobenzidine 
tetrahydrochloride 
DAPI 4',6-diamidino-2-phenylindole 
DES diethylstilbestrol 
DMEM Dulbecco´s Modified Eagle´s 
Medium 
DNMT1 DNA methyltransferase 1 
ECM extracellular matrix 
EGF epithelial growth factor 
ELISA enzyme-linked immunosorbent 
assay 
EMT epithelial-to-mesenchymal transition 
EpCAM epithelial cell adhesion molecule 
ESRP epithelial splicing regulatory protein 
FAP fibroblast activation protein 
FBC full blood count 
FBS foetal bovine serum 
FGF fibroblast growth factor 
FIPA familial isolated pituitary adenoma 
FLI-1 Friend leukaemia virus integration 1 
FOXP3 forkhead box P3 
FSH follicle-stimulating hormone 
FT4 free thyroxine 
GAPDH glyceraldehyde-3-phosphate 
dehydrogenase 
GFAP glial fibrillary acidic protein 
GH growth hormone 
GHRH growth hormone-releasing 
hormone 
GLUL glutamate-ammonia ligase 
GM-CSF granulocyte macrophage-colony 
stimulating factor 
GNAS guanine nucleotide-activating α-
subunit 
GnRH gonadotrophin-releasing hormone 
HIF-1α hypoxia-inducible factor-1α 
HPF high power field 
HSP90 heat shock protein 90 
IGF-1 insulin-like growth factor-1 
IFNγ interferon gamma 
IL interleukin 
IL-1ra interleukin-1 receptor antagonist 
iNOS inducible nitric oxide synthase 
JAK janus-activated kinase 
LCA leukocyte common antigen 
LH luteinising hormone 
LIF leukaemia inhibitory factor 
LMR lymphocyte-to-monocyte ratio 
MAPK mitogen-activated protein kinase 
MEN1 multiple endocrine neoplasia type 1 
MEN1mut MEN1 mutation-positive 
MEN4 multiple endocrine neoplasia type 4 
MET mesenchymal-to-epithelial 
transition 
MIF migration inhibitory factor 
MMP matrix metalloproteinase 
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MRI magnetic resonance imaging 
MVD microvessel density 
NCAM neural cell adhesion molecule 
NET neuroendocrine tumour 
NF-kβ nuclear factor-kβ 
NFPA non-functioning pituitary adenoma 
NLR neutrophil-to-lymphocyte ratio 
NP normal pituitary 
NK natural killer 
PA pituitary adenoma 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PDE2A phosphodiesterase subtype 2A 
PDE4A5 phosphodiesterase subtype 4A5 
PDGF platelet-derived growth factor 
PD-L1 programmed death ligand 1 
PERP TP53 apoptosis effector 
PHPT primary hyperparathyroidism 
PI3K phosphatidylinositol 3-kinase 
PIK3CA phosphatidylinositol 3-kinase 
subunit p110α 
Pit-1 pituitary-specific transcription factor 
1 
PKC protein kinase C 
PKP2 plakophilin 2 
PLR platelet-to-lymphocyte ratio 
PMA phorbol 12-myristate 13-acetate 
pNET pancreatic neuroendocrine tumour 
PPIase peptidyl-prolyl cis-trans isomerase 
PRKAR1A protein kinase A type 1α regulatory 
subunit 
PRL prolactin 
RET rearranged during transfection 
tyrosine-kinase receptor 
ROBO1 roundabout axon guidance receptor 
homolog 1 
RT-qPCR real-time quantitative polymerase 
chain reaction 
SD standard deviation 
SDF-1 stromal cell-derived factor-1 
SDH succinate dehydrogenase 
SEM standard error of the mean 
SF-1 steroidogenic factor-1 
SOCS suppressors of cytokine signalling 
SSA somatostatin analogue 
SST somatostatin receptor 
STAT signal transducer and activator of 
transcription 
TAF tumour-associated fibroblast 
TCDD 2,3,7,8-tetrachloro-p-dioxin 
TGF transforming growth factor 
TIL tumour-infiltrating lymphocyte 
TME tumour microenvironment 
TMVA total microvessel area 
TNF tumour necrosis factor 
T-Pit T-box transcription factor TBX19 
TPR tetratricopeptide-repeat 
Tregs T regulatory cells 
TRH thyrotrophin-releasing hormone 
TSH thyroid-stimulating hormone 
ULN upper limit of the normal 
USP8 ubiquitin-specific protease 8 
VEGF vascular endothelial growth factor 
XLAG X-linked acrogigantism 
yr year 
ZEB1 zinc finger E-box binding 
homeobox 1 
23 
 
Acknowledgments 
 
I would like to acknowledge Barts and The London Charity for generously funding two years of my 
research and the Centre for Endocrinology, William Harvey Research Institute for supporting my 
third PhD year awarding me with the Joan Adams Fellowship. I’m also grateful to the Society for 
Endocrinology and to the Portuguese Society of Endocrinology, Diabetes and Metabolism who 
funded my participation in national and international conferences over the last 3 years, allowing 
me to present my research, to network with other colleagues and to identify new research 
directions. 
 
I am especially thankful to Professor Márta Korbonits for the opportunity to integrate her research 
group and for her guidance, encouragement, support and availability, but also for her friendship, 
throughout these 3 years of my PhD. Márta is definitely the best mentor I could ever wish for, 
contributing enormously for my academic and clinical careers. I also would like to thank all the 
other colleagues and friends from the Centre for Endocrinology for their technical assistance, 
cooperation and dedication, particularly Dr David Collier, Dr Sayka Barry and Dr Edwin Garcia who 
helped me the most in mastering the different lab techniques and completing my research 
projects.   
 
I would like to thank my second supervisor, Professor Frances Balkwill, for her support and 
guidance in my research. I also would like to express my gratitude to Professor Ashely Grossman 
for his positive influence in my PhD and for proofreading this thesis. 
 
A special thanks to my first two mentors Professor Valeriano Leite and Professor Maria João 
Bugalho, who were determinant for my clinical training in Endocrinology and Diabetes in Portugal, 
but also an inspiration to pursue a career in science. 
 
I am infinitely grateful to my fabulous wife Patricia for her love, support and patience, as well as 
to all my family and friends which were essential in the different stages of this journey. 
 
 
 
 
 
24 
 
Details of collaboration 
 
Collaborations: 
This work was supported by the Barts and The London Charity [Clinical Research Training 
Fellowship] and by the Centre for Endocrinology, William Harvey Research Institute and the 
Medical College of Saint Bartholomew´s Hospital Trust [Joan Adams Fellowship]. 
 
Dr Giulia Marelli (Barts Cancer Institute, London, UK) – provided the RAW 264.7 macrophages for 
cell culture experiments 
 
Dr Leo Guasti (William Harvey Research Institute, London, UK) - provided the normal skin 
fibroblasts for cell culture experiments 
 
Dr Hilde van Esch and Dr Wim Huybrechts (UZ Leuven Belgium, UK) - provided the AIP mutation-
positive skin fibroblasts for cell culture experiments 
 
Dr Oliver Haworth (William Harvey Research Institute, London, UK) - provided assistance with flow 
cytometry, as well as some reagents and antibodies for this experiment 
 
Dr George Elia (Pathology Services, Barts Cancer Institute, London, UK) – performed the Ventana 
immunostainings  
 
Dr Eivind Carlsen (Telemark Hospital Pathology Department, Skien, Norway) – provided assistance 
with the quantification of immunoreactivities  
 
Dr Federico Roncaroli (Division of Neuroscience and Experimental Pathology, Faculty of Biology, 
Medicine and Health, University of Manchester, Manchester, UK) – provided critical input 
regarding immunohistochemical studies 
 
Dr Daniela Magalhães (Centro Hospitalar de São João, Porto, Portugal) – collected the clinico-
pathological data from the MEN1 patients included in the clinical study   
 
Dr Sherine Awad (William Harvey Research Institute, London, UK) – performed the data 
deconvolution using the webtool xCell from Affymetrix microarray data generated previously by 
Dr Sayka Barry (William Harvey Research Institute, London, UK) as part of another study 
 
Eve Technologies (Calgary, Canada) – performed the multiplex cytokine arrays  
25 
 
General aims of the study 
 
 
1) To characterise the tumour microenvironment in pituitary adenomas and its role in the 
clinical phenotype and tumour aggressiveness, focusing on the cytokine network and 
infiltrating immune cells and their complex interaction 
 
2) To characterise the cytokine secretome of pituitary adenoma-associated fibroblasts and 
study its role in the clinical phenotype and pituitary tumour aggressiveness, as well as its 
responsiveness to somatostatin analogues  
 
3) To study the role of the cytokine network and infiltrating immune cells or pituitary 
adenoma-associated fibroblasts within the microenvironment of pituitary adenomas in 
the modulation of different oncogenic mechanisms 
 
4) To investigate the role of AIP deficiency in the pituitary tumour cell cytokine secretome 
 
5) To study the benefits of genetic and clinical screening of AIP mutation carriers by 
characterising prospectively-diagnosed AIPmut pituitary adenomas and compare to those 
with a clinical presentation 
 
6) To characterise AIPmut and MEN1mut pituitary adenoma patients in general and by 
subtype and to provide a comparative analysis between AIPmut and MEN1mut pituitary 
adenomas 
 
 
 
 
 
 
 
 
26 
 
Chapter 1: Introduction 
 
1.1  The pituitary gland 
The pituitary gland, or hypophysis, is one of the most important glands of the endocrine system 
as it is involved in the regulation of other endocrine glands, such as thyroid, adrenals or gonads. 
The pituitary gland secretes different hormones that regulate numerous physiological processes 
such as growth, sexual development, reproduction, metabolism, thermoregulation, sleep, water 
balance, stress responses and adaptation to the external environment, among others1. 
 
Anatomy 
The pituitary is a small gland with a size in adults of approximately 13 mm across by 3-9 mm in 
height and 9 mm in the anteroposterior depth; its weight ranges from 0.5 to 1.0 g, but it can be 
larger in younger individuals, in female adolescence or in pregnancy2,3.  
The pituitary is located in the sella turcica, a depression in the sphenoid bone of the skull4, and 
covered superiorly by dura mater (the diaphragma sellae) through which the pituitary stalk passes, 
a structure composed of axons of the hypothalamic neuronal cell bodies and blood vessels 
connecting the hypophysis to the hypothalamus5.  
The lateral walls of the sella turcica are formed by the cavernous sinuses6, which contain the 
internal carotid artery and the cranial nerves III, IV, V1,V2 and VI, and superiorly lies the optic 
chiasm (Figure 1.1)7.  
These anatomical relationships of the pituitary are critical in processes causing enlargement of the 
gland, such as a pituitary tumour, which may lead to significant mass effects: a tumour extending 
superiorly impinging on the optic chiasm may lead to visual deficits, most frequently bitemporal 
hemianopia, whereas a pituitary tumour extending laterally may cause oculomotor paralysis8. 
 
27 
 
 
Figure 1.1: Anatomy surrounding the pituitary gland 
CN, cranial nerve. Molitch (2017)7. 
 
 
Structure 
The pituitary gland is divided into 2 main parts: the adenohypophysis (anterior pituitary) and the 
neurohypophysis (posterior pituitary). The adenohypophysis, originated from oral epithelia, is 
arranged in clumps or branching cords of cells separated by capillaries and sinusoids, and contains 
5 main different hormone-secreting cell types: corticotrophs that produce adrenocorticotropic 
hormone (ACTH), gonadotrophs that produce luteinising hormone (LH) and follicle-stimulating 
hormone (FSH), thyrotrophs that produce thyroid-stimulating hormone (TSH), somatotrophs that 
produce growth hormone (GH), and lactotrophs that produce prolactin (PRL). A small subset of 
mammo-somatotrophs producing both GH and PRL is also recognised9. There are also non-
hormone producing cells in the anterior pituitary, namely the agranular folliculo-stellate cells 
accounting for 5-10% of all adenohypophyseal cells which provide mainly mechanical support, but 
they also have other functions such as nurture of the secretory cells, phagocytosis of debris and 
apoptotic cells, regulation of ion balance and water transport10,11. The neurohypophysis, 
originating from the neural tissue of the forebrain, consists mainly of axons of hypothalamic 
neurons that secrete arginine-vasopressin (AVP) (or antidiuretic hormone) involved in the 
regulation of water balance, and oxytocin involved in social and biological behaviours as well as in 
uterine contractions during deliver and milk letdown12. A third pituitary lobe, termed the 
intermediate lobe, is recognised in other species, particularly in rodents, and it is regarded as a 
homogeneous area of melanotroph cells that synthesise peptide products of the 
proopiomelanocortin gene (α-melanotrophin or α-melanocyte-stimulating hormone (α-MSH)). 
However, in the human, only a vestigial fragment remains in adult life12. 
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Function and regulation 
The major role of the hypothalamus in the regulation of pituitary function was first recognised by 
Harris13. The pituitary hormones are secreted in a pulsatile manner, reflecting the fact that the 
pituitary is under the control of the nervous system through the hypothalamus. External stimuli, 
such as environment temperature, physical exercise, stress, nutrients, among others, lead to a 
secretion of specific hypothalamic releasing or inhibitory factors5. These hypothalamic factors are 
transported through the hypophyseal portal system and act on the surface receptors of 
adenohypophyseal cells. As a response, pituitary hormones are synthesised and secreted or 
inhibited5,12: corticotrophin-releasing hormone (CRH) and AVP induce ACTH secretion; 
thyrotrophin-releasing hormone (TRH) induces TSH secretion; GH secretion is stimulated by GH-
releasing hormone (GHRH) and ghrelin and is inhibited by somatostatin; gonadotrophs have 
receptors for gonadotrophin-releasing hormone (GnRH) and when stimulated will produce 
variable amounts of LH and FSH, depending on the frequency and amplitude of GnRH pulses14; 
PRL is the only hormone that is not stimulated by a specific hypothalamic releasing factor 
(although in severe primary hypothyroidism TRH may lead to PRL secretion), but remains under 
the negative influence of dopamine14,15. 
The pituitary hormones are released by exocytosis of the storage granules and diffuse through the 
perivascular extracellular space to the blood vessels, and thereafter elicit specific responses in 
peripheral target tissues, mainly in endocrine glands: ACTH regulates cortisol and, in some extent, 
the androgen production by the adrenals; LH and FSH stimulate sex hormone production by the 
gonads, playing a key role in the regulation of the reproduction; TSH stimulates the production 
and release of thyroid hormones; GH targets different tissues directly or through the production 
of insulin-like growth factor-1 (IGF-1) in the liver, playing a crucial role in linear growth and in 
metabolic processes; PRL is the main regulator of lactation5,12, but has also been involved in the 
maturation and regulation of the immune system16-18.  
The specific hormones produced by stimulated peripheral glands, in turn, will act via a feedback 
loop to control anterior pituitary function. There are mainly 2 mechanisms by which peripheral 
gland hormones regulate hypothalamus and pituitary functions: negative and positive feedback. 
The negative feedback, which is the main regulatory mechanism, is exerted by hormones released 
from the target glands: pituitary GH secretion is inhibited both by GH and by IGF-1; glucocorticoids 
secreted by the adrenals inhibit the secretion of both ACTH and CRH; TSH and TRH are negatively 
regulated by the thyroid hormones produced in the thyroid gland; FSH and LH are inhibited by a 
negative feedback of sex steroid hormones 5,12. The positive feedback is less common, from which 
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the main example is the positive feedback exerted by oestrogens during the female menstrual 
cycle, resulting in the midcycle LH surge and ovulation14. 
 
1.2  Pituitary adenomas 
Definition and epidemiology 
Pituitary adenomas (PAs) are common tumours arising from adenohypophysis cells, accounting 
for 15% of all intracranial tumours, corresponding to the third most common intracranial 
neoplasm after meningiomas and gliomas19. The term pituitary neuroendocrine tumour has been 
suggested to replace the term PA, as it may reflect more accurately the complex biology and the 
clinico-pathological aspects of pituitary tumours20, however this proposal is controversial and not 
supported by many authors21. The prevalence of PAs is high in autopsy and radiological studies, 
ranging from 14.4 up to 22.5%, but most have no clinical relevance22. In fact, up to 10% of PAs are 
discovered on imaging in asymptomatic or individuals previously unsuspected to have a pituitary 
lesion (pituitary incidentaloma)23,24. Clinically relevant PAs are less common, with a prevalence 
varying from 1:1064 up to 1:1470 in the general population22.  
The great majority of PAs are histologically benign; however, they can cause a significant burden 
to patients due to tumour mass effects on relevant surrounding structures and/or due to 
hypersecretion or hyposecretion of some or all (pan-hypopituitarism) pituitary hormones7. 
Pituitary carcinomas with distant metastasis or discontinuous intracranial extension are rare, 
accounting only for 0.1-0.2% of all pituitary tumours25. 
About two thirds of PAs may secrete pituitary hormones in excess7,26, with the most common type 
being prolactinomas (prevalence ranges between 46.2-66.2%), followed by non-functioning PAs 
(NFPAs) (14.7-37%), somatotrophinomas (9-16.5%), corticotrophinomas (1.58-5.9%), and more 
rarely thyrotrophinomas (0-1.2%)22,27-31. 
 
Histopathological and clinical classifications 
Following the 2017 WHO guidelines32, PAs and their clinical syndromes are classified according to 
the type of endocrine cell they arise from and the hormone in excess: prolactinomas (PRL excess 
leading to galactorrhoea, amenorrhoea and other hypogonadal symptoms), TSH-secreting PA 
(secondary hyperthyroidism), ACTH-secreting PA (Cushing’s disease), GH-secreting PA 
(acromegaly or gigantism), as well as LH/FSH-positive PAs, corresponding to most clinically NFPAs, 
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as these PAs, although histologically usually display immunoreactivity for LH and/or FSH, lack 
clinically relevant LH or FSH overproduction (occasionally measurable in the serum of NFPA 
patients), hence not leading to an sex hormone excess syndrome33; clinically active gonadotroph 
adenomas, leading to enlarged ovaries or testes, have been described but are rare34. Sometimes, 
however, clinically NFPAs do not stain for gonadotropins and demonstrate immunoreactivity for 
ACTH, TSH, GH or PRL (or for the corresponding transcription factors T-Pit (T-box transcription 
factor TBX19) and Pit-1 (pituitary-specific transcription factor 1) consistent with a well-
differentiated lineage-specific adenoma34 despite not oversecreting these hormones, thus 
referred to as “silent” corticotroph, thyrotroph, somatotroph or rarely lactotroph tumours, 
respectively7,26. Following this concept, the majority of clinically NFPAs are silent gonadotroph 
tumours expressing LH, FSH and/or their transcription factor SF-1 (steroidogenic factor-1). A very 
rare category that do not exhibit immunoreactivity for pituitary hormones or transcription factors 
is identified and termed as null-cell PAs35. 
PAs have been classified for years based on their histopathological features and hormone content 
assessed by immunohistochemistry and tumoural cells’ ultrastructural features36. However, with 
the most recent 2017 WHO classification of pituitary tumours, the main principle guiding PA 
classification is the adoption of a pituitary adenohypophyseal cell lineage: acidophilic lineage 
(somatotroph, lactotroph and thyrotroph), corticotroph and gonadotroph lineages. The 
adenohypophyseal cell lineage differentiation is driven by transcription factors during the 
maturation of neuroendocrine cells from Rathke´s pouch, and shown to be expressed in PAs in a 
similar pattern to normal pituitary (NP). Thus, the classical immunohistochemistry for pituitary 
hormones, when appropriate, can be combined with immunostaining for pituitary transcription 
factors such as T-Pit, SF-1 and Pit-1 (Table 1.1)32. 
Pituitary 
adenoma type 
Morphological variants Pituitary hormones Transcription factors 
and other co-factors 
Somatotroph 
adenomas 
Densely-granulated adenoma 
Sparsely-granulated adenoma 
Mammo-somatotroph adenoma 
Mixed somatotroph-lactotroph 
adenoma 
GH ± PRL ± α-subunit 
GH ± PRL 
GH ± PRL (same cells) ± α-
subunit 
GH ± PRL (different cells) ± 
α-subunit 
Pit-1 
Pit-1 
Pit-1, ERα 
Pit-1, ERα 
Lactotroph 
adenomas 
Densely-granulated adenoma 
Sparsely-granulated adenoma 
Acidophilic stem cell adenoma 
PRL 
PRL 
PRL, GH (focal and variable) 
Pit-1, ERα 
Pit-1, ERα 
Pit-1, ERα 
Thyrotroph 
adenomas 
 β-TSH, α-subunit Pit-1 
Corticotroph 
adenomas 
Densely-granulated adenoma 
Sparsely-granulated adenoma 
Crooke´s cell adenoma 
ACTH 
ACTH 
ACTH 
T-Pit 
T-Pit  
T-Pit 
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Gonadotroph 
adenomas 
 β-FSH, β-LH, α-subunit 
(various combinations) 
SF-1, GATA-2, ERα 
Null-cell 
adenomas 
 None None 
Plurihormonal 
adenomas 
Plurihormonal Pit-1 positive 
adenoma 
Adenomas with unusual 
immunostaining combinations 
GH, PRL, β-TSH ± α-subunit 
Various combinations: 
ACTH+GH or PRL 
Pit-1 
Table 1.1: Classification of pituitary adenomas according to 2017 WHO classification 
Adapted from Lloyd (2017)32. 
 
 
In the 2017 WHO classification of pituitary tumours, there are morphological variants recognised 
as potentially more aggressive due to their intrinsic histological features: sparsely-granulated 
somatotroph adenomas, silent corticotroph adenomas, Crooke´s cell adenomas (corticotroph 
adenomas composed mainly by cells with a ring-like deposition of cytokeratin) and plurihormonal 
Pit-1 positive adenomas32. 
Most of the PAs are monohormonal, but some may be plurihormonal (secreting 2 or more 
hormones, most commonly GH and PRL)26. Plurihormonal PAs may be monomorphous when there 
is one cell type producing more than one pituitary hormone, or plurimorphous consisting of 2 (or 
more) distinct cell populations each secreting different pituitary hormones34. 
PAs are classified according to their diameter into microadenomas (<10 mm), macroadenomas 
(≥10 mm) or giant adenomas (≥40 mm). Macroadenomas account for around 50% of all PAs7. 
 
Aggressiveness of pituitary adenomas 
The definition of an aggressive PA varies in the literature, from that of a large invasive rapidly 
growing PA to a tumour with early recurrence despite optimal surgical or medical treatment34,37. 
In general, the concept of an aggressive PA entails an adenoma that deviates from the typical 
benign clinical behaviour34. Raverot et al. defined aggressive PAs as a “subset of non-metastatic 
invasive tumours displaying aggressive behaviour leading to multiple recurrences and resistant to 
conventional treatment including radiation therapy”25. Furthermore, the terms “aggressive” and 
“invasive” are often used interchangeably and synonymously to describe such cases37. 
To aid clinicians identifying such cases, in the 2004 WHO classification of pituitary tumours, apart 
from the benign “typical” adenomas and the aggressive pituitary carcinomas, identified a third 
category of clinically aggressive adenomas – termed “atypical adenomas” - as these tumours had 
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“atypical” morphological features, high mitotic index, Ki-67>3% as well as extensive p53 nuclear 
staining36. However, several studies demonstrated that not all atypical PAs were associated to 
aggressive clinical behaviour38,39. Hence, in the revised 2017 WHO classification of pituitary 
tumours, the term “atypical adenoma” has been abandoned: emphasis is still given to the 
evaluation of Ki-67 and mitotic count (but no specific cut-offs recommended) and in tumoural 
invasion of soft tissue or bone as determined radiologically or histopathologically32.  
Some radiological markers, as cavernous/sphenoid sinus invasion or bone erosion (Knosp40 and 
Hardy41 classifications), as well as histological markers (Ki-67, mitotic count, p53 staining, certain 
histiotypes such as Crooke´s adenoma, sparsely-granulated somatotroph adenomas or null-cell 
PAs) are regarded as indicators of aggressiveness37. Extensive research has identified different 
biological markers for PA aggressiveness, including chromosomal alterations, DNA aneuploidy, 
altered microRNAs, overexpression of growth factors and their receptors, alteration of factors 
related to angiogenesis (such as vascular endothelial growth factor (VEGF)) or to cell adhesion 
(matrix metalloproteinases, neural cell adhesion molecule (NCAM) or galectin-3), but no single 
biomarker independently predicts aggressiveness, and thus none is routinely used in clinical 
practice37. 
Aiming to determine the PA aggressiveness and predict the probability of post-operative complete 
remission, as well as to identify patients with high risk of early recurrence or progression, a new 
prognostic clinicopathological classification has been proposed42,43. This classification (Trouillas 
classification) is based on 3 main characteristics: tumour diameter given by MRI scanning, tumour 
type determined by immunocytochemistry (GH, PRL, ACTH, LH/FSH and TSH), and tumour grade 
determined by invasion defined as histological or radiological signs of cavernous or sphenoid sinus 
invasion and proliferation determined by p53 staining, Ki-67 and mitoses. Of these, evidence of 
invasion and the Ki-67 index are most important. Five grades are established: 1a: non-proliferative 
and non-invasive, 1b: proliferative but non-invasive, 2a: invasive but non-proliferative, 2b: 
invasive and proliferative, and 3: metastatic43.  
 
Pituitary tumourigenesis 
PAs are believed to be monoclonal in origin, expanding from intrinsic molecular genetic 
abnormalities in a single somatic anterior pituitary cell (except folliculo-stellate cells)44. In early 
tumour clonality studies, through X-chromosomal inactivation analysis, the monoclonal origin of 
GH, PRL and ACTH-secreting PAs as well as in NFPAs was seen in female patients heterozygous for 
variant alleles of X-linked genes. PAs have only one X-inactivation type, paternal or maternal, and 
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never both44-49. PA monoclonality is supported by other findings: the tissue surrounding the PA 
normally has no hyperplasia features; complete resection may result in long-term remission; 
activating or inactivating mutations in hypothalamic hormone receptors are not common26. 
But why are the vast majority of pituitary tumours benign50? Cellular senescence has been 
suggested to explain the benign nature of PAs. Cellular senescence is an anti-proliferative 
response, induced by DNA damage, oxidative stress, age-linked telomere shortening, 
chromosomal instability and aneuploidy, loss of tumour suppressor genes or, paradoxically, by 
oncogene activation, which leads to irreversible cell cycle arrest. Senescent pituitary cells are 
growth-constrained by cell cycle inhibitors, and thus protected from deleterious consequences of 
oncogenes or transforming factors preventing malignant transformation26,51,52, but the 
senescence pathway may not be universal for all PAs53.  
The majority of PAs occur sporadically (95%). Factors most commonly involved in the pituitary 
tumourigenesis are cell cycle deregulation, altered signaling pathways, epigenetically silenced 
tumour suppressor genes or overexpressed oncogenes, growth factors and hormonal 
overstimulation26,45,54,55. The role of environmental factors has also been suggested56-58. Acquired 
genetic or epigenetic changes confer an advantage to modified cells in terms of abnormal cell 
cycle activation, growth and proliferation, allowing monoclonal expansion. PAs have lower levels 
of somatic mutations compared to other tumours, but they frequently have cell cycle proteins and 
altered expression of growth factors, often due to epigenetic mechanisms19.  
Cell cycle protein expression abnormalities may be present in up to 80% of PAs59. The main cell 
cycle regulators are cyclin-dependent kinases (CDKs) and their inhibitors (CDKIs). CDKs are 
activated by cyclins promoting initiation and progression of the cell cycle60-62. In sporadic PAs, 
CDKIs are often downregulated as consequence of epigenetic alterations such as promoter 
hypermethylation or histone modification63-66. On the other hand, overexpression of cyclins has 
been documented in PAs60,67-69. Altered expression of other genes have been reported in PAs 
(Appendix 1). Growth factors, signal transduction mediators, such as protein kinase C (PKC) and 
phosphatidylinositol 3-kinase (PI3K) subunit p110α (PIK3CA)70-72, and transcription factors, are 
commonly overexpressed in PAs (Appendix 1)22,73-75. The expression of microRNAs, small 
noncoding RNA involved in post-translational gene expression regulation76, is often altered in PAs 
and may contribute to the pituitary tumourigenesis51,76-78.  
Genetic alterations in sporadic PAs include also somatic mutations typically in oncogenes, such as 
in the guanine nucleotide-activating α-subunit (GNAS) gene responsible for up to 40% of 
somatotrophinomas, or in ubiquitin-specific protease 8 (USP8) gene in corticotrophinomas 
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causing about 1 to 2 thirds of Cushing´s disease cases26,79-81, or gene amplifications as in the PIK3CA 
found in up to 1 third of all PAs71,82. Mutations in tumour suppressor genes such as TP53 and RB1, 
or in oncogenes such as HRAS and MYC, are rarely seen and exclusively found in aggressive PAs or 
carcinomas51,71,83,84. In particular, HRAS mutations were found mostly in carcinomas, which 
suggests that this must be important in malignant transformation rather than PA initiation22,83. 
PAs can also occur in the context of mosaic mutations, such as McCune-Albright syndrome and 
some patients with X-linked acrogigantism (XLAG). McCune-Albright  syndrome is caused by 
GNAS1 gene mutations occurring at a post-zygotic level (i.e. somatic) and characterised by the 
triad polyostotic fibrous dysplasia, café-au-lait skin pigmentation and precocious puberty, but also 
other endocrinopathies can be found, including acromegaly or gigantism85 due to pituitary 
hyperplasia or GH-secreting PAs86-88.  
 
1.3  Familial pituitary adenomas (due to germline alterations) 
Although most PAs occur sporadically, 5% of PAs occur in a familial setting, due to a germline 
genetic defect that predisposes to PAs, either isolated or as part of a syndrome (Figure 1.2)19. 
Despite their rarity, inherited PAs are important entities because they often present in younger 
patients, have a more aggressive course and are more refractory to therapy51.  
Syndromic presentation occurs in multiple endocrine neoplasia type 1 (MEN1), MEN4, Carney 
complex (CNC) and, more rarely, in DICER1 syndrome and in familial phaeochromocytoma/ 
paraganglioma syndrome due to germline genetic abnormalities in the genes SDH (succinate 
dehydrogenase)19 or MAX89,90.  
Familial isolated PAs (FIPA) can be observed in aryl hydrocarbon receptor-interacting protein (AIP) 
mutation-positive cases91 and in XLAG syndrome due to GPR101 duplications92,93. More recently, 
4 patients with ACTH-secreting macroadenomas were identified with germline mutations in the 
Cdk5 and ABL enzyme substrate 1 (CABLES1) gene94. Germline mutations in the gene CDH23, 
encoding the cadherin-related 23 protein, were found in both familial and sporadic PAs, raising 
the possibility for its involvement in pituitary tumourigenesis95.  
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Figure 1.2: Pituitary adenomas due to a genetic origin 
Adapted from Marques & Korbonits (2017)19. *There was a patient recently described with a de novo 
germline USP8 mutation with recurrent Cushing´s disease and multiple other medical problems 
(developmental delay, dysmorphic features, ichthyosiform hyperkeratosis, chronic lung disease, chronic 
kidney disease, hyperglycaemia, dilated cardiomyopathy, hyperinsulinism and partial GH deficiency), 
suggesting that Cushing´s disease can also occur as part of an hereditary complex syndrome related to 
germline USP8 mutations96. 
 
 
Syndromes predisposing to pituitary adenomas 
Multiple Endocrine Neoplasia type 1 (MEN1) 
MEN1 is an autosomal dominant disorder caused by mutations in the MEN1 gene that predisposes 
mainly to primary hyperparathyroidism (PHPT), pancreatic neuroendocrine tumours (pNETs) and 
PAs, but other tumours can also occur such as adrenocortical tumours, thyroid tumours, lipomas, 
angiofibromas, meningiomas, gastric, thymic and bronchial neuroendocrine tumours (NETs)97,98. 
MEN1 diagnosis is established in a patient with 2 or more MEN1-associated tumours, in a patient 
with one MEN1-associated tumour and a first-degree relative with MEN1, or in a MEN1 mutation 
(MEN1mut) carrier97,98. 
 
Clinical features 
The prevalence of MEN1 is approximately 1:30,000 occurring in 1-18% of patients with PHPT, 16-
38% of patients with gastrinomas and <3% of patients with PAs97. MEN1 penetrance is generally 
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high, with biochemical manifestations present by the 5th decade of life in 95% of cases. However, 
MEN1 penetrance depends on patient’s age and gender and is organ-specific98,99.  
The penetrance of PAs in MEN1 is 30-40%, although can vary from 10 up to 76%100-102. The mean 
age at PA presentation is 38 years, but these can occur as early as the age of 5 or late in the 9th 
decade of life98,103,104. PAs are more common in females, which is as yet unexplained but it has 
been postulated that oestrogens may exert a proliferative stimulus leading to 
tumourigenesis103,105 considering their stimulatory effects on pituitary lactotroph secretion and 
proliferation106,107. Prolactinomas are the most common PA subtype in MEN1, occurring in 60-70% 
of cases, followed by NFPAs (15-20%), somatotrophinomas (10%), corticotrophinomas (5%) and 
rarely thyrotrophinomas (<1%)98,100-103,108. MEN1mut PAs occur at younger age and are frequently 
more aggressive, bigger and refractory to treatment97,103,109,110.  
 
Genetic testing and clinical screening 
MEN1 genetic analysis allow clinicians to confirm the diagnosis in a MEN1 patient and to identify 
other MEN1 mutation-positive (MEN1mut) relatives who may benefit from appropriate screening 
and monitoring98,111. MEN1 analysis should be undertaken in: i) index cases with 2 or more MEN1-
asociated endocrine tumours; ii) asymptomatic first-degree relatives of a known MEN1mut 
carrier; iii) first-degree relatives of a MEN1mut carrier expressing familial MEN1; iv) individuals 
with suspicious or atypical MEN1 (PHPT before the age of 30 or multigland parathyroid disease, 
gastrinoma or multiple pNETs at any age, existence of two or more non-classical MEN1 tumours98). 
Patients with childhood-onset macroprolactinomas, especially if there is a positive family history 
of prolactinomas, should also be considered for genetic analysis110,112. MEN1 analysis in 
asymptomatic individuals should be performed in the first decade of life, as there have been 
endocrine tumours reported by the age of 5 years97,98,104. 
 
MEN1 gene / menin protein 
The MEN1 gene encodes the menin protein and is regarded as tumour suppressor gene because 
heterozygous inactivating mutations predispose to neoplasia, and most MEN1-related tumours 
show loss of heterozygosity at 11q13113,114. Menin is ubiquitously expressed, predominantly 
located in the nucleus, and has several functions in transcription regulation, genome stability, cell 
division and cell cycle control, apoptosis and epigenetic regulation97,108,115,116, as a result of its 
numerous interaction partners97,117. Menin interacts with activin in NP, negatively regulating cell 
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proliferation and secretion of PRL, GH and ACTH. Different proliferative factors in endocrine 
neoplasms are negatively modulated by menin, such as IGF binding protein-2, IGF-2 and 
parathyroid hormone-related protein118,119. Menin may also increase or decrease the expression 
of different genes97,120. Menin activates the transcription of CDKN1B and CDKN1C, genes 
predominantly expressed in endocrine organs, which can explain, at least in part, the selectivity 
of MEN1 tumourigenesis121.  More recently, it was shown that MEN1 loss leads to activation of 
DNA (cytosine-5)-methyltransferase 1 (DNMT1) involved in DNA hypermethylation and driving 
MEN1-related tumourigenesis in endocrine tissues (but not in exocrine tissues)117.  
More than 1500 MEN1 mutations are known, and they are distributed throughout the whole gene, 
involving coding regions and splice sites115,122. The majority of MEN1 mutations are deletions or 
insertions resulting in frameshift or nonsense mutations, leading to truncation or absence of 
menin115,123. Most MEN1 mutations are familial, but 10% of the cases occur due to de novo MEN1 
mutations97,124. The clinical phenotype of MEN1 patients, family members, even identical twins, 
or unrelated families, with the same MEN1 mutation may differ108,115,125. A recent study involving 
797 MEN1 patients from 265 kindreds reported significant intra-familial correlations for PAs, 
adrenal tumours and thymic NETs, estimating their heritability (proportion of the phenotypic 
expression that is attributable to gene effects) at 64%, 65% and 97%126.  
 
Multiple Endocrine Neoplasia type 4 (MEN4) 
MEN4 is a rare autosomal dominant syndrome seen in patients with MEN1-like features but no 
mutations in the MEN1 gene. Around 3% of patients with MEN1-associated tumours fulfilling the 
clinical diagnostic criteria for MEN1, but with no MEN1 mutations, carry a germline mutation in 
the CDKN1B gene97,116. Mutations in other genes coding CDKIs have also been reported: p15 
(CDKN2B, 1%), p18 (CDKN2C, 0.5%) and p21 (CDKN1A, 0.5%)127. A comprehensive MEN4 
phenotype is not yet established due to the small number of cases identified thus far, but it seems 
to resemble the MEN1 phenotype which is likely explained by the known interactions between 
these CDKIs and the protein menin97,116. 
 
Carney complex (CNC) 
CNC is a rare autosomal dominant multiple neoplasia syndrome caused mainly by an inactivating 
germline mutation in the protein kinase A type 1α regulatory subunit (PRKAR1A) gene, responsible 
for more than 70% of CNC cases128. A second genetic locus located at 2p16 has been also 
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associated with CNC, but the gene residing in this region remains unknown129. Moreover, 
duplications of the catalytic subunit gene PRKACB has been linked with CNC130.  
CNC manifestations include skin pigmentation alterations, blue nevus, myxomas (benign tumours 
of skin, breast, heart and other sites), non-endocrine (breast ductal adenomas, schwannomas, 
osteochondromyxomas) and endocrine tumours (thyroid, testis and adrenals), as well as 
somatotroph hyperplasia and PAs131. Cyclic adenosine 3´5´-monophosphate (cAMP) pathway 
upregulation affects somatotrophs and lactotrophs, with up to 75% of CNC patients displaying 
abnormal GH, IGF-1 or PRL levels, but PAs can be detected in only 10% of cases132,133. CNC-
associated PAs are mostly GH or GH/PRL-secreting PAs, frequently multiple, small and surrounded 
by hyperplasia regarded as a putative precursor of PAs131. Acromegaly prevalence in CNC is 
estimated at 10-12%, and usually apparent by the third decade of life128,131. Pure 
prolactinomas134,135 and Cushing´s disease136,137 are very rare.  
 
Phaeochromocytoma/Paraganglioma and Pituitary Adenoma syndrome 
In 2006 a patient with PA and an SDHB mutation138, and later in 2008 a patient with PA and a SDHC 
mutation-related paraganglioma were described139. The coexistence of these 2 diseases could be 
a coincidence, but loss of heterozygosity and immunohistochemistry studies confirmed the 
predisposition to phaeochromocytomas, paragangliomas and PAs in subjects carrying germline 
SDHx mutations140-142. SDHx mutation-positive PAs can be somatotrophinomas, prolactinomas or 
NFPAs, and are more commonly macroadenomas, aggressive and refractory to treatment140,141,143.  
Although the coexistence of PAs and phaeochromocytomas/paragangliomas is usually associated 
with SDHx mutations144, pathogenic variants in the gene MAX (another predisposing gene for 
hereditary phaeochromocytomas/paragangliomas145) have recently been described in 4 patients 
with PAs (two with acromegaly and two with prolactinoma) and phaeochromocytomas/ 
paragangliomas89,90. 
 
DICER1 syndrome 
DICER1 syndrome is a rare disorder caused by a heterozygous germline mutations in the DICER1 
gene that encodes a small RNA endoribonuclease that regulates RNA expression146,147. The main 
DICER1 syndrome manifestations are pleuropulmonary blastomas, cystic nephromas, Sertoli-
Leydig cell tumours, goitre, and more rarely pituitary blastomas148-150. The first case of pituitary 
blastoma was described in a 13 month-old female who presented with Cushing´s disease and 
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diabetes insipidus. The “blastoma” designation was given to reflect the embryonic-primordial 
appearance and neonatal presentation151, and is now recognised in the most recent 2017 WHO 
classification of pituitary tumours32. Pituitary blastoma is regarded as a pathognomonic feature of 
DICER1 syndrome and has low penetrance (<1%), but can behave aggressively, metastasising or 
being lethal in approximately 40% of the cases146,147.  
 
Familial Isolated Pituitary Adenomas (FIPA) 
FIPA is a term used to describe the occurrence of a PA in 2 or more members of the same family 
in the absence of other syndromic clinical features, such as those characteristic of MEN1, MEN4 
or CNC152. FIPA is a heterogeneous condition with significant differences in phenotype among the 
various subtypes. FIPA kindreds may have the same PA type among affected family members 
(homogeneous FIPA) or a mixture of different PA types (heterogeneous FIPA)19. Most of 
homogeneous FIPA kindreds consist of acromegaly (54% of homogeneous FIPA), followed by 
prolactinomas (27%) and NFPAs (17%), whereas heterogeneous FIPA kindreds have different PA 
types, with the acromegaly and prolactinoma combination being the most common phenotype91. 
Despite the numerous studies on PA pathogenesis in FIPA, the genetic aetiology for most of FIPA 
cases remains unknown. However, significant advances in this field have been made since 2006, 
when a linkage analysis study in 2 Finnish FIPA families identified a truncating germline mutation 
in the AIP gene (p.Q14*) as predisposing for PA - AIP mutation-positive (AIPmut) FIPA19,153. Isolated 
familial PAs can also be observed in XLAG due to GPR101 duplications93. Whether CABLES194 and 
CDH2395 gene can cause FIPA remains to be proven.  
 
AIP mutation-positive FIPA 
Heterozygote loss-of-function germline AIP mutations are responsible for around 20% of all FIPA 
cases, with a prevalence up to 50% in families with only somatotrophinomas19,152,154. Up to 8% of 
apparently sporadic PA cases are due to an AIP mutation91. The AIP mutation prevalence is even 
higher in young patients (under the age of 30 years) with sporadic pituitary macroadenomas (12%) 
or in apparently sporadic pediatric PAs (20%)155. In fact, germline AIP mutations can be identified 
in seemingly sporadic cases due to the low penetrance of PAs, and therefore lacking a suggestive 
family history19. 
 
40 
 
Clinical features 
AIPmut FIPA patients present at a younger age and usually with large, invasive, functional PAs 
(mainly GH and/or PRL-secreting) and poorly responsive to therapy19. Clinical manifestations are 
related to hormone excess or mass effects, with gigantism being particularly frequent, 
representing over one third of AIPmut patients91,92,152.  AIPmut patients are also at increased risk 
for pituitary apoplexy91,156-158. Most AIPmut PAs are macroadenomas (90%), commonly invasive 
and/or with extrasellar extension (>50%). Around 80% of these are GH- and/or PRL-secreting PAs, 
with some clinically NFPAs being found (although they often have GH and/or PRL 
immunoreactivity), while corticotrophinomas and thyrotrophinomas are rare91,154. AIPmut PAs are 
more aggressive than sporadic PAs152: they are more often sparsely-granulated156 and have lower 
cellular AIP levels, a possible marker for PA invasiveness159,160. 
AIPmut PAs require a multimodal therapeutic approach often including more than one surgery. 
Prolactinomas often require surgery possibly due to reduced dopamine agonist responsiveness161, 
and AIPmut somatotrophinomas are commonly resistant to somatostatin analogues (SSA), having 
lower GH/IGF-1 reductions and tumour shrinkage to SSA in comparison to AIP mutation-negative 
somatotrophinomas155,156,161. Interestingly, AIP is upregulated in sporadic somatotrophinomas 
treated with SSA prior to surgery, and the AIP expression may predict SSA responsiveness162,163. 
Sporadic PAs with low AIP were resistant to first-generation SSAs, while they had similar 
responsiveness to pasireotide in comparison to tumours with conserved AIP expression. Tumours 
with low AIP had reduced somatostatin receptor (SST) type 2 compared to normal AIP expressing 
PAs, but no differences regarding SST5 expression164. 
 
Genetic testing and clinical screening 
Genetic screening is now available for selected patients with PAs (Figure 1.3). The detection of a 
germline mutation in the AIP or other PA-related genes will have major implications not only for 
the patient (namely in syndromic forms), but also for his/her relatives at risk of carrying the same 
genetic abnormalities and thus to develop the disease. The penetrance of PAs among AIPmut 
carriers is around 12-30%. Data from large families have shown an overall penetrance of 23%91. 
This relatively low penetrance of PAs among AIPmut carriers, together with their variable features, 
suggests the involvement of other disease-modifying genes or factors165,166. 
Genetic testing and clinical screening will allow the early detection of PAs in apparently unaffected 
subjects facilitating its management and avoiding some consequences of unrecognised PAs19,167. 
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If a patient with a PA has a relative with a PA without associated syndromic features, the diagnosis 
of FIPA is made and genetic testing for AIP mutations could be offered168. Genetic testing for AIP 
is suggested in FIPA cases, childhood-onset PAs of any size, and young-onset (<30 years) 
macroadenomas even in the absence of family history of PA167,168. Recently, a risk categorisation 
system was proposed based on 4 independent predictors (age of onset, family history, GH excess 
and tumour size) aiming to aid clinicians identifying PA patients at higher risk for AIP mutation169. 
If an AIP mutation is identified in a kindred, genetic screening should be then offered to first 
degree family members, taking into account its autosomal dominant inheritance pattern. AIPmut 
carriers should undergo baseline assessments as approximately a quarter of subjects initially 
thought to be unaffected AIPmut carriers may have pituitary and/or biochemical abnormalities91. 
Clinical evaluation including monitoring of children growth, PRL and IGF-1 measurements, and a 
baseline pituitary MRI scan, is recommended91. If a PA is diagnosed prospectively in an apparently 
unaffected AIPmut carrier, its management should be similar as for sporadic PAs23,170,171. For 
unaffected AIPmut subjects, annual clinical assessment and pituitary function tests are 
recommended, as some PAs may emerge during follow-up167.  
Figure 1.3: An approach to genetic testing in a patient with a pituitary adenoma 
Marques & Korbonits (2017)19. 
AIP gene / protein 
The AIP gene was first described in 1996 as an inhibitor of hepatitis B virus X protein-mediated 
transactivation172. Mapping the AIP gene in PA patients was a long process which started in 1993 
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when 4 non-MEN1 patients with acromegaly and loss of heterozygosity for chromosome 11q13 
were reported173. This region was further narrowed in 1999174, and later in 2005175. Interestingly, 
MEN1 is located in this region, but as the phenotype is different and linkage analysis showed close 
by different location, the existence of a different gene was predicted. In 2006 Vierimaa et al. found 
linkage to chromosome 11q12-q13 by genotyping 2 large Finnish FIPA families153, which turned 
out to be of the same genetic origin. AIP is located at chromosomal region 11q13.2, has 6 exons, 
and encodes the AIP protein with 330 amino-acids. The AIP protein is a co-chaperone that belongs 
to the group of proteins harbouring conserved C-terminal tetratricopeptide-repeat (TPR) domains 
of 34 amino-acids residues forming 2 palindrome α-helices. AIP contains 3 TPR domains and a final 
helix in the C-terminal region; the N-terminal has a peptidyl-prolyl cis-trans isomerase (PPIase)-
like domain (Figure 1.4-A)176-178. 
Figure 1.4: AIP protein structure (A) and interaction partners (B) 
A) The most highly conserved residues are in the tetratricopeptide-repeat (TPR) domains, 3 antiparallel
double helices and the final α-helix; the N-terminal has a peptidyl-prolyl cis-trans isomerases (PPIase)-like
domain. B) AIP interaction partners and their functional class of protein. AIP, aryl hydrocarbon receptor
interacting protein; AHR, aryl hydrocarbon receptor; ARNT, AHR nuclear translator; EBNA-3, Epstein Barr
virus nuclear antigen 3; EGFR, epidermal growth factor receptor; ERα, estrogen receptor-α; Gα13, guanine
nucleotide binding protein (G protein) α 13; Gαq, G protein α q peptide; GR, glucocorticoid receptor; HBV-
X, hepatitis B virus X protein; HSC70, heat shock cognate 70; HSP90, heat shock protein 90; PDE,
phosphodiesterase; PPARα, peroxisome proliferator-activated receptor-α; RET, rearranged during
transfection tyrosine kinase receptor; THRβ, thyroid hormone receptor-β; TNNI3K, cardiac troponin-I
interacting protein kinase; TOMM20, mitochondrial import receptor subunit TOM20 homolog. Adapted
from Aflorei et al. (2018)178, and Beckers et al. (2013)152.
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AIP is ubiquitously expressed in both developmental and adult stages, with some variation among 
different tissues, but is particularly concentrated in heart, brain, skeletal, liver, muscle, kidney, 
testis, ovary and pituitary172,176. At the cellular level AIP is predominantly located in the cytoplasm, 
but nuclear expression has been reported. In NP, AIP is expressed predominantly in somatotrophs 
and lactotrophs, normally within cytoplasmic secretory vesicles, but is absent in normal 
corticotrophs and gonadotrophs. In sporadic PAs, AIP is expressed in all types: in sporadic 
somatotrophinomas AIP co-localises with GH in secretory vesicles, but in sporadic prolactinomas, 
NFPAs and corticotrophinomas AIP resides in the cytoplasm156.  
 
AIP involvement in pituitary tumourigenesis 
Several binding partners of the AIP protein have been identified: aryl hydrocarbon receptor (AHR), 
heat shock protein 90 (HSP90), phosphodiesterase subtype 4A5 (PDE4A5), PDE2A, heat shock 
cognate 70, survivin, peroxisome proliferator-activated receptor-α, thyroid hormone receptor β1, 
oestrogen receptor-α, Epstein-Barr virus-encoded nuclear protein-3, hepatitis B virus X protein, 
rearranged during transfection tyrosine-kinase receptor (RET), along with many other proteins 
(Figure 1.4-B)152,176. Thus, AIP inactivation may interfere with several cell and environmental 
signals. 
The best known AIP binding partner is AHR, which is a ligand-activated transcription factor. It was 
originally described as the mediator of the toxic effects of the environmental toxin 2,3,7,8-
tetrachloro-p-dioxin (TCDD), but endogenous ligands have been described since. Upon TCDD 
binding, the cytoplasmic AHR+AIP+HSP90 complex is translocated to the nucleus, where AHR is 
released from the complex and creates a dimer with AHR nuclear translator (ARNT) to bind to 
xenobiotic response element regions of DNA. The role of AHR may include regulation of the 
activity of other nuclear receptors, transcription factors and protein kinases, leading to changes 
in cell cycle, adhesion, migration and intracellular signaling152,177. However, AHR involvement in 
pituitary tumourigenesis is unclear. AHR knockout mice do not develop PAs179-182. AHR promotes 
the cell cycle in the absence of ligand binding183 and interacts with cyclin D1 and CDK4 in breast 
cancer cells 184. AIPmut PAs have decreased AHR and ARNT levels, whereas the AHR repressor is 
overexpressed in sporadic somatotrophinomas185,186. Genetic variants in AHR pathway might be 
associated with larger somatotrophinomas and SSA resistance in polluted areas56, but further 
studies are needed to confirm these data.  
 cAMP-PKA pathway disruption is important for somatotroph tumourigenesis as seen in CNC and 
McCune-Albright syndrome85. AIP interacts with PDE4A5, an enzyme involved in the inactivation 
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of cAMP, and AIP mutations lead to the loss of this AIP-PDE4A5 interaction156,187. AIP deficiency 
causes a dysfunction in cAMP signalling, elevating cAMP concentrations through defective Gαi-2 
and Gαi-3 proteins, which normally inhibit cAMP synthesis. Additionally, immunostaining of Gαi-
2 showed that AIP deficiency is associated with decreased Gαi-2 protein expression in human and 
mouse GH-secreting PAs highlighting a defective Gαi signaling. Thus, failure to inhibit cAMP 
synthesis through dysfunctional Gαi signaling may explain the development of AIPmut 
somatotrophinomas188. There are other mechanisms potentially involved in AIP-related pituitary 
tumourigenesis (Figure 1.4-B), particularly those related to the Survivin and RET pathways189.  
It is postulated that in AIPmut PAs, AIP loses the ability to bind its partners, and thus loses its 
activity as tumour suppressor152,154,176. The role of AIP as tumour suppressor gene is supported by 
the association of several loss-of-function mutations with the development of PAs and the 
presence of loss of heterozygosity in 11q13 in AIPmut PAs19. Heterozygote AIP knockout mice 
develop GH-secreting PAs, with 100% penetrance by the age of 18 months, which differs from the 
wild-type mice where only around one third spontaneously developed prolactinomas but no 
somatotrophinomas190. Moreover, AIP overexpression decreases cell proliferation while AIP 
knockdown increases156,162,185,186, with AIPmut PAs displaying low AIP expression156,186. Enhanced 
proteasomal degradation is one of the pathogenic mechanisms for most AIP missense mutations 
and the nonsense p.R304* mutation191.  
More than 100 AIP gene variants are described, including insertions, deletions, single nucleotide 
polymorphisms, nonsense and missense mutations, duplications, promoter and splice-site 
mutations and large genomic deletions. Truncating mutations account for most AIP mutations, 
and around 70% of all known AIP mutations cause a disruption in the C-terminus91,152. The most 
common mutation site is p.R304 locus (R304*)91,152. The R304* site is a mutational hotspot and 
has been identified independently in several countries. One of these represent a founder mutation 
in Ireland192, as the same haplotype including the p.R304* mutation was found in several Irish 
families, including in a ‘giant’ from the 18th century192,193. Other hotspots are in codons R81 and 
R271110,153,194,195.  
 
GPR101 duplication in X-linked acrogigantism 
X-linked acrogigantism (XLAG) syndrome was identified in patients with very young-onset 
gigantism and PA or hyperplasia93, and is responsible for 10% of pituitary gigantism cases92,196. 
XLAG is caused by microduplications of the orphan G-protein coupled receptor GPR101 located at 
the Xq26.3 locus93. Most patients with XLAG syndrome have been reported as having sporadic de 
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novo duplications with a few having familial germline Xq26.3 microduplications196-198. In addition, 
mosaic mutations have been described in males92,198,199. 
XLAG syndrome clinical features are striking, with the cardinal manifestation being rapid growth 
(gigantism) starting at a very early age, between the age of 1-24 months92,196,197. Other features 
include: acral enlargement, coarsen facies, increased appetite, and less frequently sleep apnea, 
hyperhidrosis, acanthosis nigricans and/or abdominal distension196,197,200.  
Patients with XLAG may develop pituitary macroadenomas, but some have isolated hyperplasia 
or hyperplasia combined with PA, together with marked GH and IGF-1 elevations. 
Hyperprolactinaemia accompanies GH elevations in 85% of cases92. Histologically, most XLAG-
related PAs are mixed somatotroph and lactotroph adenomas containing both densely and 
sparsely granulated somatotrophs, and usually have a low Ki-67 and negligible mitotic counts92.  
 
CABLES1 mutation-positive FIPA 
Four out of 181 (2.2%) patients with Cushing´s disease due ACTH-secreting PAs were identified 
with germline mutations in CABLES1 gene94. Although further studies are needed to establish the 
role of CABLES1 gene in corticotrophinomas, it has been postulated that CABLES1 is a tumour 
suppressor gene that negatively regulates cell cycle by inactivating several CDKs and may also 
interfere with the signalling pathway of the epidermal growth factor (EGF)94,201. All 4 reported 
patients were affected with large corticotrophinomas with a high Ki-67 and difficult to manage94. 
 
CDH23 mutation-positive FIPA 
Recently, germline mutations in the CDH23 gene, encoding the protein cadherin-related 23 which 
display functions in cell-cell interactions and adhesion, were associated with familial and sporadic 
PAs, suggesting the involvement of CDH23 in the PA pathogenesis. A kindred with 4 members with 
PAs and 17 asymptomatic members underwent whole-exome sequencing, which identified the 
co-segregation of PA phenotype with a heterozygous CDH23 missense mutation, predicted to 
impair cell-cell adhesion. Genomic screening was then performed in 12 FIPA families, in 125 
patients with sporadic PAs and in 260 healthy controls, with functional CDH23 variants being 
identified in 33, 12 and 0.8% of the cases in each group, respectively95. However, CDH23 is a large 
gene associated with the Usher syndrome leading to deafness and none of the patients reported 
had deafness202; there is no known association between deafness and PAs, thus further research 
focusing on this genetic defect is needed.  
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FIPA with undetermined genetic cause 
AIP mutation-negative (AIPneg) FIPA display age of onset similar to sporadic PAs, while tumour 
behaviour is often more aggressive. The penetrance is incomplete, even lower than in AIPmut 
kindreds. The distribution of PAs types in AIPneg FIPA kindreds is heterogeneous (Figure 1.5)19. 
Genetic and clinical screening of AIPneg PA families is controversial. Several PAs have been 
prospectively-diagnosed in AIPneg FIPA families, thus education for PA symptoms should be given, 
and eventually baseline screening and follow-up can be considered in some cases. As PA are 
relatively common, there is a possibility that some AIPneg FIPAs might be coincidental203 or due 
to unknown complex pituitary-related mutant gene(s)19. 
 
 
Figure 1.5: Distribution of PA types in AIPneg FIPA kindreds 
Examples of the most commonly found AIP mutation-negative FIPA family trees, with representative 
percentage proportions in a cohort of 179 AIPneg kindreds. Adapted from Marques & Korbonits (2017)19. 
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1.4  Tumour microenvironment (TME) 
Tumours are more than just a mass of malignant cells, but rather they are a complex and 
heterogeneous conjunction of tumour and non-tumoural cells (such as immune and stromal cells), 
together with enzymes, growth factors and cytokines within the local extracellular matrix (ECM), 
which form the basis of the so-called tumour microenvironment (TME) (Figure 1.6)204.  
Figure 1.6: The tumour microenvironment 
Adapted from Balkwill et al. (2012)204. 
The TME concept emerged in 1989, when Stephen Paget proposed the “seed and soil” theoretical 
hypothesis based on his observations, on an autopsy series of 735 breast tumours, in which 32.8% 
of patients had liver metastasis and only 2.3% had spleen metastasis205. This non-random pattern 
of metastasis suggested that some tumours have a specific affinity for certain organs. Paget 
described tumour cells (with metastatic ability) as the “seed” and the host microenvironment 
(organs providing advantage for “seeds to grow”) as the “soil”, and their interaction crucial for 
disseminated tumour cells to grow205. A current perspective of “seed and soil” hypothesis includes 
three principles: 1) neoplasms consist of both tumour and host cells, which are heterogeneous 
and contain populations of cells with different metastatic properties; 2) the metastatic process is 
selective, favouring growth and survival of a cell population from primary neoplasm; 3) metastases 
can only develop in specific organs, given that the TME from different organs (“soil”) are 
biologically unique, and may influence behaviour of metastases206. 
TME has emerged as a key modulator of tumour initiation, progression, invasion and therapy 
responses207,208. The TME is determined by the surrounding cells including inflammatory (such as 
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macrophages or lymphocytes), stromal (such as fibroblasts), endothelial cells and pericytes (Figure 
1.6), and is well-known that tumour cells and non-tumour cells influence each other207. The 
communication between different cells in the TME is driven by a complex network of cytokines, 
growth factors and matrix-remodelling enzymes204,209-211. In cancer, cytokines and chemokines and 
their receptors are essential TME elements, promoting cell trafficking and contributing to the 
phenotype of tumour-associated immune and stromal cells, angiogenesis, invasion and 
metastatisation processes209.  
1.5  The cytokine network in pituitary adenomas 
Cytokines: structure, receptors, pathways, biological functions and role in cancer 
Cytokines are soluble peptide mediators controlling autocrine or paracrine communications 
within and between individual cell types, playing important roles in immunity, inflammation, 
repair, cell growth and differentiation, as well as in tissue homeostasis212. Cytokines are small 
(around 150 amino-acids) but extremely potent peptides, pleiotropic in nature, meaning that they 
are produced by different cells and act on multiple cell types (Table 2). Another recognised 
cytokine property is redundancy, i.e. multiple cytokines can exert similar actions213. Cytokines may 
act, in paracrine or autocrine ways, on the same cells in which they are produced214. Cytokines are 
generally produced by haematopoietic or inflammatory cells, but other cell types can also produce 
them including cells of the endocrine system215. Cytokines are secreted or expressed directly in 
the cell membrane or accumulate in the ECM. Cytokine expression is usually induced by infectious 
agents, toxic stress, or other stress-induced molecules, and may occur both transcriptionally as 
well as by precursor processing216. However, cellular cytokine reservoirs cytoplasmic granules are 
available for rapid release in response to stimulation216.  
Cytokines are traditionally classified regarding their immune response nature, i.e. grouped by their 
pro-inflammatory or by their anti-inflammatory actions on adaptive immune system cells (Table 
1.2)213,217,218. Cytokines can also be classified according to their main source, target cells or their 
specific roles (Table 1.2)213,217. T lymphocytes, namely those expressing CD4 (known as T helper 
cells), are a crucial source of cytokines during inflammatory processes. T-cell derived cytokines are 
often categorised as Th1 or Th2 cytokines depending on their effect in inflammatory responses: 
Th1 cytokines, such as interferon gamma (IFNγ) and interleukin (IL)-2, are pro-inflammatory, 
leading to neutrophil/macrophage activation, viral immunity by killing intracellular parasites and 
perpetuating inflammation; Th2 cytokines (IL-4, IL-5, IL-10, IL-13) are anti-inflammatory, 
counteracting Th1 responses, and they are also associated to humoral responses213,217.  
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Classification of cytokines by immune response 
Immune response Members 
Adaptive 
immunity 
IL-2, IL-3, IL-4, IL-5, IL-7, IL-9, IL-13, IL-15, IL-21, GM-CSF, G-CSF, M-CSF, EPO, TSLP 
Pro-inflammatory 
signalling 
IL-1 (IL-1α, IL-1β, IL-1ra), IL-6, IL-11, IL-17A, IL-18, IL-25, IL-31, IL-33, IL-36, IL-36ra, IL-37, 
IFNα, IFNβ, IFNγ, IFNλ, IFNκ, TNFα, TNFβ, CNTF, CT-1, LIF, OPN, OSM, Limitin 
Anti-inflammatory 
signalling 
IL-10, IL-12, IL-19, IL-20, IL-21, IL-22, IL-24, IL-26, IL-27, IL-28, IL-29, IL-35 
Classification of cytokines by main source, target cell and primary function 
Family Cytokine Main source Target cell Primary function 
 
 
 
 
 
 
 
 
 
 
 
Interleukins 
IL-1 M, DC, B 
cells 
B, NK and T cells Pyrogenic, pro-inflammatory, proliferation, 
differentiation, angiogenic 
IL-2 T cells B, NK and T cells Proliferation, cell activation (Th1 cytokine) 
IL-3 T cells, NK 
cells 
B and T cells, SC Haematopoietic precursor proliferation and 
differentiation 
IL-4 Th cells B cells, T cells, 
M 
Proliferation of B and T cells, stimulation of IgG and 
IgE production, enhances MHC class II expression 
IL-6 Th cells, 
fibroblasts, 
M 
Activated B 
cells, plasma 
cells 
Differentiation into plasma cells, IgG production, 
pro-inflammatory, proliferation (Th1 cytokine), 
angiogenic 
IL-7 BM stromal 
cells, EC 
SC B and T cell growth factor, thymocyte growth, 
survival T cells, haematopoiesis 
IL-8 M Neutrophils Chemotaxis, pro-inflammatory 
IL-9 T cells T cell Cell growth and proliferation 
IL-10 T cells M, B cells Inhibits cytokine production and mononuclear cell 
function, anti-inflammatory (Th2 cytokine) 
IL-11 BM stromal 
cells 
B cells Differentiation, induction of acute phase proteins 
IL-12 T cells NK cells Activation of NK cells, pro-inflammatory (Th1 
cytokine) 
IL-13 T cells M, B cells Inhibits cytokine production and mononuclear cell 
function, anti-inflammatory (Th2 cytokine) 
IL-15 Monocytes T, NK and mast 
cells 
Mast cell growth, NK cell development and activity, 
T cell proliferation 
IL-18 T cells B, NK and T cells Proliferation, cell activation (Th1 cytokine) 
IL-21 T cells B cells Inhibits B cell proliferation 
Tumour 
necrosis 
factors 
TNF-α M, 
monocytes 
M, tumour cells Phagocyte cell activation, endotoxic shock, Tumour 
cytotoxicity 
TNF-β T cells Phagocytes, 
tumour cells 
Chemotaxis, phagocytosis, oncostatic, induction of 
other cytokines 
 
Interferons 
IFN-α Leukocytes Various Anti-viral, anti-angiogenic 
IFN-β Fibroblasts Various Anti-viral, anti-proliferative, anti-angiogenic 
IFN-γ T cells Various Anti-viral, macrophage activation, increase 
neutrophil function, increase expression of MHC 
 
Colony 
stimulating 
factors 
G-CSF Fibroblasts, 
endothelial 
cells 
SC in BM Granulocyte production 
GM-CSF T cells, M, 
fibroblasts  
SC in BM Granulocytes, monocytes and eosinophils 
production 
M-CSF Fibroblasts, 
endothelial 
cells 
SC in BM Monocyte production and activation 
EPO Endothelial 
cells 
SC in BM Red blood cell production 
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Others 
TGF-β T and B cells Activated T and 
B cells 
Inhibit T and B cell proliferation, inhibit 
haematopoiesis, promotes fibrosis and wound 
healing 
FGF Various Fibroblasts Angiogenic, promotes fibrosis and wound healing, 
cell proliferation and differentiation, fibroblast 
proliferation 
VEGF Various Endothelium Angiogenic, lymphangiogenesis, chemotaxis 
Table 1.2: Classification of cytokines  
BM, bone marrow; CNTF, ciliary neurotrophic factor; CT-1, cardiotrophin-1; DC, dendritic cells; EC, epithelial 
cells; EPO, erythropoietin; FGF, fibroblast growth factor; G-CSF, granulocyte-colony stimulating factor; GM-
CSF, granulocyte macrophage-colony stimulating factor; IFN, interferon; Ig, immunoglobulin; IL, interleukin; 
LIF; leukaemia inhibitory factor; M, macrophage; M-CSF, macrophage-colony stimulating factor; MHC, 
major histocompatibility complex; NK, natural killer; OPN, osteopontin; OSM, oncostatin; SC, stem cells; 
TGF, transforming growth factor; TNF, tumour necrosis factor; TSLP, thymic stromal lymphopoietin; VEGF, 
vascular endothelial growth factor.  
 
Cell surface cytokine receptors belong to the tyrosine kinase receptors family, usually grouped in 
4 large families of receptors (types I-IV)214, which are linked to intracellular pathways that impact 
on nuclear transcriptional events213. Several cytokine pathways are described213,218, with janus-
activated kinase (JAK)-signal transducer and activator of transcription (STAT), nuclear factor-kβ 
(NF-kβ) or hypoxia-inducible factor 1α (HIF-1α) pathways being particularly relevant in cancer and 
inflammation (Figure 1.7-A)210,219. In cancer, cytokines coordinate host responses against cancer, 
but also they can promote tumour growth, invasion, neovascularisation, ECM remodelling, host 
immunosuppression and survival of tumour cells (Figure 1.7-B)212,220-222. 
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Figure 1.7: Relationship between cytokines, inflammation and cancer  
A) Connections between inflammation and cancer. Chronic inflammation and/or inflammatory cells may 
induce a transformation in the epithelial cells, including leading to a genetic event that cause neoplasia 
(such as oncogene activation by mutation, chromosomal rearrangement or amplification, or also tumour 
suppression genes inactivation). Tumour cells acquire specific properties including the capacity to produce 
inflammatory mediators (cytokines, chemokines and growth factors), thereby generating/modulating the 
inflammatory surrounding tumour microenvironment (TME). Following activation of certain transcription 
factors, mainly the JAK-STAT, NF-kβ and hypoxia-inducible factor 1α, cytokines are produced and secreted 
in the TME, and in turn they can themselves stimulate transcription of such factors amplifying the cancer-
related inflammatory and subsequently tumour cell behaviour and aggressiveness. B) Signal transduction 
pathways and major biological responses of inflammation-modulating cytokines in cancer. The pathways 
shown in the figure are some of the main cytokine-related cancer signalling pathways and demonstrate how 
cytokines can control tumour development, either directly in tumour cells or indirectly through immune or 
endothelial cells. gp130, glycoprotein 130; IKK, Ikβ kinase; JAK, Janus activated kinase; NF-kβ, nuclear factor- 
kβ; STAT, signal transducer and activator of transcription; TRAF, TNF receptor–associated factor 2; TYK2, 
tyrosine kinase 2. Adapted from Mantovani et al. (2008)222 and Lin & Karin (2007)219. 
 
 
Chemokines: structure, receptors, pathways, biological functions and role in cancer 
Chemokines are a group of small cytokines that act together with their cell surface receptors in 
normal physiology and immune responses, directing cells to specific locations in the body. 
Chemokines control the movement of immune and non-immune cells, immune system 
development, normal haematopoiesis, cell growth, neovascularisation, ECM remodelling and 
inflammatory responses, and they also regulate embryo implantation and organogenesis209,212.  
Chemokines are small peptides that possess conserved amino-acids important for their tertiary 
structure, such as the four cysteines that interact with each other in pairs to create their 
typical Greek key shape. Intramolecular disulphide bonds typically join the first to third, and the 
second to fourth cysteine residues, numbered as they appear in the chemokine protein sequence. 
Chemokines are divided into four families based on the number and spacing of the cysteine 
residues in the N-terminus as C, CXC, CC and CX3C (Figure 1.8)209,212. 
Chemokine receptors are G protein-coupled receptors usually found on the leucocyte surface, but 
not exclusively. In general, several chemokines can bind to one receptor, and conversely, a given 
chemokine may recognise more than one receptor, hence there is redundancy in the chemokine 
system223. Approximately 19 chemokine receptors have been characterised to date, which are 
divided into 4 families depending on binding chemokine type: CXCR binds CXC chemokines, CCR 
binds CC chemokines, CX3CR1  binds only CX3CL1, and XCR1  binds the two XC chemokines (XCL1 
and XCL2) (Figure 1.8)224,225. Chemokine receptor activation leads to 2 main responses: 1) integrin 
activation, which causes adhesion of the cells, and 2) polarisation of the actin cytoskeleton by 
accumulation of small GTPases at the leading edge resulting in actin polymerisation and F-actin 
formation209. 
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Figure 1.8: Chemokine general structures and classes 
Chemokines possesses conserved amino-acids important for their tertiary structure, creating their typical 
Greek key shape. The chemokine wheel shows the major constituents of the chemokine system. 
“Inflammatory” chemokines are inducible and involved in all processes of immune response. “Homeostatic” 
chemokines are usually involved in the development and in normal physiological processes. “Atypical” 
chemokine receptors are generally silent and can act negatively in the regulation of different systems. 
“Viral” chemokine and their respective receptors allow pathogens to modulate immune responses following 
an infection. Inflammatory, homeostatic and atypical chemokines can be found in the tumour 
microenvironment. Adapted from Bestebroer et al. (2010)225, and Balkwill (2012)209. 
 
Chemokine system dysfunction is involved in many diseases, including immunodeficiency, 
autoimmune or chronic inflammatory disorders, neurodegenerative diseases and cancer211. The 
role of chemokines and their receptors has been well demonstrated in many cancers, such as in 
breast, prostate, melanoma, oesophageal, lung, bladder and pancreas cancer209,226, and also in 
some endocrine tumours such as thyroid cancer227; however, remains largely unexplored in PAs. 
In cancer, chemokines are produced by malignant and stromal cells in the TME, contributing to 
cell trafficking, angiogenesis, modulation of immune cells and survival of malignant cells. 
Chemokines are highly soluble in the ECM or become immobilised on the cell surfaces, creating a 
concentration gradient essential for cell trafficking into and out of the TME227. Tumour cell or 
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stromal cell-derived chemokines lead to the recruitment of immune cells such leukocytes or 
monocytes/macrophages, which in turn influence the phenotype, proliferation, survival, 
migratory and invasive properties of tumour cells209. In general, CC chemokines attract cells of 
myeloid lineage, dendritic cells, natural killer (NK) cells, mast cells and basophils, whereas CXC 
chemokines attract mainly neutrophils and B or T lymphocytes. Thus, chemokines are important 
contributors to the inflammatory milieu, regulating the amount of inflammatory cells in the TME 
and their activity209. 
In tumour cells, certain oncogenic changes are known to modulate the chemokine system: in some 
cancers, there is an overexpression of certain chemokines, leading to increased inflammatory cell 
content and a deleterious TME, whereas in other tumours downregulation of certain chemokines 
impair immune cytotoxic responses against tumour cells209,227. Several oncogenes, such as the 
tyrosine kinase RET in papillary thyroid cancer or beta-catenin in breast cancer, activate a 
transcriptional profile which includes cytokines and chemokines209,210,228. Tumour cells often 
acquire chemokine receptors, not found in their normal counterparts, which contribute to their 
migratory and metastatic activity, as then malignant cells respond to chemokine gradients at 
metastasis sites209.  
Chemokine receptor activation in tumour cells may also lead to activation of signalling pathways, 
such as tyrosine kinase receptors and the JAK–STAT pathway, relevant for proliferation and 
survival of tumour cells209. Chemokines are also important for angiogenesis, regulating different 
mechanisms such as endothelial cell proliferation, the release of angiogenic factors, activation of 
metalloproteases involved in ECM degradation, and recruitment of angiogenic cells (such as 
macrophages, fibroblasts or endothelial cells) into the TME209,222,226,228,229.  
 
 
Cytokine-chemokine network in the normal pituitary 
Cytokines and chemokines play important roles in pituitary function and physiology, affecting not 
only the hormone secretion but also cell proliferation. The effects of cytokines in the pituitary 
have been extensively investigated214,216,230. The pituitary gland is not only an important target of 
cytokines, but is itself a site of cytokine production215. A summary of the expression and effects of 
the most studied cytokines/chemokines and their receptors in the NP, as well as in human PAs 
and pituitary tumour cell lines is provided in the Table 1.3. 
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Cytokine Expression 
and effects 
Normal 
human 
pituitary 
Normal rat (R) / mouse (M) 
pituitary 
Human pituitary 
adenoma 
Pituitary adenoma cell lines 
IL-1 
Expression ND IL-1β, IL-1ra (R,M), higher after 
LPS 
Yes ND 
Receptors ND IL-1β receptor (R,M) ND IL-1β receptor in AtT-20 cells 
Proliferation ND IL-1 inhibits, effect reverted by IL-
1ra (R,M). IL-1β stimulates (R) 
ND Stimulates in AtT-20 cells 
No effect in GH3 cells 
Hormone 
secretion 
ND IL-1β stimulates ACTH, GH, LH 
and TSH, while inhibits PRL (R) 
IL-1α has no effect on ACTH (R) 
Stimulates ACTH in 
corticotroph cell 
cultures 
Stimulates GH in GH3 cells 
IL-1β increase CRH-stimulated 
ACTH in AtT-20 cells 
IL-2 
Expression/ 
Production 
Yes ND In 
corticotrophinomas 
Expressed by both AtT-20 and 
GH3 cells 
Receptors IL-2 receptor 
present 
IL-2 receptor (R) IL-2 receptor 
present 
IL-2 receptor present in AtT-20 
and GH3 cells 
Proliferation ND Inhibits (R) ND Stimulates in both GH3 and 
AtT-20 cells 
Hormone 
secretion 
ND Stimulates ACTH, TSH, PRL (R) 
Inhibits GH, FSH, LH (R) 
ND Stimulates PRL in GH3 cells, 
and ACTH in AtT-20 cells 
IL-6 
Expression/ 
Production 
Yes (ACTH 
and LH/FSH 
cells) 
Yes, and expression stimulated by 
LPS, IFN, TNF-α, PACAP, VIP (R) 
Expression in all PA 
types, mainly 
ACTH- and GH-PAs 
ND 
Receptors IL-6 receptor 
present 
IL-6 receptor (R) Mainly in ACTH- 
and GH-PAs 
ND 
Proliferation ND Inhibits (R) Stimulates Stimulates in GH3 cells 
Hormone 
secretion 
Stimulates 
GH, PRL 
Inhibits TSH 
Stimulates ACTH, PRL, GH, LH, 
FSH (R) 
Stimulates GH in 
GH-PAs, and ACTH 
in ACTH-PAs 
Stimulates GH, PRL in GH3 
cells, and ACTH in AtT-20 cells 
TNF-α 
Expression/ 
Production 
ND ND Yes Expressed by both AtT-20 and 
GH3 cells 
Receptors ND Binding sites detected (R,M) ND Binding sites in AtT-20 cells 
Proliferation ND Inhibits (R) ND ND 
Hormone 
secretion 
Activates the 
PRL promoter 
Stimulates ACTH, GH, TSH in 
hemipituitary cultures. Chronic  
exposure to TNF-α inhibits GH, 
PRL, TSH (R) 
ND ND 
IFN-γ 
Expression/ 
Production 
ND ND ND ND 
Receptors IFNγ R1/2 in 
ACTH cells 
ND IFNγ R1/2 in 
corticotrophinomas 
IFNγ R1/2 expressed in AtT-20 
cells 
Proliferation ND ND ND Inhibits in AtT-20 cells 
Hormone 
secretion 
ND Inhibits ACTH and GH 
Stimulates PRL (via IL-6) 
Inhibits ACTH in 
corticotrophinomas 
Inhibits ACTH in AtT-20 cells 
LIF 
Expression/ 
Production 
Yes Yes, present in rat explants, and 
induced in mouse by LPS 
Mainly in GH and 
ACTH-secreting PAs 
ND 
Receptors Yes LIF receptor induced by LPS (M) Yes Receptor present in AtT-20 
cells 
Proliferation ND Stimulates corticotrophs, inhibits 
somatotrophs in a transgenic 
mice overexpressing LIF 
ND Inhibits in AtT-20 cells 
Hormone 
secretion 
ND ND ND Stimulates ACTH in AtT-20 
cells 
MIF 
Expression/ 
Production 
Yes ND Yes, higher than in 
NP 
ND 
Receptors ND ND ND ND 
Proliferation ND ND ND ND 
Hormone 
secretion 
ND ND ND ND 
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TGF-β 
Expression/ 
Production 
TGF-β1, β2 
and β3 in 
lactotrophs 
ND Yes, TGF-β1, TGF-
β2 and TGF-β3 
present 
ND 
Receptors TGF-β-R-II TGF-β-R-II (R) TGF-β-R-II present 
in different PAs 
TGF-β receptor described in 
GH3 cells 
Proliferation ND Inhibits in oestrogen-treated rats Inhibits Inhibits in GH3 and GH4 cells 
Hormone 
secretion 
ND Inhibits PRL (M) TGF-β1 inhibits/ 
stimulates FSH at 
high/low 
concentrations 
ND 
 
 
 
BMP-4 
Expression/ 
Production 
Yes Increased in oestrogen-treated 
rats; present in DA-R knockout 
mice 
Higher in 
prolactinomas 
Lower in 
corticotrophinomas 
ND 
Receptors ND ND ND ND 
Proliferation ND ND ND Stimulates in GH3 cells 
Inhibits in AtT-20 cells 
Hormone 
secretion 
ND ND ND Inhibits ACTH in AtT-20 cells 
 
 
 
 
CXCL12 
Expression/ 
Production 
Yes, mostly in 
corticotrophs, 
also in FS 
cells 
Yes (R) Yes, higher than in 
NP 
Expressed by AtT-20 cells, but 
not by GH3 and GH4 cells 
Receptors CXCR4 in 
around 34% 
pituitary cells 
CXCR4 present in normal rat 
pituitary, and also in embryonic 
mouse pituitary 
CXCR4 present 
CXCR7 present 
CXCR4 both present in AtT-20 
and GH3 and GH4 cells  
CXCR7 present in AtT-20 cells 
Proliferation ND ND Stimulates Stimulates in GH3 and GH4 
cells, and in AtT-20 cells 
Hormone 
secretion 
ND Stimulates GH (R) 
 
ND Stimulates GH in GH3 cells, 
and GH, PRL in GH4 cells 
 
 
IL-8 
Expression Not 
expressed 
ND Yes, in different PA 
types 
ND 
Receptors CXCR2 
present 
CXCR2 present (R) CXCR2 present ND 
Proliferation ND ND ND ND 
Hormone 
secretion 
ND Inhibits FSH, LH (R) ND ND 
 
 
CXCL1 
Expression ND Yes (R) Yes ND 
Receptors CXCR2 
present 
CXCR2 present (R) CXCR2 present ND 
Proliferation ND ND ND ND 
Hormone 
secretion 
ND Stimulates PRL, GH and ACTH (R) 
Inhibits FSH and LH (R) 
ND ND 
 
 
CXCL10 
Expression ND CXCL10 expressed in FS cells (R) ND ND 
Receptors ND CXCR3, TLR4 in ACTH cells (R) ND ND 
Proliferation ND ND ND ND 
Hormone 
secretion 
ND ND ND ND 
Table 1.3: Cytokines and their receptors in normal and neoplastic pituitary 
Expression and effects of cytokines and their receptors on human, rat and mouse normal pituitary, as well 
as in human pituitary adenomas and pituitary adenoma cell lines (mouse corticotrophinoma AtT-20 cells 
and rat somatomammotroph adenoma GH3/GH4 cells)211,214,215,223,230,231 
BMP-4, bone morphogenetic protein-4; CRH, corticotropin-releasing hormone; DA-R, dopamine receptor; 
FS, folliculo-stellate; IFNγ, interferon-γ; IL, interleukin; IL-1ra, interleukin-1 receptor antagonist; LIF, 
leukemia inhibitory factor; LPS, lipopolysaccharide; MIF, macrophage migration inhibitory factor; ND, not 
determined; NP, normal pituitary; PA, pituitary adenoma; PACAP, pituitary adenylate cyclase-activating 
polypeptide; TGF-β, transforming growth factor-β; TLR4, toll-like receptor-4; TNF-α, tumour necrosis factor-
α; VIP, vasoactive intestinal peptide. 
56 
 
Cytokine-chemokine network in the neoplastic pituitary 
The cytokine network may play key roles in PAs, affecting not only their hormone secretion, but 
also different intrinsic tumourigenic mechanisms such as angiogenesis, invasion, proliferation and 
modulation of the TME and immune cell infiltrates (Figure 1.9). 
 
Figure 1.9: Cytokine network role in different tumourigenic mechanisms in PAs 
Grizzi et al. (2015)211.  
 
However, in contrast to the extensive available data regarding cytokines in the NP, the amount of 
studies exploring the cytokine network in pituitary tumours is remarkably scarce. Nevertheless, 
some cytokines, chemokines and growth factors have been investigated in PAs, particularly IL-8, 
IL-6, IL-1, CXCL12, transforming growth factor-β (TGF-β), tumour necrosis factor-α (TNF-α), VEGF, 
as summarised in the Table 1.3 and described in detail below. 
 
IL-8 (or CXCL8) 
In 1996, Green et al. reported one of the first studies exploring the cytokine expression profile in 
17 human PAs, using RT-PCR to identify the presence of mRNA of the following cytokines: IL-1α, 
IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, TNF-α, TNF-β, TGF-β1, TGF-β2 and TGF-β3. All PAs expressed 
IL-8 and none expressed IL-2, IL-5 or IL-7, suggesting that IL-8 may be important for pituitary 
tumourigenesis. IL-6 was expressed in all 4 somatotrophinomas, 3/7 NFPAs, 2/4 prolactinomas 
and in the corticotrophinoma case. At least one TGF-β isoform was found in all but 2 PAs, while 
IL-1α, IL-β, IL-4, TNF-α and TNF-β were sporadically expressed232.  
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In 1999, Suliman et al. studied IL-8 expression in 25 human PAs and 2 NPs using in situ 
hybridisation. IL-8 mRNA was not identified in 2 NP specimens, and only 12% of PAs (3/25) were 
positive for IL-8 mRNA. There was no difference in size, type or degree of vascularisation between 
IL-8 positive and IL-8 negative PAs233. These findings contrast with those earlier reported232, likely 
due to different study methods or due to PA heterogeneity. 
Later in 2011, Vindelov et al. shown that IL-8, and also IL-6, are secreted from primary human 
somatotroph adenoma cells in significant concentrations and in a constant manner; GHRH and 
somatostatin were shown to inhibit IL-8 and IL-6 secretion, while IL-1β stimulated the secretion 
of IL-8, IL-6 and also GH234. Such findings confirmed a physiological relation between endocrine 
cells and cytokines reflecting their possible involvement in pituitary tumourigenesis, as well as a 
potential therapeutical effect of drugs targeting the cytokine network in acromegaly. 
Recently, Salomon et al. contrasted RNAseq data from 7 recurrent and 23 non-recurrent PAs 
identifying 68 genes that were significantly differentially expressed. Of these, genes involved in 
chemokine receptor binding were highly enriched in recurrent PAs particularly those integrating 
the IL-8 pathway (IL8, CXCR1 and CXCR2)235, suggesting the IL-8 involvement in PA aggressiveness 
and/or resistance to treatment, as well-known in other cancers236.  
IL-6 
IL-6 is one of the most studied cytokines in PAs, displaying potential roles in the development, 
progression and biological behaviour of PAs. IL-6 production has been localised to folliculo-stellate 
cells in the NP, whereas in PAs is secreted by adenohypophyseal tumour cells230. IL-6 mRNA was 
detected in different PA subtypes214. Jones et al. cultured 100 human PAs and found that 53% 
expressed and secreted IL-6, synthesised by adenohypophyseal tumour cells as shown by in situ 
hybridization for IL-6 mRNA in 3 out of 4 PAs237. IL-6 and its receptor are expressed in human 
PAs238,239 more prominently in somatotrophinomas and corticotrophinomas239, as well as in a 
human pituitary cell line240.  
In rat GH3 cells, IL-6 stimulates GH and PRL release, as well as proliferation and DNA synthesis; 
however, at the same concentration IL-6 inhibited the growth of pituitary cells241. In AtT-20 cells 
and human corticotrophinoma cultures, IL-6 stimulates ACTH secretion242,243. In TtT/GF and MtT/E 
cells, IL-6 stimulated growth244-246. Moreover, IL-6 enhances VEGF release230,247 and alter the 
production of matrix metalloproteinases (MMPs) by folliculo-stellate cells244,248, contributing to 
angiogenesis and ECM remodelling, and thus favouring tumour progression and invasiveness. 
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An immunohistochemical study analysed IL-6 and TNF-α expression in 40 invasive and 40 non-
invasive PAs, both expressed mainly in the tumour cell cytoplasm. Of the invasive PA, 67.5% had 
IL-6 expression, whereas only 22.5% of non-invasive PAs stained for IL-6. Similarly, higher number 
of invasive PAs had positive TNF-α expression (65%, comparing to 25% in non-invasive PAs)249. 
These data suggest that IL-6 and TNF-α may play a role in the invasiveness of PAs. 
Paoletta et al. measured serum IL-6 and IL-1β levels in 11 Cushing´s disease patients undergoing 
bilateral inferior petrosal sinus sampling. ACTH and cytokine levels were higher in the ipsilateral 
petrosal sinus than in the contralateral one or in peripheral blood, and after CRH infusion these 
interleukins raised and correlated with stimulated ACTH levels, suggesting that central production 
of IL-6 and IL-1β can potentially be involved in autocrine-paracrine ACTH hypersecretion in 
Cushing´s disease250. However, in an earlier study including six Cushing´s disease patients, IL-6 (as 
well as IL-1α, IL-β, TNF-α and IL-2) were undetectable in most samples collected during bilateral 
inferior petrosal sinus sampling251. Shah et al. reported elevated serum IL-6 (and IL-1β) levels in 
patients with active Cushing´s disease in comparison to healthy controls: these remained raised 
despite surgical remission and decrease in body mass index, insulin-resistance, visceral, hepatic 
and inter-muscular adiposity, reflecting a chronic inflammatory state in Cushing´s disease despite 
cure that may contribute to the increased cardiovascular mortality associated to this condition252. 
IL-6 has also been involved in PA senescence. A dual role of IL-6 in both pituitary tumourigenesis 
and senescence seems to be demonstrable in PAs, as IL-6 paracrine effects seems to allow initial 
pituitary cell growth, whereas the IL-6 autocrine effects in the same tumour promote senescence 
and restrains aggressive growth and malignant transformation253,254. 
 
IL-1 
IL-1 production has been demonstrated in human PAs232, and its receptor was found in NP, as well 
as in the mouse AtT-20 and rat GH3 tumour cell lines230,255. IL-1 is associated with a stimulatory 
effect on hormone secretion214,230,256, except for PRL which is inhibited by IL-1230,231, but its effect 
in the tumourigenesis remains unknown. Some studies have also shown an inhibitory effect of IL-
1 in TSH and ACTH secretion216,257-259. IL-1’s stimulatory effect on ACTH and GH secretion was 
shown in AtT-20260 and GH3 cells261, respectively, as well as in human somatotrophinomas234. 
Patients with active acromegaly had also increased serum levels of IL-1, but not IL-6262. 
The role of IL-1 in pituitary cell proliferation and in the tumourigenesis remains controversial. IL-1 
inhibited the growth of normal rat pituitary cells215,230. However, IL-1 has been reported to show 
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no effect on GH3 cell growth263, and there is even a stimulatory effect of IL-1β on normal rat 
pituitary proliferation264. 
 
CXCL12 (and its receptors CXCR4 and CXCR7) 
CXCR4 is a key receptor in the crosstalk between tumour cells and the surrounding TME in cancer, 
and one of its ligands is CXCL12 (also known as stromal cell-derived factor-1, SDF-1)265.  
The CXCL12/CXCR4 axis has been studied in normal and neoplastic pituitary211. CXCL12 binding 
sites were first described in adult rat pituitary by an autoradiographic assay using 125I labelled 
CXCL12266. In contrast to rats, human pituitary CXCR4 expression is confined to a subset of cells, 
particularly GH, PRL and ACTH-producing cells, where its ligand CXCL12 is mostly, but not 
exclusively, found in ACTH-producing cells223,267. The expression levels of CXCR4 and CXCL12 are 
lower in NP than in human PAs268, suggesting a possible role in tumourigenesis223. Moreover, 
pituitary cells do not co-express CXCL12 or CXCR4, contrarily to what happens in PAs, reinforcing 
the involvement of this axis in PAs211,268. Horiguchi et al. also showed that CXCL12 and CXCR4 are 
expressed in S100β-protein-positive cells of the anterior pituitary, and CXCL12/CXCR4 axis 
between its cells have a role in the extension of cytoplasmic processes and interconnections269. 
Barbieri et al. showed that CXCL12 is markedly overexpressed in PAs in comparison to NP268. In 
another study, CXCR4 was highly expressed in somatotrophinomas and NFPAs270. 
In vitro studies in rat and human pituitary tumour cells supported the stimulatory effect of CXCL12 
in cell proliferation, DNA synthesis and GH secretion271-273, corroborated by the findings that a 
CXCR4 antagonist inhibits GH production and cell proliferation, and also induced GH3 cell 
apoptosis268,274. Combined treatment with CXCR4 antagonist and octreotide was more effective in 
inhibiting somatolactotroph adenoma formation274, and in another study a CXCR4 antagonist 
suppressed hypoxia-mediated GH production from GH3 cells275. These findings suggest that 
antagonising CXCR4, in isolation or in combination with SSAs, may have a role in the management 
of patients with acromegaly274.  
Xing et al. studied CXCR4 and CXCL12 expression levels in human PAs and their correlation with 
invasiveness. Flow cytometry studies showed that the percentage of CXCR4 and CXCL12-positive 
cells from invasive PAs was higher than from non-invasive counterparts, and CXCR4 and CXCL12 
staining scores were higher in invasive PAs than from non-invasive PAs276. 
CXCL12 expression was correlated with microvasculature density in PAs, suggesting that hypoxia 
may regulate this chemokine277. CXCL12 behave as an angiogenic factor in PAs, mobilising 
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endothelial progenitor cells to the tumour parenchyma under hypoxic conditions277. In vitro 
CXCL12 secretion by mouse AtT-20 cells was inversely correlated to oxygen levels, with more 
severe hypoxia degrees leading to increased CXCL12 secretion277. 
The distribution and function of another CXCL12 receptor, CXCR7, was studied in human PAs and 
AtT-20 cells278. CXCR7 is expressed in human PAs, more prominently in macroadenomas and in GH 
and PRL-secreting PAs. CXCR7 was associated with upregulation of cell cycle genes and with 
downregulation of other genes related to amino-acid metabolism and ligase activity278. 
Immunohistochemical analysis of neuroendocrine cells and their neoplastic counterparts showed 
high expression of CXCR2 in both human PAs and NP268,279. 
Transforming growth factor-β (TGF-β) 
TGF-β is expressed in most human PAs232, as well as in normal and neoplastic rat pituitary230,280. 
TGF-β has been studied in prolactinomas, in which there is a reduced expression and activity of 
TGF-β1. TGF-β inhibits lactotroph proliferation and PRL secretion280,281. The anti-proliferative 
effect of TGF-β was demonstrated in rat GH3 and GH4 cells230,282, and in the human pituitary 
tumour HP75 cell line283. Treatment of HP75 cells with TGF-β for 24 hours changed the RNA 
profiling, with a large number of genes becoming up or downregulated, some of them involved in 
cell proliferation283. 
TGF-β signalling was investigated in a study including 29 invasive NFPAs, 21 non-invasive NFPAs 
and 5 NPs. Smad3 and p-Smad3 protein levels decreased from NP, to non-invasive PAs and to 
invasive PAs. TGF-β1 mRNA level decreased while the Smad7 mRNA increased from NP to non-
invasive PAs and to invasive PAs. Moreover, proliferating cell nuclear antigen mRNA was markedly 
increased in invasive NFPAs compared to non-invasive ones and its level correlated negatively with 
Smad3 mRNA. These data suggest that TGF-β pathway may be restrained in NFPAs and can be 
associated with tumour development and invasion284. 
Gu et al. studied the expression of TGF-β receptor I and II by RT-qPCR, western blot and 
immunohistochemistry in invasive and non-invasive NFPAs. mRNA and protein levels of TGF-β 
receptor II decreased progressively from NP to non-invasive NFPAs and then to invasive NFPAs, 
while TGF-β receptor I expression levels did not differ between NP and PAs. These data suggest 
that TGF-β receptor II (but not receptor I) may contribute to the tumourigenesis and invasiveness 
of NFPAs285. 
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Tumour necrosis factor-α (TNF-α) 
TNF-α expression has been demonstrated in AtT-20 and GH3 cells286 and in human PAs232,249. TNF-
α has effects on cultured pituitary cells, blunting ACTH release and other pituitary hormones in 
response to hypothalamic factors287. However, in ovine pituitary cells TNF-α enhanced GH 
expression288, and increased ACTH, GH and TSH secretion from hemipituitaries289. TNF-α may play 
a role in PA intra-tumoural haemorrhage by upregulating VEGF and MMP-9. TNF-α administration 
caused haemorrhagic transformation and enhanced VEGF and MMP-9 expression in PA cell 
xenografts in mice290. Arita et al. found a positive relation between haemorrhage and VEGF in 
human PAs291 but other studies showed no association292,293, hence TNF-α role in PA haemorrhage 
remains unclear.  
TNF-α expression has also been correlated with PA invasiveness. Wu et al. reported more often 
TNF-α expression in invasive (65%) than in non-invasive PAs (25%)249, and later Zhu et al. observed 
higher TNF-α expression in bone-invasive than in non-invasive PAs, which together with in vitro 
data, suggested that TNF-α can induce osteoclast differentiation in bone-invasive PAs294. 
 
VEGF 
The role of VEGF in proliferation and angiogenesis has been studied in PAs295-297. McCabe et al. 
showed an increase in VEGF expression in human PAs in comparison to NP, despite PAs being less 
vascular298. VEGF expression was also associated with suprasellar extension299,300, and pituitary 
carcinomas showed stronger VEGF immunoreactivity than PAs299. VEGF expression was higher in 
dopamine agonist resistant prolactinomas than somatotrophinomas, NFPAs and 
corticotrophinomas301. However, Lloyd et al. reported decreased VEGF expression in PAs in 
comparison to NP, in keeping with the subnormal microvessel densities and PA benign 
behaviour299,302,303. Moreover, Takano et al. reported a limited role for VEGF in the development 
of vascular architecture and angiogenesis in PAs304. Lohrer et al. showed that most human PAs 
secrete VEGF, and PACAP-38, TGF-α and IGF-1 increase VEGF expression in NFPAs, 
somatotrophinomas and prolactinomas305. Patients with PAs had higher plasma VEGF levels than 
controls306.  A high proportion of GH3 cells express VEGF, which may be altered by different growth 
factors307. GH3 cell conditioned medium have 13 times higher VEGF levels than control media, 
which might explain the stimulated growth of endothelial cells after treatment with GH3 
conditioned medium308. VEGF is also produced by folliculo-stellate cells and by lactotrophs within 
the normal anterior pituitary, and its secretion can be influenced by the ECM309. 
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Drugs targeting VEGF pathway have been used to treat aggressive or refractory PAs, namely 
bevacizumab, which can be effective as monotherapy or in combination with other treatments in 
some cases310,311 (reviewed in detail in312). Other drugs targeting VEGF have also been used but 
with minimal success312.  
 
Other cytokines, chemokines or growth factors in pituitary adenomas 
In 2011, Qiu et al. reported positivity for IL-17, IL-17R and MMP-9 expression in invasive PAs, and 
a positive correlation between IL-17 and IL-17R and MMP-9 expression levels. Moreover, higher 
serum IL-17 levels were found in patients with invasive PAs313. Qiu et al. collected blood samples 
from 75 patients with PAs, pre-operatively and at 1, 3, and 6 months after surgery, and measured 
serum IL-17, IL-4, IL-5, TNF-α, INF-γ. Serum IL-4, IL-5 and IL-17 were higher before surgery and 
decreased significantly after surgery. Pre-operative IL-17 levels were also higher in the subgroup 
with invasive PAs. Among the invasive subgroup, patients with PAs totally excised presented lower 
IL-17 than those with residual PA after surgery301,302. Glebauskiene et al. reported higher serum 
concentrations of IL-17A in 60 PA patients in comparison to 64 control subjects, but there was no 
association between IL-17A serum levels and PA invasiveness or recurrence314. These findings 
suggest that different interleukins, particularly IL-17, might be important for PA tumourigenesis 
or invasiveness313,315. 
IL-2 expression, as well as its receptor, were detected in human corticotrophinomas, in mouse 
AtT-20 and in rat GH3 cells316. They co-localize with PRL, GH and ACTH230, and it was shown that 
IL-2 may influence the secretion of these hormones317,318, as well as stimulate the growth of 
human somatotrophinoma and GH3 cells241,319. However, IL-2 expression was not shown in all 
studies, with some reporting absent IL-2 expression among all PAs studied232.  
Cannavo et al. reported higher serum IL-22 in subjects with PAs, and patients with prolactinomas 
had significantly higher IL-22 levels than NFPAs, but no correlation was noted with size or pituitary 
dysfunction. These authors found also strong IL-22 receptor immunoreactivity in 4/4 
prolactinomas and 6/10 NFPAs320.  
IFNγ was associated with inhibition of hormonal secretion and cell proliferation214,230, as shown in 
human corticotrophinomas and mice AtT-20 cells via JAK-STAT1/NF-kβ inhibitory pathway321, or 
as also in folliculo-stellate cells322.  
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Granulocyte macrophage-colony stimulating factor (GM-CSF) derived from NFPA cells has been 
recently involved in the polarisation of macrophages into the M1-subtype and in the impairment 
of monocyte recruitment323.  
Migration inhibitory factor (MIF) is expressed in the pituitary, and its expression is increased in 
the cell nuclei in PAs; however, it is unclear whether it plays a role in the tumourigenic process324. 
 Leukaemia inhibitory factor (LIF) was detected in normal and neoplastic pituitary230,325. Specific 
LIF binding sites are found in AtT-20 cells, and LIF attenuates growth in this cells by blocking cell 
cycle progression. In terms of hormonal secretion, LIF stimulates ACTH secretion326, and inhibits 
the secretion of PRL and GH from the rat MtT/SM pituitary cell line327. Kontogeorgos et al. studied 
LIF expression in 98 PAs, reporting LIF immunopositivity in the majority of cases (92%) and in all 
PA subtypes. Prolactinomas had the highest immunostaining grade, but overall NFPAs had a 
significantly higher immunohistoscore when compared to functioning PAs328.  
Bone morphogenetic protein-4 (BMP-4) overexpression was reported in PAs, particularly 
prolactinomas329. In contrast, BMP-4 is differently expressed in normal and adenomatous 
corticotrophs and has an inhibitory action in corticotrophinoma cell proliferation330,331.  
 
1.6  Non-tumoural cells in the TME of pituitary adenomas 
Immune cells in pituitary adenomas 
Macrophages 
Macrophages are innate immune cells that play important roles in tissue homeostasis, responses 
to pathogens, presentation of foreign or self-antigens to immune cells, phagocytosis, 
inflammatory reactions, inflammation resolution and wound healing. Macrophages exist in almost 
all tissues, usually resulting from the differentiation of blood monocytes, but there are also tissue 
resident macrophage subpopulations, such as Langerhans cells in skin or microglia in brain332.  
Macrophages are recognised as a major component of the immune cell infiltrates in tumours and 
therefore playing a major role in the TME229. Macrophages are heterogeneous and can have 
distinct phenotypes depending on the surrounding TME. In general, two main macrophage 
phenotypes are recognised: M1 (or classically-activated) and M2 (or alternatively-activated) 
macrophages. This binominal macrophage polarisation correspond, in a simplistic way, to two 
phenotypic extremes of a continuum polarisation spectrum (Figure 1.10)229,332,333.  
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M1 and M2 macrophage types are different in terms of their biological properties, membrane 
receptors, cytokine secretome and effector functions229,332,334. M1-macrophages arise following 
stimulation with Th1 cytokines, in particular IFNγ or TNF-α, or exposure to bacterial moieties such 
as lipopolysaccharide. M2-macrophages result from direct stimuli with Th2 cytokines, particularly 
IL-4, IL-10 and IL-13, but also from other factors such TGF-β or glucocorticoids229,335.  
In terms of membrane receptors, M2-macrophages express high levels of scavenger receptors A 
and B, Mannose receptors (CD206), CD163 and CD23 (Fcε-RII), whereas in M1-macrophages these 
markers are usually not found, but others such as TLR2, TLR4 CD16, CD32, CD64, CD80 and CD86 
are normally expressed (Figure 1.10)229,335. M1-macrophages secrete high levels of 
proinflammatory cytokines such as IL-12, IL-23, IL-1, IL-6 and TNF-α, and have high concentrations 
of superoxide anions and oxygen/nitrogen radicals, agents with bactericidal and tumouricidal 
effects. In contrast, M2-macrophages produce high levels of IL-10 and IL-1 receptor antagonist (IL-
1ra), and have a predominance of the effector arginase pathway with generation of ornithine and 
polyamines which are precursors necessary for collagen synthesis, ECM remodelling and cell 
proliferation, conferring to this type functions in tissue repair, immune modulation and tumour 
progression. Polarised macrophages also tend to express different chemokines: M1-macrophages 
express higher levels of CXCL9, CXCL10, CXCL11, CCL2, CCL3, CCL4, CCL5, whereas M2-
macrophages have increased CCL16, CCL17, CCL18, CCL22 production (Figure 1.10)229,332,333.  
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Figure 1.10: M1 and M2 macrophages 
FGF, fibroblast growth factor; IFN, interferon; IL, interleukin; iNOS, inducible nitric oxide; LPS, 
lipopolysaccharide; MMP, matrix metalloproteinase; MR, mannose receptor; NO, nitric oxide; PG, 
prostaglandin; ra, receptor antagonist; ROI, reactive oxygen intermediates; TAM, tumour-associated 
macrophages; TGF, transforming growth factor; TLR, toll-like receptor; TNF, tumour necrosis factor; VEGF, 
vascular endothelial growth factor. Adapted from Mantovani et al. (2002)229. 
 
 
Both M1 and M2-macrophages have been identified in tumours. Polarised macrophages change 
their membrane markers and secretome according to the surrounding stimuli, i.e. macrophages 
can polarise in response to different stimuli present in the TME, which in turn allow them to 
modulate the inflammatory milieu of the local TME and influencing the behaviour of the tumour 
cells229,336,337. M1-macrophages usually demonstrate anti-tumour activity and are associated with 
good outcomes in cancer332,338. However, M2-macrophages are generally associated with tumour 
initiation, progression and invasiveness, angiogenesis, ECM remodelling and metastasis (Figure 
1.10), and are thus associated with poorer outcomes in cancer229,339-342. M2-macrophages may also 
directly promote epithelial-to-mesenchymal transition (EMT) through the activation of different 
pathways, such as NF-kB, TGF-β, IL-10 or FoxQ1334,335,343. 
Macrophages are present in the pituitary gland. This was first demonstrated by Hume et al. who 
identified macrophages in the anterior pituitary of mice344, and later by Mander et al. in the rat 
pituitary345. Fujiwara et al. using immunohistochemistry and electron microscopy reported M1 
and M2-macrophages in the normal rat anterior pituitary and in prolactinomas induced by 
diethylstilbestrol (DES). Most macrophages were located near capillaries in the NP, and more than 
half of the macrophages were M2-macrophages. M1 and M2-macrophages were similar in their 
structural properties, although phagosomes were only seen in the cytoplasm of M2-macrophages, 
whereas the endoplasmic reticulum and Golgi apparatus were poorly developed in M2-
macrophages. DES-induced prolactinomas had more M2-macrophages than NP, and interestingly, 
the number of M2-macrophages increased during the first 2-4 weeks of treatment with DES, 
before PA formation, supporting a potential role for M2-macrophages in the tumourigenesis346. 
Lu et al. reported CD68+ macrophage infiltration in all 35 PAs studied, with higher macrophage 
content in both sparsely-granulated somatotrophinomas and null-cell PAs in comparison to 
densely-granulated somatotrophinomas or corticotrophinomas. The number of macrophages was 
correlated with size and Knosp grades for invasiveness, i.e. macrophage-rich sparsely-granulated 
somatotrophinomas and null-cell PAs were larger and more invasive than densely-granulated 
somatotrophinomas or corticotrophinomas347. Sato et al. found more M2-macrophages in NFPAs 
with cavernous sinus invasion than in non-invasive NFPAs, but the number of infiltrating M2-
macrophages did not correlate with tumour volume348. More recently, Yagnik et al. performed 
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flow cytometry analysis of CD11b-expressing myeloid cells (precursors of macrophages) in 16 
NFPAs, and found that most CD11b-enriched NFPAs were larger and more proliferative. 
Interestingly, NFPAs with cavernous sinus invasion had a M2:M1 macrophage gene expression 
ratio>1, whereas 80% of non-invasive NFPAs showed a M2:M1 ratio<1323. M2-polarised THP-1 cells 
(monocyte cell line) conditioned medium led to increased proliferation, invasion and migration of 
primary NFPA cells compared to conditioned medium from M1-polarised THP-1 cells323. M2-
macrophage conditioned medium also increased the expression of the genes EZH2 (involved in 
cell proliferation) and S100A9 (involved in cell invasion) in primary NFPA cells323. 
These findings support an association between macrophage infiltration and PA behaviour, thus 
suggesting that macrophages may influence pituitary tumourigenesis and determine increased 
aggressiveness, as seen in neuroblastoma349, Hodgkin´s lymphoma341, breast332,350, ovarian351,352 
and prostate353 cancer, as well as in endocrine cancers such as thyroid cancer340,354 or 
neuroendocrine tumours342. 
 
Lymphocytes 
Lymphocytes are detectable in the TME or in draining lymph nodes of individuals with cancer. 
There are different tumour-infiltrating lymphocytes (TILs)204. CD8+ T lymphocytes are usually 
beneficial to the host because they are capable to initiate a cytotoxic cascade killing tumour cells. 
CD4+ T helper 1 cells usually supports cytotoxic T cells through the secretion of Th1 cytokines 
being associated with a good cancer prognosis355-357. In contrast, CD4+ T helper 2 cells produce 
immunosuppressive cytokines, such IL-4, IL-5 and IL-13, which promote tissue inflammation and 
tumour growth. A third T cell type with immunosuppressive function, so-called T regulatory cells 
(Tregs) characterised by forkhead box P3 (FOXP3) and CD25 expression, are the main sources of 
Th17 cytokines (IL-17 and IL-22). Higher Tregs content in the TME is associated with poor prognosis 
in many cancers, although in some has been linked to good outcomes204. B lymphocytes can be 
found at the invasive margin of tumours, although are more frequent in draining lymph nodes and 
lymphoid structures adjacent to the TME. B cell infiltration in the TME is usually associated with a 
good prognosis in cancer, but there has been described an immunosuppressive IL-10-secreting B 
cell population that inhibits immune responses, thereby increasing tumour aggressiveness358-361. 
Innate NK cells also infiltrate tumours and exert their tumour-killing activity, thus predicting better 
cancer outcomes. However, malignant phenotypes may induce anergic NK cells, compromising 
their cytotoxic activity204,362.  
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In contrast to autoimmune hypophysitis363-365, little data are available regarding immune infiltrates 
in PAs. One of the first studies dates from 1990, in which Rossi et al. evaluated the immune cell 
infiltrate in 28 PAs, concluding that PAs have a low degree of cellular immune response. In this 
study, CD8+ and CD4+ lymphocytes were detected in 80% and 14% of the PAs, whereas B 
lymphocytes were present in only 1 case, and NK cells were seen in 1 out of 13 cases; moreover, 
a low number of macrophages was also reported366. Another study described reduced NK cell 
activity in hyperprolactinaemic patients in comparison to bromocriptine-treated prolactinoma 
patients and healthy controls367. In another older study was reported a higher percentage of B 
cells in prolactinoma patients than in healthy subjects; in contrast, there were no differences 
regarding total T or suppressor T cells between these groups368. Later in 1998, Heshmati et al. 
reported that lymphocytic infiltrates are rare in a large series of PAs. In this study, lymphocytic 
infiltrates were stained for LCA (leukocyte common antigen), CD45RO (T cell marker) and CD20 (B 
cell marker), which were present in only 40 out of 1400 PAs and were almost exclusively T cells369.  
More recently, in a study investigating lymphocyte infiltrates in different brain tumours, it was 
noted that PAs, as well as benign meningiomas, had no infiltration of Tregs, in contrast to 
malignant tumours which exhibited remarkable infiltrates as well as increased circulating levels of 
these cells370. Lupi et al. studied TILs in patients with PAs, and reported a higher prevalence of TILs 
in PAs (25%), mostly mild infiltrations. There was no difference among the PA types: 1/14 
corticotrophinomas, 5/18 somatotrophinomas, 8/32 NFPAs, 2/4 prolactinomas and 2/4 
thyrotrophinomas. The prevalence of TILs was higher in PAs than in NP, but lower than in 
autoimmune hypophysitis. A poor outcome, assessed in terms of hormonal hypersecretion and 
structural disease by MRI, was more frequent in patients with PAs with TILs than in those with no 
TILs; moreover, a multivariate regression analysis pointed out TILs as an independent factor for 
PA persistence/recurrence371, establishing a correlation between cell-mediated autoimmunity and 
PA behaviour. Immunohistochemistry data from Qiu et al. revealed that PAs may have a higher 
number of inflammatory cells around neoplastic cells, more prominently in invasive PAs315.  
The PA infiltration of CD4+ and CD8+ T cells was relatively scant in the Lu et al. study, with 
somatotrophinomas having more CD4+ and CD8+ T lymphocytes than non-GH secreting PAs; no 
correlation was seen between the number of CD4+ cells and tumour size or invasiveness347. In Mei 
et al. study, TILs were observed in all studied PAs and correlated with the expression of 
programmed death ligand-1 (PD-L1)372, often viewed as a potential biomarker for response to 
checkpoint inhibitors373. TILs subclasses CD3+ and CD4+ were increased in functioning PAs in 
comparison to NFPAs, and all lymphocytic markers (CD3, CD4, CD8 and CD45) were higher in PAs 
with increased Ki-67. PD-L1 expression was higher in somatotrophinomas and prolactinomas, and 
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primary PAs had increased PD-L1 levels than recurrent tumours372. More recently, in a large cohort 
of 191 patients with PAs, Wang et al. described CD8+ T lymphocytes in 87% of cases. CD8+ 
lymphocytes positively correlated with PD-L1 levels, as well as with GH levels, but not with Ki-67, 
gender, age or tumour size. This study showed that PD-L1 was frequently expressed in functioning 
PAs and associated with increased aggressiveness374. High expression of PD-L1 in all PA types was 
demonstrated on another series, and somatotrophinomas tend to display higher levels of PD-L1 
than NFPAs and corticotrophinomas235. In this study, Salomon et al. observed in all PA subtypes 
that PD-L1 expression was heterogeneous throughout the tissue and coincided with presence of 
immune infiltrates235. Human corticotrophinomas are also infiltrated by T cells and express PD-
L1375. In another study, PD-L1 expression was higher in NFPAs with cavernous sinus invasion, and 
the number of CD8+ T cells tended to be higher in the invasive NFPAs than in those without 
cavernous sinus invasion348.  
In general, increased PA aggressiveness may be associated with a shift towards a more 
immunosuppressive lymphocyte phenotype. These data also highlight that immune cells within 
the TME of PAs may influence their behaviour and lead to increased aggressiveness, suggesting a 
promising role for immunotherapy, including immune checkpoint inhibitors, in the management 
of aggressive and surgically non-curable PAs348,372,374, including in Cushing´s disease375,376.  
 
Other immune cells 
Other immune cells have been described in the TME of some cancers but not in PAs, such as 
myeloid-derived suppressor cells, dendritic cells and neutrophils204.  
Myeloid-derived suppressor cells are heterogeneous inhibitory immune cells that infiltrate a 
number of tumours leading to Tregs development and M2-macrophage polarisation377-379.  
Dendritic cells play an important role in presenting antigens to the surrounding immune cells 
triggering immune responses in the TME377,380.  
The role of neutrophils in cancer is controversial, with a dual function being described to these 
cells: they may have a pro-tumour effect in some cancers by promoting angiogenesis, degrading 
ECM and inducing immunosuppression; however, some studies showed that tumour-associated 
neutrophils can eliminate malignant cells, displaying an anti-tumoural action204,381,382.  
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Stromal/mesenchymal cells in pituitary adenomas 
Tumour-associated fibroblasts 
Fibroblasts are the most abundant cell type in connective tissues, and play a key role in secreting 
ECM components forming a structural tissue framework. Fibroblasts are the main cells responsible 
for the production of ECM proteins (such as collagen, hyaluronan, fibronectin) as well as MMPs. 
Quiescent fibroblasts may undergo activation and become myofibroblasts in different processes, 
such as tissue remodelling, wound healing or fibrosis, but also in cancer. Fibroblasts are a major 
component of the tumour stroma, and in cancer they acquire morphological changes and an 
activated phenotype, often termed as tumour-associated fibroblasts (TAFs)383,384.  
TAFs are a heterogeneous cell population originating from resident fibroblasts, bone marrow-
derived mesenchymal stem cells, hematopoietic stem cells, epithelial cells, endothelial cells or 
even adipocytes. The most widely used markers to detect activated fibroblasts are α-smooth 
muscle actin (αSMA), fibroblast activation protein and fibroblast-specific protein 1, but other 
markers (tenascin-C, desmin, vimentin) may provide additional information384. 
TAFs play a crucial role in tumour proliferation, invasiveness, angiogenesis and metastasis by 
secreting various growth factors, cytokines (such as IL-6) and chemokines (such as CXCL12). TAFs 
actively remodel the ECM in the TME by promoting the expression of ECM proteins (collagen, 
hyaluronan, fibronectin), MMPs and by inducing EMT383,384. TAFs have been also associated with 
resistance to anti-cancer drugs384,385. Hence, TAFs are often associated with poor outcomes in 
cancer, as reported in breast386,387, prostate388, lung389, gastric390 and pancreatic cancer385,391. 
The role of stromal cells in PAs has been poorly studied. A variety of human collagen-producing 
cells were described in PAs, including fibroblasts, myofibroblasts, myoepithelial cells, pericytes 
and chondrocytes, but their role remains unclear392-395. Tofrizal et al. studied the characteristics of 
stromal collagen-producing cells in human PAs and NP, relying on in situ hybridisation for collagen 
I and III and immunohistochemistry for α-SMA (marker for pericytes, but also activated fibroblasts) 
and cytokeratin (an epithelial marker)395. The only collagen-producing cells in NP were pericytes, 
whereas PAs had a variety of cells: pericytes, fibroblasts, myofibroblasts (activated fibroblasts) 
and myoepithelial cells. In PAs, fibroblasts and myofibroblasts were identified in the intra-
tumoural fibrous matrix and in the PA capsule, whereas myoepithelial-like cells were located in 
the base of tumour cell clusters and had long cytoplasmic projections395. The number of collagen-
producing cells and the number of different cell types correlated with the degree of fibrous 
deposition in PAs: PAs with no or few collagen-producing cells had less fibrous matrix deposition, 
whereas PAs with more collagen-producing cells had increased desmoplasia. Thyrotrophinomas 
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more collagen-producing cells and fibrous matrix, while most somatotrophinomas and null-cell 
PAs had little fibrosis395. 
Lv et al. cultured TAFs from 3 invasive and 3 non-invasive human PAs, and found that TAFs derived 
from invasive PAs had higher expression levels of α-SMA and VEGF than non-invasive TAFs or 
normal fibroblasts. TAFs from invasive PAs lead to higher proliferation in GH3 cells, as well as to 
significant tumour growth of GH3-derived xenografts in mice, effects not observed with normal 
fibroblasts or non-invasive PA-derived TAFs. Moreover, VEGF expression was higher in mouse GH3 
xenografts co-injected with TAFs from invasive PAs than with TAFs extracted from non-invasive 
PAs or normal fibroblasts396. 
 
Pericytes 
Pericytes are stromal cells located in the perivascular spaces, integrating the tissue vasculature. In 
cancer, pericytes not only provide support to the microvasculature within the tumour, but are also 
active elements in the TME, displaying an ability to recognise pro-inflammatory stimuli and mount 
a complex secretory response producing a variety of cytokines. Pericytes also express adhesion 
molecules that regulate transendothelial migration and recruitment of immune cells to the 
TME397. Moreover, pericytes can regulate other cancer-related mechanisms such as angiogenesis 
and EMT397,398. Several studies described an association between low amounts of pericytes and 
increased cancer invasiveness and metastasis, suggesting that a normal pericytes coverage of the 
tumour vasculature may negatively regulate metastases, leading to better cancer outcomes399,400. 
In the anterior pituitary gland, collagen-producing pericytes were first described in the rat. The 
expression of collagen I and III were located around the capillaries, corresponding to pericytes, 
which were the only collagen-producing cells described in the normal rat anterior pituitary401 and 
also in the NP in humans395. Pericytes have also been described in human PAs, where they are 
mainly located in the perivascular spaces395.  
 
Folliculo-stellate cells 
The major non-hormone secreting agranular pituitary cell type are folliculo-stellate cells, 
accounting for 5-10% of all the anterior pituitary cells. Folliculo-stellate cells have a star-shaped 
morphology, and are positive for S100 protein and glial fibrillary acidic protein (GFAP). They have 
several functions in pituitary homeostasis: scavenger activity with ability to perform phagocytosis 
removing cell debris of apoptotic endocrine pituitary cells; mechanical support to the surrounding 
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endocrine cells; and regulation of ion balance, water transport, and nurture of surrounding cells. 
In addition, folliculo-stellate cells produce a wide range of cytokines, chemokines, growth factors 
and enzymes that influence the surrounding endocrine cells10,11,402.  
Several studies have investigated folliculo-stellate cells in PAs. Höfler et al. analysed 7 NPs and 28 
PAs for folliculo-stellate cell markers, and found that 5% of the normal anterior pituitary cells 
stained for S100, whereas S100 reactivity was not found in PAs except in one case403. Iwaki et al. 
reported few or no S100 or GFAP-positive cells in PAs, in comparison to NP adjacent to the 
neoplastic tissue; however, somatotrophinomas and prolactinomas had an appreciable number 
of folliculo-stellate cells404. In this study, no folliculo-stellate cells were seen in NFPAs, except in 
one case which was mainly composed by folliculo-stellate cells and immature glandular cells404. 
Other studies showed that folliculo-stellate cells are more representative of the PA cellular 
component, particularly in GH-producing PAs, in which they can be detectable in over two-
thirds405-408. Voit et al. detected folliculo-stellate cells in 198 out of 286 somatotrophinomas; 
plurihormonal PAs had the highest folliculo-stellate cells density, but no correlation was found 
with gender, age, symptoms duration or PA size408. Another study also reported no correlation 
between folliculo-stellate cells content and PA aggressiveness409. 
The role of folliculo-stellate cells in pituitary tumourigenesis is not entirely clarified. These cells 
produce nitric oxide, activin, follistatin, VEGF, FGFs (fibroblast growth factors), PDGFs (platelet-
derived growth factors), TGF-β, IL-6, IL-10, IL-11, CXCL10, CXCL12, LIF and MIF10,269,402,410,411. The 
folliculo-stellate cells’ secretome is relevant for paracrine interactions with the surrounding cells, 
and may be involved in tumourigenesis. IL-6, a key cytokine in PA development, progression and 
biological behaviour237,239, was localised to folliculo-stellate cells in the NP; however, in PAs IL-6 
seems to derive from adenohypophyseal tumour cells230,412. Immunohistochemical data from PAs 
with limited T-cell mediated inflammatory reaction within the adenomatous tissue suggested that 
folliculo-stellate cells may be induced by inflammation within the TME and perform antigen 
presentation, thus being involved in tumour immunosurveillance413.  
Folliculo-stellate cells express different integrin subunits, which are cell surface receptors for ECM, 
and display marked changes in shape and proliferative activity in the presence of laminin, 
fibronectin and different types of collagen410. Folliculo-stellate cells produce metalloproteinase 
inhibitors, which protect the basement membrane from proteolysis414. On the other hand, 
folliculo-stellate cells were shown to be involved in basal lamina degradation10,415. These findings 
support the folliculo-stellate cells’ ability to remodel the ECM in PAs. 
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Endothelial cells and angiogenesis in pituitary adenomas  
Angiogenesis is the process by which new blood vessels are formed from pre-existing ones, and is 
of major importance for solid tumours growth which is depend on the vascular network for their 
nourishment and extension303. Endothelial cells are essential for angiogenesis, which determines 
the capacity for tumour dissemination. CD31 and CD34 are both endothelial cell antigens and 
sensitive microvessel markers416. Quiescent endothelial cells ‘sense’ the stimuli in the TME 
provided by neoplastic or inflammatory/stromal cells via angiogenic growth factors (such as VEGF, 
FGF and PDGF), cytokines and chemokines (such as IL-8), or owing to hypoxic conditions within 
the TME, which results in neovascularisation. However, the new tumour vessels are usually 
abnormal in terms of structure and function417,418. Lymphatic endothelial cells are also recruited 
to the TME under the influence of growth factors and cytokines within the TME, but these 
lymphatic vessels are abnormally formed allowing the dissemination of tumour cells419,420. 
PAs have a lower microvessel density than NP, while carcinomas appear to have the highest 
microvessel densities302,303,415,421-424. In general, there are no differences in vascularisation 
between different PA histiotypes303,304,421; however, microprolactinomas421 and GH-secreting 
PAs303 may be the least vascularised. Dopamine agonists or SSAs do not seem to affect microvessel 
density303,422,425. Some studies excluded association between vessel density and PA proliferation 
or invasiveness, indicating that other factors underlie the invasive potential of PAs302,303,426,427. 
Turner et al. did not find differences in microvessel density between invasive and non-invasive 
somatotrophinomas and corticotrophinomas, although invasive prolactinomas were significantly 
more vascular than the non-invasive ones422.  
The lack of significant vascularisation in PAs, and the lack of association between vascularisation 
and invasiveness in PAs, may explain the slow pace of PAs proliferation and their benign 
nature297,303,416. In contrast, increased microvessel density described in pituitary carcinomas is in 
line with the fact that distant metastasis occurrence depends on angiogenesis303. 
Exploring this further, within the context of the complex interactions within the TME in PAs, may 
provide invaluable insights in PA pathophysiology and therapeutic advances for aggressive PAs, as 
illustrated by the case of an aggressive silent corticotrophinoma which progressed to a carcinoma 
and was treated successfully with bevacizumab (anti-VEGF monoclonal antibody)428. 
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1.7  Extracellular matrix and remodelling enzymes in pituitary adenomas 
The ECM is composed of different molecules such as collagens, glycosaminoglycans and laminin, 
and its characteristics are different from tissue to tissue, which is a determinant in the tissue-
specific features such as architecture, organisation, consistency and biological functions, 
influencing normal physiology of surrounding cells429. Besides its physiological role, the ECM plays 
a key role in several pathological conditions, including cancer. ECM’s role in TME is not limited to 
mechanical protection against tumour invasion, but also acts as a reservoir for proteins, growth 
factors and enzymes that affects the surrounding cells. In turn, tumour and stromal cells may 
modify the composition and function of ECM mainly by secreting proteases and protease 
inhibitors430-432, and thus interfere with cell-cell and cell-ECM interactions429. ECM remodelling 
proteases play a role in angiogenesis, where they can regulate endothelial cell proliferation and 
vascular morphogenesis. These proteases are needed to degrade the ECM and allow endothelial 
cells to penetrate the tumour stroma433,434. The crosstalk between ECM and neoplastic and non-
neoplastic cells affects tumour cell behaviour, proliferation, invasion and metastasis435-438. 
MMPs are one of the most important ECM-degrading proteases. They belong to the family of zinc-
binding endopeptidases, containing a signal peptide, a propeptide, a catalytic domain, and a 
hemopexin domain able to degrade ECM, basement membrane and connective tissues, essential 
for tissue remodelling, inflammatory response, and in cancer for invasion and angiogenesis207,439. 
Under inflammatory conditions, MMPs are upregulated and released in the TME either by 
neoplastic or non-neoplastic cells, such as fibroblasts or macrophages. An association between 
MMP activity and invasiveness has been shown in different cancers440-443. MMP activity is inhibited 
by tissue inhibitors of metalloproteinases439. 
In the anterior pituitary, ECM is composed mainly by collagen types I and III395,401. In PAs, ECM 
deposition is variable, and collagens are its main stromal component, although their expression 
differ from NP395,444. Jarzembowski et al. noted that PAs have less type IV collagen in their 
basement membranes445. Collagen type IV is the main component of the pituitary capsule and 
medial wall of cavernous sinus446-448. The collagen type may determine mechano-transduction 
pathways that regulate cell invasion/migration ability as seen in GH3 cells449.PAs are mostly 
‘benign’, but up 30-45% of them invade structures such as cavernous or sphenoid sinuses448,450. 
Several studies described an association between MMPs expression and invasive PAs, with a great 
focus on MMP-2 and MMP-9, considering that these are type IV collagenases, essentially 
degrading type IV collagen. Most studies indicate that MMP-2 and MMP-9 correlate with PA 
invasiveness450-453, confirmed in a meta-analysis that included in total 24 studies (1320 patients)448. 
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Patients with recurrent disease had higher MMP-9 levels providing evidence that MMP-9 
overexpression is likely associated to worse outcomes448. One study showed that MMP-2 and 
MMP-9 may stimulate hormone secretion454. The regulation of MMP-2 and MMP-9 expression in 
PAs is not yet clarified, but some different proteins may be involved455-459. A recent study analysed 
the role of MMP-14 (cleaves collagen types I, II and III) in PAs, suggesting  that MMP-14 plays a 
role in invasion and angiogenesis460. The protease kallikrein-like peptidase 10 was found 
overexpressed in PAs and correlated with aggressiveness461,462. Prolactinomas, thyrotrophinomas 
and carcinomas were strongly immunopositive for kallikrein-like peptidase 10; in gonadotroph 
adenomas and somatotrophinomas its immunoreactivity was mild to moderate and seen only in 
few cells. Another study showed higher kallikrein-like peptidase 10 expression in 
corticotrophinomas than in NFPAs or normal corticotrophs461. Expression of cathepsin B, a 
lysosomal protease with ability to degrade ECM, also correlated with the invasiveness of PAs463. 
Integrins are important transmembrane molecules that mediate cell-cell and cell-ECM adhesion. 
Farnoud et al. reported that some integrins were downregulated or abrogated in human PAs in 
comparison to NP, while the stromal cells expressed many more integrin subunits in comparison 
to normal connective pituitary tissue. However, these changes were not associated with 
invasiveness or with PA type464. Fibronectin, another ECM element, is expressed differently in the 
connective tissue of NP and PAs465. Taking these findings together, the ECM in NP differs from PAs 
which therefore may influence tumourigenic processes. 
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1.8  Epithelial-to-mesenchymal transition (EMT) in pituitary adenomas 
EMT in cancer  
EMT is a reversible complex process whereby tumour cells are reprogrammed to acquire a 
mesenchymal phenotype acquiring a migratory and invasive phenotype, by losing the epithelial 
polarity and adhesion molecules, in particular E-cadherin, and concomitantly gaining a spindle-
shaped morphology and migratory phenotype (Figure 1.11). EMT is involved in physiological 
phenomena, such embryonic development, wound healing and fibrosis466,467. In cancer, EMT is 
determined by the complex interactions between different TME elements and EMT plays a key 
role in tumourigenesis, tumour invasion, progression and metastasis466-468. The surrounding non-
neoplastic cells in the TME, such as lymphocytes, macrophages, or fibroblasts, are potent 
regulators of EMT335,466,469-472. Moreover, TME hosts cytokines, chemokines, growth factors and 
enzymes derived from tumour or non-neoplastic cells that can directly induce EMT467,469,473-478.  
Figure 1.11: EMT in cancer and its signalling pathways. 
In tumour cells, EMT-inducing transcription factors may redefine epithelial status of the cell, assigning stem 
cell (SC) characteristics to these dedifferentiated tumour cells. EMT can also redefine altered stem cells to 
be cancer stem cells (CSCs). Dissemination and subsequent migration of tumour cells after breakdown of 
the basement membrane (BM) can be achieved when all EMT component pathways are: if the tumour cell 
acquired the necessary genetic aberrations and receives the appropriate signals at the tumour–host 
interface, the cell moves towards metastasis. At this point, the contribution of the EMT-associated 
programme is to provide survival signals and to maintain the mesenchymal status of the metastasising cell. 
Moreover, it is likely that EMT also has a role in tumour progression. EMT features may further promote 
resistance during therapy, leading to recurrence and a poor cancer outcomes. The degree of EMT and 
mesenchymal-to-epithelial transition during the different steps in cancer probably depends on the 
imbalance of several regulatory networks with activated oncogenic pathways. Multiple signalling pathways 
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and agents, such as growth factors or cytokines, are able to induce EMT both during embryonic 
development and human diseases such as in cancer. BMP, bone morphogenetic protein; CSC, cancer stem 
cell; EGF, epidermal growth factor; EMT, epithelial-to-mesenchymal transition; FGF, fibroblast growth 
factor; FOXC2, fork-head box protein 2; GH, growth hormone; HGF, hepatocyte growth factor; IGF, insulin-
like growth factor; IL, interleukin; MET, mesenchymal-to-epithelial transition; MMP, matrix 
metalloproteinase; NF-kβ, nuclear factor-kβ; PDGF, platelet-derived growth factor; SC, stem cell; SCF, stem 
cell factor; SOX10, SRY-box 10;  TGF-β, transforming growth factor-β; TNF-α, tumour necrosis factor-α; 
VEGF, vascular endothelial growth factor; ZEB, zinc finger E-box-binding homeobox. Adapted from De 
Craene & Berx (2013)466, and Thiery et al. (2009)467. 
 
 
Epithelial cells that undergo EMT loose epithelial markers, most notably E-cadherin, but also 
markers such β-catenin, claudins, cytokeratins and syndecans467,479,480; concomitantly, they adopt 
a mesenchymal morphology, overexpressing mesenchymal markers such as zinc finger E-box-
binding homeobox-1 (ZEB1), N-cadherin or vimentin (Figure 1.11)466,467,481.   
EMT involves multiple regulatory pathways, which can be grouped into four main networks466: (i) 
the most extensively studied network is EMT transcription regulation by a number of transcription 
factors such as ZEB1, ZEB2, SNAIL, SLUG, TWIST, E47, KLF8, FOXC2, E2-2, homeobox protein SIX1 
and goosecoid. SNAIL, ZEB and TWIST are regarded as the master EMT transcription factor 
regulators as they repress not only the promoter of CDH1 (encoding E-cadherin), but also other 
epithelial adhesion molecules such claudins or desmossomes466,467,481-487; (ii) expression of small 
non-coding RNAs, in particular miR200, miR34, miR101, potent modifiers of gene expression 
which are able to influence cell phenotype by suppressing genes involved in epithelial or 
mesenchymal states488-490; (iii) EMT-related alternative splicing events, in which different splicing 
of mRNA precursors lead to distinct proteins from the same gene466, with epithelial splicing 
regulatory proteins 1 and 2 (ESRP1 and ESRP2) being particularly relevant in cancer491-494; (iv) post-
translational dysregulation of EMT-transcription factors, affecting their protein structure and 
function466,495-498.  
Recent studies have suggested that GH can induce EMT either indirectly via IGF-1 or through the 
activation of several signalling pathways (JAK-STAT or mitogen-activated protein kinase (MAPK) 
pathways) with subsequent influence in the transcription of EMT-related genes, in both non-
cancerous or cancerous epithelial cells, as shown in melanoma, breast, colorectal, endometrial 
and pancreatic cancer499.   
EMT-related reversible plasticity, i.e. when mesenchymal cells revert to an epithelial phenotype, 
a phenomenon termed mesenchymal-to-epithelial transition (MET), has been shown in cancer, 
and seems crucial for the establishment of metastatic deposits466,467. Cancer behaviour is 
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intrinsically related to this EMT-MET balance. Advanced carcinomas may adopt some 
mesenchymal features, yet retaining well-differentiated epithelial features, and this tumour 
heterogeneity may be due to incomplete EMT or reversion to an epithelial phenotype (partial 
MET). Hence, EMT is part of the complex metastatic process500,501. 
 
EMT in pituitary adenomas 
The relevance of EMT to the pituitary embryonic development is being increasingly revealed. 
Recent studies have shown that Sox2-expressing stem/progenitor pituitary cells undergo EMT 
under the control of specific EMT transcription factors, but also by some pituitary specific 
transcription factors. These progenitor cells change their properties by EMT under the influence 
of the local microenvironment, acquiring migratory ability during embryogenesis but also in the 
postnatal period, and develop ultimately into anterior pituitary specialised cells55,502.  
EMT in pituitary tumourigenesis is, however, largely unexplored. Qian et al. have shown that the 
expression of E-cadherin and β-catenin seem to be significantly lower in invasive prolactinomas in 
comparison to non-invasive ones: macroprolactinomas had lower E-cadherin expression, and 
decreased E-cadherin expression was associated with a higher Ki-67. These findings suggest that 
reduced expression of E-cadherin and β-catenin may lead to more aggressive prolactinomas503. 
Later in 2007, Qian et al. shown that downregulation and methylation of CDH1 (E-cadherin) and 
CDH13 (H-cadherin) genes correlate with more aggressive PAs. In this study, reduced expression 
of H-cadherin was noted in 54% of PAs and was associated with more aggressiveness; on the other 
hand, E-cadherin expression was reduced in 32% and completely lost in 30%, and its expression 
was lower in grade II, III, and IV than in grade I PAs. Promoter hypermethylation of CDH13 and 
CDH1 was detected in 30% and 36% of the 69 PAs, respectively, but not in 5 NPs, and was 
associated with PA invasiveness. CDH1 and CDH13 downregulation was correlated with the 
respective promoter hypermethylation suggesting that the tumour-specific methylation and 
downregulation of CDH13 and CDH1 is involved in the development of PAs504. 
In acromegaly, lower E-cadherin expression was associated to larger PAs, increased invasiveness 
and reduced response to SSA449,460,461. In contrast, E-cadherin was positively correlated with GH 
mRNA and GH serum levels, and also with serum IGF-1505. Lekva et al. performed a microarray 
analysis on 16 somatotrophinomas, 8 with low and 8 with high E-cadherin expression, and 
reported 29 known EMT-related genes differentially regulated. None of the classical EMT 
regulators (ZEB1, ZEB2, SNAIL, SLUG, TWIST, E47, Goosecoid) nor the classical mesenchymal 
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markers (vimentin, desmin, N-cadherin) were increased in GH-secreting PAs with low E-cadherin 
expression. This show that despite the E-cadherin decrease, these PAs do not have a true EMT 
phenotype. This is consistent with the fact that PAs are benign and rarely metastasise, which may 
explain this partial EMT signature505. Human microarray data was validated by RT-qPCR, which 
showed lower expression of ESPR1, plakophilin 2 (PKP2), TP53 apoptosis effector (PERP), 
interferon regulatory factor 6, roundabout axon guidance receptor homolog 1 (ROBO1), bicaudal 
C homolog 1 and serine peptidase Kunitz type I, and higher expression of clusterin and glutamate-
ammonia ligase (GLUL) in PAs with low E-cadherin expression. Considering that ESPR1 is a key 
gene in EMT-alternative splicing, and was downregulated in somatotrophinomas expressing low 
E-cadherin505, further studies silencing Esrp1 in GH3 cells were performed, showing that Esrp1 
transiently regulates several EMT-related genes, whereas Cdh1 silencing in GH3 cells changed 
expression of only 2 genes (Glul and Pkp2), indicating that E-cadherin is likely a marker but not a 
mediator of EMT in GH3 cells505. These findings suggest ESRP1 as an EMT regulator in 
somatotrophinomas505. 
Chen et al. investigated the expression of the transmembrane proteins involved in cell adhesion 
TROP1 (also known as epithelial cell adhesion molecule (EpCAM)) and TROP2 in PAs, with both 
being overexpressed in PAs and associated with tumour invasiveness and higher Ki-67506. 
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Chapter 2: Materials and methods 
 
Materials 
Human pituitary adenoma samples 
Fresh human PA tissues from 24 patients were obtained at the time of transsphenoidal surgery 
from the National Hospital for Neurology and Neurosurgery, UCLH, NHS Trust. A fragment was 
processed for the primary culture studies, whereas the other part was processed for the 
immunohistochemical studies as well as for the histopathological diagnosis. The clinico-
pathological and biochemical data from each patient were collected from their medical records, 
clinical letters and imaging and/or pathology reports. This study was approved by the local Ethics 
Committee (MREC No. 06/Q0104/133) and written informed consent was obtained from all the 
patients. NP autopsy samples from my lab collection (specimens derived from healthy subjects 
deceased from road traffic accidents, who had no autoimmune, inflammatory or oncological 
disorders, neither were on medications that could potentially affect the immune system such as 
glucocorticoids or immunosuppressive drugs) were included in the immunohistochemical studies 
for comparison. 
 
Human PA and skin fibroblasts 
Human PA-associated fibroblasts were isolated from 16 out of the 24 PA samples obtained after 
surgery, as described below. Early passage human skin fibroblasts, isolated from skin biopsies on 
two healthy young individuals (one male and one female), were a kind gift from Dr. Leo Guasti 
(William Harvey Research Institute, Queen Mary University of London, UK). Early passage human 
skin fibroblasts from individuals with germline AIP mutations (in homozygosity and in 
heterozygosity), used in the cytokine array studies (Chapter 6), were a kind gift from Dr. Hilde van 
Esch and Dr. Wim Huybrechts (UZ Leuven, Belgium). 
 
Cell lines 
The rat pituitary somatomammotroph GH3 cell line was obtained from the European Collection 
of Authenticated Cell Cultures. A stably lentiviral-transduced shRNA knockdown of Aip in the GH3 
cells (GH3-Aip-KD), as well as a non-targeting shRNA control (GH3-NT), were produced by Sirion 
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Biotech, Germany 507, and used in the cytokine array studies (Chapter 6).  Early passage murine 
RAW 264.7 macrophages were a kind gift from Dr. Giulia Marelli (Barts Cancer Institute, Queen 
Mary University of London, UK).  
 
Methods 
Primary cell culture of pituitary adenomas 
Fresh human PA tissue was obtained at transsphenoidal surgery and collected in complete 
medium - high glucose Dulbecco´s Modified Eagle´s Medium (DMEM, Sigma, Gillingham, UK, cat. 
no. D6429) supplemented with 10% heat-inactivated foetal bovine serum (FBS, Gibco, 
Loughborough, UK, cat. no. 16000044) and 0.5% gentamicin (Sigma, cat. no. G1397). The PA 
samples were carried to the laboratory and the primary cultures established on the same day of 
the operation. Representative images from PAs on pre-operative MRI scans, and the appearances 
of a tumour fragment before culturing and of a PA primary culture prior to supernatant collection, 
are shown in Figure 2.1. 
Figure 2.1: Appearances of a PA on MRI, a PA fragment before culturing and a PA primary culture  
A) Macroscopic appearance of a fresh human pituitary adenoma (PA) fragment. This small piece of tissue 
(approximately 10 mm) was obtained via transsphenoidal surgery, collected on complete medium, and 
washed before mechanical and enzymatic dispersion. B-C) Pituitary MRI of a NFPA (B) and a 
somatotrophinoma (C). In both cases, the MRI scan at the time of diagnosis show a pituitary macroadenoma 
with suprasellar extension impinging the optic chiasma. D-E) Somatotrophinoma primary culture prior to 
supernatant collection after 24h on serum-free medium. Seeding concentration per well: 2x106 cells (6-well 
plates). Picture magnifications: 4x (D) and 10x (E). 
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The excised PA tissue was placed in a Petri dish, washed at least 3 times with magnesium and 
calcium-free Phosphate Buffered Saline (PBS) (Sigma, cat. no. D8537), cut into small pieces and 
incubated for 45min at 37ºC in 10 times diluted Trypsin-EDTA 0.05% (1X) Phenol Red (Gibco, cat. 
no. 25300054) with frequent pipetting allowing effective cell dispersion. Trypsin digestion was 
stopped by adding complete medium, then cells were transferred to a tube and allowed to stand 
for 10min for sedimentation of undigested debris (used for isolation of PA-associated fibroblasts 
as explained below). Supernatants containing tumour cells were transferred to a separate tube, 
centrifuged at 800g for 5min, and gently re-suspended in 1mL complete medium. Viable cells were 
assessed with Tryptan Blue Solution (Sigma, cat. no. T8154) and manually counted using a 
haemocytometer. When cell viability was >90%, 2x106 cells were seeded in complete medium in 
a well from a 6-well plate previously coated with Poly-L-lysine (Sigma, cat.no. P4707). The well 
coating was done by completely covering the well surface with a mixture containing Poly-L-lysine 
(10µL) and PBS (1mL) for at least 5min at room temperature, after which this solution was 
aspirated and the well washed with PBS in order to prevent toxicity to the cells. Cells were then 
incubated overnight at 5% CO2 and 37ºC overnight. Next day the cells were examined under a 
bright field microscope, then old medium was aspirated and new medium was added.   
 
Primary cell culture of fibroblasts 
PA-associated fibroblasts (TAFs) were isolated through the so-called outgrowth method391: 
undigested debris pieces, obtained after mechanical and enzymatic dispersion of freshly collected 
human PA tissues (as explained above), were placed in a manually scratched uncoated 6-well plate 
and incubated at 5% CO2 and 37ºC in complete medium. Plates were examined under the 
microscope daily, and complete medium was replaced 3 times a week. After 2-3 weeks, TAFs 
migrated out of the debris and, when confluent (about 4 weeks later), were transferred to 
uncoated culture flasks; no other cells, including pituitary tumour cells, were seen at this late 
stage. Healthy human skin fibroblasts, as well as human AIPmut skin fibroblasts, were grown in 
complete medium replaced 3 times a week. Trypsin-EDTA 0.05% (1X) Phenol Red was used for 
mobilising both TAFs and skin fibroblasts after incubation at 5% CO2 at 37ºC for 5min. 
 
Cell lines culture 
Cell lines (GH3 cells and RAW 264.7 macrophages) were incubated at 5% CO2 and 37ºC, and 
cultured in complete medium (high glucose DMEM supplemented with 10% FBS and 0.5% 
82 
 
gentamycin). 100 µL of puromycin (10mg/mL, Science Warehouse, cat. no. P9620) was added to 
GH3 cells medium allowing a positive selection for GH3-Aip-KD and GH3-NT cells. Once cells were 
70-90% confluent, they were passaged after aspirating medium, 2 washes with magnesium- and 
calcium-free PBS and mobilisation with Trypsin-EDTA 0.05% (1X) phenol-red solution for GH3 cells, 
or with Accutase® solution (Sigma, cat. no. A6964) for RAW 264.7 macrophages. Once cells were 
detached (confirmed by light microscopy), the cell/trypsin solution was put into new flasks or spun 
(3min, 1200g), and re-suspended in DMEM to be further use in in vitro experiments. 
 
Preparation of cell culture conditioned medium for in vitro experiments and supernatants for 
cytokine multiplex array 
GH3 cell conditioned medium (CM) was generated by seeding 5x106 GH3 cells in T75 culture flasks 
for 72h in 10mL complete medium. Macrophage-CM was generated from 5x106 RAW 264.7 
macrophages in T75 culture flasks for 24h in 10mL of complete medium (-PMA_Raw-CM) or 
stimulated with 5nM of Phorbol 12-Myristate 13-Acetate (PMA) (Sigma, cat. no. P8139) in 10mL 
of complete medium (+PMA_Raw-CM). 
Cell culture supernatants for cytokine array were generated by seeding 5x105 GH3 cells in 12-well 
plates for 24h in serum-free medium conditions at baseline and after treatment with RAW 264.7 
macrophage-CM. Supernatants were collected by tilting the plate (avoiding direct contact with 
the cells) and transferred to clean 1.5mL-Eppendorf tubes and immediately placed on ice (to avoid 
cytokine degradation). The tubes were then centrifuged at 10,000rpm for 10min at 4ºC (to remove 
cellular debris), and supernatants containing the cytokines were collected in a new tube and 
stored in -80ºC (for a short time, 3-6 months) until assay.  
Fibroblast supernatants for cytokine array were collected from 5x105 early passage fibroblasts 
seeded in T75 culture flasks and grown in complete medium until 90% of confluence. Following 
washes, and culture in 6mL serum-free medium, supernatant was collected after 24h and stored 
at -80ºC until assay. After 48h in complete medium, cells were treated with 10-7M pasireotide 
(Novartis Pharma, Basel, Switzerland) in 6mL serum-free medium for 24h. The supernatants were 
then carefully transferred to clean tubes, centrifuged at 10,000rpm for 10min at 4ºC, and then 
collected and stored in -80ºC for 3-6 months until assay. CM from TAFs or normal human skin 
fibroblasts were generated similarly, but in complete medium conditions.  
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Cytokine multiplex arrays 
Cytokine arrays on human primary culture supernatants (PAs, TAFs and skin fibroblasts) were 
performed by Eve Technologies (Calgary, Alberta, Canada), according to their protocol (available 
at https://www.evetechnologies.com/discovery-assay/) by using the Bio-Plex™ 200 system (Bio-
Rad Laboratories, Inc., Hercules, CA, USA) and the human cytokine/chemokine array with IL-18 
(HD42) kit (Millipore, St. Charles, USA). This array measures 42 different cytokines, chemokines 
and growth factors in the same sample: G-CSF, GM-CSF, IFNα2, IFNγ, IL-1α, IL-1β, IL-1ra, IL-2, IL-3, 
IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17A, IL-18, CXCL1, CXCL10, 
CCL2, CCL3, CCL4, CCL5, CCL7, CCL11, CCL22, CX3CL1, sCD40L, Flt-3L, PDGF-AA, PDGF-BB, TGF-α, 
TNF-α, TNF-β, VEGF-A, EGF and FGF-2.  
Cytokine array studies on supernatants from rat GH3 cells and mouse RAW 264.7 macrophages 
were also performed by Eve Technologies, using a different species-specific kit array. In GH3 cells 
supernatants  27 different cytokines were measured with the rat cytokine/ chemokine array 27-
plex (RD27) kit (Millipore): G-CSF, GM-CSF, IFNγ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12(p70), 
IL-13, IL-17A, IL-18, CXCL1, CXCL2, CXCL5, CXCL10, CCL2, CCL3, CCL5, CCL11, CX3CL1, TNF-α, VEGF, 
EGF and Leptin.  
Mouse RAW 264.7 macrophages supernatants were assessed with the mouse cytokine/ 
chemokine array 31-plex (MD31) kit (Millipore) measuring: G-CSF, GM-CSF, M-CSF, IFNγ, IL-1α, IL-
1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17A, CXCL1, 
CXCL2, CXCL5, CXCL9, CXCL10, CCL2, CCL3, CCL4, CCL5, CCL11, TNF-α, VEGF and LIF.  
The multiplexing Millipore MILLIPLEX cytokine arrays provided by Eve Technologies is based on 
colour-coded polysterene beads conferring unique colour/fluorophore signature that can be 
individually identified by the bead analyser Bio-Plex 200 system. Bio-Plex 200 includes a dual-laser 
system, one laser activating the fluorescent dye within the beads and the second laser exciting 
the fluorescent conjugate streptavidin-phycoerythrin, as well as a flow cytometry system. The 
amount of the conjugate detected by the analyser is directly proportional to the amount of the 
target analyte. The results are quantified according to a standard curve. With this assay, different 
analytes (i.e. cytokines, chemokines or growth factors) can be measured concomitantly in the 
same sample, and each one can be distinguished from the others because they are bound to 
different coloured/fluorescent beads (Figure 2.2)508.  
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Figure 2.2: Overview of the multiplexing cytokine bead-based immunoassays 
Adapted from Stenken & Poschenrieder (2015)508. 
 
 
Enzyme-linked immunosorbent assay (ELISA) 
The CX3CL1 (fractalkine) rat ELISA Kit (Abcam, cat. no. ab100761) was used for the quantitative 
measurement of CX3CL1 in GH3 cell supernatants, following the manufacturer´s protocol. Briefly, 
this assay employs a specific antibody for rat CX3CL1 coated on the 96-well plate. A fresh set of 
standards were prepared through serial dilutions from the vial of CX3CL1 standard prior to use, 
and ELISA kit reagents were also prepared fresh before the experiment. The ELISA procedure was 
done at room temperature. Standards and samples were pipetted into the wells (100µL) and 
incubated for 2.5h (allowing the CX3CL1 present in the samples and in the standards to bind to 
the wells by the immobilised antibody). The wells were washed and 1X biotinylated anti-rat 
CX3CL1 detection antibody was added (100µL) and incubated for 1h. After washing away unbound 
biotinylated antibody, 1X HRP-conjugated streptavidin (100µL) was pipetted to the wells, 
following which the wells were washed and a TMB one-step substrate reagent was added (100µL) 
and incubated for 30min at room temperature in the dark on a plate shaker. The colour developed 
in proportion to the amount of CX3CL1 bound to the wells, and the Stop solution (50µL) changed 
the colour from blue to yellow, and its intensity measured at 450nm in a time-resolved 
fluorometer. The obtained optical density data for each sample were uploaded into an ELISA 
Analysis Website (http://www.elisaanalysis.com/app) which assisted with the calculation of each 
sample CX3CL1 concentration extrapolated from the standard curve. 
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Cell morphology analysis 
Cell shape analysis and morphological changes were assessed by measuring 6 different shape 
parameters using the software ImageJ (National Institutes of Health, USA): area (area of selection 
in calibrated square units, μm2); perimeter (μm); Feret’s diameter (longest distance between any 
2 points along selection boundary); roundness (representing shape, 4 × [Area] / π × [Major axis]2, 
with value of 1 for a circle and 0 for very elongated shape); circularity (representing perimeter 
smoothness, 4π × [Area][Perimeter]2, with a value of 1 indicating a perfect circle and value close 
to 0 indicating elongated shape) and solidity (representing cell stiffness and deformability, [area] 
/[Convex area], with a value of 1 indicating more stiff and less deformable cell). Per treatment 
condition, 5 images at 40x were taken and 15 cells were measured per image, hence 75 cells were 
analysed per experiment (a minimum of 3 experiments were done). 
 
Invasion assay 
Invasion assays were carried out using the BioCoat Matrigel Invasion Chambers with 8μm pores 
(24-well insert; BD Biosciences, CA, USA, cat. no. 354480). Invasion chambers were hydrated for 
2h with 500μl of serum-free medium at 5% CO2 at 37oC. After matrigel rehydration, 750μL of 
macrophage-CM, TAF-CM, normal skin fibroblast-CM or complete medium was added to the lower 
chamber (acting as chemoattractant) and 2.5x104 GH3 cells in 500μL serum-free medium were 
added to the upper chamber and incubated at 37ºC. After 72h, invading cells through matrigel 
were fixed in 100% methanol and stained with 2% Giemsa blue (Sigma-Aldrich, MO, USA, cat. no. 
G5637-5G). The total number of invading cells per chamber were counted, and normalised to 
invading cells towards complete medium. Invasion assays were run in duplicates and were 
repeated at least 3 times. 
 
Transwell migration assay 
GH3 cell migration and macrophage chemotaxis were evaluated by using transwell biocoat cell 
culture migration insert plates with 8μm pores (24-well insert; Corning Fisher Scientific, USA), 
following a similar protocol as described for the invasion assay. The total number of migrated cells 
per chamber were counted, and normalised to migrated cells towards complete medium. 
Transwell migration assays were run in duplicates and were repeated at least 3 times. 
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Wound healing migration assay 
GH3 cell migration was also assessed by wound healing assay using Ibidi culture inserts (two 
reservoirs in μ-Dish 35 mm; Ibidi GmbH, Germany, cat. no. 81176) as follows: GH3 cells were 
seeded in complete medium to the inserts (70μl; 7×105 cells/mL), and incubated at 5% CO2 at 37oC. 
After 24h, inserts were removed to generate a 500μm cell-free gap in a monolayer of cells. 
Detached cells were removed by replacing with the fresh complete medium or macrophage-CM. 
Photographs of the gap area were taken immediately and then at different times by an inverted 
microscope. 
 
Immunocytochemistry 
Fibroblasts or GH3 cells (5x104) were plated on 15mm coverslips in 12-well plates in complete 
medium. After overnight attachment, fibroblasts were fixed and stained, while GH3 cells were 
further treated for 24h under different conditions (-PMA_Raw-CM, +PMA_Raw-CM, TAF-CM or 
complete medium). Cells were fixed in 4% paraformaldehyde for 15min at room temperature, 
following washes with PBS cells were permeabilised with 0.1% Triton X-100 in PBS for 5min at 4oC. 
Cells were washed and blocked with 1% bovine serum albumin for 30min at room temperature, 
and then incubated with primary antibodies (listed in Appendix 2) followed by a 30min incubation 
with secondary conjugated antibodies (Alexa Fluor 568-conjugated goat anti-mouse IgG, Alexa 
Fluor 488-conjugated donkey anti-mouse IgG and Alexa Fluor 488-conjugated donkey anti-rabbit 
IgG; Molecular Probes, Invitrogen; dilution 1:1000). Actin staining was performed using Actin Stain 
(Molecular Probes, cat.no. R37110, 2 drops/ml, dilution 1:500). Coverslips with stained cells were 
mounted with Fluoroshield with 4',6-diamidino-2-phenylindole (DAPI) mounting medium (Sigma, 
cat. no. F6057). Stained slides were visualised on a confocal microscope LSM 880 Zeiss and images 
taken at 63x magnification. E-cadherin and ZEB1 fluorescent intensities were quantified using the 
software Carl Zeiss Zen Blue Edition v2.3. 
 
Flow cytometry 
Cells were harvested and spun down into a pellet (1200g/8min). The cell pellet was resuspended 
in PBS, and then transferred to a 96-well plate (100µL/well). The plate was spun at 2000g for 5min, 
and after plate was flicked to remove the supernatant. Fc receptors were blocked using 50µL of 
supernatant harvested from the 2.4G2 (CD16/32) hybridoma (kind gift from Dr. Oliver Haworth 
(1:5 dilution on PBS) and incubated on ice for 20min. The plate was again spun at 1200rpm for 
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5min, supernatants discarded, then the mix solution containing the antibodies (anti-CD86, 
eBioscience, cat. no. E20040-104; anti-CD206, BioLegend, cat. no. 141721; anti-MHCII, BioLegend, 
cat. no. 107621; anti-CCR2, R&D Systems, cat. no. FAB5538P; anti-CCR5, BioLegend, cat. no. 
107055) diluted in PBS-20%FBS (1:200), as well as the respective isotype controls, were added to 
the corresponding well (50µL/well) and allowed to incubate for 20min on ice in the dark. 
Supernatants were discarded, cell resuspended in PBS-20%FBS (100µL/well) and then the plate 
was carried to the BD LSRFortessa 2 cell analyser (BD Biosciences). The data were analysed with 
the software FlowJo (FlowJo LLC, USA). 
 
RNA extraction 
RNA from GH3 cells, RAW 264.7 macrophages, TAFs and normal skin fibroblasts was extracted 
using Qiagen´s RNeasy mini kit (Qiagen, cat. no. 74004) following the manufacturer´s protocol. 
Cells were harvested and homogenised through repeated pipetting within a proprietary solution 
containing a high concentration of guanidine isothiocyanate which acts as an RNase enzyme 
inhibitor. Ethanol was added to aid the binding of RNA to the silic-based membrane found within 
the Qiagen spin columns. DNase digestion was performed with the Qiagen kit DNase I incubation 
mix, which was applied directly to the RNeasy MinElute spin column membrane (avoiding the walls 
or the O-ring of the spin column) in order to ensure complete DNAse digestion and to prevent 
DNA contamination in further RT-qPCR experiments. Centrifugation enables the contaminants to 
be isolated and washed away. RNA was eluted in distilled water, and its concentration and purity 
assessed with the NanoDrop ND-1000 spectrophotometer (A260/280 ratio should range between 
1.8–2.1; values outside this interval indicate DNA or protein contamination, and in that case such 
samples were discarded and not used for further experiments). 
 
Reverse transcription 
Complementary DNA (cDNA) was synthesised from 1µg of RNA using the High-Capacity cDNA 
Reverse Transcription Kit (Thermofisher Scientific, cat. no. 4374966), following the manufacturer´s 
protocol. Briefly, 2X RT Master Mix was prepared on ice and with RNase-free reagents (to avoid 
RNase contamination), by adding per reaction 2.0µL 10X RT Buffer, 0.8µL 25X dNTP Mix (100mM), 
2.0µL 10X RT Random Primers, 1.0µL MultiScribe™ Reverse Transcriptase, 1.0µL RNase inhibitor, 
3.2µL Nuclease-free water. Then, 10µL of 2X RT Master Mix was added to 10µL of water in an 
individual tube (one per reaction), mixed well and shortly spun (to allow its content to settle down 
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and to eliminate any air bubbles). Negative RT control samples (–RT), where reverse transcriptase 
was omitted, were also prepared. The reverse transcription was performed in a thermal cycler 
according with the following 4-step programme: step 1) 25ºC for 10min; step 2) 37ºC for 120min; 
step3) 85ºC for 5min; Step4) 4ºC ∞. Synthesised cDNA was stored at -20ºC.  
 
Real-time quantitative polymerase chain reaction (RT-qPCR) 
RT-qPCR reactions were prepared using Brilliant III Ultra-Fast SYBR Green QPCR Master Mix 
(Agilent Technologies, Palo Alto, CA, USA, cat. no. 600882), as a fluorescent reported dye. The 
qPCR Master Mix was prepared on ice as follows (amount of reagent per reaction): MM Brilliant 
III SYBR Green PCR (10µL), Forward and Reverse Primer 10µM (0.3 µL of each), specific for the 
gene of interest and for the reference gene for normalisation of the data (GAPDH, glyceraldehyde-
3-phosphate dehydrogenase), and nuclease-free water (7.4µL). After vortex, 18µL of the Master 
Mix was added per well to a PCR 96-well plate placed on ice, and then 2µL of the prepared –RT 
control and +RT cDNA samples was added (cDNA concentration at 5ng/µL, meaning adding a total 
of 10 ng of cDNA per well). After loading the PCR plate, the wells were covered with plastic strips, 
the plate was centrifuged for 3min at 2,000rpm (this corrects any adherent drop and bottom-
bubbles), and then placed in the Thermal Cycler with MxPro software (Agilent) running on the 
channel “SYBR Green (with Dissociation Curve)”, with the following 2-step thermal programme: 
pre-incubation 3min at 95ºC, then 40 cycles of 20s at 95ºC and 20s at 60ºC. Upon qPCR reaction 
completion, cycle threshold (CT) values were analysed by comparative relative quantification 
using the ∆∆CT quantification method for RT-qPCR in the cell lines, and the standard curve method 
for RT-qPCR in human samples from TAFs and skin fibroblasts. In RT-qPCR experiments involving 
human samples, the standard curve was generated from qPCR Human Reference cDNA Olido(dT)-
primed (Clontech, cat. no. 639654), as well as a positive control template for validation of each 
gene primer design. Target gene expression was normalised to GAPDH expression used as internal 
control. In order to assess the reaction specificity, dissociation curves were obtained per gene, 
where a single peak (narrow and symmetric) were observed. The sequence of the primers (Sigma-
Aldrich) used in the RT-qPCR experiments are listed in Appendix 3. 
 
Ventana immunohistochemistry  
Immunostains were performed on 4µm paraffin-embedded tissue sections using Ventana 
Discovery DAB Map System (Ventana, Illkirch, France). In this automated immunohistochemistry 
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system, streptavidin-horseradish peroxidase conjugate (OmniMap HRP) is used to catalyse the 
3,3´-diaminobenzidine tetrahydrochloride (DAB) / H2O2 reaction to produce an insoluble dark 
brown precipitate that can be visualised targeting the antigen of interest. Briefly, the slides were 
deparaffinised and processed for antigen retrieval for 30min with cell conditioning solution CC1 
(Ventana), which is a Tris base buffer (pH~9). After blocking with Blocker D solution (Ventana), 
slides were incubated with primary antibody for 60min (listed in Appendix 2) and then with the 
universal secondary antibody (Ventana) for 20min. Slides were counterstained with haematoxylin. 
A negative control, where primary antibody was omitted, was included per experiment, to exclude 
areas of endogenous peroxidase activity and/or non-specific antibody binding, ensuring the 
specificity of the staining reaction. A positive control, using a tissue with known high expression 
levels of the protein of interest (tissues where the dilution and immunohistochemical experiment 
conditions were first optimised for each one of the primary antibody), was also included per 
experiment serving as a baseline for evaluating run-to-run and/or day-to-day consistency. 
Automated immunohistochemistry with Ventana is a powerful tool in showing antigens in tissues 
and cells with enhanced specificity and sensitivity, providing stainings with clean background and 
remarkable signal-to-noise ratios. Other advantages of immunohistochemistry with Ventana in 
comparison to manual immunohistochemistry procedures are: automation of antigen retrieval 
and staining protocols allow standardisation and reproducibility between experiments; 
performing the Ventana protocols on automated instruments are less time-consuming and less 
demanding; and the staining process is also less affected by the researcher’s expertise, providing 
lower intra- and inter-individual methodology variabilities509. 
 
Immunohistochemical analysis 
Stained slides were scanned and analysed with Pannoramic Scanner and Viewer Software 
(3DHISTECH, Budapest, Hungary). Immunohistochemical studies assessed macrophages using 
CD68, CD163 and HLA-DR, lymphocytes using CD8 for cytotoxic T cells, CD4 for T helper cells, 
FOXP3 for T regulatory cells, CD20 for B cells and neutrophil elastase for neutrophils. Endothelial 
cells were assessed with CD31 and fibroblasts with vimentin as well as by their location and 
morphology.  
Immunopositive cells were counted in 5 different “hot spots” high power field (HPF) using the 
software ImageJ (National Institutes of Health, USA); counterstained nuclei identifying tumour 
cells were also counted, and the data were expressed as percentage of immunopositive immune 
cells relatively to the total number of tumour cells per HPF.  
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Vessels (stained for CD31) were manually counted in 3-5 different fields (20x magnification) 
allowing the estimation of microvessel density (number of vessels per HPF), and the vessels 
contour was manually traced using ImageJ to obtain an estimation of total microvessel area (μm2). 
E-cadherin and ZEB1 (markers used to study EMT), as well as, MMP-9, MMP-14 and NCAM
immunoreactivities were measured semi-quantitatively by an experienced pathologist (Dr. Eivind 
Carlsen, Skien, Norway) blinded to the diagnosis or clinicopathological features of each case, on 
the basis of both the extent and intensity of the immunoreactivity. The extent of immunoreactivity 
was scored according to the percentage of stained cells in relation to the entire section as (0 points 
for no staining, 1 point for less than 20%, 2 points for 20-50% and 3 points for more than 50% of 
the cells). Staining intensity was graded on a 0-3 scale 0 (no staining), 1 (weak), 2 (moderate) and 
3 (strong). Sum of extent and intensity scores was used as final staining score. 
RNAscope 
RNAscope is a novel in situ hybridization technique identifying mRNA transcripts in tissue sections 
at the single cell level within its morphological/spatial context and in a highly specific and sensitive 
manner through a probe design strategy (double Z) and effective hybridization-based signal 
amplification system (Figure 2.3)510. Thus, RNAscope offers significant advantages over 
conventional techniques to assess gene expression changes511, being increasingly used in many 
research areas, and is particularly useful to investigate different elements of the TME374,511,512.  
Figure 2.3: RNAscope assay procedure 
In step 1, cells or tissues are fixed and permeabilised to allow target probe access. In step 2, target RNA-
specific oligonucleotide probes (Z) are hybridized in pairs (ZZ) to multiple RNA targets. Each target probe 
contains an 18- to 25-base region complementary to the target RNA molecule, a spacer sequence, and a 14-
base tail sequence (conceptualized as Z). A pair of target probes (double Z), each possessing a different type 
of tail sequence, hybridize contiguously to a target region (~50 bases). The two tail sequences together 
form a 28-base hybridization site for the preamplifier, which contains 20 binding sites for the amplifier, 
which in turn contains 20 binding sites for the label probe. In step 3, multiple signal amplification molecules 
are hybridized, each recognising a specific target probe, and each unique label probe is conjugated to a 
different enzyme or fluorophore. In step 4, signals are detected using a bright-field microscope (for enzyme 
label) or epifluorescent microscope (for fluorescent label). Wang et al. (2012)510. 
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 IL-8 and CCL2 and the chemokine receptors CXCR2 and CCR5 were detected using the RNAscope 
2.5 HD Duplex Chromogenic Assay (Advanced Cell Diagnostics, ACD, USA), according to the 
manufacturer´s protocol (available at https://acdbio.com/rnascope%C2%AE-25-hd-duplex-assay). 
Briefly, 4µm paraffin-embedded PA tissue sections were baked at 60ºC for 90min and then 
deparaffinised in xylene and ethanol. To block endogenous peroxidases, 5-8 drops of H2O2 was 
added to cover each tissue section and incubated at room temperature for 10min, after which the 
H2O2 was removed by tapping the slide on absorbent paper and immediately submerged in 
distilled water. Afterwards, the slides were boiled with pre-treatment 1X Target Retrieval Reagent 
(ACD) for 15min and then washed in distilled water and 100% ethanol. Protease digestion was 
performed at 40ºC for 30min, followed by hybridization for 2h at 40ºC in the HybEZ II Oven (ACD) 
with Probe mix according to 1:50 ratio of C2 to C1 probes: mix IL-8 (ACD, cat. no. 310381-C2) and 
CXCR2 (ACD, cat. no. 468411), and mix CCR5 (ACD, cat. no. 601501-C2) and CCL2 (ACD, cat. no. 
423811). Hybridization signals were amplified using the Amp 1-10 Reagents (ACD) and visualised 
with RNAscope 2.5 HD Duplex Chromogenic Assay reagents (Red and Green solutions, ACD). Cell 
nuclei were counterstained with haematoxylin, and slides were mounted with VectaMount 
mounting medium (Vector Laboratories, cat. no. H-5000). Probe-DapB (ACD) was used as negative 
control. Slides were scanned and analysed with Pannoramic Scanner and Viewer Software 
(3DHISTECH, Budapest, Hungary). 
 
Affymetrix microarray analysis and xCell deconvolution 
As part of Dr. Barry´s study513, total RNA from a different set of human sporadic PA samples (3 
somatotrophinomas and 4 NFPAs) and 5 NPs were isolated using the Qiagen´s RNeasy micro kit 
according to the manufacturer’s protocol. RNA samples were assessed by NanoDrop ND-1000 
spectrophotometer and Agilent Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). Target 
labelling and hybridization were performed using Affymetrix GeneChip 3′ IVT Express Kit 
(Affymetrix, Santa Clara, CA, USA) according to the manufacturer’s instructions. Briefly, 250ng of 
total RNA was reverse-transcribed using the T7-(T)24 primer and cDNA synthesis kit. Double 
stranded cDNA was used as a template for in vitro transcription and amplification reaction in the 
presence of biotin-labelled ribonucleotides; 15µg of labelled biotinylated cRNA was fragmented, 
mixed with hybridization solution and hybridized to Affymetrix Human Gene Chip HG-U133 Plus 
2.0 arrays for 16h at 45oC. After hybridization and scanning, raw data were analysed using 
Bioconductor packages (www.bioconductor.org) within the open source ‘R’ statistical 
environment (www.r-project.org). Microarray data have been deposited with the National Center 
PDAC TMA samples datasheet: 
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for Biotechnology Information Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo, accession 
number GSE63357). For deconvolution, Dr. Sherine Awad used the webtool xCell514,515, which 
infers different immune and stromal cells from microarray expression data (Figure 2.4) giving an 
xCell Fraction Score per cell type.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: xCell study design 
The data sources to generate xCell gene signatures, the compendium of the 64 human cell type gene 
signatures (based in 489 reliable cell type gene signatures) and the xCell pipeline are shown. The raw xCell 
score is given based on the average score of all signatures corresponding to the cell type, and then from 
simulations of gene expression for each cell type the non-linear scores are transformed to linear scores after 
which dependencies between cell type scores are adjusted by a spill over compensation correction method. 
Adapted from Aran et al. (2017)514. 
 
DNA extraction 
In order to study loss of heterozygosity in TAFs derived from a patient with a proven germline 
AIPmut (c.910C>T; p.R304*), DNA from 2x106 TAFs isolated in vitro was extracted with the 
Qiagen´s QIAamp DNA Mini Kit (Qiagen, cat. no. 51304) according to manufacturer´s protocol 
(“Protocol: DNA Purification from Blood or Body Fluids (Spin Protocol)” and ”Appendix B: Protocol 
for Cultured Cells” both available in the kit user’s manual). QIAamp DNA purification procedure 
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was carried out using the QIAamp Mini-spin columns. The lysate buffering conditions are adjusted 
to allow optimal DNA binding to the QIAamp membrane before the sample is loaded onto the 
QIAamp spin column. DNA is adsorbed onto the QIAamp silica membrane during centrifugation, 
but proteins and other contaminants (that can inhibit the PCR and other downstream enzymatic 
reactions) are not retained in the membrane. Purified DNA was eluted from the QIAamp Mini spin 
column in Buffer AE. 
 
Polymerase chain reaction and DNA sequencing 
After extracting DNA from AIPmut PA-associated TAFs, I aimed to amplify the DNA region where 
the known germline AIP mutation c.910C>T is by PCR before sequencing this genomic region. 
Primers comprising an amplicon (size 244bp) in the AIP region of interest (exon 6) were designed: 
Forward primer sequence 5´-GTGTGGAATGCCCAGGAG-3´; Reverse primer sequence 5´-
TGCTGCGTCATGCTTCTG-3´.  
The PCR master mix was prepared on ice as follows: 9.9375µL of deionized water, 1.25µL of 10X 
Taq buffer, 0.25µL of 10mM dNTPs, 0.25µL of 10µM Forward Primer, 0.25µL of 10µM Reverse 
Primer, 0.0625µL of Taq polymerase – total volume per reaction 12µL. The PCR master mix was 
then vortexed and shortly spin. In separate PCR tubes, 3µL of DNA sample (at concentration of 
33.3ng/µL, i.e. a total of 100ng) was added to 22µL of the master mix. A negative control using 
3µL of deionized water (instead of DNA) was included. The PCR reaction was done in the thermal 
cycler G-Storm GT-12061 under the following conditions: initiation at 95ºC for 5min, then 40 
cycles - denaturation step at 95ºC for 30s, annealing step for 30s at 60ºC and elongation step for 
30s at 68ºC. The samples (5µL) were mixed with glycerol (5µL) and then loaded into a 2% Agarose 
gel (containing 10µL of Gel Red per 100mL allowing the DNA bands visualisation), after loading in 
the first gel well 5µL of the ladder mix (GeneRuler 1kb plus DNA Ladder, ThermoFisher Scientific, 
cat. no. SM1331) and in the last well water was loaded serving as negative control (to exclude 
contamination in the PCR reaction). Gel electrophoresis was performed in a BioRad PowerPac 
machine at 100V for approximately 40-50min, and the gel/bands then visualised in the LI-COR 
Odyssey machine (images acquired with the Image Studio software).  
The amplified DNA was sent to GATC Biotech company (Germany) for Sanger DNA sequencing 
(together with 2µL of Forward and Reverse Primers required for the sequencing reaction). The 
DNA sequencing results were then analysed in the software FinchTV (Geospiza, Inc, USA). 
 
94 
 
Serum inflammation-based scores 
Pre-operative full blood count (FBC) data from the included PA patients were collected from their 
medical records, including the overall white cell count, as well as the differential neutrophil, 
lymphocyte, monocyte, eosinophil and basophil count, and also the platelet and red blood cell 
counts. The immune inflammation score ratios were calculated per patient from these FBC data 
as follows: i) the neutrophil-to-lymphocyte ratio (NLR) was calculated by dividing the absolute 
neutrophil count by the absolute lymphocyte count; ii) lymphocyte-to-monocyte ratio (LMR) was 
calculated by dividing the absolute lymphocyte count by the absolute monocyte count iii) platelet-
to-lymphocyte ratio (PLR) was calculated by dividing the absolute platelet count by the absolute 
lymphocyte count. 
 
Clinical databases – International FIPA Consortium 
Clinico-pathological data from each case were retrieved from hospital notes, clinical reports 
(blood test, imaging, histopathological) and from letters, fax or emails sent to us from the different 
referring clinicians integrating the International FIPA Consortium research group 
(http://www.fipapatients.org/fipaconsortium/). Informed consent was obtained from all patients 
before their inclusion in the study. The International FIPA Consortium database has been under 
constant updating since February 2007, when the study commenced, until April 2019. I have been 
updating this database since September 2016. I transferred the data stored in the Microsoft Office 
Excel® FIPA database into a database created with the software SPSS (version 20, IBM, USA) for 
the purpose of statistical analysis. 
 
Statistical analysis 
Quantitative (or continuous) variables, represented as mean and standard deviation (SD) or 
standard error of the mean (SEM), were tested for Gaussian distribution with the Shapiro-Wilk 
test, and non-parametric and parametric data were further analysed with the Mann-Whitney U 
test and Student´s T test, respectively, and one-way or two-way ANOVA tests with post-hoc 
comparison tests were also applied as appropriate. Chi-squared test and Exact Fisher´s test were 
applied to analyse qualitative (or categorical) variables. Correlation between continuous variables 
were determined by the Pearson correlation coefficient r. P values <0.05 were considered 
significant. All the statistical analyses were carried out using the SPSS version 20 (IBM, USA), and 
the graphs and figures designed in the GraphPad version 6 (Prism, USA). 
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Chapter 3: The cytokine network and immune cells in the tumour 
microenvironment of pituitary adenomas 
 
Introduction 
The TME consists of neoplastic, immune and stromal cells together with enzymes, growth factors 
and cytokines within the ECM and plays a crucial role in tumour initiation, progression, invasion, 
metastasis and angiogenesis204,207,209-211. Chemokines produced by neoplastic cells contribute to 
immune cell trafficking, as well as to invasion and survival of tumour cells204,209,227. Immune cells 
are recruited to the tumour by a chemokine gradient or recognition of tumour antigens211,223,231. 
Macrophages are a major component of the TME and determinant for tumour aggressiveness, 
particularly M2-macrophages229,339-342. CD8+ T cells are beneficial to the host as they are cytotoxic 
to tumour cells. CD4+ Th1 cells are associated with good outcomes, whereas CD4+ Th2 cells and 
FOXP3+ Tregs are immunosuppressive204,516; B cells are usually associated with good outcomes but 
an immunosuppressive B cell population has been described358-361. Neutrophils orchestrate 
responses against tumour cells, although their effects can be also detrimental517,518.  
The TME has been widely investigated204,207,209-211, but little is known about it in PAs. However, 
there is some evidence that different TME elements may determine increased aggressiveness, 
rendering PAs larger278,347, more proliferative268,372,519 and more invasive275,276,313,371. Investigating 
the TME in PAs may provide novel insights into PA biology and identify markers for aggressiveness 
which can be useful for patient risk stratification and management. Moreover, it may lead to 
therapy advances, namely immunotherapy, which is a promising option for aggressive PAs374, as 
recently shown in a patient with an ACTH-secreting pituitary carcinoma managed with ipilimumab 
and nivolumab376, in a prolactinoma treated with immunotherapy520 or in a murine model of 
Cushing´s disease375. Previous studies assessed CXCL12268,271-273,276-278, IL-8232-234 and immune 
cells204,347,371,372,374 in PAs, but the interactions between the PA cytokine network and immune cells, 
and their role in determining PA aggressiveness, has not been comprehensively explored. 
Serum inflammation-based scores, estimated from the pre-treatment differential FBC data, have 
been increasingly used in cancer521,522. Such scores are inexpensive and widely available, as 
virtually every patient will have a pre-treatment FBC, and several lines of evidence show these can 
predict cancer outcomes and prognosis521,522. Different scores have been used, with the most well-
established being the neutrophil-to-lymphocyte ratio (NLR)522-524. Platelet-to-lymphocyte ratio 
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(PLR) and lymphocyte-to-monocyte ratio (LMR) were also shown to have a prognostic value in 
some cancers522,525,526. In general, increased NLR, increased PLR and low LMR are indicative of poor 
cancer outcomes41,44,45. There are no data on serum inflammation-based scores in PAs.  
 
 
Aims 
Overall aim 
To characterise the TME in PAs and its role in the clinical phenotype and tumour aggressiveness, 
focusing on the cytokine network and infiltrating immune cells and their complex interactions. 
 
Specific aims 
1. To study the main human PA-derived cytokines and their role in recruiting immune cells 
into the TME and in determining the clinical phenotype and aggressiveness of PAs 
2. To characterise different immune cell types within the TME of PAs and their role in 
determining the clinical phenotype and aggressiveness of PAs 
3. To assess the functional effect of pituitary tumour-derived factors in macrophage 
chemotaxis and in its biological behaviour  
4. To assess the functional effect of macrophage-derived factors in pituitary tumour 
biological behaviour, migration, invasiveness and EMT pathway activation 
5. To characterise the circulating immune cells and inflammation-based scores in patients 
with PAs and study their relationship with PA phenotype and aggressiveness, aiming to 
determine whether these have any value predicting outcomes and prognosis of patients 
with PAs 
 
 
Results 
The cytokine network in human pituitary adenomas 
Pituitary tumour cells are an active source of cytokines particularly chemokines 
In order to identify the most relevant cytokines derived from human PAs, we established primary 
cultures from 24 PAs.  The baseline clinicopathological features of these 24 patients are shown in 
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the Table 3.1. We studied 16 NFPAs and 8 somatotrophinomas: all cases were macroadenomas, 
10 had cavernous sinus invasion and 5 had a Ki-67≥3%. We had more PAs deriving from males 
(66.7%) and the patients’ mean age at diagnosis was 48.8±15.5 years. The mean number of 
treatments and operations were relatively low, respectively 1.6±0.9 and 1.2±0.5, taking into 
account the short follow-up duration of this cohort (2.5±9.1 years).  
Clinicopathological features Total of PAs (n=24) 
Gender [n (%)]        
        Male 
        Female 
 
16 (66.7%) 
8 (33.3%) 
Current age (years) [mean±standard deviation (SD)] 51.9 ± 15.1 
Age at diagnosis (years) [mean±SD] 48.8 ± 15.5 
Clinical diagnosis [n (%)] 
           Acromegaly 
           NFPA 
 
8 (33.3%) 
16 (66.7%) 
Hyperprolactinaemia at diagnosis [n (%)] 8 (33.3%) 
Headache [n (%)] 8 (33.3%) 
Visual Impairment [n (%)] 13 (54.2%) 
Hypopituitarism at diagnosis [n (%)] 11 (45.8%) 
Macroadenoma [n (%)] 24 (100%) 
Suprasellar extension [n (%)] 24 (100%) 
Cavernous sinus invasion [n (%)] 10 (41.7%) 
Ki-67 ≥ 3% [n (%)] 5 (20.8%) 
Mean number of treatments [mean±SD] 1.6 ± 0.9 
Mean number of surgeries [mean±SD] 1.2 ± 0.5 
Re-operation [n (%)] 5 (20.8%) 
Radiotherapy [n (%)] 3 (12.5%) 
Hypopituitarism at last follow-up [n (%)] 14 (58.3%) 
Active disease at last follow-up [n (%)] 4 (16.7%) 
Follow-up duration (years) [mean±SD] 2.5 ± 9.1 
Table 3.1: Baseline features of the 24 studied patients with PAs 
 
I assessed 42 different cytokines in fresh culture supernatants from these 24 PAs (Table 3.2). The 
cytokine array identified IL-8, CCL2, CCL3, CCL4, CXCL10, CCL22, CXCL1 and CX3CL1 as the main 
PA-derived cytokines, all chemokines specialised in immune cell recruitment209, followed by FGF-
2, IL-6, PDGF-AA and VEGF-A. In general, interleukins were undetectable or in low concentrations. 
IL-1ra, IL-2, IL-3, IL-5, IL-7, IL-9, IL-13, CCL7, sCD40L, TNF-β and TGF-α were undetectable in PA-
derived supernatants (Table 3.2). 
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Cytokine/ 
Chemokine/ 
Growth factor 
Overall PAs (n=24) 
Mean concentration 
(pg/mL) ± SEM 
Serum-free medium 
Concentration  
(pg/mL) 
NFPAs (n=16) 
Mean concentration 
(pg/mL) ± SEM 
Somatotrophinomas (n=8) 
Mean concentration 
(pg/mL) ± SEM 
IL-8 854.18 ± 445.79 7.06 1250.95 ± 652.15 60.65 ± 36.68 
CCL2 578.03 ± 222.66 4.00 839.92 ± 316.52 54.27 ± 23.69 
CCL3 150.55 ± 88.22 0 224.04 ± 129.69 3.57 ± 0.86 
CCL4 94.25 ± 47.20 3.09 139.32 ± 68.67 4.11 ± 1.86 
CXCL10 76.67 ± 47.58 0 112.04 ± 70.39 5.94 ± 2.80 
CCL22 67.25 ± 16.74 20.78 68.36 ± 22.62 65.03 ± 19.25 
CXCL1 60.30 ± 26.14 20.78 80.62 ± 38.46 19.65 ± 6.39 
CX3CL1 35.14 ± 17.12 6.73 46.09 ± 25.42 13.23 ± 4.12 
FGF-2 26.65 ± 4.11 0 21.40 ± 4.91 37.15 ± 6.33 
IL-6 24.90 ± 19.27 0 37.21 ± 28.70 0.28 ± 0.11 
PDGF-AA 22.36 ± 6.78 0.12 30.09 ± 9.50 6.89 ± 3.83 
VEGF-A 15.85 ± 4.06 0 16.01 ± 5.15 15.51 ± 7.01 
PDGF-BB 13.37 ± 6.09 0 18.35 ± 8.94 3.41 ± 1.34 
IFNα2 4.90 ± 1.00 1.79 4.61 ± 1.27 5.48 ± 1.68 
IL-4 4.75 ± 1.47 0 4.26 ± 1.83 5.74 ± 2.62 
G-CSF 3.97 ± 1.25 0 4.14 ± 1.85 3.61 ± 0.88 
GM-CSF 3.89 ± 1.71 0 4.93 ± 2.53 1.79 ± 0.62 
CCL5 3.83 ± 0.97 0.66 4.33 ± 1.39 2.84 ± 0.81 
IL-12p40 3.66 ± 0.96 0 3.49 ± 1.24 3.98 ± 1.58 
TNF-α 3.01 ± 2.24 0.19 4.33 ± 3.35 0.37 ± 0.09 
IL-18 2.87 ± 0.66 1.91 2.78 ± 0.84 3.06 ± 1.14 
Flt3L 2.79 ± 0.34 1.72 2.82 ± 0.47 2.74 ± 0.44 
CCL11 2.77 ± 0.66 0 2.83 ± 0.87 2.66 ± 1.02 
IL-1α 1.75 ± 0.70 0 2.61 ± 0.99 0.04 ± 0.04 
EGF 1.69 ± 0.43 0 1.37 ± 0.52 2.33 ± 0.75 
IFNγ 1.23 ± 0.24 0.34 1.33 ± 0.35 1.03 ± 0.22 
IL-10 1.16 ± 0.39 0.55 1.02 ± 0.49 1.43 ± 0.68 
IL-1β 0.90 ± 0.24 0.06 1.05 ± 0.36 0.61 ± 0.13 
IL-12p70 0.86 ± 0.22 0.11 0.75 ± 0.27 1.06 ± 0.41 
IL-15 0.76 ± 0.20 0.55 0.69 ± 0.27 0.88 ± 0.30 
IL-17A 0.68 ± 0.12 0.01 0.73 ± 0.18 0.59 ± 0.14 
Table 3.2: Cytokine secretome from the 24 human PA-derived supernatants  
PA-derived cell culture supernatants were collected at 24h on serum-free medium and the cytokine 
secretome determined with the human Millipore MILLIPLEX cytokine 42-plex array. Data are shown as 
concentration (pg/mL), mean±SEM for all detectable cytokines, chemokines and growth factors for the 
overall cohort of PAs (n=24), and for the NFPA (n=16) and somatotrophinoma (n=8) subgroups. IL-1ra, IL-2, 
IL-3, IL-5, IL-7, IL-9, IL-13, CCL7, sCD40L, TNF-β and TGF-α were undetectable (i.e. below the lowest standard 
curve point and serum-free medium). 
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In Table 3.3 is shown the proportion of PA cases with detectable level of cytokines (i.e. 
concentrations below the lowest standard curve point and the serum-free medium). Ninety 
percent of the PAs secreted IL-8, CCL2 and CCL3, while CXCL1 and CXCL10 were secreted by half 
of the PAs; CCL4, CX3CL1, FGF-2 and VEGF-A were secreted by three-quarters of the PAs, whereas 
IL-6 was found in 50% of the cases. TNF-α, IL-1 α, EGF, IL-10, IL12p70, IL-15 and IL-17A were 
present in less than 50% of cases (Table 3.3). 
 
Cytokine/ 
Chemokine/ 
Growth factor 
n (%) of PAs  
with detectable 
cytokine (n=24) 
n (%) of NFPAs  
with detectable 
cytokine (n=16) 
n (%) of somatotrophinomas 
with detectable cytokine 
(n=8) 
p value 
(NFPAs vs somato-
tropinomas) 
IL-8 22 (91.7%) 16 (100%) 8 (75.0%) 0.037 
CCL2 21 (87.5%) 16 (100%) 5 (62.5%) 0.009 
CCL3 22 (91.7%) 15 (93.8%) 7 (87.5%) 0.602 
CCL4 18 (75.0%) 14 (87.5%) 4 (50.0%) 0.046 
CXCL10 14 (58.3%) 10 (62.5%) 4 (50.0%) 0.558 
CCL22 15 (62.5%) 10 (62.5%) 5 (62.5%) 1.000 
CXCL1 12 (50.0%) 8 (50.0%) 4 (50.0%) 1.000 
CX3CL1 19 (79.2%) 14 (87.5%) 5 (62.5%) 0.155 
FGF-2 19 (79.2%) 11 (68.8%) 8 (100%) 0.076 
IL-6 12 (50.0%) 11 (68.8%) 1 (12.5%) 0.009 
PDGF-AA 20 (83.3%) 16 (100%) 4 (50.0%) 0.002 
VEGF-A 18 (75.0%) 13 (81.2%) 5 (62.5%) 0.317 
PDGF-BB 15 (62.5%) 10 (62.5%) 5 (62.5%) 1.000 
IFNα2 13 (54.2%) 8 (50.0%) 5 (62.5%) 0.562 
IL-4 11 (45.8%) 7 (43.8%) 4 (50.0%) 0.772 
G-CSF 19 (79.2%) 12 (75.0%) 7 (87.5%) 0.477 
GM-CSF 15 (62.5%) 11 (68.8%) 4 (50.0%) 0.371 
CCL5 16 (66.7%) 11 (68.8%) 5 (62.5%) 0.759 
IL-12p40 12 (50.0%) 8 (50.0%) 4 (50.0%) 1.000 
TNF-α 6 (25.0%) 5 (31.2%) 1 (12.5%) 0.317 
IL-18 12 (50.0%) 8 (50.0%) 4 (50.0%) 1.000 
Flt3L 17 (70.8%) 11 (68.8%) 6 (75.0%) 0.751 
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CCL11 12 (50.0%) 8 (50.0%) 4 (50.0%) 1.000 
IL-1α 8 (33.3%) 8 (50.0%) 0 (0%) 0.014 
EGF 11 (45.8%) 6 (37.5%) 5 (62.5%) 0.247 
IFNγ 15 (62.5%) 10 (62.5%) 5 (62.5%) 1.000 
IL-10 10 (41.7%) 5 (31.2%) 5 (62.5%) 0.143 
IL-1β 12 (50.0%) 8 (50.0%) 4 (50.0%) 1.000 
IL-12p70 10 (41.7%) 6 (37.5%) 4 (50.0%) 0.558 
IL-15 8 (33.3%) 4 (25.0%) 4 (50.0%) 0.221 
IL-17A 10 (41.7%) 7 (43.8%) 3 (37.5%) 0.770 
Table 3.3: Detectable cytokine levels in the supernatant of 24 human PA primary cultures  
PA-derived cell culture supernatants were collected at 24h on serum-free medium and the cytokine 
secretome determined with the human Millipore MILLIPLEX cytokine 42-plex array. Data are shown as the 
n(%) of PAs with detectable cytokine levels (i.e. cytokine concentration above the lowest standard curve 
point and serum-free medium quantification). Data are shown for the overall cohort of PAs (n=24), and for 
the NFPA (n=16) and somatotrophinoma (n=8) subgroups. Chi-squared test was used to calculate p value 
for the comparative analysis between NFPAs and somatotrophinomas. 
 
 
NFPAs release higher amounts of cytokines and are more often secretory than 
somatotrophinomas 
NFPAs secreted higher amounts of cytokines/chemokines than somatotrophinomas, especially 
CCL2 (16x more), IL-8 (25x more) and CCL4 (27x more), except for FGF-2 which was found in higher 
concentrations in somatotrophinoma supernatants than in NFPAs (p=0.076) (Table 3.2 and Figure 
3.1-A).  
NFPAs were more often secretory in comparison to somatotrophinomas, particularly regarding IL- 
8 (100 vs 75%, p=0.037), CCL2 (100 vs 62.5%, p=0.009), CCL4 (87.5 vs 50%, p=0.046), IL-6 (68.8 vs 
12.5%, p=0.009), PDGF-AA (100 vs 50%, p=0.002) and IL-1α (50 vs 0%, p=0.014) (Table 3.3 and 
Figure 3.1-B). 
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Figure 3.1: Cytokine secretome differences between NFPAs and somatotrophinomas  
A) Cytokine secretome from NFPAs (n=16) and somatotrophinomas (n=8). Data are shown for the top 12 
secreted proteins as concentration (pg/mL), mean±SEM. *, <0.05, **, <0.01, ***, <0.001 (Mann Whitney U 
test). B) Percentage of NFPAs and somatotrophinomas with detectable cytokine levels (i.e. concentration 
above the lowest standard curve and serum-free medium quantification). Data are shown as percentage 
and for the top 12 secreted proteins as identified by the Millipore MILLIPLEX assay in primary cell culture 
supernatants. *, <0.05, **, <0.01, ***, <0.001 (Chi-squared test). 
 
 
 
Secretome differences between NFPAs and somatotrophinomas were not explained by pre-
operative SSA treatment, as there were no secretome differences between pre-treated and non-
pre-treated somatotrophinomas (Figure 3.2-A), nor by the cytokeratin granulation pattern in 
somatotrophinomas as there were no secretome differences between sparsely-granulated and 
densely-granulated somatotrophinomas (Figure 3.2-B). 
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Figure 3.2: Somatotrophinoma secretome according to pre-operative SSA or granulation pattern 
A) Cytokine secretome from somatotrophinomas treated pre-operatively with somatostatin analogues (Pre-
op SSA, n=5) vs not treated (No pre-op SSA, n=3). B) Cytokine secretome from densely-granulated (n=3) vs 
sparsely-granulated (n=5) somatotrophinomas. Data are shown for the top 12 secreted proteins as 
concentration (pg/mL), mean±SEM. p values were non-significant (Mann Whitney U test). 
 
 
Cytokine secretome of PAs and clinico-pathological features 
The PA-derived cytokine secretome was not significantly associated per se with an elevated Ki-67 
or cavernous sinus invasion (Table 3.4), recognised markers of PA aggressiveness7,37,43,527. Less 
proliferative PAs showed a tendency to have higher absolute concentrations for most of the top 
12 highly secreted cytokines. Regarding cavernous sinus invasion, there were no significant 
differences (or trends) among invasive and non-invasive PAs for each one of the top 12 highly 
secreted cytokines (Table 3.4). There were also no cytokine secretome differences among the 
different PA grades (Table 3.5) according to the prognostic grade classification proposed by 
Trouillas et al.43.  
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Cytokine/ 
Chemokine/ 
Growth factor 
Ki-67 
Mean concentration (pg/mL) ± SEM 
Cavernous sinus invasion 
Mean concentration (pg/mL) ± SEM 
<3% 
(n=19) 
≥3% 
(n=5) 
p value 
No 
(n=14) 
Yes 
(n=10) 
p value 
IL-8 1058.49 ± 556.36 77.80 ± 36.54 0.383 821.71 ± 620.08 899.64 ± 664.01 0.934 
CCL2 674.97 ± 227.06 209.67 ± 113.38 0.135 593.55 ± 322.21 556.30 ± 306.65 0.936 
CCL3 185.26 ± 110.61 18.66 ± 9.97 0.455 70.81 ± 36.77 262.20 ± 206.46 0.295 
CCL4 114.41 ± 59.03 17.66 ± 6.48 0.417 84.23 ± 63.50 108.29 ± 73.96 0.808 
CXCL10 92.76 ± 59.83 15.55 ± 9.24 0.522 91.91 ± 75.42 55.34 ± 47.92 0.714 
CCL22 65.30 ± 20.95 74.66 ± 14.47 0.826 78.82 ± 27.21 51.06 ± 13.11 0.426 
CXCL1 69.62 ± 32.76 24.89 ± 10.52 0.499 49.45 ± 28.33 75.49 ± 50.22 0.634 
CX3CL1 40.54 ± 21.56 14.60 ± 2.73 0.550 45.21 ± 28.93 21.03 ± 8.21 0.498 
FGF-2 25.75 ± 3.95 30.06 ± 14.01 0.681 27.46 ± 4.88 25.52 ± 7.44 0.822 
IL-6 31.24 ± 24.26 0.82 ± 0.26 0.534 34.44 ± 32.68 11.54 ± 9.18 0.570 
PDGF-AA 25.09 ± 8.21 12.00 ± 9.06 0.445 30.15 ± 10.65 11.54 ± 9.18 0.179 
VEGF-A 15.79 ± 4.83 16.04 ± 7.54 0.981 18.71 ± 5.98 11.84 ± 5.10 0.417 
Table 3.4: Cytokine secretome of PAs according to Ki-67 and cavernous sinus invasion 
Data are shown as concentration (pg/mL), mean±SEM for the top 12 secreted cytokines/chemokines as 
identified by the Millipore MILLIPLEX assay in the primary cell culture supernatants of the 24 PAs. p values 
were non-significant for the comparative analysis between less vs more proliferative PAs, as well as for PAs 
without or with cavernous sinus invasion (Mann Whitney U test). 
 
 
Cytokine/ 
Chemokine/ 
Growth factor 
Grade 1a (non-invasive 
and non-proliferative) 
n=11 
Grade 1b (non-invasive 
and proliferative) 
n= 3 
Grade 2a  
(invasive) 
n=8 
Grade 2b (invasive 
and proliferative)  
n=2 
p 
value 
IL-8 1032.91 ± 784.43 47.31 ± 21.31  1093.67 ± 825.47 123.53 ± 92.23 0.867 
CCL2 676.41 ± 408.35 289.75 ± 182.92 672.99 ± 375.84 89.56 ± 64.15 0.876 
CCL3 82.66 ± 46.46 27.35 ± 15.37 326.34 ± 256.07 5.62 ± 1.49 0.588 
CCL4 100.99 ± 80.84 22.73 ± 10.04 132.84 ± 91.44 10.07 ± 4.60 0.871 
CXCL10 111.92 ± 95.97 18.52 ± 15.91 66.41 ± 60.01 11.08 ± 7.74 0.907 
CCL22 82.43 ± 34.62 65.58 ± 33.15 41.76 ± 13.78 88.27 ± 26.21 0.759 
CXCL1 55.12 ± 36.07 28.64 ± 15.09 89.54 ± 62.45 19.26 ± 19.26 0.862 
CX3CL1 54.31 ± 36.69 11.86 ± 1.10 21.62 ± 10.32 18.70 ± 6.54 0.802 
FGF-2 28.02 ± 5.48 25.41 ± 13.03 22.64 ± 5.83 37.04 ± 37.04 0.843 
IL-6 43.60 ± 41.57 0.87 ± 0.48 14.24 ± 11.41 0.76 ± 0.08 0.854 
PDGF-AA 33.73 ± 12.97 17.01 ± 15.57 13.20 ± 6.76 4.49 ± 0.60 0.491 
VEGF-A 18.75 ± 7.05 18.54 ± 13.14 11.73 ± 6.39 12.29 ± 5.20 0.890 
Table 3.5: Cytokine secretome of PAs according to Trouillas grade classification system 
Data are shown as concentration (pg/mL), mean±SEM for the top 12 secreted cytokines/chemokines as 
identified by the Millipore MILLIPLEX assay in primary cell culture supernatants of the 24 PAs. p values were 
not significant for the comparison for each cytokine among different grades (one-way ANOVA test). 
 
There were also no differences between cytokine-secreting vs non-secreting PAs and high Ki-67 
or presence of cavernous sinus invasion (Table 3.6) or tumour grade (Table 3.7). However, there 
was a tendency for more proliferative PAs being more often secretory, particularly for CCL4 
(p=0.147), CCL22 (p=0.052), IL-6 (p=0.132) and VEGF-A (p=0.147), and more invasive PAs tended 
to be more often secretory for CCL4 (p=0.151). 
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Cytokine-
secreting PAs 
Ki-67 Cavernous sinus invasion 
<3% 
(n=19) 
≥3% 
(n=5) 
p value 
No 
(n=14) 
Yes 
(n=10) 
p value 
IL-8 17 (89.5%) 5 (100%) 0.449 13 (92.9%) 9 (90.0%) 0.803 
CCL2 16 (84.2%) 5 (100%) 0.342 12 (85.7%) 9 (90.0%) 0.754 
CCL3 18 (94.7%) 4 (80.0%) 0.289 12 (85.7%) 10 (100%) 0.212 
CCL4 13 (68.4%) 5 (100%) 0.147 9 (64.3%) 9 (90.0%) 0.151 
CXCL10 10 (52.6%) 4 (80.0%) 0.269 7 (50.0%) 7 (70.0%) 0.327 
CCL22 10 (52.6%) 5 (100%) 0.052 8 (57.1%) 7 (70.0%) 0.521 
CXCL1 9 (47.4%) 3 (60.0%) 0.615 6 (42.9%) 6 (60.0%) 0.408 
CX3CL1 14 (73.7%) 5 (100%) 0.197 11 (78.6%) 8 (80.0%) 0.932 
FGF-2 16 (84.2%) 3 (60.0%) 0.236 12 (85.7%) 7 (70.0%) 0.350 
IL-6 8 (42.1%) 4 (80.0%) 0.132 7 (50.0%) 5 (50.0%) 1.000 
PDGF-AA 15 (78.9%) 5 (100%) 0.261 13 (92.9%) 7 (70.0%) 0.139 
VEGF-A 13 (68.4%) 5 (100%) 0.147 11 (78.6%) 7 (70.0%) 0.633 
Table 3.6: Ki-67 and cavernous sinus invasion among cytokine-secreting PAs 
Data are shown as n(%) representing the proportion of PAs with detectable cytokine levels (i.e. cytokine 
secreting PAs) regarding the top 12 secreted proteins as identified by the Millipore MILLIPLEX assay in the 
primary cell culture supernatants of the 24 PAs. p values were non-significant for the comparison between 
less vs more proliferative PAs, and PAs without vs with cavernous sinus invasion (Chi-squared test). 
 
 
Cytokine-
secreting PAs 
Grade 1a (non-invasive 
and non-proliferative) 
n=11 
Grade 1b (non-invasive 
and proliferative) 
n= 3 
Grade 2a  
(invasive) 
n=8 
Grade 2b (invasive 
and proliferative)  
n=2 
p 
value 
IL-8 10 (90.9%) 3 (100%) 7 (87.5%) 2 (100%) 0.886 
CCL2 9 (81.8%) 3 (100%) 7 (87.5%) 2 (100%) 0.792 
CCL3 10 (90.9%) 2 (66.7%) 8 (100%) 2 (100%) 0.338 
CCL4 6 (54.5%) 3 (100%) 7 (87.5%) 2 (100%) 0.188 
CXCL10 5 (45.5%) 2 (66.7%) 5 (62.5%) 2 (100%) 0.508 
CCL22 5 (45.5%) 3 (100%) 5 (62.5%) 2 (100%) 0.225 
CXCL1 4 (36.4%) 2 (66.7%) 5 (62.5%) 1 (50.0%) 0.648 
CX3CL1 8 (72.7%) 3 (100%) 6 (75.0%) 2 (100%) 0.642 
FGF-2 10 (90.9%) 2 (66.7%) 6 (75.0%) 1 (50.0%) 0.509 
IL-6 5 (45.5%) 2 (66.7%) 3 (37.5%) 2 (100%) 0.403 
PDGF-AA 10 (90.9%) 3 (100%) 5 (62.5%) 2 (100%) 0.266 
VEGF-A 8 (72.7%) 3 (100%) 5 (62.5%) 2 (100%) 0.500 
Table 3.7: Trouillas grade classification among cytokine-secreting PAs 
Data are shown as n(%) representing the proportion of PAs with detectable cytokine levels (i.e. cytokine 
secreting PAs) regarding the top 12 secreted proteins as identified by the Millipore MILLIPLEX assay in the 
primary cell culture supernatants of the 24 PAs. p values were non-significant for the comparative analysis 
between the different PA grades (Chi-squared test). 
 
The supernatants of cultured PA cells from male patients had in general higher absolute levels of 
cytokines than those from females, nearly significant for IL-8 (p=0.088), CCL2 (p=0.092) and CCL4 
(p=0.097) (Figure 3.3). It is unclear, however, if there is a gender difference in the PA cytokine 
secretome, or whether this finding is only due to the higher proportion of males in the NFPA group 
(75%), the more active PA subtype in terms of cytokine secretion (Table 3.2 and Figure 3.1). 
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Figure 3.3: Cytokine secretome of PAs according to gender 
Data are shown as concentration (pg/mL), mean±SEM for the top 12 secreted cytokines as identified by the 
Millipore MILLIPLEX assay in primary culture supernatants of 24 PAs. p values were non-significant (Mann 
Whitney U test). 
 
 
In general, except for FGF-2, CX3CL1 and VEGF-A, the age at diagnosis positively correlated with 
the concentration of cytokines, significant for IL-8 and CCL4 and borderline for IL-6 (p=0.051) 
(Table 3.8), suggesting that older patients may have PAs secreting more actively cytokines.  
 age at diagnosis (years) n pituitary deficiencies at diagnosis 
IL-8 
Pearson correlation r 0.435 0.047 
p value 0.034 0.831 
CCL2 
Pearson correlation r 0.264 0.177 
p value 0.213 0.419 
CCL3 
Pearson correlation r 0.319 0.247 
p value 0.128 0.255 
CCL4 
Pearson correlation r 0.419 0.107 
p value 0.041 0.628 
CXCL10 
Pearson correlation r -0.057 0.188 
p value 0.828 0.390 
CCL22 
Pearson correlation r 0.053 -0.270 
p value 0.807 0.213 
CXCL1 
Pearson correlation r 0.342 0.098 
p value 0.101 0.658 
CX3CL1 
Pearson correlation r -0.038 0.072 
p value 0.860 0.743 
FGF-2 
Pearson correlation r -0.385 -0.430 
p value 0.063 0.041 
IL-6 
Pearson correlation r 0.403 -0.115 
p value 0.051 0.601 
PDGF-AA 
Pearson correlation r 0.298 -0.128 
p value 0.158 0.562 
VEGF-A 
Pearson correlation r -0.117 -0.162 
p value 0.585 0.461 
Table 3.8: Cytokine secretome of PAs and age or number of pituitary deficiencies at diagnosis  
p value was determined by the Pearson correlation coefficient r. 
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Headache, visual impairment and hypopituitarism at diagnosis are clinical features suggestive of 
more aggressive behaviour of PAs, as they usually are more common in patients with large and 
invasive PAs7. There were no secretome differences between PAs presented with headache vs no 
headache (Figure 3.4-A), or those who presented with visual impairment vs normal vision (Figure 
3.4-B). Similarly, there were also no differences between PAs associated with hypopituitarism at 
diagnosis vs those diagnosed in eupituitarism (Figure 3.4-C), as well as no correlation between the 
number of pituitary deficiencies at diagnosis and the different PA-derived cytokines, excepting the 
significant negative correlation with FGF-2 (Table 3.6). 
 
Figure 3.4: Cytokine secretome of PAs according to headache, visual impairment or hypopituitarism at 
diagnosis 
Data are shown as concentration (pg/mL), mean±SEM for the top 12 secreted cytokines/chemokines as 
identified by the Millipore MILLIPLEX assay in primary culture supernatants of 24 PAs. P values were non-
significant for the different comparative analysis (Mann Whitney U test). 
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Patients with no headache at diagnosis had less often IL-8-secreting PAs (p=0.037), while visual 
impairment at diagnosis was more frequent in CCL2 (p=0.044) and PDGF-AA (p=0.017) secreting 
PAs, but there were no other significant associations between cytokine-secreting vs non-secreting 
PAs and headache, visual impairment or hypopituitarism at diagnosis (Table 3.9).  
Cytokine-
secreting 
PAs 
Headache Visual impairment Hypopituitarism at diagnosis 
No 
(n=16) 
Yes 
(n=8) 
p 
value 
No 
(n=11) 
Yes 
(n=13) 
p 
value 
No 
(n=13) 
Yes 
(n=11) 
p 
value 
IL-8 16 (100%) 6 (75.0%) 0.037 9 (81.8%) 13 (100%) 0.108 12 (92.3%) 10 (90.9%) 0.902 
CCL2 14 (87.5%) 7 (87.5%) 1.000 8 (72.7%) 13 (100%) 0.044 11 (84.6%) 10 (90.9%) 0.642 
CCL3 15 (93.8%) 7 (87.5%) 0.602 10 (90.9%) 12 (92.3%) 0.902 13 (100%) 9 (81.8%) 0.108 
CCL4 11 (68.8%) 7 (87.5%) 0.317 8 (72.7%) 10 (76.9%) 0.813 10 (76.9%) 8 (72.7%) 0.813 
CXCL10 8 (50.0%) 6 (75.0%) 0.242 7 (63.6%) 7 (53.8%) 0.628 8 (61.5%) 6 (54.5%) 0.729 
CCL22 9 (56.2%) 6 (75.0%) 0.371 7 (63.6%) 8 (61.5%) 0.916 7 (53.8%) 8 (72.7%) 0.341 
CXCL1 7 (43.8%) 5 (62.5%) 0.386 6 (54.5%) 6 (46.2%) 0.682 6 (46.2%) 6 (54.5%) 0.682 
CX3CL1 12 (75.0%) 7 (87.5%) 0.477 7 (63.6%) 12 (92.3%) 0.085 10 (76.9%) 9 (81.8%) 0.769 
FGF-2 12 (75.0%) 7 (87.5%) 0.477 10 (90.9%) 9 (69.2%) 0.193 11 (84.6%) 8 (72.7%) 0.475 
IL-6 8 (50.0%) 4 (50.0%) 1.000 4 (36.4%) 8 (61.5%) 0.219 5 (38.5%) 7 (63.6%) 0.219 
PDGF-AA 15 (93.8%) 5 (62.5%) 0.053 7 (63.6%) 13 (100%) 0.017 10 (76.9%) 10 (90.9%) 0.360 
VEGF-A 12 (75.0%) 6 (75.0%) 1.000 7 (63.6%) 11 (84.6%) 0.237 11 (84.6%) 7 (63.6%) 0.237 
Table 3.9: Headache, visual damage and hypopituitarism at diagnosis among cytokine-secreting PAs 
Data are shown as n(%) representing the proportion of PAs with detectable cytokine levels (i.e. cytokine 
secreting PAs) regarding the top 12 secreted proteins as identified by the Millipore MILLIPLEX assay in the 
primary culture supernatants from 24 PAs. p values were non-significant for the comparison between PAs 
with vs without headache, visual impairment or hypopituitarism at diagnosis (Chi-squared test). 
 
 
Association between cytokine secretome and clinico-pathological features 
Taking into account that the cytokine secretome between NFPAs and somatotrophinomas was 
significantly different (Table 3.2 and Figure 3.1-A), clinical features were analysed in each 
subgroup aiming to dissect potential associations between secreted cytokines and clinico-
pathological features within NFPAs or somatotrophinomas.  
In general, less proliferative NFPAs tended to have higher absolute concentrations of cytokines 
than those with a Ki-67≥3%, although lacking statistical significance (trend for CCL2, p=0.079) 
(Figure 3.5-A). The opposite was observed for somatotrophinomas, although we had only one case 
with Ki-67≥3% which secreted significantly more CCL4 and FGF-2 than less proliferative 
somatotrophinomas (Figure 3.5-B). No secretome differences were seen between non-invasive 
PAs and PAs invading the cavernous sinus, either in NFPAs (Figure 3.5-C) or somatotrophinomas 
(Figure 3.5-D). 
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Figure 3.5: NFPAs and somatotrophinomas secretome according to Ki-67 and cavernous sinus invasion 
A) NFPA cytokine secretome according to Ki-67; B) Somatotrophinoma cytokine secretome according to Ki-
67; C) NFPA cytokine secretome according to cavernous sinus invasion; D) Somatotrophinoma cytokine 
secretome according to cavernous sinus invasion. Data are shown as concentration (pg/mL), mean±SEM 
and for the top 12 secreted proteins as identified by the Millipore MILLIPLEX assay in the primary culture 
supernatants of the 24 PAs. *, <0.05, **, <0.01, ***, <0.001 (Mann Whitney U test). 
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In general, there were no differences regarding low/high Ki-67 and absence/presence of 
cavernous sinus invasion between cytokine-secreting vs NFPAs or somatotrophinomas not 
secreting cytokines (Table 3.10). 
 Ki-67 Cavernous sinus invasion 
<3% ≥3% p value No Yes p value 
C
yt
o
ki
n
e
-s
e
cr
e
ti
n
g 
N
FP
A
s 
(n
=
1
6
) 
IL-8 12/12 (100%) 4/4 (100%) 1.000 10/10 (100%) 6/6 (100%) 1.000 
CCL2 12/12 (100%) 4/4 (100%) 1.000 10/10 (100%) 6/6 (100%) 1.000 
CCL3 12/12 (100%) 3/4 (75.0%) 0.074 9/10 (90.0%) 6/6 (100%) 0.424 
CCL4 10/12 (83.3%) 4/4 (100%) 0.383 8/10 (80.0%) 6/6 (100%) 0.242 
CXCL10 7/12 (58.3%) 3/4 (75.0%) 0.551 6/10 (60.0%) 4/6 (66.7%) 0.790 
CCL22 6/12 (50.0%) 4/4 (100%) 0.074 6/10 (60.0%) 4/6 (66.7%) 0.790 
CXCL1 6/12 (50.0%) 2/4 (50.0%) 1.000 5/10 (50.0%) 3/6 (50.0%) 1.000 
CX3CL1 10/12 (83.3%) 4/4 (100%) 0.383 9/10 (90.0%) 5/6 (83.3%) 0.696 
FGF-2 9/12 (75.0%) 2/4 (50.0%) 0.350 8/10 (80.0%) 3/6 (50.0%) 0.210 
IL-6 8/12 (66.7%) 3/4 (75.0%) 0.755 7/10 (70.0%) 4/6 (66.7%) 0.889 
PDGF-AA 12/12 (100%) 4/4 (100%) 1.000 10/10 (100%) 6/6 (100%) 1.000 
VEGF-A 9/12 (75.0%) 4/4 (100%) 0.267 9/10 (90.0%) 4/6 (66.7%) 0.247 
C
yt
o
ki
n
e
-s
e
cr
e
ti
n
g 
so
m
at
o
tr
o
p
h
in
o
m
as
  (
n
=8
) 
IL-8 5/7 (71.4%) 1/1 (100%) 0.537 3/4 (75.0%) 3/4 (75.0%) 1.000 
CCL2 4/7 (57.1%) 1/1 (100%) 0.408 2/4 (50.0%) 3/4 (75.0%) 0.465 
CCL3 6/7 (85.7%) 1/1 (100%) 0.686 3/4 (75.0%) 4/4 (100%) 0.285 
CCL4 3/7 (42.9%) 1/1 (100%) 0.285 1/4 (25.0%) 3/4 (75.0%) 0.157 
CXCL10 3/7 (42.9%) 1/1 (100%) 0.285 1/4 (25.0%) 3/4 (75.0%) 0.157 
CCL22 4/7 (57.1%) 1/1 (100%) 0.408 2/4 (50.0%) 3/4 (75.0%) 0.465 
CXCL1 3/7 (42.9%) 1/1 (100%) 0.285 1/4 (25.0%) 3/4 (75.0%) 0.157 
CX3CL1 4/7 (57.1%) 1/1 (100%) 0.408 2/4 (50.0%) 3/4 (75.0%) 0.465 
FGF-2 7/7 (100%) 1/1 (100%) 1.000 4/4 (100%) 4/4 (100%) 1.000 
IL-6 0/7 (100%) 1/1 (100%) 0.005 0/4 (0%) 1/4 (25.0%) 0.285 
PDGF-AA 3/7 (42.9%) 1/1 (100%) 0.285 3/4 (75.0%)  1/4 (25.0%) 0.157 
VEGF-A 4/7 (57.1%) 1/1 (100%) 0.408 2/4 (50.0%) 3/4 (75.0%) 0.465 
Table 3.10: Ki-67 and cavernous sinus invasion in cytokine-secreting NFPAs and somatotrophinomas 
Data are shown as n cases/total cases (% of the total) representing the proportion of PAs with detectable 
cytokine levels (i.e. cytokine secreting PAs) regarding the top 12 secreted proteins as identified by the 
Millipore MILLIPLEX assay in the primary culture supernatants of the 24 PAs. p values were non-significant 
for the comparative analysis between less vs more proliferative PAs, as well as for PAs without or with 
cavernous sinus invasion (Chi-squared test). 
 
There were no differences between the cytokine secretome of NFPAs or somatotrophinomas that 
presented with headache vs no headache (Figure 3.6-A). There were also no differences within 
NFPAs presenting with visual impairment vs normal vision, or hypopituitarism vs eupituitarism at 
diagnosis (Figure 3.6-B). Within somatotrophinomas, of the 8 cases only 1 presented with visual 
impairment at diagnosis and only 2 had hypopituitarism at diagnosis, and their secretomes did not 
seem to differ from cases with normal vision or eupituitarism at diagnosis (statistical analysis not 
shown in Figure 3.6 due to low sample sizes for this subgroup analysis).  
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Supernatants of cultured NFPAs from male patients had in general higher absolute levels of 
cytokines than those from females except for FGF-2 (non-significant p value), whereas 
somatotrophinoma females had higher absolute concentrations of almost all cytokines, although 
statistical significance was lacking (Figure 3.6-C). Hence, the gender effect in the NFPA or 
somatotrophinoma cytokine secretion is unclear. 
Figure 3.6: Cytokine secretome NFPAs and somatotrophinomas according to different clinical features 
A) Headache at diagnosis shown for both NFPAs and somatotrophinomas; B) Visual impairment and 
hypopituitarism at diagnosis for NFPAs; C) Gender distribution for both NFPAs and somatotrophinomas. 
Data are shown as concentration (pg/mL), mean±SEM for the top 12 secreted proteins as identified by the 
Millipore MILLIPLEX assay in primary culture supernatants of the 24 PAs. p values were non-significant 
(Mann Whitney U test). 
 
Patients with acromegaly often have increased PRL7,170. Somatotrophinomas from patients with 
concomitant hyperprolactinaemia at diagnosis had increased levels of IL-8 in their supernatants 
comparing to those with a normal serum PRL (Figure 3.7). CCL4 and FGF-2 levels in 
somatotrophinoma supernatants were positively correlated with serum PRL, while PDGF-AA and 
VEGF-A were positively associated with basal GH and IGF-1 levels (Figure 3.8).  
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Figure 3.7: Cytokine secretome of somatotrophinomas with normal PRL or hyperprolactinaemia 
Data are shown as concentration (pg/mL), mean±SEM for the top 12 secreted cytokines/ chemokines as 
identified by the Millipore MILLIPLEX assay in primary culture supernatants of the 6 somatotrophinoma 
cases with available PRL biochemical data. *, <0.05, **, <0.01, ***, <0.001 (Mann Whitney U test). 
 
 
 
Figure 3.8: Correlation between cytokine secretome from somatotrophinomas and serum hormones  
p value was determined by the Pearson correlation coefficient r. 
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There were no significant correlations between the cytokine secretome from NFPAs and serum 
pituitary hormone levels, but this needs to be interpreted cautiously as most NFPA patients had 
hypopituitarism at diagnosis related to the tumour mass effect, thus limiting the conclusions 
regarding a possible effect of cytokines on hormone secretion among NFPAs (Table 3.11). 
Cytokine/ Chemokine/ 
Growth factor 
GH 
(mcg/L) 
IGF-1 
(nmol/L) 
PRL 
(mU/L) 
TSH 
(µU/mL) 
FT4 
(pmol/L) 
LH 
(U/L) 
FSH 
(U/L) 
Cortisol 
(nmol/L) 
 
IL-8        Pearson r -0.197 -0.050 -0.281 0.118 -0.179 -0.188 -0.191 -0.132 
                p value 0.539 0.866 0.330 0.688 0.541 0.520 0.512 0.667 
                    n 12 14 14 14 14 14 14 13 
 
CCL2        Pearson r -0.259 -0.159 -0.353 0.135 -0.265 -0.253 -0.177 -0.253 
                  p value 0.417 0.588 0.216 0.646 0.361 0.383 0.546 0.405 
                    n 12 14 14 14 14 14 14 13 
 
CCL3        Pearson r -0.117 0.133 -0.222 0.009 -0.282 -0.177 -0.169 -0.099 
                  p value 0.718 0.649 0.445 0.976 0.329 0.546 0.564 0.747 
                    n 12 14 14 14 14 14 14 13 
 
CCL4        Pearson r -0.220 -0.087 -0.307 0.117 -0.224 -0.207 -0.188 -0.128 
                  p value 0.491 0.767 0.286 0.691 0.442 0.479 0.521 0.677 
                    n 12 14 14 14 14 14 14 13 
 
CXCL10   Pearson r -0.226 -0.106 -0.245 0.073 -0.225 -0.220 -0.126 -0.316 
                 p value 0.481 0.718 0.398 0.803 0.439 0.449 0.668 0.293 
                    n 12 14 14 14 14 14 14 13 
 
CXCL1    Pearson r -0.139 0.058 -0.268 0.093 -0.212 -0.177 -0.167 -0.060 
                p value 0.666 0.844 0.354 0.753 0.467 0.545 0.568 0.844 
                    n 12 14 14 14 14 14 14 13 
 
CCL22    Pearson r -0.025 -0.031 -0.137 0.174 -0.022 -0.173 -0.180 0.195 
                p value 0.938 0.917 0.641 0.553 0.939 0.555 0.538 0.523 
                    n 12 14 14 14 14 14 14 13 
 
CX3CL1   Pearson r -0.204 -0.004 -0.229 0.091 -0.165 -0.204 -0.145 -0.283 
                 p value 0.525 0.989 0.430 0.757 0.572 0.484 0.621 0.350 
                    n 12 14 14 14 14 14 14 13 
 
FGF-2      Pearson r 0.264 0.264 -0.134 0.137 0.143 0.058 0.047 0.158 
                p value 0.407 0.362 0.649 0.641 0.626 0.845 0.873 0.606 
                    n 12 14 14 14 14 14 14 13 
 
PDGF-AA Pearson r -0.253 -0.099 -0.482 0.118 -0.002 -0.023 -0.041 -0.070 
                  p value .427 0.736 0.081 0.689 0.995 0.938 0.889 0.819 
                    n 12 14 14 14 14 14 14 13 
 
VEGF-A   Pearson r -0.220 -0.074 -0.362 0.204 -0.083 -0.003 -0.080 0.043 
                 p value .493 0.801 0.203 0.484 0.778 0.993 0.786 0.890 
                    n 12 14 14 14 14 14 14 13 
Table 3.11: Correlation between cytokine secretome of NFPAs and serum hormonal levels 
 p value was determined by the Pearson correlation coefficient r. 
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Infiltrating immune cells in human pituitary adenomas 
In the same cohort of PAs used for primary culture and cytokine secretome assessment, I analysed 
macrophages, CD4+ T helper cells, cytotoxic CD8+ T cells, FOXP3+ Tregs, B cells and neutrophils 
by immunohistochemistry; 5 NP sections were also included for comparison (Figure 3.9). 
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Figure 3.9: Immunohistochemical analysis of immune cells in PAs and NPs  
Immune cells analysed: macrophages (CD68+), cytotoxic T lymphocytes (CD8+), T helper lymphocytes 
(CD4+), T regulatory cells (FOXP3+), B cells (CD20+) and neutrophils (neutrophil elastase+).  Data are shown 
as mean±SEM for percentage of immune cells compared to the total number of tumour cells, and for 
CD8:CD4 or CD8:FOXP3 cell ratios. Representative images are shown for a NFPA, somatotrophinoma and 
NP (normal pituitary). Scale bar 50µm. PAs, n=24; NPs, n=5. *,<0.05, **,<0.01, ***,<0.001 (two-way ANOVA 
with Bonferroni test for immunopositive cell analysis; Mann Whitney U test for ratios analysis).  
 
Compared to NPs, PAs contained more CD68+ macrophages (4.6±0.4 vs 1.2±0.2%, p<0.001) and 
CD4+ T cells (1.0±0.1 vs 0.6±0.1%, p=0.005), but fewer neutrophils (0.7±0.2 vs 1.4±0.1%, p=0.047) 
and a trend for fewer CD8+ T cells (1.8±0.2 vs 2.6±0.3%, p=0.077), with a significant 2-fold 
decrease in the CD8:CD4 cell ratio. There were no significant differences in B cell or FOXP3+ T cell 
contents between PAs and NPs, or the CD8:FOXP3 cell ratio (Figure 3.9). Macrophages were the 
most abundant immune cell type in PAs, while other immune cells were present in lower amounts 
(Figure 3.9). Macrophages in PAs are predominantly M2-macrophages (CD163+), while M1-
macrophages (HLA-DR+) predominate in NPs, resulting in a 3-fold increased M2:M1 macrophage 
ratio in PAs (Figure 3.10-A). This predominant M2-macrophage phenotype in PAs may be due, at 
least in part, to higher concentrations of PA-derived M2-polarising cytokines, as IL-4 levels were 
almost 5x higher than IFNγ, a classical M1-polarising cytokine (Figure 3.10-B). 
 
Figure 3.10: M2- and M1-like macrophages and macrophage-polarising cytokines in PAs 
A) Immunohistochemical analysis of M2 (CD163+) and M1 (HLA-DR+) macrophages in PAs and normal 
pituitary (NP). Data are shown as mean±SEM for M2:M1 macrophage ratio and for the number of CD163+ 
and HLA-DR+ cells per high power field (HPF). Representative images are shown for a PA and NP. Scale bar 
50µm. ***, <0.001 (Mann Whitney U test and two-way ANOVA with Bonferroni multiple comparison test). 
B) Macrophage-polarising cytokines in PA culture supernatants. Supernatants were collected at 24h in 
serum-free medium conditions and cytokine secretome determined with the human Millipore MILLIPLEX 
cytokine 42-plex array. Results are shown as concentration (pg/mL), mean±SEM for IL-4 and IL-10 (M2-
polarising cytokines, blue bars) and IFNγ (M1-polarising cytokine, green bar). *,<0.05, **,<0.01, ***,<0.001 
(one-way ANOVA with Bonferroni multiple comparison test). 
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These immunohistochemical findings were confirmed on a different set of samples (7 PAs, 
including 4 NFPAs and 3 somatotrophinomas, as well as 5 NPs) using available gene expression 
data analysed with xCell. PAs had a higher xCell score than NPs for macrophages (0.090±0.016 vs 
0.031±0.013; p=0.025) and for M2 macrophages (0.042±0.007 vs 0; p=0.001) (Figure 3.11). 
Although significant differences were only observed for macrophages, I noted a tendency for a 
higher absolute xCell score regarding CD4+ T and B cells, and lower scores for CD8+ T cells and 
neutrophils, in PAs than in NPs in line with my immunohistochemical data. Moreover, the mean 
M2:M1 and CD8:CD4 ratios estimated from xCell, were respectively higher and lower in PAs than 
those observed in NPs (Figure 3.11), consistent with my immunohistochemical data.  
 
Figure 3.11: xCell scores in PAs and NPs 
xCell Fraction Scores were obtained from microarray expression data from a different set of samples (7 PAs, 
4 NFPAs and 3 somatotrophinomas; and 5 NPs). Data are shown as xCell Score, mean±SEM for the immune 
cell types and cell ratios previously analysed by immunohistochemistry in our cohort of 24 PAs. *, <0.05, **, 
<0.01, ***, <0.001 (Mann Whitney U test). 
 
Significant correlations were observed between PA-infiltrating immune populations, namely CD8+ 
and CD4+ T cells, CD8+ and FOXP3+ T cells, CD4+ T cells and neutrophils (Table 3.12). 
n PAs = 24 % of 
macrophages 
% of CD8+ 
T cells 
% of CD4+ 
T cells 
% of B 
cells 
% of 
neutrophils 
% of FOXP3 
Tregs 
% of 
macrophages 
Pearson correlation r 1 .349 .198 -.351 .035 .354 
p value  .095 .354 .093 .872 .089 
% of CD8+ T 
cells 
Pearson correlation r .349 1 .534** -.128 .360 .504* 
p value .095  .007 .553 .084 .012 
% of CD4+ T 
cells 
Pearson correlation r .198 .534** 1 .187 .490* .389 
p value .354 .007  .381 .015 .060 
% of B cells 
Pearson correlation r -.351 -.128 .187 1 -.092 -.060 
p value .093 .553 .381  .670 .780 
% of 
neutrophils 
Pearson correlation r .035 .360 .490* -.092 1 .050 
p value .872 .084 .015 .670  .817 
% of FOXP3+ 
Tregs 
Pearson correlation r .354 .504* .389 -.060 .050 1 
p value .089 .012 .060 .780 .817  
Table 3.12: Correlation between infiltrating immune cells in PAs 
 P value was determined by the Pearson correlation coefficient r. 
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NFPAs had more neutrophils than somatotrophinomas (0.9±0.1 vs 0.1±0.1%, p=0.002), but there 
were no differences regarding other immune cells, neither M2:M1, CD8:CD4 nor CD8:FOXP3 cell 
ratios (Table 3.13). There were no significant differences in infiltrating immune cells among the 
different NFPA subtypes (Table 3.13). 
 Gonadotroph 
adenoma 
(n=13) 
Silent 
corticotroph 
adenoma (n=1) 
Null cell 
adenoma 
(n=2) 
p value 
(GA vs SCA 
vs NCA) 
NFPAs 
(n=16) 
Som 
(n=8) 
p value 
(NFPA 
vs Som) 
% of macrophages 4.23 ± 0.60 4.97 6.37 ± 1.79 0.456 4.54 ± 0.54 4.66 ± 0.70 0.897 
% of CD8+ T cells 1.62 ± 0.29 1.17 1.76 ± 0.61 0.891 1.61 ± 0.24 2.09 ± 0.29 0.245 
% of CD4+ T cells 1.10 ± 0.17 0.81 1.12 ± 0.20 0.897 1.09 ± 0.14 0.96 ± 0.20 0.629 
% of B cells 1.03 ± 0.48 0.66 0.68 ± 0.18 0.946 0.97 ± 0.39 0.84 ± 0.33 0.836 
% of neutrophils 1.05 ± 0.24 0.09 0.50 ± 0.13 0.420 0.92 ± 0.21 0.14 ± 0.06 0.002 
% of FOXP3+ Tregs 0.34 ± 0.10 0.85 0.28 ± 0.34 0.372 0.37 ± 0.09 0.52 ± 0.11 0.310 
M2:M1 ratio 2.36 ± 0.22 1.98 1.96 ± 0.77 0.752 2.29 ± 0.19 1.98 ± 0.25 0.351 
CD8:CD4 ratio 1.79 ± 0.38 1.33 1.50 ± 0.23 0.391 1.73 ± 0.31 2.62 ± 0.60 0.154 
CD8: FOXP3 ratio 6.12 ± 1.12 1.33 5.08 ± 0.42 0.678 5.69 ± 0.95 5.56 ± 1.25 0.932 
Table 3.13: Immune cells and cell ratios among NFPA types, and between NFPAs vs somatotrophinomas  
Immune cells analysed: macrophages (CD68+), CD163+ macrophages, HLA-DR macrophages, cytotoxic T 
lymphocytes (CD8+), T helper lymphocytes (CD4+), T regulatory lymphocytes (FOXP3+), B cells (CD20+) and 
neutrophils (neutrophil elastase+). Data are shown as mean±SEM for percentage of immune cells compared 
to the total number of tumour cells and for cell ratios. One way-ANOVA test was used to calculate p value 
among the NFPA types: gonadotroph adenoma, silent corticotroph adenoma and null cell adenoma (GA vs 
SCA vs NCA). Mann Whitney U test was used to calculate p value for the comparison NFPAs vs 
somatotrophinomas (NFPA vs Som).  
 
 
 
Recruitment of immune cells into the TME of pituitary adenomas  
PAs with a higher macrophage content were associated with higher levels of IL-8 (p=0.023), CCL2 
(p=0.216), CCL3 (p=0.065), CCL4 (p=0.036) and CXCL1 (p=0.024) (Figure 3.12-A), chemokines 
known to promote macrophage chemotaxis209,226,333,528.  
Higher CCL2 (p=0.036), CCL4 (p=0.086), CXCL10 (p=0.134) and VEGF-A (p=0.025) levels were found 
in supernatants from PAs with higher CD8+ T cell contents (Figure 3.12-B).  
PAs with more neutrophils released higher levels of CCL2 (p=0.033) and CCL4 (p=0.044), 
chemokines classically involved in macrophage recruitment209,226,333,528 but that also attract 
neutrophils517,529,530. PA with higher contents of neutrophils also showed a trend to secrete higher 
levels of chemokines involved in neutrophil chemotaxis, namely IL-8 (p=0.073), CXCL1 (p=0.097) 
and CXCL10 (p=0.098) (Figure 3.12-C).  
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Figure 3.12: Cytokine secretome of PAs and infiltrating immune cells 
A) Cytokine secretome from primary cell culture supernatants of PAs with lower vs higher content of 
macrophages (A), CD8+ T cells (B) and neutrophils (C). The cut-offs used to define low and high immune cell 
contents were: 6% for macrophages, 1% for CD8+ T cells and 0.5% for neutrophils. Data are shown as 
concentration (pg/mL), mean±SEM for the top 12 secreted proteins. *, <0.05, **, <0.01, ***, <0.001 (Mann 
Whitney U test). 
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There were no significant associations between PA-derived cytokine secretome and infiltrating 
CD4+ T, FOXP3+ T and B cells (Figure 3.13).  
 
Figure 3.13: Cytokine secretome of PAs and infiltrating CD4+ T cells, Tregs and B cells 
The cutoffs used to define low and high immune cell contents were: 1% for CD4+ T cells, 0.5% for B cells and 
0.3% for FOXP3+ T cells. Data are shown as concentration (pg/mL), mean±SEM for the top 12 secreted 
proteins. p values were non-significant (Mann Whitney U test). 
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RNAscope data showed that CCL2 and IL-8, the two highly secreted chemokines released by the 
great majority of PAs, are mainly synthesised by pituitary tumour cells where most mRNA 
transcripts for these chemokines are detectable in the PA tissue section. However, pituitary 
tumour cells have low expression of the respective chemokine receptors CXCR2 and CCR5, which 
were in turn are strongly expressed in scattered perivascular cells morphologically distinct from 
tumour cells, likely corresponding to immune cells potentially transmigrating from the blood 
vessels into the TME of PAs (Figure 3.14). 
 
Figure 3.14: IL8-CXCR2 and CCL2-CCR5 mRNA expression in PAs 
RNAscope staining of IL8 (green)-CXCR2 (red) and CCL2 (red)-CCR5 (green) mRNA in a NFPA and in a 
somatotrophinoma. CCL2 and IL-8 are mainly expressed in pituitary tumour cells, while the chemokine 
receptors are strongly expressed in scattered perivascular cells morphologically distinct from tumour cells, 
likely corresponding to immune cells. Scale bar 20µm. 
 
PA-infiltrating immune cells did not correlate with circulating immune cell types, suggesting that 
immune infiltrates are subject to differential recruitment into the PA rather than altered bone 
marrow production (Figure 3.15). There was only one significant correlation between serum 
lymphocyte count and PA-infiltrating CD8+ T cells, but this seems to be due to an outlier case.  
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Figure 3.15: Correlation between PA tissue infiltrating and circulating immune cell subpopulations  
p values were determined by the Pearson correlation coefficient r. 
 
The role of infiltrating immune cells in the PA phenotype and aggressiveness 
PAs with a higher Ki-67 (≥3%) had a lower CD8:CD4 ratio, as well as lower CD8:FOXP3 and 
CD68:FOXP3 ratios as a result of an increased infiltration of FOXP3+ T cells (0.7±0.2 vs 0.3±0.6%; 
p=0.013) (Figures 3.16-A and B). Macrophages and CD4+ T helper lymphocytes were found in 
significantly higher amounts in PAs comparing to NP, the B cell content tended to be higher in PAs 
in immunohistochemical (Figure 3.9) and xCell (Figure 3.11) data, and FOXP3+ T cells were 
associated to a higher Ki-67 (Figure 3.16-A), suggesting the involvement of these immune cell 
types in the pituitary tumourigenic process and a “deleterious effect” in PA phenotype, as shown 
in other cancers332,359,360,531,532. In fact, all PAs with a “deleterious immune infiltrate phenotype”, 
i.e. higher content of macrophages, CD4+ T, FOXP3+ and B cells (CD68hiCD4hiFOXP3hiCD20hi) had a 
Ki-67≥3% (Figure 3.16-C and D). There were no differences between PAs with or without 
cavernous sinus invasion regarding immune cell contents or ratios (Figure 3.16-E). These data 
suggest that, at least in part, immune cells in the TME of PAs may determine increased 
aggressiveness, namely tumour proliferation. 
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Figure 3.16: Immune cell infiltrates in PAs and Ki-67 and cavernous sinus invasion 
Immune cell infiltrates (A) and cell ratios (B) in PAs with lower (<3%) vs higher (≥3%) Ki-67. PAs with lower 
Ki-67, n=19; PAs with higher Ki-67, n=5. *, <0.05, **, <0.01, ***, <0.001 (Mann Whitney U test). C) 
Percentage of PAs with Ki-67≥3% according to presence of a “deleterious immune infiltrate phenotype”, i.e. 
higher content of macrophages, CD4+ T cells, FOXP3+ T cells and B cells (CD68hiCD4hiFOXP3hiCD20hi). PAs 
with “deleterious immune infiltrate phenotype”, n=4; PAs without “deleterious immune infiltrate 
phenotype”, n=20. *, <0.05, **, <0.01, ***, <0.001 (Exact Fisher´s test). D) Representative images are shown 
from a somatotrophinoma with high Ki-67 and cavernous sinus invasion which had a “deleterious immune 
infiltrate phenotype”, and from a NFPA with low Ki-67 and no cavernous sinus invasion which did not display 
a “deleterious immune infiltrate phenotype”. Scale bar 50µm. E) Immune cell infiltrates and cell ratios in 
PAs with (n=10) vs without (n=14) cavernous sinus invasion. *, <0.05, **, <0.01, ***, <0.001 (Mann Whitney 
U test).    
 
 
M2:M1 macrophage ratio (CD163+:HLA-DR+ cells) was positively correlated with microvessel 
density (p=0.015) and total microvessel area (p<0.001) (Figure 3.17), suggesting that immune cells, 
particularly M2-macrophages, may influence PA angiogenesis (details in Chapter 5).  
Figure 3.17: M2 and M1 macrophages and angiogenesis in PAs  
Microvessel density (MVD) or total microvessel area (TMVA) correlation with M2:M1 macrophage ratio. 
Representative images are shown from samples with low and high M2:M1 macrophage ratio. Scale bar 
100µm, n=24. P values were determined by the Pearson correlation coefficient r.  
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The effect of immune cell infiltrates on the phenotype of PAs  
The immune cell infiltrates did not differ between NFPAs and somatotrophinomas, except for 
neutrophil content which was lower in somatotrophinomas (Table 3.13). Nevertheless, the effect 
of infiltrating immune cells on the phenotype of NFPAs and somatotrophinomas can be different 
considering the distinct histiotypes and the fact that gonadotrophs or somatotrophs may respond 
or interact differently with the surrounding immune cells. This could theoretically influence 
different clinico-pathological features including pituitary hormone secretion. Hence, a 
comprehensive subanalysis was performed in the subgroup of NFPAs and somatotrophinomas, 
and the results shown in the supplemental tables in Appendix 4. 
Overall, infiltrating immune cells do not seem to impact significantly on the different clinico-
pathological features among NFPAs. There were also no correlations between serum pituitary 
hormone levels and NFPA-infiltrating immune cells, except for the negative correlation noted 
between infiltrating neutrophils and IGF-1 index (r=-0.582 p=0.029). However, there was a trend 
for female patients to have higher content of macrophages and FOXP3+ T cells than males (6.0±0.7 
vs 4.1±0.6%, p=0.118 and 0.7±0.3 vs 0.3±0.1%, p=0.174, respectively), as well as a higher M2:M1 
ratio (2.8±0.4 vs 2.1±0.2, p=0.173) and lower CD8:FOXP3 (3.3±1.0 vs 6.5±1.1, p=0.154). There were 
almost significant correlations between age at diagnosis and FOXP3+ T cell amount (r=-0.480; 
p=0.060), CD8:CD4 ratio (r=0.424; p=0.102) and CD8:FOXP3 ratio (r=0.447; p=0.109). PAs with 
cavernous sinus invasion tended to be associated with a higher content of CD4+ T cells than non-
invasive ones (1.2±0.2 vs 0.9±0.1%, p=0.187). PAs with Ki-67≥3% tended to have more FOXP3+ T 
cells (0.7±0.3 vs 0.3±0.1%, p=0.163) and a significantly lower CD8:FOXP3 ratio (2.4±0.7 vs 6.8±1.1, 
p=0.037) than less proliferative PAs. The M2:M1 ratio correlated positively with microvessel area 
(r=0.676, p=0.004) (Appendix 4). 
Regarding somatotrophinomas, there were significant correlations between age at diagnosis and 
both FOXP3+ cell amount (r=-0.746; p=0.034) and M2:M1 ratio (p=0.856, p=0.007). A significantly 
higher CD8:CD4 ratio was noted in the somatotrophinoma case with visual impairment (p=0.036) 
and for the 2 cases with hypopituitarism at diagnosis (p=0.005). There were no correlations 
between infiltrating immune cells or cell ratios and GH or IGF-1 levels. There was one highly 
proliferative somatotrophinoma (Ki-67=15%) which had twice more macrophages than all others 
(8.4 vs 4.1±0.5%). M2:M1 and CD8:CD4 ratios correlated positively with microvessel density and 
area (p=0.017 and p=0.045) (Appendix 4). 
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In vitro studies investigating interactions between macrophages and pituitary tumour cells 
To study the interactions between pituitary tumour cells, modelled here by GH3 
mammosomatotroph tumour cell line, and macrophages (RAW 264.7 cell line), I established an in 
vitro model using conditioned medium (CM) from each of the cell lines as a chemoattractant agent 
for the other. My in vitro studies focused on macrophages, as these were the predominant 
immune cell type in PAs (Figure 3.9).  
I selected the murine RAW 264.7 macrophage cell line for a number of reasons: i) lack of a reliable 
rat macrophage cell line; ii) high homology between mouse and rat cytokines; iii) is an appropriate 
cell line to study cell interactions and cytokine effects, including CX3CL1,  the main GH3 cell-
derived chemokine according to my cytokine array data (Appendix 5), which express high levels of 
its receptor CX3CR1533; and iv) to validate some of Dr. Sayka Barry’s previous observations on a 
different cell model employing primary bone-marrow derived rat macrophages and GH3 cells513. 
Figure 3.18 illustrates the in vitro cell model and the functional studies to investigate the 
interaction between pituitary tumour cells and macrophages. Briefly, RAW 264.7 macrophages 
were cultured with GH3-CM. Following washes and medium change, supernatants were collected 
at 24h and secretome changes assessed by cytokine bead array and RT-qPCR. I performed also 
morphology studies and chemotaxis assay to study how GH3 tumour cells influence macrophages. 
Flow cytometry and RT-qPCR experiments were conducted to assess whether GH3-CM induce 
macrophage polarisation assessing different M1-like (CD86, IFNyhigh, IL-12high) and M2-like (CD163, 
CD206, IL-10high, IL-12low) macrophage markers before and after treatment with GH3-CM. On the 
other hand, GH3 cells were cultured with macrophage-CM. Secretome profile using cytokine 
array, morphological studies, RT-qPCR and immunocytochemistry for EMT markers (E-cadherin, 
ZEB1) were performed. I also performed transwell and wound healing migration assays and 
matrigel invasion assays to evaluate how macrophages influence GH3 cells migratory behaviour. 
 
Figure 3.18: In vitro cell model using GH3 cells and RAW 264.7 macrophages 
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GH3 cell-derived factors increase macrophage chemotaxis and alter their morphology 
To investigate the role of GH3 cell-derived factors in macrophage chemotaxis, I performed a 
transwell migration assay experiment in which I observed a remarkable 36-fold increase in 
macrophage migration towards GH3-CM in comparison to complete medium or recombinant 
CX3CL1 (Figure 3.19-A). This prominent macrophage chemoattractant effect of pituitary tumour 
cell-derived secretions is consistent with the association between high PA-derived chemokine 
levels and more infiltrating macrophages in human PAs (Figure 3.12). 
Immune cell chemotaxis depends not only on tissue chemokine gradient, but also on chemokine 
receptor expression in trafficking cells209. My RNAscope data in human PA samples showed strong 
expression of chemokine receptors in perivascular immune cells, presumably contributing to their 
recruitment and transmigration into the TME in response to a gradient created by chemokines 
mainly synthesised by pituitary tumour cells (Figure 3.14). GH3-CM increased more than 12x the 
expression of Cx3cr1 (chemokine receptor with specific affinity for CX3CL1 and highly expressed 
in RAW 264.7 macrophages533), and the Ccr5 expression (p=0.051) (Figure 3.19-B). Thus, the GH3-
CM chemoattractant effect can be explained, at least in part, by upregulation of chemokine 
receptor expression in RAW 264.7 macrophages.  
 
Figure 3.19: GH3-CM effect on macrophage chemotaxis and their chemokine receptor expression  
A) Transwell chemotaxis assay performed on RAW 264.7 macrophages towards complete medium, GH3-CM 
and recombinant CX3CL1 (rCX3CL1) at concentration 100ng/mL for 72h. Data are shown as mean ±SEM for 
the ratio of migrated macrophages towards GH3-CM or rCX3CL1 in relation to migrated macrophages in 
complete medium. n=6. *, <0.05, **, <0.01, ***, <0.001 (one way-ANOVA with Bonferroni multiple 
comparison test). B) Cx3cr1 and Ccr5 expression in RAW 264.7 macrophages determined by RT-qPCR after 
treatment with GH3-CM for 24h vs complete medium. Data are shown as mean±SEM for Cx3cr1 or Ccr5 
mRNA expression fold change relative to Gapdh, determined by the ∆∆CT method. n=3. *, <0.05, **, <0.01, 
***, <0.001 (Mann Whitney U test). 
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Following GH3-CM treatment, macrophages showed morphological changes typical of activated 
macrophages: an increase in area, perimeter, Feret’s diameter and spindle-shaped 
morphology229,339 and a decrease in solidity, roundness and circularity (Figure 3.20), representing 
macrophages with an enhanced migration phenotype.  
 
Figure 3.20: GH3-CM effect on macrophage morphology 
Morphological evaluation of RAW 264.7 macrophages after treatment for 72h with complete medium (n=3), 
GH3-CM and recombinant CX3CL1 (rCX3CL1) at concentration of 100ng/mL. Data are shown as mean±SEM 
for the 6 morphological parameters evaluated by Image J: cell area (µm2), Feret’s diameter (µm), solidity (0-
1), perimeter (µm), roundness (0-1) and circularity (0-1). Per experiment 75 cells were analysed, with a 
minimum of 3 experiments per treatment condition. Scale bar 25µm. *, <0.05, **, <0.01, ***, <0.001 (one-
way ANOVA with Bonferroni multiple comparison test). 
 
Recombinant CX3CL1 was used as positive control, as this was the chemokine with the highest 
concentration in GH3 supernatants (Appendix 5), and has a recognised potent chemoattractant 
effect on RAW 264.7 macrophages533. I could verify this CX3CL1 chemotaxis effect in my dose-
response optimisation migration experiments (Figure 3.21-B), and I also noted that recombinant 
CX3CL1 induced morphology changes in RAW 264.7 macrophages (Figure 3.21-A), more markedly 
at 100ng/mL (this dose was then used in the chemotaxis and morphology studies).  
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Figure 3.21: CX3CL1 dose-response optimisation for migration and morphological studies 
A) Morphological evaluation of RAW 264.7 macrophages cells after treatment for 72h with different 
concentrations of recombinant CX3CL1 (rCX3CL1). Most prominent changes were seen at 100ng/mL. Data 
are shown as mean±SEM for the 6 morphological parameters evaluated by Image J: cell area (µm2), Feret´s 
diameter (µm), solidity (0-1), perimeter (µm), roundness (0-1) and circularity (0-1). Per experiment 75 cells 
were analysed; n=3. Scale bar 25µm. B) Migration assays performed on RAW 264.7 macrophages through 
transwell chambers towards complete medium (vehicle) and different rCX3CL1 concentrations after 72h. 
Data are represented as number of cells migrating in the different conditions and as a ratio of migrating 
macrophages towards rCX3CL1 in relation to migrated cells towards vehicle, mean±SEM. n=4. *, <0.05, **, 
<0.01, ***, <0.001 (two-way ANOVA with Bonferroni multiple comparison test).  
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GH3 cell-derived factors induce secretome changes in RAW 264.7 macrophages 
In different cancers, tumour cell-derived cytokines can modulate the surrounding TME non-
neoplastic cells, including their cytokine secretome220-222. To investigate whether GH3 cells are 
able to induce changes in the macrophage cytokine secretome, I analysed the secretome in 
supernatants from RAW 264.7 macrophages treated with GH3 cell-CM (using CM from both GH3-
NT and GH3-Aip-KD) and compared to untreated macrophages secretome (Appendix 5).  
The first observation was that RAW 264.7 macrophages display a secretome considerably different 
from GH3 cells, secreting high amounts of chemokines, particularly CCL3 and CCL4, but low 
amounts of interleukins (Appendix 5). The second observation is that GH3 cell-CM was able to 
induce changes in the macrophage secretome, with 10 different cytokines being differentially 
secreted upon treatment with GH3 cell-CM, in most of cases resulting in higher concentrations 
after treatment (Appendix 5). The third observation is that GH3-Aip-KD-CM induced changes in 
more macrophage-derived cytokines, and more prominently than GH3-NT-CM, increasing most of 
the cytokines except IL-1β (Figure 3.22). Hence, GH3-Aip-KD cells displayed a more potent effect 
on macrophage secretome than GH3-NT cells. These findings suggest that AIP deficiency may 
modulate the surrounding TME, in particular the secretome from non-neoplastic cells such as 
macrophages, and thus the cytokine network in the TME, potentially leading to increased 
aggressiveness associated with AIPmut PAs19,91,161, and the presence of more macrophages in 
AIPmut somatotrophinomas513 (discussed in Chapter 6). 
Figure 3.22: GH3-CM effect on macrophage cytokine secretome 
RAW 264.7 macrophage secretome changes induced by GH3-CM (NT and Aip-KD) after treatment for 24h. 
Data are shown for the most significantly changed macrophage-derived cytokines or those cytokines found 
at higher concentrations in macrophage supernatants after GH3 cell-CM treatment in comparison to the 
baseline evaluation, and expressed as ratio between cytokine concentration after 24h of treatment with 
GH3 cell-CM and 24h of treatment with serum-medium. Cytokine were assessed by Millipore MILLIPLEX 
assay (mouse cytokine/chemokine array 32-plex). Data are shown as mean±SEM, n=3. *, <0.05, **, <0.01, 
***, <0.001 (Mann-Whitney U test). 
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By RT-qPCR, the expression of some cytokines and growth factors identified by the cytokine array 
as differentially secreted upon GH3 cell-CM was studied. My RNA expression data did not overlap 
with the protein cytokine array data, except for VEGF which was found significantly overexpressed 
in macrophage treated with either GH3-NT and GH3-Aip-KD cell-CM, and also for IL-1α whose RNA 
was significantly upregulated in macrophages treated with GH3-NT cells and showing a trend to a 
2-fold increase in those exposed to GH3-Aip-KD cells (Figure 3.23).  Cxcl10, Ccl2 and Ccl4 mRNA 
(for macrophages treated with GH3-Aip-KD-CM) were downregulated contrary to the cytokine 
array data (Figure 3.23). 
 
Figure 3.23: GH3-CM effect on macrophage cytokine gene expression 
Cytokine expression changes on macrophages after treatment for 24h with GH3-NT and GH3-Aip-KD cell-
CM, determined by RT-qPCR. The genes analysed are correspondent to those cytokines identified on the 
preliminary cytokine array data. Data are shown as mRNA expression fold change relative to Gapdh, 
mean±SEM, and determined by the ∆∆CT method. n=3. *, <0.05, **, <0.01, ***, <0.001 (one-way ANOVA 
test).  
 
Thus, RNA and protein data not always correlate, and this is particularly valid for cytokines whose 
regulation is complex, with translation often mismatching transcription, and they are also subject 
to autocrine/paracrine feedback loops as a putative mechanism to prevent cell 
overstimulation534,535. GH3 cell-derived factors likely stimulate the release of pre-synthesised 
cytokines (stored in vesicles), whose concentration increases rapidly in the supernatants and over 
a 24h period and may exert a negative feedback effect supressing their own transcription. 
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 GH3 cell-derived factors are unable to induce polarisation of RAW 264.7 macrophages 
In different cancers, tumour cells are able to activate immune or stromal cells in the surrounding 
TME, including macrophages229,332,334. To investigate whether GH3 cell-derived factors could lead 
to RAW 264.7 macrophage polarisation into the pro-tumoural M2-like subtype229, the 
predominant macrophage subtype in human PAs (Figure 3.10), I conducted a RT-qPCR study 
assessing the expression of iNos (M1-macrophage marker), Arg1 and CD206 (M2-macrophage 
marker) (Figure 3.24-A), as well as a flow cytometry experiment (Figure 3.24-B) after treating 
macrophages with GH3 cell-CM (from both GH3-Aip-KD and GH3-NT cells).  
 
Figure 3.24: GH3-CM effect on macrophage polarisation 
A) M1 and M2 macrophage markers expression in RAW 264.7 macrophages after treatment with GH3-NT-
CM and GH3-Aip-KD-CM for 24h vs untreated, determined by RT-qPCR. Data are shown as mRNA expression 
fold change to relative Gapdh, mean±SEM, determined by the ∆∆CT method. n=3. *, <0.05, **, <0.01, ***, 
<0.001 (one-way ANOVA test). B) MHC-II and CD86 (M1-like macrophage markers) and CD206 (M2-like 
macrophage markers) expression levels in RAW 264.7 macrophages treated with GH3-NT and GH3-Aip-KD 
cell-CM for 24h, assessed by flow cytometry. Fluorescent peaks of RAW 264.7 macrophages for different 
receptors after treatment with medium, GH3-NT or GH3-Aip-KD GH3 cell-CM and PMA (5nM)-medium, and 
a table with percentage and median marker expression per treatment condition, are shown.  
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These data showed that GH3 cell-CM was unable to fully polarise RAW 264.7 macrophages. Such 
findings are not surprising in the view of the low cytokine levels in GH3 supernatants (Appendix 
5), particularly those leading to M2 polarisation (IL-4, IL-10 and IL-13)229. 
 
RAW 264.7 macrophage-derived factors affect the behaviour and invasiveness of GH3 cells 
CM from untreated (-PMA_Raw-CM) or PMA-treated macrophages (+PMA_Raw-CM) increased 
GH3 cell area, perimeter and Feret’s diameter and reduced their solidity, circularity and roundness 
(Figure 3.25) indicating that GH3 cells acquired an EMT-like phenotype. Macrophage-induced 
morphology changes in GH3 cells were confirmed with actin immunocytochemistry: GH3 cells 
treated with macrophage-CM developed a granular pattern of actin with prominent stress fibres 
and numerous spikes (Figure 3.25) representing an EMT-like cytoskeletal change536.  
 
 
132 
 
Figure 3.25: Macrophage-CM effect on GH3 cells morphology 
Morphological evaluation of GH3 cells after treatment for 72h with serum-medium and RAW 264.7 
macrophage-CM, either from untreated (-PMA_Raw-CM) or PMA-treated macrophages (+PMA_Raw-CM). 
Data are shown as mean±SEM for the 6 morphology parameters assessed by ImageJ. 75 cells were analysed 
per experiment, minimum of 3 experiments per condition. Scale bar 25µm. *,<0.05, **,<0.01, ***,<0.001 
(one-way ANOVA with Bonferroni multiple comparison test). Alterations on actin fibers in GH3 cells after 
treatment with macrophage-CM for 72h in comparison to serum-medium are shown; representative images 
were taken on a confocal microscope at 63x; DAPI was used to stain the nuclei. 
 
Migration is defined as any directed cell movement within the body, allowing cells to change 
position in a tissue, whereas invasion requires motility and ability to penetrate tissue barriers, i.e. 
to invade a cell needs degrade the surrounding ECM mainly by proteolysis and at same time 
migrate through its components537. GH3 cells showed increased invasion towards +PMA_Raw-CM 
and tended to invade more towards -PMA_Raw-CM (p=0.079) (Figure 3.26-A).  
As invasion depends on cell ability to secrete proteases to degrade ECM, I hypothesised that 
macrophage-CM upregulates MMPs expression in GH3 cells allowing them to invade. MMP-9 is a 
key protease for type IV collagen (main component of matrigel538, and of pituitary capsule and 
cavernous sinus wall446-448), as well as MMP-9 overexpression is associated with PA invasiveness448. 
Hence, Mmp9 expression in GH3 cells was studied after treatment with macrophage-CM, and a 
significant Mmp9 upregulation in GH3 cells exposed to macrophage-derived factors was observed 
(Figure 3.26-C).  
In the transwell migration assay, GH3 cells demonstrated a non-significant trend for increased 
migration towards inactivated or PMA-activated macrophage-CM in comparison to complete 
medium (p=0.103 and p=0.119, respectively) (Figure 3.26-B). 
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Figure 3.26: Macrophage-CM effect on GH3 cell invasion and migration 
Matrigel-coated chamber invasion assays (B) and transwell migration assays (C) on GH3 cells towards serum-
medium, -PMA_Raw-CM and +PMA_Raw-CM after 72h. Data are shown as mean±SEM for the ratio of 
invading/migrated GH3 cells towards -PMA_Raw-CM and +PMA_Raw-CM in relation to invading/ migrated 
GH3 cells in serum-medium. Invasion studies were repeated 4x in duplicate, and migration assays were 
repeated 3x in duplicate. *, <0.05, **, <0.01, ***, <0.001 (one-way ANOVA with Bonferroni multiple 
comparison test). C) Mmp9 expression assessed by RT-qPCR in GH3 cells in medium or after treatment for 
24h with +PMA_Raw-CM. Data are shown for Mmp9 mRNA expression fold change relative to Gapdh, 
mean±SEM, as determined by ∆∆CT method. n=3. *, <0.05, **, <0.01, ***, <0.001 (Mann Whitney U test). 
 
To further characterise the GH3 cells migration under macrophage-CM conditions, I performed a 
wound healing assay (Figure 3.27). After 24h there were no changes in the wound area closed, 
thus no significant GH3 cell migration was detected either in macrophage-CM but also in complete 
medium. Although after 24h wound healing assay does not differentiate properly migration vs cell 
proliferation/survival537,539, the assay was run for up to 6 days due to poor GH3 cell migration at 
the 24h time-point. A small wound area was covered over this period, more prominently in 
complete medium than in macrophage-CM conditions, likely reflecting increased proliferation 
rather than cell motility as perceived by the cell density visible in the images (Figure 3.27). These 
results, as opposed to those obtained in the transwell migration assay, are not surprising as GH3 
cells are unable to migrate properly on plain plastic surfaces (as shown in unpublished work from 
my group540). Wound healing assays may also poorly reflect migration and often have discordant 
results from those in transwell assays539. Moreover, migration and invasion are often uncoupled, 
with increased migration not constituting an inexorable consequence of EMT539. In fact, invasion 
rather than migration, is regarded as EMT hallmark539, although cells undergoing EMT often show 
both features467,537.  
 
Figure 3.27: Macrophage-CM effect on GH3 cell migration assessed by wound healing assay 
Wound healing assay (Ibidi culture-inserts chambers) performed on GH3 cells under complete medium, 
inactivated (-PMA_Raw-CM) or PMA-activated RAW 264.7 macrophage-CM (+PMA_Raw-CM), and assessed 
at different time-points. Representative of wound healing assay images are displayed at baseline, day 3 and 
day 6 showing the wound uncovered area.  
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The observed morphology changes and increased invasion/migration induced by macrophage-CM 
strongly suggest that macrophage-derived factors induce EMT in GH3 cells. I further studied the 
expression of classical markers of EMT (E-cadherin and ZEB1)467 by immunocytochemistry in GH3 
cells untreated vs treated with macrophage-CM. Macrophage-CM induced EMT activation in GH3 
cells decreasing E-cadherin and increasing ZEB1 expression (Figure 3.28), two hallmarks of EMT 
activation466.  
 
 
Figure 3.28: Macrophage-CM inducing EMT in GH3 cells assessed by immunocytochemistry 
Alterations in E-cadherin and ZEB1 expression by GH3 cells after treatment for 72 hours with complete 
medium, -PMA_Raw-CM or +PMA_Raw-CM. Untreated GH3 cells show strong E-cadherin with membranous 
localisation but also in the cytoplasm as well as low nuclear ZEB1 expression, while macrophage-CM treated 
GH3 cells display decreased E-cadherin expression and increased nuclear ZEB1 expression. Pictures were 
taken on confocal microscope at 63x magnification. DAPI was used to stain the nuclei. E-cadherin and ZEB1 
fluorescent intensities were quantified in 30 cells per treatment condition using Carl Zeiss Zen Blue Edition 
v2.3 software. Data are shown as fluorescent intensity, mean±SEM. n=30. *,<0.05, **,<0.01, ***,<0.001 
(one-way ANOVA with Bonferroni multiple comparison test). 
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In order to validate the EMT immunocytochemistry data at the RNA level, I further conducted RT-
qPCR assessing Cdh1 and Zeb1 expression in GH3 cells treated with macrophage-CM vs untreated. 
However, macrophage-CM did not show decreased expression of neither  Cdh1 nor upregulated 
Zeb1  (p=0.150 and p=0.337, respectively) (Figure 3.29).  
 
Figure 3.29: Macrophage-CM inducing EMT in GH3 cells assessed by RT-qPCR 
E-cadherin (encoded by Cdh1) and Zeb1 expression in GH3 cells untreated and treated with PMA-activated 
RAW 264.7 macrophage-CM (+PMA_Raw-CM) for 24h, determined by RT-qPCR. Data are shown as mRNA 
fold change expression relative to Gapdh, mean±SEM, determined by ∆∆CT method. n=6. *, <0.05, **, <0.01, 
***, <0.001 (Mann-Whitney U test). 
 
I also found that PMA-activated macrophage-CM is able to induce cytokine secretion changes in 
GH3 cells (both in GH3-Aip-KD and GH3-NT cells), increasing the release of CX3CL1, CCL3, CXCL1, 
CXCL10, IL-1β, IL-10, IL-13 and VEGF (Figure 3.30 and Appendix 5), peptides that play a role in 
different tumourigenic mechanisms209,210,222,226.  
Figure 3.30: Macrophage-CM effect on GH3 cell cytokine secretome 
GH3 cells secretome changes (in both NT and Aip-KD) induced by PMA-activated RAW 264.7 macrophage-
CM after treatment for 24h. Data are shown for the most significantly changed cytokines after macrophage-
CM treatment in comparison to the baseline evaluation and/or cytokines which were found at higher 
concentrations in the GH3 supernatants. Data are represented as ratio of cytokines after 24h of treatment 
with PMA (5nM)-activated RAW 264.7macrophage-CM, mean±SEM. Cytokine were assessed by the 
Millipore MILLIPLEX assay (rat cytokine/chemokine array 27-plex). n=3. *, <0.05, **, <0.01, ***, <0.001 
(two-way ANOVA with Bonferroni multiple comparison test).  
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By RT-qPCR, I observed a tendency for overexpression of the different cytokines identified in the 
cytokine array after treating GH3 cells with macrophage-CM, although statistical significance was 
not reached (Figure 3.31), in part due to the considerable variability in the cytokine gene 
expression results from experiment to experiment. 
 
Figure 3.31: Macrophage-CM effect on GH3 cell cytokine expression 
Cytokine expression changes from GH3-NT and GH3-Aip-KD cells treated with PMA-activated RAW 264.7 
macrophage-CM for 24h, assessed by RT-qPCR. The cytokines analysed were the most significantly changed 
after macrophage-CM treatment in comparison to the baseline evaluation as identified by the cytokine 
array. Data are shown as mRNA fold change expression relative to Gapdh, mean±SEM, determined by ∆∆CT 
method. n=3. *, <0.05, **, <0.01, ***, <0.001 (two-way ANOVA with Bonferroni multiple comparison test).  
 
Such lack of a correlation of RNA and protein data is typical in cytokine studies, as previously 
discussed, in part due to their physiological properties, strong bioactivity and secretion in low 
amounts. Cytokines are stored in cell vesicles and released upon stimulation, thus there is a 
mismatch with transcription, as well as they are subject of posttranslational changes. Moreover, 
cytokines can regulate their expression in a paracrine or autocrine manner, and thus the release 
of cytokines may signal its suppression via negative feedback loop of which one of the most well-
studied mediator is SOCS (suppressors of cytokine signalling) able to suppress the transcription of 
the respective cytokine or others, as well as inhibit cytokine pathways such as JAK-STAT534. These 
findings suggest that macrophages can induce changes in the cytokine secretion from GH3 cells, 
which can potentially influence their own behaviour (via paracrine or autocrine loops) or other 
non-neoplastic surrounding cells in the TME. My data does not suggest a relevant role for AIP in 
terms of secretome changes following an external macrophage stimuli, although CXCL10 and IL-
1β were secreted in higher amounts from macrophage-CM treated GH3-Aip-KD cells (not 
confirmed by RT-qPCR) but also secreted significantly less CXCL1 (Figure 3.30). 
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Circulating immune cells and inflammation-based scores in patients with PAs 
Serum inflammatory-based scores NLR, PLR and LMR were calculated for each case of my cohort 
of 24 patients with PAs from pre-operative FBC data (Table 3.14). The relation between these 
ratios and clinico-pathological, biochemical, cytokine and immune infiltrates, was analysed.  
 
Pre-operative haematological parameters  
Overall cohort 
PAs (n=24) 
Mean ± SD 
NFPAs  
(n=16) 
Mean ± SD 
Som  
(n=8) 
Mean ± SD 
p value 
(NFPAs 
vs Som) 
Red cell count (1012/L)   [NR: M 4.4-5.8 / F 3.95-5.15] 
Haemoglobin (g/L)         [NR: M 130-170 / F 115-155] 
Haematocrit (%)                [NR: M 37-50 / F 33-45] 
White cell count (109/L)        [NR: 3.0-10.0] 
Neutrophil count (109/L)       [NR: 2.0-7.5] 
Lymphocyte count (109/L)    [NR: 1.2-3.65] 
Monocyte count (109/L)        [NR: 0.2-1.0] 
Eosinophil count (109/L)      [NR: 0.0-0.4] 
Basophil count (109/L)         [NR: 0.0-0.1] 
Platelet count (109/L)           [NR: 150-400] 
4.58 ± 0.46 
132.46 ± 12.47 
40.24 ± 3.79 
7.08 ± 3.39 
3.73 ± 1.51 
2.71 ± 2.25 
0.44 ± 0.13 
0.17 ± 0.11 
0.03 ± 0.02 
234.96 ± 62.18 
4.63 ± 0.49 
131.00 ± 12.01 
40.09 ± 3.99 
7.33 ± 3.81 
3.87 ± 1.48 
2.86 ± 2.71 
0.43 ± 0.10 
0.15 ± 0.11 
0.02 ± 0.01 
229.63 ± 59.92 
4.49 ± 0.40 
135.38 ± 13.68 
40.54 ± 3.58 
6.58 ± 2.26 
3.43 ± 1.63 
2.42 ± 0.86 
0.48 ± 0.19 
0.23 ± 0.10 
0.03 ± 0.02 
245.63 ± 69.40 
0.482 
0.430 
0.794 
0.618 
0.512 
0.660 
0.413 
0.079 
0.233 
0.564 
 
Pre-operative serum inflammation-based scores 
 
Overall cohort 
PAs (n=24) 
Mean ± SD 
NFPAs  
(n=16) 
Mean ± SD 
Som  
(n=8) 
Mean ± SD 
p value 
(NFPAs 
vs Som) 
Neutrophil-to-lymphocyte ratio (NLR) 
Lymphocyte-to-monocyte ratio (LMR) 
Platelet-to-lymphocyte ratio (PLR) 
1.63 ± 0.76 
6.53 ± 5.58 
108.48 ± 45.03 
1.70 ± 0.76 
6.95 ± 1.67 
104.99 ± 39.91 
1.51 ± 0.78 
5.68 ± 0.81 
115.46 ± 56.27 
0.572 
0.603 
0.609 
Table 3.14: Pre-operative haematological parameters and scores of the 24 patients with PAs 
Data are shown as mean±standard deviation (SD) for pre-operative haematological parameters and serum 
inflammation-based scores. Mann Whitney U test was used to calculate p value for the comparison NFPAs 
vs somatotrophinomas (NFPA vs Som). F, females; M, males; NFPA, non-functioning pituitary adenoma; NR, 
normal range; Som, somatotrophinoma. 
 
 
 
Circulating immune cells and inflammation-based scores and clinical features 
There were no significant associations between cavernous sinus invasion or a high Ki-67 (≥3%) in 
PAs and the pre-operative scores NLR, LMR or PLR, neither with the circulating immune cell counts 
(Table 3.15). However, there was a trend for patients with PAs invading cavernous sinus to have 
lower neutrophil counts than in patients with non-invasive PAs (p=0.06). 
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Pre-operative 
haematological 
parameters and ratios 
Ki-67 Cavernous sinus invasion 
<3% 
(n=19) 
≥3% 
(n=5) 
p value 
No 
(n=14) 
Yes 
(n=10) 
p value 
Red cell count (1012/L) 4.56 ± 0.11 4.64 ± 0.19 0.757 4.60 ± 0.15 4.55 ± 0.10 0.765 
White cell count (109/L) 7.26 ± 0.83 6.40 ± 0.96 0.622 7.90 ± 1.09 5.94 ± 0.43 0.161 
Neutrophil count (109/L) 3.80 ± 0.34 3.45 ± 0.80 0.662 4.21 ± 0.44 3.05 ± 0.31 0.060 
Lymphocyte count (109/L) 2.80 ± 2.52 2.35 ± 0.61 0.699 3.04 ± 0.77 2.26 ± 0.23 0.415 
Monocyte count (109/L) 0.45 ± 0.14 0.40 ± 0.05 0.446 0.45 ± 0.11 0.43 ± 0.05 0.771 
Eosinophil count (109/L) 0.18 ± 0.03 0.16 ± 0.05 0.814 0.17 ± 0.03 0.18 ± 0.03 0.897 
Basophil count (109/L) 0.03 ± 0.00 0.03 ± 0.01 0.436 0.03 ± 0.01 0.03 ± 0.00 0.812 
Platelet count (109/L) 227.79 ± 13.70 262.20 ± 31.64 0.281 219.07 ± 16.69 257.20 ± 18.19 0.142 
NLR 1.65 ± 0.18 1.48 ± 0.30 0.623 1.74 ± 0.20 1.49 ± 0.24 0.434 
LMR 6.69 ± 1.44 5.93 ± 0.43 0.793 7.05 ± 1.90 5.81 ± 0.74 0.603 
PLR 106.09 ± 10.80 117.57 ± 17.64 0.623 97.24 ± 11.18 124.21 ± 14.77 0.152 
Table 3.15: Haematological parameters/scores and Ki-67/cavernous sinus invasion  
Data are shown as mean±SEM for the different haematological parameters and inflammation-based scores 
NLR, LMR and PLR. p values were non-significant for the comparative analysis between less vs more 
proliferative PAs, and for PAs without vs with cavernous sinus invasion (Mann-Whitney U test). 
 
There were also no significant associations between pre-operative serum inflammation-based 
scores or circulating immune cells and PA grades as per Trouillas classification43 (Table 3.16). 
Pre-operative 
haematological 
parameters and ratios 
Grade 1a (non-
invasive) 
n=11 
Grade 1b (non-
invasive and 
proliferative)  
n= 3 
Grade 2a 
(invasive) 
n=8 
Grade 2b 
(invasive and 
proliferative)   
n=2 
p 
value 
Red cell count (1012/L) 4.60 ± 0.18 4.63 ± 0.28 4.52 ± 0.10 4.66 ± 0.34 0.974 
White cell count (109/L)         8.08 ± 1.36 7.21 ± 1.48 6.12 ± 0.51 5.20 ± 0.58 0.542 
Neutrophil count (109/L)        4.17 ± 0.51 4.36 ± 1.06 3.29 ± 0.34 2.10 ± 0.09 0.215 
Lymphocyte count (109/L)     3.24 ± 0.98 2.28 ± 0.36 2.21 ± 0.27 2.46 ± 0.58 0.790 
Monocyte count (109/L)         0.47 ± 0.03 0.39 ± 0.08 0.44 ± 0.07 0.43 ± 0.02 0.829 
Eosinophil count (109/L)       0.18 ± 0.04 0.14 ± 0.07 0.17 ± 0.03 0.20 ± 0.09 0.930 
Basophil count (109/L)          0.03 ± 0.01 0.04 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.313 
Platelet count (109/L)            206.91 ± 14.71 263.67 ± 56.69 256.50 ± 22.77 260.00 ± 19.00 0.252 
NLR 1.70 ± 0.25 1.87 ± 0.32 1.64 ± 0.28 0.90 ± 0.17 0.539 
LMR 7.32 ± 2.44 6.06 ± 0.37 5.83 ± 0.91 5.74 ± 1.15 0.947 
PLR 90.35 ± 11.65 122.53 ± 29.96 127.73 ± 18.17 110.14 ± 18.06 0.331 
Table 3.16: Haematological parameters/scores and Trouillas grade classification 
Data are shown as mean±SEM for the different haematological parameters and the inflammation-based 
scores NLR, LMR and PLR. p values were non-significant for the comparative analysis between the different 
PA grades as per Trouillas grade classification43 (one-way ANOVA test). 
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Similarly, there were no significant correlations between pre-operative serum inflammation-
based scores or circulating immune cells and the presence of headache, visual impairment or 
hypopituitarism at diagnosis (Table 3.17).  
Pre-operative 
haematological 
parameters 
Headache at diagnosis Visual impairment at diagnosis Hypopituitarism at diagnosis 
No 
(n=16) 
Yes 
(n=8) 
p No 
(n=11) 
Yes 
(n=13) 
p No 
(n=13) 
Yes 
(n=11) 
p 
Red cell count 
(1012/L) 
4.50 ± 0.10 4.75 ± 0.18 0.206 4.55 ± 0.11 4.61 ± 0.15 0.741 4.53 ± 0.12 4.64 ± 0.15 0.588 
White cell 
count (109/L) 
7.16 ± 0.98 6.92 ± 0.70 0.874 6.70 ± 0.64 7.40 ± 1.15 0.617 7.80 ± 1.20 6.23 ± 0.39 0.262 
Neutrophil 
count (109/L) 
3.55 ± 0.38 4.07 ± 0.53 0.441 3.70 ± 0.50 3.75 ± 0.40 0.940 4.07 ± 0.51 3.31 ± 0.27 0.225 
Lymphocyte 
count (109/L) 
2.94 ± 0.68 2.26 ± 0.28 0.498 2.32 ± 0.23 3.04 ± 0.83 0.442 3.06 ± 0.84 2.30 ± 0.19 0.424 
Monocyte 
count (109/L) 
0.46 ± 0.04 0.41 ± 0.04 0.378 0.46 ± 0.05 0.43 ± 0.03 0.681 0.46 ± 0.04 0.43 ± 0.04 0.633 
Eosinophil 
count (109/L) 
0.18 ± 0.03 0.16 ± 0.03 0.588 0.20 ± 0.03 0.15 ± 0.03 0.352 0.18 ± 0.03 0.16 ± 0.03 0.641 
Basophil count 
(109/L) 
0.03 ± 0.00 0.03 ± 0.01 0.362 0.03 ± 0.01 0.02 ± 0.00 0.274 0.03 ± 0.01 0.03 ± 0.00 0.570 
Platelet count 
(109/L) 
218.25 ± 10.62 268.38 ± 29.42 0.144 242.09 ± 19.22 228.92 ± 17.40 0.616 239.08 ± 21.74 230.09 ± 11.57 0.733 
NLR 1.49 ± 0.18 1.92 ± 0.28 0.193 1.70 ± 0.25 1.58 ± 0.20 0.717 1.73 ± 0.25 1.53 ± 0.17 0.532 
LMR 6.94 ± 1.69 5.72 ± 0.61 0.627 5.64 ± 0.63 7.28 ± 2.05 0.485 7.32 ± 2.07 5.60 ± 0.53 0.463 
PLR 98.50 ± 10.40 128.45 ± 17.76 0.127 116.86 ± 15.45 101.39 ± 11.03 0.414 110.14 ± 15.28 106.52 ± 9.60 0.850 
Table 3.17: Haematological parameters and headache, visual damage or hypopituitarism at diagnosis 
Data are shown as mean±SEM for the different haematological parameters and inflammation-based scores 
NLR, LMR and PLR. p values were non-significant for the different comparative analysis (Mann-Whitney U 
test). 
 
 
In general, there were no significant correlations between pre-operative serum inflammation-
based scores or circulating immune cells and age at diagnosis, number of pituitary deficiencies at 
diagnosis or at last follow-up, and number of total treatments that patients have received (Table 
3.18). However, significant correlations were noted for the basophil count which positively 
correlated with the number of pituitary deficiencies at diagnosis (p=0.047) and number of 
treatments received (p=0.036), as well as for neutrophil and red cell counts which correlated 
positively with age at diagnosis (p=0.043) and number of pituitary deficiencies at last follow-up 
(p=0.038), respectively (Table 3.18). 
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 Age at 
diagnosis 
(yrs) 
n of pituitary 
deficiencies at 
diagnosis 
n of total 
treatments 
n of pituitary 
deficiencies at 
last follow-up 
Red cell count 
Pearson correlation r -0.005 0.129 0.362 0.427 
p value 0.983 0.559 0.082 0.038 
N 24 23 24 24 
White cell count 
Pearson correlation r 0.356 -0.101 -0.045 -0.080 
p value 0.088 0.647 0.836 0.709 
N 24 23 24 24 
Neutrophils 
count 
Pearson correlation r 0.416 -0.152 0.072 0.067 
p value 0.043 0.488 0.738 0.756 
N 24 23 24 24 
Lymphocytes 
count 
Pearson correlation r 0.228 -0.063 -0.116 -0.161 
p value 0.284 0.774 0.588 0.453 
N 24 23 24 24 
Monocytes 
count 
Pearson correlation r 0.341 0.104 -0.032 0.115 
p value 0.103 0.637 0.882 0.594 
N 24 23 24 24 
Eosinophils 
count 
Pearson correlation r 0.060 0.052 0.006 -0.254 
p value 0.782 0.815 0.979 0.231 
N 24 23 24 24 
Basophils count 
Pearson correlation r -0.324 0.418 0.430 0.280 
p value 0.123 0.047 0.036 0.184 
N 24 23 24 24 
Platelet count 
Pearson correlation r -0.046 0.010 -0.055 -0.124 
p value 0.832 0.962 0.800 0.565 
N 24 23 24 24 
NLR 
Pearson correlation r 0.267 -0.256 0.087 0.120 
p value 0.207 0.239 0.686 0.577 
N 24 23 24 24 
LMR 
Pearson correlation r 0.162 -0.117 -0.138 -0.241 
p value 0.449 0.596 0.521 0.256 
N 24 23 24 24 
PLR 
Pearson correlation r -0.126 -0.232 -0.020 -0.082 
p value 0.556 0.286 0.924 0.705 
N 24 23 24 24 
Table 3.18: Haematological parameters and age at diagnosis, number of pituitary deficiencies and 
treatments 
p values were determined by the Pearson correlation coefficient r. 
 
Circulating immune cells and serum inflammation-based scores and pituitary function 
In general, there were no correlations between pre-operative serum inflammation-based scores 
or circulating immune cells and pituitary hormone levels in NFPAs, or in GH/IGF-1 levels in 
somatotrophinomas (Appendix 6). However, within somatotrophinomas correlations were noted 
between FT4 and neutrophil (r=0.790, p=0.035), monocyte count (r=0.927; p=0.003) and NLR 
(r=0.865, p=0.012); LH and FSH correlated with NLR (r=0.907, p=0.005 and r=0.808, p=0.028, 
respectively), and LH and monocyte count also correlated (r=0.779, p=0.39) (Appendix 6). 
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Circulating immune cells and serum inflammation-based scores and PA cytokine secretome 
In general, there were no significant correlations between pre-operative serum inflammation-
based scores or circulating immune cells and the PA cytokine secretome assessed in the primary 
culture supernatants, except for the significant positive correlations between PA-derived FGF-2 
and PLR (p=0.005), and between NLR and PDGF-AA (p=0.043) and IL-6 (p=0.037) (Figure 3.32 and 
Appendix 6).  
 
Figure 3.32: Correlation between serum inflammation-based scores and PA-derived cytokines 
p values were determined by the Pearson correlation coefficient r. 
 
When pre-operative serum inflammation-based scores or circulating immune cells and the PA 
cytokine secretome were analysed per histiotypes, additional significant correlations among 
NFPAs were noted: CCL22 with both NLR (r=0.670, p=0.005) and PLR (r=0.500, p=0.048); FGF-2 
with both NLR (r=0.693, p=0.003) and PLR (r=0.712, p=0.002); IL-6 with NLR (r=0.509, p=0.044); 
PDGF-AA with NLR (r=0.560, p=0.024); VEGF-A with platelet count (r=501, p=0.048) (Appendix 6).   
Among somatotrophinoma subgroup, PA-derived levels of CXLC1 negatively correlated with 
neutrophil (r=-0.754, p=0.031) and monocyte count (r=-0.733, p=0.039), while PA-derived CCL2 
levels significantly correlated with the monocyte count (r=-0.723, p=0.043) (Appendix 6). 
These data suggest that some of the PA-derived cytokines may reach the circulation and 
eventually influence the haematopoiesis and confer some degree of systemic inflammation (i.e. 
increased NLR and PLR), with FGF-2 and PDGF-AA emerging as possibly the most relevant ones. 
However, in the whole study cohort, most of the correlations between PA-derived cytokines and 
the haematological parameters here analysed were indeed non-significant, suggesting that the 
effects of PA-derived cytokines on the bone marrow may not be that relevant biologically. 
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Discussion 
In this study, using a comprehensively phenotyped cohort of human PAs with cytokine array data 
from primary culture, immunohistochemical immune infiltrates and clinicopathological data, PAs 
were found to be an active source of chemokines which facilitate macrophage, neutrophil and 
lymphocyte recruitment into the TME. Infiltrating immune cells once in the TME of PAs may 
determine increased PA aggressiveness, particularly tumour proliferation. My human data are 
strengthened by my in vitro functional data providing mechanistic insights into the crosstalk 
pituitary tumour cells-macrophages. My in vitro data confirmed that pituitary tumour-derived 
factors promote macrophage chemotaxis, while macrophage factors influence tumour cell 
behaviour leading to morphology changes, increased invasion, cytokine secretome changes and 
EMT activation. Thus, the cytokine network in the TME of PAs, derived from both tumour and 
immune cells, as well as PA-associated fibroblasts (Chapter 4), may play a role in the modulation 
of the TME and aggressiveness of PAs (Figure 3.33). 
 
Figure 3.33: The tumour microenvironment of PAs  
Pituitary tumour cells release different chemokines directly into the TME promoting the recruitment of 
immune cells, including macrophages, lymphocytes and neutrophils. PA-infiltrating immune cells change 
the behaviour of tumour cells, namely increasing their proliferative capacity. PA-associated fibroblasts also 
secrete cytokines, including IL-6 and other chemokines, which lead to increased invasion of tumour cells.  
143 
 
Pituitary tumour cells are an active source of chemokines which lead to immune cell recruitment 
into the TME of PAs 
IL-8, CCL2, CCL3 and CCL4 were highly secreted by the great majority of PAs. A similar cytokine 
secretome analysis has not previously been performed in PAs, but interestingly cytokine array 
data from 48 human craniopharyngiomas identified CCL2 and IL-8 as the most secreted cytokines 
in plasma, primary culture supernatants, cell and tissue lysates541. There are no previous data on 
CCL2, CCL3 or CCL4 in PAs, but these chemokines are involved in tumour growth and invasion in 
other tumours209,226, as well as in immune cell chemotaxis in cancer209,226,333,517,529,530,542,543. I found 
no association between CCL2, CCL3 or CCL4 levels and PA aggressiveness, but PAs with a high 
content of macrophages, CD8+ T cells and neutrophils secreted higher levels of these chemokines, 
supporting their role in recruiting such cells.  
PAs with more macrophages were associated with higher levels of IL-8, and there was also a non-
significant trend for PAs with increased neutrophil amounts to release more IL-8. IL-8 is a 
chemokine that recruits immune cells, classically neutrophils but also macrophages, as well as 
influencing several oncogenic pathways236,528. IL-8 mRNA was previously found in PAs, although 
different methods provide a wide range of expression levels232-234. I also identified other 
chemokines potentially relevant in PAs, namely CXCL10, CCL22, CXCL1 and CX3CL1, all well studied 
in other cancers209,226, but not in PAs. My data suggest CXCL1 and CXCL10 as potential modulators 
of PA-infiltrating neutrophils and macrophages. CXCL1 and its receptor CXCR2 were previously 
identified in human PAs279, but there are no data regarding CXCL10, CCL22 and CX3CL1. Together, 
these findings suggest a link between endocrine cells and chemokines reflecting their possible 
involvement in tumourigenesis and modulation of immune infiltrates, constituting a promising 
target for drugs affecting the PA cytokine network, as already explored for other cancers210,226,544. 
NFPAs secreted cytokines more often and in higher amounts than somatotrophinomas. These 
secretome differences are unlikely to be explained by pre-operative exposure to SSAs, as 
untreated or pre-treated somatotrophinoma patients had similar cytokine secretome. This 
phenomenon has not been reported before; however, in a study analysing IL-6 release from 100 
primary cultures of human PAs, IL-6 levels in NFPAs reached higher absolute levels than in 
somatotrophinomas, with six NFPAs releasing >500U/L while only a single somatotrophinoma had 
IL-6 levels >500U/L237. In another study, CXCL12 expression was detected in more NFPAs (78%) 
than somatotrophinomas (63%)268. Despite these cytokine secretome differences between NFPAs 
and somatotrophinomas, there were no major differences regarding infiltrating immune cells or 
ratios among these. However, somatotrophinomas had significantly fewer neutrophils than NFPAs 
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which could be due to this prominently reduced chemokine release, particularly IL-8, but other 
aspects may be involved such as impaired neutrophil chemotaxis545; this difference is thought not 
to be attributable to haematopoietic differences among NFPAs and somatotrophinomas, as 
neutrophil counts did not differ between NFPA and somatotrophinoma patients.    
 
Immune infiltrates in PAs differ from NP and potentially contribute to pituitary tumourigenesis 
Macrophages are present in NP344,345 and PAs346,347,513. My immunohistochemical and xCELL data 
showed that PAs contained 3-4x more macrophages than NPs, and they are the predominant 
immune cell type in PAs. I found no association between PA-infiltrating macrophages and 
cavernous sinus invasion, and correlation with high Ki-67 was borderline. Lu et al. reported that 
macrophage content was correlated with size and invasiveness347. AIPmut somatotrophinomas 
often more aggressive19,167, have more macrophages than sporadic somatotrophinomas or NPs513.  
Next, I studied the phenotype of infiltrating macrophages in human PAs and NPs using the 
macrophage markers CD163 (M2) and HLA-DR (M1)229,546,547. I noted a 3-fold increased M2:M1 
macrophage ratio in PAs compared to NPs, in line with my xCell data (M2-macrophage score was 
>4x higher in PAs). The predominance of M2-macrophages in PAs can be due, at least in part, to 
higher concentrations of PA-derived M2-polarising cytokines, namely IL-4, which was 5x higher 
than IFNγ, the main M1-polarising cytokine229,339. M1- and M2 macrophages have been described 
in normal rat pituitary and in DES-induced prolactinomas346, with prolactinomas having 
remarkably more M2-macrophages than NP. M2-macrophage number increased during the first 
weeks of DES treatment, even before tumour formation, suggesting a role for M2-macrophages 
in initiating tumourigenesis. During DES treatment capillaries became more tortuous with 
increased calibre and developed haemorrhage areas suggesting a possible role for M2-
macrophages in angiogenesis and vasculature modulation in PAs346, in agreement with the 
observed correlations between M2:M1 ratio and PA microvessel density and area. These findings 
support a role for M2-macrophages in PA angiogenesis, as in other cancers229,297,332,339,417,548. 
 
Infiltrating immune cells may influence aggressiveness and tumourigenic mechanisms in PAs 
I found that a low CD8:CD4 ratio is associated with a higher Ki-67, suggesting that relatively low 
CD8+ to high CD4+ T cells, rather than absolute CD8+ and CD4+ T cell amounts per se, represent a 
relative imbalance potentially affecting tumour proliferation. This has been described in gliomas, 
where the number of tumour-infiltrating CD8+ and CD4+ cells alone had no prognostic value, while 
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low CD8:CD4 ratio was an independent predictor of poor progression-free and survival549. Poor 
clinical outcome and persistence/recurrence was described in PAs with TILs371. Another study 
found no association between CD8+ T cell count and Ki-67, tumour size, gender or age374. I 
observed more CD4+ and fewer CD8+ cells, with a significant 2-fold decrease in CD8:CD4 ratio in 
comparison to NPs, supporting the known anti-tumour role of cytotoxic CD8+ T cells and the pro-
tumour effect of CD4+ T cells, possibly Th2516,532,549. Indeed, downregulation of Th1 pathway-
related genes was observed in aggressive PAs550. M2-macrophages support CD4+ Th2 cells and 
prevent the expression of cytokines required for Th1 cells347,551, which may further contribute to 
a Th2 phenotype in PAs. Vice versa, Th2 cytokines in the TME sustain M2-macrophages229,333,551 
possibly contributing to the predominant M2-macrophage phenotype I observed in PAs.  
Although I found generally low amounts of FOXP3+ T cells in PAs, as previously shown370, PAs with 
a higher Ki-67 had significantly more FOXP3+ T cells. Moreover, a significant 3-fold reduced 
CD8:FOXP3 ratio was noted in PAs with a higher Ki-67, revealing that a deleterious imbalance 
between CD8+ and FOXP3+ T cells may increase proliferation and thereby aggressiveness, as 
described for other cancers552,553. In this study, all PAs with a “deleterious immune phenotype” 
(i.e. high content of macrophages, T helper lymphocytes, FOXP3+ T regulatory and B cells) had a 
Ki-67≥3%, which together with results regarding the ratios CD68:FOXP3, CD8:CD4 and CD8:FOXP3, 
highlights that the pooled inflammatory context integrating different immune subpopulations 
within the TME of PAs is more relevant for the biological behaviour and aggressiveness than each 
distinct PA-infiltrating immune cell per se.   
There is some variability in the PA-infiltrating immune cells reported in literature347,366,369,371,372,374. 
This inconsistency can reflect the variable level of immunosurveillance from tumour to 
tumour516,554,555, patient selection347, or can be due to a lack of standardisation method reporting 
immune infiltrates347,371,374, such as reporting hotspots or taking random HPFs, or reporting 
interstitial areas or perivascular inflammatory cells347, use of different cell markers and antibodies 
to detect the same immune cell type347,369,371, or assessment of full slides versus tissue 
microarrays, which can greatly influence the results. Despite these issues, the current 
immunohistochemical data are in line with the xCELL data, and with previous data347,371,372,374. 
 
The functional crosstalk between pituitary tumour cells and macrophages 
My in vitro cell line experiments focused on macrophages as these are the predominant immune 
cell type in PAs, and I selected RAW 264.7 macrophages for the reasons previously stated. My in 
vitro observations, consistent with previous findings in a different cell model513, show a 
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remarkable macrophage chemoattractant effect induced by GH3 cell-derived factors, an effect 
explained not only by the chemokine gradient but also by their ability to upregulate chemokine 
receptor expression. These findings are in line with the human data (association between PA-
infiltrating macrophages and PA-derived chemokine levels), suggesting that pituitary tumour cells 
are able to attract immune cells, namely macrophages.  
On the other hand, I confirmed that macrophage-derived factors induced numerous effects on 
GH3 cells, including changes in morphology, invasion, EMT activation and cytokine secretome 
alterations, suggesting that immune cell-derived factors can influence pituitary tumour 
mechanisms leading to increased aggressiveness of PAs, as seen in my cohort of human PAs 
(Figure 3.16) and in another in vitro model using GH3 cells and bone-derived rat macrophages513, 
as well as in other cancers209,210,222,226.  
 
Circulating immune cells and inflammation-based scores do not predict aggressiveness of PAs 
The serum inflammation-based scores, namely NLR, LMR and PLR, have been used in cancer as 
predictors of outcomes and prognosis521-526, including in endocrine-related neoplasms such as 
thyroid cancer556-558, neuroendocrine tumours559-562 and craniopharyngiomas563,564. However, 
there are no data in PAs. Identifying any of these scores as predictors of aggressiveness and/or 
prognosis would provide significant advances in risk stratification and potentially in the 
management algorithms for patients with PAs.  
Neutrophilia and thrombocytopenia in aggressive cancers occur due to myeloid-derived factors 
from cancer secondary to inflammation, tissue destruction or cytokine production, while the 
lymphopenia signify impaired innate cell immunity against malignancy. These cancer-related 
haematopoietic effects, typical in highly malignant/metastatic neoplasms, result in elevated NLR 
and PLR and decreased LMR which translate excessive but ineffective immune response to the 
tumour or imbalanced inflammatory state which can facilitate its growth522,556. In fact, the mean 
NLR and PLR scores in my cohort of PAs were relatively lower (1.6±0.8 and 108.5±45.0, 
respectively) than those reported for other aggressive malignant neoplasms41,45,46, with NLR>5.0 
and PLR>300 commonly indicating poor prognosis522,565-569. On the other hand, the mean LMR in 
PAs is relatively high (6.5±1.6), in keeping with less lymphopenia, low systemic inflammation and 
indolent biological disease in patients with PAs, in comparison to other malignant neoplasms 
where LMR<2.38-4.01 indicate aggressive disease and poor outcomes 525,526,570. These finding are 
not surprising taking into account that PAs are benign, lacking major biological aggressiveness and 
metastatic potential. This is translated into little or no systemic inflammation in patients with PAs 
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driven by pituitary tumour-derived factors (if) released in low amounts into the circulation. In 
contrast, the systemic inflammation can be prominent in other highly malignant neoplasms, such 
as in breast, gastric, pancreas, colorectal cancer or melanoma, hence these inflammation-based 
ratios are valuable41,45,46. Nevertheless, some PA-derived cytokines may modulate the circulating 
immune cells and/or systemic inflammation in patients with PAs as suggested by the correlations 
between PA-derived FGF-2 and PDGF-AA and NLR or PLR ratios, or by the significant correlation 
between serum monocyte count and PA-derived levels of CCL22, and between neutrophil count 
and PA-derived CXLC1 among somatotrophinoma patients. 
Overall, no association was seen between the inflammation-based scores NLR, LMR and PLR (nor 
white cell counts) and clinical (headache, visual damage or hypopituitarism) or aggressiveness 
(cavernous sinus invasion or high Ki-67) features in my cohort of patients with PAs suggesting that 
these tools may not be useful in predicting aggressiveness of PAs. There were also no correlations 
between pre-operative serum NLR, LMR and PLR or circulating immune cells and pituitary 
hormone levels in NFPAs or GH/IGF-1 levels in somatotrophinomas, suggesting that PA-related 
hormonal status may not be relevant in determining systemic inflammation in patients with PAs.  
 
Limitations of this study 
Limitations of my study include the fact that I have a relatively small cohort of cases, and thus 
these observations need to be validated in larger series, preferably including all different PA types. 
The small sample size is a particular issue for the assessment of inflammation-based scores in 
predicting aggressiveness of PAs, as provides insufficient statistical power to detect differences 
(for an α-error 0.05), also considering that NLR, PLR and LMR vary substantially from case to case, 
and thus the negative findings here reported may not reflect the lack of association but instead 
the few cases included for comparative subanalysis (for example, only had 5 PAs had a Ki-67≥3%). 
As the study was based on fresh primary culture, I inevitably had a relative short postoperative 
follow-up of patients, rendering data on recurrence unavailable.  
In the in vitro cell model I used a rat rather than human cell line, as no suitable human pituitary 
cell line exists; moreover, my monolayer cell cultures are unable to investigate the complex 
paracrine and autocrine interactions occurring in vivo within the TME, which involves a wider 
range of immune cells besides macrophages, as well as stromal cells, endothelial cells, pericytes 
and ECM204.  
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I used a distinction between macrophages based on CD163 and HLA-DR surface markers229,332,339, 
and I acknowledge this is simplistic and may not comprehensively address the heterogeneous and 
complex macrophage phenotypes571. In fact, there is a notable heterogeneity on methods to study 
macrophages, particularly regarding the selection of surface markers. We selected CD68 that 
satisfactorily identify general macrophages, and CD163 for M2 macrophages229,332,339; however, 
studying M1 macrophages is more challenging, as a specific marker is lacking, but HLA-DR or iNOS 
are often used for this purpose229,572,573. Thus, the immunohistochemical findings may well be 
influenced by such elements; nevertheless, the data were reproduced on a separate set of 
samples using a different methodology (xCell), providing another layer of evidence regarding the 
macrophage phenotype of human PAs.  
 
 
Conclusions 
In summary, these data suggest that pituitary tumour cells are an active source of cytokines, 
particularly chemokines, which facilitate immune cell recruitment into the TME of PAs, which in 
turn may influence tumourigenic mechanisms such as tumour proliferation and angiogenesis. The 
in vitro findings confirm increased macrophage chemotaxis towards pituitary tumour cell-derived 
factors, and on the other hand, macrophage secreting-factors influence pituitary tumour cells 
inducing morphological changes, increasing invasion and migration, as well as inducing cytokine 
secretome changes and the EMT pathway. Serum inflammation-based scores or circulating 
immune cell counts appears to have no value in predicting aggressiveness of PAs. 
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Chapter 4: Fibroblasts in the tumour microenvironment of 
pituitary adenomas 
 
Introduction 
Tumour behaviour is influenced by the surrounding stromal cells, including fibroblasts, via 
crosstalk with neoplastic cells mediated by a complex cytokine network, which plays a key role in 
tumour initiation, progression, angiogenesis, invasion and metastasis204,207,209-211. Fibroblasts are 
present in tumours (TAFs)383,384, and constitute an important source of cytokines and growth 
factors, mediators of their pro-tumour effects384,391,574. In numerous cancers, such as breast386,387, 
prostate388, lung389, gastric390 and pancreas cancer385,391, increased density of TAFs are associated 
with aggressiveness and poor outcomes. The role of PA-derived TAFs in pituitary tumour 
behaviour remains unknown.  
Somatostatin is a ubiquitous neuropeptide that interacts with G-protein coupled somatostatin 
receptors (SSTs), of which 5 types have been identified (SST1 to SST5), all binding somatostatin 
with high affinity575. Somatostatin inhibits numerous biological functions, including endocrine and 
exocrine secretion, cell proliferation and angiogenesis, as well as inducing apoptotic cell 
death391,575.  
These anti-proliferative and anti-secretory effects of somatostatin have generated interest in the 
oncology field, particularly in endocrine-related cancer. However, the usefulness of somatostatin 
is limited due to short half-life (~1.5min), which has led to the development of SSAs with higher 
stability and longer half-lives. Despite their lower affinity for SSTs in comparison to exogenous 
somatostatin, SSA have been effectively used to treat some neoplasms, including neuroendocrine 
tumours576 and PAs, particularly in acromegaly and thyrotrophinomas, but also in Cushing´s 
disease577. 
Currently, there are 3 SSA available and approved for clinical practice: octreotide and lanreotide, 
both with high affinity for SST2, but lower affinities for SST3 or SST5 and none for SST1 and SST4577; 
and pasireotide (SOM230) a second-generation SSA, which is considered as an “universal” SSA as 
it binds with high affinity to SST1, SST2, SST4 and SST5 (Figure 4.1)577-580. 
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Figure 4.1: Somatostatin and SSA affinity for the different somatostatin receptors  
Adapted from Fleseriu & Petersenn (2012)578.  
 
The effects of SSAs are initiated by their interaction with cell membrane SSTs, and mediated by 
different intracellular signalling pathways, including membrane-bound or cytoplasmic kinases, 
phosphatases, lipases, cyclic nucleotide synthases, ion channels, among others575,577,580. In 
addition to their direct inhibitory effects on tumour cells577, SSAs may also display an indirect anti-
tumour effect by targeting non-neoplastic cells within the TME, as shown in a recent study where 
the anti-proliferative, anti-invasive and anti-metastatic effects of pasireotide were mediated 
through pharmacological inhibition of stromal pancreas cancer fibroblasts391.  
 
Aims 
Overall aim 
To characterise the cytokine secretome of PA-associated TAFs and study its role in the clinical 
phenotype and pituitary tumour aggressiveness.  
 
Specific aims 
1. To confirm the presence of TAFs in PAs and isolate and characterise these cells in vitro 
2. To characterise the PA-derived TAF cytokine secretome and define its role in the 
phenotype and aggressiveness of PAs 
3. To assess the functional effect of TAF-derived factors in the behaviour, migration, invasion 
and EMT activation of pituitary tumour cells 
4. To study the effect of SSAs in the TAF-derived cytokine secretome  
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Results 
Detection and in vitro isolation of PA-derived tumour-associated fibroblasts  
Vimentin-positive TAFs were identified in my experimental sample set of PAs both in the intra-
tumoural area and in a rim of fibrous connective tissue (Figure 4.2 A-D), representing the tumour 
pseudo-capsule581,582. Isolated TAFs showed spindle-shaped morphology (Figure 4.2 E-F), stained 
for actin and vimentin in all TAFs with some expressing α-SMA (Figure 4.2 G-H), suggesting that 
only some TAFs display an active phenotype. TAF supernatants and CM was generated from this 
mixed TAF population (i.e. αSMA-positive and αSMA-negative TAFs).  TAF morphology differed 
from the appearance of skin fibroblasts from healthy individuals (Figure 4.2 I-J), having a more 
prominent spindle-like shape with several cell projections, and being more irregularly distributed 
in the culture flasks. 
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Figure 4.2: TAFs in PAs and their in vitro isolation  
Immunohistochemical detection and in vitro isolation of PA-derived tumour-associated fibroblasts (TAFs). 
A-D: Vimentin immunostain of PAs shows positive staining in spindle-shaped and long cells with cytoplasmic 
projections (red arrows), located in the intra-tumoural areas (A-B) but also in a rim of fibrous connective 
tissue probably representing the tumour pseudo-capsule (C-D). Vimentin staining is also positive in 
endothelial cells, distinguishable from fibroblasts by their morphology and localisation in vessels lumen. 
Representative photographs at different magnifications are shown (A, 20x; B, 40x; C, 5x; D, 5x). E-F: TAFs 
isolated in vitro after migrating out from a debris tissue piece (E) and after reaching confluency in culture 
flasks (F). G-H: Immunofluorescent staining for actin (G) and for vimentin (red) and α-SMA (green) with 
vimentin expression seen in all TAFs, whereas α-SMA expression seen in many but not all TAFs (H), 
suggesting that only some TAFs have an active phenotype (63x). I-J: Morphological appearance of dermal 
fibroblasts from 2 different healthy individuals, having a less prominent spindle-like shape with shorter 
projections and being more regularly distributed in the culture flask surface. 
 
 The presence of TAFs was further assessed with the gene-signature based method xCell on a 
different set of samples including 7 PAs (4 NFPAs, 3 somatotrophinomas) with an estimated mean 
xCell fraction scores of 0.0196±0.017 (vs 0.007±0.007 in 5 NPs; p=0.572). 
 
 
The role of TAF cytokine secretome in the phenotype and aggressiveness of PAs 
I hypothesised that TAFs, as a relevant source of cytokines and growth factors, would influence 
PAs aggressiveness. To address this, I established primary cultures of TAFs from 16 human PAs 
(clinico-pathological features from these patients shown in Table 4.1), and then I further assessed 
their cytokine secretome (Table 4.2 and Appendix 7).  
Patients clinico-pathological features TAFs (n=16) 
Gender     Male 
[n (%)]       Female 
11 (68.8%) 
5 (31.2%) 
Age at first symptoms (yrs)   [mean± SD] 50.1 (±13.9) 
Age at diagnosis (yrs)   [mean±SD] 51.8 (±13.6) 
Clinical diagnosis        Acromegaly 
 [n (%)]                           NFPA 
5 (31.2%) 
11 (68.8%) 
Headache at diagnosis   [n (%)] 8 (50.0%) 
Visual impairment at diagnosis   [n (%)] 9 (56.3%) 
Hypopituitarism at diagnosis   [n (%)] 7 (43.8%) 
Pituitary deficiencies at diagnosis   [mean±SD] 0.9 (±1.2) 
Macroadenoma   [n (%)] 16 (100%) 
Suprasellar extension   [n (%)] 16 (100%) 
Cavernous sinus invasion   [n (%)] 6 (37.5%) 
Ki-67 ≥ 3%   [n (%)] 3 (18.8%) 
Table 4.1: Baseline features of the 16 patients with PAs from whom TAFs were isolated 
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The most highly secreted cytokines/growth factors by TAFs were CCL2, CCL11, VEGF-A, CCL22, IL-
6, FGF-2 and IL-8 (Table 4.2). IL-1α, IL-2, IL-3, IL-5, IL-7, IL-9, IL-10, IL-13, IL-1ra, CCL4, TNF-α and 
TGF-α were undetectable in TAF supernatants, and some cytokines were detected in low 
concentrations such as IL-17A, IL-1β, IFNγ and CCL3 (Appendix 7). TAF secretomes from NFPAs and 
somatotrophinomas did not significantly differ (Table 4.2), suggesting that TAFs may exert similar 
functions within the TME of both NFPAs and somatotrophinomas. I also analysed the cytokine 
secretome of skin fibroblasts from 2 healthy controls, demonstrating an overall tendency for lower 
cytokine concentrations, prominent for CCL2, VEGF-A, CCL22, IL-8, CX3CL1, and in the cases of 
CCL11 and PDGF-AA not detectable, suggesting that PA-derived TAFs and healthy skin fibroblast 
secretomes are distinct (Appendix 7). 
Cytokine/ 
Chemokine/ 
Growth factor 
Mean concentration (pg/mL) ± SEM 
TAFs 
n=16 
Serum-free 
medium 
NFPA-TAFs 
(n=11) 
Somatotrophinoma-TAFs 
(n=5) 
CCL2 4786.86 ± 642.17 4.00 4782.87 ± 903.21 4795.62 ± 679.53 
CCL11 836.27 ± 328.16 0 399.44 ± 168.63 1797.30 ± 894.43 
VEGF-A 174.29 ± 80.60 0 70.06 ± 46.86 403.59 ± 240.29 
CCL22 62.54 ± 21.50 20.78 74.17 ± 29.63 36.96 ± 21.92 
IL-6 54.76 ± 6.50 0 50.60 ± 8.17 63.89 ± 10.45 
FGF-2 42.93 ± 5.82 0 45.96 ± 8.24 36.29 ± 4.13 
IL-8 42.20 ± 11.11 7.06 31.53 ± 7.10 65.69 ± 31.66 
CXCL1 28.20 ± 6.56 20.78 26.23 ± 6.44 32.54 ± 16.78 
CX3CL1 26.86 ± 8.34 6.73 29.86 ± 12.09 20.26 ± 3.86 
CCL7 13.83 ± 5.97 8.20 9.43 ± 3.67 23.51 ± 17.89 
PDGF-AA 11.64 ± 3.71 0.12 7.40 ± 3.44 20.98 ± 8.29 
IFNα2 8.82 ± 2.40 1.79 10.25 ± 3.38 5.68 ± 1.54 
Table 4.2: PA-derived TAF cytokine secretome 
Top 12 highly secreted cytokines, chemokines and growth factors in primary culture supernatants from TAFs 
isolated from PAs. TAF supernatants were collected following 24h on serum-free medium conditions and 
the cytokine secretome determined with the human Millipore MILLIPLEX cytokine 42-plex array. Results are 
shown as concentration (pg/mL), mean±SEM. p values were non-significant for comparative analysis per 
cytokine between TAFs derived from NFPAs (NFPA-TAFs) or from somatotrophinomas (Somatotrophinoma-
TAFs) (Mann Whitney U test). 
 
TAF-derived IL-6 levels were higher in PAs with cavernous sinus invasion in comparison to non-
invasive PAs (72.7±10.7 vs 43.9±6.3 pg/mL; p=0.027), while there was a trend (p=0.058) for TAFs 
isolated from PAs with a higher Ki-67 to secrete more CCL2 (Figure 4.3).  
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Figure 4.3: TAF cytokine secretome according to cavernous sinus invasion (A) or Ki-67 (B)  
Data are shown as concentration (pg/mL), mean±SEM for the top 12 secreted cytokines, chemokines and 
growth factors, as determined in PA-derived TAF supernatants by the human Millipore MILLIPLEX cytokine 
42-plex array. n=16. *, <0.05, **, <0.01, ***, <0.001 (Mann Whitney U test). 
 
 
CCL2 secretion was higher in TAFs derived from females than males (6698±1831 vs 3918±220 
pg/mL; p=0.04), but there were no gender differences regarding other cytokines (Figure 4.4). CCL2 
secretion was not dependent on age or the females’ pre or postmenopausal status. 
 
Figure 4.4: TAF cytokine secretome according to gender 
Data are shown as concentration (pg/mL), mean±SEM for the top 12 secreted cytokines, chemokines and 
growth factors, as determined in PA-derived TAF supernatants by the human Millipore MILLIPLEX cytokine 
42-plex array. n=16. *, <0.05, **, <0.01, ***, <0.001 (Mann-Whitney U test). 
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The presence of headache, hypopituitarism or visual impairment at diagnosis were not associated 
with differences in TAF cytokine release (Table 4.3).  
Cytokine/ chemokine 
derived from TAFs 
Presence of headache at diagnosis 
p 
value 
No headache (n=8) 
Mean concentration (pg/mL) ± SEM  
Headache (n=8) 
Mean concentration (pg/mL) ± SEM 
CCL2  5066.78 ± 1245.42 4506.93 ± 440.36 0.678 
CCL11 256.07 ± 83.42 1416.48 ± 598.65 0.095 
VEGF-A 42.99 ± 15.28 305.59 ± 150.60 0.105 
CCL22 62.39 ± 15.45 62.70 ± 41.75 0.994 
IL-6 50.64 ± 7.85 58.88 ± 10.69 0.545 
FGF-2 38.66 ± 5.83 47.21 ± 10.29 0.482 
IL-8 32.67 ± 9.18 51.73 ± 20.46 0.410 
CXCL1 21.49 ± 4.18 34.92 ± 21.42 0.323 
CX3CL1 21.66 ± 6.20 32.06 ± 15.87 0.551 
CCL7 5.47 ± 2.27  22.18 ± 11.31 0.188 
PDGF-AA 8.21 ± 5.40 15.07 ± 5.16 0.374 
IFNα2 6.83 ± 1.84 10.81 ± 4.48 0.425 
Cytokine/ chemokine 
derived from TAFs 
Presence of visual impairment at diagnosis 
p 
value 
No visual impairment (n=7) 
Mean concentration (pg/mL) ± SEM  
Visual impairment (n=9) 
Mean concentration (pg/mL) ± SEM 
CCL2  4533.52 ± 508.44 4983.90 ± 1101.24 0.741 
CCL11 1556.89 ± 666.40 275.80 ± 100.76 0.104 
VEGF-A 321.27 ± 174.25 59.98 ± 14.46 0.185 
CCL22 88.94 ± 46.11 42.01 ± 13.44 0.294 
IL-6 65.23 ± 10.31 46.61 ± 7.72 0.162 
FGF-2 48.11 ± 11.00 38.91 ± 6.14 0.452 
IL-8 59.81 ± 23.14 28.51 ± 6.73 0.235 
CXCL1 39.58 ± 13.59 19.35 ± 3.67 0.195 
CX3CL1 35.86 ± 18.03 19.86 ± 5.30 0.359 
CCL7 4533.52 ± 508.44 4983.90 ± 1101.24 0.741 
PDGF-AA 1556.89 ± 666.40 275.80 ± 100.76 0.104 
IFNα2 321.27 ± 174.25 59.98 ± 14.46 0.185 
Cytokine/ chemokine 
derived from TAFs 
Presence of hypopituitarism at diagnosis 
p 
value 
Eupituitarism (n=9) 
Mean concentration (pg/mL) ± SEM  
Hypopituitarism (n=7) 
Mean concentration (pg/mL) ± SEM 
CCL2  4400.58 ± 412.30 5283.49 ± 1411.38 0.514 
CCL11 830.04 ± 408.12 844.28 ± 574.28 0.984 
VEGF-A 139.57 ± 87.74 218.93 ± 152.75 0.642 
CCL22 73.36 ± 32.27 48.64 ± 18.16 0.586 
IL-6 49.70 ± 4.96 61.25 ± 13.65 0.396 
FGF-2 45.55 ± 9.74 39.57 ± 5.25 0.627 
IL-8 36.78 ± 9.41 49.17 ± 23.21 0.598 
CXCL1 22.28 ± 8.02 35.82 ± 10.89 0.323 
CX3CL1 31.74 ± 13.99 20.58 ± 7.06 0.526 
CCL7 9.38 ± 4.38 19.55 ± 12.70 0.417 
PDGF-AA 16.86 ± 5.71 4.94 ± 3.11 0.092 
IFNα2 10.29 ± 4.06 6.93 ± 1.88 0.504 
Table 4.3: TAF secretome according to headache, visual impairment or hypopituitarism at diagnosis 
Cytokine secretome from TAF supernatants according to the presence of headache, visual impairment or 
hypopituitarism at diagnosis. Data are shown as concentration (pg/mL), mean±SEM for the top 12 secreted 
cytokines, chemokines and growth factors as identified by the human Millipore MILLIPLEX 42-plex assay. p 
values were non-significant for all cytokine comparisons per feature (Mann-Whitney U test). 
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There were some significant correlations between TAF cytokines and serum pituitary hormone 
levels (Appendix 8). Among NFPA-derived TAFs, significant correlations were noted between 
PDGF-AA and IGF-1 (r=0.658, p=0.039), FT4 (r=0.662, p=0.037) and FSH (r=0.677, p=0.032), and 
between IL-6 and FT4 (r=-0.747, p=0.013). Among somatotrophinoma-derived TAFs, there were 
correlations between IFNα2 and GH (r=-0.939, p=0.018), FGF-2 and TSH (r=-0.886, p=0.045), and 
between CCL22 and LH (r=0.968, p=0.007) and FSH (r=-0.969, p=0.006) (Appendix 8). 
The levels of TAF-derived CCL2, a chemokine with angiogenic functions583,584, were positively 
correlated with microvessel area (r=0.672; p=0.004) suggesting a possible role for TAF-derived 
factors in PA angiogenesis (Table 4.4), as shown in other cancers384,585-587. Further details regarding 
angiogenesis in PAs are discussed in the Chapter 5. 
Cytokine/ Chemokine/ Growth factor 
TAFs n=16 
Microvessel 
density 
Microvessel 
area 
E-cadherin 
immunoreactivity 
ZEB1 
immunoreactivity 
CCL2 
Pearson correlation r 0.440 0.672 -0.217 -0.039 
p value 0.088 0.004 0.419 0.887 
CCL11 
Pearson correlation r -0.193 -0.347 0.174 -0.401 
p value 0.474 0.189 0.519 0.124 
VEGF-A 
Pearson correlation r -0.173 -0.255 0.188 -0.318 
p value 0.521 0.340 0.486 0.230 
CCL22 
Pearson correlation r -0.029 -0.051 0.331 0.071 
p value 0.915 0.852 0.211 0.793 
IL-6 
Pearson correlation r -0.466 -0.318 0.278 -0.056 
p value 0.069 0.231 0.298 0.838 
FGF-2 
Pearson correlation r 0.177 -0.016 0.337 0.061 
p value 0.511 0.954 0.201 0.821 
IL-8 
Pearson correlation r -0.079 -0.270 0.372 -0.228 
p value 0.772 0.311 0.156 0.396 
CXCL1 
Pearson correlation r -0.100 -0.181 0.497 -0.246 
p value 0.713 0.503 0.050 0.359 
CX3CL1 
Pearson correlation r -0.089 -0.161 0.173 -0.221 
p value 0.744 0.552 0.523 0.410 
CCL7 
Pearson correlation r -0.076 -0.199 0.426 -0.248 
p value 0.779 0.460 0.100 0.354 
PDGF-AA 
Pearson correlation r -0.267 -0.482 -0.564 -0.409 
p value 0.317 0.058 0.023 0.116 
IFNα2 
Pearson correlation r 
p value 
-0.095 
0.726 
-0.143 
0.598 
0.175 
0.516 
-0.129 
0.633 
Table 4.4: TAF cytokine secretome and PA angiogenesis and EMT 
Correlations between the cytokine secretome from PA-derived TAFs and microvessel density (number of 
vessels/HPF), microvessel area (µm2/HPF), E-cadherin and ZEB1 immunoreactivities in PAs. Data are shown 
for the top 12 highly secreted cytokines, chemokines and growth factors in supernatants from TAFs. p values 
were determined by the Pearson correlation coefficient r.  
 
PDGF-AA levels were negatively correlated with E-cadherin expression (r=-0.564, p=0.023), 
suggesting a possible role for the TAF secretome in promoting EMT by downregulating E-cadherin 
(Table 4.4 and Figure 4.5), an effect recognised to PDGFs and their receptors588-590. However, I 
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found no other correlation between E-cadherin or ZEB1 immunoreactivity in my cohort of PAs and 
TAF-derived cytokine levels (Table 4.4). This lack of significant association can be explained by the 
lack of an EMT signature in PAs as discussed in Chapter 5, or alternatively could be explained by 
the lack or only very mild effect of TAFs in the EMT in PAs. 
 
Figure 4.5: Correlation between TAF-derived FGF-2 levels and E-cadherin immunoreactivity in PAs 
p value was determined by the Pearson correlation coefficient r. n=16. 
 
TAFs have been implicated in the recruitment of immune cells into the TME384,585,591. I found a 
positive correlation between the PA-infiltrating macrophages content and TAF-derived FGF-2 
(Figure 4.6), a protein with recognised macrophage chemotaxis properties592-594.  
 
Figure 4.6: Correlation between PA-infiltrating macrophages and TAF-derived FGF-2  
p value was determined by the Pearson correlation coefficient r. 
 
PAs with a M2:M1 macrophage ratio ≥2 were associated with higher TAF-derived levels of FGF-2 
and CXCL1 (Figure 4.7), two proteins able to promote M2-macrophage polarisation595-597.   
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Figure 4.7: TAF cytokine secretome and M2:M1 macrophage ratio 
Cytokine secretome profile of TAF supernatants according to lower (<2) vs higher (≥2) M2:M1 macrophage 
ratio. Data are shown as concentration (pg/mL), mean±SEM, and for the top secreted proteins as identified 
by the Millipore MILLIPLEX assay. *,<0.05, **,<0.01, ***,<0.001 (Mann-Whitney U test). 
 
TAF-derived IL6 levels were also inversely correlated with CD4+ T cells, but there were no other 
correlations between TAF-derived cytokines and other PA immune cells (Table 4.5). 
TAF-derived cytokine 
secretome (n=16) 
% of 
macrophages 
% of CD4+ 
T cells 
% of CD8+ 
T cells 
% of FOXP3+ 
T cells 
% of 
neutrophils 
CCL2 
Pearson correlation r .295 .110 -.080 -.158 -.323 
p value .267 .684 .769 .560 .222 
CCL11 
Pearson correlation r .098 -.414 -.036 -.197 -.270 
p value .717 .110 .893 .464 .312 
VEGF-A 
Pearson correlation r .055 -.328 .068 -.041 -.270 
p value .841 .214 .801 .879 .312 
CCL22 
Pearson correlation r .325 .058 .091 -.293 .410 
p value .220 .831 .737 .271 .115 
IL-6 
Pearson correlation r -.138 -.503 -.066 .149 -.203 
p value .610 .047 .807 .582 .450 
FGF-2 
Pearson correlation r .499 .064 .186 -.352 .437 
p value .049 .813 .490 .182 .091 
IL-8 
Pearson correlation r .359 -.385 .191 -.083 -.173 
p value .172 .141 .478 .760 .522 
CXCL1 
Pearson correlation r .422 -.199 .273 -.171 .110 
p value .104 .461 .306 .527 .685 
CX3CL1 
Pearson correlation r .329 -.016 -.048 -.358 .333 
p value .213 .953 .861 .173 .208 
CCL7 
Pearson correlation r .311 -.234 .242 -.047 -.073 
p value .241 .383 .366 .862 .790 
PDGF-AA 
Pearson correlation r -.413 .002 -.205 .380 -.408 
p value .112 .995 .446 .147 .117 
IFNα2 
Pearson correlation r .292 .010 .024 -.260 .405 
p value .272 .970 .928 .331 .120 
Table 4.5: TAF cytokine secretome and PA-infiltrating immune cells 
p value was determined by the Pearson correlation coefficient r. n=16. 
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In vitro studies investigating the interactions between fibroblasts and pituitary tumour cells 
TAF-derived factors increase invasion, migration and induce EMT-like phenotype in GH3 cells  
To study the effects of TAF-derived factors in pituitary tumour cells, in the absence of an 
appropriate human pituitary tumour cell line, I assessed morphology, migration, invasion and EMT 
activation of GH3 cells in response to TAF-CM or skin fibroblast-CM.  
GH3 cells showed significantly higher migration and invasion towards TAF-CM compared to 
complete medium, but not towards normal skin fibroblast-conditioned medium. Skin fibroblasts 
were not able to increase invasion, while TAF-CM led to an 11-fold increased invasiveness in 
comparison to complete medium (Figure 4.8). Skin fibroblasts are also a source of cytokines and 
chemokines598,599, hence it was not surprising to report the non-significant trend for increased GH3 
cell migration observed in the presence of skin fibroblast-CM. However, skin fibroblasts were not 
able to increase GH3 cell invasion, while TAF-CM lead to an 11-fold increased invasiveness (Figure 
4.8). In fact, invasion requires not only the capacity for cells to migrate, but also ability to secrete 
enzymes and proteases to degrade matrigel600, which seems to be induced by TAF-derived factors, 
but not by skin fibroblast-derived factors. 
 
Figure 4.8: TAF-CM effect on GH3 cell invasion and migration 
Matrigel-coated chamber invasion assays (A) and transwell migration assays (B) performed on GH3 cells 
towards complete medium, tumour-associated fibroblasts-conditioned medium (TAF-CM) and CM from 
dermal fibroblasts from healthy individuals (F-CM) after 72h. Data are represented as a ratio of invading or 
migrated GH3 cells towards TAF-CM or F-CM in relation to invading/migrated GH3 cells in serum-medium, 
mean±SEM. *,<0.05, **,<0.01, ***,<0.001 (one way-ANOVA with Bonferroni multiple comparison test).  
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TAF-CM, but not skin fibroblast-CM, induced EMT-like morphological changes in GH3 cells, leading 
to a significant increase in cell area, perimeter and Feret’s diameter, with decreased solidity, 
roundness and circularity (Figure 4.9). These changes result in larger cells with an elongated shape 
which are more deformable and have a better ability to migrate and invade, in line with the 
migration and invasion experiments (Figure 4.8). These morphological changes were accompanied 
by granular actin staining with prominent stress fibres and spikes, characteristic of EMT-like 
cytoskeletal changes536, while untreated GH3 cells showed actin distributed in a cortical ring 
(Figure 4.9).  
 
Figure 4.9: TAF-CM effect on GH3 cell morphology 
Morphology of GH3 cells after treatment for 72h with serum-medium (n=3), tumour-associated fibroblasts-
conditioned medium (TAF-CM) (n=4) and with CM from dermal fibroblasts from healthy individuals (F-CM) 
(n=3). GH3 cell morphology was evaluated for six parameters using ImageJ: cell area, Feret’s diameter, 
solidity, perimeter, roundness and circularity. 75 cells were analysed per experiment, with a minimum of 3 
experiments per treatment condition. Data are shown as mean±SEM. Scale bar: 25µm. *,<0.05, **,<0.01, 
***,<0.001 (two-way ANOVA with Bonferroni multiple comparison test). On the right, actin immunostaining 
is shown of GH3 cells after treatment with TAF-CM for 72h in comparison to serum-medium, (63x) 
magnification; DAPI was used to stain the nuclei. 
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TAF-CM induced EMT in GH3 cells, significantly decreasing E-cadherin and increasing nuclear ZEB1 
expression (hallmarks of EMT pathway activation466), while untreated GH3 cells showed strong E-
cadherin with membranous localisation but also in the cytoplasm as well as low nuclear ZEB1 
expression (Figure 4.10). Direct induction of EMT, in line with increased invasiveness, migration 
and altered cell shape, suggests that TAF-derived factors interact with pituitary tumour cells to 
influence their behaviour and invasiveness. 
Figure 4.10: TAF-CM inducing EMT activation in GH3 cells 
Alterations in the E-cadherin and ZEB1 expression by GH3 cells after treatment for 72h with TAF-CM or 
complete medium. Pictures were taken on confocal microscope at 63x magnification. DAPI was used to stain 
the nuclei. E-cadherin and ZEB1 fluorescent intensities were quantified in 30 different cells per treatment 
condition using the Carl Zeiss Zen Blue Edition version 2.3 software. Data are shown as fluorescent intensity, 
mean±SEM. *,<0.05, **,<0.01, ***,<0.001 (Mann-Whitney U test). 
 
 
 
Somatostatin analogue effect in TAF cytokine secretome 
TAFs express somatostatin receptors, predominantly the type 1 
To investigate whether SSA affect TAF cytokine secretome, I first determined SST expression in 
TAFs. SST1 was the predominant type in TAFs (Figure 4.11), as it is in pancreatic cancer-associated 
fibroblasts385,391, while the expression of SST2 and SST5 was minimal (Figure 4.11).  
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Figure 4.11: SST expression profile in TAFs 
Somatostatin receptor expression profile in human PA-derived TAFs assessed by RT-qPCR. Data are shown 
as SSTx mRNA fold change expression relative to GAPDH, mean±SEM, determined by the standard curve 
method. n=16.*,<0.05, **,<0.01, ***,<0.001 (one way-ANOVA with Bonferroni multiple comparison test).  
 
TAF expression of SSTx did not differ between NFPA-TAFs vs somatotrophinoma-TAFs, as well as 
between PAs with low vs high Ki-67 or with vs without cavernous sinus invasion (Figure 4.12).  
 
 
163 
 
Figure 4.12: SST expression profile in TAFs according to PA subtype, Ki-67 or cavernous sinus invasion 
Somatostatin receptor (SST) expression in human PA-derived TAFs assessed by RT-qPCR according to: A) PA 
type (NFPAs or somatotrophinomas (GHomas)); B) low vs high Ki-67; C) cavernous sinus invasion vs no 
invasion. Data shown as SSTx mRNA expression fold change relative to GAPDH, mean±SEM, determined by 
the standard curve method. NFPA-TAFs, n=11; Somatotrophinoma-TAFs, n=5. PAs with cavernous sinus 
invasion n=6; PAs without invasion, n=10. PAs with Ki-67<3%, n=13; PAs with Ki-67≥3%, n=3. p values were 
non-significant for all the comparative analysis (Mann-Whitney U test).  
 
 
Pasireotide inhibits cytokine secretion from TAFs 
As TAFs mainly expressed SST1, I used pasireotide (10-7M) treatment385,391 to assess TAF cytokine 
secretome responses to SSAs. Pasireotide treatment significantly decreased IL-6 release by 80% 
(p<0.001) and CCL2 by 35% (p=0.038), while the other factors showed a trend for reduction but 
this was not statistically significant (Figure 4.13-A and Appendix 7).  
IL-6 secretion was reduced in all 16 TAFs treated with pasireotide, while CCL2 decreased in 10 out 
of 16 cases (62.5%) (Figure 4.13-B and Table 4.6). CCL2, CCL11, VEGF-A, IL-8, PDGF-AA, FGF-2 and 
IFNα2 decreased in more than 50% of treated TAFs (Figure 4.14), whereas CCL22, CX3CL1, CXCL1 
and CCL7 decreased in less than 50% of the pasireotide-treated TAFs (Figure 4.15). 
Figure 4.13: TAF cytokine secretome at baseline and after pasireotide treatment 
Cytokine secretome from human PA-derived TAFs at baseline (untreated) and after treatment with 
pasireotide (10-7M). Data are shown as concentration (pg/mL), mean±SEM for the top 12 highly secreted 
proteins in PA-derived TAF supernatants collected following 24h on serum-free medium conditions with 
pasireotide (10-7M) or without (A). IL-6 and CCL2 levels before (left side, square mark) and after pasireotide 
treatment (right side, triangle mark) are shown per case individually (B). n=16. *,<0.05, **,<0.01, ***,<0.001 
(Mann Whitney U test).  
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Cytokine/ 
Chemokine/ 
Growth factor 
 Number of cases with decreased  
levels after pasireotide 
n (%) 
Concentrations difference 
untreated vs pasireotide  
(pg/mL, mean±SEM) 
Mean fold-change after 
treatment pasireotide 
(% (±SEM)) 
CCL2 10 (62.5%) - 1681.43 ± 547.05 -30.50% (±10.02) 
CCL11 13 (81.3%) -306.45 ± 241.92 -37.78% (±20.24) 
VEGF-A 14 (87.5%) -40.18 ± 21.72 -29.22% (±11.10) 
CCL22 5 (31.3%) -3.40 ± 13.07 +60% (±30.9) 
IL-6 16 (100.0%) -42.93 ± 6.16 -75.78% (±5.40) 
FGF-2 11 (68.8%) -4.31 ± 4.79 +6.13% (±16.27) 
IL-8 10 (62.5%) -12.00 ± 9.29 -21.97% (±14.89) 
CXCL1  4 (25.0%) -0.07 ± 4.60 +23.31% (±12.83) 
CX3CL1 8 (50.0%) -2.82 ± 4.78 +22.70% (±23.18) 
CCL7 8 (50.0%) -3.36 ± 3.60 +49.28% (52.44) 
PDGF-AA 11 (68.8%) -6.28 ± 2.82 -15.93% (±18.37) 
IFNα2 10 (62.5%) -2.06 ± 1.42 +8.88% (±24.87) 
Table 4.6: Quantification of the TAF cytokine secretome responses to pasireotide  
Number of cases which cytokine concentrations have decreased after treatment with pasireotide (10-7M), 
and also mean concentration difference and mean-fold change between untreated and pasireotide-treated 
TAFs derived from 16 PAs. Data are shown as n(%) or expressed as concentration (pg/mL), mean±SEM, and 
for the top 12 secreted proteins as identified by the Millipore MILLIPLEX assay in TAF supernatants. 
 
 
Figure 4.14: Cytokines decreased in more than half of pasireotide-treated TAFs 
Cytokines that decreased in more than 50% (>8 out of 16) in the supernatants of TAFs after treatment with 
10-7M of pasireotide (SOM230). Data are shown in concentration (pg/mL) for each individual case before 
(on the left side, square mark) and after treatment with SOM230 (on the right side, triangle mark), per 
cytokine, chemokine or growth factor. n=16. 
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Figure 4.15: Cytokines decreased in less than half of pasireotide-treated TAFs 
Cytokines that decreased in less than 50% (<8 out of 16) in the supernatants of TAFs after treatment with 
10-7M of pasireotide (SOM230). Data are shown in concentration (pg/mL) for each individual case before 
(on the left side, square mark) and after treatment with pasireotide (on the right side, triangle mark), per 
cytokine, chemokine or growth factor. n=16. 
 
 
Interestingly, the TAF expression levels of SST2 increased after pasireotide treatment (p=0.020), 
although there were no changes in the expression of SST1 and SST5 (Figure 4.16).  
Figure 4.16: SST expression profile in TAFs at baseline and after pasireotide treatment 
Somatostatin receptor (SST) expression profile in human PA-derived TAFs determined by RT-qPCR, at 
baseline and after treatment with pasireotide (SOM230). Data are shown as relative SSTx mRNA fold change 
expression to GAPDH, mean±SEM, determined using the standard curve method. n=16. *,<0.05, **,<0.01, 
***,<0.001 (Mann Whitney U test). 
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Discussion 
TAFs determine tumour initiation, proliferation, invasiveness and clinical outcomes for many types 
of tumours383,384, but their role in PAs has never been studied. My data suggest that PA-derived 
TAFs are a source of cytokines which may impact on tumour behaviour. Of the TAF-derived 
cytokines studied, IL-6 and CCL2 emerged as potential mediators of PA invasiveness. My human 
data are strengthened by in vitro data providing mechanistic insights into the crosstalk between 
TAFs and pituitary tumour cells. In my in vitro cell model, I confirmed that TAF-derived factors 
influence pituitary tumour cells leading to morphological changes, increased invasion and 
migration, and EMT activation, effects not induced by normal skin fibroblast-derived factors. 
Hence, TAF-derived cytokines, together with factors released from tumour or immune cells 
(Chapter 3), may play a key role in TME modulation and in the aggressiveness of PAs (Figure 3.33). 
The observed inhibitory effect of pasireotide on TAF cytokine secretion highlights a promising 
indirect anti-tumoural effect of SSAs by targeting TAFs, in addition to any direct effect on tumour 
cells391,577.  
 
TAFs are an active source of cytokines which can influence PA phenotype and aggressiveness 
TAFs are components of the TME in different tumours, including in PAs395, and these cells are 
active sources of cytokines and growth factors383,384,574. I found highly secreted levels of CCL2, 
CCL11, VEGF-A, CCL22, IL-6, FGF-2 and IL-8 in TAF supernatants. The secretome from NFPA-TAFs 
and somatotrophinoma-TAFs did not differ suggesting that TAF intrinsic biology within the TME of 
PAs may not vary according to the PA histiotype. 
CCL2 levels were higher from TAFs isolated from PAs with more proliferation and more capillaries, 
suggesting a role for TAF-derived CCL2 in PA aggressiveness and angiogenesis. The reason for the 
observed gender difference in CCL2 secretion is unclear, as no gender-specific effect has 
previously been described for CCL2 release601,602. CCL2 has a number of roles, including in 
angiogenesis, cell proliferation and invasion583. While CCL2 in PAs has not previously been 
described in the literature, cell culture supernatants and lysates of craniopharyngiomas show 
significant release of CCL2541. CCL2 was also one of the main chemokines released from primary 
cultured PA cells (Chapter 3).  
IL-6 plays a role in the progression and aggressiveness of PAs214,230,237-239. Invasive PAs have a high 
proportion of IL-6 expression (67.5%), while non-invasive PAs expressed IL-6 only in 22.5% of 
cases249. Suppression of the cytokine transducer gp130, which usually results in inhibition of IL-6 
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secretion, impaired the development of transplanted GH3 cell tumours in nude mice603. In GH3 
cells, IL-6 stimulates cell proliferation and DNA synthesis, as well as GH and PRL release241. IL-6 can 
also be secreted by non-tumoural folliculo-stellate cells, which can have paracrine effect on 
pituitary tumour cells causing increased proliferation and aggressiveness230,248,253,254. My study 
showed that TAF-derived IL-6 levels were higher in PAs with cavernous sinus invasion, supporting 
a possible role for the paracrine effects of IL-6 in PA invasiveness. Thus, IL-6 may represent a drug 
target for PAs to reduce the paracrine effects of TAFs.  
Chemokines and growth factors, such as PDGFs588,590, often secreted by TAFs or other non-
tumoural cells of the TME, and are able to induce EMT466-468. In my study, TAF-derived PDGF-AA 
levels were negatively correlated with E-cadherin expression, suggesting a possible role for the 
TAF secretome in promoting EMT in PAs, in line with data from my in vitro experiments.  
TAFs have been implicated in the recruitment of immune cells into the TME591, including 
macrophages, and they can even promote macrophage polarisation into the M2 subtype604, thus 
contributing for the remodeling of the TME384,585. In my study, I found a correlation between TAF-
derived FGF-2 levels and the amount of PA-infiltrating macrophages, suggesting a potential 
chemotaxis role for some of the TAF-derived factors. FGF-2 is a growth factor secreted by different 
cells, including TAFs, and has a recognised role in macrophage chemotaxis592-594 among other 
biological functions605. I also observed that PAs with relatively more M2-macrophages and fewer 
M1-macrophages (M2:M1 ratio ≥2) had higher TAF-derived FGF-2 and CXCL1 levels, two proteins 
able to induce M2-macrophage polarisation595-597. 
 
The functional crosstalk between pituitary tumour cells and fibroblasts 
My in vitro data showed that TAF-derived factors, but not normal skin fibroblasts factors, are able 
to induce numerous effects on GH3 cells. Direct induction of EMT, in line with increased invasion, 
migration and altered cell shape, suggest that TAF-derived factors interact with pituitary tumour 
cells to influence their behaviour and invasiveness. I noted a non-significant trend for increased 
GH3 cell migration towards skin fibroblast-CM, less marked than in the presence of TAF-CM, which 
is not surprising considering that skin fibroblasts are also a source of cytokines and 
chemokines598,599, suggesting that fibroblast factors in general may alter tumour cell migration. 
However, invasion requires not only the capacity for cells to migrate, but also their ability to 
secrete enzymes to degrade matrigel537,606; this seems to be induced only by TAF-derived factors, 
and not by factors derived from normal skin fibroblasts. In fact, skin fibroblast-CM was not able to 
increase invasion, whereas TAF-CM remarkably increased GH3 cell invasion in comparison to 
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complete medium, and almost significantly in comparison to skin fibroblast-CM. EMT induction by 
TAF-derived factors, a crucial process for migration and invasion of neoplastic cells466, support my 
human data linking cavernous sinus invasion and TAF-derived cytokines, particularly IL-6, an 
interleukin of high importance for fibroblast biology586,607.  
 
Pasireotide inhibits cytokine secretion from TAFs 
Considering that TAF-derived IL-6 can be involved in cavernous sinus invasion, and CCL2 may be 
relevant for proliferation and angiogenesis of PAs (as suggested by this study), the anti-secretory 
effect of pasireotide observed for these 2 particularly TAF-derived cytokines may be of most 
importance in the modulation of the TME and the aggressiveness of PAs.  
Somatostatin controls hormone secretion and proliferation in normal and neoplastic pituitary, and 
reduced IL-6 and IL-8 in human somatotrophinoma cultures234,608. The inhibitory effect of 
somatostatin on IL-6 secretion was also shown in non-pituitary cells609-611. In a study using human 
NFPA primary cultures, it was demonstrated that pasireotide can inhibit tumour cell viability by 
inhibiting VEGF secretion612. Pasireotide, by activating SST1 expressed in pancreas cancer-
associated fibroblasts, inhibited various cytokines including IL-6, with abrogation of metastasis 
and prevention of EMT385,391. The inhibitory effect of pasireotide on IL-6 release from PAs-derived 
TAFs observed here suggests that this effect may play a role in the effectiveness of pasireotide. 
Furthermore, the benefits of targeting TAFs with pasireotide likely extends beyond its role in 
inhibiting cytokine release. Fibroblasts are mediators of fibrosis due to their ability to secrete 
collagen, proteoglycans and other ECM proteins383,585. A correlation between collagen-producing 
cells and fibrous deposition was seen in PAs, with thyrotrophinomas having the highest number 
of collagen-producing cells and fibrous matrix395, in line with their recognised firm consistency613, 
which may hinder surgical resection614. Thus, a drug able to target TAFs and reduce fibrosis may 
be valuable in improving outcomes in patients with PAs. Emerging data support the anti-fibrotic 
properties of SSA, mainly by inhibition of fibroblast proliferation and induction of apoptosis615-617. 
Pasireotide was effective as methylprednisolone in patients with Graves´ orbitopathy618, a 
condition in which SST-expressing orbital fibroblasts are key pathophysiological elements616,617. 
The anti-secretory and anti-proliferative effects of a specific SSA in a certain PA depends on its SST 
expression pattern and the SST binding profile of that SSA164,577,619. However, the mere abundance 
of a given SST does not necessarily correlate with the level of response to a SSA with strong affinity 
for that SST619. In fact, some studies found no correlation between the inhibitory effects of 
octreotide or pasireotide and a particular SST expression pattern, or even less prominent response 
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to pasireotide in pituitary tumour cells expressing high levels of SST5619,620. The reasons for such 
discrepancies are unknown, but may well be related to the extrapituitary effects of SSAs, such as 
their modulatory effect directly to non-tumour cells present in the TME, including TAFs. The 
pharmacological effect on TAFs might also explain why in vivo pasireotide efficacy is superior than 
octreotide in patients with acromegaly621,622, while in vitro pasireotide and octreotide inhibit 
pituitary tumour cells similarly619,620. There are contradictory observations in NFPAs, where 
octreotide was able to stabilise the tumour size in most patients623 whereas in vitro there was a 
poor response or even a paradoxical increase in cell viability after treatment with both octreotide 
and pasireotide619. 
 
Limitations of this study 
The limitations of this study include the fact that I studied only a small cohort of cases with a 
relatively short postoperative follow-up, as this study is based on fresh primary cell culture, 
rendering data on longer term clinical outcomes and recurrence unavailable. The cytokine array 
experiments lack fresh fibroblasts derived from NP as controls, thus I used an alternative suitable 
control - normal skin fibroblasts. In the in vitro experiments I used a rat pituitary tumour cell line 
rather than a human cell line, as a human pituitary tumour cell line does not exist. 
 
 
Conclusions 
TAFs, as part of the TME of PAs, represent a source of cytokines influencing tumour proliferation, 
invasiveness and neovascularisation, with IL-6 and CCL2 emerging as key mediators. My in vitro 
findings confirm that TAF-derived factors, but not normal skin fibroblast-CM, influence pituitary 
tumour cells inducing EMT-like morphological changes, increasing invasion and migration, as well 
as activating EMT. My data also suggest that the inhibitory effects of pasireotide on cytokine 
release from TAFs may play a key role in its anti-tumoural effects. 
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Chapter 5: Other tumour microenvironment-related oncogenic 
mechanisms in pituitary adenomas 
 
Introduction 
The TME is determined by the non-tumour cells surrounding neoplastic cells, including immune 
cells (such as macrophages, lymphocytes and neutrophils) or stromal cells (such as fibroblasts), 
which determine not only the biological behaviour of tumour cells but also modulate different 
oncogenic mechanisms such as angiogenesis, ECM remodelling and EMT through a complex 
network of cytokines, chemokines and growth factors (Figure 5.1)204,207,429.  
 
Figure 5.1: TME-related oncogenic mechanisms 
Tumour cells release different cytokines and growth factors promoting the recruitment and modulation of 
immune cells (including macrophages, lymphocytes and neutrophils) and stromal cells (including 
fibroblasts) within the tumour microenvironment (TME). In turn, these TME elements and their crosstalk 
influence several oncogenic mechanisms, such as angiogenesis, extracellular matrix remodelling and 
epithelial-to-mesenchymal transition.  
 
Angiogenesis is an essential process for tumour development, growth, invasion and metastasis 
and is regulated by different non-cellular TME components, such as cytokines, chemokines, 
growth factors or ECM-remodelling enzymes297,304,421, as well as by different cells such as 
macrophages339 or TAFs469,585. The degree of tumour angiogenesis is commonly assessed by the 
microvessel density, i.e. the number of vessels per given area which can be, for instance, a high-
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power field, although other vascular parameters are also relevant304. Although angiogenesis has 
been studied to some extent in PAs297,304,421, research exploring the relationship between 
angiogenic processes in PAs and its TME is lacking, contrasting with the extensive data available 
for other cancers417,548,624.  
 
Different proteases, including MMPs, are able to change the ECM in the TME430-432, interfering 
with the tumour/non-tumour cell and ECM interactions429. ECM remodelling plays a role in several 
oncogenic mechanisms, such as angiogenesis, proliferation and metastasis, and thus ECM-
degrading proteases have an important role in the modulation of the TME. MMPs are important 
ECM proteases in cancer207,439, being upregulated and released into the TME either by neoplastic 
or non-neoplastic cells (Figure 5.2)435-438. Associations between MMP activity and invasiveness 
have been shown in different cancers440-443. Several studies described an association between 
MMP expression and invasive PAs, particularly MMP-2 and MMP-9 (type IV collagenases 
essentially to degrade type IV collagen present in the cavernous sinus)448,450-453, but also MMP-
14460. Nevertheless, the modulatory role of the different TME components in the expression of 
MMPs has never been addressed in PAs. 
Figure 5.2: MMPs main sources within the TME and their role in the modulation of the TME 
Several oncogenic mechanisms that are modulated by matrix metalloproteases (MMPs) in the tumour 
microenvironment (TME). In the figure are represented the most important families of ECM-degrading 
proteases: MMPs and ADAMs, both able to modulate and promote pro- or anti-tumoural effects within the 
TME. MMPs are mainly provided by non-malignant cells, such as inflammatory or stromal cells present in 
the TME, including neutrophils, macrophages, lymphocytes, mast cells, fibroblasts and endothelial cells, 
however neoplastic cells can also release MMPs into the TME. Adapted from Kessenbrock et al. (2010)441. 
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EMT, a process that increases the invasiveness of a tumour, is characterised by the loss of E-
cadherin and is determined by complex interactions between different TME elements, including 
cytokines, chemokines and growth factors, as well as different TME cells, playing a key role in 
tumourigenesis, invasion, progression and metastasis466-468. EMT and its complex regulation 
remain largely unexplored in PAs. It has been shown that PAs may undergo EMT, although they 
often they display a partial/incomplete EMT signature505,513. Research linking cellular and non-
cellular TME elements and EMT in PAs is lacking. 
 
Neural cell adhesion molecule (NCAM), also known as CD56, is a cell surface glycoprotein 
important for the mechanical stability and cohesion among cells, as well as between cells and the 
ECM. In addition, NCAM also participates in other cellular activities including proliferation, 
differentiation, mitogenesis and apoptosis625,626. NCAM multiple functions depend mainly on its 
various forms resulting from alternative splicing, glycosylation or polysialylation status, and 
expression patterns at different developmental stages625,627. NCAM, characterised by 5 
extracellular immunoglobulin-like and 2 fibronectin III domains (explaining its adhesion 
properties), is mainly expressed by neural tissues (neurons and glia) where it mediates homophilic 
adhesion of neural cells, activating a number of intracellular signalling cascades and regulating 
neurite outgrowth (Figure 5.3)625,626. NCAM is also found in haematopoietic cells, including NK 
cells628, muscle tissues and endocrine cells625,629. 
 
Figure 5.3: Molecular mechanisms of NCAM action in neuronal tissues 
2-AG, 2-arachidonoylglycerol; AA, arachidonic acid; Ca, calcium; CaMK, calmodulin protein kinase; CREB, 
cAMP response element binding; DAG, diacylglycerol; ERK, extracellular-signal-regulated kinase; FGFR, 
fibroblast growth factor receptor; IP3, inositol triphosphate; IP3R, inositol triphosphate receptor; NCAM, 
neural cell adhesion molecule; NSCC, non-selective cationic channel; PKC, protein kinase C; PLC, 
phospholipase C; VDCC, voltage-dependent calcium channel. Weledji & Assob (2014)625. 
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NCAM is overexpressed in many cancers, particularly in gliomas, neuroblastomas, astrocytomas, 
medulloblastomas, retinoblastomas, rhabdomyosarcomas, thyroid cancer, small cell lung cancer 
and haematological malignancies625,630,631, with modest expression levels in other solid tumours 
(Figure 5.4). Increased NCAM expression is generally associated with poorer outcomes in cancer, 
which may result from the ectopic expression of NCAM and/or from the shed of its extracellular 
domain which stimulates migration, invasion and survival of tumour cells625,630,632-634. However, in 
some malignancies the NCAM loss has been linked with tumourigenesis, invasiveness and/or 
unfavourable cancer outcomes, most likely as a result of lacking NCAM adhesion properties635,636. 
Figure 5.4: RNA expression levels of NCAM in different malignancies 
Adapted from Protein Atlas (https://www.proteinatlas.org/ENSG00000149294-NCAM1/pathology). 
 
NCAM is expressed by foetal and adult rat pituitary cells637, and may regulate various pituitary 
functions including hormone secretion626. NCAM was expressed in most PAs, without major 
differences among PA subtypes, except for prolactinomas which express lower levels of 
NCAM626,629,638-640. The release of soluble NCAM was also observed in some PAs640. Increased 
NCAM was associated with PA invasion, particularly its polysialylated form, which was not 
detected in the NP627,641. However, other studies have reported no association between NCAM 
expression and tumour invasiveness639,642. The influence of the different elements of the TME in 
the expression of NCAM in PAs has not currently been studied. 
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Aims 
Overall aim 
To study the role of different TME components (cytokines, immune cells and TAFs) in the 
modulation of different oncogenic mechanisms in PAs. 
 
Specific aims 
1. To characterise angiogenesis in human PAs and in NP 
2. To study PA microvessel density and vascular architecture in view of PA- and TAF-derived 
cytokines and PA-infiltrating immune cells 
3. To study the expression of ECM-remodelling enzymes MMP-9 and MMP-14 in human PAs 
and in NP  
4. To study the role of PA- and TAF-derived cytokines and PA-infiltrating immune cells in the 
modulation of MMP-9 and MMP-14 expression 
5. To characterise EMT in human PAs and in NP 
6. To study the role of the PA- and TAF-derived cytokines and PA-infiltrating immune cells in 
the modulation of EMT in PAs 
7. To characterise the expression of NCAM in human PAs and in NP 
8. To study the role of PA- and TAF-derived cytokines and PA-infiltrating immune cells in the 
modulation of NCAM expression in PAs 
 
 
 
Results 
Angiogenesis in human pituitary adenomas 
I analysed my cohort of 24 PAs with clinico-pathological, cytokine and infiltrating immune cells 
data for microvessel density and vasculature architecture parameters, staining the vessels with 
the specific endothelial marker CD31643, aiming to study the influence of the cytokine network and 
immune infiltrates in the TME of human PAs.  
 
 
175 
 
Angiogenesis in PAs vs NPs 
The vasculature is significantly different between PAs and NP (Figure 5.5), as shown 
previously297,304,421,427. When compared to NP, PAs showed remarkably lower microvessel density 
(p=0.015) and microvessel area/HPF (p<0.001). In terms of vascular architecture parameters, 
there were no major differences except for the fact that vessels were less round in PAs than those 
seen in NPs (p<0.001) (Figure 5.5). 
Figure 5.5: Angiogenesis in PAs and in NPs 
Microvessel density (MVD) and vasculature architecture parameters differences between human pituitary 
adenomas (PA) and normal pituitary (NP) are shown. PA (n=24) and NP (n=5) tissue sections were stained 
for CD31. CD31-vessels were counted in 3 different high power fields (HPF) to obtain MVD (number of 
vessels/HPF). CD31-stained 20x magnification fields were analysed with ImageJ and vessel contour was 
manually traced in order to obtain the vasculature architecture parameters: total microvessel area, area 
occupied per vessel, vessel perimeter, vessel Feret’s diameter and roundness. Data are shown as 
mean±SEM. Representative images of vessels from 2 PAs and 1 NP are shown (20x). *, <0.05, **, <0.01, ***, 
<0.001 (Mann Whitney U test).   
 
 
Angiogenesis and clinical features in PAs 
I found no association between microvessel density, total area or vascular architecture 
parameters and the different PA clinico-pathological features. In particular, there were no 
correlations with cavernous sinus invasion, Ki-67 or PA grades according to the Trouillas 
classification43. However, re-operated PAs tended to have increased microvessel density (p=0.072) 
and vessel roundness (p=0.074) than PAs operated for the first time (Table 5.1). 
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Table 5.1: Angiogenesis and clinical features in PAs 
Microvessel density (MVD), total microvessel area (TMVA) and vascular architecture parameters among the 
cohort of 24 PAs according to different clinical features. MVD is expressed as vessels/HPF. TMVA is 
expressed as percentage of microvessel area/HPF. Vascular architecture parameters are expressed as 
follows: perimeter and Feret’s diameter in µm; area occupied per vessel in percentage of the HPF; 
roundness is expressed with a numeric value comprised between 0-1. Data are shown as mean±SEM, per 
feature. p values were non-significant for all comparisons. §, 0.05 < 0.1 (Mann Whitney U test were used 
for all comparisons, except for variable Trouillas grade classification where one-way ANOVA test was used). 
 
 
Angiogenesis in NFPAs vs somatotrophinomas 
Microvessel density did not differ among NFPAs and somatotrophinomas, but the total area, 
vessel perimeter and Feret’s diameter were significantly higher in NFPAs in comparison to 
somatotrophinomas (Figure 5.6). The area occupied per vessel tended to be also higher in NFPAs 
in comparison to somatotrophinoma vessels (p=0.097). 
n PAs = 24 
MVD 
Mean ± SEM 
TMVA 
Mean ± SEM 
Perimeter 
Mean ± SEM 
Feret’s 
diameter 
Mean ± SEM 
Area per 
vessel 
Mean ± SEM 
Roundness 
Mean ± SEM 
Gender      
Male (n=16) 
Female (n=8) 
 
34.77 ± 5.18 
41.54 ± 8.88 
 
6.84 ± 0.72 
8.96 ± 2.13 
 
106.17 ± 8.46 
101.45 ± 6.57 
 
43.15 ± 3.53 
41.06 ± 2.47 
 
0.25 ± 0.49 
0.22 ± 0.36 
 
0.47 ± 0.15 
0.47 ± 0.01 
Headache at diagnosis 
Yes (n=8) 
No (n=16) 
 
36.88 ± 8.96 
37.11 ± 5.24 
 
6.37 ± 1.27 
8.14 ± 1.11 
 
98.21 ± 6.62 
107.79 ± 8.36 
 
39.69 ± 2.50 
43.83 ± 3.48 
 
0.19 ± 0.02 
0.27 ± 0.05 
 
0.45 ± 0.15 
0.47 ± 0.01 
Visual impairment at diagnosis 
Yes (n=13) 
No (n=11) 
 
40.23 ± 7.43 
33.24 ± 4.46 
 
8.51 ± 1.23 
6.42 ± 1.13 
 
112.52 ± 8.97 
95.23 ± 6.99 
 
46.05 ± 3.77 
38.19 ± 2.63 
 
0.27 ± 0.06 
0.20 ± 0.03 
 
0.46 ± 0.02 
0.47 ± 0.01 
Hypopituitarism at diagnosis 
Yes (n=11) 
No (n=13) 
 
39.06 ± 6.42 
35.31 ± 6.44 
 
8.72 ± 1.23 
6.55 ± 1.15 
 
111.35 ± 9.27 
98.88 ± 7.74 
 
45.09 ± 3.76 
40.21 ± 3.26 
 
0.28 ± 0.07 
0.21 ± 0.03 
 
0.47 ± 0.01 
0.47 ± 0.02 
Cavernous sinus invasion  
Yes (n=10) 
No (n=14)  
 
32.00 ± 6.18 
40.62 ± 6.30 
 
7.53 ± 1.14 
7.56 ± 1.25 
 
115.30 ± 12.40 
96.95 ± 4.64 
 
46.69 ± 5.10 
39.42 ± 1.96 
 
0.31 ± 0.08 
0.19 ± 0.01 
 
0.45 ± 0.02 
0.48 ± 0.01 
Ki-67  
< 3% (n=19) 
≥ 3% (n=5) 
 
37.18 ± 4.69 
36.47 ± 13.39 
 
7.19 ± 0.81 
8.92 ± 2.87 
 
101.13 ± 6.81 
117.75 ± 11.74 
 
40.88 ± 2.77 
48.42 ± 5.03 
 
0.23 ± 0.04 
0.27 ± 0.04 
 
0.48 ± 0.01 
0.43 ± 0.03 
Trouillas grade classification  
1a (n=11) 
1b (n=3) 
2a (n=8) 
2b (n=2) 
 
38.24 ± 6.47 
49.33 ± 19.73 
35.71 ± 7.17 
17.17 ± 1.84 
 
6.65 ± 0.99 
10.90 ± 4.74 
7.93 ± 1.41 
5.95 ± 0.36 
 
94.12 ± 5.53 
107.35 ± 4.85 
110.78 ± 14.16 
133.37 ± 30.03 
 
38.23 ± 2.35 
43.77 ± 1.87 
44.52 ± 5.72 
55.39 ± 12.69 
 
0.18 ± 0.02 
0.21 ± 0.01 
0.30 ± 0.10 
0.35 ± 0.06 
 
0.49 ± 0.01 
0.45 ± 0.02 
0.46 ± 0.01 
0.40 ± 0.07 
Re-operation 
Yes (n=5) 
No (n=19) 
 
52.67 ± 11.66§ 
32.91 ± 4.47 
 
8.78 ± 1.77 
7.22 ± 0.98 
 
85.88 ± 5.83 
109.52 ± 7.02 
 
34.71 ± 2.76 
44.49 ± 2.87 
 
0.17 ± 0.02 
0.26 ± 0.04 
 
0.50 ± 0.01§ 
0.46 ± 0.01 
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Figure 5.6: Angiogenesis in NFPAs and somatotrophinomas 
Microvessel density (MVD) and vasculature architecture parameters differences between human NFPAs and 
somatotrophinomas are shown. NFPA (n=16) and somatotrophinoma (n=8) tissue sections were stained for 
CD31. CD31-vessels were counted in 3 different high power fields (HPF) to obtain MVD (number of 
vessels/HPF). CD31-stained 20x magnification fields were analysed with Image J and vessel contour was 
manually traced in order to obtain the vasculature architecture parameters: total microvessel area, area 
occupied per vessel, vessel perimeter, vessel Feret’s diameter and roundness. Data are shown as 
mean±SEM. *, <0.05, **, <0.01, ***, <0.001 (Mann Whitney U test).   
 
There were no differences between somatotrophinomas untreated (n=2) and those pre-treated 
with SSAs (n=6) regarding microvessel density (p=0.740), total microvessel area (p=0.221), vessel 
perimeter (p=0.637), Feret’s diameter (p=0.496), area occupied per vessel (p=0.541) or 
microvessel roundness (p=0.539). 
Overall, there were not many correlations between microvessel density, total microvessel area 
and the vascular architecture parameters, and pituitary hormonal levels in my cohort of PAs as a 
whole and per PA subtype (Appendix 9). However, I found a significant negative correlation 
between serum IGF-1 and both perimeter and Feret’s diameter in the whole cohort of PAs (both 
NFPAs and somatotrophinomas) (Figure 5.7), suggesting a possible role for GH/IGF-1 levels in the 
differential modulation of the vessel architecture among NFPAs and somatotrophinomas. This 
statistical significance was lost when the different PA subtypes were analysed separately 
(Appendix 9), suggesting that the absolute GH/IGF-1 levels, or the extent of GH excess in 
somatotrophinomas, may not explain the vascular architecture heterogeneity observed within the 
same PA subgroup.  
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Figure 5.7: Correlation between serum IGF-1 levels and vessel perimeter and Feret’s diameter in PAs 
Number of PAs analysed = 24. p values were determined by the Pearson correlation coefficient r. 
 
Within the somatotrophinoma subgroup, there was a correlation between serum PRL and area 
occupied per vessel (r=0.958, p=0.010, Figure 5.8-A), and within the NFPA subgroup I also noted a 
positive correlation between serum PRL and microvessel density (r=0.542, p=0.045, Figure 5.8-B), 
suggesting a possible role for PRL in the modulation of angiogenesis in both somatotrophinomas 
and NFPAs.  
Serum levels of FT4 were also correlated with microvessel density among somatotrophinomas 
(r=0.875, p=0.010, Figure 5.8-C), consistent with the angiogenic properties of thyroid hormones644-
646, but not within the NFPA subgroup (Appendix 9). 
Figure 5.8: Serum pituitary hormone levels and vessel parameters in PAs 
Statistical significant correlations between: A) serum PRL levels and area occupied per vessel/HPF within 
somatotrophinomas (n=8); B) serum PRL levels and microvessel density (MVD) within NFPAs (n=16); C) FT4 
levels and MVD in somatotrophinomas (n=8). p values were determined by the Pearson correlation 
coefficient r. 
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Angiogenesis and PA-derived cytokine secretome 
There were no significant correlations between PA-derived cytokines and microvessel density or 
microvessel area (Appendix 9), even for molecules with recognised angiogenic properties such as 
VEGF-A, IL-8, FGF-2 and CCL2297,417. However, there was a negative correlation between PA-
derived FGF-2 levels and vessel perimeter (r=-0.407, p=0.048) (Figure 5.9-A). There was also as a 
significant correlation between PA-derived CXCL10 and the area occupied per vessel (r=0.407, 
p=0.049), but this statistical significance was driven by 2 outliers while the remaining 22 cases 
demonstrated no correlation (Figure 5.9-B).  Nevertheless, these findings highlight the ability for 
some of these secreted proteins to affect PA vessel morphology, specifically FGF-2365. 
When the data were analysed separately per PA type, within the NFPA subgroup no correlations 
between PA-derived cytokines and microvessel density or any of the vasculature architecture 
parameters were seen (Appendix 9). Among somatotrophinomas, I observed a correlation 
between the area occupied per vessel and PA-derived IL-8 (r=0.725, p=0.042) (Figure 5.9-C) and 
FGF-2 (r=0.769, p=0.026) (Figure 5.9-D). 
Figure 5.9: PA-derived cytokines and vessel parameters in PAs 
Statistical significant correlations between: A) FGF-2 levels and vessel perimeter in the whole cohort of PAs 
(n=24); B) CXCL10 levels and area occupied per vessel/HPF in the whole cohort of PAs (n=24); C) IL-8 levels 
and area occupied per vessel/HPF within somatotrophinomas (n=8); D) FGF-2 levels and area occupied per 
vessel/HPF in somatotrophinomas (n=8). p values were determined by Pearson correlation coefficient r. 
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Angiogenesis and PA-infiltrating immune cells 
Microvessel density was higher in PAs with lower FOXP3+ T cells content (Figure 5.10-A and 
Appendix 9) and also tended to be higher in PAs with more macrophages (Figure 5.10-B) and more 
CD4+ T cells (Figure 5.10-C). PAs with more CD4+T cells were significantly associated with 
increased total microvessel area (Figure 5.10-D). M2:M1 macrophage ratio was also positively 
correlated with microvessel density (p=0.015) and microvessel area (p<0.001) (Figure 3.17 in 
Chapter 3 and Appendix 9). Infiltrating immune cells do not seem to affect PA vessel morphology, 
as there were no correlations between different infiltrating immune cells and vessel architecture, 
except regarding B cells which content was associated with increased microvessel roundness 
(Figure 5.10-F and Appendix 9). 
Figure 5.10: PA-infiltrating immune cells and angiogenesis in PAs 
Microvessel density (MVD) and vascular architecture parameters in PAs with lower vs higher amounts of 
FOXP3+ T cells (A), macrophages (B and E), CD4+ T cells (C and D) and B cells (F). Data are shown as 
mean±SEM. *, <0.05, **, <0.01, ***, <0.001 (Mann Whitney U test).   
 
NFPAs with a higher content of PA-infiltrating CD4+ T cells (≥1%) had increased microvessel 
density (50.67±10.93 vs 26.56±4.64 vessels/HPF, p=0.044), increased total microvessel area 
(6.47±0.68 vs 11.24±2.11%, p=0.032) and were more round (0.50±0.01 vs 0.43±0.02, p=0.004) 
than NFPAs with lower amounts of CD4+ T cells (<1%). Vessels were also more round in NFPAs 
with less PA-infiltrating B cells (0.38±0.14 vs 0.24±0.03, p=0.048). Vessels from NFPAs with more 
infiltrating FOXP3+ T cells had increased diameter (132.42±13.42 vs 53.80±5.61µm, p=0.029) and 
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Feret’s diameter (53.80±5.61 vs 40.95±2.05µm, p=0.033) than those NFPAs with fewer FOXP3+ T 
cells. M2:M1 macrophage ratio was also positively correlated with total microvessel area (r=0.676; 
p=0.004) and tended to correlate with microvessel density (r=0.408; p=0.117) and area occupied 
per vessel (r=0.408; p=0.117) (Appendix 9). 
Somatotrophinomas with increased amounts of macrophages (≥6%) had larger microvessels than 
those cases with lower PA-infiltrating macrophages (namely higher perimeter: 101.41±1.93 vs 
78.98±5.14µm, p=0.007; higher Feret’s diameter: 41.12±1.59 vs 31.90±2.06, p=0.019; each vessel 
occupied increased area: 0.23±0.06 vs 0.13±0.01%, p=0.031). Among somatotrophinomas there 
was also a positive correlation between M2:M1 ratio and microvessel density (r=0.801; p=0.017) 
and between CD8:CD4 ratio and microvessel area (r=0.718; p=0.045) (Appendix 9). 
 
Angiogenesis and TAF-derived cytokine secretome 
Within the whole TAF cohort (n=16), TAF-derived levels of CCL2 were positively correlated with 
microvessel area (r=0.672; p=0.004) (Table 4.4 in Chapter 4 and Appendix 9). However, there were 
no further correlations between microvessel density or area neither with vessel architecture 
parameters nor other TAF-derived cytokines (Appendix 9), including for VEGF-A, FGF-2 or PDGF-
AA, proteins secreted by fibroblasts with known angiogenic functions384. 
The cytokine secretome analysis from TAFs derived from NFPAs showed significant correlations 
between CCL2 and total microvessel area (r=0.828; p=0.002), as well as between IL-6 levels and 
vessel perimeter (r=0.651; p=0.030), Feret’s diameter (r=0.618; p=0.043) and area occupied per 
vessel (r=0.674; p=0.023) (Appendix 9).  
There were some significant correlations between released cytokines from TAFs isolated from 
somatotrophinomas and angiogenic parameters: somatotrophinoma-TAF-derived IL-6 levels 
correlated with area occupied per vessel (r=0.912; p=0.031), CCL2 levels correlated with both 
microvessel density (r=0.937, p=0.019) and total microvessel area (r=0.916, p=0.029), and CCL11 
concentrations correlated with area occupied per vessel (r=0.883, p=0.092) (Appendix 9). 
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ECM-remodeling matrix metalloproteinases in human pituitary adenomas 
MMP-9 and MMP-14 expression in PAs vs NPs 
The expression of both MMP-9 and MMP-14, as measured by immunohistochemistry, differed 
between PAs and NPs, being remarkably higher in the normal gland than in neoplastic pituitary 
(Figure 5.11). MMP-9 was expressed by 12 out of 24 PAs (50%) and MMP-14 was detected in 9 
out of 24 PAs (37.5%), whereas in NP the MMP-9 and MMP-14 expression was detected in 100% 
(5/5) and 80% (4/5) respectively.  
The expression levels of MMP-9 and MMP-14 did not correlate within the whole cohort of PAs (r=-
0.119; p=0.578) or in the NPs alone (r=0.058; p=0.926). 
 
Figure 5.11: MMP-9 and MMP-14 expression in PAs and in NPs 
MMP-9 and MMP-14 immunoreactivity differences between human pituitary adenomas (PAs) and normal 
pituitary (NPs) are shown. PA (n=24) and NP (n=5) tissue sections were stained for MMP-9 and MMP-14 and 
immunoreactivities measured using a semi-quantitative method. Representative images from MMP-9 and 
MMP-14 expression in a PA and in a NP are shown (20x). Data are shown as mean±SEM. *, <0.05, **, <0.01, 
***, <0.001 (Mann Whitney U test).   
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MMP-9 and MMP-14 expression and clinical features in PAs 
PAs with higher Ki-67 had significantly lower MMP-9 immunoreactivity (p=0.028) and in PAs from 
patients who presented with visual impairment (p=0.037). On the other hand, PAs from patients 
who had headache at diagnosis had increased MMP-9 expression (p=0.010). There were no 
correlation with cavernous sinus invasion or PA grade according to the Trouillas classification43 
and MMP-9 expression (Table 5.2). I found no associations between MMP-14 immunoreactivity 
and different clinical features (Table 5.2). 
Table 5.2: MMP-9 and MMP-14 expression and clinical features in PAs 
MMP-9 and MMP-14 immunoreactivities according to different clinical features among the cohort of 24 
PAs. Data are shown as mean±SEM for MMP-9 and MMP-14 immunoreactivities, per clinical feature. *, 
<0.05, **, <0.01, ***, <0.001 (Mann Whitney U test were used for all comparisons, except regarding the 
Trouillas grade classification variable where one-way ANOVA test was used). 
PA n = 24 MMP-9 immunoreactivity 
Mean ± SEM 
MMP-14 immunoreactivity 
Mean ± SEM 
Gender      
Male (n=16) 
Female (n=8) 
 
2.13 ± 0.63 
2.38 ± 0.73 
p=0.799 
 
1.56 ± 0.48 
0.63 ± 0.42 
p=0.158 
Headache at diagnosis 
Yes (n=8) 
No (n=16) 
 
3.88 ± 0.64 
1.38 ± 0.54 
p=0.010 
 
1.75 ± 0.68 
1.00 ± 0.42 
p=0.333 
Visual impairment at diagnosis 
Yes (n=13) 
No (n=11) 
 
1.31 ± 0.58 
3.27 ± 0.68 
p=0.037 
 
1.08 ± 0.50 
1.45 ± 0.53 
p=0.610 
Hypopituitarism at diagnosis 
Yes (n=11) 
No (n=13) 
 
1.73 ± 0.74 
2.62 ± 0.63 
p=0.923 
 
1.00 ± 0.45 
1.46 ± 0.55 
p=0.635 
Cavernous sinus invasion  
Yes (n=10) 
No (n=14)  
 
2.00 ± 0.68 
2.36 ± 0.68 
p=0.721 
 
1.40 ± 0.62 
1.14 ± 0.44 
p=0.731 
Ki-67  
< 3% (n=19) 
≥ 3% (n=5) 
 
2.63 ± 0.55 
0.60 ± 0.60 
p=0.028 
 
1.21 ± 0.39 
1.40 ± 0.98 
p =0.835 
Trouillas grade classification  
1a (n=11) 
1b (n=3) 
2a (n=8) 
2b (n=2) 
 
2.73 ± 0.80 
1.00 ± 1.00 
2.50 ± 0.76 
0 
p=0.374 
 
1.27 ± 0.54 
0.67 ± 0.67 
1.13 ± 0.58 
2.50 ± 2.50 
p=0.733 
Re-operation 
Yes (n=5) 
No (n=19) 
 
2.80 ± 1.16 
2.05 ± 0.53 
p=0.537 
 
1.00 ± 0.63 
1.32 ± 0.43 
p=0.728 
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Consistent with the above observations, PAs with no expression of MMP-9 were associated more 
often with visual impairment at diagnosis (75.0 vs 33.3%, p=0.041) and less headache at diagnosis 
(8.3 vs 58.3%, p=0.009) (Table 5.3). There were no differences regarding these different clinical 
features in PAs with or without expression of MMP-14 (Table 5.3). 
 
MMP-9 immunoreactivity MMP-14 immunoreactivity 
Positive 
(n=12) 
Negative 
(n=12) 
p value 
Positive 
(n=9) 
Negative 
(n=15) 
p value 
Gender      
Male (n=16) 
Female (n=8) 
 
7 (58.3%) 
5 (41.7%) 
9 (75.0%) 
3 (25.0%) 
 
0.386 
 
7 (77.8%) 
2 (22.2%) 
9 (60.0%) 
6 (40.0%) 
 
0.371 
Headache at diagnosis 
Yes (n=8) 
No (n=16) 
 
7 (58.3%) 
5 (41.7%) 
1 (8.3%) 
11 (91.7%) 
 
0.009 
 
5 (55.6%) 
4 (44.4%) 
4 (26.7%) 
11 (73.3%) 
 
0.371 
Visual impairment at diagnosis 
Yes (n=13) 
No (n=11) 
4 (33.3%) 
8 (66.7%) 
9 (75.0%) 
3 (25.0%) 
 
0.041 4 (44.4%) 
5 (55.6%) 
9 (60.0%) 
6 (40.0%) 
 
0.459 
Hypopituitarism at diagnosis 
Yes (n=11) 
No (n=13) 
4 (33.3%) 
8 (66.7%) 
7 (58.3%) 
5 (41.7%) 
 
0.219 4 (44.4%) 
5 (55.6%) 
7 (46.7%) 
8 (53.3%) 
 
0.916 
Cavernous sinus invasion  
Yes (n=10) 
No (n=14)  
7 (58.3%) 
5 (41.7%) 
7 (58.3%) 
5 (41.7%) 
 
1.000 5 (55.6%) 
4 (44.4%) 
9 (60.0%) 
6 (40.0%) 
 
0.831 
Ki-67  
< 3% (n=19) 
≥ 3% (n=5) 
11 (91.7%) 
1 (8.3%) 
8 (66.7%) 
4 (33.3%) 
 
0.132 7 (77.8%) 
2 (22.2%) 
12 (80.0%) 
3 (20.0%) 
 
0.897 
Trouillas grade classification  
1a (n=11) 
1b (n=3) 
2a (n=8) 
2b (n=2) 
6 (50.0%) 
1 (8.3%) 
5 (41.7%) 
0 
5 (41.7%) 
2 (16.7%) 
3 (25.0%) 
2 (16.7%) 
 
0.403 4 (44.4%) 
1 (11.1%) 
3 (33.3%) 
1 (11.1%) 
7 (46.7%) 
2 (13.3%) 
5 (33.3%) 
1 (6.7%) 
 
0.984 
Re-operation 
Yes (n=5) 
No (n=19) 
3 (25.0%) 
9 (75.0%) 
2 (16.7%) 
10 (83.3%) 
 
0.615 2 (22.2%) 
7 (77.8%) 
3 (20.0%) 
12 (80.0%) 
 
0.897 
Table 5.3: Positive/negative MMP-9 and MMP-14 expression and clinical features in PAs 
Positive vs negative MMP-9 and MMP-14 immunoreactivities in PAs according to the respective different 
clinical features among the cohort of 24 PAs. Data are shown as n(%) per clinical feature. p values were 
calculated using the Chi-square test. 
 
MMP-9 and MMP-14 expression in NFPAs vs somatotrophinomas 
Somatotrophinomas had significantly increased MMP-9 immunoreactivity compared to NFPAs, 
while there were no differences regarding the expression of MMP-14 (Figure 5.12). 
MMP-9 was expressed by 7 out of 8 (87.5%) somatotrophinomas and in only 5 out 16 (31.2%) of 
the studied NFPAs (p=0.009), whereas positive expression of MMP-14 was observed in 43.8% 
(7/16) and in 25.0% (2/8) of NFPAs and somatotrophinomas respectively (p=0.371). 
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Figure 5.12: Expression of MMP-9 and MMP-14 in NFPAs and somatotrophinomas 
MMP-9 and MMP-14 immunoreactivity differences between NFPAs (n=16) and somatotrophinomas (n=8). 
Tissue sections were stained for MMP-9 and MMP-14 and immunoreactivities measured using a semi-
quantitative method. Representative images from MMP-9 and MMP-14 expression in a NFPA and in a 
somatotrophinoma are shown (20x). Data are shown as mean±SEM for MMP-9 and MMP-14 
immunoreactivities. *, <0.05, **, <0.01, ***, <0.001 (Mann Whitney U test).   
 
There were no significant correlations between MMP-9 and MMP-14 immunoreactivities and 
serum pituitary hormones, except in the case of serum IGF-1 and IGF-1 index and MMP-9 (Figures 
5.13-A and 5.13-B, and Appendix 9). This association may suggest a possible role for GH/IGF-1 in 
the differential expression of MMP-9 between NFPAs and somatotrophinomas, or the different 
MMP-9 expression may be a consequence of different IGF-1 levels in NFPAs and in 
somatotrophinomas. This association between MMP-9 and serum IGF-1 was not observed in the 
separate analysis within the NFPA and somatotrophinoma subgroups (Figures 5.13-C and 5.13-D), 
suggesting that GH/IGF-1 levels may not per se determine the extent of MMP-9 expression in each 
of these PA subtypes. Of the somatotrophinomas, I observed a negative correlation between 
serum PRL and MMP-9 immunoreactivity (r=-0.963, p=0.009) (Appendix 9), but this significance 
was driven by an outlier case that had elevated PRL at 5289 mU/L and no expression of MMP-9. 
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Figure 5.13: Serum IGF-1 and MMP-9 expression 
Correlation between: MMP-9 immunoreactivity and serum IGF-1 and IGF-1 index in the cohort of 24 PAs (A 
and B); MMP-9 immunoreactivity and serum IGF-1 among the 16 NFPAs (C); MMP-9 immunoreactivity and 
serum IGF-1 among the 8 somatotrophinomas (D). p values were determined by the Pearson correlation 
coefficient r. 
 
 
MMP-9 and MMP-14 expression and PA-derived cytokine secretome 
There were no significant correlations between PA-derived cytokines and MMP-9 and MMP-14 
immunoreactivities among the whole cohort of PAs (Appendix 9), except between PA-derived 
CCL2 levels and MMP-9 immunoreactivity (r=-0.450; p=0.027).  
When the data were analysed separately per PA subtype, within the NFPA subgroup there were 
no correlations between NFPA-derived cytokines and MMP-9 and MMP-14 expression (Appendix 
9); however, among somatotrophinomas, I observed negative correlations between MMP-9 
immunoreactivity and PA-derived CCL4 (r=-0.864; p=0.006), CXCL10 (r=-0.747; p=0.033), FGF-2 
(r=-0.809; p=0.015) and IL-6 (r=-0.738; p=0.037) (Figure 5.14 and Appendix 9).   
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Figure 5.14: PA-derived cytokines and MMP-9 expression in somatotrophinomas  
Correlation between MMP-9 immunoreactivity and PA-derived levels of CCL4 (A), CXCL10 (B), FGF-2 (C) and 
IL-6 (D) among somatotrophinomas (n=8). p values were determined by Pearson correlation coefficient r. 
 
These findings suggest that some PA-derived cytokines may influence the MMP-9 expression in 
somatotrophinomas, downregulating its expression, an effect possibly not occurring in NFPAs. If 
PA-derived cytokines indeed inhibit MMP-9 expression in PAs, the differential expression of MMP-
9 between somatotrophinomas and NFPAs could be potentially explained by the fact that NFPAs 
released significantly higher amounts of cytokines than somatotrophinomas (Figure 3.1 in Chapter 
3) which may have downregulated MMP-9 in NFPAs. 
 
MMP-9 and MMP-14 expression and PA-infiltrating immune cells 
PAs with more macrophages (≥6%) were associated with lower expression of MMP-9 (0.71±0.71 
vs 2.82±0.55, p=0.042) (Appendix 9) and displayed more often no MMP-9 expression (50.0 vs 
8.3%; p=0.025) (Table 5.4). PAs with more neutrophils (≥0.5%) had increased expression of MMP-
14 (2.18±0.59 vs 0.46±0.31, p=0.020) (Appendix 9) and had more often positive MMP-14 
immunoreactivity (Table 5.4). There were no other associations between MMP-9 or MMP-14 
immunoreactivity and immune cell ratios in the whole cohort of PAs (Appendix 9 and Table 5.4). 
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MMP-9 immunoreactivity MMP-14 immunoreactivity 
Positive (n=12) Negative (n=12) p value Positive (n=9) Negative (n=15) p value 
Infiltrating macrophages     
<6% (n=17) 
≥6% (n=7) 
 
11 (91.7%) 
1 (8.3%) 
6 (50.0%) 
6 (50.0%) 
 
0.025 
 
6 (66.7%) 
3 (33.3%) 
11 (73.3%) 
4 (26.7%) 
 
0.728 
Infiltrating CD8+ T cells     
<1% (n=6) 
≥1% (n=18) 
 
2 (16.7%) 
10 (83.3%) 
4 (33.3%) 
8 (66.7%) 
 
0.346 
 
2 (22.2%) 
7 (77.8%) 
4 (26.7%) 
11 (73.3%) 
 
0.808 
Infiltrating CD4+ T cells     
<1% (n=15) 
≥1% (n=9) 
8 (66.7%) 
4 (33.3%) 
7 (58.3%) 
5 (41.7%) 
 
0.673 5 (55.6%) 
4 (44.4%) 
10 (66.7%) 
5 (33.3%) 
 
0.459 
Infiltrating B cells     
<0.5% (n=8) 
≥0.5% (n=16) 
5 (41.7%) 
7 (58.3%) 
3 (25.0%) 
9 (75.0%) 
 
0.386 2 (22.2%) 
7 (77.8%) 
6 (40.0%) 
9 (60.0%) 
 
0.371 
Infiltrating neutrophils     
<0.5% (n=13) 
≥0.5% (n=11) 
8 (66.7%) 
4 (33.3%) 
5 (41.7%) 
7 (58.3%) 
 
0.219 2 (22.2%) 
7 (77.8%) 
11 (73.3%) 
4 (26.7%) 
 
0.015 
Infiltrating FOXP3+ T cells     
<0.3% (n=12) 
≥0.3% (n=12) 
5 (41.7%) 
7 (58.3%) 
7 (58.3%) 
5 (41.7%) 
 
0.414 3 (33.3%) 
6 (66.7%) 
9 (60.0%) 
6 (40.0%) 
 
0.206 
Immune cell ratios 
M2:M1 
CD8:CD4 
CD8:FOXP3 
CD68:FOXP3 
2.09 ± 0.20 
2.25 ± 0.43 
5.99 ± 1.11 
11.63 ± 2.59 
2.28 ± 0.24 
1.80 ± 0.41 
5.29 ± 1.03 
22.18 ± 5.77 
 
0.570 
0.456 
0.650 
0.116 
1.88 ± 0.18 
1.50 ± 0.19 
5.82 ± 1.64 
16.89 ± 6.84 
2.37 ± 0.21 
2.34 ± 0.44 
5.54 ± 0.73 
16.91 ± 3.51 
 
0.133 
0.097 
0.862 
0.997 
Table 5.4: Positive/negative MMP-9 and MMP-14 expression and PA-infiltrating immune cells 
Positive vs negative MMP-9 and MMP-14 immunoreactivities in PAs according to the infiltrating immune 
cells and immune cell ratios among the cohort of 24 PAs. Data are shown as n(%) per PA-infiltrating immune 
cells and as mean±SEM for immune cell ratios. p values were calculated using the Chi-square test for PA-
infiltrating immune cells and Mann Whitney U test for immune cell ratios. 
 
NFPAs with increased contents of macrophages (≥6%) and lower amounts of B cells (<0.5%) had 
negative expression of MMP-9, while NFPAs with lower contents of neutrophils (<0.5%) were 
associated with absent MMP-14 immunoreactivity (Appendix 9). No significant associations were 
noted among the subgroup of somatotrophinomas (Appendix 9). Overall, these data suggest that 
some infiltrating immune cells may influence the expression of MMP-9 and MMP-14, namely 
macrophages and neutrophils, and thus may have a modulatory role in the remodelling of the 
ECM within the TME of PAs, as shown in other cancers435-438. 
 
MMP-9 and MMP-14 expression and TAF-derived cytokine secretome 
Overall, there were no associations between TAF-derived cytokines and MMP-9 and MMP-14 
immunoreactivity in the cohort of 24 PAs. However, within somatotrophinomas I observed 
significant correlations between MMP-14 immunoreactivity and TAF-derived CX3CL1 levels (r=-
0.901; p=0.037) and IFNα2 (r=-0.911; p=0.031) (Appendix 9). 
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Epithelial-to-mesenchymal transition in human pituitary adenomas 
EMT and its regulatory mechanisms remain largely unexplored in PAs. It was previously shown 
that PAs may have a partial EMT phenotype505, which is consistent with the fact that PAs are 
benign and rarely metastasise. Data from Dr. Barry suggest that somatotrophinomas - particularly 
those due to an AIP mutation - undergo EMT (Figure 5.15), but her gene expression data showed 
no upregulation of some classical mesenchymal markers such as vimentin or N-cadherin in AIPmut 
somatotrophinomas, which indeed suggest an incomplete EMT signature513.  
Figure 5.15: EMT in human AIPmut and AIPneg somatotrophinomas 
A) Immunohistochemical analysis of E-cadherin and ZEB1 (EMT markers) in AIP mutation-positive 
somatotrophinomas (AIPpos GH), sporadic somatotrophinomas (Sp GH) and normal pituitary (NP), and its 
respective validation with RT-qPCR. Representative immunohistochemistry images at x20 magnification are 
shown, and for RT-qPCR experiment data are shown as relative mRNA expression. *, <0.05, **, <0.01, ***, 
<0.001 (Kruskal-Wallis test followed by Conover–Inman test for individual comparisons). B) Ingenuity 
pathway analysis of canonical pathways significantly altered in AIPpos and sporadic somatotrophinomas in 
comparison to NP. The differentially expressed genes in these 2 comparisons were analysed using Ingenuity 
pathway multiple comparison analysis. The top significant canonical pathways are shown, and was noted 
that “Regulation of the Epithelial-Mesenchymal Transition Pathway” is one of the most significantly altered 
pathways in AIPpos compared to sporadic somatotrophinomas. The horizontal line parallel to the X axis 
indicates a threshold for p=0.05 (Dr. Sayka Barry´s data513). 
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EMT in PAs vs NPs 
In my study, E-cadherin immunoreactivity did not differ between PAs and NPs, whereas the 
expression of ZEB1 was significantly higher in PAs than in NP which did not express ZEB1 in any of 
the studied specimens (Figure 5.16). In general, normal pituitary cells and most PA cells showed 
uniform moderate to strong membranous staining for E-cadherin and cytoplasmic positivity. 
Regarding ZEB1, normal pituitary cells were completely negative in all 10 cases, whereas some 
NFPAs and somatotrophinomas (not all) exhibited weak to moderate positive nuclear staining in 
some cells (not all), suggesting that those cells may be undergoing EMT, a process 
heterogeneously occurring in the PA tissue (Figure 5.16). 
 
Figure 5.16: E-cadherin expression in PAs and in NPs 
Immunohistochemical analysis of E-cadherin and ZEB1 in human pituitary adenomas (PAs, n=24) and in 
normal pituitaries (NPs, n=10). The stained sections were scored using a semi-quantitative method on the 
basis of both extent and intensity of the immunoreactivity. The extent of immunoreactivity was scored 
according to the percentage of stained cells in relation to the entire section as 0 points for no staining, 1 
point for <20%, 2 points for 20-50% and 3 points for >50% of the cells. Staining intensity was graded on a 
scale including 0 (no staining), 1 (weak), 2 (moderate) and 3 (strong). The sum of the intensity and extent 
scores was used as final score. E-cadherin and ZEB1 expression are shown as mean±SEM. Representative 
images of a PA and in a NP are shown. *, <0.05, **, <0.01, ***, <0.001 (Mann Whitney U test).   
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Unexpectedly, E-cadherin and ZEB1 immunoreactivities correlated positively (r=0.404; p=0.041) 
(Figure 5.17). 
Figure 5.17: Correlation between E-cadherin and ZEB1 immunoreactivity in PAs 
N PAs analysed = 24. p value was determined by the Pearson correlation coefficient r. 
 
 
EMT and clinical features in PAs 
E-cadherin and ZEB1 expression were not associated with PA aggressiveness, as determined by 
the presence of cavernous sinus invasion or by higher Ki-67; however, PAs with Ki-67≥3% tended 
to display lower levels of E-cadherin expression (4.00±0.60 vs 4.79±0.21, p=0.123) (Table 5.5). 
There were no associations between E-cadherin or ZEB1 immunoreactivities and other clinical 
features at presentation (Table 5.5). 
 n PAs = 24 E-cadherin immunoreactivity 
Mean ± SEM 
ZEB1 immunoreactivity 
Mean ± SEM 
Gender      
Male (n=16) 
Female (n=8) 
 
4.88 ± 0.20 
4.13 ± 0.44 
p=0.087 
 
1.19 ± 0.43 
0.75 ± 0.53 
p=0.547 
Headache at diagnosis 
Yes (n=8) 
No (n=16) 
 
4.25 ± 0.45 
4.81 ± 0.21 
p=0.207 
 
0.63 ± 0.42 
1.25 ± 0.45 
p=0.387 
Visual Impairment at diagnosis 
Yes (n=13) 
No (n=11) 
 
4.38 ± 0.29 
4.91 ± 0.29 
p=0.214 
 
1.15 ± 0.48 
0.91 ± 0.48 
p=0.722 
Hypopituitarism at diagnosis 
Yes (n=11) 
No (n=13) 
 
4.55 ± 0.28 
4.69 ± 0.31 
p=0.732 
 
0.64 ± 0.34 
1.38 ± 0.54 
p=0.253 
192 
 
Table 5.5: E-cadherin and ZEB1 expression and clinical features in PAs 
E-cadherin and ZEB1 immunoreactivities according to different clinical features among the cohort of 24 PAs. 
Data are shown as mean±SEM per feature. *,<0.05, **,<0.01, ***,<0.001 (Mann Whitney U test were used 
for all comparisons, except for Trouillas grade classification where one-way ANOVA test was used). 
 
 
EMT in NFPAs vs somatotrophinomas 
There were no differences in E-cadherin or ZEB1 immunoreactivities between NFPAs and 
somatotrophinomas (Figure 5.18), suggesting that the EMT signature may not differ between 
these 2 PA subtypes. 
 
Figure 5.18: Expression of E-cadherin and ZEB1 in NFPAs and somatotrophinomas 
E-cadherin and ZEB1 immunoreactivity differences between NFPAs (n=16) and somatotrophinomas (n=8). 
Representative images from E-cadherin and ZEB1 expression in a NFPA and in a somatotrophinoma are 
shown (20x). Data are shown as mean±SEM. *, <0.05, **, <0.01, ***, <0.001 (Mann Whitney U test).   
Cavernous sinus invasion  
Yes (n=10) 
No (n=14)  
 
4.80 ± 0.29 
4.50 ± 0.29 
p=0.487 
 
1.30 ± 0.56 
0.86 ± 0.42 
p=0.523 
Ki-67  
< 3% (n=19) 
≥ 3% (n=5) 
 
4.79 ± 0.21 
4.00 ± 0.60 
p=0.123 
 
1.00 ± 0.38 
1.20 ± 0.80 
p =0.813 
Trouillas grade classification  
1a (n=11) 
1b (n=3) 
2a (n=8) 
2b (n=2) 
 
4.82 ± 0.26 
3.33 ± 0.67 
4.75 ± 0.37 
5.00 ± 0.00 
p=0.122 
 
0.91 ± 0.51 
0.67 ± 0.67 
1.13 ± 0.58 
2.00 ± 2.00 
p=0.835 
Re-operation 
Yes (n=5) 
No (n=19) 
 
5.00 ± 0.48 
4.53 ± 0.23 
p=0.364 
 
1.40 ± 0.60 
0.95 ± 0.39 
p=0.591 
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There were no significant correlations between E-cadherin and ZEB1 immunoreactivities and 
serum pituitary hormones in the whole cohort of 24 PAs, and also among NFPAs (Appendix 9). 
However, within the subgroup of somatotrophinomas I observed a significant negative correlation 
between E-cadherin immunoreactivity and serum GH levels (r=-0.801; p=0.031), as well as a trend 
for negative correlation between E-cadherin immunoreactivity and serum IGF-1 (r=-0.719; 
p=0.069) (Figure 5.19), suggesting a potential effect for GH/IGF-1 excessive levels in patients with 
somatotrophinomas to promote EMT. 
Figure 5.19: Serum GH and IGF-1 and E-cadherin expression in somatotrophinomas 
Correlation between E-cadherin immunoreactivity and serum levels of GH and IGF-1 within the subgroup of 
somatotrophinomas (n=8). p values were determined by the Pearson correlation coefficient r. 
 
 
EMT and PA-derived cytokine secretome 
In general, there were no significant correlations between E-cadherin immunoreactivity and PA-
derived cytokine levels in the primary culture supernatants of the 24 PAs, except for VEGF-A which 
negatively correlated with E-cadherin expression (r=-0.476; p=0.019) (Figure 5.20 and Appendix 
9). VEGF-A is a growth factor known to induce EMT647, in part by repressing E-cadherin expression 
in tumour cells, in a similar manner to other cytokines/growth factors467,647.  
Regarding ZEB1 expression, I observed an overall tendency for negative correlations between all 
PA-derived cytokines and ZEB1 immunoreactivity, but statistical significance was only reached for 
PA-derived FGF-2 (r=-0.543; p=0.006) (Figure 5.20 and Appendix 9).  
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Figure 5.20: PA-derived VEGF-A and FGF-2 and E-cadherin/ZEB1 expression in PAs 
N PAs analysed = 24. p values were determined by the Pearson correlation coefficient r. 
 
 
Considering the marked differences between NFPA and somatotrophinoma cytokine secretomes 
(Figure 3.1 in Chapter 3), I performed a separate subanalysis between E-cadherin and ZEB1 
immunoreactivities and cytokine levels among these PA subtypes. Within somatotrophinomas 
CCL3 and VEGF-A levels were negatively correlated with E-cadherin immunoreactivity (r=-0.817; 
p=0.013 and r=-0.886; p=0.003 respectively), while for NFPAs no correlation between cytokines 
and E-cadherin immunoreactivity was noted. On other hand, among NFPAs a negative correlation 
between FGF-2 levels and ZEB1 immunoreactivity was noted (r=-0.612; p=0.012) while no 
significant correlations were seen in somatotrophinomas (Appendix 9). 
 
EMT and PA-infiltrating immune cells 
I did not observe correlations between PA-infiltrating immune cells and E-cadherin or ZEB1 
expression, which can again be explained, at least in part, by the lack of true EMT signature in my 
cohort of PAs, as discussed. However, there was a significant correlation between M2:M1 ratio 
and ZEB1 expression among somatotrophinomas (r=0.773; p=0.024) (Appendix 9), suggesting that 
the relative imbalance of more M2-macrophages and less M1-macrophages may promote EMT by 
upregulating ZEB1 in patients with somatotrophinomas. 
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EMT and TAF-derived cytokine secretome 
In different cancer models, cancer-associated fibroblasts have been shown to induce EMT387,388,390. 
TAF-derived PDGF-AA levels were negatively correlated with E-cadherin expression (r=-0.564, 
p=0.023), suggesting a possible role for TAF secretome in promoting EMT by downregulating E-
cadherin (Figure 4.5 in Chapter 4 and Appendix 9). ZEB1 expression was also negatively correlated 
with TAF-derived FGF-2 levels (r=-0.543; p=0.006) (Appendix 9). I found no other correlations 
between TAF-derived cytokine levels and E-cadherin or ZEB1 immunoreactivities (Table 4.4 in 
Chapter 4 and Appendix 9).  
 
 
Neural cell adhesion molecule in human pituitary adenomas 
NCAM expression in PAs vs NPs 
The expression of NCAM was not different between PAs and NPs (4.96±0.14 vs 5.40±0.25; 
p=0.192) (Figure 5.21). All PA and NP cases displayed NCAM intense immunoreactivity mainly 
visible in the cell membrane but also in the cytoplasm, consistent with previous descriptions639. 
 
Figure 5.21: NCAM expression in PAs and in NPs 
NCAM immunoreactivity differences between human pituitary adenomas (PAs) and normal pituitary (NPs) 
are shown. NCAM immunoreactivity was measured using a semi-quantitative method. Representative 
images from NCAM expression in a PA and in a NP are shown (20x). Data are shown as mean±SEM for NCAM 
immunoreactivity. *, <0.05, **, <0.01, ***, <0.001 (Mann Whitney U test).   
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NCAM expression and clinical features in PAs 
There was no association between different clinico-pathological features and NCAM 
immunoreactivity in my cohort of 24 PAs (Table 5.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.6: NCAM expression and clinical features in PAs 
NCAM immunoreactivity according to different clinical features among the cohort of 24 PAs. Data are shown 
as mean±SEM for NCAM immunoreactivity, per feature. *,<0.05, **,<0.01, ***,<0.001 (Mann Whitney U 
test were used for all comparisons, except for Trouillas grade classification where one-way ANOVA test was 
used). 
 
 
NCAM expression in NFPAs vs somatotrophinomas 
NCAM expression did not differ among NFPAs and somatotrophinomas (p=0.415) (Figure 5.22). 
 n PAs = 24 NCAM immunoreactivity 
Mean ± SEM 
Gender      
Male (n=16) 
Female (n=8) 
 
4.88 ± 0.16 
5.13 ± 0.30 
p=0.415 
Headache at diagnosis 
Yes (n=8) 
No (n=16) 
 
4.88 ± 0.23 
5.00 ± 0.18 
p=0.685 
Visual impairment at diagnosis 
Yes (n=13) 
No (n=11) 
 
4.92 ± 0.18 
5.00 ± 0.23 
p=0.792 
Hypopituitarism at diagnosis 
Yes (n=11) 
No (n=13) 
 
4.82 ± 0.12 
5.08 ± 0.23 
p=0.372 
Cavernous sinus invasion  
Yes (n=10) 
No (n=14)  
 
5.20 ± 0.20 
4.79 ± 0.19 
p=0.151 
Ki-67  
< 3% (n=19) 
≥ 3% (n=5) 
 
4.95 ± 0.14 
5.00 ± 0.48 
p=0.883 
Trouillas grade classification  
1a (n=11) 
1b (n=3) 
2a (n=8) 
2b (n=2) 
 
4.73 ± 0.20 
5.00 ± 0.58 
5.25 ± 0.16 
5.00 ± 1.00 
p=0.469 
Re-operation 
Yes (n=5) 
No (n=19) 
 
4.80 ± 0.37 
5.00 ± 0.15 
p=0.576 
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Figure 5.22: NCAM expression in NFPAs and in somatotrophinomas 
NCAM immunoreactivity differences between human NFPAs (n=16) and NPs (n=8) are shown. NCAM 
immunoreactivity was measured using a semi-quantitative method. Representative images from NCAM 
expression in a NFPA and in a somatotrophinomas are shown (20x). Data are shown as mean±SEM for NCAM 
immunoreactivity. *, <0.05, **, <0.01, ***, <0.001 (Mann Whitney U test).   
 
There was a correlation between NCAM expression and serum LH (r=0.518; p=0.016) and FSH 
(r=0.487; p=0.025) in the whole cohort of PAs (Figures 5.23-A and 5.23-B), but there were no other 
significant correlations between serum pituitary hormones including GH/IGF-1 and PRL and NCAM 
expression (Appendix 9). Within the NFPA subgroup there were also no correlation between 
pituitary hormones and NCAM immunoreactivity, and in somatotrophinomas PRL correlated with 
NCAM expression (r=-0.989; p=0.001) but this was driven by an outlier case (Figure 5.23-C); there 
was however no correlation with GH/IGF-1 levels (Appendix 9). 
Figure 5.23: Serum pituitary hormones and NCAM expression in PAs  
Statistical significant correlations between: A) serum LH levels and NCAM immunoreactivity within the 
cohort of 24 PAs; B) serum FSH levels and NCAM immunoreactivity within the cohort of 24 PAs; C) serum 
PRL levels and NCAM immunoreactivity within somatotrophinomas (n=8). p values were determined by the 
Pearson correlation coefficient r. 
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NCAM expression and PA-derived cytokine secretome 
There were no correlation between PA-derived cytokine levels and NCAM immunoreactivity in the 
overall cohort of PAs (Appendix 9). As NFPA and somatotrophinoma secretomes differed (Figure 
3.1 in Chapter 3), these PA types were analysed individually. In NFPAs there were no correlations 
(Appendix 9), but somatotrophinomas with lower NCAM expression had higher levels of CCL4 
(p=0.026), CXCL1 (p=0.045), FGF-2 (p=0.021) and IL-6 (p=0.030) (Figure 5.24 and Appendix 9).   
 
Figure 5.24: PA-derived cytokines and NCAM expression in somatotrophinomas 
Number of somatotrophinomas = 8. p values were determined by the Pearson correlation coefficient r. 
 
NCAM expression and PA-infiltrating immune cells 
Overall, there was no association between the NCAM immunoreactivity and PA-infiltrating 
immune cell contents, neither with immune cell ratios (Appendix 9). 
 
NCAM expression and TAF-derived cytokine secretome 
TAF-derived FGF-2 was negatively correlated with NCAM immunoreactivity in overall cohort of 24 
PAs (r=-0.631; p=0.009) (Appendix 9). Among NFPAs, NCAM negatively correlated also with TAF-
derived FGF-2 levels (r=-0.716; p=0.013), as well as with CXCL1 (r=-0.661; p=0.027) and CCL7 (r=-
0.609; p=0.047). In the somatotrophinomas subgroup, I found a positive correlation between TAF-
derived CCL22 levels and NCAM expression (r=0.978; p=0.004) (Appendix 9). 
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Discussion 
Using a comprehensively phenotyped cohort of human PAs with cytokine data from primary 
cultures of PA cells and TAFs as well as immunohistochemical immune infiltrates data, I found that 
some elements within the TME of PAs may modulate different oncogenic mechanisms, as 
summarised in Figure 5.25.  
Figure 5.25: Modulation of oncogenic mechanisms in PAs by different TME components  
Different proteins are secreted by the non-neoplastic tumour-associated fibroblasts (TAFs) and infiltrating 
immune cells, as well as from pituitary adenoma (PA) cells into the tumour microenvironment (TME). These 
proteins are able to influence and modulate distinct oncogenic mechanisms, including angiogenesis, matrix 
metalloproteinases expression, epithelial-to-mesenchymal transition activation (E-cadherin downregula-
tion and/or ZEB1 upregulation) and expression of the neural cell adhesion molecule (NCAM). CD4+T, CD4+ 
T cells; CD8:CD4, CD8+ T cytotoxic –CD4+ T helper cell ratio; CD20+B, CD20+ B lymphocytes; FOXP3+T, 
FOXP3+ T regulatory cells; FSH, follicle-stimulating hormone; FT4, free thyroxine; GH, growth hormone; 
GHomas, somatotrophinomas; IGF-1, insulin-like growth factor-1; LH, luteinising hormone; MΦ, CD68+ 
macrophages; M2:M1, M2-M1 macrophage ratio; MMP, matrix metalloproteinase;  NCAM, neural cell 
adhesion molecule; NFPA, non-functioning pituitary adenoma; PA, pituitary adenoma; PRL, prolactin; TAF, 
tumour associated fibroblast. 
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Angiogenesis in pituitary adenomas 
Angiogenesis provides tumour cells with energy supply and oxygen necessary for tumour growth, 
and increased requirements are needed for aggressive tumour growth416,417. Angiogenesis has 
been studied in the neoplastic and normal pituitary in the past, but little is known about the role 
of different cellular and non-cellular TME elements in pituitary angiogenesis297,416.  
PAs are less vascularised than NP302,421,427, and in general previous studies have shown that there 
is no association between PA vascularisation and invasiveness297,303,416, consistent with my own 
observations. These observations raise uncertainty about the role of angiogenesis in PAs, as 
opposed to other malignancies in which the neovascularisation correlates with tumour growth, 
invasion and metastasis297,417,648. However, the lack of increased angiogenesis in PAs in comparison 
to NP, and the lack of association between vascularisation and PA aggressiveness, may underlie 
the low growth rate and benign nature of PAs which uncommonly metastasise297,303,416. This 
apparent paradox can be partially explained by the lower oxygen consumption rate of PA cells. 
Tumour vessels can themselves be hypoxic and carry little oxygen, or can have oscillating rather 
than directed blood flows and thus be ineffective at transporting oxygen. Moreover, tumour cells 
are known to tolerate oxygen deprivation and be resistant to apoptosis under hypoxia, which 
allows for increased intercapillary distance643. Nevertheless, increased microvessel density was 
described for pituitary carcinomas compared to PAs and NP suggesting that angiogenesis may be 
a relevant mechanism, at least for highly aggressive pituitary tumours303. 
I observed that somatotrophinomas were less vascularised than NFPAs, in line with previous 
observations303,649, and have smaller vessels (lower perimeter and Feret’s diameter). However, 
some other series have reported no differences between distinct PA subtypes304,421,422. The 
observed difference is unlikely due to pre-operative SSA treatment as there were no angiogenic 
differences between untreated vs pre-treated somatotrophinomas. This corresponds to previous 
studies showing that SSA or dopamine agonists do not affect PA microvessel density303,422,425. I 
found a negative correlation between serum IGF-1 levels and perimeter and Feret’s diameter 
suggesting that GH/IGF-1 hypersecretion may decrease vessel size and area occupied by vessels 
in PAs possibly explaining the differences between NFPAs and somatotrophinomas. These findings 
are somewhat surprising owing the angiogenic properties of IGF-1650,651. 
I noted a positive correlation between PRL and area occupied per vessel in somatotrophinomas, 
and between PRL and microvessel density among NFPAs, suggesting a possible role for PRL in 
stimulating angiogenesis in both somatotrophinomas and NFPAs. PRL has recognised angiogenic 
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properties652,653, and previous studies showed that prolactinomas have higher microvessel density 
than other PA types304,421,422, which can be at least in part due to PRL hypersecretion.  
PA-derived FGF-2 levels were associated with smaller vessels in PAs, and in somatotrophinomas 
FGF-2 and IL-8 correlated with increased area occupied per vessel. FGF-2 and IL-8 are expressed 
in PAs by both somatotroph and gonadotroph cells232,416 and have angiogenic properties297,417, 
thus may be able to modulate PA angiogenesis. However, most of my data correlating PA-derived 
secretome and angiogenic parameters were negative, including for VEGF-A (strong angiogenic 
factor in PAs301,304), suggesting that cytokines released by PA cells per se may play a limited role in 
tumoural angiogenesis. Other factors such as the hormonal milieu in PAs or secreted pro-
inflammatory cytokines from TME non-neoplastic cells, as described for other cancers648,654,655, 
may be more relevant for the regulation of PA angiogenesis, as discussed below. 
Increased microvessel density and area were associated with more macrophages in the TME of 
PAs and correlated with the M2:M1 ratio. My data together with a recent study showing more 
M2-macrophages in rat prolactinomas than in NP, and that tumour M2-macrophage content 
increase as capillaries became more tortuous and of increased calibre346, suggest an angiogenic 
role for M2-macrophages in PAs, as shown for other cancers229,297,332,339,417,548,648,656. Increased 
microvessel density/area were also associated with more PA-infiltrating CD4+ T cells, whereas PAs 
with more FOXP3+ T cells showed decreased microvessel density. Among NFPAs, increased 
amount of PA-infiltrating CD4+ and FOXP3+ T cells were associated to bigger vessels while in 
somatotrophinomas larger vessels were associated with more macrophages. The crosstalk 
between tumour and immune cells in hypoxic and cytokine-rich TME result in the induction of pro-
angiogenic behaviour in both cell types and thus promoting tumour neovascularisation648,657. 
Macrophages, CD4+ T and FOXP3+ T cells are strong promoters of angiogenesis in 
tumours648,655,657, in line with my data. However, the FOXP3+ T cell immunosuppressive activity 
directly to macrophages and CD4+ T cells may impair their angiogenic functions resulting in 
vascularisation suppression658, possibly explaining why PAs with more FOXP3+ T cells had lower 
vessel density. Overall, these data suggest that immune cells may influence the angiogenesis in 
PAs, particularly macrophages and T lymphocytes, active sources of angiogenic cytokines and 
growth factors in the TME648,654,655. However, the modest infiltration of immune cell seen in PAs, 
and thus the lower degree of tumour inflammation resulting in lower pro-inflammatory and pro-
angiogenic factors compared to malignant tumours, may explain the reduced angiogenesis in PAs. 
In addition to inflammatory cell-derived angiogenic compounds, TAF-derived levels of CCL2, a 
chemokine with known angiogenic functions583,584, correlated with microvessel area, suggesting a 
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possible role for some TAF-derived factors in PA angiogenesis as described in other cancers384,585-
587. Thus, together with immune cells, stromal cells may influence PA neovascularisation. 
Angiogenesis is commonly evaluated by immunohistochemistry assessing microvessel density and 
vasculature morphology by examining CD31- or CD34-stained tissue sections in image analyser 
systems297,304,643, a method I used in my study. However, immunohistochemical assessment of 
angiogenesis has a number of shortcomings that can explain some inconsistencies among previous 
studies and represent limitations to my study. Firstly, as in any tumour, PAs have a complex 
biology and irregular geometry of the vascular system, which vary from case to case and also 
among different subtypes304,416, leading to variable results. Secondly, some tumours, including 
PAs, have lower microvessel density than the corresponding normal tissues, hence the assessment 
of microvessel density may not be sufficient to reveal the functional or angiogenic status of a 
tumour643. Thirdly, is important to take into account vessel topography in the selection of the 
fields to assess, differentiating vessels into those supplying invading tumour edges, those serving 
the inner tumour area and those in the peripheral tumour areas usually composed of capillaries 
with endothelial cells derived from pre-existing vessels643. Fourthly, attention should be paid to 
vessel diameter, where tumours with high metabolic rate usually have small vessel diameter and 
high vascular density; in contrast, tumours of low metabolic rate have larger vessels with many 
cell layers and a relatively low vascular density. Fifthly, variability in the results can be also due to 
the lack of standardised protocols in manual or automated vessel counting or due to technical 
aspects such as observer subjectivity, choice to count vessels in hot spot areas vs randomly chosen 
fields, field magnification, and the selection of the endothelial marker to use on 
immunohistochemical studies643. 
 
Matrix metalloproteinases in pituitary adenomas 
MMP-9 and MMP-14 have been studied in PAs, particularly their role in PA aggressiveness and 
phenotype450-453,460,659. However, studies analysing MMP-9 and MMP-14 expression in PAs vs NP 
are scarcer, and there are no series assessing the role of TME elements in MMP regulation.  
I observed that MMP-9 and MMP-14 expression were remarkably more prominent in NPs than in 
PAs, in line with Knappe et al. findings660. However, Turner et al. reported no MMP-9 expression 
in all the 4 NPs analysed421, and Pereda et al. found MMP-2 expression only in some PAs but not 
in the NPs studied454. I noted positive MMP-9 expression in half of the PAs, which is line with 
Knappe study reporting positive MMP-9 expression in 41 out of 84 PAs660; on other hand, only 
37.5% of my PAs expressed MMP-14. 
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In my cohort of PAs, there were no association between MMP-9 and MMP-14 and cavernous sinus 
invasion or PA angiogenesis, suggesting that MMP-9’s differential expression may not be that 
relevant or the leading mechanism to determine PA invasiveness. These findings are in line with 
some reports which found no association between MMPs and PA invasiveness660,661. However, 
other studies, including a large meta-analysis, showed that MMP-9 expression is associated with 
PA invasiveness313,448,450,452-454. I found that patients who had headache at diagnosis had 
significantly more expression of MMP-9. MMP-9 has never been implicated in the aetiology of 
headache in patients with PAs, although it has been linked with neuropathic pain and migraines 
in other settings662-665; moreover, MMP-9 is involved in the development of haemorrhage or 
apoplexy within PAs, phenomenon that can itself elicit headache666.  
Serum IGF-1 and MMP-9 expression levels correlated which may explain the increased MMP-9 
immunoreactivity observed in somatotrophinomas in my study and elsewhere660, consistent with 
the fact that expression and enzymatic activity of MMPs can be upregulated by IGF-1667,668 or by 
other related mitogenic factors such as insulin433,441,669. Nevertheless, other series reported no 
MMP-9 expression differences among PA types, including NFPAs and somatotrophinomas448,450,452. 
Cytokines can upregulate MMP expression and activity. Hence, the negative correlations I 
observed between MMP-9 and PA-derived CCL2 levels in my cohort of PAs, and with CCL4, CXCL10, 
FGF-2 and IL-6 among somatotrophinomas, the lack of correlation between PA-derived cytokines 
and MMP-14 expression and the lack of association between TAF-derived cytokines and MMPs 
expression, were rather unexpected. Nevertheless, cytokines within the TME are also derived 
from other cell types, including immune cells, which can strongly modulate the expression of 
MMPs433,441, possibly explaining the observed correlation between MMP-14 expression and PA-
infiltrating neutrophils. 
MMP activity is balanced by tissue inhibitors of metalloproteinases433,441,453,454, which I have not 
analysed in my study, hence the relative imbalance between MMPs and their tissue inhibitors, 
cannot be fully assessed in my study. Moreover, my cohort of PAs and NPs is probably too small 
to properly assess differences between PAs and NPs, as well as to define the role of MMPs in PA 
phenotype and invasiveness, previously shown in larger studies313,448,450,452-454,460,659. Another 
aspect to consider is that tumour cells are not the only source of MMPs, which can also be derived 
from stromal or immune cells present in the TME433, and thus the assessed MMP-9 and MMP-14 
immunoreactivities in my study (and others) account not only PA cells but also non-neoplastic 
cells. Together, these reasons may explain some of my unexpected findings such as higher 
expression of MMP-9 and MMP-14 in NPs than in PAs, the association between higher Ki-67 and 
low MMP-9 expression and the lack of correlation between MMPs expression and cavernous sinus 
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invasion, taking into account that MMPs are involved in early stages of tumour development and 
mechanisms including proliferation, survival, invasion and angiogenesis433,441. Moreover, these 
reasons can also partially explain the lack of association between PA-derived or TAF-derived 
cytokines, PA-infiltrating immune cells and MMPs expression generally observed in my study, 
despite the known role for these TME elements in the regulation of MMP expression433,441. 
 
EMT in pituitary adenomas 
EMT is determined by the interactions between different TME elements, including cytokines, as 
well as different non-tumour cells, and play a key role in the tumourigenesis, tumour progression 
and invasion466-468. There are no studies assessing the role of the TME in the EMT in PAs. PAs may 
have a partial/incomplete EMT phenotype505,513, consistent with the fact that PAs are benign and 
rarely metastasise. My data corroborate this, as I observed no differences between PAs and NPs 
in terms of E-cadherin expression (the main EMT hallmark466), but a significant upregulation of 
ZEB1 (a marker whose over-expression suggests EMT activation466) in PAs in comparison to NP 
(none of the 10 studied NPs expressed ZEB1). The observed positive correlation between E-
cadherin and ZEB1 expression was unexpected considering that ZEB1 represses E-cadherin, 
further supporting the notion of a partial EMT signature in PAs. My data also suggest that ZEB1 
may be superior to E-cadherin to identify (early) EMT activation in PAs; in fact, factors promoting 
mesenchymal phenotype, such as ESRP1505 or indeed ZEB1513, seemed more adequate to assess 
EMT in PAs than epithelial markers which can be due to the fact that PA cells difficultly lose 
epithelial phenotype in keeping with their inability to metastasize.  
In my study, there were no significant associations between E-cadherin or ZEB1 expression and 
clinico-pathological features, but I observed that PAs with higher Ki-67 tended to have lower E-
cadherin expression, as expected, because E-cadherin downregulation and hence EMT activation, 
is associated with increased aggressiveness in cancer466-468, and in PAs449,460,461. 
There were no differences regarding E-cadherin or ZEB1 immunoreactivities between NFPAs and 
somatotrophinomas. However, within somatotrophinomas E-cadherin expression and serum GH 
and IGF-1 correlated negatively, suggesting a potential effect for GH/IGF-1 excessive levels to 
induce EMT in patients with somatotrophinomas by downregulating E-cadherin, an effect already 
described for GH which is regarded as a strong EMT inducer499. However, my data contrast with 
those from Lekva’s study showing positive correlation between E-cadherin and GH/IGF-1 levels505. 
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Cytokines and growth factors are recognised EMT promoters due to their repressive effect on E-
cadherin expression, but also by upregulating mesenchymal markers such as ZEB1466. E-cadherin 
downregulation was correlated with VEGF-A, a growth factor known to induce EMT647, in part by 
repressing E-cadherin expression in tumour cells467,647. TAF-derived PDGF-AA also correlated 
negatively with E-cadherin expression suggesting a possible role for TAF secretome in promoting 
EMT by downregulating E-cadherin. PDGFs are growth factors secreted by different cells, including 
fibroblasts, and has been shown that different PDGF isoforms and their receptors have important 
roles in the regulation of tumourigenesis, proliferation and survival of tumour cells, angiogenesis 
and in promoting EMT588-590.   
Despite the fact that immune cells within the TME are well-known promoters of EMT466, I found 
no associations between PA-infiltrating immune cells and E-cadherin/ZEB1 expression, suggesting 
the lack or (very) mild effect of these non-neoplastic TME cells in the EMT modulation in PAs in 
vivo, although in vitro macrophage-derived factors were able to induce EMT in GH3 cells (Chapter 
3). The lack of a true EMT signature in my cohort of PAs may actually explain, at least in part, these 
negative data and the contrast findings between my in vitro and human data. There was, however, 
a positive correlation between M2:M1 ratio and ZEB1 expression in somatotrophinomas, 
suggesting that, at least in this subtype, the predominance of M2 over M1-macrophages may 
activate EMT, an effect well-recognised to M2-macrophages229,334,466,670. 
  
NCAM in pituitary adenomas 
In my study, there were no NCAM expression differences between NFPAs and 
somatotrophinomas, as described in another study37. While there were no associations with 
clinico-pathological features, PAs with cavernous sinus tended to exhibit increased NCAM 
expression in line with data linking NCAM expression to aggressiveness and poor outcome in 
cancer36,40,42-44 and to higher PA invasion627,641. However, other studies showed no relation 
between NCAM expression and PA invasiveness639,642. 
In my study, I found no association between NCAM expression and GH/IGF-1 levels, despite the 
fact that NCAM increase GH release from foetal pituitary cultures and cultured somatotrophinoma 
cells626. However, NCAM expression correlated with serum LH and FSH, which may be due to a 
direct effect on gonadotropin secretion taking into account that pituitary hormone secretion is 
regulated by cell-cell contact (as shown for GH626 and PRL671). I noted a negative correlation 
between serum PRL and NCAM expression only in somatotrophinomas, but this result was driven 
by an outlier, thus is unlikely that PRL have any effect in NCAM expression, or the other way 
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around (i.e. NCAM overexpression unlikely decrease PRL secretion). In fact, as for GH626, NCAM 
may stimulate PRL secretion, as shown in GH4 pituitary tumour cells in which NCAM induction 
increased 40-fold PRL secretion671. However, in rat transplantable pituitary tumours 
polysialylated-NCAM expression did not correlate with GH or PRL secretion641. 
The role of cytokines in the modulation of cell adhesion molecules, including NCAM, has been 
described672, but in my study I generally found no correlation between PA-derived cytokines and 
NCAM expression in PAs. However, among somatotrophinomas increased levels of PA-derived 
CCL4, CXCL1, FGF-2 and IL-6 correlated with lower NCAM expression. Regarding TAF-derived 
cytokines, NCAM expression correlated only with FGF-2. These data suggest that cytokines derived 
from PA cells or TAFs may not have a major role in the modulation of NCAM in PAs. However, FGF-
2 may indeed modulate NCAM expression in PAs taking into account that NCAM intracellular 
signalling and physiological effects are mediated by FGF-receptors673,674. 
The role of immune cells in modulating cell adhesion molecules expression, including NCAM, is 
well-known. Immune cells can down or upregulate cell adhesion molecules, depending on many 
factors, including the surrounding TME. On the other hand, cell adhesion molecules can also 
influence immune infiltrates in tissues, including in the TME, as they play important roles in 
immune cell recruitment and transmigration675-678. Nevertheless, I found no association between 
NCAM expression and PA-infiltrating immune cells, suggesting that immune infiltrates in the TME 
of PAs may not play a crucial role in the modulation of NCAM expression.  
Overall, my data suggest that NCAM expression in PAs may not be dependent of cellular or non-
cellular TME elements, as PA-infiltrating immune cells and PA- or TAF-derived cytokines do not 
affect NCAM expression. However, I have only analysed the general form of NCAM and these data 
cannot be extrapolated to its different isoforms, including the polysialylated form, which may be 
more relevant to the PA biology considering that hypersialylation is a mechanism that confer 
increased aggressiveness to tumours679 and polysialylated-NCAM was associated with PA 
invasiveness627,641. 
 
 
Conclusions 
In summary, my data suggest that some of the different cellular and non-cellular TME elements 
within PAs may have a modulatory role in distinct oncogenic mechanisms. PA-derived cytokines 
(namely FGF-2 and IL-8), as well as TAF-derived cytokines (namely CCL2) may influence the PA 
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angiogenesis, although the modulatory angiogenic effect of immune cells seems to prevail, with 
macrophages (M2), CD4+ T and FOXP3+ T cells appearing particularly relevant. PA- and TAF-
derived cytokines (CCL2, CCL4, FGF-2, IL-6, CXCL1) influenced MMP and NCAM expression in PAs, 
more prominently among somatotrophinomas than in NFPAs, with PA-infiltrating immune cells 
showing little or no correlation with MMP and NCAM. In terms of EMT, my human PA data showed 
no association between immune cells and E-cadherin or ZEB1 expression, as well as minor 
influence from PA or TAF-derived factors in the expression of EMT markers, supporting a lacking 
or mild effect exerted by these cells in EMT modulation in PAs, contrasting with in vitro data 
showing that macrophage-derived factors induce EMT in pituitary tumour cells (Chapter 3). The 
partial EMT signature in my cohort of PAs (ZEB1 upregulated but no E-cadherin downregulation in 
comparison to NP) may explain, at least in part, some of my negative or unexpected results, as 
well as the discrepancies between my human PA and in vitro data. 
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Chapter 6: The effect of AIP deficiency in the pituitary tumour 
cytokine secretome 
 
Introduction 
The AIP protein is an ubiquitously expressed co-chaperone binding to several partners (Figure 1.4 
in Chapter 1), including the AHR which is one of the main AIP partners152,176. AHR is a ligand-
activated transcription factor classically involved in the toxic effects of the environmental toxin 
TCDD152,177. However, AHR has been involved in immune system regulation177,680,681, such as 
regulating the production of cytokines and reactive oxygen species682, controlling the 
differentiation and activity of T helper 17 cells683, modulating adaptive immune responses681,684, 
influencing biological processes in immune cells681 including polarisation of macrophages685 or  the 
development of germinal centre B cells686, as well as interacting with some components of the NF-
kβ signalling pathway687,688, an important pathway for the regulation and activation of immune 
responses including cytokine secretion689. 
The cytokine network in cancer is complex and predisposes to tumour initiation and growth, 
particularly in highly or chronic inflammatory conditions. However, not only does inflammation 
promote tumourigenesis, but also tumours can produce inflammation as a result of tumour cell 
secretion of mediators as cytokines, chemokines and growth factors into the TME, which can be a 
direct consequence of a certain oncogenic change such as a oncogene or tumour suppressor gene 
mutation209,210. Borrello et al. provided the first evidence for this showing that the rearrangement 
of the RET tyrosine kinase (recognised partner of AIP152) in thyrocytes represent a frequent, early 
and causative genetic event in the pathogenesis of papillary thyroid carcinoma, with the 
oncogenic change RET/PTC in primary human thyrocytes resulting in inflammation activation, 
including a number of different inflammatory mediators such as CCL2, CCL20 and IL-8690. Currently, 
other oncogenic changes affecting different genes (such as VHL, TP53, MYC) are known to 
modulate the cytokine network in the TME and thus tumour-related inflammation209,210. In fact, 
oncogenic changes in tumour cells may disrupt the cytokine/chemokine system: in some cancers, 
there is overexpression of certain chemokines leading to increased inflammatory cell contents and 
creating a tumour supportive TME, whereas in others chemokine downregulation impair anti-
tumour immune responses209,227.  
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Hence, I hypothesised that AIP loss could influence the pituitary tumour cytokine secretome, and 
if so, perhaps differential cytokine secretory activities among AIP deficiency vs AIP normal tumour 
cells may constitute an explanation for the increased AIPmut PA aggressiveness19,91,161,691 and high 
number of macrophages and FOXP3+ T cells observed in AIPmut PAs513. 
 
 
Aims 
Overall aim 
To investigate the role of AIP deficiency in the pituitary tumour cell cytokine secretome. 
 
Specific aims 
1. To determine the role of AIP deficiency in the pituitary tumour cell cytokine secretome 
2. To determine the role of AIP deficiency in the cytokine secretome of non-neoplastic cells, 
in particular tumour-associated fibroblasts and dermal fibroblasts  
3. To assess the role of AIP deficiency in the cytokine secretome response to somatostatin 
analogues 
 
 
 
Results 
Detecting differences in the cytokine secretome between AIPmut PAs and AIPneg PAs could 
explain some of the biological and phenotype differences among them, namely, the increased 
aggressiveness of AIPmut PAs19,152 (discussed in detail in Chapters 7 and 8). Differential AIPmut 
PA-associated cytokine and chemokine secreting abilities could also explain the higher amount of 
macrophages seen in human (Figure 6.1-A) and mouse (Figure 6.1-B) AIPmut 
somatotrophinomas513, as well as the increased chemotaxis induced by GH3-Aip-KD cells in 
RAW264.7 macrophages observed in my own in vitro functional experiments (Figure 6.1-C) and in 
bone marrow-derived rat macrophages as reported by Dr. Barry513 (Figure 6.1-D), findings that 
indeed prompted me to assess the cytokine secretome differences among pituitary tumour cells 
with and without AIP deficiency.  
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Figure 6.1: Increased macrophage infiltrates and chemotaxis in AIP mutation-positive tumours 
A) Immunohistochemical analysis of macrophages in human AIP mutation-positive somatotrophinomas 
(AIPpos), sporadic somatotrophinomas (Sp GH) and normal pituitary (NP). Data are shown as mean±SEM 
for the percentage of CD68+ cells per high power magnification field, counted on 3-5 random fields; n=5 in 
each subgroup. Representative images are shown, at x200 magnification. Scale bar=100μm. *, <0.05, **, 
<0.01, ***, <0.001 (Kruskal-Wallis test followed by Conover–Inman test for individual comparisons) – Dr. 
Sayka Barry´s data513. B) The graph bar shows the increased number of macrophages in Aip-knockout mice 
(AipFlox/Flox;Hesx1Cre/+) compared to wild type (WT). Representative images of macrophage infiltration in WT 
and homozygote Aip-knockout mice as determined by F4/80 staining (mouse macrophage marker) and 
quantified as percentage of F4/80+ cells. n=4 per genotype. Scale bar = 50μm. *, <0.05, **, <0.01, ***, 
<0.001 (Mann Whitney U test) (Dr. Sayka Barry´s data513). C) Transwell assay performed on RAW 264.7 
macrophages towards serum-medium, GH3-NT-CM, GH3-Aip-KD-CM and recombinant CX3CL1 (rCX3CL1) at 
100ng/mL for 72h. Data are shown as mean±SEM for the ratio of migrated macrophages towards GH3-NT-
CM or GH3-Aip-KD-CM or rCX3CL1 in relation to migrated macrophages in serum-medium. n=6. *, <0.05, 
**, <0.01, ***, <0.001 (two way-ANOVA with Bonferroni multiple comparison test).  D) Transwell migration 
assay representative images showing that bone-derived rat macrophages migration was more prominent 
towards GH3-Aip-KD-CM compared to GH3-NT-CM (Dr. Sayka Barry´s data513). 
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Considering the extreme rarity of AIPmut PAs available as a fresh sample for culture, it was not 
possible to conduct a proper cytokine study on freshly cultured human AIPmut PAs in order to 
investigate the effects of AIP deficiency in the pituitary tumour cytokine secretome. However, I 
had a single sample available. As a model, therefore, I have assessed the cytokine profile in 
supernatants from a stably lentiviral-transduced shRNA knockdown of Aip in the rat pituitary 
somatomammotroph cell line GH3 (GH3-Aip-KD), which was available in our laboratory, and 
compare this to the cytokine secretome from non-targeting GH3 cells (GH3-NT) with normal AIP 
levels. These GH3-Aip-KD cells show 80% reduced AIP protein in comparison to the GH3-NT cells 
(Figure 6.2).  
 
Figure 6.2: GH3-Aip-KD cells have 80% reduced levels of AIP comparing to GH3-NT cells 
AIP protein expression in shRNA transduced GH3 cells (GH3-Aip-KD) compared to NT shRNA GH3 cells (GH3-
NT), assessed by immunoblotting. A representative image is shown. Data are shown as mean±SEM, is 
normalised to GAPDH and compared to GH3-NT cells, n=8 (Mann Whitney U test). Data from Dr. Stiles. 
 
During the time of this study, I had one AIPmut somatotrophinoma operated from which I could 
set up primary cultures of both PA cells and TAFs, and then assess their cytokine secretome in 
culture supernatants. I also had the opportunity to culture skin fibroblasts derived from subjects 
carrying germline AIP mutations in homozygosity and heterozygosity (unpublished patients), and 
then being able to analyse their secretomes and compare it to those from skin fibroblasts collected 
from healthy subjects. These unique data will be shown here, despite the fact that the low number 
of cases does not allow a proper statistical analysis of the results. 
 
The role of AIP deficiency in the cytokine secretome of GH3 cells  
Supernatants from GH3-Aip-KD and from GH3-NT cells were collected at different time-points (24, 
48 and 72h) and then assessed by the rat cytokine Millipore MILLIPLEX 27-plex assay. Of the 27 
cytokines measured simultaneously by this assay (Appendix 5), CX3CL1 was the only significantly 
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increased in the GH3-Aip-KD supernatants at both 24h and 48h when compared to GH3-NT cell 
supernatants (Figure 6.3-A). Increased CX3CL1 expression in GH3-Aip-KD was validated by RT-
qPCR (Figure 6.3-B). CX3CL1 receptor (CX3CR1) is not expressed by GH3-Aip-KD or GH3-NT cells, 
as confirmed by RT-qPCR.  
 
Figure 6.3: CX3CL1 in GH3-Aip-KD vs GH3-NT cells 
A) CX3CL1 (fractalkine) concentration in GH3-NT vs GH3 Aip-KD cells. Millipore MILLIPLEX assay measured 
simultaneously 27 different cytokines, chemokines and growth factors. CX3CL1 levels were significantly 
higher in GH3-Aip-KD supernatants than in GH3-NT cells supernatants at 24 and 48h. Data are shown as 
mean±SEM for concentration (pg/mL), n=6. *, <0.05, **, <0.01, ***, <0.001 (Mann Whitney U test) B) Cx3cl1 
expression in GH3-NT and GH3-Aip-KD cells determined by RT-qPCR. GH3-Aip-KD cells have higher Cx3cl1 
expression than GH3-NT cells. Data are shown as relative Cx3cl1 mRNA expression fold change relative to 
Gapdh, mean±SEM, determined by ∆∆CT method. n=3. *, <0.05, **, <0.01, ***, <0.001 (Mann Whitney U 
test).  
 
Increased CX3CL1 levels in GH3-Aip-KD cells supernatants seems to be due its increased synthesis, 
rather than due to increased cleavage in its shed form, as no differences were noted in ADAM10, 
ADAM17 and MMP-9 expression among GH3-Aip-KD and GH3-NT cells (Figure 6.4). 
 
Figure 6.4: CX3CL1 cleavage-related proteases expression in GH3-NT and GH3-Aip-KD cells 
Data are shown as Adam10, Adam17 and Mmp9 mRNA fold expression relative to Gapdh, mean±SEM, 
determined by RT-qPCR using ∆∆CT method. n=3. *, <0.05, **, <0.01, ***, <0.001 (Mann Whitney U test).  
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However, the association AIP deficiency and differential CX3CL1 expression/secretion was not 
confirmed in the gene expression data previously generated by my colleagues Dr. Craig Stiles and 
Dr. Sayka Barry, in both human PAs (Figure 6.5-A) and in GH3 cells transiently knockdown for AIP 
(Figure 6.5-B). I performed an ELISA experiment measuring CX3CL1 levels on GH3-Aip-KD and GH3-
NT cell supernatants at both 24h and 48h (Figure 6.5-C), which failed to validate the differences 
seen in the cytokine array and in the RT-qPCR experiment.  
Figure 6.5: Effect of AIP mutation or AIP knockdown in CX3CL1 expression  
A) Affymetrix gene expression data regarding mRNA CX3CL1 expression in human pituitary adenoma 
samples. Two CX3CL1 probes were available in Affymetrix assay (823_at and 203687_at). There were no 
differences in CX3CL1 expression between AIP mutation-positive PAs (AIPpos, n=6) vs normal pituitary (NP, 
n=5), or vs AIP mutation-negative PAs (AIPneg, n=5). B) Affymetrix gene expression data regarding mRNA 
Cx3cl1 expression in siRNA GH3-Aip-KD cells (transient knockdown) vs GH3-NT cells (n=2). No statistical 
difference in Cx3cl1 expression between GH3-NT and transient GH3-Aip-KD cells was noted (Dr. Craig Stiles´ 
data). C) CX3CL1 concentration in GH3-NT vs GH3-Aip-KD cells quantified by ELISA. No differences in CX3CL1 
levels were seen in GH3-Aip-KD supernatants in comparison to GH3-NT at both 24 and 48h. Data are shown 
as mean±SEM (n=3). p values were non-significant (Mann Whitney U test). 
 
CX3CL1 levels in the PA cell supernatant from the cultured human AIPmut somatotrophinoma 
were less than those observed in AIPneg somatotrophinomas (3.98 vs 13.23±4.12pg/mL, Table 
6.1). AIPmut somatotrophinoma-associated TAFs had lower CX3CL1 concentration (22.96 pg/mL) 
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in their supernatants than the CX3CL1 levels seen in sporadic PA-associated TAF supernatants 
(26.86±8.34pg/mL, Table 6.2). CX3CL1 levels were also lower in supernatants from skin fibroblast 
from individuals carrying an AIP mutation in homozygosity and in heterozygosity in comparison to 
those seen in healthy skin fibroblast (Table 6.3). These data, together with those summarised in 
Figure 6.3, contradicted the hypothesis raised by my preliminary cytokine and RT-qPCR data that 
AIP deficiency could lead to increased expression and secretion of CX3CL1 from AIPmut pituitary 
tumour cells (Figure 6.3). 
Considering these inconsistent findings regarding CX3CL1, a recognised macrophage-attracting 
chemokine477,692, differential secretion of other chemokines/factors derived from tumour cells 
with and without AIP deficiency could then potentially explain, at least in part, the increased 
amount of infiltrating macrophages in AIPmut PAs and the increased macrophage chemotaxis 
promoted by tumour cells with AIP deficiency (Figure 6.1), including CCL2, CCL5 or CCL17.  
From the cytokine data, I noted that the absolute CCL2 concentrations were higher in GH3-Aip-KD 
than in GH3-NT cells at 24, 48 and 72h (non-significantly), but statistical significance was almost 
reached for the time-point 24h (141.52±18.86 vs 82.61±25.47, p=0.088) (Appendix 5). Of note, 
CCL2 levels were marginally increased in the AIPmut somatotrophinoma supernatant in 
comparison to AIPneg somatotrophinomas (62.55 vs 54.27±23.69 pg/mL) (Table 6.1), but CCL2 
levels were higher in AIPmut somatotrophinoma-TAF supernatants (14354.69 pg/mL) than in 
sporadic somatotrophinoma-TAFs (4795.62±679.53 pg/mL) or in the overall TAFs (4786.86± 
642.17pg/mL) (Table 6.2).  
Dr. Barry’s previous study found increased CCL5 levels in GH3-Aip-KD cells in comparison to GH3-
NT cells513, but I did not observe this difference in my cytokine bead array data on GH3-Aip-KD and 
GH3-NT cells supernatants, in which CCL5 levels did not differ among them, and were even slightly 
higher in GH3-NT supernatants at both 24h and 48h (Appendix 5). Moreover, CCL5 levels in the 
human AIPmut somatotrophinoma were lower than the mean CCL5 concentration observed in 
supernatants from AIPneg ones (1.28 vs 2.84±0.81pg/mL) (Table 6.1). Hence, according to these 
data, differential CCL5 release may not explain the macrophage infiltrates differences between 
AIPmut and AIPneg PAs. 
Although CCL17 was upregulated in GH3-Aip-KD cells in comparison to GH3-NT cells in Dr. Stiles’ 
Affymetrix gene expression data (Figure 6.6-A), I failed to identify differences in CCL17 expression 
between GH3-NT and GH3-Aip-KD cells in my RT-qPCR experiments (Figure 6.6-B), suggesting that 
differential CCL17 secretion among AIPmut and AIPneg PAs may also not be the explanation for 
more infiltrating macrophages in AIPmut PAs. 
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Figure 6.6: Effect of AIP knockdown in CCL17 expression in GH3 cells  
A) Affymetrix gene expression data regarding mRNA Ccl17 expression in siRNA GH3-Aip-KD cells (transient 
knockdown) vs GH3-NT cells (n=2). No statistical difference in Cx3cl1 expression between GH3-NT and 
transient GH3-Aip-KD cells was noted (Dr. Craig Stiles data). B) CCL17 expression in GH3-NT and GH3-Aip-
KD cells determined by RT-qPCR. GH3-Aip-KD cells have increased CCL17 expression in comparison to GH3-
NT cells. Data are shown as relative CCL17 mRNA expression fold change to GAPDH, mean±SEM, determined 
by ∆∆CT method. n=3. p value was non-significant (Mann Whitney U test). 
 
Tumour cells with AIP deficiency may have differential cytokine secretion after stimulation than 
those with normal AIP levels. Although the GH3 cell secretome was not assessed after stimulation 
with a specific cytokine or growth factor, GH3-NT and GH3-Aip-KD secretomes were determined 
after treatment with RAW 264.7 macrophage-CM and compared to baseline. This macrophage-
CM was able to induce GH3 cytokine release, namely CX3CL1, CCL3, CXCL1, CXCL10, IL-1β, IL-10, 
IL-13 and VEGF, in general more prominently for GH3-Aip-KD cells (statistical significance noted 
for CXCL10 and IL-1β) (Appendix 5 and Figure 3.30 in Chapter 3). 
On other hand, GH3-Aip-KD-CM induced more prominent changes in the RAW 264.7 macrophage 
secretome than GH3-NT-CM, raising the secretion of most cytokines, notably CCL2, CCL4, CCL5, 
TNF-α, VEGF, CXCL10, IL-1α, IL-2 and IL-17 (Appendix 5 and Figure 3.22 in Chapter 3). This suggest 
that GH3-Aip-KD cell-CM may have a more potent effect in releasing macrophage cytokines and 
chemokines which in turn will act further as chemoattractant for immune cells including 
macrophages (explaining the increased immune infiltrates in AIPmut PAs513) and may confer 
increased aggressiveness (explaining the invasive phenotype recognised to AIPmut PAs19,152).  
 
The role of AIP deficiency in the cytokine secretome of a human AIPmut somatotrophinoma 
Due to the rarity of AIPmut PAs19,152, I have cytokine secretome data from only one human AIPmut 
somatotrophinoma (AIPmut c.910C>T; p.R304*), rendering these data unique, but at the same 
time limited to properly infer secretome differences among AIPmut and AIPneg PAs.  
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Observing the AIPmut somatotrophinoma cytokine data, I cannot identify striking differences in 
comparison to AIP mutation-negative somatotrophinomas. The levels of most cytokines were 
actually lower in the AIPmut somatotrophinoma, except for CCL2, CCL3 and PDGF-AA which were 
slightly elevated than in the AIPneg cases (Table 6.1).  
Cytokine 
AIP mutation-positive 
somatotrophinoma (n=1) 
AIP mutation-negative 
somatotrophinomas (n=8) 
IL-8 26.28 60.65 ± 34.68   [0.67, 220.70] 
CCL2 62.55 54.27 ± 23.69   [0, 153.71] 
CCL3 8.94 3.57 ± 0.86   [0, 7.62] 
CCL4 2.58 4.11 ± 1.86   [0, 14.67] 
CXCL10 0 5.94 ± 2.80   [0, 18.82] 
CCL22 13.17 65.03 ± 19.25   [11.50, 138.28] 
CXCL1 13.96 19.65 ± 6.39   [0, 40.13] 
CX3CL1 3.98 13.23 ± 4.12   [0, 31.14] 
FGF-2 23.70 37.15 ± 6.32   [20.22, 74.07] 
IL-6 0 0.28 ± 0.12  [0, 0.83] 
PDGF-AA 8.57 6.89 ± 3.83   [0, 27.58] 
VEGF-A 10.15 15.51 ± 7.01   [0, 52.49] 
PDGF-BB 0.25 3.41 ± 1.34   [0, 10.79] 
INFα2 0.87 5.48 ± 1.68   [0.18, 11.14] 
IL-4 0 5.74 ± 2.62   [0, 20.18] 
G-CSF 2.15 3.61 ±0.88   [0.64, 8.40] 
GM-CSF 0.48 1.79 ± 0.62   [0.07, 4.34] 
CCL5 1.28 2.84 ± 0.81   [0, 5.69] 
IL-12 p40 0 3.98 ± 1.58   [0, 11.69] 
TNF-α 0.15 0.37 ± 0.09   [0.08, 0.76] 
Flt3L 0.3 2.74 ± 0.44   [1.40, 4.50] 
IL-18 0 3.06 ± 1.14   [0, 7.15] 
CCL11 3.28 2.66 ± 1.02   [0, 6.39] 
EGF 2.21 2.33 ± 0.75   [0, 5.52] 
Table 6.1: Cytokine secretome from an AIP mutation-positive vs 8 AIPneg somatotrophinomas 
Cytokine secretomes were determined by the human Millipore MILLIPLEX 42-plex assay in supernatants 
from a human AIP mutation-positive somatotrophinoma (n=1) in comparison to AIP mutation-negative 
somatotrophinomas (n=8). Only detectable cytokines, chemokines or growth factors are represented in the 
table. Data are shown as concentration (pg/mL), mean±SEM. Minimum and maximum cytokine levels are 
shown in square brackets for the subgroup of AIP mutation-negative somatotrophinomas. 
 
 
The role of AIP deficiency in the cytokine secretome of AIPmut somatotrophinoma TAFs  
In order to study loss of heterozygosity these TAFs isolated from this AIPmut somatotrophinoma 
with proven germline AIPmut (c.910C>T; p.R304*), I extracted DNA and amplified the region of 
interest by PCR and then sequenced this genomic region. I confirmed that these TAFs were 
heterozygous for this AIP mutation, hence there was no loss of heterozygosity (Figure 6.7). 
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Figure 6.7: AIPmut PA-associated TAFs had no loss of heterozygosity at the AIP locus 
On the left panel is shown the DNA amplified band with 244bp (as expected) in a DNA sample from AIPmut 
PA-associated TAFs and from a healthy subject (positive control confirming that the PCR reaction worked), 
and the negative control (water instead of DNA excluding genomic contamination in the PCR reaction). On 
the right panel is shown the Sanger sequencing results (GATC company) as displayed by FinchTV software 
showing the heterozygous status of the known AIP mutation. 
 
My cytokine array data on supernatants from AIPmut somatotrophinoma-derived TAFs showed 
remarkably high CCL2 levels, 3x times more than those seen in sporadic somatotrophinoma TAFs 
or in sporadic overall PA-derived TAFs. AIPmut TAF-derived levels of CCL7 were 4-fold increased 
comparing to sporadic somatotrophinoma-derived TAFs and 6-fold increased than in the sporadic 
PA-derived TAFs. CCL22, FGF-2, CXCL1 were also modestly higher in AIPmut TAFs (Table 6.2). 
Cytokine/  
chemokine/  
growth factor 
AIPmut somatotrophinoma- 
derived TAFs (n=1) 
Mean concentration (pg/mL) ± SEM 
Sporadic somatotrophinoma- 
derived TAFs (n=5) 
Mean concentration (pg/mL) ± SEM 
Overall sporadic PA-derived 
TAFs (n=16) 
Mean concentration (pg/mL) ± SEM 
CCL2 14354.69 4795.62 ± 679.53 4786.86 ± 642.17 
CCL11 1038.78 1797.30 ± 894.43 836.27 ± 328.16 
VEGF-A 220.49 403.59 ± 240.29 174.29 ± 80.60 
CCL22 78.02 36.96 ± 21.92 62.54 ± 21.50 
IL-6 36.14 63.89 ± 10.45 54.76 ± 6.50 
FGF-2 52.23 36.29 ± 4.13 42.93 ± 5.82 
IL-8 32.93 65.69 ± 31.66 42.20 ± 11.11 
CXCL1 37.04 32.54 ± 16.78 28.20 ± 6.56 
CX3CL1 22.96 20.26 ± 3.86 26.86 ± 8.34 
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CCL7 91.48 23.51 ± 17.89 13.83 ± 5.97 
PDGF-AA 7.89 20.98 ± 8.29 11.64 ± 3.71 
IFNα2 7.08 5.68 ± 1.54 8.82 ± 2.40 
Table 6.2: AIPmut PA-derived TAF cytokine secretome and comparison to sporadic PA-associated TAFs 
Top 12 highly secreted cytokines, chemokines and growth factors in primary culture supernatants from 
tumour-associated fibroblasts (TAFs) isolated from PAs, including from the AIPmut somatotrophinoma case 
and from other sporadic somatotrophinomas (n=5) and overall PAs (n=16, 5 from somatotrophinomas and 
11 from NFPAs). PA-derived TAF supernatants were collected following 24h on serum-free medium 
conditions and the cytokine secretome determined with the human Millipore MILLIPLEX cytokine 42-plex 
array. Data are shown as concentration (pg/mL), mean ±SEM.  
 
The role of AIP deficiency in the cytokine secretome of skin fibroblasts from AIPmut subjects  
During the course of this study, our lab obtained skin fibroblasts from a kindred with seven AIPmut 
individuals, encoded as “Family F487”. Interestingly, there were 2 individuals (M1 and M8) who 
died in the first few months of life for unclear reasons and who carried an AIP mutation in 
homozygosity. The complete lack of AIP protein in their skin fibroblasts, as shown in the Figure 
6.7, suggest that this missense change resulted in an instable protein, as shown by our laboratory 
using cycloheximide chase study (data not shown). We also received skin fibroblasts from 2 
members carrying AIP mutation in heterozygosity (M2 and M3) with detectable AIP but, as 
expected, in less amount than wild-type skin fibroblasts (Figure 6.8). 
Figure 6.8: AIPmut kindred with subjects carrying AIP mutation in homozygosity and in heterozygosity 
AIP mutation-positive kindred including 2 individuals with AIP mutations in homozygosity (F487M1 and M8)  
leading to lack of AIP protein in skin fibroblasts, and 2 members carrying an AIP mutation in heterozygosity 
(F487M2 and M3) expressing less amounts of AIP protein in their skin fibroblasts than in wild-type 
fibroblasts, as demonstrated by immunoblotting. The western blot shown was performed by Dr. Chung Lim. 
 
When I compared the mean concentration of each cytokine measured in the supernatants from 
skin fibroblasts from homozygous AIPmut (n=2) vs heterozygous AIPmut (n=2) vs wild-type (n=2) 
subjects, there were no significant differences except for EGF (0 vs 0 vs 2.16±0.40pg/mL, p<0.05) 
(Table 6.3). The low number of samples limit conclusions from these data.  
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However, some observations can be made. For most cytokines, the lowest concentrations were 
seen in the heterozygous AIPmut subgroup vs homozygous AIPmut vs healthy subgroup, which 
had in general similar concentrations, with a pattern notable for CCL2 (269.62±28.92 vs 1310.22± 
705.11 vs 2756.56±28.92pg/mL, respectively), VEGF-A (30.38±7.73 vs 117.81±15.72 vs 96.09± 
29.12pg/mL, respectively), CCL7 (7.02±5.83 vs 29.96±16.94 vs 26.18 ±15.71pg/mL, respectively) 
and FGF-2 (20.07±6.08 vs 33.86±7.71 vs 28.40±0 pg/mL respectively).  
In the case of IL-8, AIPmut status was associated with a higher concentration (homozygosity: 
64.29±43.35; heterozygosity: 21.84±1.31; wild-type: 1.89±0.27pg/mL), but not consistent with 
data from cultured AIPmut somatotrophinoma cells.  
In the case of IL-6, AIPmut status was associated to lower levels (homozygosity: 34.60±30.52; 
heterozygosity: 17.18±3.42; wild-type: 68.42±7.82pg/mL) (Table 6.3). 
Cytokine/ 
chemokine/ 
growth factor 
Homozygous 
AIPmut  
(M1) 
Homozygous 
AIPmut  
(M8) 
Heterozygous 
AIPmut  
(M2) 
Heterozygous 
AIPmut  
(M3) 
Wild-type 
male skin 
fibroblasts 
Wild-type 
female skin 
fibroblasts 
Serum-
free 
medium 
CCL2 605.11 2015.33 298.53 240.70 1171.34 4341.78 4.00 
CXCL1 51.68 498.59 26.79 33.81 56.87 0 20.78 
VEGF-A 102.09 133.52 22.65 38.10 66.97 125.21 0 
IL-8 18.94 109.64 20.53 23.14 2.15 1.62 7.06 
IL-6 4.08 65.11 13.76 20.59 60.60 76.24 0 
FGF-2 41.57 26.15 26.15 13.99 28.4 28.4 0 
CCL7 10.02 43.90 12.84 1.19 10.47 41.88 8.20 
CCL22 16.00 13.73 17.15 9.30 13.73 16.00 20.78 
CX3CL1 7.86 5.53 0 2.42 7.86 10.96 6.73 
Flt3L 2.95 2.69 2.12 0 2.69 2.69 1.72 
IL-15 1.31 2.53 0.31 0.08 2.09 1.98 0.55 
G-CSF 1.22 1.90 0.25 0.16 1.16 1.05 0 
IFNα2 2.49 0 0.18 1.33 2.25 0.18 1.79 
GM-CSF 0.85 1.47 0.02 0.64 1.16 1.05 0 
IFNγ 1.56 0.64 0.64 1.1 2.25 0.87 0.34 
EGF 0 0 0 0 2.57* 1.78* 0 
Table 6.3: Cytokine secretome from AIPmut skin fibroblasts 
Cytokine secretome results determined by Millipore MILLIPLEX human 42-plex assay in supernatants from 
skin fibroblasts derived from 2 individuals with AIP mutations in homozygosity (M1, M8), 2 members 
carrying an AIP mutation in heterozygosity (M2, M3) and 2 healthy controls. Undetectable cytokines (i.e. 
readings below the assay quantification) were: CCL11, CCL3, CCL4, CCL5, CXCL10, IL-1A, IL-1B, IL-2, IL-3, IL-
4, IL-5, IL-7, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-17A, IL-18, PDGF-AA, PDGF-BB, sCD40L, TNF-α, TNF-β, 
TGF-α. Data are shown as concentration (pg/mL). Mean of each one of the 3 subgroups (each n=2) were 
calculated with no statistical significance obtained for any subgroup comparison except for the significantly 
higher levels of EGF in healthy fibroblasts comparing to both homozygous and heterozygous AIPmut cases. 
 
220 
 
AIP mutation-positive fibroblasts cytokine secretome response to pasireotide  
As seen for sporadic PA-derived TAFs (data shown in more detail in the Chapter 4 in Figure 4.13-
A and Table 4.6, and in Appendix 7), the AIPmut somatotrophinoma-derived TAF cytokine 
secretome showed remarkable responsiveness to pasireotide, with the levels from all cytokines 
decreasing significantly after 24h of pasireotide treatment (10-7M), except in the case of FGF-2 
whose levels doubled after treatment (Table 6.4).  
In sporadic PA-derived TAFs, pasireotide secretome responses were most noted for IL-6 and CCL2 
reduction by 80% (p<0.001) and by 35% (p=0.038), respectively (Figure 4.13-A and Appendix 7). In 
the case of AIPmut TAFs the degree of pasireotide responsiveness was even higher, with IL-6 
reducing by 90% and CCL2 by 80%. This pasireotide inhibitory effect in AIPmut TAFs was also 
prominent for CCL11 (reduced by 90%), CCL7 (reduced by 89%), PDGF-AA (reduced by 84%), IL-8 
(reduced by 62%) and VEGF-A (reduced by 60%) (Table 6.4).  
Table 6.4: AIPmut TAF cytokine secretome at baseline and after pasireotide treatment 
Cytokine secretome from the human AIPmut somatotrophinoma-derived TAFs at baseline (untreated) and 
after treatment with pasireotide (10-7M), and from the overall sporadic PA-derived TAFs (n=16). Data are 
shown as concentration (pg/mL), mean±SEM for the top 12 highly secreted proteins in PA-derived TAF 
supernatants collected following 24h on serum-free medium conditions with pasireotide or without. In the 
pasireotide treatment column, the cytokines which levels decreased after treatment with pasireotide are 
represented in green, whereas the cytokines that increased are represented in red. 
 
Cytokine/ 
chemokine/ 
growth factor 
AIPmut somatotrophinoma-derived TAFs 
(n=1) 
Mean concentration (pg/mL) ± SEM 
Overall sporadic PA-derived TAFs 
(n=16) 
Mean concentration (pg/mL) ± SEM 
UNTREATED PASIREOTIDE UNTREATED PASIREOTIDE 
CCL2 14354.69 2919.48 4786.86 ± 642.17 3105.43 ± 434.95 
CCL11 1038.78 117.39 836.27 ± 328.16 529.82 ± 173.32 
VEGF-A 220.49 81.79 174.29 ± 80.60 134.11 ± 69.96 
CCL22 78.02 61.47 62.54 ± 21.50 59.15 ± 14.64 
IL-6 36.14 4.25 54.76 ± 6.50 11.83 ± 2.77 
FGF-2 52.23 111.30 42.93 ± 5.82 38.62 ± 4.32 
IL-8 32.93 12.35 42.20 ± 11.11 30.21 ± 9.38 
CXCL1 37.04 23.93 28.20 ± 6.56 28.13 ± 4.32 
CX3CL1 22.96 20.29 26.86 ± 8.34 24.04 ± 5.21 
CCL7 91.48 10.46 13.83 ± 5.97 10.47 ± 3.29 
PDGF-AA 7.89 1.28 11.64 ± 3.71 5.37 ± 1.38 
IFNα2 7.08 4.09 8.82 ± 2.40 6.76 ± 1.35 
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As seen in PA-associated TAFs (Figure 4.11 in Chapter 4), SST1 was the predominant receptor type 
in skin fibroblasts (Figure 6.9). Hence, I have used pasireotide treatment in a similar manner and 
in the same dose (10-7M) to assess the pasireotide cytokine secretome responsiveness of skin wild-
type and AIPmut fibroblasts (Table 6.4). 
 
Figure 6.9: SST expression profile in human skin fibroblasts 
Somatostatin receptor (SST) expression profile in human PA-derived TAFs assessed by RT-qPCR. Data are 
shown as SSTx mRNA fold change expression relative to GAPDH, mean±SEM, determined by the standard 
curve method. n=2. *,<0.05, **,<0.01, ***,<0.001 (one way-ANOVA with Bonferroni multiple comparison 
test).  
 
 
In general, homozygous and heterozygous AIPmut skin fibroblasts showed marked responsiveness 
to pasireotide in terms of cytokine secretome inhibition, with most cytokines decreasing following 
pasireotide treatment, with IL-6 decreasing by and CCL2 decreasing by 52% and by 95%. Among 
heterozygous AIPmut skin fibroblasts, the IL-6 and CCL2 decrease was almost statistically 
significant (p=0.051 and p=0.072 respectively), despite the low number of cases analysed (Table 
6.5 and Figure 6.10).  
In contrast, wild-type skin fibroblasts the pasireotide-induced cytokine concentrations reductions 
were smaller, for instance for CCL2 with a very modest reduction by 4%. The release of some 
cytokines from wild-type skin fibroblasts increased after pasireotide treatment including CXCL1, 
VEGF-A, FGF-2 (p<0.05), CCL7, CCL22, Flt3L, GM-CSF (p=0.087) and IL-15 (Table 6.5 and Figure 
6.10).  
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Cytokine/ 
chemokine
/ growth 
factor 
Homozygous AIPmut  
skin fibroblasts (n=2) 
Mean concentration (pg/mL) ± SEM 
Heterozygous AIPmut  
skin fibroblasts (n=2) 
Mean concentration (pg/mL) ± SEM 
Wild-type  
skin fibroblasts (n=2) 
Mean concentration (pg/mL) ± SEM 
UNTREATED PASIREOTIDE UNTREATED PASIREOTIDE UNTREATED PASIREOTIDE 
CCL2 1310.22 ± 705.11 637.17 ± 303.80 2756.56 ± 1585.22 127.22 ± 17.55 269.62 ± 28.92 259.73 ± 88.14 
CXCL1 275.14 ± 223.46 132.71 ± 54.58 28.44 ± 28.44 37.24 ± 7.97 30.30 ± 3.51 33.90 ± 22.25 
VEGF-A 117.81 ± 15.72 80.35 ± 19.53 96.09 ± 29.12 25.92 ± 6.01 30.38 ± 7.73 48.75 ± 2.43 
IL-8 64.29 ± 43.35 17.18 ± 3.96 1.89 ± 0.27 8.20 ± 2.94 21.84 ± 1.31 2.39 ± 0.30 
IL-6 34.60 ± 30.52 2.89 ± 2.05 68.42 ± 7.82 1.96 ± 1.09 17.18 ± 3.42 4.45 ± 0.89 
FGF-2 33.86 ± 7.71 28.53 ± 4.83 28.40 ± 0.00 26.58 ± 2.88 20.07 ± 6.08 22.33 ± 1.37 
CCL7 26.96 ± 16.94 12.70 ± 12.70 26.18 ± 15.71 0 7.02 ± 5.83 7.89 ± 0.61 
CCL22 14.87 ± 1.13 19.53 ± 3.53 14.87 ± 1.14 10.45 ± 4.41 13.23 ± 3.93 18.93 ± 2.93 
CX3CL1 6.70 ± 1.17 3.98 ± 2.33 9.41 ± 1.55 5.53 ± 1.55 1.21 ± 1.21 0.83 ± 0.82 
Flt3L 2.82 ± 0.13 2.19 ±0.22 2.69 ± 0.00 1.95 ± 0.46 1.06 ± 1.06 1.69 ± 1.00 
IL-15 1.92 ± 0.61 2.28 ± 0.42 2.04 ± 0.06 0.51 ± 0.19 0.20 ± 0.12 1.42 ± 0.22 
G-CSF 1.56 ± 0.34 0.35 ±0.19 1.10 ± 0.06 0.23 ± 0.22 0.21 ± 0.05 0.18 ± 0.18 
IFNα2 1.25 ± 1.25 0.78 ± 0.78 1.22 ± 1.04  0.41 ± 0.23 0.76 ± 0.58 0.41 ± 0.23 
GM-CSF 1.16 ± 0.31 0.89 ± 0.89 1.10 ± 0.06 0.28 ± 0.16 0.33 ± 0.31 0.44 ± 0.20 
IFNy 1.10 ± 0.46 0.55 ± 0.55 1.56 ± 0.69 0.70 ± 0.29 0.87 ± 0.23 0.64 ± 0.23 
EGF 0 0 2.18 ± 0.40 0.89 ± 0.89 0 0 
Table 6.5: AIPmut skin fibroblasts cytokine secretome at baseline and after pasireotide treatment 
Cytokine secretome from skin fibroblasts derived from subjects with AIP mutations in homozygosity (n=2), 
in heterozygosity (n=2) and wild-type controls (n=2) at baseline and after pasireotide treatment. 
Undetectable cytokines were: CCL11, CCL3, CCL4, CCL5, CXCL10, IL-1A, IL-1B, IL-2, IL-3, IL-4, IL-5, IL-7, IL-9, 
IL-10, IL-12p40, IL-12p70, IL-13, IL-17A, IL-18, PDGF-AA, PDGF-BB, sCD40L, TNF-α, TNF-β, TGF-α. Data are 
shown as concentration (pg/mL), mean±SEM. In pasireotide treatment column, cytokines which levels 
decreased after treatment are represented in green, whereas those cytokines that increased are shown in 
red. 
 
 
On an individual basis (i.e. subject by subject), the levels of IL-6, CCL2, VEGF-A, IL-8, CCL7 and INFy 
decreased consistently in all the AIPmut (homozygous and heterozygous) and wild-type skin 
fibroblasts following pasireotide treatment (Figures 6.11). For other cytokines there were 
inconsistent responses variable from subject to subject regardless genotype (Figure 6.12). 
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Figure 6.10: AIPmut skin fibroblasts cytokine secretome responsiveness to pasireotide 
Cytokine secretome results at baseline and after treatment with 10-7M pasireotide (SOM230) as assessed 
by the human Millipore MILLIPLEX 42-plex assay in supernatants from skin fibroblasts derived from subjects 
with AIP mutations in homozygosity (n=2, red), in heterozygosity (n=2, blue) and wild-type controls (n=2, 
green). Only detectable cytokines are shown in the figure. Data are shown as concentration (pg/mL), 
mean±SEM. n=2 per skin fibroblast subgroup, identified with different colours. *,<0.05, **,<0.01, 
***,<0.001 (Mann Whitney U test was used to compare baseline vs pasireotide within each subgroup). 
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Figure 6.11: Cytokines decreased in all pasireotide-treated skin fibroblasts 
Cytokines that decreased consistently in supernatants of skin fibroblasts after treatment with 10-7M of 
pasireotide (SOM230). Data are shown as concentration (pg/mL), per case before (left, square mark) and 
after pasireotide (right, triangle mark), per cytokine. Subjects with AIP mutations in homozygosity (n=2), in 
heterozygosity (n=2) and wild-type controls (n=2) are identified in red, blue and green, respectively. 
 
Figure 6.12: Cytokines responding inconsistently to pasireotide among the skin fibroblast subgroups 
Cytokines with inconsistent responses to 10-7M pasireotide (SOM230) treatment (i.e. in some cases 
decreased and others increased). Data are shown as concentration (pg/mL) per case before (left, square 
mark) and after SOM230 (right, triangle mark), per cytokine. Subjects with AIP mutations in homozygosity 
(n=2), heterozygosity (n=2) and wild-type controls (n=2) are identified in red, blue and green, respectively. 
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Discussion 
The cytokine secretome from different cells with AIP deficiency was studied and compared to the 
corresponding cell types with normal AIP levels: GH3-Aip-KD vs GH3-NT rat pituitary tumour cells; 
human AIPmut somatotroph adenoma cells vs sporadic AIPneg somatotrophinoma cells; human 
AIPmut somatotrophinoma-associated TAFs vs TAFs derived from sporadic PAs and namely from 
somatotrophinomas; and human AIPmut skin fibroblasts vs wild-type fibroblasts. 
 
CX3CL1 in AIPmut vs AIPneg pituitary tumour cells 
CX3CL1 was found in higher concentrations in supernatants from GH3-Aip-KD cells than in GH3-
NT cells, and the CX3CL1 mRNA expression was also increased in GH3-Aip-KD cells. These data 
suggested that CX3CL1 could be differentially secreted between pituitary tumour cells with and 
without AIP deficiency.  
CX3CL1 is a chemokine that promotes tumour growth223, macrophage chemotaxis and polarisation 
to the M2-macrophage phenotype, EMT pathway477,692, and also leukocyte adhesion to activated 
endothelial cells, thus having important roles in the TME. CX3CL1 and its receptor CX3CR1 are 
expressed in different cancers and have well-known pro-tumourigenic effects, for instance in 
nervous system malignancies228; however, owing to its adhesive properties, CX3CL1 can also exert 
anti-tumour effects228,693 (Appendix 10). 
CX3CL1 comprises 5 domains (Figure 6.13-A), including a mucin-like stalk structure similar to some 
ECM proteins indicating its ability to interact with ECM, thus explaining some its functions as 
leukocyte transmigration or cell adhesion694. CX3CL1 exists in 2 forms: membrane-attached and 
shed forms. Shedding of the membrane CX3CL1 into soluble forms represents a regulatory 
mechanism for CX3CL1 signalling. The liberation of soluble CX3CL1 is mainly done by the 
metalloproteinases ADAM10, ADAM17, but other MMPs can be involved (Figure 6.13-B)693,695. This 
prompted me to assess the Adam10, Adam17 and Mmp9 expression in GH3-Aip-KD and GH3-NT 
cells to understand whether the increased CX3CL1 levels in GH3-Aip-KD supernatants seen in my 
cytokine array data could reflect an increased CX3CL1 cleavage rather than increased production. 
There were no differences in the expression of these metalloproteinases between GH3-Aip-KD 
and GH3-NT cells, suggesting that GH3-Aip-KD cells may release more CX3CL1 due to increased 
synthesis rather than increased cleavage associated to metalloproteinase enzymatic activity. 
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Figure 6.13: CX3CL1 structure and its location to the membrane and cleavage 
Fractalkine (CX3CL1), the only member of the chemokine subgroup CX3C, is a large 373 amino-acids protein 
containing five domains: signal peptide sequence; N-terminal chemokine domain (residues 1-76); unique 
mucin-like stalk (residues 77-317); transmembrane domain (residues 337-373) (A). The mature 
transmembrane CX3CL1 can be cleaved from the cell surface by proteases, mainly ADAM10 and ADAM17, 
producing a soluble fractalkine fragment that contains the chemokine domain (B).  
 
My preliminary findings suggesting increased expression and release of CX3CL1 in GH3-Aip-KD 
cells were not validated further by ELISA, and my primary culture cytokine array data from human 
AIPmut somatotrophinoma, AIPmut somatotrophinoma-TAFs and AIPmut skin fibroblasts (either 
in homozygosity or heterozygosity) actually showing lower CX3CL1 levels in these cell 
supernatants than in the corresponding normal cell types, contradicting my initial hypothesis 
established from my preliminary cytokine and RT-qPCR data. Hence, taking these data together, 
the AIP mutational status may not be determining for the CX3CL1 synthesis/release in PAs. 
 
The role of AIP deficiency in the cytokine secretome from tumour and non-tumoural cells  
The initial hypothesis that AIP deficiency would increase the release of (some) cytokines and 
chemokines was in general not consistently seen in my cytokine data, except in the case of CCL2 
(although I analysed a very low number of samples which is a major limitation of my study). CCL2 
levels were higher in the GH3-Aip-KD supernatants (non-significantly, but nearly significant at 
72h), in the AIPmut somatotroph adenoma cells and respective TAFs culture supernatants, and 
also in AIPmut skin fibroblast supernatants. These findings suggest that AIP deficiency may affect 
CCL2 release, the main macrophage chemoattractant696, which could explain the increased 
content of macrophages in AIPmut PAs513. 
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The levels of CCL5, another relevant macrophage-related chemokine333,339, were lower in both 
GH3-Aip-KD cell and in the human AIPmut somatotrophinoma supernatants. However, my 
colleague Dr. Barry has shown increased CCL5 expression in human AIPmut PAs compared to 
normal pituitary, and higher secreted levels of CCL5 in GH3-Aip-KD than in GH3-NT cell 
supernatants as determined by ELISA513. Dr. Barry’s in vitro data showed that the CCL5-dependent 
macrophage chemotaxis increased significantly towards GH3-Aip-KD-CM compared to GH3-NT-
CM and disruption of this signalling with maraviroc (CCR5 antagonist697) reduced macrophage 
migration by 50%513. Dr. Barry also described higher expression of FLI-1 (Friend leukaemia virus 
integration 1) in human AIPmut somatotrophinomas at both RNA and protein levels513, a 
transcription regulator able to upregulate different cytokines and chemokines, including CCL5 and 
CCL2698-700. Dr. Barry´s data strongly implicate CCL5/CCR5 axis, as well as FLI-1, in AIP-related 
pituitary tumourigenesis and possibly in the recruitment of macrophages into their TME, 
explaining the higher macrophage content seen in AIPmut PAs513. 
 As a co-chaperone, AIP may interact with FLI-1, and loss of AIP may well result in FLI-1 
overexpression with subsequent FLI-1-mediated upregulation of different cytokines, an effect 
previously described for FLI-1 which is able to increase cytokine expression, including CCL5699 
supporting Dr. Barry´s findings, as well as CCL2698 which could explain my own observations of 
higher CCL2 levels secreted from AIP deficient cells.  
AIP inactivation by mutation can also interfere with the STAT3 pathway, which potentially induces 
further alterations in cytokine (namely IL-6) and hormone (namely GH) production701,702. In fact, it 
was recently shown that AIP mutation-positive GH3 cells have increased level of phosphorylated 
STAT3 and secrete higher amounts of IL-6 than wild-type GH3 cells701. In AIP deficient PA cell 
supernatants (GH3 and AIPmut somatotrophinoma cells), IL-6 was practically undetectable, but 
IL-6 levels were higher in AIPmut skin fibroblast supernatants (homozygous and heterozygous) 
than in wild-type skin fibroblasts, which is not consistent with the reported higher secretion of IL-
6 in AIP mutation-positive GH3 cells701. 
AIP can theoretically modulate the cytokine secretome via other mechanisms unrelated to FLI-1 
or STAT3. The other obvious candidate would be via AHR, which is a recognised AIP partner and a 
modulator of several immune-related processes including cytokine secretion177,680,681,689.  AIP can 
also modulate cytokine secretome by interacting with other cytokine transcription factors, 
including the IRF7 (interferon regulatory factor 7). IRF7 is a key regulator of type 1 interferon and 
its activation prevent excessive inflammation and autoimmunity. AIP inhibits IRF7 suppressing the 
induction of interferon. In fact, knocking down AIP has led to increased production of IFNα/β703. 
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Overall, I was not able to find major cytokine secretome differences among GH3 cells, human 
somatotroph adenoma cells, TAFs and skin fibroblasts with different AIP mutational status. There 
were no specific cytokines or groups of cytokines released by the AIP deficient cells that were not 
secreted by wild-type cells. I observed differences in absolute levels for some cytokines, some of 
them possibly related to the assay variability or technical issues. In general, the cytokine 
secretome from AIPmut primary cells (pituitary tumour cells and fibroblasts) showed a decreased 
number of cytokines with higher concentrations than the respective sporadic wild-type cells.  
My cell line and primary cell culture cytokine data suggest a limited role for AIP in defining the 
cytokine secretome of pituitary tumour cells, at least in basal/unstimulated conditions. 
Nevertheless, the AIP loss may instead (or mainly) affect the cytokine secretome under 
stimulatory circumstances (but not in basal conditions) which may differentially modulate the 
secretory ability of non-neoplastic cells in the TME (such as macrophages), as supported by my in 
vitro data regarding the secretome changes induced by macrophage-derived factors in both GH3-
Aip-KD and GH3-NT cells. 
This lack of major cytokine secretome differences between (unstimulated) AIPmut and AIPneg 
cells is in line with the fact that immune-related diseases such as autoimmune diseases, 
haematological malignancies, or immunosuppression-related issues such as frequent or atypical 
infections, are not reported in AIPmut patients who are at risk only for isolated PAs91,152,161. 
Moreover, gene expression data generated from Dr. Barry revealed no differential expression of 
cytokine genes between AIPmut (n=6) and sporadic AIPneg (n=4) somatotrophinomas 513. 
 
The role of AIP deficiency in the cytokine secretome responsiveness to pasireotide  
The concentrations from all cytokines decreased after pasireotide treatment in AIPmut 
somatotrophinoma-derived TAFs (except FGF-2), and the degree of pasireotide cytokine response 
tended to be higher in AIPmut TAFs than in sporadic PA-associated TAFs, with prominent 
pasireotide-induced reduction in the secretion of IL-6 (by 90%), CCL2 (by 80%), CCL11 (by 90%), 
CCL7 (by 89%), PDGF-AA (by 84%), IL-8 (by 62%) and VEGF-A (by 60%).  
Similar trends were observed in AIPmut skin fibroblasts, where pasireotide remarkably decreased 
the secretion of most cytokines, with prominent reductions noted for IL-6, CCL2, VEGF-A, CCL7, 
whereas in wild-type skin fibroblasts the reductions were more modest and in some cases  
pasireotide even increased the cytokine levels (e.g. for VEGF-A and CCL7).  
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This study data suggest that AIP deficiency may not confer resistance to the inhibitory effect of 
pasireotide in terms of cytokine release, at least in fibroblasts. In fact, the opposite notion 
transpires from my data, which suggest that AIP loss may facilitate pasireotide’s inhibitory effect 
on cytokine secretion, but the number of samples here analysed are far too small to allow any 
valid conclusions and further studies, with larger number of samples and including other cell types 
lacking AIP, are needed. Interestingly, pasireotide controlled GH excess in 2 patients with AIPmut 
acromegaly resistant to first-generation somatostatin analogues704. Overall, these data suggest 
that AIP deficiency may not impair pasireotide anti-secretory activity, in contrast to the reduced 
octreotide effectiveness in inhibiting GH secretion in AIPmut somatotrophinomas161,575,577. 
 
 
Conclusions 
In summary, my cell line and primary cell culture cytokine data suggest a limited role for AIP in 
determining the cytokine secretome of pituitary tumour cells. In fact, my data suggest that AIP 
deficiency is unlikely to induce major stimulatory (or inhibitory) effects on the cell cytokine 
secretome, at least under basal/unstimulated conditions. AIP deficiency also seems to create no 
resistance to (and indeed possibly enhances) the inhibitory pasireotide effect in terms of cytokine 
release, at least in fibroblasts, in contrast with the well-known reduced effectiveness of SSAs in 
inhibiting GH secretion in AIPmut somatotrophinomas. 
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Chapter 7: Characterisation of AIP mutation-positive pituitary 
adenomas and screening for AIP mutations: benefits of the 
genetic and clinical screening of AIP mutation carriers 
 
Introduction 
Most PAs occur sporadically, but about 5% of all PAs are familial7,691. FIPA is a heterogeneous 
condition that involves the presence of PAs in 2 or more members of the same family in the 
absence of other syndromic manifestations, such as those seen in MEN1, MEN4 or Carney 
complex691. Up to 20% of all FIPA and 50% of familial acromegaly kindreds carry germline 
mutations in the AIP gene91,152,161. These mutations are also seen in sporadically diagnosed PAs 
(simplex cases), particularly in young patients, where the lack of a family history is usually due to 
incomplete penetrance rather than de novo mutations110,155,705,706. The typical AIP mutation-
positive (AIPmut) phenotype is characterised by a young patient presenting with a large invasive 
GH-secreting PA that is refractory to conventional treatments91,152,153,161,169,705,707, with AIPmut 
somatotrophinomas being responsible in one study for 29% of pituitary gigantism cases196. 
Family members at risk of inheriting an AIP mutation are recommended to undergo genetic testing 
and carriers should be referred for clinical screening of pituitary disease91,152,167,168,708. The 
rationale behind this strategy is that identifying PAs in AIPmut carriers with otherwise 
unrecognised disease at an early stage increases the likelihood of effective treatment and 
remission91,152,167. The assumption is that screening-discovered PAs are diagnosed at a less 
advanced stage and are less invasive than PAs with a clinical presentation, and thus should show 
a more favourable response to treatment and better clinical outcomes. However, these predicted 
advantages have never been actually shown.  
 
 
Aims 
Overall aim 
To study the benefits of genetic and clinical screening of AIP mutation carriers by characterising 
prospectively-diagnosed AIPmut PAs and to compare to those with a clinical presentation. 
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Specific aims 
1. To characterise prospectively-diagnosed AIPmut PAs and compare to clinically-presenting 
AIPmut PAs in order to assess the benefits of screening AIPmut carriers  
2. To expand the knowledge regarding the clinical features, disease course and outcomes of 
patients with AIPmut PAs, providing a comparison with AIPneg cases  
3. To study phenotype-genotype correlations in patients with AIPmut PAs 
4. To describe AIPmut vs AIPneg FIPA kindreds 
 
 
Methods 
Study population 
I selected my study population from our cohort (2079 patients with PAs and their 1029 unaffected 
relatives) recruited via the collaborative research network of the International FIPA Consortium 
(http://www.fipapatients.org/fipaconsortium/) between February 2007 and April 2019. All 
participants gave written informed consent approved by the local Ethics Committee. 
Indications for AIP genetic testing were: i) FIPA patients; ii) sporadic macroadenomas with disease 
onset ≤30 years; and iii) sporadic microadenomas with disease onset ≤18 years. First-degree family 
members of individuals carrying AIPmut were offered genetic testing. We included in our analysis 
all patients with known AIP mutational status matching these criteria (n=1477). We excluded 
patients with undetermined affected status (i.e. proven AIPmut carriers who did not undergo 
clinical screening or had pending clinical test results by the time of data analysis). Patients with 
XLAG, MEN1, MEN4, Carney complex, SDHx-related, McCune-Albright and DICER1 syndromes, 
identified on the basis of clinical, biochemical and genetic testing as appropriate, were excluded. 
Of 1477 patients included in the study, 167 were AIPmut, 154 with documented germline AIP 
pathogenic/likely pathogenic variant and 13 affected subjects with predicted AIPmut status 
(obligate carriers in AIPmut kindreds but not formally tested, including subjects already deceased). 
The variant pathogenicity was assessed using Mutation Taster (http://www.mutationtaster.org/), 
Annovar709 and Variant Effect Predictor in silico prediction programmes710, as well as published 
clinical and experimental data on these variants169. Only pathogenic/likely pathogenic variants 
were considered as ‘mutations’. The AIPneg subgroup included 1310 patients with PAs in which a 
232 
 
germline AIP mutation was excluded by genetic testing of all simplex probands and of the 
youngest affected member in the families.  
 
AIP genetic testing and clinical screening 
AIP testing was performed using either Sanger sequencing and multiplex ligation-dependent 
probe amplification, or targeted next generation sequencing on genomic DNA obtained from 
blood or saliva samples91,169,711. All the unaffected individuals with positive genetic screening for 
AIP were advised to undergo clinical, biochemical and image screening tests by their local 
physician for the early diagnosis of possible pituitary disease. Follow-up was advised on an annual 
basis or as appropriate91,152,168. 
 
Definition of AIP mutation-positive (AIPmut) and AIP mutation-negative (AIPneg) subgroups 
Out of 1477 patients, 167 were AIPmut, 154 with documented germline AIP pathogenic/likely 
pathogenic variant and 13 predicted AIPmut (obligate carriers in AIPmut kindreds but not formally 
tested, including subjects already deceased or that refused genetic test). The AIPneg subgroup 
included 1310 patients with PAs, in which a germline AIP mutation was excluded by genetic testing 
in 1062 patients, while 248 subjects were predicted AIPneg (patients who had at least one affected 
relative tested negative for AIP mutation and who had individual or familial phenotypes not 
suggestive of AIPmut, i.e. subjects not affected with young-onset somatotrophinomas or 
prolactinomas and not deriving from homogeneous somatotrophinoma families or with relatives 
with gigantism). 
 
Study groups and clinical parameters 
The familial cohort was comprised of FIPA patients. The sporadic cohort included patients with 
young onset PAs (≤30yr) with no known family history of PAs or syndromic disease. The clinical 
diagnoses were established as GH excess (acromegaly and gigantism), prolactinomas (PRLomas), 
NFPAs, Cushing’s disease (ACTHomas) and thyrotrophinomas (TSHomas), as previously 
described91. Cases where the diagnosis was not specified due to unavailability of histopathological, 
clinical or biochemical data, were termed as “PA not specified” (PA-NS). Age of onset was defined 
as the age of presentation of first symptoms. Macroadenomas were defined as tumour size 
≥10mm. Hypopituitarism at diagnosis and at last follow-up was defined as the presence of at least 
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one pituitary deficiency documented biochemically. The number of treatments included the 
number of individual treatments given (each medication, surgery and radiotherapy). Multimodal 
treatment was defined as the employment of two or more distinct forms of treatment in patient 
management. The reoperation subgroup involved patients who had at least one additional surgery 
following their first operation. Active disease was considered in patients with secretory PAs 
displaying the respective pituitary hormone above the normal assay range, and/or evidence of 
persistent or recurrent progressive tumour remnants in the surveillance pituitary MRI scan for 
both secretory PAs and NFPAs. Small persistent tumour remnants after operation, stable over a 
period of time and requiring no further intervention, were considered as not active NFPAs. 
 
 
Results 
General characterisation of the study population 
Of the 1477 patients with PAs, 167 were AIPmut (11.3%) and 1310 were AIPneg patients (FIPA or 
age ≤30yr at onset). Demographic and clinical characteristics and comparative analysis of AIPmut 
vs AIPneg PAs are presented in Table 7.1 and Figure 7.1.  
 AIPmut vs AIPneg PAs Study 
population 
n=1477 
AIPmut 
n=167 
AIPneg 
n=1310 
p 
value 
Cohort type based on family history of PAs 
Familial cohort 
Sporadic cohort 
 
114 (68.3%) 
53 (31.7%) 
[n=167] 
 
586 (44.7%) 
724 (55.3%) 
[n=1310] 
 
<0.001 
 
700 (47.4%) 
777 (52.6%) 
[n=1477] 
Gender 
Male 
Female 
 
102 (61.1%) 
65 (38.9%) 
[n=167] 
 
591 (45.2%) 
716 (54.8%) 
[n=1307] 
 
<0.001 
 
693 (47.0%) 
781 (53.0%) 
[n=1474] 
Age at disease onset ≤ 18 yr 94 (64.8%) 
[n=145] 
311 (28.8%) 
[n=1080] 
<0.001 405 (33.1%) 
[n=1225] 
Age at first symptoms (yr) 19.0 ± 9.5 
[n=139] 
26.8 ± 13.1 
[n=1058] 
<0.001 25.9 ± 13.0 
[n=1197] 
Age at diagnosis (yr) 24.3 ± 11.9 
[n=160] 
30.0 ± 13.5 
[n=1187] 
<0.001 29.4 ± 13.5 
[n=1347] 
Delay in diagnosis (yr) 4.1 ± 6.6 
[n=138] 
3.2 ± 4.9 
[n=1058] 
0.212 3.3 ± 5.1 
[n=1196] 
GH excess 136 (81.4%) 
[n=167] 
650 (49.6%) 
[n=1310] 
<0.001 786 (53.2%) 
[n=1477] 
Pituitary apoplexy 12 (8.2%) 
[n=146] 
37 (3.6%) 
[n=1032] 
0.009 49 (4.2%) 
[n=1173] 
Hypopituitarism at diagnosis 32 (42.7%) 
[n=75] 
173 (49.0%) 
[n=353] 
0.318 205 (47.9%) 
[n=428] 
Number of pituitary deficiencies at 
diagnosis 
0.84 ± 1.11 
[n=75] 
0.79 ± 1.03 
[n=353] 
0.841 0.80 ± 1.05 
[n=428] 
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Macroadenoma 124 (83.2%) 
[n=149] 
844 (79.2%) 
[n=1065] 
0.259 968 (79.7%) 
[n=1214] 
Maximum tumour diameter (mm) 20.1 ± 13.0 
[n=74] 
22.8 ± 16.0 
[n=575] 
0.281 22.5 ± 15.7 
[n=649] 
Suprasellar extension 44 (54.3%) 
[n=81] 
253 (42.4%) 
[n=596] 
0.043 297 (43.9%) 
[n=677] 
Cavernous sinus invasion 29 (36.7%) 
[n=79] 
164 (28.3%) 
[n=580] 
0.122 193 (29.3%) 
[n=659] 
Ki-67 > 3% 12 (41.4%) 
[n=29] 
48 (41.0%) 
[n=117] 
0.972 60 (41.1%) 
[n=146] 
Number of treatments 2.07 ± 1.66 
[n=160] 
1.87 ± 1.32 
[n=934] 
0.228 1.90 ± 1.38 
[n=1094] 
Number of surgeries 0.93 ± 0.79 
[n=162] 
0.87 ± 0.72 
[n=980] 
0.468 0.88 ± 0.73 
[n=1142] 
Re-operation 27 (23.1%) 
[n=117] 
119 (16.9%) 
[n=704] 
0.106 146 (17.8%) 
[n=821] 
Radiotherapy 53 (32.9%) 
[n=161] 
201 (21.5%) 
[n=933] 
0.002 254 (23.2%) 
[n=1094] 
Multimodal treatment 90 (67.2%) 
[n=134] 
414 (47.0%) 
[n=880] 
<0.001 504 (49.7%) 
[n=1014] 
≥ 3 treatments 54 (40.3%) 
[n=134] 
229 (25.8%) 
[n=886] 
<0.001 283 (27.7%) 
[n=1020] 
Active disease at last follow-up 31 (25.0%) 
[n=124] 
203 (34.5%) 
[n=589] 
0.041 234 (32.8%) 
[n=713] 
Hypopituitarism at last follow-up 16 (29.6%) 
[n=54] 
80 (33.6%) 
[n=238] 
0.574 96 (32.9%) 
[n=292] 
Number of pituitary deficiencies at last 
follow-up 
0.45 ± 0.96 
[n=49] 
0.77 ± 1.27 
[n=224] 
0.148 0.71 ± 1.22 
[n=273] 
Follow-up duration (yr) 11.2 ± 12.3 
[n=128] 
7.8 ± 9.5 
[n=703] 
0.008 8.4 ± 10.1 
[n=831] 
Table 7.1: Characteristics of the study population and comparative analysis of AIPmut vs AIPneg PAs 
Categorical data are shown as n(%); continuous variables are shown as mean±SD. In square brackets is 
indicated the number of cases where data was available regarding each parameter/variable.  
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Figure 7.1: Distribution of AIPmut vs AIPneg PAs according to age at onset (A) and clinical diagnosis (B) 
Numbers above the columns represent percentage of patients. We note that the two AIPmut cases with 
first symptoms in the 5th and 6th decade, both had macroprolactinomas, one presenting with apoplexy. 
ACTHoma, ACTH-secreting adenoma or Cushing´s disease; AIPmut, AIP mutation-positive; AIPneg, AIP 
mutation-negative; NFPA, non-functioning pituitary adenoma; PA-NS, pituitary adenoma not specified; yr, 
years. 
 
The familial cohort (355 families, 700 patients, 47% of the whole study population) consisted of 
37 AIPmut kindreds (114 patients) and 318 AIPneg families (586 patients). Of the 37 AIPmut 
families, 36 (97.8%) had at least one somatotrophinoma case, 19 were homogeneous 
somatotrophinoma kindreds and one was homogeneous prolactinoma family. Of the 318 AIPneg 
families, 146 (46%) were homogeneous and 172 were heterogeneous, with detailed subtypes 
shown in Table 7.2. In the sporadic cohort (n=777), 53 (6.8%) had an AIP mutation. Within the 
sporadic tumour subgroup, 10.5% (50 out of 477) of somatotrophinomas, 1.5% (3 out of 197) of 
prolactinomas and none (0 out of 54) of the NFPA cases were found to harbor a germline AIP 
mutation (Tables 7.3 and 7.4). 
PA types within the same kindred 
AIPmut kindreds 
n=37 
AIPneg kindreds 
n=318 
Total 
n=355 
ACTHoma only 0 7 (2.2%) 7 (2.0%) 
ACTHoma + FSHoma 0 1 (0.3%) 1 (0.3%) 
ACTHoma + Somatotrophinoma 0 7 (2.2%) 7 (2.0%) 
ACTHoma + NFPA 0 1 (0.3%) 1 (0.3%) 
ACTHoma + NFPA + PA-NS 0 1 (0.3%) 1 (0.3%) 
ACTHoma + NFPA + Prolactinoma 0 1 (0.3%) 1 (0.3%) 
ACTHoma + PA-NS 0 2 (0.6%) 2 (0.6%) 
ACTHoma + PRLoma 0 8 (2.5%) 8 (2.3%) 
Somatotrophinoma only 19 (51.4%) 68 (21.4%) 87 (24.5%) 
Somatotrophinoma + NFPA 8 (21.6%) 25 (7.9%) 33 (9.3%) 
Somatotrophinoma + NFPA + Prolactinoma 1 (2.7%) 4 (1.3%) 5 (1.4%) 
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Somatotrophinoma + PA-NS 0 19 (6.0%) 19 (5.3%) 
Somatotrophinoma + PA-NS + Prolactinoma 0 1 (0.3%) 1 (0.3%) 
Somatotrophinoma + Prolactinoma 8 (21.6%) 45 (14.2%) 53 (14.9%) 
NFPA only 0 24 (7.5%) 24 (6.8%) 
NFPA + PA-NS 0 14 (4.4%) 14 (3.9%) 
NFPA + Prolactinoma 0 24 (7.5%) 24 (6.8%) 
Prolactinoma only 1 (2.7%) 47 (14.8%) 48 (13.5%) 
Prolactinoma + FSHoma 0 1 (0.3%) 1 (0.3%) 
Prolactinoma + PA-NS 0 18 (5.7%) 18 (5.1%) 
Table 7.2: AIPmut and AIPneg FIPA kindreds according to PA types 
Data are shown as n(%). ACTHoma, ACTH-secreting adenoma or Cushing´s disease; AIPmut, AIP mutation-
positive; AIPneg, AIP mutation-negative; FSHoma, FSH-secreting adenoma; NFPA, non-functioning pituitary 
adenoma; PA-NS, pituitary adenoma not specified. 
 
Comparative analysis between AIPmut and AIPneg PAs 
AIPmut patients were more frequently males (61% vs 45%; p<0.001) compared to AIPneg patients, 
8yr younger at first symptoms (19±10 vs 27±13yr; p<0.001) and 6yr younger at diagnosis (24±12 
vs 30±14yr; p<0.001), with disease onset ≤18yr in 65% and <30yr in 87%, in contrast to the AIPneg 
subgroup with 29% (p<0.001) and 72% (p<0.001) (Table 7.1 and Figure 7.1-A). AIPmut PAs were 
more often associated with GH excess (81% vs 50%; p<0.001), with gigantism being the 
predominant diagnosis (Figure 7.1-B and Figure 7.2). AIPmut PAs had a higher rate of apoplexy 
(8% vs 4%; p=0.009) and suprasellar extension (54% vs 42%; p=0.043). AIPmut patients required 
radiotherapy (33% vs 22%; p=0.002) and multimodal treatment (67% vs 47%; p<0.001) more 
often, with ≥3 treatments given in 40% of AIPmut patients vs 26% in AIPneg ones (p<0.001) (Table 
1). AIPmut patients had lower rates of active disease at last follow-up (25% vs 35%; p=0.041). As 
AIPmut had a longer follow-up, I analysed only patients with no longer than 10yr follow-up, and 
then there was no difference in the rate of active disease at last follow-up (39% vs 43%; p=0.642). 
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Figure 7.2: Clinical diagnosis according to age of onset among AIPmut (A) and AIPneg (B) PA patients  
In this comparison, GH/PRL positive pituitary adenomas were added to the gigantism or acromegaly group, 
as appropriate. ACTHoma, ACTH-secreting adenoma or Cushing´s disease; AIPmut, AIP mutation-positive; 
AIPneg, AIP mutation-negative; NFPA, non-functioning pituitary adenoma; PA-NS, pituitary adenoma not 
specified; PRLoma, prolactinoma; TSHoma, thyrotrophinomas; yr, years. 
 
 
Comparisons of AIPmut vs AIPneg patients by tumour type 
AIPmut patients with GH excess (n=136) were younger at first symptoms (18±8 vs 26±12yr; 
p<0.001) and at diagnosis (23±11 vs 30±12yr; p<0.001) than AIPneg cases (n=650) (Table 4). The 
predominant clinical diagnosis of AIPmut cases was gigantism (56% vs 18%, p<0.001). There was 
no difference in IGF-1 levels at diagnosis between clinically-presenting AIPmut and AIPneg 
patients (p=0.696, Table 7.3). All AIPmut somatotrophinomas were sparsely-granulated in 
contrast to 68% of the AIPneg ones (p<0.001); similar ratios were seen only considering AIPmut 
and AIPneg giants. AIPmut somatotrophinomas were associated to higher rates of apoplexy (8% 
vs 3%; p<0.001), suprasellar extension (60% vs 46%; p=0.042), radiotherapy (39 vs 28%; p=0.018) 
and reoperation (25% vs 16%; p=0.025), and showed trends for an increased need for multimodal 
therapy (p=0.076) and ≥3 treatments (p=0.079). The mean final height was higher in the AIPmut 
somatotrophinoma subgroup (p<0.001) both for males (193±18 vs 185±14 cm; p=0.004) and 
females (175±13 vs 169±9 cm; p=0.017) (Table 4). AIPmut somatotrophinoma patients had lower 
rates of active disease at last follow-up (28% vs 43%; p=0.005).   
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 AIPmut vs AIPneg somatotrophinomas Overall somato-
trophinomas 
n=786 
AIPmut 
n=136 
AIPneg 
n=650 
p value 
Cohort type based on family history of PAs 
Familial cohort 
Sporadic cohort 
 
86 (63.2%) 
50 (36.8%) 
[n=136] 
 
223 (34.3%) 
427 (65.7%) 
[n=650] 
 
<0.001 
 
309 (39.3%) 
477 (60.7%) 
[n=786] 
Gender 
Male 
Female 
 
84 (61.8%) 
52 (38.2%) 
[n=136] 
 
332 (51.3%) 
315 (48.7%) 
[n=647] 
 
0.026 
 
416 (53.1%) 
367 (46.9%) 
[n=783] 
Age at disease onset ≤ 18 yr 85 (67.5%) 
[n=126] 
142 (25.0%) 
[n=569] 
<0.001 227 (32.7%) 
[n=695] 
Age at first symptoms (yr) 18.1 ± 8.4 
[n=122] 
26.1 ± 11.8 
[n=563] 
<0.001 24.7 ± 11.7 
[n=685] 
Age at diagnosis (yr) 23.2 ± 10.8 
[n=133] 
30.2 ± 12.2 
[n=609] 
<0.001 28.9 ± 12.3 
[n=742] 
Delay in diagnosis (yr) 4.3 ± 6.5 
[n=120] 
4.2 ± 5.4 
[n=563] 
0.371 4.2 ± 5.6 
[n=683] 
Gigantism 76 (55.9%) 
[n=136] 
118 (18.2%) 
[n=650] 
<0.001 194 (24.7%) 
[n=786] 
Pituitary apoplexy 10 (8.3%) 
[n=121] 
15 (2.8%) 
[n=533] 
0.005 25 (3.8%) 
[n=654] 
Height at diagnosis (cm) 
Males    [n=250] 
Females [n=196] 
 
188.8 ± 19.7 
170.4 ± 11.2 
 
183.5 ± 14.7 
168.9 ± 9.0 
 
0.054 
0.392 
 
184.8 ± 16.2 
169.3 ± 9.5 
Height Z-score at diagnosis 2.7 ± 2.4 
[n=103] 
1.5 ± 1.9 
[n=339] 
<0.001 1.8 ± 2.1 
[n=442] 
IGF-1 xULN at diagnosis 2.5 ± 3.5 
[n=41] 
2.7 ± 3.8 
2.9 ± 2.3 
[n=195] 
2.9 ± 2.3 
<0.001 
 
0.696 
2.8 ± 2.5 
[n=236] 
2.9 ± 2.5 
Hypopituitarism at diagnosis 26 (46.4%) 
[n=56] 
74 (49.0%) 
[n=151] 
0.742 100 (48.3%) 
[n=207] 
Number of pituitary deficiencies at 
diagnosis 
0.89 ± 1.12 
[n=56] 
0.71 ± 0.90 
[n=151] 
0.565 0.76 ± 0.97 
[n=207] 
Macroadenoma 108 (90.0%) 
[n=120] 
487 (89.2%) 
[n=546] 
0.796 595 (89.3%) 
[n=666] 
Maximum tumour diameter (mm) 23.0 ± 11.9 
[n=56] 
24.8 ± 13.6 
[n=303] 
0.403 24.5 ± 13.3 
[n=359] 
Suprasellar extension 38 (60.3%) 
[n=63] 
133 (46.2%) 
[n=288] 
0.042 171 (48.7%) 
[n=351] 
Cavernous sinus invasion 26 (41.9%) 
[n=62] 
101 (35.7%) 
[n=283] 
0.356 127 (36.8%) 
[n=345] 
Granulation pattern 
Densely -granulated 
Sparsely-granulated 
 
0 (0%) 
32 (100%) 
[n=32] 
 
23 (31.9%) 
49 (68.1%) 
[n=72] 
 
<0.001 
 
23 (22.1%) 
81 (77.9%) 
[n=104] 
Ki-67 > 3% 11 (44.0%) 
[n=25] 
25 (35.7%) 
[n=70] 
0.519 36 (37.9%) 
[n=95] 
Number of treatments 2.35 ± 1.68 
[n=130] 
2.30 ± 1.41 
[n=490] 
0.821 2.31 ± 1.47 
[n=620] 
Number of surgeries 1.06 ± 0.78 
[n=132] 
1.07 ± 0.61 
[n=516] 
0.606 1.07 ± 0.65 
[n=648] 
Re-operation 27 (25.2%) 
[n=107] 
74 (16.1%) 
[n=461] 
0.025 101 (17.8%) 
[n=568] 
Radiotherapy 51 (38.9%) 
[n=131] 
138 (28.2%) 
[n=489] 
0.018 189 (30.5%) 
[n=620] 
Somatostatin analogues 59 (45.4%) 
[n=130] 
264 (54.2%) 
[n=487] 
0.073 323 (52.4%) 
[n=617] 
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Dopamine agonists 31 (23.8%) 
[n=130] 
128 (26.3%) 
[n=487] 
0.572 159 (25.8%) 
[n=617] 
Pegvisomant 14 (10.8%) 
[n=130] 
33 (6.8%) 
[n=487] 
0.127 47 (7.6%) 
[n=617] 
Multimodal treatment 84 (72.4%) 
[n=116] 
305 (63.7%) 
[n=479] 
0.076 389 (65.4%) 
[n=595] 
≥ 3 treatments 53 (45.7%) 
[n=116] 
47.7% 
178 (36.9%) 
[n=483] 
36.9% 
0.079 
 
0.039 
231 (38.6%) 
[n=599] 
39.0% 
Active disease at last follow-up 28 (27.7%) 
[n=101] 
139 (43.3%) 
[n=321] 
0.005 167 (39.6%) 
[n=422] 
Hypopituitarism at last follow-up 13 (36.1%) 
[n=36] 
36 (39.1%) 
[n=92] 
0.752 49 (38.3%) 
[n=128] 
Number of pituitary deficiencies at last 
follow-up 
0.48 ± 0.93 
[n=31] 
0.79 ± 1.22 
[n=85] 
0.288 0.71 ± 1.15 
[n=116] 
Final height (cm) 185.9 ± 18.3 
[n=95] 
177.9 ± 14.3 
[n=329] 
<0.001 179.7 ± 15.6 
[n=424] 
Final height (cm) by gender 
Males    [n=241] 
Females [n=183] 
 
192.8 ± 17.6 
174.8 ± 13.4 
 
185.2 ± 13.8 
168.9 ± 8.7 
 
0.004 
0.017 
 
187.1 ± 15.1 
170.1 ± 10.0 
Follow-up duration (yr) 11.4 ± 12.8 
[n=103] 
7.4 ± 8.9 
[n=388] 
0.027 8.3 ± 10.0 
[n=491] 
Table 7.3: Comparative analysis between AIPmut vs AIPneg somatotrophinomas 
Categorical data are shown as n(%); continuous variables are shown as mean±SD. In square brackets is 
indicated the number of cases where data was available regarding each parameter/variable. Data for 
clinically-presenting somatotrophinomas comparison are added in italics where showing different results. 
AIPmut, AIP mutation-positive; AIPneg, AIP mutation-negative; PA, pituitary adenoma; ULN, upper limit of 
the normal; yr, years. 
 
Patients with AIPmut prolactinomas had higher rates of apoplexy (17% vs 3%; p=0.009) and a more 
frequent family history of PAs (82% vs 49%; p=0.006) than AIPneg counterparts, and these 
remained significant when considering only clinically-presenting cases (Table 7.4). AIPmut NFPAs 
had lower rates of macroadenomas (31% vs 85%; p<0.001), hypopituitarism at last follow-up (10% 
vs 46%; p=0.040), lower tumour diameter (9±10 vs 23±16mm; p=0.001) and pituitary deficiencies 
at diagnosis (0.2±0.6 vs 1.0±1.4; p=0.045), and required fewer treatments (0.5±0.8 vs 1.2±1.0; 
p=0.005) and surgery (0.3±0.5 vs 0.9±0.7; p=0.001). However, when excluding the 10 
prospectively-diagnosed NFPA patients these significant differences were lost (Table 7.4).  
 Prolactinomas NFPAs 
AIPmut 
n=17 
AIPneg 
n=377 
p 
value 
AIPmut 
n=14 
AIPneg 
n=172 
p 
value 
Cohort type Familial cohort 
                      Sporadic cohort 
14 (82.4%) 
3 (17.6%) 
[n=17] 
183 (48.5%) 
194 (51.5%) 
[n=377] 
0.006 14 (100%) 
0 (0%) 
[n=14] 
118 (68.6%) 
54 (31.4%) 
[n=172] 
0.013 
Gender       Male 
                    Female 
9 (52.9%) 
8 (47.1%) 
[n=17] 
125 (33.2%) 
252 (66.8%) 
[n=377] 
0.092 9 (64.3%) 
5 (35.7%) 
[n=14] 
98 (57.0%) 
74 (43.0%) 
[n=172] 
0.595 
Age at disease onset  
≤ 18 yr 
5 (45.5%) 
[n=11] 
40.0% 
123 (40.6%) 
[n=303] 
 
0.747 
 
0.970 
4 (50.0%) 
[n=8] 
33.3% 
17 (12.4%) 
[n=137] 
0.003 
 
0.291 
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Age at first symptoms (yr) 27.5 ± 17.9 
[n=10] 
24.1 ± 10.8 
[n=290] 
0.959 22.6 ± 7.7 
[n=7] 
36.6 ± 17.3 
[n=136] 
0.016 
Age at diagnosis (yr) 30.7 ± 16.5 
[n=15] 
32.0 ± 16.4 
26.2 ± 11.2 
[n=340] 
 
0.619 
 
0.346 
29.2 ± 14.8 
[n=12] 
27.0 ± 11.5 
39.4 ± 17.3 
[n=159] 
0.038 
 
0.189 
Delay in diagnosis (yr) 4.5 ± 8.8 
[n=11] 
2.4 ± 4.6 
[n=290] 
0.665 1.1 ± 2.3 
[n=7] 
1.5 ± 3.3 
[n=136] 
0.761 
Pituitary apoplexy 2 (16.7%) 
[n=12] 
20.0% 
8 (2.8%) 
[n=283] 
0.009 
 
0.003 
0 
[n=13] 
12 (8.6%) 
[n=139] 
0.270 
Hypopituitarism at 
diagnosis 
5 (62.5%) 
[n=8] 
83.3% 
72 (59.0%) 
[n=132] 
0.846 
 
0.235 
1 (9.1%) 
[n=11] 
100% 
22 (41.5%) 
[n=53] 
0.041 
 
0.238 
Number of pituitary 
deficiencies at diagnosis 
1.38 ± 1.51 
[n=8] 
1.83 ± 1.47 
0.93 ± 1.04 
[n=122] 
0.470 
 
0.088 
0.18 ± 0.60 
[n=11] 
2.00 ± 0 
1.00 ± 1.40 
[n=53] 
0.045 
 
0.344 
Macroadenoma 12 (75.0%) 
[n=16] 
193 (63.7%) 
[n=303] 
0.358 4 (30.8%) 
[n=13] 
130 (85.0%) 
[n=153] 
<0.001 
Maximum tumour 
diameter (mm) 
14.4 ± 16.1 
[n=7] 
16.3 ± 16.8 
20.6 ± 19.7 
[n=161] 
0.270 
 
0.591 
9.0 ± 9.8 
[n=11] 
35.0 
22.8 ± 15.9 
[n=86] 
0.001 
 
0.330 
Suprasellar extension 3 (42.9%) 
[n=7] 
60.0% 
67 (34.9%) 
[n=192] 
0.665 
 
0.247 
3 (27.3%) 
[n=11] 
100% 
45 (56.2%) 
[n=80] 
0.071 
 
0.245 
Cavernous sinus invasion 1 (16.7%) 
[n=6] 
25.0% 
42 (22.7%) 
[n=185] 
0.728 
 
0.914 
2 (18.2%) 
[n=11] 
50.0% 
17 (22.4%) 
[n=76] 
0.753 
 
0.391 
Ki-67 > 3% 0 
[n=1] 
9 (52.9%) 
[n=17] 
0.303 1 (33.3%) 
[n=3] 
50.0% 
7 (63.2%) 
[n=19] 
0.907 
 
0.716 
Number of treatments 1.12 ± 0.78 
[n=17] 
1.20 ± 0.78 
1.39 ± 0.90 
[n=247] 
0.212 
 
0.479 
0.46 ± 0.78 
[n=13] 
1.33 ± 0.58 
1.19 ± 1.01 
[n=127] 
0.005 
 
0.648 
Number of surgeries 0.35 ± 0.49 
[n=17] 
0.40 ± 0.51 
0.35 ± 0.68 
[n=253] 
0.609 
 
0.396 
0.31 ± 0.48 
[n=13] 
1.00 ± 0 
0.89 ± 0.66 
[n=141] 
0.001 
 
0.728 
Re-operation 0 
[n=6] 
13 (18.6%) 
[n=70] 
0.246 0 
[n=4] 
15 (13.9%) 
[n=108] 
0.423 
Radiotherapy 1 (5.9%) 
[n=17] 
6.7% 
18 (7.2%) 
[n=250] 
0.838 
 
0.938 
1 (7.7%) 
[n=13] 
33.3% 
26 (20.8%) 
[n=125] 
0.257 
 
0.864 
Dopamine agonists 12 (70.6%) 
[n=17] 
73.3% 
214 (86.6%) 
[n=247] 
0.068 
 
0.362 
1 (7.7%) 
[n=13] 
0 
9 (7.2%) 
[n=125] 
0.948 
 
0.622 
Multimodal treatment 4 (28.6%) 
[n=14] 
30.8% 
54 (22.8%) 
[n=237] 
0.618 
 
0.507 
2 (50.0%) 
[n=4] 
33.3% 
28 (28.9%) 
[n=97] 
0.365 
 
0.867 
≥ 3 treatments 1 (7.1%) 
[n=14] 
7.7% 
19 (8.0%) 
[n=237] 
0.907 
 
0.966 
0 
[n=4] 
13 (13.3%) 
[n=98] 
0.435 
 
0.499 
Active disease at last 
follow-up 
2 (15.4%) 
[n=13] 
16.7% 
44 (29.1%) 
[n=151] 
0.289 
 
0.356 
1 (10.0%) 
[n=10] 
50.0% 
13 (18.8%) 
[n=69] 
0.494 
 
0.274 
Hypopituitarism at last 
follow-up 
2 (25.0%) 
[n=8] 
33.3% 
23 (23.0%) 
[n=100] 
0.897 
 
0.563 
1 (10.0%) 
[n=10] 
100% 
16 (45.7%) 
[n=35] 
0.040 
 
0.310 
Number of pituitary 
deficiencies at last 
follow-up 
0.75 ± 1.49 
[n=8] 
1.00 ± 1.67 
0.58 ± 1.16 
[n=98] 
0.847 
 
0.515 
0.10 ± 0.31 
[n=10] 
1.00 ± 0 
1.16 ± 1.50 
[n=33] 
0.067 
 
0.771 
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Follow-up duration (yr) 13.6 ± 12.5 
[n=13] 
14.3 ± 12.8 
9.3 ± 10.1 
[n=172] 
0.150 
 
0.131 
7.5 ± 7.1 
[n=12] 
19.5 ± 0.7 
8.1 ± 11.3 
[n=94] 
0.551 
 
0.094 
Table 7.4: Comparative analysis between AIPmut vs AIPneg prolactinomas and NFPAs  
Categorical data are shown as n(%); continuous variables as mean±SD. In square brackets is indicated the 
number of cases where data was available regarding each parameter/variable. Data for clinically-presenting 
AIPmut prolactinomas (n=15) and NFPAs (n=4) comparison are added in italics. AIPmut, AIP mutation-
positive; AIPneg, AIP mutation-negative; NFPA, non-functioning pituitary adenoma; yr, years. 
 
 
Prospectively-diagnosed vs clinically-presenting AIPmut PAs 
Genetic testing of AIPmut kindreds identified 187 apparently unaffected AIPmut carriers. 165 
AIPmut carriers were disease-free at both baseline screening and at last follow-up assessment 
(mean follow-up duration 5.9 ±3.3yr, ranging between 1-11yr), while 22 subjects (11.8%) were 
prospectively-diagnosed with a PAs. The mean age at diagnosis of prospectively-diagnosed AIPmut 
PA patients (30.4±15.7yr) and the age at genetic testing of unaffected AIPmut carriers 
(35.9±24.1yr) did not differ (p=0.453). There was no significant difference in the gender 
distribution either: 49.7% prospectively-diagnosed males vs 63.6% unaffected carrier males 
(p=0.219). 
Three of these prospectively-diagnosed cases had normal biochemistry and contrast-enhanced 
pituitary MRI at baseline screening, but went on to develop a PA during the subsequent follow-
up: 2 small NFPAs and 1 microprolactinoma, being stable since their initial detection and none 
requiring intervention to date. Eight of these 22 cases (36%) had retrospectively symptoms that 
could be attributed to pituitary disease. Prospectively-diagnosed PAs were smaller than clinically-
presenting PAs (10±7 vs 24±13mm; p<0.001), and 68% vs 8% were microadenomas (p<0.001, 
Table 7.5). Prospectively-diagnosed PAs were associated with lower rates of hypopituitarism at 
diagnosis (0 vs 58%; p<0.001), suprasellar extension (11% vs 68%; p<0.001), and cavernous sinus 
invasion (11% vs 44%; p=0.010), and none had pituitary apoplexy (vs 10%; p=0.118, Table 3). 
Prospectively-diagnosed PAs required fewer treatments (0.7±1.0 vs 2.3±1.7; p<0.001) and 
operations (0.4±0.5 vs 1.0±0.8; p<0.001), none required radiotherapy (vs 38%; p<0.001) and had 
decreased rates of active disease (6 vs 28%; p=0.039) and hypopituitarism at last follow-up (0 vs 
41%; p=0.003, Table 7.5).      
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 AIPmut PAs 
Prospectively-diagnosed 
n=22 
Clinically-presenting 
n=145 
p value 
Gender 
Male 
Female 
 
14 (63.6%) 
8 (36.4%) 
[n=22] 
 
88 (60.7%) 
57 (39.3%) 
[n=145] 
 
0.792 
Age at diagnosis (yr) 30.4 ± 15.7 
[n=20] 
23.5 ± 11.1 
[n=140] 
0.065 
Clinical diagnosis 
Acromegaly 
Gigantism 
Prolactinoma 
NFPA 
 
8 (36.4%) 
2 (9.1%) 
2 (9.1%) 
10 (45.4%) 
[n=22] 
 
52 (35.9%) 
74 (51.0%) 
15 (10.3%) 
4 (2.8%) 
[n=145] 
 
<0.001 
GH excess 10 (45.5%) 
[n=22] 
126 (86.9%) 
[n=145] 
<0.001 
Pituitary apoplexy 0 (0%) 
[n=22] 
12 (9.7%) 
[n=124] 
0.118 
Hypopituitarism at diagnosis 0 (0%) 
[n=20] 
32 (58.2%) 
[n=55] 
<0.001 
Number of pituitary deficiencies at 
diagnosis 
0 
[n=20] 
1.15 ± 1.19 
[n=55] 
<0.001 
Macroadenoma 7 (31.8%) 
[n=22] 
117 (92.1%) 
[n=127] 
<0.001 
Maximum tumour diameter (mm) 9.5 ± 7.2 
[n=19] 
23.8 ± 12.6 
[n=55] 
<0.001 
Suprasellar extension 2 (10.5%) 
[n=19] 
42 (67.7%) 
[n=62] 
<0.001 
Cavernous sinus invasion 2 (11.1%) 
[n=18] 
27 (44.3%) 
[n=61] 
0.010 
Ki-67 > 3% 1 (16.7%) 
[n=6] 
11 (47.8%) 
[n=23] 
0.168 
Number of treatments 0.68 ± 0.95 
[n=22] 
2.29 ± 1.65 
[n=138] 
<0.001 
Number of surgeries 0.36 ± 0.49 
[n=22] 
1.01 ± 0.79 
[n=140] 
<0.001 
Re-operation 0 
[n=8] 
27 (24.8%) 
[n=109] 
0.108 
Radiotherapy 0 
[n=22] 
53 (38.1%) 
[n=139] 
<0.001 
Multimodal treatment 5 (55.6%) 
[n=9] 
85 (68.0%) 
[n=125] 
0.443 
≥ 3 treatments 1 (11.1%) 
[n=9] 
53 (42.4%) 
[n=125] 
0.065 
Active disease at last follow-up 1 (5.6%) 
[n=18] 
30 (28.3%) 
[n=106] 
0.039 
Hypopituitarism at last follow-up 0 
[n=15] 
16 (41.0%) 
[n=39] 
0.003 
Number of pituitary deficiencies at 
last follow-up 
0 
[n=15] 
0.65 ± 1.10 
[n=34] 
0.014 
Follow-up duration (yr) 5.3 ± 4.5 
[n=21] 
12.4 ± 13.0 
[n=107] 
0.067 
Table 7.5: Comparative analysis between prospectively-diagnosed vs clinically-presenting AIPmut PAs 
Categorical data are shown as n(%); continuous variables are shown as mean±SD. In square brackets is 
indicated the number of cases where data was available regarding each parameter/variable. AIPmut, AIP 
mutation-positive; AIPneg, AIP mutation-negative; GH, growth hormone; PA, pituitary adenoma; yr, years. 
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Prospectively-diagnosed PAs (10 somatotrophinomas, 10 NFPAs and 2 prolactinomas) had lower 
rates of hypopituitarism at diagnosis, macroadenomas and suprasellar extension, requiring fewer 
treatments than those clinically presented (Table 7.6). Prospectively-diagnosed AIPmut 
somatotrophinomas were also significantly smaller and none had radiotherapy (p=0.009). None 
of the prospectively-diagnosed AIPmut NFPAs had hypopituitarism or active disease at last follow-
up (Table 7.6). Two AIPmut patients had prospectively-diagnosed microprolactinomas with no 
suprasellar extension or cavernous sinus invasion, and were eupituitary at diagnosis and at last 
follow-up: one responded well to dopamine agonist and the other is under observation (described 
in detail as case 5 in my recent publication167). 
 AIPmut somatotrophinomas AIPmut NFPAs 
Prospectively
-diagnosed 
n=10 
Clinically-
presenting 
n=126 
p 
value 
Prospectively
-diagnosed 
n=10 
Clinically-
presenting 
n=4 
p 
value 
Gender        Male 
                     Female 
7 (70.0%) 
3 (30.0%) 
[n=10] 
77 (61.1%) 
49 (38.9%) 
[n=126] 
0.578 6 (60.0%) 
4 (40.0%) 
[n=10] 
3 (75.0%) 
1 (25.0%) 
[n=4] 
0.597 
Age at diagnosis (yr) 32.6 ± 15.7 
[n=10] 
22.4 ± 10.0 
[n=123] 
0.022 29.9 ± 16.3 
[n=9] 
27.0 ± 11.5 
[n=3] 
1.000 
Pituitary apoplexy 0 
[n=10] 
10 (9.0%) 
[n=111] 
0.322 0 
[n=10] 
0 
[n=3] 
1.000 
Hypopituitarism at 
diagnosis 
0 
[n=10] 
26 (54.2%) 
[n=48] 
0.004 0 
[n=10] 
1 (100.0%) 
[n=1] 
0.001 
Number of pituitary 
deficiencies at diagnosis 
0 
[n=8] 
1.04 ± 1.15 
[n=48] 
0.008 0 
[n=10] 
2 
[n=1] 
0.002 
Macroadenoma 6 (60.0%) 
[n=10] 
102 (92.7%) 
[n=110] 
0.001 1 (10.0%) 
[n=10] 
3 (100.0%) 
[n=3] 
0.003 
Maximum tumour 
diameter (mm) 
14.1 ± 7.6 
[n=8] 
24.5 ± 11.9 
[n=48] 
0.015 6.4 ± 5.0 
[n=10] 
35.0 
[n=1] 
0.113 
Suprasellar extension 1 (12.5%) 
[n=8] 
37 (67.3%) 
[n=55] 
0.003 1 (11.1%) 
[n=9] 
2 (100.0%) 
[n=2] 
0.011 
Cavernous sinus 
invasion 
1 (14.3%) 
[n=7] 
25 (45.5%) 
[n=55] 
0.115 1 (11.1%) 
[n=9] 
1 (50.0%) 
[n=2] 
0.197 
Ki-67 > 3% 1 (20.0%) 
[n=5] 
10 (50.0%) 
[n=20] 
0.227 0 
[n=1] 
1 (50.0%) 
[n=2] 
0.386 
Number of treatments 1.20 ± 1.03 
[n=10] 
2.45 ± 1.69 
[n=120] 
0.015 0.20 ± 6.32 
[n=10] 
1.33 ± 0.58 
[n=3] 
0.010 
Number of surgeries 0.70 ± 0.48 
[n=10] 
1.09 ± 0.79 
[n=122] 
0.105 0.10 ± 0.32 
[n=10] 
1.33 ± 0.58 
[n=3] 
0.004 
Re-operation 0 
[n=7] 
27 (27.0%) 
[n=100] 
0.112 0 
[n=1] 
0 
[n=3] 
1.000 
Radiotherapy 0 
[n=10] 
51 (42.1%) 
[n=121] 
0.009 0 
[n=10] 
1 (33.3%) 
[n=3] 
0.057 
Multimodal treatment 4 (57.1%) 
[n=7] 
80 (73.4%) 
[n=109] 
0.351 1 (100.0%) 
[n=1] 
1 (33.3%) 
[n=3] 
0.248 
≥ 3 treatments 1 (14.3%) 
[n=7] 
52 (47.7%) 
[n=109] 
0.085 0 
[n=1] 
1 (33.3%) 
[n=3] 
1.000 
Active disease at last 
follow-up 
1 (11.1%) 
[n=9] 
27 (29.3%) 
[n=92] 
0.243 0 
[n=8] 
1 (50.0%) 
[n=2] 
0.035 
Hypopituitarism at last 
follow-up 
0 
[n=4] 
13 (40.6%) 
[n=32] 
0.111 0 
[n=9] 
1 (100.0%) 
[n=1] 
0.002 
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Number of pituitary 
deficiencies at last 
follow-up 
0 
[n=4] 
0.56 ± 0.97 
[n=27] 
0.220 0 
 [n=9] 
1.00 
[n=1] 
0.003 
Follow-up duration (yr) 5.5 ± 4.8 
[n=10] 
12.0 ± 13.2 
[n=93] 
0.276 5.1 ± 4.7 
[n=10] 
19.5 ± 0.7 
[n=2] 
0.030 
Table 7.6: Prospectively-diagnosed vs clinically-presenting AIPmut somatotrophinomas or NFPAs  
Categorical data are shown as n(%); continuous variables are shown as mean±SD. In square brackets is 
indicated the number of cases where data was available regarding each parameter/variable. AIPmut, AIP 
mutation-positive; AIPneg, AIP mutation-negative; NFPA, non-functioning pituitary adenoma; yr, years. 
 
 
AIP mutations in the study population and genotype-phenotype correlation 
Forty-four germline pathogenic/likely pathogenic AIP mutations were identified, including 5 
mutations not previously described (exon 1 deletion; c.344delT (p.L115fs*41); c.773T>G 
(p.L258R); c.779delA (p.K260fs*44); c.863_864del (p.F288Cfs*?)), among the 167 AIPmut patients 
(Table 7.7). The most common mutation types were nonsense (27%) and frameshift mutations 
(25%), followed by missense (18%), splice site (7%), in-frame insertions/deletions (9%) and large 
genomic deletions (7%). Of 167 AIPmut PAs, 127 (76%) were due to a truncating mutation, and 
the most frequent AIP mutation was c.910C>T (p.R304*), which was detected in 57 patients.  
In the study population, I identified 17 different AIP variants classified as benign, likely benign or 
variants of uncertain significance according to American College of Medical Genetics and 
Genomics and the Association for Molecular Pathology criteria712 (Table 7.8). Of note, one of the 
most common AIP variants identified, p.R304Q, although controversial, is currently classified as 
variant of uncertain significance713, so patients from these kindreds were considered AIPneg. 
Of 167 AIPmut PAs, 126 were due to a truncating mutation, and the most frequent AIP mutation 
was c.910C>T (p.R304*) detected in 57 patients. No differences were found regarding proportion 
of gigantism or GH excess cases, age at onset or at diagnosis, pituitary apoplexy, hypopituitarism 
at diagnosis, macroadenomas, suprasellar extension, cavernous sinus invasion, radiotherapy, 
active disease at last follow-up and hypopituitarism at last follow-up between PAs due to 
truncating vs non-truncating AIP mutations, or between PAs associated with p.R304* vs non-
p.R304* AIP mutation (Table 7.9). However, fewer treatments (p=0.026) and operations (p<0.001) 
were seen in p.R304*AIPmut patients, as well as in AIPmut patients with truncating mutation 
(p=0.040 and p=0.014, respectively). Truncating AIPmut PAs had less frequently multimodal 
treatment and SSAs, fewer males and shorter diagnosis delay in comparison with the non-
truncating mutation subgroup (Table 7.9).   
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AIP mutation 
Prevalence within  
AIPmut PAs (n=167) 
Mutation type Location in the AIP protein 
References to previously published 
mutations / brief description of patients 
with novel AIP mutations 
g.4856_4857CG>AA (p.?) 2 (1.2%) Promoter 5-UTR (not in protein) 156,175,187 
c.1-?_993+?del- (p.0?) (whole 
gene deletion) 
8 (4.8%) Large genomic deletion Absence of whole protein 187 
c.(?-50)_(99+1_100-1)del (p.0?) 
(exon 1 deletion) 
1 (0.6%) Large genomic deletion Absence of whole protein Female, age at onset 17yr, age at diagnosis 
19yr, acromegaly, macroadenoma  
c.3G>A (p.?) 2 (1.2%) Start codon N-terminus 192 
c.40C>T (p.Q14*) 2 (1.2%) Nonsense N-terminus 91,153,714,715 
c.70G>T (p.E24*) 7 (4.2%) Nonsense N-terminus 156,174 
c.74_81delins7 (p.L25Pfs*130) 4 (2.4%) Frameshift PPIase domain 187,716 
c.100-1025_279+357del 
(p.A34_K93del) (exon 2 deletion) 
6 (3.6%) Large genomic deletion PPIase domain 717 
c.140_163del (p.G47_R54del) 1 (0.6%) In-frame deletion PPIase domain 161 
c.240_241delinsTG 
(p.M80_R81delinsIG) 
1 (0.6%) In-frame deletion 
insertion 
PPIase domain 169 
c.241C>T (p.R81*) 7 (4.2%) Nonsense PPIase domain 156,175,718-720 
c.249G>T (p.G83Afs*15) 3 (1.8%) Splice site PPIase domain 187 
c.333delC (p.K112Rfs*44) 1 (0.6%) Frameshift PPIase domain 169 
c.338_341dup (p.L115Pfs*16) 2 (1.2%) Frameshift PPIase domain 91,721 
c.344delT (p.L115Rfs*41) 1 (0.6%) Frameshift PPIase domain Male, age at onset 15yr, age at diagnosis 
16yr, prolactinoma, microadenoma 
c.376_377delCA (p.Q126Dfs*3) 1 (0.6%) Frameshift PPIase domain 169 
c.427C>T (p.Q143*) 2 (1.2%) Nonsense Between PPlase and TPR1 domains 91 
c.469-2A>G (p.E158_Q184del) 1 (0.6%) Splice site (resulting in 
in-frame deletion) 
TPR1 domain 705,722,723 
c.490C>T (p.Q164*) 2 (1.2%) Nonsense Between PPlase and TPR1 domains 187 
c.504G>A (p.W168*) 1 (0.6%) Nonsense TPR1 domain 724 
c.562C>T(p.R188W) 1 (0.6%) Missense TPR1 domain 191 
c.570C>G (p.Y190*) 4 (2.4%) Nonsense TPR1 domain 91 
c.605A>G (p.Y202C) 1 (0.6%) Missense TPR1 domain 169 
c.645+1G>C (p.?) 1 (0.6%) Splice site TPR1 domain 169 
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c.662dupC (p.E222*) 2 (1.2%) Frameshift Between TPR1 and TPR2 domains 187 
c.713G>A (p.C238Y) 3 (1.8%) Missense TPR2 domain 156,174 
c.760T>C (p.C254R) 1 (0.6%) Missense TPR2 domain 191 
c.762C>G (p.C254W) 2 (1.2%) Missense TPR2 domain 191 
c.773T>G (p.L258R) 1 (0.6%) Missense# TPR2 domain Male, age at onset 21yr, age at diagnosis 
29yr, prolactinoma, macroadenoma 
c.779delA (p.K260Sfs*44) 1 (0.6%) Frameshift PPIase domain Male, age at onset 8yr, age at diagnosis 
12yr, gigantism, macroadenoma 
c.783C>G (p.Y261*) 2 (1.2%) Nonsense TPR2 domain 91,110,705 
c.804C>A (p.Y268*) 3 (1.8%) Nonsense TPR3 domain 91,720,725 
c.805_825dup (p.F269_H275dup) 16 (9.6%) In-frame insertion TPR3 domain 156,175,705 
c.811C>T (p.R271W) 8 (4.8%) Missense TPR3 domain 155,187,707,726 
c.815G>A (p.G272D) 1 (0.6%) Missense TPR3 domain 192,727 
c.816delC (p.K273Rfs*30) 1 (0.6%) Frameshift TPR3 domain 91 
c.863_864del (p.F288Cfs*?) 1 (0.6%) Frameshift TPR3 domain Female, age at onset 16yr, age at diagnosis 
31yr, acromegaly, macroadenoma 
c.868A>T (p.K290*) 1 (0.6%) Nonsense TPR3 domain 91 
c.872_877delTGCTGG 
(p.V291_L292del) 
1 (0.6%) In-frame deletion TPR3 domain 728 
c.910C>T (p.R304*) 57 (34.1%) Nonsense C-terminal α-helix 110,153,155,156,705,707,722,729 
c.967delC (p.R323Gfs*39) 1 (0.6%) Frameshift C-terminal α-helix 91 
c.976_977insC (p.G326Afs*?) 1 (0.6%) Frameshift C-terminal α-helix 91 
c.978dupG (p.I327Dfs*?) 1 (0.6%) Frameshift C-terminal α-helix 91 
c.991T>C (p.*331R) 1 (0.6%) Stop-loss C-terminal α-helix 169 
Table 7.7: List of AIP pathogenic/likely pathogenic mutations identified in our cohort  
Mutations in bold are novel mutations not previously described. None of these were found in GnomAD (https://gnomad.broadinstitute.org/gene/ENSG00000110711). All 5 
patients with novel mutations were simplex cases. #Revel score730 of this variant is 0.989 out of the maximum 1, strongly suggesting pathogenic status and Gavin score731 is 
‘pathogenic’. AIPmut, AIP mutation-positive; PA, pituitary adenoma; PPIase, peptidylprolyl isomerase; TPR, tetratricopeptide repeat; UTR, untranslated region. 
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Variant HGVS 
nomenclature: DNA 
(protein) 
dbSNP ID 
American College of Medical Genetics 
and Genomics and the Association for 
Molecular Pathology category 
Revel and 
Gavin scores 
Number of subjects in 
our study population 
MAF in our cohort - 
affected individuals 
(n=1216) (%) 
MAF in GnomAD 
exomes and 
genomes (%) 
c.47G>A (p.R16H) rs145047094 benign 0.777 / benign 4 (all affected) 0.3289 0.2082 
c.100-18C>T (p?) rs202156895 likely benign *n/a / benign 7 (all affected) 0.5757 0.3147 
c.132C>T (p.D44=) rs11822907 benign *n/a / benign 3 (all affected) 0.2467 0.7984 
c.144C>T (p.T48=) rs772658134 benign *n/a / benign 1 (affected) 0.0822 0.0064 
c.468+9C>T (p?) rs373159347 likely benign *n/a / benign 1 (affected) 0.0822 0.0066 
c.469-13C>T (p?) n/a VUS *n/a / benign 1 (affected) 0.0822 n/a 
c.516C>T (p.D172=) rs2276020 benign *n/a / benign 
22 (nineteen affected, 
three unaffected [one 
homozygous]) 
1.56 3.4314 
c.579G>T (p.G193=) rs1194122725 likely benign *n/a / benign 1 (unaffected) 0 n/a 
c.682A>C (p.K228Q) † rs641081 likely benign 0.117 / benign 18 (all affected) 1.4803 5.0202 
c.787+9C>T (p?) rs749392143 VUS *n/a / benign 1 (affected) 0.0822 0.0047 
c.807C>T (p.F269=) rs139407567 VUS *n/a / benign 11 (five affected) 0.4112 0.0550 
c.831C>T (p.A277=) rs531331351 VUS 
*n/a / 
pathogenic 
1 (affected) 0.0822 0.0016 
c.891C>A (p.A297=) rs35665586 benign *n/a / benign 2 (affected) 0.1645 0.1813 
c.896C>T (p.A299V) rs148986773 likely benign 
0.292 / 
pathogenic 
5 (one affected)# 0.0822 0.0544 
c.906G>A (p.V302=) rs142912418 benign *n/a / benign 2 (one affected) 0.0822 0.0086 
c.911G>A (p.R304Q) rs104894190 VUS 0.31 / benign 32 (sixteen affected) 1.32 0.1568 
 
Table 7.8: List of non-pathogenic AIP variants identified in the study population 
n/a, not available; VUS, variant of uncertain significance. *n/a, Revel score not available as this scoring system only consider missense variants. †There is a Q at this position 
in the AIP reference sequence, but we consider K as the wild-type amino-acid, due to its higher prevalence in the population screened so far (GnomAD, 1000Genomes); we 
considered A at this position as the reference allele when analysing GnomAD data. #Two of the unaffected subjects carry the R304* and the A299V variants on 2 different 
alleles, strongly suggesting that the A299V variant is benign708. Variant nomenclature was based on transcript NM_003977.4. Categorisation of variants was based on the 
combination of multiple in silico prediction tools, clinical and experimental data. 
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 AIPmut PAs: 
 truncating vs non-truncating mutation 
AIPmut PAs: 
 p.R304* vs non-p.R304*  
Truncating 
AIPmut 
n=126 
Non-truncating 
AIPmut 
n=41 
 
p 
value 
p.R304* 
AIPmut 
n=57 
non-p.R304* 
AIPmut 
n=110 
p 
value 
Cohort type based on 
family history of PAs 
Familial cohort 
Sporadic cohort 
 
 
95 (75.4%) 
31 (24.6%) 
[n=126] 
 
 
19 (46.3%) 
22 (53.7%) 
[n=41] 
 
 
0.001 
 
 
44 (77.2%) 
13 (22.8%) 
[n=57] 
 
 
70 (63.6%) 
40 (36.4%) 
[n=110] 
 
 
0.074 
Gender 
Male 
Female 
 
69 (54.8%) 
57 (45.2%) 
[n=126] 
 
33 (80.5%) 
8 (19.5%) 
[n=41] 
 
0.003 
 
33 (57.9%) 
24 (42.1%) 
[n=57] 
 
69 (62.7%) 
41 (37.3%) 
[n=110] 
 
0.544 
Age at disease onset     
≤18 yr 
70 (65.4%) 
[n=107] 
24 (63.2%) 
[n=38] 
0.802 31 (67.4%) 
[n=46] 
63 (63.6%) 
[n=99] 
0.659 
Age at first symptoms 
(yr) 
19.3 ± 10.2 
[n=104] 
18.2 ± 7.4 
[n=35] 
0.940 19.4 ± 10.1 
[n=44] 
18.8 ± 9.3 
[n=95] 
0.834 
Age at diagnosis (yr) 24.8 ± 12.6 
[n=121] 
22.9 ± 9.6 
[n=39] 
0.700 24.9 ± 12.5 
[n=54] 
24.0 ± 11.7 
[n=106] 
0.632 
Delay in diagnosis (yr) 3.8 ± 6.7 
[n=103] 
5.0 ± 6.3 
[n=35] 
0.013 3.4 ± 6.0 
[n=44] 
4.5 ± 6.9 
[n=94] 
0.221 
GH excess 99 (78.6%) 
[n=126] 
37 (90.2%) 
[n=41] 
0.095 43 (75.4%) 
[n=57] 
93 (84.5%) 
[n=110] 
0.151 
Gigantism 56 (44.5%) 
[n=126] 
20 (48.8%) 
[n=41] 
0.273 25 (43.9%) 
[n=57] 
51 (46.4%) 
[n=110] 
0.688 
Pituitary apoplexy 9 (8.0%) 
[n=112] 
3 (8.8%) 
[n=34] 
0.884 5 (10.0%) 
[n=50] 
7 (7.3%) 
[n=96] 
0.572 
Height at diagnosis 
(cm) 
180.1 ± 18.9 
[n=89] 
180.4 ± 19.7 
[n=27] 
0.759 181.7 ± 16.9 
[n=38] 
179.4 ± 20.4 
[n=78] 
0.508 
Height Z-score at 
diagnosis 
2.5 ± 2.4 
[n=89] 
1.9 ± 2.6 
[n=26] 
0.243 2.7 ± 2.0 
[n=38] 
2.3 ± 2.7 
[n=71] 
0.151 
IGF-1 xULN at 
diagnosis 
2.4 ± 3.7 
[n=37] 
1.7 ± 0.8 
[n=13] 
0.691 1.5 ± 1.0 
[n=14] 
2.5 ± 3.7 
[n=36] 
0.191 
Hypopituitarism at 
diagnosis 
24 (40.0%) 
[n=60] 
8 (53.3%) 
[n=15] 
0.350 14 (45.2%) 
[n=31] 
18 (40.9%) 
[n=44] 
0.714 
Number of pituitary 
deficiencies at 
diagnosis 
0.78 ± 1.12 
[n=60] 
1.07 ± 1.22 
[n=15] 
0.348 1.00 ± 1.29 
[n=31] 
0.73 ± 1.02 
[n=44] 
0.464 
Macroadenoma 93 (81.6%) 
[n=114] 
31 (88.6%) 
[n=35] 
0.333 40 (80.0%) 
[n=50] 
84 (84.8%) 
[n=99] 
0.455 
Maximum tumour 
diameter (mm) 
18.7 ± 12.4 
[n=58] 
25.2 ± 14.8 
[n=16] 
0.109 18.0 ± 12.3 
[n=28] 
21.4 ± 13.4 
[n=46] 
0.315 
Suprasellar extension 32 (52.5%) 
[n=61] 
12 (60.0%) 
[n=20] 
0.557 13 (48.1%) 
[n=27] 
31 (57.4%) 
[n=54] 
0.430 
Cavernous sinus 
invasion 
21 (36.8%) 
[n=57] 
8 (36.4%) 
[n=22] 
0.968 8 (34.8%) 
[n=23] 
21 (37.5%) 
[n=56] 
0.820 
Ki-67 > 3% 11 (47.8%) 
[n=23] 
1 (16.7%) 
[n=6] 
0.168 3 (27.3%) 
[n=11] 
9 (50.0%) 
[n=18] 
0.228 
Number of 
treatments 
1.90 ± 1.73 
[n=122] 
2.61 ± 1.33 
[n=38] 
0.002 1.75 ± 1.72 
[n=56] 
2.24 ± 1.62 
[n=104] 
0.026 
Number of surgeries 0.86 ± 0.82 
[n=124] 
1.13 ± 0.62 
[n=38] 
0.014 0.61 ± 0.62 
[n=56] 
1.09 ± 0.81 
[n=106] 
<0.001 
Re-operation 19 (22.9%) 
[n=83] 
8 (23.5%) 
[n=34] 
0.941 4 (13.3%) 
[n=30] 
23 (26.4%) 
[n=87] 
0.142 
Radiotherapy 39 (31.7%) 
[n=123] 
14 (36.8%) 
[n=38] 
0.556 18 (32.1%) 
[n=56] 
35 (33.3%) 
[n=105] 
0.878 
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Somatostatin 
analogues 
38 (31.1%) 
[n=122] 
21 (55.3%) 
[n=38] 
0.007 17 (30.4%) 
[n=56] 
42 (40.4%) 
[n=104] 
0.210 
Pegvisomant 8 (6.6%) 
[n=122] 
6 (15.8%) 
[n=38] 
0.079 4 (7.1%) 
[n=56] 
10 (9.6%) 
[n=104] 
0.598 
Dopamine agonists 32 (26.2%) 
[n=122] 
12 (31.6%) 
[n=38] 
0.519 19 (33.9%) 
[n=56] 
25 (24.0%) 
[n=104] 
0.181 
Multimodal 
treatment 
60 (61.9%) 
[n=97] 
30 (81.1%) 
[n=37] 
0.034 25 (59.5%) 
[n=42] 
65 (70.7%) 
[n=92] 
0.203 
≥ 3 treatments 35 (36.1%) 
[n=97] 
19 (51.4%) 
[n=37] 
0.107 16 (38.1%) 
[n=42] 
38 (41.3%) 
[n=92] 
0.725 
Active disease at last  
follow-up 
21 (22.1%) 
[n=95] 
10 (34.5%) 
[n=29] 
0.178 8 (17.4%) 
[n=46] 
23 (29.5%) 
[n=78] 
0.133 
Hypopituitarism at 
last follow-up 
8 (21.6%) 
[n=37] 
8 (47.1%) 
[n=17] 
0.057 3 (14.3%) 
[n=21] 
13 (39.4%) 
[n=33] 
0.049 
Number of pituitary 
deficiencies at last 
follow-up 
0.49 ± 1.04 
[n=37] 
0.33 ± 0.65 
[n=12] 
0.975 0.43 ± 1.12 
[n=21] 
0.46 ± 0.84 
[n=28] 
0.361 
Final height (cm) 185.6 ± 17.2 
[n=79] 
180.4 ± 19.7 
[n=27] 
0.759 188.0 ± 16.9 
[n=34] 
183.3 ± 18.3 
[n=71] 
0.151 
Follow-up duration 
(yr) 
11.7 ± 12.9 
[n=102] 
9.3 ± 9.5 
[n=26] 
0.593 14.0 ± 13.7 
[n=47] 
9.6 ± 11.2 
[n=81] 
0.054 
Table 7.9: AIPmut PAs due to truncating vs non-truncating mutations or due to p.R304* vs non-p.R304* 
Categorical data are shown as n(%); continuous variables are shown as mean±SD. In square brackets is 
indicated the number of cases where data was available regarding each specific parameter/variable. 
AIPmut, AIP mutation-positive; PA, pituitary adenoma; ULN, upper limit of the normal; yr, years. 
 
 
Discussion 
In this study, I analysed a large cohort of patients with familial and young-onset PAs, of whom 
11.3% had germline AIP mutations, focusing on the prospectively-diagnosed AIPmut PAs as 
characterisation of this particular subgroup, crucial to assess the potential benefits of genetic 
screening for AIP mutations, is lacking. I also aimed to expand the current knowledge on AIPmut 
PAs clinical, therapeutic and outcome characteristics.  
My data suggest that the clinical phenotypic spectrum of AIP-related pituitary disease is wide, 
wider than previously thought. Characteristic patients present with aggressive PAs requiring a 
complex therapeutical approach; however, prospectively-diagnosed AIPmut PAs are less invasive 
and usually require a less complex treatment due to their intrinsic less aggressiveness and/or 
detection in an early stage facilitating its management.  
Hence, prospectively-diagnosed AIPmut PAs are those most likely benefiting from early detection 
via genetic and clinical screening, highlighting the role for genetic screening of at-risk family 
members in AIPmut families and emphasise the benefits of screening AIPmut carriers (Figure 7.3). 
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Figure 7.3: Heterogeneous clinical phenotype and management of patients with AIPmut PAs, and the 
benefits of their early detection by genetic and clinical screening 
 
AIPmut PAs are more aggressive and refractory to conventional therapy, but AIP-related 
pituitary disease can be controlled with multimodal therapeutical approach 
In the AIPmut and AIPneg comparison, AIPmut tumours presented earlier and more aggressively 
than AIPneg ones. Multimodal treatment, including radiotherapy and three or more treatments, 
were required more often in the AIPmut setting. Such observations reflect the more aggressive 
nature and poorer responsiveness of AIPmut PAs, as seen in previous studies91,161,705,707,732, but the 
inclusion of aggressive or therapy resistant pituitary disease did not improve the identification of 
AIP mutations in a recent study733. In fact, our data show that some AIPmut PAs will not display 
an aggressive phenotype155,161,196,734. Moreover, the rate of active disease at last follow-up was 
10% lower in the AIPmut PAs group, suggesting that AIPmut PAs can be satisfactorily controlled 
despite requiring more complex and multimodal therapeutic schemes196,310,704,735,736. Although 
these data may seem paradoxical (more aggressive disease at presentation in the AIPmut patients, 
but better controlled disease at last follow-up), they could be explained by a more aggressive 
treatment approach in AIPmut cases, especially the use of radiotherapy. Another possibility is that 
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the follow-up of AIPneg cases in our cohort was somewhat shorter; indeed, considering a cut-off 
of maximum 10yr follow-up, there was no difference in rate of active disease between the 2 
groups. Rostomyan et al. also reported higher rates of biochemical control at last follow-up and a 
trend for increased long-term controlled disease in patients with AIPmut pituitary gigantism in 
comparison to those with genetically-negative gigantism196. Thus, these data suggest that 
management of AIPmut PA patients can be challenging, but the disease is controllable in a 
significant proportion of cases.  
 
AIPmut somatotrophinomas present earlier, are more aggressive and require more often 
radiotherapy, with patients ending up taller than those with AIPneg somatotrophinomas 
Among AIPmut patients, somatotrophinomas were the main PA subtype and gigantism the 
predominant diagnosis, as previously shown161,169. AIPmut somatotrophinoma patients were 
younger at first symptoms and at diagnosis, and had higher rates of apoplexy and suprasellar 
extension, consistent with previous studies91,161,196,728. IGF-1 levels at diagnosis did not differ 
between clinically-presenting AIPmut and AIPneg somatotrophinoma patients, suggesting that 
AIPmut somatotrophinomas are not biochemically more active at presentation than their AIPneg 
counterparts, similar to earlier data161. AIPmut patients with gigantism also showed similar IGF-1 
levels in our cohort92, although AIPneg giants had higher IGF-1 in another cohort196. AIPmut 
somatotrophinoma patients tended to require multimodal and multiple therapy, and had 
significantly more radiotherapy than AIPneg patients, for which a nonsignificant trend had been 
observed previously161. Stature and final adult height are regarded as markers for disease course, 
aggressiveness and effective management in patients with pituitary gigantism737,738. The mean 
final height in my cohort was higher in the AIPmut somatotrophinoma subgroup, with both 
AIPmut males and females ending up taller than AIPneg counterparts, although this has not been 
consistently shown in other series196. The taller final height in the AIPmut somatotrophinoma 
patients is likely due to earlier onset of disease, but may reflect the management difficulties, as 
suggested by the high proportion of patients requiring radiotherapy and multiple therapy. 
 
AIPmut prolactinomas present more often with apoplexy than AIPneg prolactinomas 
Patients with AIPmut prolactinomas had higher rates of pituitary apoplexy and more frequently 
had a family history of PAs than AIPneg prolactinomas. We found no differences regarding 
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treatment and clinical outcomes in the comparative analysis of AIPmut vs AIPneg prolactinomas. 
Although the numbers are relatively small, this suggests that AIPmut prolactinomas may not be 
more refractory to medical therapy, in line with the previous report showing that presence of an 
AIP mutation in children or adolescents with macroprolactinomas does not influence the 
response/resistance to dopamine agonists734. Of the 13 AIPmut prolactinoma patients reported 
by Daly et al., 12 received primary dopamine agonist therapy, with initial normalisation of PRL in 
5 cases, 1 with initial response but resistance later, and 6 uncontrolled with dopamine agonists 
requiring surgery, together with radiotherapy given to 3 patients161. In Daly et al. AIPmut 
prolactinoma cohort, long-term control was achieved in 61.5% (8 out of 13 patients)161, which is 
lower than the rates of controlled disease we found in our cohort (84.6%). 
 
AIPmut NFPAs may display an indolent course of disease and have similar features and clinical 
outcomes as AIPneg NFPAs, some of these possibly representing incidentalomas 
AIPmut NFPAs had lower rates of macroadenomas, hypopituitarism at last follow-up, lower 
maximum tumour diameter, number of pituitary deficiencies at diagnosis and required fewer 
treatments and operations than AIPneg NFPAs. However, these differences were lost when the 10 
prospectively-diagnosed cases were excluded from the analysis, highlighting the remarkable 
difference in terms of aggressiveness between clinically-presenting and prospectively-diagnosed 
AIPmut NFPAs. In fact, clinically-presenting AIPmut NFPAs were macroadenomas, had suprasellar 
extension and hypopituitarism at diagnosis/last follow-up, and half remain uncontrolled at last 
follow-up. Clinically-presenting AIPmut NFPAs reported previously were also noted for their 
aggressive behaviour161. Some of the small prospectively-diagnosed AIPmut NFPAs may represent 
incidentalomas similar to those often observed in the general population, although 
incidentalomas are more common in older subjects7,23. MEN1mut prospectively-diagnosed NFPAs 
also display an indolent behaviour, do not progress to macroadenomas and often require no 
intervention99,101. Nevertheless, some of these patients will have aggressive AIPmut NFPAs which 
will benefit from early detection by genetic testing and clinical screening. 
 
Phenotype spectrum of AIPmut PA patients is heterogeneous: not all AIPmut PAs are associated 
with aggressive behaviour or poor clinical outcomes 
My data show that not all AIPmut PAs are aggressive or difficult to manage, particularly those 
prospectively-diagnosed, as some patients have stable or indolent course of disease, including 
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very early cases of acromegaly with no/mild symptoms and subtle biochemical burden as well as 
microprolactinomas or small NFPAs (possibly incidentalomas) requiring no treatment. AIPmut 
prolactinomas were not more difficult to manage than AIPneg prolactinomas and the rates of 
active disease at last follow-up were lower in patients with AIPmut somatotrophinomas 
suggesting that AIPmut PAs can respond to treatment. Hence, my findings do not fully support the 
increased aggressiveness or necessarily poor prognosis recognised to AIPmut PAs, highlighting 
that the phenotypic spectrum of AIP-related pituitary disease is wider than previously 
suggested91,161,705. Interestingly, the inclusion of aggressive or therapy resistant pituitary disease 
did not increase the frequency of AIP mutations in a recent study733. This also supports the current 
recommendations for managing familial PAs in a similar manner as sporadic AIPneg PAs23,167,170,171. 
 
Prospectively-diagnosed AIPmut PAs are less aggressive and have better outcomes than 
clinically-presenting PAs highlighting the benefits of testing AIPmut carriers 
In this study, I focused on prospectively-diagnosed AIPmut patients, as the clinical and therapeutic 
characterisation of this subgroup, crucial to assess the potential benefits of genetic testing and 
clinical screening, is lacking. The clinical screening of carrier family members of AIPmut probands 
has been recommended on the assumption that the early detection of PAs might be associated 
with more favourable outcomes91,152,167,168; however, these predicted advantages had not been 
previously demonstrated. Among the 187 apparently unaffected AIPmut carriers, 22 (11.8%) were 
identified with a prospectively-diagnosed PA by clinical, biochemical and imaging screening. 
Prospectively-diagnosed PAs were not present at baseline assessment in 3 AIPmut carriers (2 cases 
previously reported167) but emerged during the follow-up (5 to 7 years after the initial screening), 
reinforcing the need for long-term surveillance of unaffected AIPmut carriers as currently 
recommended91,152,167,168. Tichomirowa et al. identified 2 patients with PAs among the 21 AIPmut 
carriers screened (9.5%), both clinically silent microadenomas requiring no intervention155. In this 
series, as a group, prospectively-diagnosed AIPmut PAs were mainly microadenomas, smaller and 
associated with lower rates of suprasellar extension, cavernous sinus invasion, hypopituitarism at 
diagnosis, and required fewer treatments, operations, no radiotherapy, and had reduced rates of 
active disease and hypopituitarism at last follow-up when compared to their clinically-presenting 
counterparts. Similar results were obtained when prospectively-diagnosed AIPmut somatotrophi-
nomas and AIPmut NFPAs were analysed separately. Overall, prospectively-diagnosed AIPmut PAs 
are significantly less invasive and associated with better outcomes than those with a clinical 
presentation, highlighting the benefits of AIP genetic testing of family members at risk and the 
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screening of individuals carrying an AIP mutation, thus providing strong evidence to justify current 
screening recommendations152,154,168,169.  
Considering the relatively low penetrance of PAs among AIPmut carriers (20-23%)91,152 and the 
benign nature of their potential condition, AIPmut carriers can be reassured and informed about 
the benefits of early disease detection clearly demonstrated in this study. The advantages of 
genetic testing and clinical screening are recognised for many familial endocrine tumours, 
including phaeochromocytomas/paragangliomas739,740, medullary thyroid cancer741, parathyroid 
tumours116 and MEN199. Some of the screening-detected MEN1-related PAs are non-functioning 
microadenomas99, similarly to what we have identified in our cohort. Both AIPmut and MEN1mut 
prospectively-diagnosed PAs are suggested to be managed according to current 
guidelines23,98,99,170,742-744. As most clinically-presenting AIPmut cases show symptoms by the age 
of 3091,152,167,168, and no patient has been described to date with normal findings at age 30yr and 
developing disease later, the surveillance of AIPmut carriers could be relaxed after this age91,167.  
 
Three key questions for clinicians managing PA patients regarding AIP testing  
(1) Which clinically-presenting PA patient should be tested for AIP mutations? Four simple 
factors (age of onset, family history, tumor type and size), may predict the risk of carrying 
an AIP mutation in a patient with a PA169. As mutation status correlates with age of disease 
onset better than age of diagnosis91, careful history taking is key. For example, the age at 
onset between 19-30yr is an independent risk factor for sporadic PA patients to carry 
an AIP mutation; however, patients in this age group without GH excess or an absence of 
family history have a lower risk169. Hence, risk prediction should take several parameters 
into account, and for patients with fewer risk factors the age cut-off for AIP testing could 
be lower than 30yr169,733. My study shows that many sporadic PA patients who 
undergo AIP analysis based on age at onset ≤30yr91,169 will have negative results. In the 
young-onset sporadic PA cohort 6.8% were AIPmut with slightly higher rates in the 
sporadic somatotrophinoma group (10.5%) this is at the level of usual risk recommenda-
tion for genetic testing, but I identified low rates in sporadic prolactinomas (1.5%) with no 
cases of NFPAs or corticotrophinomas. 
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(2) When to initiate genetic screening for family members of a proband? Germline AIP
mutation genetic testing should be offered at the earliest opportunity to first-degree
relatives including children, because the disease may manifest by the age of 4 yr310.
(3) What should be the clinical follow-up of AIPmut carriers? Based on this study, careful
baseline assessment of AIPmut carriers (including clinical examination, measurement of
serum IGF-1 and PRL, and pituitary MRI scan) picks up the largest number of pituitary
abnormalities. As AIP mutation testing has only been established just over a decade ago,
the age range of establishing carrier status was wide in my cohort. However, as testing is
now routinely available, we predict that a larger number of carriers will be followed
starting at an early age. As the age of disease onset has an inverted U shape, the
recommendation for AIPmut carrier follow-up could be different for the various age
groups. For AIPmut carriers until the age of 20yr, annual clinical assessment with
measurement of serum IGF-1 and PRL and baseline MRI (starting at 10yr for younger
carriers) followed by 5-yearly scans could be appropriate. Follow-up between 21-30yr, if
assessment is normal at age 20yr, probably could be relaxed. My data would also raise the
possibility that adult AIPmut carriers with a normal baseline assessment could be followed
with clinical and biochemical assessment, with further pituitary MRI scan only indicated
in case of symptoms or biochemical abnormalities. Most clinically-presenting cases show
symptoms before the age of 30yr91,152, and I am not aware of any case with a normal full
assessment at age 30yr who later developed a PA. However, a cost-effectiveness analysis
evaluating the economic burden of genetic and clinical screening programs in this setting,
while weighing the benefits of early detection of AIPmut PAs, is currently lacking.
Limitations of this study 
There are some limitations in my study. Firstly, I used the onset of symptoms age cut-off ≤30yr as 
a criterion to guide AIP genetic testing in patients with young-onset sporadic PAs, as in previous 
AIP-related studies91,161,169,705. This age cut-off relies on age of onset which can be subjective; 
however, age of onset rather than age at diagnosis is suggested to be a better option to guide 
genetic testing as PAs are often diagnosed with significant delay169. Secondly, our patients were 
recruited from different countries and thus their characteristics and outcomes may be affected by 
their different genetic backgrounds and/or different local clinical practice. Thirdly, I assigned, 
based on current experimental, clinical and in silico data, the AIP variants into pathogenic/likely 
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pathogenic, or variant of uncertain significance/likely benign/benign groups; however, these 
categories may change as these variants are better characterised. Fourthly, clinico-therapeutical 
features and outcome data were not accessible/available for all patients, limiting statistical power 
of some of my comparative analysis. Fifthly, since the apparently unaffected participants of our 
study were genetically and clinically screened at various ages, we cannot determine, at this point, 
the disease penetrance for the prospectively-diagnosed cohort per age group. We also cannot 
fully exclude that any of the predicted AIPneg patients could eventually carry an AIP mutation; 
however, as these cases had at least one affected relative tested negative for AIP mutation and 
their familial phenotypes are not suggestive of AIPmut, it is very unlike that we have missed 
phenocopy families in this study. 
 
 
Conclusions 
Genetic testing followed by clinical screening in AIPmut kindreds can detect clinically-relevant 
pituitary disease, where earlier intervention results in better outcomes. While clinically-
presenting AIPmut PAs occur in younger patients with more advanced disease, complex treatment 
strategies can result in well-controlled disease. There is a wider spectrum of disease severity in 
AIPmut PA patients, even within the same family, than previously suspected. When considering 
patients for AIP mutation testing, key clinical factors help to predict the risk level to guide decision 
making. 
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Chapter 8: Characterisation of MEN1 mutation-positive pituitary 
adenomas and comparison with AIP mutation-positive ones: 
remarkable phenotypic differences in patients with distinct forms 
of familial pituitary adenomas 
 
Introduction 
Familial forms of PAs can occur as part of a complex syndrome, such as in the MEN1 
syndrome19,691, an autosomal dominant disorder usually associated with MEN1 gene mutations 
that predisposes mainly to PHPT, PAs and pNETs97,98. The prevalence of PAs in MEN1 vary from 
10-76% depending on the series100-102, and pituitary involvement can be the first manifestation in 
up to a third of MEN1 patients99,745. Studies analysing PAs in MEN1 patients are relatively 
scarce99,101,103,109,746-748, nevertheless MEN1mut PAs are recognised in young patients, more 
invasive and large as well as is often more challenging to normalise pituitary hypersecretion than 
in MEN1 mutation-negative PAs 100,103,109.  
AIP and MEN1 mutations are the main cause of familial forms of PAs, thus genetic analysis of these 
genes is recommended in PA screening algorithms97,98,110,168,691. The order of genes to test in a 
patient with a suspected familial PA is often dictated by the presence of syndromic manifestations; 
however, isolated PAs can occur in MEN1, either as first MEN1 manifestation and/or cases where 
may be the only penetrant condition at that point in time, raising challenges in terms of which 
gene to test first (AIP or MEN1) and being misleading if only AIP is tested110.  
A comparative analysis between AIPmut and MEN1mut PAs may provide insights in terms of 
genetic analysis prioritisation in familial PA cases, besides providing further knowledge on these 2 
rare inherited forms of PAs.  
 
 
Aims 
General 
To characterise AIPmut and MEN1mut PA patients in general and by subtype and to provide a 
comparative analysis between AIPmut and MEN1mut PAs. 
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Specific 
1. To characterise PAs in AIPmut and MEN1mut patients in general and by PA subtype 
2. To provide a comparative analysis between AIPmut and MEN1mut PAs 
3. To determine phenotypic or clinical features that may aid prioritising genetic analysis in 
young patients presenting with isolated PAs 
 
 
Methods 
Study population 
Patients were selected from The International FIPA Consortium research group database 
(http://www.fipapatients.org/fipaconsortium/). Data from each case was collected from medical 
records and clinical letters as provided by referral clinicians. In this database, we have a total of 
99 MEN1 individuals genetically confirmed, including 70 patients with PAs, 18 patients with non-
pituitary MEN1-related manifestations and 11 asymptomatic MEN1mut carriers. We also have 
2079 FIPA patients of which 167 are due to a germline AIP mutation (details about the cases 
included in the AIPmut subgroup in Chapter 7). My study population consisted of 70 patients with 
MEN1mut PAs and 167 patients with AIPmut PAs. 
 
MEN1 and AIP genetic analysis 
MEN1 genetic testing was offered to index patients with MEN1 (two or more MEN1-related 
endocrine tumours) or patients with suspicious or atypical MEN1 phenotype (PHPT before the age 
of 30,  multigland parathyroid disease, gastrinoma or multiple pNET at any age, individuals with 
isolated young-onset AIPneg PAs particularly prolactinomas, or individuals who have 2 or more 
MEN1-related tumours not part of the classical MEN1 triad), as previously recommended98. 
Indications for AIP genetic testing are described in Chapter 7. 
AIP and MEN1 genetic testing and pathogenicity determination of MEN1 or AIP variants were 
performed as described in the Chapter 7. First-degree family members of individuals carrying 
MEN1 or AIP mutations were offered genetic testing, and mutation carriers then had a baseline 
clinical,  biochemical and imaging screening, in line with current recommendations98,152,167,168.  
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Definition of MEN1mut and AIPmut PA subgroups 
MEN1mut subgroup consisted of 70 patients with PAs identified with a MEN1 mutation: 68 had a 
documented germline MEN1 mutation and 2 were predicted MEN1mut (both obligate carriers 
affected with PA, PHPT and pNET, and both belonging to a MEN1mut kindred with at least one 
MEN1mut relative). AIPmut subgroup consisted of 167 patients with familial isolated and young-
onset PAs with known AIP mutation, defined as described in Chapter 7. I excluded patients with 
PAs with unknown AIP or MEN1 genetic status, including those with a diagnosis of MEN1 based 
on clinical criteria, but without documented MEN1 mutation. Individuals carrying AIP or MEN1 
mutations but with undetermined PA status (AIPmut or MEN1mut carriers who did not undergo 
clinical screening or had pending results by the time of data analysis) were also excluded.  
 
Definitions of MEN1-related diseases and the study clinical parameters 
PAs were defined based on histopathology and/or radiological examination (MRI showing a PA) 
and/or symptoms caused by elevated anterior pituitary hormone levels in accordance to current 
guidelines23,170,171. The clinical diagnoses were categorised as prolactinoma, acromegaly or 
gigantism and clinically NFPAs. There were no Cushing´s disease or thyrotrophinomas in the 
MEN1mut or AIPmut PA subgroups. PHPT, pNETs, thymic carcinoid tumours, adrenocortical 
tumours and other MEN1-related tumours were defined and diagnosed according to 
corresponding guidelines98,749-752. The definition of clinical parameters and outcomes are 
described in detail in Chapter 7.  
 
 
Results 
General characterisation of the MEN1mut cohort 
Out of 99 individuals carrying a MEN1mut included in the database, 56 were initially diagnosed 
based on clinical criteria, 13 had a familial MEN1 diagnosis, while 30 individuals were diagnosed 
via genetic testing. Eleven MEN1mut carriers remain free-of-disease, whereas 88 individuals had 
at least one MEN1 manifestation at last observation (mean number of manifestations 2.4±1.4). 
PA was the most prevalent manifestation affecting 70 subjects (70.7%), followed by PHPT and 
pNETs seen in 66 and 56 subjects, with 35.4% being affected simultaneously by a PA+PHPT+pNET 
(Figure 8.1). Less commonly, adrenal tumours (26.3%), lipomas (14.1%), carcinoid tumours (9.1%), 
thyroid tumours (7.1%), angiofibromas/collagenomas (3%) and meningiomas (1%) were seen.  
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Figure 8.1: Main MEN1-related manifestations among the cohort of 99 MEN1 patients 
MEN1mut, MEN1 mutation-positive; PA, pituitary adenoma; PHPT, primary hyperparathyroidism; pNET, 
pancreatic neuroendocrine tumour. 
 
The mean current age of MEN1mut individuals is 42.2±14.2yr (29 subjects below the age of 30), 
differing considerably among subjects unaffected or subjects affected with one or more MEN1 
manifestations (p<0.001): 13 patients affected only with PAs had a current mean age of 
29.9±14.3yr, similar to unaffected subjects (29.3±20.3yr), whereas patients with PA+PHPT+pNET 
had a mean current age of 53.4±15.7yr (Figure 8.2). 
 
Figure 8.2: Current age among the cohort of 99 MEN1 patients according to main manifestations 
Data are shown as mean±SD. MEN1mut, MEN1 mutation-positive; PA, pituitary adenoma; PHPT, primary 
hyperparathyroidism; pNET, pancreatic neuroendocrine tumour. 
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Twenty-one different germline MEN1 mutations were identified in my study population, and are 
listed in Table 8.1 (AIP mutations in the study population are listed in Table 7.7 in Chapter 7). 
c.231C>G (p.Y77*) 
c.249_252delGTCT (p.I85Sfs) 
c.292del (p.R98fs) 
317ins5 
c.378G>A (p.W126*) 
c.406del (p.D136fs) 
c.446-1G>A (p.?) 
c.461G>T (p.S154I) 
c.478G>C (p.A160P) 
c.490G>C (p.A164P) 
c.590C>T (p.T197I) 
c.628_631delACAG (p.T210Sfs) 
c.738_741delACAG 
c.784-9G>A (p.?) 
c.784-15_784-14delTC 
c.1243C>T (p.R415*) 
c.1328C>A (p.S443Y) 
c.1350+1_1350+11delGTGAGGGACAG (p.?) 
c.1452delG 
c.1546dupC (p.Arg516Profs) 
1657insC 
Table 8.1: List of MEN1 mutations identified in the study population 
 
MEN1mut PAs characterisation and comparative subanalysis by PA type 
In the MEN1mut PA cohort, PAs were the most frequent first MEN1-related manifestation (58.8%), 
followed by PHPT (27.5%) and pNET (13.7%); PHPT and pNETs were the most common second and 
third manifestations respectively (Table 8.2).  
Main MEN1-related 
manifestations 
First MEN1 
manifestation 
Second MEN1 
manifestation 
Third MEN1 
manifestation  
PA 
PHPT 
pNET 
30 (58.8%) 
14 (27.5%) 
7 (13.7%) 
[n=51] 
11 (35.5%) 
12 (38.7%) 
8 (25.8%) 
[n=31] 
7 (43.7%) 
1 (6.3%) 
8 (50.0%) 
[n=16] 
Table 8.2: Main MEN1-related manifestations order of onset in patients with MEN1mut PAs 
Categorical data are shown as n (%). In square brackets is indicated the number of cases where data was 
available. MEN1, multiple endocrine neoplasia type 1; PHPT, primary hyperparathyroidism; PA, pituitary 
adenoma; pNET, pancreatic neuroendocrine tumour. 
 
The mean age at PA diagnosis was lower in patients with PA only than in patients with PA and 
additional MEN1-related manifestations (Figure 8.3).  
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Figure 8.3: Age at PA diagnosis among 70 MEN1 patients with PAs according to different combination of 
MEN1 manifestations  
Data are shown as mean±SD. MEN1mut, MEN1 mutation-positive; PA, pituitary adenoma; PHPT, primary 
hyperparathyroidism; pNET, pancreatic neuroendocrine tumour; yr, years. 
 
Male:female ratio was 1:1.12 with a mean age at first symptoms and at diagnosis of PA of 
21.6±11.7 and 29.6±16.6yr respectively. There were no cases of apoplexy among MEN1mut PA 
patients, and the rates of hypopituitarism at diagnosis, macroadenoma, extrasellar/suprasellar 
extension and cavernous sinus invasion were 21, 42, 29 and 27% respectively. MEN1mut PAs 
required a relatively low number of treatments and surgeries, radiotherapy was used in 13%, and 
only 3% were active at last follow-up (Table 8.3). 
 MEN1mut vs AIPmut PAs 
MEN1mut 
n=70 
AIPmut 
n=167 
p value 
Clinical diagnosis 
Acromegaly 
Gigantism 
NFPA 
Prolactinoma 
 
8 (11.4%) 
1 (1.4%) 
20 (28.6%) 
41 (58.6%) 
[n=70] 
 
60 (35.9%) 
76 (45.5%) 
14 (8.4%) 
17 (10.2%) 
[n=167] 
 
<0.001 
GH excess 9 (12.9%) 
[n=70] 
136 (81.4%) 
[n=167] 
<0.001 
Gender 
Male 
Female 
 
33 (47.1%) 
37 (52.9%) 
[n=70] 
 
102 (61.1%) 
65 (38.9%) 
[n=167] 
 
0.048 
Age at disease onset ≤ 18 yr 13 (44.8%) 
[n=29] 
94 (64.8%) 
[n=145] 
0.043 
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Age at first symptoms (yr) 21.6 ± 11.7 
[n=29] 
19.0 ± 9.5 
[n=139] 
0.420 
Age at diagnosis (yr) 29.6 ± 16.6 
[n=51] 
24.3 ± 11.9 
[n=160] 
0.063 
Delay in diagnosis (yr) 2.0 ± 2.7 
[n=138] 
4.1 ± 6.6 
[n=138] 
0.097 
Prospective diagnosis 7 (10.6%) 
[n=66] 
22 (13.2%) 
[n=167] 
0.593 
Pituitary apoplexy 0 
[n=57] 
12 (8.2%) 
[n=146] 
0.026 
Hypopituitarism at diagnosis 12 (21.4%) 
[n=56] 
32 (42.7%) 
[n=75] 
0.011 
Number of pituitary deficiencies at diagnosis 0.34 ± 0.77 
[n=56] 
0.84 ± 1.11 
[n=75] 
0.006 
Macroadenoma 25 (42.4%) 
[n=59] 
124 (83.2%) 
[n=149] 
<0.001 
Maximum tumour diameter (mm) 14.6 ± 15.0 
[n=39] 
20.1 ± 13.0 
[n=74] 
0.005 
Extrasellar extension 14 (28.6%) 
[n=49] 
60 (66.7%) 
[n=90] 
<0.001 
Suprasellar extension 14 (28.6%) 
[n=49] 
44 (54.3%) 
[n=81] 
0.004 
Cavernous sinus invasion 13 (26.5%) 
[n=49] 
29 (36.7%) 
[n=79] 
0.233 
Number of treatments 1.01 ± 0.95 
[n=67] 
2.07 ± 1.66 
[n=160] 
<0.001 
Number of surgeries 0.21 ± 0.45 
[n=67] 
0.93 ± 0.79 
[n=162] 
<0.001 
Re-operation 1 (7.7%) 
[n=13] 
27 (23.1%) 
[n=117] 
0.201 
Radiotherapy 9 (13.4%) 
[n=67] 
53 (32.9%) 
[n=161] 
0.003 
Multimodal treatment 14 (30.4%) 
[n=46] 
90 (67.2%) 
[n=134] 
<0.001 
≥ 3 treatments 4 (8.7%) 
[n=46] 
54 (40.3%) 
[n=134] 
<0.001 
Active disease at last follow-up 2 (4.7%) 
[n=43] 
31 (25.0%) 
[n=124] 
0.004 
Hypopituitarism at last follow-up 14 (25.9%) 
[n=54] 
16 (29.6%) 
[n=54] 
0.667 
Number of pituitary deficiencies at last 
follow-up 
0.60 ± 1.34 
[n=5] 
0.45 ± 0.96 
[n=49] 
0.984 
Follow-up duration (yr) 10.7 ± 10.0 
[n=40] 
11.2 ± 12.3 
[n=128] 
0.480 
Table 8.3: Comparative analysis between MEN1mut vs AIPmut PAs 
Categorical data are shown as n(%); continuous variables are shown as mean±SD. In square brackets is 
indicated the number of cases where data was available regarding each specific parameter/variable. 
AIPmut, AIP mutation-positive; GH, growth hormone; MEN1mut, MEN1 mutation-positive; PA, pituitary 
adenoma; yr, years. 
 
Within our MEN1mut PA subgroup, 41 (58.6%) patients had prolactinomas, 20 (28.6%) had NFPAs 
and 9 (12.8%) had somatotrophinomas. Demographic, clinical, treatment and disease outcome 
parameters, as well as a comparative analysis by PA type among MEN1mut PA patients, are shown 
in the Table 8.4. MEN1mut prolactinomas were diagnosed on average 14 and 5 years earlier than 
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NFPAs and somatotrophinomas (p=0.026), with a tendency for higher rates of hypopituitarism at 
diagnosis than MEN1mut NFPAs or somatotrophinomas (30.3 vs 5.9 vs 16.7%; p=0.131). MEN1mut 
prolactinomas occurred more in females (63.5%), in contrast to MEN1mut somatotrophinomas 
(45%) and MEN1mut NFPAs (22.2%) both more predominant in males (p=0.057). MEN1mut 
prolactinomas when compared to NFPAs and somatotrophinomas were larger (21.8±17.1 vs 
5.0±3.6 vs 13.0±11.2mm; p=0.003) and had higher rates of cavernous sinus invasion (41.4 vs 6.2 
vs 0%; p=0.017). MEN1mut prolactinomas required less frequently multimodal treatment than 
NFPAs and somatotrophinomas (17.6 vs 60 vs 71.4%; p=0.006). MEN1mut NFPAs were diagnosed 
at older ages, were smaller and predominantly microadenomas, and required fewer treatments 
(0.4±0.8) than both MEN1mut prolactinomas (1.2±0.8) and MEN1mut somatotrophinomas 
(1.7±1.3). MEN1mut somatotrophinomas required more often multimodal treatment (p=0.006) 
than MEN1mut prolactinomas and MEN1mut NFPAs (Table 8.4). 
 MEN1mut 
prolactinomas 
n=41 
MEN1mut 
NFPAs 
n=20 
MEN1mut 
somatotrophinomas 
n=9 
p value 
Gender 
Male 
Female 
 
15 (36.6%) 
26 (63.4%) 
[n=41] 
 
11 (55.0%) 
9 (45.0%) 
[n=20] 
 
7 (77.8%) 
2 (22.2%) 
[n=9] 
 
0.057*a 
Age at disease onset ≤ 18 yr 12 (52.2%) 
[n=23] 
0 
[n=2] 
1 (25.0%) 
[n=4] 
0.251 
Age at first symptoms (yr) 18.9 ± 8.2 
[n=23] 
53.5 ± 5.0 
[n=2] 
21.8 ± 6.9 
[n=4] 
<0.001*b 
Age at diagnosis (yr) 24.9 ± 15.4 
[n=29] 
38.9 ± 17.9 
[n=15] 
29.6 ± 10.9 
[n=7] 
0.026*c 
Delay in diagnosis (yr) 1.6 ± 2.2 
[n=22] 
4.0 
[n=1] 
4.0 ± 4.3 
[n=4] 
0.183 
Prospective diagnosis 5 (13.2%) 
[n=38] 
2 (10.5%) 
[n=19] 
0 
[n=9] 
0.515 
Pituitary apoplexy 0 
[n=33] 
0 
[n=16] 
0 
[n=8] 
1.000 
Hypopituitarism at diagnosis 10 (30.3%) 
[n=33] 
1 (5.9%) 
[n=17] 
1 (16.7%) 
[n=6] 
0.131*c 
Number of pituitary 
deficiencies at diagnosis 
0.52 ± 0.94 
[n=33] 
0.06 ± 0.24 
[n=17] 
0.17 ± 0.41 
[n=6] 
0.117 
Macroadenoma 19 (54.3%) 
[n=35] 
2 (11.8%) 
[n=17] 
4 (57.1%) 
[n=7] 
0.010*b 
Maximum tumour diameter 
(mm) 
21.8 ± 17.1 
[n=20] 
5.0 ± 3.6 
[n=14] 
13.0 ± 11.2 
[n=5] 
0.003*c 
Extrasellar extension 11 (37.9%) 
[n=29] 
2 (12.5%) 
[n=16] 
1 (25.0%) 
[n=4] 
0.193 
Suprasellar extension 11 (37.9%) 
[n=29] 
2 (12.5%) 
[n=16] 
1 (25.0%) 
[n=4] 
0.193 
Cavernous sinus invasion 12 (41.4%) 
[n=29] 
1 (6.2%) 
[n=16] 
0 
[n=4] 
0.017*c 
Number of treatments 1.18 ± 0.77 
[n=38] 
0.40 ± 0.75 
[n=20] 
1.67 ± 1.32 
[n=9] 
<0.001*b 
Number of surgeries 0.16 ± 0.44 
[n=38] 
0.20 ± 0.41 
[n=20] 
0.44 ± 0.53 
[n=9] 
0.223 
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Re-operation 1 (20.0%) 
[n=5] 
0 
[n=4] 
0 
[n=4] 
0.420 
Radiotherapy 5 (13.2%) 
[n=38] 
1 (5.0%) 
[n=20] 
3 (33.3%) 
[n=9] 
0.117*d 
Multimodal treatment 6 (17.6%) 
[n=34] 
3 (60.0%) 
[n=5] 
5 (71.4%) 
[n=7] 
0.006*e 
≥ 3 treatments 2 (5.9%) 
[n=34] 
0 
[n=5] 
2 (28.6%) 
[n=7] 
0.117 
Active disease at last  
follow-up 
2 (8.3%) 
[n=24] 
0 
[n=14] 
0 
[n=5] 
0.436 
Hypopituitarism at last 
follow-up 
9 (28.1%) 
[n=32] 
2 (12.5%) 
[n=16] 
3 (50.0%) 
[n=6] 
0.183 
Follow-up duration (yr) 10.9 ± 9.0 
[n=20] 
9.0 ± 10.8 
[n=14] 
14.0 ± 12.2 
[n=6] 
0.599 
Table 8.4: Comparative analysis by subtype among MEN1mut PAs 
Categorical data are shown as n(%); continuous variables are shown as mean±SD. In square brackets is 
indicated the number of cases where data was available regarding each specific parameter. *a p<0.05 only 
between prolactinomas and somatotrophinomas. *b p<0.05 between NFPAs and both prolactinomas and 
somatotrophinomas, but no differences between prolactinoma and somatotrophinomas. *c p<0.05 only 
between prolactinomas and NFPAs. *d p<0.05 only between somatotrophinomas and NFPAs. *e p<0.05 
between prolactinomas and both NFPAs and somatotrophinomas, but no differences between NFPAs and 
somatotrophinomas. NFPA, non-functioning pituitary adenoma; yr, years. 
 
AIPmut PAs characterisation and comparative subanalysis by PA type 
Out of 167 AIPmut PA patients, 102 were males (male:female ratio 1.57:1) and 94 had disease 
onset ≤18yr with a mean age at first symptoms and at diagnosis of 19.0±9.5 and 24.3±11.9yr 
respectively. Twelve AIPmut PA patients suffered apoplexy, 43% had hypopituitarism at diagnosis, 
83% had a macroadenoma, and the rates of extrasellar, suprasellar extension and cavernous sinus 
invasion were 67, 54 and 37% respectively. AIPmut PAs required a relatively high number of 
treatments and surgeries (2.07±1.66 and 0.93±0.79 respectively), multimodal therapy was given 
in 67%, radiotherapy in 33%, and the rate of active disease at last follow-up was 25% (Table 8.3).  
Within the AIPmut PA subgroup, 136 (81.4%) patients had somatotrophinomas, 17 (10.2%) had 
prolactinomas and 14 (8.4%) had NFPAs. Demographic, clinical, treatment and disease outcome 
parameters, as well as a comparative analysis by PA type among AIPmut PA patients, are shown 
in the Table 8.5. AIPmut somatotrophinomas had lower ages at first symptoms and at diagnosis, 
and also required more frequently multimodal (p=0.003) and multiple treatments (p=0.005) than 
AIPmut prolactinomas (but not AIPmut NFPAs). AIPmut somatotrophinomas when compared to 
both NFPAs and prolactinomas were associated to higher rates of extrasellar extension (p=0.002), 
and required more treatments (p<0.001), surgeries (p<0.001) and radiotherapy (p=0.003). AIPmut 
NFPAs had significantly less hypopituitarism at diagnosis, lower rates of macroadenomas and were 
smaller than AIPmut somatotrophinomas (p=0.035, p<0.001 and p=0.002) but did not differ from 
AIPmut prolactinomas (Table 8.5). 
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 AIPmut 
prolactinomas 
n=17 
AIPmut 
NFPAs 
n=14 
AIPmut 
somatotrophinomas 
n=136 
p value 
Gender      Male 
                   Female 
9 (52.9%) 
8 (47.1%) 
[n=17] 
9 (64.3%) 
5 (35.7%) 
[n=14] 
84 (61.8%) 
52 (38.2%) 
[n=136] 
0.755 
Age at disease onset ≤ 18 yr 5 (45.5%) 
[n=11] 
4 (50.0%) 
[n=8] 
85 (67.5%) 
[n=126] 
0.227 
Age at first symptoms (yr) 27.5 ± 17.9 
[n=10] 
22.6 ± 7.7 
[n=7] 
18.1 ± 8.4 
[n=122] 
0.006*a 
Age at diagnosis (yr) 30.7 ± 16.5 
[n=15] 
29.2 ± 14.8 
[n=12] 
23.2 ± 10.8 
[n=133] 
0.022*a 
Delay in diagnosis (yr) 4.5 ± 8.8 
[n=11] 
1.14 ± 2.3 
[n=7] 
4.3 ± 6.5 
[n=120] 
0.469 
Prospective diagnosis 2 (11.8%) 
[n=17] 
10 (71.4%) 
[n=14] 
10 (7.4%) 
[n=136] 
<0.001*b 
Pituitary apoplexy 2 (16.7%) 
[n=12] 
0 
[n=13] 
10 (8.3%) 
[n=121] 
0.317 
Hypopituitarism at diagnosis 5 (62.5%) 
[n=8] 
1 (9.1%) 
[n=11] 
26 (46.4%) 
[n=56] 
0.035*b 
Number of pituitary deficiencies 
at diagnosis 
1.38 ± 1.51 
[n=8] 
0.18 ± 0.60 
[n=11] 
0.89 ± 1.12 
[n=56] 
0.060 
Macroadenoma 12 (75.0%) 
[n=16] 
4 (30.8%) 
[n=13] 
108 (90.0%) 
[n=120] 
<0.001*b 
Maximum tumour diameter 
(mm) 
14.4 ± 16.1 
[n=7] 
9.0 ± 9.8 
[n=11] 
23.0 ± 11.9 
[n=56] 
0.002*c 
Extrasellar extension 4 (44.4%) 
[n=9] 
3 (27.3%) 
[n=11] 
53 (75.7%) 
[n=70] 
0.002*d 
Suprasellar extension 3 (42.9%) 
[n=7] 
3 (27.3%) 
[n=11] 
38 (60.3%) 
[n=63] 
0.104*c 
Cavernous sinus invasion 1 (16.7%) 
[n=6] 
2 (18.2%) 
[n=11] 
26 (41.9%) 
[n=62] 
0.183 
Number of treatments 1.12 ± 0.78 
[n=17] 
0.46 ± 0.78 
[n=13] 
2.35 ± 1.68 
[n=130] 
<0.001*d 
Number of surgeries 0.35 ± 0.49 
[n=17] 
0.31 ± 0.48 
[n=13] 
1.06 ± 0.78 
[n=132] 
<0.001*d 
Re-operation 0 
[n=6] 
0 
[n=4] 
27 (25.2%) 
[n=107] 
0.194 
Radiotherapy 1 (5.9%) 
[n=17] 
1 (7.7%) 
[n=13] 
51 (38.9%) 
[n=131] 
0.003*d 
Multimodal treatment 4 (28.6%) 
[n=14] 
2 (50.0%) 
[n=4] 
84 (72.4%) 
[n=116] 
0.003*a 
≥ 3 treatments 4 (28.6%) 
[n=14] 
2 (50.0%) 
[n=4] 
84 (72.4%) 
[n=116] 
0.005*a 
Active disease at last follow-up 2 (15.4%) 
[n=13] 
1 (10.0%) 
[n=10] 
28 (27.7%) 
[n=101] 
0.326 
Hypopituitarism at last follow-up 2 (25.0%) 
[n=8] 
1 (10.0%) 
[n=10] 
13 (36.1%) 
[n=36] 
0.265 
Number of pituitary deficiencies 
at last follow-up 
0.75 ± 1.49 
[n=8] 
0.10 ± 0.32 
[n=10] 
0.48 ± 0.93 
[n=31] 
0.348 
Follow-up duration (yr) 13.6 ± 12.5 
[n=13] 
7.5 ± 7.1 
[n=12] 
11.4 ± 12.8 
[n=103] 
0.453 
Table 8.5: Comparative analysis by subtype among AIPmut PAs 
Categorical data are shown as n(%); continuous variables are shown as mean±SD. In square brackets is 
indicated the number of cases where data was available regarding each specific parameter. *a p<0.05 only 
between prolactinomas and somatotrophinomas. *b p<0.05 between NFPAs and both prolactinomas and 
somatotrophinomas, but no differences between prolactinomas and somatotrophinomas. *c p<0.05 only 
between somatotrophinomas and NFPAs. *d p<0.05 between somatotrophinomas and both prolactinomas 
and NFPAs, but no differences between prolactinomas and NFPAs.  
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Comparative analysis MEN1mut vs AIPmut PAs 
MEN1mut PAs were less often associated with GH excess (12.9% vs 81.4%; p<0.001) with 
prolactinoma being the predominant diagnosis (58.6%), in contrast to the AIPmut PA subgroup 
where gigantism and acromegaly (45.5 and 35.9% respectively) were the most frequent diagnoses 
(Table 8.3). In comparison to patients with AIPmut PAs, MEN1mut PA patients were more 
frequently females (52.9% vs 38.9%; p=0.048), had less commonly disease onset ≤18yr (44.8% vs 
64.8%; p=0.043) and a trend for older age at diagnosis (29.6±16.6 vs 24.3±11.9yr; p=0.063). 
MEN1mut PAs had also lower rates of hypopituitarism at diagnosis (21.4% vs 42.7%; p=0.011), 
macroadenomas (42.4% vs 83.2%; p<0.001), extrasellar extension (28.6% vs 66.7%; p<0.001), 
suprasellar extension (28.6% vs 54.3%; p=0.004), as well as fewer pituitary deficits (0.3±0.8 vs 
0.8±1.1; p=0.006) and smaller tumours (14.6±15.0 vs 20.1±13.0mm; p=0.005) at diagnosis, and 
none had pituitary apoplexy (vs 8.2%; p=0.026).  
MEN1mut PA patients required fewer treatments (1.01±0.95 vs 2.07±1.66; p<0.001) and surgeries 
(0.21±0.45 vs 0.93±0.79; p<0.001), less often radiotherapy (13.4% vs 32.9%; p=0.003) and 
multimodal treatment (30.4% vs 67.2%; p<0.001), and a smaller proportion were active at last 
follow-up (4.7% vs 25%; p=0.004) in comparison to AIPmut PAs (Table 8.3). 
Taking into account the significant differences in terms of clinical diagnoses distribution among 
MEN1mut and AIPmut PAs, a comparative subanalysis per PA subtypes was then conducted (Table 
8.6 and Table 8.7).  
In comparison to AIPmut prolactinomas, MEN1mut prolactinomas had lower rate of pituitary 
apoplexy (0 vs 16.7%; p=0.016), and a tendency for older ages at onset (27.5±17.9 vs 18.9±8.2yr; 
p=0.158), lower rates of macroadenoma (54.3% vs 75%; p=0.160) and hypopituitarism at diagnosis 
(30.3% vs 62.5%; p=0.090) with fewer pituitary deficiencies (0.5±0.9 vs 1.4±1.51; p=0.066). 
MEN1mut prolactinomas also tended to require fewer surgeries than AIPmut prolactinomas 
(0.16±0.44 vs 0.35±0.49; p=0.072) (Table 8.6).  
MEN1mut NFPA features, treatment and outcome parameters did not differ from AIPmut NFPAs, 
except for higher age at first symptoms (53.5±5.0 vs 22.6±7.7yr; p=0.040) and tendency for smaller 
tumours (5.0±3.6 vs 9.0±9.8mm; p=0.126) among MEN1mut NFPAs. Both MEN1mut and AIPmut 
NFPAs had relatively low rates of hypopituitarism at diagnosis (5.9% and 9.1%), macroadenoma 
(11.8% and 30.8%), extrasellar/suprasellar extension (12.5% and 27.3%), cavernous sinus invasion 
(6.2% and 18.2%), low number of treatments (0.4±0.8 and 0.5±0.8) and surgeries (0.2±0.4 and 
0.3±0.5), and low rates of active disease (0 and 10%) and hypopituitarism at last-follow-up (12.5% 
and 10%) (Table 8.6).  
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 Prolactinomas NFPAs 
MEN1mut 
n=41 
AIPmut 
n=17 
p 
value 
MEN1mut 
n=20 
AIPmut 
n=14 
p 
value 
Gender        Male 
                     Female 
15 (36.6%) 
26 (63.4%) 
[n=41] 
9 (52.9%) 
8 (47.1%) 
[n=17] 
0.250 11 (55.0%) 
9 (45.0%) 
[n=20] 
9 (64.3%) 
5 (35.7%) 
[n=14] 
0.588 
Age at disease onset ≤ 18 yr 12 (52.2%) 
[n=23] 
5 (45.5%) 
[n=11] 
0.714 2 (100.0%) 
[n=2] 
4 (50.0%) 
[n=8] 
0.197 
Age at first symptoms (yr) 18.9 ± 8.2 
[n=23] 
27.5 ± 17.9 
[n=10] 
0.158 53.5 ± 5.0 
[n=2] 
22.6 ± 7.7 
[n=7] 
0.040 
Age at diagnosis (yr) 24.9 ± 15.4 
[n=29] 
30.7 ± 16.5 
[n=15] 
0.244 38.9 ± 17.9 
[n=15] 
29.2 ± 14.8 
[n=12] 
0.136 
Delay in diagnosis (yr) 1.6 ± 2.2 
[n=22] 
4.5 ± 8.8 
[n=11] 
0.773 4.0 
[n=1] 
1.1 ± 2.3 
[n=7] 
0.211 
Pituitary apoplexy 0 (0%) 
[n=33] 
2 (16.7%) 
[n=12] 
0.016 0 
[n=16] 
0 
[n=13] 
1.000 
Hypopituitarism at diagnosis 10 (30.3%) 
[n=33] 
5 (62.5%) 
[n=8] 
0.090 1 (5.9%) 
[n=17] 
1 (9.1%) 
[n=11] 
0.747 
Number of pituitary 
deficiencies at diagnosis 
0.52 ± 0.94 
[n=33] 
1.38 ± 1.51 
[n=8] 
0.066 0.06 ± 0.24 
[n=17] 
0.18 ± 0.60 
[n=11] 
0.712 
Macroadenoma 19 (54.3%) 
[n=35] 
12 (75.0%) 
[n=16] 
0.160 2 (11.8%) 
[n=17] 
4 (30.8%) 
[n=13] 
0.197 
Maximum tumour diameter 
(mm) 
21.8 ± 17.1 
[n=20] 
14.4 ± 16.1 
[n=7] 
0.375 5.0 ± 3.6 
[n=14] 
9.0 ± 9.8 
[n=11] 
0.126 
Extrasellar extension 11 (37.9%) 
[n=29] 
4 (44.4%) 
[n=9] 
0.727 2 (12.5%) 
[n=16] 
3 (27.3%) 
[n=11] 
0.332 
Suprasellar extension 11 (37.9%) 
[n=29] 
3 (42.9%) 
[n=7] 
0.810 2 (12.5%) 
[n=16] 
3 (27.3%) 
[n=11] 
0.332 
Cavernous sinus invasion 12 (41.4%) 
[n=29] 
1 (16.7%) 
[n=6] 
0.254 1 (6.2%) 
[n=16] 
2 (18.2%) 
[n=11] 
0.332 
Number of treatments 1.18 ± 0.77 
[n=38] 
1.12 ± 0.78 
[n=17] 
0.804 0.40 ± 0.75 
[n=20] 
0.46 ± 0.78 
[n=13] 
0.759 
Number of surgeries 0.16 ± 0.44 
[n=38] 
0.35 ± 0.49 
[n=17] 
0.072 0.20 ± 0.41 
[n=20] 
0.31 ± 0.48 
[n=13] 
0.487 
Re-operation 1 (20.0%) 
[n=5] 
0 
[n=6] 
0.251 0 
[n=4] 
0 
[n=4] 
1.000 
Radiotherapy 5 (13.2%) 
[n=38] 
1 (5.9%) 
[n=17] 
0.424 1 (5.0%) 
[n=20] 
1 (7.7%) 
[n=13] 
0.751 
Dopamine agonists 31 (81.6%) 
[n=38] 
12 (70.6%) 
[n=17] 
0.362 3 (15.0%) 
[n=20] 
1 (7.7%) 
[n=13] 
0.530 
Multimodal treatment 6 (17.6%) 
[n=34] 
4 (28.6%) 
[n=14] 
0.397 3 (60.0%) 
[n=5] 
2 (50.0%) 
[n=4] 
0.764 
≥ 3 treatments 2 (5.9%) 
[n=34] 
1 (7.1%) 
[n=14] 
0.907 0 
[n=5] 
0 
[n=4] 
1.000 
Active disease at last  
follow-up 
2 (8.3%) 
[n=24] 
2 (15.4%) 
[n=13] 
0.510 0 
[n=14] 
1 (10.0%) 
[n=10] 
0.227 
Hypopituitarism at last 
follow-up 
9 (28.1%) 
[n=32] 
2 (25.0%) 
[n=8] 
0.859 2 (12.5%) 
[n=16] 
1 (10.0%) 
[n=10] 
0.846 
Number of pituitary 
deficiencies at last follow-up 
0 
[n=3] 
0.75 ± 1.49 
[n=8] 
0.364 0 
[n=1] 
0.10 ± 0.31 
[n=10] 
0.752 
Follow-up duration (yr) 10.9 ± 9.0 
[n=20] 
13.6 ± 12.5 
[n=13] 
0.671 9.0 ± 10.8 
[n=14] 
7.5 ± 7.1 
[n=12] 
0.959 
Table 8.6: Comparison between MEN1mut vs AIPmut prolactinomas and MEN1mut vs AIPmut NFPAs 
Categorical data are shown as n(%); continuous variables are shown as mean±SD. In square brackets is 
indicated the number of cases where data was available regarding each specific parameter. AIPmut, AIP 
mutation-positive; MEN1mut, MEN1 mutation-positive; NFPA, non-functioning pituitary adenoma; yr, 
years. 
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AIPmut somatotrophinoma patients were commonly diagnosed with gigantism (55.9%), whereas 
only 1 out of 9 MEN1mut somatotrophinoma patients had gigantism (p=0.052). In comparison to 
AIPmut somatotrophinomas, MEN1mut somatotrophinomas had lower rates of macroadenoma 
(57.1% vs 90%; p=0.009) and extrasellar extension (25% vs 75.7%; p=0.026), and required fewer 
surgeries (0.4±0.5 vs 1.1±0.8; p=0.009). MEN1mut somatotrophinomas also showed a tendency 
for less cavernous sinus invasion (0 vs 41.9%; p=0.096), and none were active at last follow-up (vs 
27.7% in AIPmut somatotrophinoma subgroup; p=0.170) (Table 8.7). 
 
 MEN1mut 
somatotrophinomas 
n=9 
AIPmut 
somatotrophinomas 
n=136 
p value 
Gender     Male 
                  Female 
7 (77.8%) 
2 (22.2%) 
[n=9] 
84 (61.8%) 
52 (38.2%) 
[n=136] 
0.336 
Age at disease onset ≤ 18 yr 1 (25.0%) 
[n=4] 
85 (67.5%) 
[n=126] 
0.077 
Age at first symptoms (yr) 21.8 ± 7.0 
[n=4] 
18.1 ± 8.4 
[n=122] 
0.291 
Age at diagnosis (yr) 29.6 ± 10.9 
[n=7] 
23.2 ± 10.8 
[n=133] 
0.101 
Delay in diagnosis (yr) 4.0 ± 4.3 
[n=4] 
4.3 ± 6.5 
[n=120] 
0.708 
Gigantism 1 (11.1%) 
[n=9] 
76 (55.9%) 
[n=136] 
0.052 
Pituitary apoplexy 0 
[n=8] 
10 (8.3%) 
[n=121] 
0.397 
Height at diagnosis (cm) 172.0 ± 6.1 
[n=4] 
181.5 ± 19.1 
[n=103] 
0.221 
Hypopituitarism at diagnosis 1 (16.7%) 
[n=6] 
26 (46.4%) 
[n=56] 
0.162 
Number of pituitary deficiencies 
at diagnosis 
0.17 ± 0.41 
[n=6] 
0.89 ± 1.12 
[n=56] 
0.125 
Macroadenoma 4 (57.1%) 
[n=7] 
108 (90.0%) 
[n=120] 
0.009 
Maximum tumour diameter (mm) 13.0 ± 11.2 
[n=5] 
23.0 ± 11.9 
[n=56] 
0.123 
Extrasellar extension 1 (25.0%) 
[n=4] 
53 (75.7%) 
[n=70] 
0.026 
Suprasellar extension 1 (25.0%) 
[n=4] 
38 (60.3%) 
[n=63] 
0.165 
Cavernous sinus invasion 0 
[n=4] 
26 (41.9%) 
[n=62] 
0.096 
Number of treatments 1.67 ± 1.32 
[n=9] 
2.35 ± 1.68 
[n=130] 
0.252 
Number of surgeries 0.44 ± 0.53 
[n=9] 
1.06 ± 0.78 
[n=132] 
0.009 
Re-operation 0 
[n=4] 
27 (25.2%) 
[n=107] 
0.248 
Radiotherapy 3 (33.3%) 
[n=9] 
51 (38.9%) 
[n=131] 
0.739 
Somatostatin analogues 3 (33.3%) 
[n=9] 
59 (45.4%) 
[n=130] 
0.482 
Dopamine agonists 5 (55.6%) 
[n=9] 
31 (23.8%) 
[n=130] 
0.036 
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Pegvisomant 0 
[n=9] 
14 (10.8%) 
[n=130] 
0.299 
Multimodal treatment 5 (71.4%) 
[n=7] 
84 (72.4%) 
[n=116] 
0.955 
≥ 3 treatments 2 (28.6%) 
[n=7] 
53 (45.7%) 
[n=116] 
0.376 
Active disease at last follow-up 0 
[n=5] 
28 (27.7%) 
[n=101] 
0.170 
Hypopituitarism at last follow-up 3 (50.0%) 
[n=6] 
13 (36.1%) 
[n=36] 
0.517 
Number of pituitary deficiencies 
at last follow-up 
3.00 
[n=1] 
0.48 ± 0.93 
[n=31] 
0.047 
Final height (cm) 177.0 ± 13.3 
[n=4] 
185.9 ± 18.3 
[n=95] 
0.290 
Follow-up duration (yr) 14.0 ± 12.2 
[n=6] 
11.4 ± 12.8 
[n=103] 
0.296 
Table 8.7: Comparative analysis between MEN1mut vs AIPmut somatotrophinomas 
Categorical data are shown as n(%); continuous variables are shown as mean±SD. In square brackets is 
indicated the number of cases where data was available regarding each specific parameter. AIPmut, AIP 
mutation-positive; MEN1mut, MEN1 mutation-positive; ULN, upper limit of the normal; yr, years. 
 
 
Discussion 
In this study, I analysed a cohort of patients with two distinct familial forms of PAs aiming to 
expand the current knowledge on AIPmut and MEN1mut PAs and to provide the first detailed 
comparative analysis between AIPmut and MEN1mut PAs, in general and by PA type.  
 
PAs are common in MEN1 and often the first MEN1-related manifestation 
PA was the most prevalent manifestation in my MEN1 cohort, seen in 70.7% of the MEN1mut 
individuals, notably higher than previously reported (30-40%98,99,102). PAs were also the most 
frequent first manifestation in MEN1mut PA patients (58.8%), contrarily to previous series 
reporting PHPT as the predominant first manifestation99,101,102,745,753. On the other hand, the 
prevalence of PHPT in our cohort (66.7%) was lower than the previously reported incidences of 
approximately 90%98,102,103,746; however, a recent MEN1 series focused in PAs described a similarly 
low PHPT prevalence of 68.5%101. This relatively high PA prevalence and low PHPT prevalence, as 
well as the high frequency of PA as first MEN1 manifestation, may reflect a referral bias to the 
International FIPA Consortium study which is focused on PAs. Additionally, it may also be 
explained by the fact that some MEN1 manifestations (namely PHPT) may not yet penetrated in 
my relatively young cohort of MEN1 patients (mean current age 42.2yr) particularly in those 
affected only with PAs (mean current age 29.9yr). This might also explain the relatively low 
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proportion of MEN1 patients with combined PA+PHPT+pNET in my study (35.4%) when compared 
to other series101,103,746,754. The mean age at PA diagnosis in my MEN1mut cohort (29.6±16.6yr) 
was relatively lower than reported by most series, usually describing age at diagnosis well above 
the age of 30102,103,746, and some above 40754 or even 50 years101. The mean age at PA diagnosis 
was lower in the subgroup of MEN1 affected only with PAs. Hence, suspicion for MEN1 should be 
raised in young patients presenting with isolated PAs (often the first MEN1 manifestation), and 
thus genetic analysis of MEN1 should be offered to young patients with sporadic PAs110 particularly 
the AIPneg ones. 
 
MEN1-related PAs occur more in females and are often prolactinomas, in contrast with AIPmut 
PAs which affect mostly males and are somatotrophinomas 
We observed a higher proportion of females among the MEN1mut PA group, namely among 
MEN1mut prolactinomas, in line with previous studies101-103,755. The explanation for female 
predomi-nance in MEN1 is unknown, although it has been postulated that oestrogens may exert 
a stimulus for cell proliferation leading to pituitary tumourigenesis103,105 taking into account the 
well-known stimulatory effects of oestrogens on pituitary lactotroph secretion and 
proliferation106,107. In contrast, AIPmut PAs occur predominantly in males consistent with previous 
reports156,161,187, although this male predominance might be influenced by an ascertainment bias 
for gigantism, a condition more prevalent in men in part due to later puberty and later growth 
cessation19,196.  
Diagnosis among MEN1mut and AIPmut PA patients differed significantly, with the former group 
composed mainly by prolactinomas (58.6%), while 81.4% of AIPmut patients had a somatotrophi-
noma (45.5% gigantism; 35.9% acromegaly), in line with previous reports91,102,103,161,169,746.  
Hence, such differences regarding gender and clinical diagnoses between patients with MEN1mut 
and AIPmut PAs may guide clinicians deciding which gene test first in young patients with isolated 
PAs: a young female presenting with isolated prolactinoma may be a candidate for MEN1 genetic 
analysis first, whereas AIP should be first tested in a young male with gigantism/acromegaly. 
 
MEN1mut PAs are not particularly aggressive and can be controlled with conventional therapy 
Within my cohort of patients with MEN1mut PAs, 42% had macroadenomas, 29% had extrasellar 
and suprasellar extension, 27% had cavernous sinus invasion, and they required a relatively low 
number of treatments and surgeries, with 97% having cured/controlled disease at last follow-up. 
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My findings do not support the increased aggressiveness recognised of MEN1mut PAs and are 
divergent from previous series reporting higher rates of macroadenomas up to 85% (vs 42% in 
non-MEN1 PAs)103, higher rates of cavernous sinus invasion up to 31.3% (vs 14% in non-MEN1 
PAs)109 or less frequent normalisation of pituitary hypersecretion of about 42% (vs 90% in non-
MEN1 PAs)103 in patients with MEN1mut PAs. However, similar to my findings, some other studies 
also debate the previous notion of increased aggressiveness to MEN1mut PAs reporting lower 
rates of macroadenomas (18.5-37.1%)99,101,746 with high dopamine agonist response rate of >90% 
in patients with MEN1mut prolactinomas99. Ki-67 and mitotic count were not higher in MEN1mut 
PAs in comparison to sporadic PAs109, and MEN1mut non-functioning microadenomas have an 
indolent behaviour, do not progress to macroadenomas and most often require no treatment99,101.  
 
AIPmut PAs are more aggressive than MEN1mut PAs, with somatotrophinomas imposing most 
of the management challenges  
AIPmut PAs were remarkably more aggressive than MEN1mut PAs, showing significantly higher 
rates of macroadenomas (larger tumour diameter), extrasellar extension, suprasellar extension, 
hypopituitarism at diagnosis (more pituitary deficiencies) and apoplexy. Moreover, AIPmut PAs 
required significantly more treatments, surgeries, radiotherapy, multimodal treatment and a 
higher proportion of cases were active at last follow-up in comparison to MEN1mut PAs. 
Aggressive PAs and/or PAs with poor response to therapy should raise suspicion for an AIPmut 
particularly in young subjects with GH-secreting PAs and family history of PAs169. In AIPneg PA 
patients with aggressive or unresponsive to therapy, MEN1 analysis unlikely will identify mutation 
carriers, as shown in a recent study733. Thus, an individual-based approach focused on clinical 
elements should prevail for genetic screening of patients with aggressive and refractory PAs. 
Considering that clinical diagnoses differed between MEN1mut and AIPmut PAs, which may 
grossly explain their distinct clinical features and outcomes, I further conducted a comparative 
analysis per PA subtype within and between these subgroups.  
MEN1mut prolactinomas, diagnosed earlier than MEN1mut NFPAs and somatotrophinomas and 
predominantly in females, were larger, had higher rates of cavernous sinus invasion, and had a 
trend for higher rates of hypopituitarism at diagnosis and more extrasellar/suprasellar extension, 
displaying overall a more aggressive phenotype than MEN1mut NFPAs or MEN1mut 
somatotrophinomas. However, the management of MEN1mut somatotrophinomas was more 
challenging than MEN1mut prolactinomas requiring more often multimodal and ≥3 treatments, 
including surgeries, and a greater tendency for hypopituitarism at last follow-up despite the fact 
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that all MEN1mut somatotrophinoma cases were cured/controlled at last assessment. On the 
other hand, MEN1mut NFPAs were predominantly microadenomas, smaller and required fewer 
treatments than both MEN1mut prolactinomas and MEN1mut somatotrophinomas, thus being 
the most indolent MEN1mut PA subtype, in line with previous reports99,101.  
Within the AIPmut setting, somatotrophinomas was the most detrimental AIPmut PA subtype, 
displaying higher rates of extrasellar extension, cavernous sinus invasion and requiring more 
treatments, surgeries and radiotherapy than both AIPmut prolactinomas and AIPmut NFPAs; 
conversely, AIPmut NFPAs were the less detrimental AIPmut subtype. 
MEN1mut prolactinomas had lower rate of pituitary apoplexy and showed trend for lower rates 
of macroadenoma, hypopituitarism at diagnosis and for requiring fewer surgeries than AIPmut 
prolactinomas. These findings suggest that AIPmut prolactinomas may be more aggressive than 
MEN1mut prolactinomas, contrasting with the findings of increased dopamine agonists associated 
to MEN1 mutation status, but not with AIP mutations, recently shown in young patients with 
macroprolactinomas734. MEN1mut somatotrophinomas had less aggressive phenotype than 
AIPmut somatotrophinomas displaying lower rates of macroadenoma and extrasellar extension, 
required fewer surgeries, and a tendency for less hypopituitarism at diagnosis and less cavernous 
sinus invasion. MEN1mut and AIPmut NFPAs did not differ and both displayed an indolent 
behaviour and disease course, as previously shown for MEN1mut NFPAs99,101, as well as for AIPmut 
NFPAs (Chapter 7). In fact, some of these small NFPAs may represent prospectively-diagnosed 
pituitary incidentalomas similar to those often observed in the general population7,23.  
 
Main highlights from this study  
The comparative analysis MEN1mut vs AIPmut PAs highlights the following points: 1) different 
familial forms of PAs may be associated with different degrees of aggressiveness; 2) AIPmut PAs 
display, in general, a more aggressive phenotype and poorer clinical course than MEN1mut PAs; 
3) AIPmut prolactinomas and somatotrophinomas were associated with increased aggressiveness 
and poorer outcomes than MEN1mut prolactinomas and somatotrophinomas respectively; 4) 
both AIPmut and MEN1mut NFPAs had a indolent course of disease; 5) not all familial forms of 
PAs are inexorably aggressive, with some cases being particularly indolent (e.g. AIPmut and 
MEN1mut NFPAs) and responsive to treatment (e.g. MEN1mut prolactinomas and MEN1mut 
somatotrophinomas); 6) the PA subtype may be more determinant for the clinical course than the 
specific AIP or MEN1 gene mutation.  
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This study not only expands the knowledge and characterisation of these 2 rare familial forms of 
PAs, but provides, for the first time, a comparison between MEN1mut and AIPmut PAs, in general 
and by PA subtype, which may be useful for redefinition of genetic screening guidance in patients 
with PAs. Firstly, my study show that a significant proportion (71%) of MEN1 patients may present 
a PA as first manifestation, needing differentiation from AIPmut FIPA patients, which raises the 
question of what gene analyse first, however many centres are currently offering genetic testing 
panels which include all, or at least the most relevant PA-predisposing genes such as AIP and 
MEN1. In fact, suspicion for MEN1 should be raised in young patients presenting with isolated PAs, 
and thus MEN1 genetic test should be offered even in the absence of syndromic manifestations. 
Secondly, the gender and clinical diagnosis differences among our young MEN1mut and AIPmut 
PA patients support that young females with isolated prolactinomas could be considered for 
MEN1 genetic testing in the first place, while young males with gigantism/acromegaly should be 
first tested for AIP mutations. Thirdly, PAs with aggressive behaviour and/or poor responsiveness 
to therapy may raise suspicion for a familial form, particularly for AIP-related disease, taking into 
account other clinical elements (such as age of onset, family history, GH excess and tumour 
size169). Our data also support the current recommendations for managing familial PAs in a similar 
manner as non-MEN1mut and non-AIPmut PAs23,170,171. In fact, not all MEN1mut and AIPmut PAs 
are aggressive, with some being particularly responsive to treatment such as MEN1mut 
prolactinomas while others have indolent disease course such as MEN1mut and AIPmut NFPAs, 
thus requiring an approach as recommended for patients with sporadic non-familial PAs. 
 
Limitations of this study 
There are some limitations associated with my study. Firstly, the study population was recruited 
from different countries as part of The International FIPA Consortium study, and thus patients’ 
characteristics and outcomes may be affected by their distinct genetic backgrounds and/or 
different local clinical practise. Secondly, the MEN1 cohort is most likely affected by a referral bias 
as clinicians more likely refer us MEN1 patients with PAs to our International multicentric pituitary 
study, as reflected by the relatively high PA and low PHPT proportions in my cohort. I indeed 
acknowledge that my MEN1 cohort may not represent the most typical setting of MEN1 patients, 
being more closely to a MEN1 setting from a dedicated pituitary centre; however, it does provide 
a unique population of MEN1 patients with predominant pituitary involvement ideal to specifically 
study PAs in MEN1. Thirdly, clinical and outcome data were not available for all the patients, 
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which, together with the relative small size of some subgroups, limited the statistical power of 
some of my comparative subanalysis.  
 
 
Conclusions 
MEN1mut and AIPmut PAs are different familial forms of PA with distinct genetic basis, clinical 
features, disease courses, outcomes and aggressiveness profile. AIPmut PAs are in general more 
aggressive than MEN1mut PAs, which are in turn probably not as aggressive as previously 
reported. Both AIPmut prolactinomas and AIPmut somatotrophinomas have more unfavourable 
course of disease and clinical outcomes than MEN1mut prolactinomas and MEN1mut 
somatotrophinomas. Not all AIPmut and MEN1mut PAs are inexorably aggressive and poorly 
responsive to therapy, particularly AIPmut and MEN1mut NFPAs which showed an indolent course 
of disease and often require no treatment, or MEN1mut prolactinomas and MEN1mut 
somatotrophinomas which may respond well to the conventional forms of treatment. 
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Chapter 9: General conclusions and future research directions 
 
The studies presented in this thesis aimed to understand the role of the different TME elements, 
including the cytokine network (Chapter 3), infiltrating immune cells (Chapter 3) and tumour-
associated fibroblasts (Chapter 4), in the clinical phenotype and aggressiveness of PAs, as well as 
in different TME-related tumourigenic mechanisms (Chapter 5). In general, the data from these 
studies support the concept that different cellular and non-cellular TME components may affect 
the biological behaviour, oncogenic mechanisms and aggressiveness of PAs; however, many 
questions remain still open and represent excellent avenues for future research. 
On the topic of familial PAs, particularly those due to germline AIP mutations, I developed a project 
exploring the role of AIP deficiency in the cytokine secretome of pituitary tumour (and non-
neoplastic) cells (Chapter 6), and a project studying the clinical phenotype and outcomes of 
patients with familial PAs. Specifically those due to mutations in the PA-predisposing genes AIP 
(Chapter 7) and MEN1 (Chapter 8). In general, my data suggest that AIP deficiency may not be 
determinant to the cytokine secretome, and does not affect the inhibitory effect of pasireotide in 
terms of cytokine release. From the clinical study, it is clear that the phenotypes of AIPmut and 
MEN1mut PAs are variable and heterogeneous, including highly aggressive cases, but also cases 
with indolent behaviour such as prospectively-diagnosed AIPmut PAs or MEN1mut NFPAs; my 
data also highlight the benefits of genetic screening of family members at risk for inheriting a PA-
predisposing gene mutation and the clinical assessment of mutation carriers. 
In the following paragraphs, I will summarise the main results from my research projects 
presented in this thesis, emphasising the novel findings as well as pointing out different aspects 
and questions that could be addressed in future studies. 
 
The role of the TME in the phenotype of PAs 
Pituitary tumour cell-derived chemokines recruit immune cells into the TME 
Using a 42-multiplex cytokine array, I comprehensively assessed the cytokine secretome from 
primary cultured pituitary tumour cells. My data suggest that pituitary tumour cells are an active 
source of chemokines, namely IL-8, CCL2, CCL3 and CCL4, which have not previously been 
described in PAs apart from IL-8232-234. PA-derived chemokines may facilitate the immune cell 
recruitment into the TME of PAs, as higher contents of PA-infiltrating macrophages, neutrophils 
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and CD8+ T cells correlated with higher chemokine levels. My in vitro functional data confirmed 
increased macrophage chemotaxis driven by pituitary tumour cell-derived factors. 
 
Infiltrating immune cells in the TME affect the biology and aggressiveness of PAs 
Immune cell infiltrates differ between PAs and NPs, with PAs displaying higher content of 
macrophages and CD4+ T cells and fewer neutrophils and CD8+ T cells. Moreover, the macrophage 
phenotype in PAs is primarily M2-like with a 3-fold increased M2:M1 macrophage ratio in PAs 
compared to NP. A higher content of the immunosuppressive FOXP3+ T cells per se, lower 
CD8:CD4 and CD8:FOXP3 ratios, and a deleterious immune cell phenotype (higher content of 
macrophages, T-helper lymphocytes, FOXP3+ T regulatory and B cells) were associated with 
increased tumour proliferation. My in vitro cell line data confirmed that macrophage secreted-
factors influence pituitary tumour cells, being able to induce morphological changes, cytokine 
secretome changes and EMT, as well as an increased invasion/migration from tumour cells.  
 
TAFs release cytokines which influence the phenotype and aggressiveness of PAs 
My data support the concept that TAFs are a component of the TME of PAs and can be isolated in 
vitro. They represent an important source of cytokines, with IL-6 and CCL2 emerging as key 
mediators for cavernous sinus invasion, proliferation and neovascularisation. My in vitro data 
confirm that TAF-derived factors, but not normal skin fibroblast factors, influence pituitary tumour 
cells, inducing morphological changes, increasing invasion and migration and activating EMT.  
 
Pasireotide inhibits the cytokine secretion from TAFs 
My data support the inhibitory effect of pasireotide on cytokine release from TAFs, particularly IL-
6 and CCL2, which may play a key role in its recognised anti-tumoural effects in patients with PAs. 
This pasireotide cytokine inhibitory effect is most likely mediated by SST1, the predominant SST 
in TAFs, in line with the findings reported in pancreatic cancer-associated fibroblasts385,391. 
 
Cytokine network and infiltrating immune cells in the TME modulate PA oncogenic mechanisms 
PA-derived cytokines (namely FGF-2 and IL-8) as well as TAF-derived cytokines (namely CCL2) may 
influence angiogenesis in PAs, although the modulatory effect of infiltrating immune cells in PA 
angiogenesis seems more prominent, with M2-macrophages, CD4+ T and FOXP3+ T cells emerging 
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as the most relevant immune cell types influencing neovascularisation and vessel morphology in 
PAs. Certain PA- and TAF-derived cytokines (CCL2, CCL4, FGF-2, IL-6, CXCL1), but not infiltrating 
immune cells, influence the expression of MMPs and NCAM in PAs, more remarkably in 
somatotrophinomas. In terms of EMT, my human data showed no association between PA-
infiltrating immune cells and E-cadherin or ZEB1 expression, as well as little influence from PA or 
TAF-derived factors in the expression of these EMT markers, supporting a lack or only a mild effect 
exerted by these cells in EMT modulation in PAs: the partial or incomplete EMT signature in PAs 
may explain, at least in part, some of these negative/unexpected findings. In contrast, in vitro 
macrophage-derived factors induced EMT in pituitary tumour cells. 
 
Avenues for future research 
The role of the main PA-derived chemokines CCL2 and IL-8 (as identified in my cytokine array 
study) could be further studied, particularly their effects in immune cell chemotaxis (macrophages 
and neutrophils essentially) and on tumour proliferation and invasion, as well as in other 
tumourigenic mechanisms such as in angiogenesis, EMT and ECM-remodelling, possibly using 
similar methods used in my research projects but in a larger cohort of cases.  
Attempting to further characterise the cellular components of TME of PAs, the immune cell types 
could be performed by immunohistochemical analysis, possibly combined with other laboratory 
techniques such as FACS sorting, magnetic beads for immune cell separation, in situ hybridization 
with RNAscope or gene-signature methodologies such as xCell, in a much larger cohort of PAs; 
other immune cell types could also be assessed such as NK cells, Th17 cells, dendritic cells and 
mast cells, among others. The phenotype of PA-infiltrating macrophages (M2 or M1 macrophages) 
could be further assessed, and possibly using double immunohistochemistry for CD68 and CD163 
or CD206 (marking M2-macrophages) and for CD68 and HLA-DR or iNOS (marking M1-
macrophages). Stromal cells such as TAFs (using a combination of markers such as FAP, vimentin, 
α-SMA, CD90) or pericytes (CD31 and α-SMA) could be characterised in the same cohort of cases, 
quantified in the tissue sections and then correlated with the amounts of PA-infiltrating immune 
cells, with angiogenesis, EMT activation or for instance with tumour fibrosis, cell proliferation or 
apoptosis. Correlation with clinical features including resistance to medical therapy could be 
assessed for both immune cell and stromal cell infiltrates among the same large cohort of PAs. 
The potential direct effects on pituitary tumour cells resulting from pasireotide’s inhibitory effect 
on TAF cytokine secretome requires further research. Studies assessing proliferation, migration, 
invasion, EMT, apoptosis in pituitary tumour cells (GH3 cells and primary PA cells) after exposure 
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to pasireotide vs untreated TAFs (eventually using simultaneously antibodies neutralising IL-6 or 
blocking IL-6 receptor), using CM or co-cultures, may prove that the benefits of pasireotide on PA 
cells depend on the TAF secretome, observed in my studies. Perhaps it would be better to conduct 
studies in rodents implanting pituitary tumourlets under different conditions (untreated vs 
pasireotide treated vs pasireotide treated plus IL-6 neutralising antibodies), as reported in 
previous studies investigating the pasireotide effect in pancreas cancer fibroblasts385,391. 
Functional in vitro experiments are needed to investigate some of the modulatory effects from 
factors derived from pituitary tumour cells, immune cells and TAFs in different tumourigenic 
mechanisms such as angiogenesis, EMT and ECM remodelling. To investigate the interactions 
between pituitary tumour cells and immune/stromal cells, in vitro functional studies using 3D 
culturing techniques and/or co-culture, where tumour cells are able to form cohesive structures 
with ECM deposition (more similar to TME) and are in more physiological contact with surrounding 
cells, would be more appropriate than the 2D culture methods that I have used in my research 
projects. In fact, in the studies I conducted in vitro cells are grown in a 2D environment in non-
physiological conditions (plastic growth surfaces, culture medium and lack of cell-cell contact in 
all directions) and do not entirely resemble the complex crosstalk between tumour cells and non-
neoplastic cells within the TME (acknowledging that the in vivo TME is nearly impossible to 
replicate in vitro), despite the fact that 2D culture methods are still widely used.  
A more physiological way to assess the crosstalk between pituitary tumour cells and surrounding 
TME non-neoplastic cells would be to innoculate into rodents tumourlets of pituitary tumour cells 
(primary PA cells and/or GH3 cells), either in isolation, combined with immune/stromal cells (e.g. 
macrophages or fibroblasts), or eventually after being co-cultured or treated with CM from some 
of these non-neoplastic cells. Tumourlets could be allowed to grow to verify the effects of 
immune/stromal cell-derived factors in terms of cell proliferation, with the animals eventually 
sacrificed to measure tumour size/weight, and to collect the tumourlet for further 
immunohistochemical studies assessing for instance Ki-67, EMT, MMPs expression, fibrosis, 
angiogenesis and apoptosis, among others. 
 
The role of AIP deficiency in the pituitary tumour cytokine secretome 
My cell line and primary cell culture cytokine data suggested overall a limited role for AIP in 
determining the cytokine secretome of pituitary tumour cells and fibroblasts. Indeed, my data 
suggest that AIP deficiency unlikely induce major stimulatory (or inhibitory) effects in the cytokine 
secretory function, at least under basal/unstimulated conditions. CX3CL1 first emerged from my 
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cytokine array and RT-qPCR data on GH3 cells as differentially secreted between GH3-Aip-KD vs 
GH3-NT cells, but other lines of evidence from my experiments and from available data from my 
laboratory does not support the suggestion that CX3CL1 expression and release is enhanced by 
AIP deficiency. CCL2 would be a possible chemokine differentially secreted between AIPmut and 
AIPneg, and the AIP-induced overexpression of FLI-1 could be the underlying mechanism by which 
CCL2 and also CCL5513 expression would be increased in AIPmut pituitary tumour cells.  
AIP deficiency seems to create no resistance to (and possibly enhances) the inhibitory effect  of 
pasireotide in terms of cytokine release, at least in fibroblasts, in contrast to the well-known 
reduced effectiveness of pasireotide in inhibiting GH secretion in AIPmut somatotrophinomas. 
 
Avenues for future research 
From my data, CCL2 appears an interesting candidate to explain why AIPmut PAs have increased 
amount of macrophages than AIPneg PAs513, as well as why AIPmut are in general more aggressive 
and refractory to treatment19. The role of AIP deficiency in the expression of CCL2 could be then 
further investigated using similar in vitro studies, as well as immunohistochemical studies (or 
RNAscope) in human AIPmut and AIPneg somatotrophinoma tissue sections, likewise the studies 
recently conducted from Dr. Barry to investigate CCL5 in AIPmut vs AIPneg PAs. Further cytokine 
arrays could be done in supernatants from other cell types (e.g. mouse-embryonic fibroblasts or 
HEK293 cells) after knocking down and/or overexpressing AIP and compare to the respective wild-
type; cytokines differentially secreted could be further validated with RT-qPCR, Western blotting 
or by ELISA, and by immunohistochemistry or RNAscope in human PA samples. Cytokine arrays 
could also be done on supernatants after stimulation for instance with TNF-α, IFN-γ or IGF-1 to 
assess the role of AIP deficiency in the cytokine secretome under stimulatory circumstances. 
 
Phenotype of AIPmut and MEN1mut familial PAs and the benefits of genetic/clinical screening 
In this study, I analysed a large cohort of patients with familial and young-onset PAs, of whom 167 
had germline AIP mutations and 70 had MEN1 mutations, aiming to expand the current knowledge 
on characteristics and outcomes of familial forms of PAs, but at the same time greatly focusing on 
the prospectively-diagnosed AIPmut PAs as a characterisation of this particular group, crucial to 
assess the potential benefits of genetic screening for AIP mutations, is lacking.  
My study allowed some interesting observations, some of them not previously reported in the 
literature: i) AIPmut PAs were in general more aggressive and refractory to conventional therapy, 
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requiring more complex and multimodal management approaches; however AIP-related pituitary 
disease can be controlled in a significant proportion of cases; ii) AIPmut somatotrophinomas 
present earlier, are more aggressive and require more often radiotherapy, with patients ending 
up taller than those with AIPneg somatotrophinomas; iii) AIPmut prolactinomas present more 
often with apoplexy, but are not necessarily more invasive or refractory to conventional therapy, 
in comparison with AIPneg prolactinomas; iv) AIPmut NFPAs may display an indolent course of 
disease and have similar features and clinical outcomes (or even more favourable) than AIPneg 
NFPAs, highlighting that the clinical phenotypic spectrum of AIP-related pituitary disease is wider 
than previously reported, including also indolent and non-aggressive PAs sometimes requiring no 
treatment at all; v) prospectively-diagnosed AIPmut PAs are less aggressive and have better 
outcomes than clinically-presenting PAs, highlighting the benefits of genetic analysis and clinical 
screening of AIPmut carriers; vi) PAs are common in MEN1 and are often the first MEN1-related 
manifestation; vii) MEN1mut PAs affect more frequently females and are often prolactinomas, 
contrasting with AIPmut PAs which occur more in males and are usually somatotrophinomas; viii) 
MEN1mut PAs are not particularly aggressive and can be controlled with conventional therapy, 
contrasting with the previous notion that MEN1mut PAs was more aggressive and refractory to 
therapy; ix) MEN1mut NFPAs display indolent behaviour and little invasiveness, as the AIPmut 
NFPAs; x) AIPmut PAs are in general more aggressive than MEN1mut PAs, but not all familial PA 
forms are inexorably aggressive, with some cases being indolent (AIPmut and MEN1mut NFPAs) 
and responding well to treatment (MEN1mut prolactinomas and MEN1mut somatotrophinomas). 
 
Avenues for future research 
Much data are now available regarding the characteristics of AIPmut and MEN1mut PAs, and this 
study expands the phenotypic spectrum of these 2 familial forms of PAs and illustrate the benefits 
of genetic and clinical screening in particular for AIPmut carriers. Probably future studies (clinical 
and experimental in vitro studies) should focus in the AIP (and MEN1) variants of uncertain 
significance in order to clarify their role in the pathogenesis of PAs. This is definitely an important 
direction of future research as it will allow clinicians to better advise their PA patients carrying a 
variant of uncertain significance as to whether that variant indeed caused the PA and whether 
family members need to be genetically tested and mutation carriers clinically assessed. Confirming 
the lack pathogenicity from some of these variants will spare the psychological distress and 
unnecessary assessment of patients’ relatives, as well as will limit the economic burden associated 
with unneeded medical, clinical, genetic, biochemical and imaging assessments in this setting. 
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Appendix 1: Supplemental tables with genes with altered expression in 
sporadic pituitary adenomas, and the corresponding literature references 
 
 
Oncogene Normal function Altered function in PAs / PA 
types 
References 
AKT1 Regulation of metabolism, differentiation, 
growth, proliferation and angiogenesis 
Increased expression 
Various PA types, mainly NFPAs 
Musat et al 20051 
AKT2 Regulation of metabolism, differentiation, 
growth, proliferation and angiogenesis 
Increased expression 
Various PA types 
Musat et al 20051 
BAG1 Inhibits chaperone activity of 
HSP70/HSC70 and the pro-apoptotic 
function of PPP1R15A 
Increased expression 
Various PA types 
Morris et al 20052 
BMI1 Repress the transcription of many genes Increased expression; genetic 
amplification in PAs 
Various PA types 
Sanchez-Beato et al 20063 
Palumbo et al 20134 
Westerman et al 20125 
CCNA1  
(cyclin A1) 
Regulation of G1-S and G2-M phases of 
the cell cycle 
Increased expression 
Various PA types 
Turner et al 20006 
Nakabayashi et al 20017 
CCNB1  
(cyclin B1) 
Regulation of G2-M transition of the cell 
cycle 
Increased expression 
Various PA types 
Turner et al 20006 
Wierinckx et al 20078 
CCNB2  
(cyclin B2) 
Regulation of G2-M transition of the cell 
cycle 
Increased expression 
Various PA types 
De Martino et al 20099 
 
CCND1  
(cyclin D1) 
Progression through G1-S phase of the cell 
cycle 
Increased expression 
Somatotrophinomas and NFPAs 
Hibberts et al 199910 
Jordan et al 200011 
Turner et al 20006 
Simpson et al 200112 
CCNE1  
(cyclin E1) 
Progression through the G1-S phase of the 
cell cycle 
Increased expression 
Mainly corticotrophinomas 
Jordan et al  200011 
Turner et al 20006 
COPS5 Involved in different cellular and 
developmental processes 
Increased expression 
Pituitary carcinomas 
Korbonits et al 200213 
CREB Transcriptional activator of CREs, 
regulating differentiation and 
proliferation 
Constitutive activation by 
phosphorylation in 
somatotrophinomas 
Bertherat et al 199514 
DNMT3 Mediator of epigenetic control by histone 
modifications of gene expression  
Increased expression 
Various PA types 
Zhu et al 200815 
EGFR Transmembrane glycoprotein needed for 
cell proliferation, survival and 
differentiation  
Increased expression 
NFPAs, mainly aggressive PAs 
Chaidarun et al 199416 
ERα Mediates the actions of estrogens  Increased expression 
Prolactinomas 
Delgrange et al 201517 
EZH2 Regulation of the cell cycle Increased expression 
Various PA types 
Schult et al 201518 
FGF2 Regulation of cell survival, proliferation, 
differentiation, migration and 
angiogenesis 
Increased expression 
Various PA types 
McCabe et al 200319 
FGF4 Membrane-anchored receptor for FGF Increased expression of a N-
terminally truncated cytoplasmic 
form by alternative transcription  
Various PA types 
Jackson et al 200620 
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FGFR1/ 
FGFR2 
FGFR4 
Involved in cell proliferation Increased expression 
Various PA types 
McCabe et al 200319 
Zhu et al 200721 
Ezzat et al 200222 
FOLR1 Binds to folate, reduces folic acid 
derivatives and mediates delivery of 5-
methyltetra-hydrofolate to the interior of 
cells 
Increased expression in NFPAs,  
Decreased expression in PRL- and 
GH-secreting PAs 
Evans et al 200123 
GHRH Stimulates GH secretion Increased expression 
Somatotrophinomas 
Thapar et al 199724 
GLI1 Involved in the Hedgehog signalling; its 
activation induce stem cell proliferation 
and pituitary hormone release 
Increased expression. 
ACTH-, GH- and PRL-secreting PAs 
Lampichler et al  201525 
GNAI2 Inhibition of adenylate cyclase and 
calcium influx 
Gain-of-function somatic 
mutations 
Various PAs types 
Williamson et al 199426 
Williamson et al 199527 
GNAS1 Stimulatory G protein α-subunit that 
activates adenylate cyclase 
Gain-of-function somatic 
mutations; loss of imprinting 
Cause 40% of sporadic GH-
secreting PAs 
Vallar et al 198728 
Landis et al  198929 
Tordjman et al 199330 
Williamson et al 199426 
HMGA1/ 
HMGA2 
Regulation of growth and development Amplification and overexpression 
Various PAs types 
De Martino et al 20099 
Finelli et al 200231 
HRAS Regulation of cell division in response to 
growth factors stimulation 
Gain-of-function somatic 
mutations 
Invasive prolactinomas/NFPAs 
and pituitary carcinomas 
Karga et al 199232 
Cai et al 199433 
Pei et al 199434 
hTERT Plays a role in cellular senescence, causing 
progressive shortening of telomeres 
Increased activating methylation 
of the promoter 
Kochling et al 201635 
IKZF1 Important function in the hematopoietic 
and immune systems 
Dominant-negative truncated 
isoform 
Ezzat et al 200336 
LAPTM4B Involved in the lysosome homeostasis, 
acidification and function 
Increased expression 
NFPAs and corticotrophinomas 
Morris et al  20052 
LGALS3 
(Galectin-3) 
Mediation of cell migration, adhesion, 
cell-to-cell interaction and apoptosis 
inhibition 
Increased expression 
Various PA types, mainly 
aggressive PAs 
Riss et al 200337 
MAGEA3 May play a role in embryonal 
development and tumour transformation 
or progression 
Increased expression by 
promoter hypomethylation and 
histone acetylation in association 
with FGFR2-downregulation 
Various PA types 
Zhu et al 200838 
MERTK  Receptor-TK involved in signal 
transduction from extracellular matrix 
into the cytoplasm 
Increased expression in 
corticotrophinomas 
Decreased expression in 
prolactinomas 
Evans et al 200123 
MST4 Involved in cellular responses to hypoxic 
environments 
Increased expression 
NFPA 
Xiong et al 201539 
MYO5A Involved in tumour cell migration, 
invasion and metastasis  
Increased expression 
NFPAs, mainly aggressive PAs 
Galland et al 201040 
OCD1 Catalyzes the decarboxylation of ornithine 
to form putrescine 
Increased expression in 
somatotrophinomas, and 
decreased in corticotrophinomas 
Evans et al 200123 
PIK3CA Regulation of proliferation, cell survival, 
migration and cell trafficking 
Gain-of-function somatic 
mutations and amplification 
Various PA types 
Lin et al 200941 
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PITX2 Involved in the Wnt/Dvl/β-catenin 
pathway 
Increased expression 
NFPA 
Acunzo et al 201142 
POU1F1 
(PIT1) 
Transcription factor involved in the 
differentiation of the anterior pituitary 
Increased expression 
Various PA types 
Palmieri et al 201243 
PRKCA  
(PKCα) 
Kinase that participates in growth factor 
and hormone signalling and cell 
proliferation 
Overexpression, gain-of-function 
somatic mutations 
NFPAs 
Alvaro et al 199344 
PTTG1 Cell cycle regulation and cell senescence Increased expression 
Corticotrophinomas and NFPAs 
Zhang et al 199945 
McCabe et al 200319 
Morris et al 20052 
PTTG1IP Facilitates nuclear translocation of PTTG1 
and potentiates transcriptional activation 
of FGF2 by PTTG1 
Increased expression 
NFPAs 
McCabe et al 200319 
RSUME RSUME increase the levels of HIF-1α, which 
is the most important transcription factor 
of cellular adaptive processes to hypoxic 
conditions 
Increased expression 
Various PA types 
Shan et al 201246 
SHH Hedgehog signalling activation induce the 
stem cell proliferation and hormone 
release in the pituitary 
Increased expression 
ACTH-, GH- and PRL-secreting PAs 
Vila et al 200547 
STAT3 Participates in cellular responses to 
cytokines and growth factors 
Decreased expression 
GH-secreting PAs 
Zhou et al 201548 
TGFα Competes with EGF for binding to EGFR 
producing a mitogenic response 
Increased expression 
Prolactinomas 
Ezzat et al 199549 
 
Genes with increased expression involved in pathogenesis of sporadic pituitary adenomas 
CREs, cAMP response elements; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; 
EMT, epithelial-mesenchymal transition; FGF, fibroblast growth factor; GH, growth hormone; LOH, loss of 
heterozygosity; NFPAs, non-functioning pituitary adenomas; PAs, pituitary adenomas; PRL, prolactin; TK, 
tyrosine kinase. Adapted from Marques & Korbonits (2017)50. 
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Tumour 
suppressor 
gene 
Normal function Altered function in PAs / PAs types References 
AIP Co-chaperone protein Decreased expression 
Somatotrophinomas 
Kasuki et al 201151 
Kasuki et al 201252 
BMP4 Regulation of differentiation and 
proliferation of pituitary cells 
Downregulated due to histone 
modification 
Prolactinomas 
Paez-Pereda et al 200353 
CABLES1 Regulation of proliferation and/or 
cell differentiation 
Decreased expression 
Corticotrophinomas 
Roussel-Gervais et al 
201654 
CDH1 Encodes E-cadherin involved in cell 
adhesion and inhibits EMT 
Decreased expression by promoter 
methylation 
Various PA types 
Qian et al 200755 
CDH13 Encodes H-cadherin involved in cell 
adhesion and inhibits EMT 
Decreased expression by promoter 
methylation 
Various PA types 
Qian et al 200755 
CDKN1A 
(p21) 
Regulation of the cell cycle 
progression at G1 
Decreased expression in NFPAs; 
increased expression in GH-secreting PAs 
Neto et al 200556 
CDKN1B 
(p27) 
Blocks cell cycle at G0-G1 phase Reduced expression 
Various PA types, mainly 
corticotrophinomas and carcinomas 
Qian et al 199657 
Lloyd et al 199758 
Jin et al 199759 
Bamberger et al 199960 
CDKN2A 
(p16) 
Induces cell cycle arrest in G1-G2 
phases 
Reduced expression 
Various PA types, mainly NFPAs 
Woloschak et al 199661 
Jaffrain-Rea et al 199962 
Korbonits et al 200213 
CDKN2B 
(p15) 
Induces cell cycle arrest at G1 phase Reduced expression 
Various PA types 
Ogino et al 200563 
Yoshino et al 200764 
CDKN2C 
(p18) 
Induces cell cycle arrest at G1 phase Reduced expression 
Various PA types 
Morris et al 20052 
Hossain et al 200965 
DAPK Positive mediator of programmed 
cell death 
Decreased expression either by 
promoter methylation or by homozygous 
deletion of promoter CpG island 
Various PA types, mainly aggressive PAs 
Simpson et al 200266 
Bello et al 200667 
DKC1 Modification of rRNA and regulation 
of telomerase activity 
Loss-of-function somatic mutation 
NFPAs 
Bellodi et al 201068 
DRD2 Dopamine G protein-coupled 
receptor 
Decreased expression 
Prolactinomas 
Caccavelli et al 199469 
FOLR1 Binds to folate, reduces folic acid 
derivatives and mediates delivery of 
5-methyltetrahydrofolate to the cell 
interior 
Increased expression in NFPA, 
Decreased expression in PRL- and GH-
secreting PAs 
Evans et al 200123 
GADD45-β Regulation of growth and apoptosis Decreased expression 
NFPAs 
Michaelis et al 201170 
GADD45-γ Regulation of growth and apoptosis Decreased expression by promoter 
methylation 
NFPAs, PRL- and GH-secreting PAs 
Zhang et al 200271 
Bahar et al 200472 
GH-R Transmembrane receptor that 
mediates GH action 
Loss-of-function somatic mutation 
Somatotrophinomas 
Asa et al 200773 
HDAC2 Enzyme that deacetylates of lysine 
residues on core histones 
Loss-of-function 
Corticotrophinomas 
Bilodeau et al 200674 
MEG3 Induces apoptosis and inhibits 
tumoural cell proliferation 
Decreased expression by promoter 
methylation 
NFPAs 
Zhang et al 200271 
Zhang et al 200375 
Zhao et al 200576 
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MEN1 Transcriptional regulator involved in 
the cell proliferation control 
Somatic mutations or deletions or 
decreased expression 
Various PA types 
Zhuang et al 199777 
Tanaka et al 199878 
Wenbin et al 199979 
MERTK Receptor-TK involved in signal 
transduction from extracellular 
matrix into the cytoplasm 
Expression increased in 
corticotrophinomas and decreased in 
prolactinomas 
Evans et al 200123 
MGMT Involved in DNA repair and cell cycle 
regulation 
Decreased expression by promoter 
methylation 
Various PA types 
Lau et al 201080 
NM23 Downregulate cyclin B and prevent 
the cell cycle progression 
Decreased expression due to allelic loss 
Various PA types, mainly aggressive PAs 
Takino et al 199581 
NR3C1 Nuclear receptor for glucocorticoids Loss-of-function somatic mutations, LOH 
Corticotrophinomas 
Karl et al 199682 
Huizenga et al 199883 
OCD1 Catalyzes the decarboxylation of 
ornithine to form putrescine 
Expression increased in 
somatotrophinomas and decreased 
in corticotrophinomas 
Evans et al 200123 
PLAGL1 
(ZAC1) 
Zinc finger transcription factor that 
plays a role in pituitary 
development, differentiation and 
tumourigenesis 
Decreased expression 
NFPAs 
Pagotto et al 200084 
Noh et al 200985 
RASSF1/ 
RASSF3 
Ras association domain family 
member-1/3, acting as p53 
activator 
Decreased expression by promoter 
methylation 
Various PA types 
Qian et al 200586 
RB1 
(pRB) 
Key regulator of cell division Decreased expression 
Aggressive PAs 
Simpson et al 200087 
Ogino et al 200563 
Yoshino et al 200664 
RHBDD3 
(PTAG) 
Pro-apoptotic mediator Decreased expression 
Various PA types 
Bahar et al 200472 
RPRM Downstream effector of p53-
induced cell cycle arrest at G2/M 
Decreased expression 
Various PA types 
Xu et al 201288 
SMARCA4 
(BRG1) 
Regulation of gene transcription by 
altering the chromatin structure 
Decreased expression, altered 
subcellular localization 
Corticotrophinomas 
Bilodeau et al 200674 
SOCS1 Inhibitor of JAK/STAT pathway Decreased expression by promoter 
methylation. Various PA types 
Buslei et al 200689 
SSTR2 G protein-coupled receptor for 
somatostatin 
Decreased expression 
Somatotrophinomas 
Corbetta et al 200190 
THRB 
(TRβ) 
Nuclear receptor that mediates 
gene regulation by thyroid 
hormones 
Loss-of-function somatic mutations or 
aberrant splicing 
Thyrotrophinomas 
Ando et al 200191 
TP53 Regulation of cell cycle, acting 
negatively in the cell division 
Loss-of-function somatic mutations 
Various PA types, mainly aggressive PAs 
Tanizaki et al 200792 
Kawashima et al 200993 
Pinto et al 201194 
WEE1 Regulation of cell cycle progression Decreased expression 
NFPAs and GH-secreting PAs 
Butz et al 201095 
WIF1 Binds Wnt proteins and inhibits 
their activities 
Decreased expression by promoter 
methylation 
Various PA types, mainly NFPAs 
Elston et al 200896 
 
Genes with decreased expression involved in pathogenesis of sporadic pituitary adenomas 
CREs, cAMP response elements; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; 
EMT, epithelial-mesenchymal transition; FGF, fibroblast growth factor; GH, growth hormone; LOH, loss of 
heterozygosity; NFPAs, non-functioning pituitary adenomas; PAs, pituitary adenomas; PRL, prolactin; TK, 
tyrosine kinase. Adapted from Marques & Korbonits (2017)50. 
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Appendix 2: Supplemental table with primary antibodies and respective 
dilutions used for immunohistochemical (IHC) and immunofluorescence (IF) 
studies 
 
Primary 
Antibodies 
Company Cat. no. Species Dilution 
IHC 
Dilution IF 
Actin Molecular Probes R37110 Mouse  2 drops/mL (1:500) 
α-SMA Sigma-Aldrich A5228 Mouse  1:500 
CD4 Abcam Ab133616 Rabbit 1:100  
CD8 DAKO M7103 Mouse 1:100  
CD20 DAKO M0755 Mouse 1:300  
CD31 DAKO M0823 Mouse 1:100  
CD68 DAKO IR613 Mouse 1:2  
CD163 Abcam Ab74604 Mouse Neat  
E-cadherin BD Biosciences 610181 Mouse 1:50 1:50 
FOXP3 Abcam Ab20034 [236A/E7] Mouse 1:50  
HLA-DR Abcam Ab20181 [TAL1B5] Mouse 1:100  
MMP-9 Abcam Ab38898 Rabbit 1:50  
MMP-14 Abcam Ab3644 Rabbit 1:30  
NCAM Roche 760-4596 Rabbit Neat  
Neutrophil elastase Abcam Ab68672 Rabbit 1:100  
Vimentin Abcam Ab16700 Rabbit  1:1000 
Vimentin DAKO M7020 Mouse 1:1000  
ZEB1 Santa Cruz 
Biotechnology 
H-102: sc-25388 Rabbit 1:50 1:50 
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Appendix 3: Supplemental table with primers used in RT-qPCR experiments 
 
Gene Forward sequence 5’-3’ Reverse sequence 5’-3’ Amplicon 
length (bp) 
Species 
Adam10 GCTGGGAGGTCAGTATGGAAAT TCGTGTGAGACTGCTCGTTT 120 r 
Adam17 GCAAACAGTCATGGAGGGGT CCAGGTCAGCCTCCTTTGTAA 133 r 
Arg1 ACATTGGCTTGCGAGACGTA ATCACCTTGCCAATCCCCAG 109 m 
αSMA CCGGGACTAAGACGGGAATC TTGTCACACACCAAGGCAGT 80 h 
CCL2 TCAAACTGAAGCTCGCACTCT GGCATTGATTGCATCTGGC 121 h 
Ccl2 GTGCTGACCCCAATAAGGAA TGAGGTGGTTGTGGAAAAGA 185 r 
Ccl2 CACTCACCTGCTGCTACTCA GCTTGGTGACAAAAACTACAGC 117 m 
Ccl4 GCAACACCATGAAGCTCTGC AGAGCCCATTGGTGCTGAGA 92 m 
Ccl5 CCAATCTTGCAGTCGTGTTTGT AGAGCAAGCAATGACAGGGA 159 m 
Ccr5 GTATGTCAGCACCCTGCCAA GAGCAGGAAGAGCAGGTCAG 200 m,r 
Cd206 TGCCCTGAACAGCAACTTGA GTTAGTGTACCGCACCCTCC 70 m,r 
Cdh1 ACATCCTGGGCAGAGTGAAA CCGTTTGACTGTGATGACGC 113 r 
Cx3cl1 CCATCATCCTGGAGACGAGA TGTCACATTGTCCACACGCT 149 r 
Cx3cr1 CCATCTGCTCAGGACCTCAC CACCAGACCGAACGTGAAGA 165 m 
Cx3cr1 GGCATGAAGAGGGACCTGAG CCCCAGCGAAAGCGTAGATA 97 r 
Cxcl10 GAAATCATCCCTGCGAGCCT AGGAGCCCTTTTAGACCTTTTT 150 m 
Cxcl10 TGCAAGTCTATCCTGTCCGC TCTTTGGCTCACCGCTTTCA 121 r 
FAP GGCACGGTATTCAAAAGTCCG TACCCAAGTCTTCATTTTTCCAGA 172 h 
GAPDH TGCACCACCAACTGCTTAG GGATGCAGGGATGATGTTC 176 h,m,r 
Il1a GTCAACTCATTGGCGCTTGA GCTTGCATCATAGAAGGATTTCTGA 155 m,r 
Il1b GCAATGGTCGGGACATAGTT AGACCTGACTTGGCAGAGGA 158 r 
IL6 ACCCCCAATAAATATAGGACTGGA CGAAGGCGCTTGTGGAGAA 129 h 
IL8 AGTTTTTGAAGAGGGCTGAGAAT TTGCTTGAAGTTTCACTGGCATC 89 h 
Il18 CGCAGTAATACGGAGCATAAATGAC GGTAGACATCCTTCCATCCTTCAC 193 r 
Inos GCAGTCTTTTCCTATGGGG TGGAACTCTGGGCTGTCAGA 81 m 
Mmp9 CTTGAAGTCTCAGAAGGTGGATC CGCCAGAAGTATTTGTCATGG 145 r 
SST1 CACATTTCTCATGGGCTTCCT ACAAACACCATCACCACCATC 165 h 
SST2 GGCATGTTTGACTTTGTGGTG GTCTCATTCAGCCGGGATTT 185 h 
SST3 TGCCTTCTTTGGGCTCTACTT ATCCTCCTCCTCAGTCTTCTCC 190 h 
SST4 TGTGCTACCTGCTCATCGTG GCTGGTCACGAAGAGGTTCA 176 h 
SST5 CTGGTGTTTGCGGGATGTT GAAGCTCTGGCGGAAGTTGT 183 h 
Tnfa CCCACGTCGTAGCAAACCA ACAAGGTACAACCCATCGGC 133 m 
Vegf GTAACGATGAAGCCCTGGAGT TGTTCTGTCTTTCTTTGGTCTGC 156 m 
Vegf ATCATGCGGATCAAACCTCACC GGTCTGCATTCACATCTGCTATGC 80 r 
Zeb1 TGGGATGTACGCATGTGACC GGGGCCTCTTACCTGTATGC 92 r 
 
ADAM, A Disintegrin And Metalloproteinase domain; ARG1, arginase 1; αSMA, α-smooth muscle actin; bp, 
base pairs; CDH1, Cadherin 1 (E-cadherin); FAP, fibroblast activation protein; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; h, human; IL, interleukin; iNOS, inducible nitric oxide synthase; m, mouse; MMP, 
matrix metalloproteinase; r, rat; SST, somatostatin receptor; TNF α, tumour necrosis factor-α; VEGF, 
vascular endothelial growth factor; ZEB1, Zinc Finger E-Box Binding Homeobox 1. 
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Appendix 4: Supplemental table with correlation between clinico-
pathological and biochemical features and infiltrating immune cells among 
NFPAs and somatotrophinomas 
 
 
NFPAs  
n = 16 
% of infiltrating immune cells 
Macrophages CD8+ T cells CD4+ T cells FOXP3+ T cells Neutrophils 
Gender     [Mean±SEM] 
Male (n=12) 
Female (n=4) 
 
4.1 ± 0.6 
6.0 ± 0.7 
p=0.118 
 
1.5 ± 0.3 
2.1 ± 0.3 
p=0.268 
 
1.0 ± 0.2 
1.4 ± 0.2 
p=0.221 
 
0.3 ± 0.1 
0.7 ± 0.3 
p=0.174 
 
1.1 ± 0.3 
0.5 ± 0.3 
p=0.284 
Age at diagnosis (yrs)  
[Pearson correlation r (p value)] 
0.247 (p=0.357) -0.169 (p=0.531) -0.378 (p=0.149) -0.480 (p=0.060) -0.075 (p=0.782) 
Headache at diagnosis   
[Mean±SEM] 
Yes (n=5) 
No (n=11) 
 
 
4.2 ± 0.9 
4.7 ± 0.7 
p=0.652 
 
 
1.4 ± 0.2 
1.7 ± 0.3 
p=0.586 
 
 
1.0 ± 0.1 
1.1 ± 0.2 
p=0.466 
 
 
0.4 ± 0.2 
0.4 ± 0.1 
p=0.933 
 
 
0.7 ± 0.3 
1.0 ± 0.3 
p=0.584 
Visual impairment   [Mean±SEM] 
Yes (n=12) 
No (n=4) 
 
4.2 ± 0.7 
5.7 ± 0.9 
p=0.231 
 
1.5 ± 0.3 
2.0 ± 0.3 
p=0.362 
 
1.1 ± 0.2 
1.1 ± 0.2 
p=0.845 
 
0.3 ± 0.1 
0.6 ± 0.3 
p=0.169 
 
0.9 ± 0.3 
1.0 ± 0.3 
p=0.916 
Hormonal data at diagnosis  
[Pearson correlation r (p value)] 
Serum GH 
Serum IGF-1 
IGF-1 index 
Serum PRL 
PRL index 
Serum TSH 
Serum FT4 
Basal plasma cortisol 
Serum LH 
Serum FSH 
 
 
-0.067 (p=0.837) 
-0.102 (p=0.729) 
-0.186 (p=0.523) 
0.286 (p=0.321) 
-0.047 (p=0.873) 
0.264 (p=0.363) 
-0.190 (p=0.515) 
-0.149 (p=0.628) 
0.065 (p=0.826) 
-0.023 (p=0.937) 
 
 
0.009 (p=0.979) 
-0.310 (p=0.281) 
-0.499 (p=0.069) 
0.142 (p=0.628) 
-0.084 (p=0.774) 
-0.123 (p=0.674) 
-0.114 (p=0.698) 
0.016 (p=0.960) 
0.294 (p=0.308) 
-0.327 (p=0.299) 
 
 
0.081 (p=0.803) 
-0.062 (p=0.832) 
-0.464 (p=0.095) 
0.244 (p=0.401) 
0.028 (p=0.924) 
-0.191 (p=0.514) 
-0.075 (p=0.800) 
-0.011 (p=0.972) 
0.119 (p=0.685) 
-0.018 (p=0.950) 
 
 
0.308 (p=0.330) 
0.151 (p=0.606) 
0.064 (p=0.827) 
0.440 (p=0.115) 
0.279 (p=0.334) 
0.383 (p=0.177) 
-0.091 (p=0.757) 
0.535 (p=0.060) 
0.180 (p=0.539) 
0.027 (p=0.928) 
 
 
0.046 (p=0.888) 
-0.154 (p=0.600) 
-0.582 (p=0.029) 
-0.187 (p=0.522) 
-0.270 (p=0.351) 
-0.232 (p=0.425) 
-0.160 (p=0.585) 
0.096 (p=0.749) 
-0.061 (p=0.835) 
-0.326 (p=0.256) 
Hypopituitarism at diagnosis  
[Mean±SEM] 
Yes (n=9) 
No (n=7) 
 
 
4.8 ± 0.8 
4.2 ± 0.7 
p=0.619 
 
 
1.5 ± 0.2 
1.7 ± 0.5 
p=0.635 
 
 
1.1 ± 0.2 
1.1 ± 0.2 
p=0.987 
 
 
0.4 ± 0.1 
0.4 ± 0.1 
p=0.992 
 
 
0.8 ± 0.2 
1.1 ± 0.4 
p=0.460 
N pit deficiencies at diagnosis  
[Pearson correlation r (p value)] 
0.097 (p=0.722) -0.138 (p=0.609) -0.156 (p=0.564) -0.092 (p=0.735) -0.318 (p=0.230) 
Cavernous sinus invasion   
[Mean±SEM] 
Yes (n=6) 
No (n=10)  
 
 
4.5 ± 1.0 
4.6 ± 0.7 
p=0.999 
 
 
1.3 ± 0.3 
1.8 ± 0.4 
p=0.402 
 
 
0.9 ± 0.1 
1.2 ± 0.2 
p=0.187 
 
 
0.3 ± 0.1 
0.4 ± 0.1 
p=0.745 
 
 
0.7 ± 0.1 
1.1 ± 0.3 
p=0.326 
Ki-67   [Mean±SEM] 
< 3% (n=12) 
≥ 3% (n=4) 
 
4.3 ± 0.6 
5.3 ± 1.4 
p=0.459 
 
1.6 ± 0.3 
1.6 ± 0.5 
p=0.969 
 
1.0 ± 0.2 
1.3 ± 0.3 
p=0.483 
 
0.3 ± 0.1 
0.7 ± 0.3 
p=0.163 
 
1.0 ± 0.2 
0.7 ± 0.3 
p=0.554 
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Hypopituitarism last follow-up   
[Mean±SEM] 
Yes (n=10) 
No (n=6) 
 
 
4.8 ± 0.8 
4.2 ± 0.7 
p=0.619 
 
 
1.7 ± 0.2 
1.5 ± 0.5 
p=0.763 
 
 
1.1 ± 0.2 
1.0 ± 0.2 
p=0.579 
 
 
0.4 ± 0.1 
0.4 ± 0.1 
p=0.911 
 
 
0.8 ± 0.2 
1.2 ± 0.4 
p=0.395 
N pit deficiencies at last follow-up  
[Pearson correlation r (p value)] 
0.035 (p=0.897) -0.146 (p=0.589) -0.051 (p=0.851) -0.214 (p=0.426) -0.370 (p=0.158) 
Microvessel density  
[Pearson correlation r (p value)] 
0.339 (p=0.199) 0.169 (p=0.483) 0.342 (p=0.195) -0.138 (p=0.611) -0.142 (p=0.601) 
Microvessel area  
[Pearson correlation r (p value)] 
0.159 (p=0.557) 0.222 (p=0.409) 0.330 (p=0.211) -0.109 (p=0.689) -0.274 (p=0.305) 
Correlation between clinico-pathological and biochemical features and infiltrating immune cells among 
NFPAs 
FSH, follicle-stimulating hormone; FT4, free thyroxine; F-up, follow-up; GH, growth hormone; IGF-1, insulin-
like growth factor-1; LH, luteinising hormone; NFPA, non-functioning pituitary adenoma; pit, pituitary; PRL, 
prolactin; TSH, thyroid-stimulating hormone; SEM, standard error of the mean; yrs, years. 
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NFPAs  
n = 16 
Cell ratios 
Ratio M2:M1 Ratio CD8:CD4 Ratio CD8:FOXP3 
Gender     [Mean±SEM] 
Male (n=12) 
Female (n=4) 
 
2.1 ± 0.2 
2.8 ± 0.4 
p=0.173 
 
1.8 ± 0.4 
1.5 ± 0.2 
p=0.624 
 
6.5 ± 1.1 
3.3 ± 1.0 
p=0.154 
Age at diagnosis (yrs) [Pearson correlation r (p value)] -0.064 (p=0.814) 0.424 (p=0.102) 0.447 (p=0.109) 
Headache at diagnosis  [Mean±SEM] 
Yes (n=5) 
No (n=11) 
 
2.2 ± 0.3 
2.3 ± 0.3 
p=0.679 
 
1.5 ± 0.2 
1.8 ± 0.4 
p=0.586 
 
7.9 ± 2.7 
4.7 ± 0.5 
p=0.315 
Visual impairment   [Mean±SEM] 
Yes (n=12) 
No (n=4) 
 
2.3 ± 0.3 
2.4 ± 0.2 
p=0.797 
 
1.7 ± 0.4 
1.8 ± 0.1 
p=0.870 
 
5.5 ± 0.9 
6.2 ± 3.0 
p=0.765 
Hormonal data at diagnosis  
[Pearson correlation r (p value)] 
Serum GH 
Serum IGF-1 
IGF-1 index 
Serum PRL 
PRL index 
Serum TSH 
Serum FT4 
Basal plasma cortisol 
Serum LH 
Serum FSH 
 
 
-0.347 (p=0.269) 
-0.630 (p=0.016) 
-0.461 (p=0.097) 
0.114 (p=0.699) 
0.083 (p=0.779) 
-0.080 (p=0.786) 
-0.137 (p=0.641) 
-0.385 (p=0.194) 
0.059 (p=0.841) 
0.164 (p=0.575) 
 
 
-0.219 (p=0.494) 
-0.604 (p=0.022) 
-0.262 (p=0.366) 
-0.004 (p=0.989) 
-0.025 (p=0.932) 
0.115 (p=0.695) 
-0.262 (p=0.366) 
-0.395 (p=0.182) 
-0.098 (p=0.740) 
-0.114 (p=0.697) 
 
 
0.186 (p=0.563) 
-0.179 (p=0.540) 
-0.187 (p=0.522) 
-0.195 (p=0.503) 
-0.146 (p=0.619) 
-0.314 (p=0.275) 
0.116 (p=0.692) 
-0.169 (p=0.581) 
-0.155 (p=0.596) 
-0.148 (p=0.613) 
Hypopituitarism at diagnosis [Mean±SEM] 
Yes (n=9) 
No (n=7) 
 
2.3 ± 0.2 
2.3 ± 0.2 
p=0.867 
 
1.9 ± 0.5 
1.5 ± 0.2 
p=0.505 
 
5.5 ± 1.1 
5.9 ± 1.7 
p=0.826 
N pit deficiencies at diagnosis  
[Pearson correlation r (p value)] 
0.260 (p=0.330) 0.458 (p=0.074) -0.188 (p=0.467) 
Cavernous sinus invasion  [Mean±SEM] 
Yes (n=6) 
No (n=10)  
 
2.1 ± 0.4 
2.4 ± 0.2 
p=0.490 
 
1.5 ± 0.3 
1.9 ± 0.5 
p=0.616 
 
3.9 ± 0.7 
6.8 ± 1.4 
p=0.154 
Ki-67   [Mean±SEM] 
< 3% (n=12) 
≥ 3% (n=4) 
 
2.2 ± 0.2 
2.5 ± 0.5 
p=0.615 
 
1.9 ± 0.4 
1.2 ± 0.2 
p=0.318 
 
6.8 ± 1.1 
2.4 ± 0.7 
p=0.037 
Hypopituitarism last follow-up  [Mean±SEM] 
Yes (n=10) 
No (n=6) 
 
2.5 ± 0.3 
2.0 ± 0.2 
p=0.194 
 
1.9 ± 0.5 
1.4 ± 0.2 
p=0.484 
 
5.8 ± 1.0 
5.5 ± 2.0 
p=0.908 
N pit deficiencies at last follow-up  
[Pearson correlation r (p value)] 
0.232 (p=0.386) 0.123 (p=0.649) 0.021 (p=0.939) 
Microvessel density [Pearson correlation r (p value)] 0.408 (p=0.117) -0.165 (p=0.563) 0.203 (p=0.451) 
Microvessel area [Pearson correlation r (p value)] 0.676 (p=0.004) -0.059 (p=0.828) 0.203 (p=0.941) 
Correlation between clinico-pathological and biochemical features and immune cell ratios among NFPAs 
FSH, follicle-stimulating hormone; FT4, free thyroxine; F-up, follow-up; GH, growth hormone; IGF-1, insulin-
like growth factor-1; LH, luteinising hormone; NFPA, non-functioning pituitary adenoma; pit, pituitary; PRL, 
prolactin; TSH, thyroid-stimulating hormone; SEM, standard error of the mean; yrs, years. 
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Somatotrophinomas  
n = 8 
% of infiltrating immune cells 
Macrophages CD8+ T cells CD4+ T cells FOXP3+ T cells Neutrophils 
Gender  [Mean±SEM] 
Male (n=4) 
Female (n=4) 
 
4.7 ± 0.7 
4.6 ± 1.3 
p=0.920 
 
2.4 ± 0.4 
1.7 ± 0.3 
p=0.249 
 
0.7 ± 0.1 
1.2 ± 0.4 
p=0.305 
 
0.5 ± 0.1 
0.5 ± 0.2 
p=0.984 
 
0.2 ± 0.1 
0.1 ± 0.0 
p=0.439 
Age at diagnosis (yrs)  
[Pearson correlation r (p value)] 
-0.422 (p=0.298) -0.184 (p=0.662) -0.362 (p=0.379) -0.746 (p=0.034) -0.174 (p=0.681) 
Headache at diagnosis  
[Mean±SEM] 
Yes (n=3) 
No (n=5) 
 
 
3.7 ± 0.9 
5.2 ± 1.0 
p=0.325 
 
 
1.9 ± 0.6 
2.2 ± 0.3 
p=0.728 
 
 
1.1 ± 0.5 
0.9 ± 0.2 
p=0.722 
 
 
0.5 ± 0.3 
0.5 ± 0.1 
p=0.976 
 
 
0.1 ± 0.0 
0.2 ± 0.1 
p=0.609 
Visual impairment [Mean±SEM] 
Yes (n=1) 
No (n=7) 
 
 
6.3 
4.4 ± 0.8 
p=0.433 
 
 
3.4 
1.9 ± 0.3 
p=0.079 
 
 
0.5 
1.0 ± 0.2 
p=0.469 
 
 
0.8 
0.5 ± 0.1 
p=0.451 
 
 
0.0 
0.2 ± 0.1 
p=0.465 
Hormonal data at diagnosis  
[Pearson correlation r (p value)] 
GH nadir on OGTT 
Serum GH 
Serum IGF-1 
IGF-1 index 
Serum PRL 
PRL index 
Serum TSH 
Serum FT4 
Basal plasma cortisol 
Serum LH 
Serum FSH 
 
 
-0.458 (p=0.542) 
-0.185 (p=0.692) 
-0.220 (p=0.635) 
-0.464 (p=0.246) 
0.729 (p=0.162) 
0.765 (p=0.132) 
-0.044 (p=0.925) 
-0.032 (p=0.945) 
0.260 (p=0.574) 
0.210 (p=0.651) 
-0.177 (p=0.704) 
 
 
0.537 (p=0.463) 
0.521 (p=0.230) 
0.550 (p=0.201) 
0.527 (p=0.179) 
-0.256 (p=0.677) 
-0.193 (p=0.756) 
-0.320 (p=0.484) 
0.271 (p=0.556) 
0.517 (p=0.235) 
0.037 (p=0.938) 
0.045 (p=0.923) 
 
 
0.440 (p=0.560) 
0.105 (p=0.823) 
0.118 (p=0.801) 
-0.003 (p=0.995) 
0.319 (p=0.601) 
0.287 (p=0.640) 
-0.081 (p=0.862) 
0.059 (p=0.900) 
0.014 (p=0.976) 
-0.353 (p=0.438) 
-0.243 (p=0.599) 
 
 
0.527 (p=0.473) 
0.462 (p=0.296) 
0.425 (p=0.342) 
0.115 (p=0.786) 
0.300 (p=0.624) 
0.326 (p=0.593) 
-0.141 (p=0.763) 
-0.097 (p=0.836) 
0.307 (p=0.503) 
-0.469 (p=0.289) 
-0.483 (p=0.272) 
 
 
0.187 (p=0.813) 
-0.008 (p=0.987) 
-0.024 (p=0.959) 
-0.349 (p=0.397) 
0.360 (p=0.552) 
0.299 (p=0.625) 
0.368 (p=0.417) 
-0.372 (p=0.411) 
-0.067 (p=0.887) 
-0.574 (p=0.187) 
-0.380 (p=0.401) 
Hypopituitarism at diagnosis   
[Mean±SEM] 
Yes (n=2) 
No (n=6) 
 
 
5.9 ± 0.4 
4.3 ± 0.9 
p=0.347 
 
 
3.1 ± 0.3 
1.7 ± 0.2 
p=0.020 
 
 
0.6 ± 0.0 
1.1 ± 0.3 
p=0.308 
 
 
0.6 ± 0.1 
0.5 ± 0.1 
p=0.600 
 
 
0.0 ± 0.0 
0.2 ± 0.1 
p=0.394 
N pit deficiencies at diagnosis  
[Pearson correlation r (p value)] 
0.085 (p=0.957) 0.711 (p=0.073) 0.157 (p=0.737) 0.580 (p=0.172) -0.024 (p=0.959) 
Cavernous sinus invasion     
[Mean±SEM] 
Yes (n=4) 
No (n=4)  
 
 
4.6 ± 1.3 
4.7 ± 0.7 
p=0.920 
 
 
1.7 ± 0.3 
2.4 ± 0.4 
p=0.249 
 
 
1.2 ± 0.4 
0.7 ± 0.1 
p=0.305 
 
 
0.5 ± 0.2 
0.5 ± 0.1 
p=0.984 
 
 
0.1 ± 0.0 
0.2 ± 0.1 
p=0.439 
Ki-67      [Mean±SEM] 
< 3% (n=7) 
≥ 3% (n=1) 
 
4.1 ± 0.5 
8.4 
p=0.031 
 
2.1 ± 0.3 
1.8 
p=0.737 
 
0.9 ± 0.2 
1.5 
p=0.342 
 
0.5 ± 0.1 
0.8 
p=0.322 
 
0.1 ± 0.1 
0.1 
p=0.959 
Pre-operative SSAs [Mean±SEM] 
Yes (n=6) 
No (n=2) 
 
4.1 ± 0.6 
6.4 ± 2.0 
p=0.171 
 
2.1 ± 0.4 
2.0 ± 0.2 
p=0.852 
 
0.9 ± 0.3 
1.1 ± 0.4 
p=0.708 
 
0.5 ± 0.1 
0.5 ± 0.3 
p=0.974 
 
0.2 ± 0.1 
0.1 ± 0.1 
p=0.553 
Hypopituitarism last follow-up  
[Mean±SEM] 
Yes (n=4) 
No (n=4) 
 
 
5.9 ± 0.4 
4.3 ± 0.9 
p=0.347 
 
 
2.4 ± 0.4 
1.7 ± 0.3 
p=0.232 
 
 
1.0 ± 0.4 
0.9 ± 0.2 
p=0.825 
 
 
0.7 ± 0.1 
0.4 ± 0.2 
p=0.238 
 
 
0.2 ± 0.1 
0.1 ± 0.0 
p=0.396 
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N pit deficiencies at last follow-up  
[Pearson correlation r (p value)] 
0.002 (p=0.996) 0.171 (p=0.686) 0.004 (p=0.992) 0.266 (p=0.525) 0.700 (p=0.053) 
Microvessel density  
[Pearson correlation r (p value)] 
-0.002 (p=0.996) 0.517 (p=0.189) -0.257 (p=0.539) -0.132 (p=0.755) -0.368 (p=0.369) 
Microvessel area  
[Pearson correlation r (p value)] 
0.433 (p=0.285) 0.598 (p=0.118) -0.264 (p=0.527) 0.059 (p=0.890) -0.583 (p=0.130) 
Correlation between clinico-pathological and biochemical features and infiltrating immune cells among 
somatotrophinomas 
FSH, follicle-stimulating hormone; FT4, free thyroxine; F-up, follow-up; GH, growth hormone; IGF-1, insulin-
like growth factor-1; LH, luteinising hormone; OGTT oral glucose tolerance test; pit, pituitary; PRL, prolactin; 
TSH, thyroid-stimulating hormone; SEM, standard error of the mean; SSAs, somatostatin analogues; yrs, 
years. 
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Somatotrophinomas  
n = 8 
Cell ratios 
Ratio M2:M1 Ratio CD8:CD4 Ratio CD8:FOXP3 
Gender  [Mean±SEM] 
Male (n=4) 
Female (n=4) 
 
1.8 ± 0.1 
2.1 ± 0.5 
p=0.653 
 
3.4 ± 1.0 
1.8 ± 0.5 
p=0.222 
 
4.5 ± 0.7 
6.6 ± 2.5 
p=0.481 
Age at diagnosis (yrs) [Pearson correlation r (p value)] 0.856 (p=0.007) 0.047 (p=0.913) 0.677 (p=0.065) 
Headache at diagnosis  [Mean±SEM] 
Yes (n=3) 
No (n=5) 
 
1.7 ± 0.2 
2.1 ± 0.4 
p=0.482 
 
2.4 ± 1.0 
2.8 ± 0.8 
p=0.777 
 
6.6 ± 2.8 
4.9 ± 1.3 
p=0.544 
Visual impairment [Mean±SEM] 
Yes (n=1) 
No (n=7) 
 
1.7 
2.0 ± 0.3 
p=0.739 
 
5.75 
2.2 ± 0.5 
p=0.036 
 
3.8 
5.8 ± 1.5 
p=0.642 
Hormonal data at diagnosis [Pearson correlation r (p value)] 
GH nadir on OGTT 
Serum GH 
Serum IGF-1 
IGF-1 index 
Serum PRL 
PRL index 
Serum TSH 
Serum FT4 
Basal plasma cortisol 
Serum LH 
Serum FSH 
 
-0.073 (p=0.927) 
-0.381 (p=0.398) 
-0.232 (p=0.616) 
0.054 (p=0.899) 
-0.413 (p=0.489) 
-0.405 (p=0.498) 
-0.370 (p=0.414) 
0.883 (p=0.008) 
0.060 (p=0.898) 
0.939 (p=0.002) 
0.915 (p=0.004) 
 
0.191 (p=0.809) 
0.347 (p=0.446) 
0.351 (p=0.440) 
0.394 (p=0.334) 
-0.427 (p=0.474) 
-0.357 (p=0.556) 
-0.326 (p=0.476) 
0.221 (p=0.634) 
0.410 (p=0.361) 
0.255 (p=0.581) 
0.156 (p=0.739) 
 
-0.407 (p=0.593) 
-0.396 (p=0.379) 
-0.376 (p=0.406) 
0.024 (p=0.955) 
-0.360 (p=0.552) 
-0.385 (p=0.522) 
0.012 (p=0.980) 
0.104 (p=0.825) 
-0.299 (p=0.515) 
0.400 (p=0.373) 
0.397 (p=0.378) 
Hypopituitarism at diagnosis   [Mean±SEM]             Yes (n=2) 
                                                                                            No (n=6) 
1.9 ± 0.1 
2.0 ± 0.3 
p=0.835 
5.0 ± 0.7 
1.8 ± 0.4 
p=0.005 
4.7 ± 0.9 
5.8 ± 1.7 
p=0.726 
N pit deficiencies at diagnosis [Pearson correlation r (p value)] -0.293 (p=0.524) 0.490 (p=0.264) -0.511 (p=0.242) 
Cavernous sinus invasion     [Mean±SEM]               Yes (n=4) 
                                                                                         No (n=4)  
2.1 ± 0.5 
1.8 ± 0.1 
p=0.653 
1.9 ± 0.6 
3.4 ± 1.0 
p=0.222 
6.6 ± 2.5 
4.5 ± 0.7 
p=0.481 
Ki-67      [Mean±SEM]                                                 < 3% (n=7) 
                                                                                        ≥ 3% (n=1) 
2.0 ± 0.3 
1.6 
p=0.597 
2.8 ± 0.7 
1.2 
p=0.402 
6.0 ± 1.3 
2.3 
p=0.372 
Pre-operative SSAs [Mean±SEM]                              Yes (n=6) 
                                                                                          No (n=2) 
1.8 ± 0.1 
2.6 ± 1.1 
p=0.555 
2.7 ± 0.8 
2.3 ± 1.1 
p=0.781 
5.4 ± 1.4 
6.0 ± 3.6 
p=0.866 
Hypopituitarism last follow-up  [Mean±SEM]       Yes (n=4) 
                                                                                         No (n=4) 
1.8 ± 0.1 
2.2 ± 0.5 
p=0.457 
3.1 ± 1.1 
2.1 ± 0.5 
p=0.442 
3.7 ± 0.7 
7.4± 2.1 
p=0.065 
N pit deficiencies at last follow-up [Pearson correlation r (p value)] -0.271 (p=0.516) 0.101 (p=0.811) -0.542 (p=0.165) 
Microvessel density [Pearson correlation r (p value)] 0.801 (p=0.017) 0.621 (p=0.100) 0.209 (p=0.620) 
Microvessel area [Pearson correlation r (p value)] 0.606 (p=0.111) 0.718 (p=0.045) 0.122 (p=0.773) 
Correlation between clinico-pathological and biochemical features and immune cell ratios among 
somatotrophinomas 
FSH, follicle-stimulating hormone; FT4, free thyroxine; F-up, follow-up; GH, growth hormone; IGF-1, insulin-
like growth factor-1; LH, luteinising hormone; OGTT oral glucose tolerance test; pit, pituitary; PRL, prolactin; 
TSH, thyroid-stimulating hormone; SEM, standard error of the mean; SSAs, somatostatin analogues; yrs, 
years. 
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Appendix 5: Supplemental tables with cytokine array data from cell lines 
 
 
 
Results from Millipore MILLIPLEX rat 27-plex assay in supernatants from GH3-Aip-KD and GH3-
NT cells collected at both 24h, 48h and 72h, measuring simultaneously 27 different cytokines/ 
chemokines. Data are shown as concentration (pg/mL), mean±SEM, and ratio between GH3-Aip-
KD and GH3-NT cell supernatants is also shown in the table (Mann Whitney U test). n=3.  
 
Cytokine 
Collection 
time 
Supernatants 
GH3-NT cells  
Mean concentration  
(pg/mL) 
SEM 
Supernatants 
GH3-Aip-KD cells 
Mean concentration 
(pg/mL) 
SEM 
p 
value 
Ratio 
KD:NT 
CX3CL1 
24h 301.80 6.76 382.66 25.74 0.024 1.27 
48h 657.77 18.85 798.69 20.87 0.001 1.22 
72h 995.36 41.46 1124.17 42.90 0.056 1.13 
IL-10 
24h 6.61 1.07 11.64 5.68 0.404 1.9 
48h 7.87 0.96 12.08 2.92 0.220 1.71 
72h 8.77 1.24 16.46 10.13 0.468 1.63 
IL-13 
24h 6.30 1.06 6.85 1.18 0.736 1.05 
48h 9.73 0.87 9.69 1.51 0.981 1.02 
72h 9.32 0.60 13.95 2.52 0.103 1.49 
IL-4 
24h 6.72 0.90 7.12 0.77 0.746 1.15 
48h 10.83 1.19 10.49 0.96 0.826 0.97 
72h 13.72 0.66 15.28 2.74 0.529 1.1 
IL-6 
24h 168.97 31.48 248.28 45.41 0.182 1.43 
48h 286.23 44.84 258.57 75.74 0.760 0.92 
72h 289.55 31.39 516.13 258.97 0.405 1.71 
IL-12 
24h 31.73 4.06 28.35 4.90 0.607 0.88 
48h 32.09 3.97 32.75 3.17 0.899 1.04 
72h 32.42 3.67 47.33 12.92 0.293 1.61 
IL-5 
24h 11.77 1.09 11.17 0.84 0.671 0.96 
48h 9.56 2.07 11.04 1.38 0.565 1.33 
72h 9.14 1.31 13.02 3.89 0.367 1.53 
IL-2 
24h 20.57 2.33 21.10 1.49 0.853 1.08 
48h 22.08 0.63 21.37 1.50 0.677 0.95 
72h 21.72 1.40 29.64 7.20 0.306 1.42 
IL-1β 
24h 6.59 1.01 6.43 1.54 0.931 1.08 
48h 5.82 1.37 5.99 1.85 0.942 0.96 
72h 6.21 1.17 12.30 6.92 0.406 1.71 
IL-1α 
24h 17.14 1.10 17.74 1.51 0.754 1.05 
48h 20.57 0.78 19.96 1.04 0.651 0.97 
72h 21.87 1.20 28.45 4.51 0.189 1.28 
IL-17A 
24h 3.19 0.53 3.74 0.87 0.603 1.34 
48h 3.61 0.70 3.53 0.86 0.944 0.98 
72h 4.19 0.60 5.43 1.63 0.491 1.27 
IL-18 
24h 3.96 1.93 6.11 1.81 0.436 2.8 
48h 6.76 1.80 4.91 1.71 0.475 0.67 
72h 5.00 0.86 20.96 13.89 0.303 5 
CXCL10 
 
24h 6.65 0.55 7.85 0.85 0.264 1.17 
48h 25.06 1.69 31.21 2.41 0.063 1.24 
72h 44.32 2.30 54.67 1.40 0.003 1.25 
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IFN-y 
24h 584.94 43.69 584.54 67.09 0.996 1 
48h 597.24 26.62 570.17 52.23 0.654 0.95 
72h 836.46 19.29 774.35 37.44 0.171 0.92 
CCL3 
 
24h 0.92 0.31 1.18 0.26 0.525 1.04 
48h 2.36 0.74 1.79 0.17 0.356 0.91 
72h 1.79 0.17 1.83 0.57 0.939 1.04 
CXCL2 
 
24h 29.67 2.33 26.94 2.81 0.470 0.92 
48h 31.39 2.8516 28.88 2.34 0.511 0.92 
72h 41.59 1.9985 41.06 5.4 0.928 0.98 
CCL2  
24h 81.61 25.47 141.52 18.86 0.088 1.99 
48h 127.39 19.16 139.80 20.92 0.671 1.19 
72h 117.41 16.34 149.78 57.18 0.598 1.26 
CCL5 
 
24h 0.45 0.03 0.37 0.02 0.068 0.85 
48h 0.57 0.01 0.52 0.03 0.173 0.91 
72h 0.47 0.02 0.48 0.05 0.901 1.01 
G-CSF 
24h 47.52 5.98 23.93 18.76 0.258 0.8 
48h 30.85 13.10 33.70 14.62 0.888 0.66 
72h 27.74 9.71 29.40 18.42 0.938 0.99 
GM-CSF 
24h 11.58 1.97 10.23 1.36 0.585 0.95 
48h 10.36 0.86 13.56 1.77 0.135 1.29 
72h 10.07 0.44 20.41 10.62 0.375 2.03 
CCL11 
24h 2.27 0.35 2.49 0.26 0.627 1.12 
48h 2.62 0.22 2.71 0.26 0.727 1.03 
72h 2.15 0.48 3.30 0.59 0.162 1.57 
LIX 
24h 25.73 0.67 26.31 2.26 0.811 1.02 
48h 35.42 0.85 36.09 1.19 0.656 1.02 
72h 41.78 1.24 43.45 1.76 0.457 1.04 
CXCL1 
 
24h 16.17 4.64 27.23 5.63 0.161 2.44 
48h 29.92 2.31 26.75 6.14 0.640 0.89 
72h 28.26 8.83 24.91 6.67 0.768 2.14 
VEGF 
24h 2534.20 97.52 2508.51 130.42 0.878 0.99 
48h 7248.94 213.86 6700.94 140.38 0.058 0.92 
72h 12440.23 526.15 10961.23 283.89 0.033 0.88 
EGF 
24h 0.19 0.01 0.19 0.03 0.883 1.03 
48h 0.21 0.02 0.18 0.02 0.278 0.9 
72h 0.19 0.01 0.26 0.09 0.451 1.35 
TNF-α 
 
24h 0.24 0.22 0.06 0.05 0.453 1.78 
48h 0.03 0.03 0.05 0.05 0.770 1.56 
72h 0.01 0.01 0.61 0.61 0.373 45.5 
Leptin 
24h 80.20 9.73 108.03 20.90 0.255 1.4 
48h 126.89 13.78 108.59 24.54 0.530 0.86 
72h 133.15 11.80 129.75 39.00 0.935 0.71 
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Results from the Millipore MILLIPLEX rat 27-plex assay in supernatants from GH3-Aip-KD and 
GH3-NT cells treated with PMA (5nM)-activated RAW 264.7 macrophage-CM (+Raw-CM) and in 
medium (untreated) for 24h, highlighting secretome changes induced by macrophage-derived 
factors. Data regarding the cytokines with measurable concentrations are shown as concentration 
(pg/mL), mean±SEM, and as ratio between untreated vs macrophage-CM treated GH3-Aip-KD and 
GH3-NT cell supernatants, mean±SEM are also shown. CCL5, G-CSF, IL-17A and TNF-α were not 
detectable in GH3 supernatants, whereas CCL11, GM-CSF, IL-1α, Leptin, EGF, IL-12 and LIX had 
very low readings (below the first standard curve point of the assay), and thus not represented. 
n=3. <0.05, **, <0.01, ***, <0.001 (two-way ANOVA with Bonferroni Multiple Comparison test). 
  
Cytokine 
GH3-NT cells  
UNTREATED 
Mean 
concentration  
(pg/mL) ± SEM 
GH3-NT cells  
+Raw-CM 
Mean 
concentration  
(pg/mL) ± SEM 
GH3-NT cells 
Ratio Raw-
CM : 
UNTREATED 
Mean ± SEM 
GH3-Aip-KD cells 
UNTREATED 
Mean 
concentration 
(pg/mL) ± SEM 
GH3-Aip-KD cells  
+Raw-CM 
Mean 
concentration  
(pg/mL) ± SEM 
GH3-Aip-KD 
cells  
Ratio Raw-CM 
: UNTREATED 
Mean ± SEM 
CX3CL1 301.80 ± 6.76 400.33 ± 31.39 1.33 ± 0.10* 382.66 ± 25.74 635.77 ± 40.27 1.66 ± 0.11* 
IL-13 6.30 ± 1.06 11.83 ± 2.99 1.88 ± 0.47* 6.85 ± 1.18 11.58 ± 3.63 1.69 ± 0.53 
IL-4 6.72 ± 0.90 6.95 ± 1.43 1.03 ± 0.21 7.12 ± 0.77 9.10 ± 2.04 1.28 ± 0.29 
IL-6 168.97 ± 31.48 169.42 ± 98.92 1.00 ± 0.59 248.28 ± 45.41 191.68 ± 22.50 0.77 ± 0.09* 
IL-5 11.77 ± 1.09 6.72 ± 4.46 0.57 ± 0.38 11.17 ± 0.84 8.95 ± 5.06 0.80 ± 0.45 
IL-2 20.57 ± 2.33 15.07 ± 9.19 0.73 ± 0.45 21.10 ± 1.49 30.49 ± 10.38 1.45 ± 0.49 
IL-1β 6.59 ± 1.01 17.32 ± 2.22 2.63 ± 0.34* 6.43 ± 1.54 24.09 ± 1.30 3.75 ± 0.20* 
IL-18 3.96 ± 1.93 10.68 ± 5.96 2.70 ± 1.50 6.11 ± 1.81 12.80 ± 6.35 2.10 ± 1.04 
CXCL10 6.65 ± 0.55 24.26 ± 1.40 3.65 ± 0.21*  7.85 ± 0.85 33.47 ± 0.96 4.26 ± 0.12 
CXCL2 29.67 ± 2.33 7.77 ± 7.77 0.26 ± 0.26* 26.94 ± 2.81 32.70 ± 4.69 1.21 ± 0.17 
CCL2 81.61 ± 25.47 48.29 ± 25.04 0.59 ± 0.31 141.52 ± 18.86 132.14 ± 67.61 0.93 ± 0.48 
CXCL1 16.17 ± 4.64 135.86 ± 12.31 8.40 ± 0.76* 27.23 ± 5.63 138.92 ± 6.25 5.10 ± 0.23* 
VEGF 2534.20 ± 97.52 4521.34 ± 548.86 1.78 ± 0.22* 2508.51 ± 130.42 4596.58 ± 368.73 1.83 ± 0.15* 
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Results from the Millipore MILLIPLEX mouse 32-plex assay in supernatants from RAW 264.7 
macrophages treated with GH3-Aip-KD and GH3-NT cell-CM and in medium (untreated) for 24h, 
highlighting secretome changes induced by GH3 cell-derived factors. IFNγ, IL-3, IL-4, IL-5, IL-6, IL-
7, IL-12, IL-13, CXCL1 were not detectable in the RAW 264.7 macrophages, whereas CCL11, GM-
CSF, IL-2, IL-10, LIF, LIX, MIG had very low readings (below the first standard curve point of the 
assay), and thus are not represented. Data are shown as concentration (pg/mL), mean±SEM, and 
as ratio between untreated vs GH3-CM treated, mean±SEM. n=3. <0.05, **, <0.01, ***, <0.001 
(Mann Whitney U test).  
 
Cytokine 
RAW macrophages 
UNTREATED 
Mean 
concentration  
(pg/mL) ± SEM 
RAW macrophages 
+GH3-NT-CM 
Mean concentration  
(pg/mL) ± SEM 
Ratio GH3-
NT-CM : 
UNTREATED 
Mean ± SEM 
RAW macrophages 
+GH3-Aip-KD-CM 
Mean concentration  
(pg/mL) ± SEM 
Ratio GH3-
Aip-KD-CM 
: UNTREATED 
Mean ± SEM 
CCL3 3224.50 ± 302.26 2782.46 ± 693.47 0.84 ± 0.16 3245.58 ± 82.10 1.03 ± 0.12 
CCL4 6310.65 ± 2686.71 3106.84 ± 1379.51 0.49 ± 0.03* 7529.29 ± 2377.61 1.32 ± 0.15* 
CCL2 242.87 ± 147.87 237.26 ± 115.92 1.93 ± 1.43 642.45 ± 341.18 2.97 ± 0.72* 
CCL5 3.81 ± 1.29 3.02 ± 0.83 0.86 ± 0.25 7.04 ± 2.23 1.87 ± 0.04* 
CXCL2 297.28 ± 135.72 332.08 ± 291.76 1.00 ± 0.56 804.11 ± 458.55 2.05 ± 0.94 
VEGF 41.24 ± 26.53 39.50 ± 27.53 0.86 ± 0.14 96.38 ± 37.92 3.26 ± 1.14* 
TNF-α 14.56 ± 5.93 13.92 ± 9.47 0.97 ± 0.39 39.03 ± 20.85 2.58 ± 0.58* 
CXCL10 6.31 ± 1.85 4.09 ± 1.05 0.68 ± 0.13* 15.13 ± 5.66 2.23 ± 0.49* 
IL-1α 3.86 ± 1.12 3.00 ± 0.73 0.99 ± 0.37 26.83 ± 12.91 5.96 ± 2.48* 
IL-1β 7.54 ± 1.39 3.57 ± 0.43 0.49 ± 0.06* 6.55 ± 1.98 0.83 ± 0.11 
IL-2 1.56 ± 0.27 1.57 ± 0.92 1.13 ± 0.63 2.85 ± 0.48 1.85 ± 0.17* 
IL-9 3.49 ± 0.14 4.60 ± 2.47 1.30 ± 0.67 14.08 ± 9.92 3.90 ± 2.72 
IL-10 2.03 ± 0.59 1.80 ± 0.57 0.93 ± 0.18 2.12 ± 0.29 1.17 ± 0.24 
IL-12 4.70 ± 0.59 4.76 ± 4.60 1.33 ± 1.30 4.04 ± 1.81 0.97 ± 0.52 
IL-15 16.24 ± 8.82 11.34 ± 5.40 1.11 ± 0.83 13.60 ± 4.03 1.54 ± 0.99 
IL-17 2.01 ± 0.31 1.33 ± 0.32 0.64 ± 0.06* 2.50 ± 0.31 1.25 ± 0.08* 
G-CSF 2.23 ± 0.85 1.39 ± 0.82 0.58 ± 0.18* 4.06 ± 1.55 1.93 ± 0.28* 
GM-CSF 2.04 ± 0.68 2.12 ± 0.46 1.26 ± 0.45 2.12 ± 0.49 1.15 ± 0.30 
M-CSF 1.32 ± 0.95 0.86 ± 0.44 4.07 ± 3.89 1.50 ± 0.23 6.22 ± 4.96 
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Appendix 6: Supplemental tables with pre-operative haematological parameters and serum inflammation-based scores 
(NLR, LMR and PLR) and pituitary function and PA-derived cytokine secretome 
 
   
Pituitary hormone levels in 
NFPAs (n=16) 
White cell 
count 
Neutrophil 
count 
Lymphocyte 
count 
Monocyte 
count 
Eosinophil 
count 
Basophil 
count 
Platelet 
count 
NLR LMR PLR 
GH (mcg/L) 
Pearson correlation r -0.428 -0.190 -0.576 -0.445 -0.188 0.055 -0.316 0.157 -0.041 0.278 
p value 0.166 0.553 0.050 0.147 0.558 0.865 0.318 0.627 0.898 0.381 
N 12 12 12 12 12 12 12 12 12 12 
IGF-1 (nmol/L) 
Pearson correlation r -0.341 -0.227 -0.323 -0.603 -0.269 0.000 -0.065 0.189 -0.198 0.233 
p value 0.233 0.436 0.259 .023 0.352 0.999 0.826 0.517 0.497 0.423 
N 14 14 14 14 14 14 14 14 14 14 
IGF-1 index 
Pearson correlation r -0.420 -0.240 -0.449 -0.276 -0.026 0.408 0.034 0.176 -0.364 0.170 
p value 0.135 0.408 0.107 0.340 0.929 0.148 0.908 0.546 0.200 0.562 
N 14 14 14 14 14 14 14 14 14 14 
PRL (mU/L) 
Pearson correlation r -0.188 -0.184 -0.159 -0.199 0.004 0.388 -0.216 -0.084 -0.120 -0.028 
p value 0.520 0.528 0.588 0.495 0.990 0.170 0.458 0.775 0.683 0.925 
N 14 14 14 14 14 14 14 14 14 14 
PRL-index 
Pearson correlation r -0.378 -0.262 -0.377 -0.038 -0.312 0.324 -0.167 0.078 -0.380 0.104 
p value 0.182 0.365 0.184 0.896 0.278 0.258 0.569 0.792 0.181 0.724 
N 14 14 14 14 14 14 14 14 14 14 
TSH (µU/mL) 
Pearson correlation r -0.294 -0.058 -0.365 -0.193 -0.320 0.417 0.295 0.186 -0.318 0.300 
p value 0.307 0.844 0.199 0.510 0.264 0.138 0.307 0.524 0.268 0.297 
N 14 14 14 14 14 14 14 14 14 14 
FT4 (pmol/L) 
Pearson correlation r -0.122 0.039 -0.184 0.075 -0.261 -0.374 -0.242 0.349 -0.197 0.125 
p value 0.678 0.895 0.530 0.800 0.368 0.187 0.404 0.221 0.501 0.670 
N 14 14 14 14 14 14 14 14 14 14 
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Basal Cortisol 
(nmol/L) 
Pearson correlation r -0.229 -0.095 -0.223 -0.451 -0.120 0.103 -0.099 0.063 0.202 0.071 
p value 0.452 0.758 0.464 0.122 0.696 0.737 0.749 0.837 0.507 0.818 
N 13 13 13 13 13 13 13 13 13 13 
LH (U/L) 
Pearson correlation r 0.214 0.259 0.155 0.116 -0.015 -0.078 0.024 0.107 0.132 -0.005 
p value 0.463 0.372 0.596 0.693 0.960 0.790 0.934 0.715 0.652 0.987 
N 14 14 14 14 14 14 14 14 14 14 
FSH (U/L) 
Pearson correlation r -0.169 -0.028 -0.222 0.196 -0.223 0.053 -0.016 0.198 -0.254 0.140 
p value 0.562 0.925 0.445 0.503 0.443 0.858 0.957 0.497 0.381 0.633 
N 14 14 14 14 14 14 14 14 14 14 
Testosterone 
(nmol/L) 
Pearson correlation r -0.056 0.113 -0.128 -0.084 -0.076 -0.368 0.270 0.218 -0.116 0.090 
p value 0.863 0.727 0.693 0.796 0.815 0.239 0.397 0.496 0.719 0.781 
N 12 12 12 12 12 12 12 12 12 12 
 
Pre-operative haematological parameters and serum inflammation-based scores (NLR, LMR and PLR) and pituitary function in NFPAs 
p values were determined by the Pearson correlation coefficient r. FSH, follicle-stimulating hormone; FT4, free thyroxine; GH, growth hormone; IGF-1, insulin-like growth 
factor-1; LH, luteinising hormone; LMR, lymphocyte-to-monocyte ratio; NFPA, non-functioning pituitary adenoma; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-
lymphocyte ratio; PRL, prolactin; TSH, thyroid-stimulating hormone. 
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Pituitary hormone levels in 
somatotrophinomas (n=8) 
White cell 
count 
Neutrophil 
count 
Lymphocyte 
count 
Monocyte 
count 
Eosinophil 
count 
Basophil 
count 
Platelet 
count 
NLR LMR PLR 
GH (mcg/L) 
Pearson correlation r 0.008 -0.220 0.306 -0.044 0.043 0.299 -0.127 -0.421 0.153 -0.441 
p value 0.986 0.635 0.505 0.926 0.926 0.515 0.787 0.347 0.744 0.322 
N 7 7 7 7 7 7 7 7 7 7 
GH nadir on 
OGTT (mcg/L) 
Pearson correlation r 0.861 0.886 0.853 0.513 0.281 0.643 0.498 -0.336 0.314 -0.559 
p value 0.139 0.114 0.147 0.487 0.719 0.357 0.502 0.664 0.686 0.441 
N 4 4 4 4 4 4 4 4 4 4 
IGF-1 (nmol/L) 
Pearson correlation r 0.096 -0.109 0.309 0.095 0.061 0.271 -0.173 -0.298 0.076 -0.478 
p value 0.838 0.817 0.499 0.839 0.897 0.557 0.711 0.516 0.871 0.278 
N 7 7 7 7 7 7 7 7 7 7 
IGF-1 index 
Pearson correlation r -0.027 -0.206 0.279 0.047 0.308 -0.061 -0.050 -0.249 0.237 -0.294 
p value 0.950 0.624 0.503 0.911 0.458 0.886 0.907 0.551 0.572 0.479 
N 8 8 8 8 8 8 8 8 8 8 
PRL (mU/L) 
Pearson correlation r -0.414 -0.500 -0.389 -0.037 0.225 -0.068 -0.307 -0.537 -0.492 0.067 
p value 0.489 0.391 0.517 0.953 0.716 0.913 0.616 0.350 0.400 0.915 
N 5 5 5 5 5 5 5 5 5 5 
PRL-index 
Pearson correlation r -0.434 -0.526 -0.410 0.016 0.199 -0.110 -0.375 -0.568 -0.565 0.030 
p value 0.465 0.363 0.492 0.980 0.748 0.860 0.534 0.318 0.321 0.962 
N 5 5 5 5 5 5 5 5 5 5 
TSH (µU/mL) 
Pearson correlation r -0.513 -0.705 -0.064 -0.523 0.333 0.181 -0.566 -0.498 0.362 -0.174 
p value 0.239 0.077 0.892 0.229 0.466 0.697 0.185 0.255 0.425 0.709 
N 7 7 7 7 7 7 7 7 7 7 
FT4 (pmol/L) 
Pearson correlation r 0.525 0.790 -0.118 0.927 -0.235 -0.352 0.035 0.865 -0.672 0.030 
p value 0.226 0.035 0.801 0.003 0.612 0.439 0.941 0.012 0.098 0.949 
N 7 7 7 7 7 7 7 7 7 7 
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Basal Cortisol 
(nmol/L) 
Pearson correlation r 0.571 0.501 0.465 0.177 0.214 0.137 0.396 -0.055 0.029 -0.283 
p value 0.180 0.252 0.294 0.704 0.644 0.770 0.379 0.906 0.952 0.539 
N 7 7 7 7 7 7 7 7 7 7 
LH (U/L) 
Pearson correlation r 0.095 0.471 -0.539 0.779 -0.372 -0.735 -0.374 0.907 -0.820 0.247 
p value 0.839 0.286 0.212 0.039 0.411 0.060 0.409 .005 0.024 0.594 
N 7 7 7 7 7 7 7 7 7 7 
FSH (U/L) 
Pearson correlation r 0.257 0.518 -0.279 0.732 -0.194 -0.470 -0.370 0.808 -0.554 0.051 
p value 0.579 0.234 0.545 0.061 0.677 0.287 0.413 0.028 0.197 0.914 
N 7 7 7 7 7 7 7 7 7 7 
Testosterone 
(nmol/L) 
Pearson correlation r -0.005 -0.327 0.365 -0.181 0.646 0.344 -0.623 -0.469 0.350 -0.658 
p value 0.992 0.526 0.477 0.732 0.166 0.504 0.186 0.348 0.496 0.156 
N 6 6 6 6 6 6 6 6 6 6 
 
Pre-operative haematological parameters and serum inflammation-based scores (NLR, LMR and PLR) and pituitary function in somatotrophinomas 
p values were determined by the Pearson correlation coefficient r. FSH, follicle-stimulating hormone; FT4, free thyroxine; GH, growth hormone; IGF-1, insulin-like growth 
factor-1; LH, luteinising hormone; LMR, lymphocyte-to-monocyte ratio; NFPA, non-functioning pituitary adenoma; NLR, neutrophil-to-lymphocyte ratio; OGTT, oral glucose 
tolerance test; PLR, platelet-to-lymphocyte ratio; PRL, prolactin; TSH, thyroid-stimulating hormone. 
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Cytokine secretome in the overall 
cohort of PAs (n=24) 
Red cell 
count 
White cell 
count 
Neutrophil 
count 
Lymphocyte 
count 
Monocyte 
count 
Eosinophil 
count 
Basophil 
count 
Platelet 
count 
NLR LMR PLR 
IL-8 
Pearson correlation r -0.078 0.064 0.217 -0.052 -0.015 0.093 -0.110 0.182 0.270 -0.018 0.110 
p value 0.719 0.765 0.309 0.810 0.944 0.667 0.610 0.394 0.202 0.934 0.610 
N 24 24 24 24 24 24 24 24 24 24 24 
CCL2 
Pearson correlation r -0.018 -0.050 0.085 -0.117 -0.097 -0.149 -0.130 0.176 0.228 -0.076 0.183 
p value 0.933 0.815 0.692 0.585 0.653 0.487 0.545 0.411 0.284 0.723 0.393 
N 24 24 24 24 24 24 24 24 24 24 24 
CCL3 
Pearson correlation r -0.155 -0.031 -0.052 -0.009 -0.224 0.228 0.107 0.112 -0.066 0.094 -0.021 
p value 0.469 0.885 0.808 0.967 0.292 0.284 0.617 0.601 0.761 0.663 0.922 
N 24 24 24 24 24 24 24 24 24 24 24 
CCL4 
Pearson correlation r -0.087 0.047 0.181 -0.053 -0.039 0.083 -0.062 0.204 0.227 -0.012 0.111 
p value 0.685 0.829 0.396 0.806 0.856 0.699 0.774 0.338 0.285 0.954 0.606 
N 24 24 24 24 24 24 24 24 24 24 24 
CXCL10 
Pearson correlation r 0.072 -0.145 -0.100 -0.122 -0.160 -0.327 -0.163 0.018 0.071 -0.088 0.142 
p value 0.737 0.499 0.640 0.572 0.456 0.119 0.447 0.933 0.742 0.682 0.509 
N 24 24 24 24 24 24 24 24 24 24 24 
CCL22 
Pearson correlation r 0.185 -0.072 0.151 -0.197 -0.099 -0.095 -0.096 0.331 0.375 -0.165 0.377 
p value 0.387 0.736 0.480 0.356 0.645 0.657 0.657 0.114 0.071 0.442 0.069 
N 24 24 24 24 24 24 24 24 24 24 24 
CXCL1 
Pearson correlation r -0.095 -0.027 0.077 -0.089 -0.155 0.146 0.028 0.223 0.153 -0.007 0.131 
p value 0.659 0.899 0.721 0.678 0.470 0.497 0.898 0.295 0.475 0.973 0.541 
N 24 24 24 24 24 24 24 24 24 24 24 
CX3CL1 
Pearson correlation r 0.073 -0.129 -0.067 -0.120 -0.194 -0.287 -0.212 -0.005 0.110 -0.074 0.144 
p value 0.736 0.547 0.757 0.575 0.363 0.173 0.320 0.983 0.609 0.730 0.501 
N 24 24 24 24 24 24 24 24 24 24 24 
FGF-2 
Pearson correlation r 0.064 -0.316 -0.133 -0.363 -0.237 -0.043 0.077 0.322 0.281 -0.264 0.550 
p value 0.767 0.133 0.534 0.081 0.264 0.841 0.720 0.125 0.184 0.213 0.005 
N 24 24 24 24 24 24 24 24 24 24 24 
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IL-6 
Pearson correlation r 0.000 0.114 0.352 -0.072 0.145 -0.013 -0.196 0.194 0.428 -0.096 0.166 
p value 0.999 0.595 0.091 0.738 0.500 0.951 0.358 0.363 0.037 0.656 0.438 
N 24 24 24 24 24 24 24 24 24 24 24 
PDGF-AA 
Pearson correlation r 0.054 0.107 0.321 -0.046 0.024 -0.177 -0.235 0.122 0.416 -0.055 0.149 
p value 0.803 0.618 0.126 0.830 0.913 0.408 0.269 0.569 0.043 0.798 0.486 
N 24 24 24 24 24 24 24 24 24 24 24 
VEGF-A 
Pearson correlation r -0.015 0.069 0.226 -0.044 -0.020 -0.071 0.011 0.480 0.256 -0.053 0.248 
p value 0.946 0.748 0.289 0.840 0.926 0.741 0.958 0.018 0.228 0.807 0.243 
N 24 24 24 24 24 24 24 24 24 24 24 
 
 
Pre-operative haematological parameters and serum inflammation-based scores (NLR, LMR and PLR) and PA-derived cytokine secretome 
p values were determined by the Pearson correlation coefficient r. FGF, fibroblast growth factor; IL, interleukin; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-
lymphocyte ratio; PDGF, platelet-derived growth factor; PLR, platelet-to-lymphocyte ratio; VEGF, vascular endothelial growth factor. 
 
 
 
 
 
 
 
 
 
 
359 
 
 
 
Cytokine secretome among 
NFPAs (n=16) 
Red cell 
count 
White cell 
count 
Neutrophil 
count 
Lymphocyte 
count 
Monocyte 
count 
Eosinophil 
count 
Basophil 
count 
Platelet 
count 
NLR LMR PLR 
IL-8 
Pearson correlation r -0.134 0.046 0.246 -0.080 0.052 0.245 -0.054 0.291 0.311 -0.048 0.203 
p value 0.621 0.867 0.359 0.768 0.848 0.360 0.842 0.275 0.241 0.861 0.451 
N 16 16 16 16 16 16 16 16 16 16 16 
CCL2 
Pearson correlation r -0.078 -0.097 0.061 -0.165 -0.053 -0.037 -0.063 0.288 0.257 -0.127 0.329 
p value 0.775 0.720 0.823 0.541 0.847 0.892 0.818 0.279 0.337 0.640 0.213 
N 16 16 16 16 16 16 16 16 16 16 16 
CCL3 
Pearson correlation r -0.229 -0.064 -0.112 -0.034 -0.303 0.413 0.229 0.190 -0.120 0.071 0.010 
p value 0.393 0.815 0.679 0.900 0.255 0.112 0.393 0.482 0.658 0.794 0.972 
N 16 16 16 16 16 16 16 16 16 16 16 
CCL4 
Pearson correlation r -0.155 0.020 0.191 -0.085 0.023 0.241 0.011 0.317 0.253 -0.047 0.206 
p value 0.567 0.941 0.478 0.754 0.933 0.369 0.967 0.232 0.345 0.862 0.444 
N 16 16 16 16 16 16 16 16 16 16 16 
CXCL10 
Pearson correlation r 0.050 -0.186 -0.165 -0.151 -0.192 -0.324 -0.149 0.051 0.063 -0.120 0.236 
p value 0.855 0.491 0.542 0.578 0.476 0.221 0.583 0.850 0.818 0.657 0.378 
N 16 16 16 16 16 16 16 16 16 16 16 
CCL22 
Pearson correlation r 0.293 -0.008 0.396 -0.223 0.187 -0.235 -0.172 0.376 0.670 -0.244 0.500 
p value 0.271 0.977 0.129 0.407 0.487 0.382 0.525 0.151 0.005 0.362 0.048 
N 16 16 16 16 16 16 16 16 16 16 16 
CXCL1 
Pearson correlation r -0.135 -0.038 0.104 -0.117 -0.118 0.278 0.111 0.318 0.198 -0.045 0.210 
p value 0.617 0.887 0.702 0.666 0.662 0.298 0.682 0.231 0.462 0.868 0.435 
N 16 16 16 16 16 16 16 16 16 16 16 
CX3CL1 
Pearson correlation r 0.060 -0.150 -0.083 -0.145 -0.199 -0.301 -0.233 0.025 0.145 -0.111 0.232 
p value 0.825 0.579 0.759 0.591 0.460 0.258 0.386 0.926 0.592 0.683 0.387 
N 16 16 16 16 16 16 16 16 16 16 16 
FGF-2 
Pearson correlation r 0.287 -0.241 0.153 -0.395 -0.231 -0.437 0.007 0.346 0.693 -0.324 0.712 
p value 0.281 0.369 0.572 0.130 0.390 0.091 0.979 0.190 0.003 0.220 0.002 
N 16 16 16 16 16 16 16 16 16 16 16 
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IL-6 
Pearson correlation r -0.034 0.104 0.421 -0.094 0.295 0.071 -0.199 0.284 0.509 -0.123 0.266 
p value 0.901 0.700 0.105 0.729 0.268 0.794 0.460 0.287 0.044 0.650 0.319 
N 16 16 16 16 16 16 16 16 16 16 16 
PDGF-AA 
Pearson correlation r 0.035 0.109 0.439 -0.086 0.155 -0.098 -0.192 0.316 0.560 -0.101 0.358 
p value 0.896 0.688 0.089 0.750 0.567 0.718 0.476 0.233 0.024 0.711 0.173 
N 16 16 16 16 16 16 16 16 16 16 16 
VEGF-A 
Pearson correlation r 0.160 0.123 0.493 -0.090 0.076 -0.190 -0.062 0.501 0.595 -0.094 0.479 
p value 0.554 0.651 0.053 0.739 0.780 0.481 0.820 0.048 0.015 0.728 0.061 
N 16 16 16 16 16 16 16 16 16 16 16 
 
Pre-operative haematological parameters and serum inflammation-based scores (NLR, LMR and PLR) and cytokine secretome among NFPAs 
p values were determined by the Pearson correlation coefficient r. FGF, fibroblast growth factor; IL, interleukin; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-
lymphocyte ratio; PDGF, platelet-derived growth factor; PLR, platelet-to-lymphocyte ratio; VEGF, vascular endothelial growth factor. 
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Cytokine secretome among 
somatotrophinomas (n=8) 
Red cell 
count 
White cell 
count 
Neutrophil 
count 
Lymphocyte 
count 
Monocyte 
count 
Eosinophil 
count 
Basophil 
count 
Platelet 
count 
NLR LMR PLR 
IL-8 
Pearson correlation r -0.492 -0.466 -0.494 -0.287 -0.010 0.085 -0.232 -0.219 -0.358 -0.379 -0.073 
p value 0.216 0.245 0.213 0.491 0.981 0.841 0.581 0.603 0.384 0.355 0.864 
N 8 8 8 8 8 8 8 8 8 8 8 
CCL2 
Pearson correlation r -0.477 -0.284 -0.424 0.067 -0.213 0.321 0.121 0.429 -0.491 0.070 0.018 
p value 0.232 0.495 0.295 0.875 0.613 0.438 0.775 0.289 0.217 0.869 0.967 
N 8 8 8 8 8 8 8 8 8 8 8 
CCL3 
Pearson correlation r -0.453 -0.392 -0.524 -0.007 -0.202 0.146 0.034 -0.103 -0.521 0.079 -0.167 
p value 0.259 0.337 0.183 0.987 0.632 0.729 0.937 0.808 0.185 0.852 0.693 
N 8 8 8 8 8 8 8 8 8 8 8 
CCL4 
Pearson correlation r -0.286 -0.316 -0.442 0.030 -0.348 0.464 0.169 0.373 -0.464 0.202 0.088 
p value 0.492 0.446 0.273 0.943 0.399 0.247 0.689 0.363 0.246 0.631 0.836 
N 8 8 8 8 8 8 8 8 8 8 8 
CXCL10 
Pearson correlation r -0.268 -0.227 -0.382 0.155 -0.390 0.483 0.265 0.540 -0.479 0.348 0.097 
p value 0.522 0.589 0.351 0.714 0.339 0.225 0.526 0.167 0.230 0.398 0.819 
N 8 8 8 8 8 8 8 8 8 8 8 
CCL22 
Pearson correlation r -0.299 -0.496 -0.652 0.035 -0.723 0.479 0.143 0.273 -0.634 0.644 0.183 
p value 0.472 0.211 0.080 0.935 0.043 0.230 0.735 0.513 0.091 0.085 0.664 
N 8 8 8 8 8 8 8 8 8 8 8 
CXCL1 
Pearson correlation r -0.431 -0.606 -0.754 -0.051 -0.733 0.420 0.074 0.241 -0.694 0.563 0.206 
p value 0.287 0.111 0.031 0.905 0.039 0.300 0.861 0.566 0.056 0.146 0.625 
N 8 8 8 8 8 8 8 8 8 8 8 
CX3CL1 
Pearson correlation r -0.176 -0.491 -0.627 0.002 -0.700 0.417 0.201 -0.008 -0.639 0.565 0.051 
p value 0.677 0.217 0.096 0.997 0.053 0.304 0.633 0.985 0.088 0.144 0.905 
N 8 8 8 8 8 8 8 8 8 8 8 
FGF-2 
Pearson correlation r -0.312 -0.552 -0.601 -0.239 -0.509 0.386 -0.076 0.213 -0.414 0.222 0.317 
p value 0.451 0.156 0.115 0.568 0.198 0.345 0.859 0.613 0.308 0.597 0.445 
N 8 8 8 8 8 8 8 8 8 8 8 
IL-6 
Pearson correlation r -0.303 -0.394 -0.531 0.035 -0.543 0.472 0.187 0.426 -0.545 0.416 0.180 
p value 0.466 0.334 0.175 0.935 0.165 0.238 0.658 0.293 0.163 0.305 0.670 
N 8 8 8 8 8 8 8 8 8 8 8 
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PDGF-AA 
Pearson correlation r -0.288 -0.320 -0.442 -0.014 -0.042 0.208 -0.135 -0.571 -0.430 -0.053 -0.403 
p value 0.489 0.439 0.273 0.975 0.922 0.621 0.749 0.139 0.287 0.901 0.323 
N 8 8 8 8 8 8 8 8 8 8 8 
VEGF-A 
Pearson correlation r -0.494 -0.130 -0.308 0.247 -0.135 0.223 0.164 0.461 -0.473 0.180 -0.098 
p value 0.213 0.760 0.457 0.555 0.750 0.596 0.697 0.250 0.236 0.669 0.818 
N 8 8 8 8 8 8 8 8 8 8 8 
 
Pre-operative haematological parameters and serum inflammation-based scores (NLR, LMR and PLR) and cytokine secretome among somatotrophinomas 
p values were determined by the Pearson correlation coefficient r. FGF, fibroblast growth factor; IL, interleukin; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-
lymphocyte ratio; PDGF, platelet-derived growth factor; PLR, platelet-to-lymphocyte ratio; VEGF, vascular endothelial growth factor. 
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Appendix 7: Supplemental table with cytokine bead array data from TAFs 
untreated (baseline) and after pasireotide treatment, as well as from 
normal untreated skin fibroblasts 
 
 
Basal and pasireotide-treated cytokine secretome from tumour-associated fibroblasts isolated 
from PAs, as well as from normal skin fibroblasts (untreated) from 2 healthy individuals. PA-
derived TAF supernatants were collected following 24h on serum-free medium conditions with 
pasireotide (10-7M) or without (untreated). Results are shown for all detectable cytokines, 
chemokines and growth factors as concentration (pg/mL), mean±SEM. IL-1α, IL-2, IL-3, IL-5, IL-7, 
IL-9, IL-10, IL-13, IL-1ra, CCL4, TNF-α and TGF-α were undetectable in the TAF supernatants (i.e. 
below the lowest standard curve point and serum-free medium), and thus not represented in the 
table. Comparative analysis regarding the TAF secretome from pasireotide treated vs untreated 
TAFs (n=16) with respective p values (Mann-Whitney U test) are shown in the table.  
 
Cytokine/ 
Chemokine/ 
Growth factor 
UNTREATED TAFs 
Mean concentration 
(pg/mL) ± SEM (n=16) 
TAFs TREATED WITH PASIREOTIDE 
Mean concentration  
(pg/mL) ± SEM (n=16) 
p 
value 
UNTREATED SKIN FIBROBLASTS 
Mean concentration  
(pg/mL) ± SEM  (n=2) 
CCL2 4786.86 ± 642.17 3105.43 ± 434.95 0.038 2756.56 ± 1585.22 
CCL11 836.27 ± 328.16 529.82 ± 173.32 0.415 0 
VEGF-A 174.29 ± 80.60 134.11 ± 69.96 0.709 96.09 ± 29.12 
CCL22 62.54 ± 21.50 59.15 ± 14.64 0.897 14.87 ± 1.14 
IL-6 54.76 ± 6.50 11.83 ± 2.77 <0.001 68.42 ± 7.82 
FGF-2 42.93 ± 5.82 38.62 ± 4.32 0.557 28.40 ± 0.00 
IL-8 42.20 ± 11.11 30.21 ± 9.38 0.416 1.89 ± 0.27 
CXCL1 28.20 ± 6.56 28.13 ± 4.32 0.993 28.44 ± 28.44 
CX3CL1 26.86 ± 8.34 24.04 ± 5.21 0.776 9.41 ± 1.55 
CCL7 13.83 ± 5.97 10.47 ± 3.29 0.626 26.18 ± 15.71 
PDGF-AA 11.64 ± 3.71 5.37 ± 1.38 0.130 0.20 ± 0.00 
IFNα2 8.82 ± 2.40 6.76 ± 1.35 0.460 1.22 ± 1.04 
IL-4 6.44 ± 4.16 5.61 ± 2.76 0.869 0 
IL-12p40 5.12 ± 2.32 4.08 ± 1.42 0.706 0.15 ± 0.15 
Flt3L 3.86 ± 0.69 3.76 ± 0.44 0.906 2.69 ± 0.00 
GM-CSF 3.50 ± 0.85 3.07 ± 0.66 0.695 1.10 ± 0.06 
CCL5 3.40 ± 0.62 2.67 ± 1.89 0.360 0.60 ± 0.60 
IL-18 3.00 ± 1.20 2.77 ± 0.96 0.880 0 
PDGF-BB 2.99 ± 1.11 2.22 ± 0.73 0.565 0 
CXCL10 2.67 ± 1.02 2.59 ± 1.02 0.954 0 
IL-15 2.57 ± 0.42 2.37 ± 0.28 0.693 2.04 ± 0.06 
CCL3 2.49 ± 0.71 2.44 ± 0.62 0.956 0.28 ± 0.28 
EGF 2.18 ± 0.68 1.70 ± 0.49 0.570 2.18 ± 0.40 
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G-CSF 2.05 ± 0.73 1.70 ± 0.53 0.701 1.10 ± 0.06 
IFNγ 1.87 ± 0.59 1.52 ± 0.39 0.627 1.56 ± 0.69 
IL-12p70 1.32 ± 0.65 1.18 ± 0.35 0.852 0 
sCD40L 0.95 ± 0.52 0.45 ± 0.12 0.369 0.27 ± 0.05 
IL-1β 0.93 ± 0.18 0.67 ± 0.14 0.253 0.36 ± 0.08 
TNF-β 0.92 ± 0.41 0.81 ± 0.25 0.831 0.52 ± 0.05 
IL-17A 0.78 ± 0.36 0.34 ± 0.14 0.880 0.62 ± 0.24 
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Appendix 8: Supplemental table with correlation between TAF-derived cytokine secretome and pituitary hormone levels 
among NFPAs and somatotrophinomas 
 
 
 
NFPA-derived TAFs (n= 11) CCL2 CCL11 VEGF-A CCL22 IL-6 FGF-2 IL-8 CXCL1 CX3CL1 CCL7 PDGF-AA IFNα2 
GH (mcg/L) 
Pearson correlation r -0.138 0.077 -0.427 -0.266 -0.437 -0.141 -0.205 -0.146 -0.203 -0.280 0.434 -0.193 
p value 0.744 0.856 0.292 0.524 0.279 0.740 0.627 0.730 0.629 0.501 0.283 0.647 
N 8 8 8 8 8 8 8 8 8 8 8 8 
IGF-1 (nmol/L) 
Pearson correlation r -0.276 0.073 -0.086 -0.101 -0.156 -0.289 -0.107 -0.239 -0.068 -0.047 0.658 0.005 
p value 0.440 0.840 0.813 0.782 0.667 0.418 0.769 0.506 0.853 0.898 0.039 0.989 
N 10 10 10 10 10 10 10 10 10 10 10 10 
IGF-1 index 
Pearson correlation r 0.156 0.218 0.275 -0.087 0.173 -0.275 -0.100 -0.126 -0.124 -0.006 0.572 -0.031 
p value 0.666 0.545 0.442 0.812 0.633 0.441 0.784 0.730 0.733 0.988 0.084 0.931 
N 10 10 10 10 10 10 10 10 10 10 10 10 
PRL (mU/L) 
Pearson correlation r 0.587 -0.360 -0.283 -0.223 -0.036 -0.172 -0.543 -0.229 -0.378 -0.248 -0.149 -0.391 
p value 0.074 0.306 0.428 0.536 0.922 0.635 0.105 0.525 0.282 0.490 0.682 0.265 
N 10 10 10 10 10 10 10 10 10 10 10 10 
PRL index 
Pearson correlation r 0.340 -0.212 -0.039 -0.043 0.269 -0.136 -0.445 -0.060 -0.215 -0.024 -0.147 -0.209 
p value 0.336 0.557 0.916 0.906 0.452 0.709 0.198 0.869 0.551 0.947 0.685 0.562 
N 10 10 10 10 10 10 10 10 10 10 10 10 
TSH (µU/mL) 
Pearson correlation r -0.095 0.196 0.601 0.289 0.523 0.114 0.294 0.330 0.191 0.466 -0.014 0.257 
p value 0.794 0.586 0.066 0.418 0.121 0.753 0.410 0.351 0.598 0.175 0.969 0.473 
N 10 10 10 10 10 10 10 10 10 10 10 10 
FT4 (pmol/L) 
Pearson correlation r -0.095 0.497 -0.134 0.092 -0.747 0.089 0.284 -0.025 0.296 0.085 0.662 0.285 
p value 0.794 0.144 0.712 0.801 0.013 0.808 0.426 0.946 0.406 0.814 0.037 0.425 
N 10 10 10 10 10 10 10 10 10 10 10 10 
Basal Cortisol 
(nmol/L) 
Pearson correlation r -0.359 0.220 -0.072 -0.205 0.067 -0.425 -0.244 -0.356 -0.378 -0.223 0.643 -0.006 
p value 0.383 0.601 0.865 0.627 0.874 0.294 0.560 0.387 0.357 0.595 0.085 0.989 
N 8 8 8 8 8 8 8 8 8 8 8 8 
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LH (U/L) 
Pearson correlation r -0.271 0.144 0.209 -0.096 -0.094 -0.114 0.332 -0.138 -0.039 -0.030 0.598 0.088 
p value 0.450 0.691 0.562 0.791 0.796 0.753 0.349 0.705 0.915 0.934 0.068 0.808 
N 10 10 10 10 10 10 10 10 10 10 10 10 
FSH (U/L) 
Pearson correlation r 0.089 0.216 0.574 -0.145 0.054 -0.424 0.265 -0.183 -0.042 -0.008 0.677 0.068 
p value 0.806 0.549 0.083 0.690 0.882 0.222 0.459 0.613 0.908 0.982 0.032 0.852 
N 10 10 10 10 10 10 10 10 10 10 10 10 
Testosterone 
(nmol/L) 
Pearson correlation r -0.066 0.335 0.338 0.600 -0.097 0.287 0.130 0.303 0.554 0.507 -0.109 0.573 
p value 0.876 0.417 0.413 0.116 0.820 0.490 0.758 0.466 0.154 0.199 0.797 0.138 
N 8 8 8 8 8 8 8 8 8 8 8 8 
 
Correlations between TAF-derived cytokines and pituitary hormone levels among NFPAs  
FSH, follicle-stimulating hormone; FT4, free thyroxine; GH, growth hormone; IGF-1, insulin-like growth factor-1; LH, luteinising hormone; NFPA, non-functioning pituitary 
adenoma; PRL, prolactin; TSH, thyroid-stimulating hormone. 
 
 
 
 
 
Somatotrophinoma-derived TAFs (n = 5) CCL2 CCL11 VEGF-A CCL22 IL-6 FGF-2 IL-8 CXCL1 CX3CL1 CCL7 PDGF-AA IFNα2 
GH (mcg/L) 
Pearson correlation r -0.203 -0.617 -0.552 -0.449 -0.674 -0.640 -0.751 -0.600 -0.865 -0.568 0.862 -0.939 
p value 0.743 0.268 0.334 0.449 0.212 0.245 0.144 0.284 0.058 0.317 0.060 0.018 
N 5 5 5 5 5 5 5 5 5 5 5 5 
IGF-1 (nmol/L) 
Pearson correlation r -0.382 -0.805 -0.755 -0.184 -0.854 -0.600 -0.766 -0.637 -0.800 -0.656 0.808 -0.837 
p value 0.526 0.100 0.140 0.767 0.066 0.285 0.131 0.248 0.104 0.230 0.098 0.077 
N 5 5 5 5 5 5 5 5 5 5 5 5 
IGF-1 index 
Pearson correlation r -0.522 -0.748 -0.750 0.018 -0.825 -0.654 -0.572 -0.442 -0.793 -0.535 0.771 -0.708 
p value 0.367 0.146 0.144 0.977 0.085 0.231 0.313 0.456 0.110 0.353 0.127 0.181 
N 5 5 5 5 5 5 5 5 5 5 5 5 
PRL (mU/L) 
Pearson correlation r 0.846 -0.179 -0.326 0.186 -0.155 -0.986 -0.785 -0.851 0.223 -0.831 0.730 -0.159 
p value 0.359 0.886 0.789 0.881 0.901 0.107 0.425 0.352 0.857 0.376 0.479 0.898 
N 3 3 3 3 3 3 3 3 3 3 3 3 
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PRL index 
Pearson correlation r 0.846 -0.177 -0.324 0.188 -0.154 -0.986 -0.784 -0.850 0.225 -0.830 0.728 -0.157 
p value 0.358 0.887 0.790 0.880 0.902 0.108 0.426 0.353 0.856 0.377 0.481 0.899 
N 3 3 3 3 3 3 3 3 3 3 3 3 
TSH (µU/ml) 
Pearson correlation r 0.208 -0.079 -0.189 -0.175 -0.180 -0.886 -0.403 -0.326 -0.554 -0.369 0.742 -0.475 
p value 0.737 0.900 0.761 0.778 0.772 0.045 0.501 0.592 0.332 0.541 0.151 0.419 
N 5 5 5 5 5 5 5 5 5 5 5 5 
FT4 (pmol/L) 
Pearson correlation r -0.557 -0.564 -0.553 0.873 -0.479 0.521 0.052 -0.060 0.490 -0.176 -0.495 0.524 
p value 0.330 0.322 0.334 0.053 0.415 0.368 0.934 0.923 0.402 0.777 0.396 0.365 
N 5 5 5 5 5 5 5 5 5 5 5 5 
Basal Cortisol 
(nmol/L) 
Pearson correlation r -0.314 0.480 0.611 -0.326 0.498 0.765 0.758 0.807 0.124 0.858 -0.572 0.165 
p value 0.606 0.414 0.274 0.592 0.393 0.131 0.138 0.099 0.843 0.063 0.313 0.791 
N 5 5 5 5 5 5 5 5 5 5 5 5 
LH (U/L) 
Pearson correlation r -0.256 -0.189 -0.266 0.968 -0.119 0.446 0.276 0.116 0.718 -0.020 -0.618 0.813 
p value 0.677 0.761 0.666 0.007 0.848 0.452 0.653 0.853 0.172 0.975 0.267 0.095 
N 5 5 5 5 5 5 5 5 5 5 5 5 
FSH (U/L) 
Pearson correlation r -0.402 -0.509 -0.594 0.969 -0.469 0.126 -0.026 -0.140 0.398 -0.306 -0.263 0.509 
p value 0.502 0.381 0.291 0.006 0.425 0.840 0.966 0.822 0.507 0.616 0.669 0.381 
N 5 5 5 5 5 5 5 5 5 5 5 5 
Testosterone 
(nmol/L) 
Pearson correlation r -0.314 -0.257 -0.313 -0.093 -0.369 -0.676 -0.208 -0.077 -0.711 -0.175 0.661 -0.540 
p value 0.606 0.676 0.608 0.881 0.541 0.210 0.738 0.902 0.178 0.779 0.225 0.347 
N 5 5 5 5 5 5 5 5 5 5 5 5 
 
Correlations between TAF-derived cytokines and pituitary hormone levels among somatotrophinomas 
FSH, follicle-stimulating hormone; FT4, free thyroxine; GH, growth hormone; IGF-1, insulin-like growth factor-1; LH, luteinising hormone; PRL, prolactin; TSH, thyroid-
stimulating hormone. 
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Appendix 9: Supplemental tables with correlations between hormonal, 
cytokine and infiltrating immune cell data and TME-related oncogenic 
mechanisms in PAs 
 
 
 
PAs 
n= 24 
MVD TMVA Perimeter 
Feret’s 
diameter 
Area per 
vessel 
Roundness 
Hormonal data  
[Pearson correlation r (p)] 
Serum IGF-1 
IGF-1 index 
Serum PRL 
PRL index 
Serum TSH 
Serum FT4 
Basal plasma cortisol 
Serum LH 
Serum FSH 
Serum testosterone 
 
 
0.192 (p=0.404) 
0.208 (p=0.353) 
-0.054 (p=0.825) 
-0.072 (p=0.768) 
-0.316 (p=0.163) 
0.207 (p=0.367) 
-0.223 (p=0.345) 
0.025 (p=0.913) 
0.084 (p=0.719) 
-0.386 (p=0.114) 
 
 
-0.269 (p=0.238) 
-0.288 (p=0.194) 
-0.023 (p=0.925) 
-0.018 (p=0.942) 
-0.088 (p=0.704) 
-0.034 (p=0.885) 
-0.285 (p=0.223) 
0.217 (p=0.344) 
0.392 (p=0.078) 
-0.442 (p=0.067) 
 
 
-0.550 (p=0.010) 
-0.605 (p=0.003) 
-0.112 (p=0.647) 
-0.047 (p=0.849) 
0.280 (p=0.219) 
-0.392 (p=0.079) 
-0.009 (p=0.970) 
0.044 (p=0.851) 
0.149 (p=0.519) 
0.071 (p=0.780) 
 
 
-0.548 (p=0.010) 
-0.601 (p=0.003) 
-0.110 (p=0.653) 
-0.051 (p=0.835) 
0.252 (p=0.270) 
-0.369 (p=0.100) 
0.014 (p=0.952) 
0.037 (p=0.873) 
0.138 (p=0.551) 
0.084 (p=0.741) 
 
 
-0.409 (p=0.066) 
-0.436 (p=0.043) 
-0.014 (p=0.955) 
0.024 (p=0.924) 
0.144 (p=0.533) 
-0.324 (p=0.152) 
-0.121 (p=0.610) 
0.037 (p=0.872) 
0.202 (p=0.380) 
-0.011 (p=0.965) 
 
 
0.246 (p=0.282) 
0.287 (p=0.196) 
0.084 (p=0.734) 
-0.012 (p=0.960) 
-0.295 (p=0.194) 
0.114 (p=0.623) 
-0.357 (p=0.122) 
0.096 (p=0.680) 
0.049 (p=0.834) 
-0.113 (p=0.656) 
PA-derived cytokine data 
[Pearson correlation r (p)] 
IL-8 
CCL2 
CCL3 
CCL4 
CXCL10 
CCL22 
CXCL1 
CX3CL1 
FGF-2 
IL-6 
PDGF-AA 
VEGF-A 
 
 
-0.088 (p=0.683) 
-0.251 (p=0.238) 
-0.057 (p=0.792) 
-0.127 (p=0.553) 
-0.266 (p=0.210) 
-0.242 (p=0.255) 
-0.116 (p=0.590) 
-0.251 (p=0.236) 
-0.146 (p=0.498) 
-0.073 (p=0.736) 
-0.194 (p=0.365) 
-0.151 (p=0.482) 
 
 
-0.128 (p=0.552) 
-0.079 (p=0.715) 
-0.093 (p=0.666) 
-0.112 (p=0.601) 
-0.041 (p=0.848) 
-0.276 (p=0.191) 
-0.154 (p=0.473) 
-0.110 (p=0.608) 
-0.338 (p=0.106) 
-0.113 (p=0.599) 
-0.122 (p=0.571) 
-0.218 (p=0.307) 
 
 
-0.004 (p=0.984) 
0.307 (p=0.145) 
-0.046 (p=0.830) 
0.088 (p=0.682) 
0.368 (p=0.077) 
-0.021 (p=0.924) 
-0.041 (p=0.850) 
0.221 (p=0.299) 
-0.407 (p=0.048) 
0.013 (p=0.953) 
0.194 (p=0.363) 
0.036 (p=0.866) 
 
 
-0.007 (p=0.973) 
0.301 (p=0.153) 
-0.040 (p=0.851) 
0.088 (p=0.684) 
0.356 (p=0.087) 
-0.020 (p=0.925) 
-0.037 (p=0.863) 
0.206 (p=0.333) 
-0.391 (p=0.059) 
0.005 (p=0.981) 
0.193 (p=0.366) 
0.045 (p=0.836) 
 
 
-0.045 (p=0.835) 
0.331 (p=0.114) 
-0.010 (p=0.964) 
0.084 (p=0.696) 
0.407 (p=0.049) 
-0.097 (p=0.652) 
-0.038 (p=0.860) 
0.204 (p=0.339) 
-0.321 (p=0.126) 
-0.069 (p=0.747) 
0.138 (p=0.520) 
-0.034 (p=0.875) 
 
 
-0.026 (p=0.904) 
-0.016 (p=0.941) 
0.109 (p=0.612) 
-0.044 (p=0.840) 
0.087 (p=0.685) 
-0.094 (p=0.661) 
0.037 (p=0.863) 
0.132 (p=0.537) 
0.265 (p=0.210) 
-0.135 (p=0.530) 
-0.065 (p=0.762) 
-0.110 (p=0.610) 
TAF cytokine data    n=16 
[Pearson correlation r (p)] 
CCL2 
CCL11 
VEGF-A 
CCL22 
IL-6 
FGF-2 
IL-8 
CXCL1 
CX3CL1 
CCL7 
PDGF-AA 
IFNα2 
 
 
0.440 (p=0.088) 
-0.193 (p=0.474) 
-0.173 (p=0.521) 
-0.029 (p=0.915) 
-0.466 (p=0.069) 
0.177 (p=0.511) 
-0.079 (p=0.772) 
-0.100 (p=0.713) 
-0.089 (p=0.744) 
-0.076 (p=0.779) 
-0.267 (p=0.317) 
-0.095 (p=0.726) 
 
 
0.672 (p=0.004) 
-0.347 (p=0.189) 
-0.255 (p=0.340) 
-0.051 (p=0.852) 
-0.318 (p=0.231) 
-0.016 (p=0.954) 
-0.270 (p=0.311) 
-0.181 (p=0.503) 
-0.161 (p=0.552) 
-0.199 (p=0.460) 
-0.482 (p=0.058) 
-0.143 (p=0.598) 
 
 
0.075 (p=0.783) 
-0.223 (p=0.406) 
-0.117 (p=0.666) 
0.062 (p=0.820) 
0.387 (p=0.139) 
-0.242 (p=0.366) 
-0.245 (p=0.361) 
-0.110 (p=0.685) 
-0.038 (p=0.888) 
-0.155 (p=0.568) 
-0.352 (p=0.182) 
0.037 (p=0.891) 
 
 
0.043 (p=0.874) 
-0.222 (p=0.409) 
-0.120 (p=0.658) 
0.034 (p=0.900) 
0.368 (p=0.161) 
-0.263 (p=0.324) 
-0.217 (p=0.420) 
-0.115 (p=0.673) 
-0.049 (p=0.856) 
-0.150 (p=0.580) 
-0.324 (p=0.220) 
0.022 (p=0.937) 
 
 
0.033 (p=0.904) 
-0.234 (p=0.383) 
-0.113 (p=0.676) 
-0.038 (p=0.888) 
0.459 (p=0.074) 
-0.326 (p=0.218) 
-0.228 (p=0.395) 
-0.112 (p=0.679) 
-0.136 (p=0.617) 
-0.173 (p=0.522) 
-0.295 (p=0.268) 
-0.065 (p=0.811) 
 
 
-0.052 (p=0.848) 
-0.051 (p=0.852) 
-0.078 (p=0.774) 
-0.063 (p=0.817) 
-0.360 (p=0.170) 
0.151 (p=0.577) 
-0.001 (p=0.997) 
0.035 (p=0.899) 
-0.043 (p=0.876) 
-0.045 (p=0.869) 
0.115 (p=0.671) 
-0.073 (p=0.787) 
PA-infiltrating 
macrophage [Mean±SEM] 
< 6% (n=17) 
≥ 6% (n=7)  
 
 
33.16 ± 5.18 
46.43 ± 8.34 
p=0.184 
 
 
6.88 ± 0.91 
9.18 ± 1.90 
p=0.228 
 
 
106.66 ± 8.33 
99.59 ± 3.76 
p=0.448 
 
 
43.36 ± 3.45 
40.24 ± 1.35 
p=0.408 
 
 
0.26 ± 0.05 
0.20 ± 0.02 
p=0.495 
 
 
0.47 ± 0.01 
0.47 ± 0.01 
p=0.711 
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PA-infiltrating CD8+ T cells 
[Mean±SEM] 
< 1% (n=6) 
≥ 1% (n=18)  
 
 
30.89 ± 6.23 
39.07 ± 5.61 
p=0.441 
 
 
6.65 ± 0.90 
7.85 ± 1.10 
p=0.557 
 
 
111.42 ± 10.89 
102.32 ± 7.18 
p=0.522 
 
 
45.90 ± 4.71 
41.30 ± 2.91 
p=0.432 
 
 
0.24 ± 0.04 
0.24 ± 0.05 
p=0.967 
 
 
0.44 ± 0.02 
0.48 ± 0.01 
p=0.064 
PA-infiltrating CD4+ T cells 
[Mean±SEM] 
< 1% (n=15) 
≥ 1% (n=9)  
 
 
32.00 ± 4.40 
45.41 ± 9.14 
p=0.152 
 
 
6.18 ± 0.61 
9.83 ± 1.86 
p=0.035 
 
 
106.28 ± 8.95 
101.78 ± 6.22 
p=0.724 
 
 
43.30 ± 3.74 
41.03 ± 2.34 
p=0.665 
 
 
0.24 ± 0.05 
0.23 ± 0.03 
p=0.878 
 
 
0.45 ± 0.01 
0.49 ± 0.01 
p=0.051 
PA-infiltrating B cells 
[Mean±SEM] 
< 0.5% (n=8) 
≥ 0.5% (n=16)  
 
 
30.21 ± 6.06 
40.44 ± 5.94 
p=0.292 
 
 
6.64 ± 0.85 
8.00 ± 1.21 
p=0.467 
 
 
118.62 ± 13.62 
97.59 ± 5.39 
p=0.098 
 
 
48.49 ± 5.76 
39.43 ± 2.10 
p=0.174 
 
 
0.30 ± 0.09 
0.21 ± 0.02 
p=0.386 
 
 
0.43 ± 0.02 
0.48 ± 0.01 
p=0.015 
PA-infiltrating neutrophils 
[Mean±SEM] 
< 0.5% (n=13) 
≥ 0.5% (n=11)  
 
 
39.74 ± 5.96 
33.82 ± 6.97 
p=0.522 
 
 
7.84 ± 1.40 
7.20 ± 0.92 
p=0.720 
 
 
97.81 ± 5.22 
112.62 ± 11.35 
p=0.225 
 
 
39.84 ± 2.05 
45.53 ± 4.77 
p=0.259 
 
 
0.20 ± 0.02 
0.28 ± 0.07 
p=0.257 
 
 
0.47 ± 0.01 
0.47 ± 0.02 
p=0.927 
PA-infiltrating FOXP3+ T 
cells [Mean±SEM] 
< 0.3% (n=12) 
≥ 0.3% (n=12)  
 
 
47.42 ± 7.53 
26.64 ± 2.79 
p=0.021 
 
 
8.70 ± 1.31 
6.39 ± 1.04 
p=0.182 
 
 
98.34 ± 4.28 
110.86 ± 11.13 
p=0.312 
 
 
39.83 ± 1.72 
45.07 ± 4.60 
p=0.304 
 
 
0.19 ± 0.01 
0.29 ± 0.07 
p=0.198 
 
 
0.47 ± 0.01 
0.46 ± 0.02 
p=0.659 
Immune cell ratios 
[Pearson correlation r (p)] 
M2:M1 
CD8:CD4 
CD8:FOXP3 
CD68:FOXP3 
 
 
0.491 (p=0.015) 
0.084 (p=0.697) 
0.203 (p=0.341) 
0.111 (p=0.606) 
 
 
0.666 (p<0.001) 
0.016 (p=0.942) 
0.043 (p=0.841) 
0.030 (p=0.890) 
 
 
0.241 (p=0.257) 
-0.073 (p=0.734) 
-0.229 (p=0.281) 
-0.115 (p=0.592) 
 
 
0.224 (p=0.292) 
-0.063 (p=0.769) 
-0.240 (p=0.259) 
-0.118 (p=0.582) 
 
 
0.353 (p=0.091) 
-0.038 (p=0.861) 
-0.228 (p=0.284) 
-0.179 (p=0.402) 
 
 
0.119 (p=0.580) 
-0.045 (p=0.833) 
0.186 (p=0.385) 
-0.015 (p=0.946) 
 
Correlation between hormonal, cytokine and infiltrating immune cell data and PA angiogenesis in the 
whole cohort of PAs (n=24) 
Microvessel density (MVD) is expressed in vessels/HPF; total microvessel area (TMVA) is expressed in % of 
the high power field; perimeter and Feret’s diameter are expressed in µm; area per vessel is expressed in % 
of the high power field; vessel roundness correspond to a value comprised between 0 and 1 (1=perfect 
circle). FSH, follicle-stimulating hormone; FT4, free thyroxine; IGF-1, insulin-like growth factor-1; LH, 
luteinising hormone; MVD, microvessel density; NFPA, non-functioning pituitary adenoma; PRL, prolactin; 
TMVA, total microvessel area; TSH, thyroid-stimulating hormone. 
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PAs 
n= 24 
MMP-9 MMP-14 E-cadherin ZEB1 NCAM 
Hormonal data  
[Pearson correlation r (p)] 
Serum IGF-1 
IGF-1 index 
Serum PRL 
PRL index 
Serum TSH 
Serum FT4 
Basal plasma cortisol 
Serum LH 
Serum FSH 
Serum testosterone 
 
 
0.678 (p=0.001) 
0.733 (p<0.001) 
-0.166 (p=0.498) 
-0.108 (p=0.659) 
-0.320 (p=0.157) 
0.375 (p=0.094) 
0.306 (p=0.190) 
0.109 (p=0.637) 
0.115 (p=0.618) 
-0.236 (p=0.345) 
 
 
-0.127 (p=0.582) 
-0.145 (p=0.521) 
-0.162 (p=0.507) 
-0.151 (p=0.537) 
0.147 (p=0.526) 
-0.277 (p=0.225) 
0.340 (p=0.142) 
-0.213 (p=0.353) 
-0.331 (p=0.143) 
0.379 (p=0.121) 
 
 
-0.127 (p=0.582) 
-0.010 (p=0.964) 
0.062 (p=0.801) 
0.066 (p=0.789) 
-0.155 (p=0.502) 
0.149 (p=0.520) 
-0.098 (p=0.681) 
0.040 (p=0.862) 
0.075 (p=0.748) 
0.251 (p=0.314) 
 
 
-0.170 (p=0.461) 
-0.133 (p=0.554) 
-0.085 (p=0.729) 
-0.087 (p=0.724) 
-0.088 (p=0.706) 
-0.104 (p=0.654) 
-0.045 (p=0.849) 
0.131 (p=0.573) 
-0.075 (p=0.747) 
0.010 (p=0.970) 
 
 
0.056 (p=0.811) 
0.154 (p=0.493) 
-0.354 (p=0.137) 
-0.354 (p=0.137) 
-0.229 (p=0.318) 
0.115 (p=0.618) 
-0.042 (p=0.861) 
0.518 (p=0.016) 
0.487 (p=0.025) 
-0.243 (p=0.331) 
PA-derived cytokine data 
[Pearson correlation r (p)] 
IL-8 
CCL2 
CCL3 
CCL4 
CXCL10 
CCL22 
CXCL1 
CX3CL1 
FGF-2 
IL-6 
PDGF-AA 
VEGF-A 
 
 
-0.350 (p=0.093) 
-0.450 (p=0.027) 
-0.312 (p=0.138) 
-0.376 (p=0.070) 
-0.309 (p=0.141) 
-0.131 (p=0.541) 
-0.325 (p=0.121) 
-0.286 (p=0.176) 
0.140 (p=0.513) 
-0.248 (p=0.243) 
-0.289 (p=0.171) 
-0.086 (p=0.690) 
 
 
0.303 (p=0.150) 
0.138 (p=0.522) 
0.134 (p=0.531) 
0.278 (p=0.188) 
-0.151 (p=0.481) 
0.371 (p=0.074) 
0.248 (p=0.243) 
-0.088 (p=0.684) 
-0.105 (p=0.626) 
0.350 (p=0.094) 
0.199 (p=0.352) 
0.227 (p=0.286) 
 
 
0.003 (p=0.987) 
0.032 (p=0.881) 
-0.086 (p=0.690) 
-0.002 (p=0.994) 
0.102 (p=0.634) 
-0.138 (p=0.520) 
-0.104 (p=0.629) 
0.073 (p=0.734) 
-0.165 (p=0.442) 
0.053 (p=0.805) 
-0.080 (p=0.709) 
-0.476 (p=0.019) 
 
 
-0.214 (p=0.315) 
-0.320 (p=0.128) 
-0.181 (p=0.398) 
-0.235 (p=0.270) 
-0.216 (p=0.311) 
-0.356 (p=0.088) 
-0.300 (p=0.154) 
-0.223 (p=0.295) 
-0.543 (p=0.006) 
-0.167 (p=0.435) 
-0.288 (p=0.172) 
-0.366 (p=0.078) 
 
 
-0.273 (p=0.197) 
-0.378 (p=0.069) 
-0.080 (p=0.709) 
-0.267 (p=0.208) 
-0.324 (p=0.123) 
-0.368 (p=0.077) 
-0.219 (p=0.304) 
-0.363 (p=0.081) 
-0.341 (p=0.103) 
-0.297 (p=0.158) 
-0.347 (p=0.097) 
-0.269 (p=0.203) 
TAF cytokine data    n=16 
[Pearson correlation r (p)] 
CCL2 
CCL11 
VEGF-A 
CCL22 
IL-6 
FGF-2 
IL-8 
CXCL1 
CX3CL1 
CCL7 
PDGF-AA 
IFNα2 
 
 
-0.133 (p=0.623) 
0.442 (p=0.086) 
0.461 (p=0.072) 
-0.389 (p=0.137) 
0.274 (p=0.305) 
-0.230 (p=0.391) 
0.288 (p=0.279) 
0.077 (p=0.778) 
-0.322 (p=0.224) 
0.276 (p=0.302) 
0.449 (p=0.081) 
-0.307 (p=0.826) 
 
 
-0.315 (p=0.235) 
-0.268 (p=0.316) 
-0.338 (p=0.200) 
0.284 (p=0.286) 
-0.169 (p=0.531) 
0.220 (p=0.412) 
-0.337 (p=0.202) 
-0.079 (p=0.770) 
0.145 (p=0.593) 
-0.187 (p=0.489) 
0.170 (p=0.529) 
0.169 (p=0.531) 
 
 
-0.217 (p=0.419) 
0.174 (p=0.519) 
0.188 (p=0.486) 
0.331 (p=0.211) 
0.278 (p=0.298) 
0.337 (p=0.201) 
0.372 (p=0.156) 
0.497 (p=0.050) 
0.173 (p=0.523) 
0.426 (p=0.100) 
-0.564 (p=0.023) 
0.175 (p=0.516) 
 
 
-0.039 (p=0.887) 
-0.401 (p=0.124) 
-0.318 (p=0.230) 
0.071 (p=0.793) 
-0.056 (p=0.838) 
0.061 (p=0.821) 
-0.228 (p=0.396) 
-0.246 (p=0.359) 
-0.221 (p=0.410) 
-0.248 (p=0.354) 
-0.409 (p=0.116) 
-0.129 (p=0.633) 
 
 
0.059 (p=0.829) 
-0.085 (p=0.755) 
-0.043 (p=0.875) 
-0.394 (p=0.131) 
0.139 (p=0.606) 
-0.631 (p=0.009) 
0.011 (p=0.967) 
-0.388 (p=0.138) 
-0.493 (p=0.052) 
-0.223 (p=0.406) 
0.301 (p=0.257) 
-0.447 (p=0.083) 
PA-infiltrating 
macrophage [Mean±SEM] 
< 6% (n=17) 
≥ 6% (n=7)  
 
 
2.82 ± 0.55 
0.71 ± 0.71 
p=0.042 
 
 
1.29 ± 0.45 
1.14 ± 0.60 
p=0.852 
 
 
4.71 ± 0.25 
4.43 ± 0.37 
p=0.554 
 
 
1.24 ± 0.44 
0.57 ± 0.37 
p=0.376 
 
 
5.12 ± 0.17 
4.57 ± 0.20 
p=0.077 
PA-infiltrating CD8+ T cells 
[Mean±SEM] 
< 1% (n=6) 
≥ 1% (n=18)  
 
 
1.50 ± 0.96 
2.44 ± 0.56 
p=0.404 
 
 
1.33 ± 0.88 
1.22 ± 0.39 
p=0.896 
 
 
4.67 ± 0.33 
4.61 ± 0.26 
p=0.910 
 
 
1.00 ± 0.68 
1.06 ± 0.39 
p=0.944 
 
 
5.00 ± 0.26 
4.94 ± 0.17 
p=0.869 
PA-infiltrating CD4+ T cells 
[Mean±SEM] 
< 1% (n=15) 
≥ 1% (n=9)  
 
 
2.47 ± 0.64 
1.78 ± 0.72 
p=0.497 
 
 
1.20 ± 0.48 
1.33 ± 0.55 
p=0.861 
 
 
4.73 ± 0.30 
4.44 ± 0.24 
p=0.511 
 
 
1.07 ± 0.42 
1.00 ± 0.58 
p=0.925 
 
 
5.13 ± 0.17 
4.67 ± 0.24 
p=0.110 
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PA-infiltrating B cells 
[Mean±SEM] 
< 0.5% (n=8) 
≥ 0.5% (n=16)  
 
 
2.00 ± 0.98 
2.31 ± 0.55 
p=0.765 
 
 
1.13 ± 0.74 
1.31 ± 0.41 
p=0.811 
 
 
4.88 ± 0.35 
4.50 ± 0.26 
p=0.405 
 
 
0.75 ± 0.53 
1.19 ± 0.43 
p=0.547 
 
 
4.88 ± 0.23 
5.00 ± 0.18 
p=0.685 
PA-infiltrating neutrophils 
[Mean±SEM] 
< 0.5% (n=13) 
≥ 0.5% (n=11)  
 
 
2.69 ± 0.65 
1.64 ± 0.69 
p=0.280 
 
 
0.46 ± 0.31 
2.18 ± 0.59 
p=0.020 
 
 
4.46 ± 0.35 
4.82 ± 0.18 
p=0.379 
 
 
0.62 ± 0.35 
1.55 ± 0.58 
p=0.187 
 
 
5.08 ± 0.18 
4.82 ± 0.23 
p=0.372 
PA-infiltrating FOXP3+ T 
cells [Mean±SEM] 
< 0.3% (n=12) 
≥ 0.3% (n=12)  
 
 
1.92 ± 0.69 
2.50 ± 0.68 
p=0.553 
 
 
0.75 ± 0.41 
1.75 ± 0.57 
p=0.167 
 
 
4.58 ± 0.26 
4.67 ± 0.33 
p=0.846 
 
 
0.83 ± 0.39 
1.25 ± 0.55 
p=0.543 
 
 
4.75 ± 0.18 
5.17 ± 0.21 
p=0.143 
Immune cell ratios 
[Pearson correlation r (p)] 
M2:M1 
CD8:CD4 
CD8:FOXP3 
CD68:FOXP3 
 
 
-0.146 (p=0.497) 
0.240 (p=0.260) 
0.127 (p=0.555) 
-0.315 (p=0.134) 
 
 
-0.268 (p=0.206) 
-0.276 (p=0.191) 
0.052 (p=0.809) 
0.002 (p=0.994) 
 
 
0.220 (p=0.301) 
-0.050 (p=0.816) 
0.195 (p=0.362) 
0.142 (p=0.508) 
 
 
0.265 (p=0.212) 
-0.127 (p=0.554) 
-0.113 (p=0.598) 
-0.157 (p=0.463) 
 
 
0.027 (p=0.901) 
0.095 (p=0.659) 
-0.219 (p=0.303) 
-0.211 (p=0.322) 
 
Correlation between hormonal, cytokine and infiltrating immune cell data and MMP-9, MMP-14, E-
cadherin, ZEB1 and NCAM immunoreactivities in the whole cohort of PAs (n=24) 
FSH, follicle-stimulating hormone; FT4, free thyroxine; IGF-1, insulin-like growth factor-1; LH, luteinising 
hormone; NFPA, non-functioning pituitary adenoma; MMP, matrix metalloproteinase; NCAM, neural cell 
adhesion molecule; PRL, prolactin; TSH, thyroid-stimulating hormone. 
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NFPAs 
n = 16 
MVD TMVA Perimeter 
Feret’s 
diameter 
Area per 
vessel 
Roundness 
Hormonal data  
[Pearson correlation r (p)] 
Serum IGF-1 
IGF-1 index 
Serum PRL 
PRL index 
Serum TSH 
Serum FT4 
Basal plasma cortisol 
Serum LH 
Serum FSH 
Serum testosterone 
 
 
-0.228 (p=0.433) 
-0.033 (p=0.912) 
0.542 (p=0.045) 
0.221 (p=0.449) 
-0.220 (p=0.450) 
-0.039 (p=0.895) 
-0.353 (p=0.237) 
-0.095 (p=0.746) 
-0.036 (p=0.902) 
-0.541 (p=0.069) 
 
 
-0.401 (p=0.156) 
-0.153 (p=0.601) 
0.359 (p=0.208) 
0.230 (p=0.430) 
-0.274 (p=0.344) 
0.043 (p=0.885) 
-0.403 (p=0.172) 
0.137 (p=0.640) 
0.359 (p=0.208) 
-0.605 (p=0.037) 
 
 
-0.247 (p=0.395) 
-0.227 (p=0.434) 
-0.219 (p=0.452) 
0.104 (p=0.724) 
-0.013 (p=0.965) 
-0.132 (p=0.653) 
-0.037 (p=0.904) 
-0.007 (p=0.981) 
0.178 (p=0.542) 
0.180 (p=0.576) 
 
 
-0.214 (p=0.462) 
-0.205 (p=0.482) 
-0.262 (p=0.366) 
0.051 (p=0.861) 
-0.049 (p=0.867) 
-0.106 (p=0.717) 
-0.017 (p=0.956) 
-0.021 (p=0.944) 
0.157 (p=0.592) 
0.197 (p=0.539) 
 
 
-0.337 (p=0.238) 
-0.202 (p=0.488) 
-0.235 (p=0.418) 
-0.010 (p=0.973) 
-0.099 (p=0.735) 
-0.162 (p=0.581) 
-0.140 (p=0.648) 
-0.006 (p=0.983) 
0.209 (p=0.474) 
-0.058 (p=0.859) 
 
 
-0.205 (p=0.482) 
-0.275 (p=0.342) 
0.023 (p=0.938) 
-0.324 (p=0.259) 
-0.334 (p=0.242) 
-0.029 (p=0.922) 
-0.350 (p=0.241) 
0.142 (p=0.629) 
0.034 (p=0.909) 
-0.486 (p=0.109) 
PA-derived cytokine data 
[Pearson correlation r (p)] 
IL-8 
CCL2 
CCL3 
CCL4 
CXCL10 
CCL22 
CXCL1 
CX3CL1 
FGF-2 
IL-6 
PDGF-AA 
VEGF-A 
 
 
-0.104 (p=0.702) 
-0.297 (p=0.264) 
-0.067 (p=0.805) 
-0.147 (p=0.587) 
-0.301 (p=0.257) 
-0.171 (p=0.528) 
-0.112 (p=0.680) 
-0.263 (p=0.325) 
-0.020 (p=0.941) 
-0.083 (p=0.760) 
-0.255 (p=0.341) 
-0.219 (p=0.416) 
 
 
-0.264 (p=0.323) 
-0.244 (p=0.362) 
-0.211 (p=0.434) 
-0.250 (p=0.351) 
-0.136 (p=0.616) 
-0.271 (p=0.309) 
-0.263 (p=0.324) 
-0.190 (p=0.480) 
-0.236 (p=0.379) 
-0.208 (p=0.440) 
-0.319 (p=0.228) 
-0.341 (p=0.196) 
 
 
-0.174 (p=0.518) 
0.170 (p=0.530) 
-0.210 (p=0.435) 
-0.066 (p=0.809) 
0.322 (p=0.224) 
-0.043 (p=0.875) 
-0.198 (p=0.463) 
0.159 (p=0.557) 
-0.421 (p=0.104) 
-0.099 (p=0.714) 
0.035 (p=0.899) 
-0.012 (p=0.964) 
 
 
-0.178 (p=0.510) 
0.161 (p=0.550) 
-0.203 (p=0.452) 
-0.067 (p=0.806) 
0.307 (p=0.247) 
-0.044 (p=0.871) 
-0.193 (p=0.473) 
0.141 (p=0.604) 
-0.407 (p=0.118) 
-0.109 (p=0.689) 
0.035 (p=0.898) 
-0.001 (p=0.997) 
 
 
-0.158 (p=0.560) 
0.241 (p=0.368) 
-0.107 (p=0.693) 
-0.017 (p=0.949) 
0.367 (p=0.162) 
-0.147 (p=0.587) 
-0.139 (p=0.607) 
0.149 (p=0.582) 
-0.367 (p=0.162) 
-0.150 (p=0.580) 
0.025 (p=0.928) 
-0.059 (p=0.828) 
 
 
0.049 (p=0.858) 
0.089 (p=0.743) 
0.198 (p=0.462) 
0.031 (p=0.911) 
0.165 (p=0.542) 
-0.139 (p=0.609) 
0.107 (p=0.693) 
0.195 (p=0.469) 
0.279 (p=0.295) 
-0.102 (p=0.706) 
-0.001 (p=0.996) 
-0.054 (p=0.841) 
TAF cytokine data   n=11 
[Pearson correlation r (p)] 
CCL2 
CCL11 
VEGF-A 
CCL22 
IL-6 
FGF-2 
IL-8 
CXCL1 
CX3CL1 
CCL7 
PDGF-AA 
IFNα2 
 
 
0.572 (p=0.066) 
-0.200 (p=0.556) 
-0.229 (p=0.497) 
-0.155 (p=0.649) 
-0.516 (p=0.104) 
0.159 (p=0.641) 
-0.340 (p=0.306) 
-0.174 (p=0.608) 
-0.129 (p=0.706) 
-0.116 (p=0.735) 
-0.234 (p=0.489) 
-0.155 (p=0.649) 
 
 
0.828 (p=0.002) 
-0.364 (p=0.270) 
-0.148 (p=0.665) 
-0.243 (p=0.472) 
-0.280 (p=0.404) 
-0.146 (p=0.668) 
-0.546 (p=0.083) 
-0.286 (p=0.393) 
-0.274 (p=0.415) 
-0.288 (p=0.391) 
-0.343 (p=0.302) 
-0.314 (p=0.347) 
 
 
0.038 (p=0.913) 
-0.221 (p=0.515) 
0.243 (p=0.471) 
-0.042 (p=0.903) 
0.651 (p=0.030) 
-0.477 (p=0.138) 
-0.259 (p=0.442) 
-0.147 (p=0.666) 
-0.164 (p=0.630) 
-0.187 (p=0.583) 
-0.101 (p=0.768) 
-0.136 (p=0.691) 
 
 
0.011 (p=0.975) 
-0.202 (p=0.552) 
0.222 (p=0.511) 
-0.079 (p=0.817) 
0.618 (p=0.043) 
-0.499 (p=0.118) 
-0.226 (p=0.504) 
-0.181 (p=0.595) 
-0.173 (p=0.611) 
-0.216 (p=0.524) 
-0.040 (p=0.907) 
-0.151 (p=0.658) 
 
 
0.020 (p=0.954) 
-0.253 (p=0.453) 
0.296 (p=0.377) 
-0.133 (p=0.698) 
0.674 (p=0.023) 
-0.462 (p=0.153) 
-0.266 (p=0.429) 
-0.134 (p=0.694) 
-0.216 (p=0.525) 
-0.226 (p=0.503) 
-0.185 (p=0.587) 
-0.182 (p=0.592) 
 
 
-0.002 (p=0.996) 
-0.088 (p=0.798) 
-0.165 (p=0.627) 
-0.031 (p=0.928) 
-0.417 (p=0.202) 
0.295 (p=0.378) 
0.027 (p=0.937) 
0.127 (p=0.709) 
0.029 (p=0.933) 
0.013 (p=0.971) 
-0.273 (p=0.417) 
0.023 (p=0.946) 
PA-infiltrating 
macrophage [Mean±SEM] 
< 6% (n=11) 
≥ 6% (n=5)  
 
 
31.15 ± 7.13 
50.20 ± 10.07 
p=0.152 
 
 
7.97 ± 1.21 
9.86 ± 2.61 
p=0.461 
 
 
121.76 ± 9.99 
98.86 ± 5.37 
p=0.162 
 
 
49.62 ± 4.14 
39.88 ± 1.86 
p=0.149 
 
 
0.32 ± 0.07 
0.19 ± 0.01 
p=0.215 
 
 
0.45 ± 0.02 
0.47 ± 0.01 
p=0.464 
PA-infiltrating CD8+ T cells 
[Mean±SEM] 
< 1% (n=5) 
≥ 1% (n=11)  
 
 
32.73 ± 7.29 
39.09 ± 8.34 
p=0.644 
 
 
7.22 ± 0.86 
9.17 ± 1.60 
p=0.444 
 
 
114.01 ± 12.95 
114.87 ± 9.54 
p=0.960 
 
 
47.37 ± 5.48 
46.21 ± 3.90 
p=0.868 
 
 
0.25 ± 0.04 
0.29 ± 0.07 
p=0.678 
 
 
0.43 ± 0.03 
0.47 ± 0.01 
p=0.189 
PA-infiltrating CD4+ T cells 
[Mean±SEM] 
< 1% (n=9) 
≥ 1% (n=7)  
 
 
26.56 ± 4.64 
50.67 ± 10.93 
p=0.044 
 
 
6.47 ± 0.68 
11.24 ± 2.11 
p=0.032 
 
 
122.25 ± 11.75 
104.77 ± 7.26 
p=0.259 
 
 
50.13 ± 4.87 
42.00 ± 2.73 
p=0.200 
 
 
0.31 ± 0.08 
0.24 ± 0.04 
p=0.477 
 
 
0.43 ± 0.02 
0.50 ± 0.01 
p=0.004 
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PA-infiltrating B cells 
[Mean±SEM] 
< 0.5% (n=5) 
≥ 0.5% (n=11)  
 
 
26.47 ± 8.04 
41.94 ± 7.83 
p=0.251 
 
 
6.98 ± 1.03 
9.28 ± 1.57 
p=0.367 
 
 
132.77 ± 19.53 
106.34 ± 5.51 
p=0.254 
 
 
54.70 ± 8.18 
42.88 ± 2.04 
p=0.226 
 
 
0.38 ± 0.14 
0.24 ± 0.03 
p=0.381 
 
 
0.38 ± 0.14 
0.24 ± 0.03 
p=0.048 
PA-infiltrating neutrophils 
[Mean±SEM] 
< 0.5% (n=6) 
≥ 0.5% (n=10)  
 
 
41.95 ± 10.49 
34.20 ± 7.70 
p=0.556 
 
 
10.16 ± 2.64 
7.60 ± 0.92 
p=0.394 
 
 
110.95 ± 5.71 
116.79 ± 11.67 
p=0.718 
 
 
45.25 ± 2.08 
47.37 ± 4.87 
p=0.751 
 
 
0.25 ± 0.04 
0.30 ± 0.07 
p=0.602 
 
 
0.45 ± 0.01 
0.46 ± 0.02 
p=0.767 
PA-infiltrating FOXP3+ T 
cells [Mean±SEM] 
< 0.3% (n=9) 
≥ 0.3% (n=7)  
 
 
46.70 ± 9.24 
24.76 ± 4.40 
p=0.071 
 
 
9.09 ± 1.67 
7.88 ± 1.56 
p=0.617 
 
 
100.74 ± 5.06 
132.42 ± 13.42 
p=0.029 
 
 
40.95 ± 2.05 
53.80 ± 5.61 
p=0.033 
 
 
0.21 ± 0.02 
0.38 ± 0.10 
p=0.137 
 
 
0.47 ± 0.01 
0.44 ± 0.03 
p=0.195 
Immune cell ratios 
[Pearson correlation r (p)] 
M2:M1 
CD8:CD4 
CD8:FOXP3 
CD68:FOXP3 
 
 
0.408 (p=0.117) 
-0.156 (p=0.563) 
0.203 (p=0.451) 
0.154 (p=0.570) 
 
 
0.676 (p=0.004) 
-0.059 (p=0.828) 
0.020 (p=0.941) 
-0.064 (p=0.814) 
 
 
0.277 (p=0.299) 
0.059 (p=0.827) 
-0.352 (p=0.182) 
-0.357 (p=0.175) 
 
 
0.239 (p=0.373) 
0.073 (p=0.789) 
-0.360 (p=0.171) 
-0.351 (p=0.182) 
 
 
0.408 (p=0.117) 
0.122 (p=0.651) 
-0.284 (p=0.287) 
-0.328 (p=0.215) 
 
 
0.222 (p=0.408) 
-0.057 (p=0.833) 
0.324 (p=0.221) 
0.118 (p=0.662) 
 
Correlation between hormonal, cytokine and infiltrating immune cell data and PA angiogenesis data 
among NFPAs (n=16) 
Microvessel density (MVD) is expressed in vessels/HPF; total microvessel area (TMVA) is expressed in % of 
the high power field; perimeter and Feret’s diameter are expressed in µm; area per vessel is expressed in % 
of the high power field; vessel roundness correspond to a value comprised between 0 and 1 (1=perfect 
circle). FSH, follicle-stimulating hormone; FT4, free thyroxine; IGF-1, insulin-like growth factor-1; LH, 
luteinising hormone; MVD, microvessel density; NFPA, non-functioning pituitary adenoma; PRL, prolactin; 
TMVA, total microvessel area; TSH, thyroid-stimulating hormone. 
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NFPAs 
n = 16 
MMP-9 MMP-14 E-cadherin ZEB1 NCAM 
Hormonal data 
[Pearson correlation r (p)] 
Serum IGF-1 
IGF-1 index 
Serum PRL 
PRL index 
Serum TSH 
Serum FT4 
Basal plasma cortisol 
Serum LH 
Serum FSH 
Serum testosterone 
0.144 (p=0.623) 
0.217 (p=0.457) 
0.155 (p=0.598) 
0.305 (p=0.289) 
0.167 (p=0.569) 
0.091 (p=0.756) 
0.421 (p=0.152) 
0.377 (p=0.184) 
0.350 (p=0.220) 
-0.423 (p=0.170) 
0.091 (p=0.757) 
-0.030 (p=0.918) 
0.147 (p=0.616) 
0.190 (p=0.516) 
-0.028 (p=0.924) 
-0.221 (p=0.447) 
-0.597 (p=0.031) 
-0.219 (p=0.453) 
-0.443 (p=0.113) 
0.303 (p=0.338) 
-0.126 (p=0.668) 
-0.263 (p=0.364) 
-0.186 (p=0.525) 
0.009 (p=0.975) 
-0.227 (p=0.435) 
0.085 (p=0.774) 
-0.269 (p=0.375) 
-0.135 (p=0.645) 
-0.056 (p=0.849) 
0.495 (p=0.102) 
-0.139 (p=0.637) 
-0.336 (p=0.241) 
0.141 (p=0.630) 
0.113 (p=0.701) 
-0.150 (p=0.609) 
-0.262 (p=0.366) 
0.030 (p=0.923) 
-0.030 (p=0.920) 
-0.295 (p=0.306) 
0.158 (p=0.623) 
-0.138 (p=0.637) 
0.002 (p=0.993) 
-0.179 (p=0.541) 
-0.170 (p=0.562) 
-0.201 (p=0.491) 
-0.025 (p=0.931) 
-0.053 (p=0.862) 
0.532 (p=0.050) 
0.460 (p=0.098) 
-0.219 (p=0.493) 
PA-derived cytokine data 
[Pearson correlation r (p)] 
IL-8 
CCL2 
CCL3 
CCL4 
CXCL10 
CCL22 
CXCL1 
CX3CL1 
FGF-2 
IL-6 
PDGF-AA 
VEGF-A 
-0.287 (p=0.281) 
-0.366 (p=0.163) 
-0.250 (p=0.350) 
-0.313 (p=0.238)
-0.262 (p=0.326) 
-0.092 (p=0.734) 
-0.264 (p=0.323) 
-0.243 (p=0.365) 
0.147 (p=0.587) 
-0.203 (p=0.452) 
-0.144 (p=0.595) 
-0.064 (p=0.813) 
0.298 (p=0.262) 
0.076 (p=0.781) 
0.098 (p=0.718) 
0.260 (p=0.331) 
-0.234 (p=0.383) 
0.329 (p=0.213) 
0.214 (p=0.425) 
-0.168 (p=0.533) 
-0.080 (p=0.769) 
0.361 (p=0.169) 
0.142 (p=0.600) 
0.152 (p=0.575) 
0.050 (p=0.854) 
0.118 (p=0.664) 
-0.090 (p=0.739) 
0.038 (p=0.888) 
0.183 (p=0.497) 
-0.062 (p=0.819) 
-0.080 (p=0.769) 
0.153 (p=0.572) 
-0.310 (p=0.243) 
0.101 (p=0.710) 
0.002 (p=0.995) 
-0.228 (p=0.395) 
-0.287 (p=0.282) 
-0.433 (p=0.094) 
-0.247 (p=0.356) 
-0.318 (p=0.230) 
-0.282 (p=0.291) 
-0.307 (p=0.247) 
-0.359 (p=0.172) 
-0.264 (p=0.323) 
-0.612 (p=0.012) 
-0.222 (p=0.408) 
-0.364 (p=0.166) 
-0.321 (p=0.225) 
-0.270 (p=0.312) 
-0.387 (p=0.138) 
-0.045 (p=0.868) 
-0.263 (p=0.324) 
-0.340 (p=0.197) 
-0.314 (p=0.237) 
-0.184 (p=0.494) 
-0.372 (p=0.156) 
-0.317 (p=0.232) 
-0.319 (p=0.228) 
-0.346 (p=0.190) 
-0.232 (p=0.387) 
TAF cytokine data   n=11 
[Pearson correlation r (p)] 
CCL2 
CCL11 
VEGF-A 
CCL22 
IL-6 
FGF-2 
IL-8 
CXCL1 
CX3CL1 
CCL7 
PDGF-AA 
IFNα2 
-0.210 (p=0.536) 
-0.086 (p=0.801) 
-0.040 (p=0.906) 
-0.333 (p=0.317) 
0.072 (p=0.833) 
-0.145 (p=0.671) 
-0.211 (p=0.533) 
-0.221 (p=0.513) 
-0.323 (p=0.332) 
-0.140 (p=0.680) 
0.380 (p=0.249) 
-0.225 (p=0.506) 
-0.310 (p=0.353) 
0.148 (p=0.664) 
-0.236 (p=0.484) 
0.353 (p=0.286) 
0.028 (p=0.935) 
0.289 (p=0.388) 
-0.101 (p=0.767) 
0.177 (p=0.602) 
0.202 (p=0.552) 
0.153 (p=0.654) 
-0.002 (p=0.996) 
0.244 (p=0.469) 
-0.205 (p=0.546) 
-0.191 (p=0.574) 
-0.161 (p=0.635) 
0.370 (p=0.263) 
0.244 (p=0.469) 
0.431 (p=0.186) 
-0.284 (p=0.398) 
0.298 (p=0.374) 
0.214 (p=0.527) 
0.217 (p=0.522) 
-0.806 (p=0.003) 
0.186 (p=0.585) 
0.006 (p=0.987) 
-0.573 (p=0.066) 
-0.502 (p=0.115) 
-0.142 (p=0.677) 
0.072 (p=0.834) 
-0.025 (p=0.941) 
-0.573 (p=0.065) 
-0.364 (p=0.271) 
-0.355 (p=0.284) 
-0.344 (p=0.300) 
-0.274 (p=0.415) 
-0.298 (p=0.374) 
0.103 (p=0.763) 
-0.298 (p=0.374) 
-0.202 (p=0.551) 
-0.537 (p=0.088) 
0.171 (p=0.615) 
-0.716 (p=0.013) 
-0.260 (p=0.440) 
-0.661 (p=0.027) 
-0.560 (p=0.073) 
-0.609 (p=0.047) 
0.599 (p=0.051) 
-0.517 (p=0.104) 
PA-infiltrating 
macrophage [Mean±SEM] 
< 6% (n=11) 
≥ 6% (n=5) 
1.73 ± 0.62 
0 
p=0.019 
1.45 ± 0.62 
1.60 ± 0.75 
p=0.893 
4.55 ± 0.28 
4.60 ± 0.40 
p=0.914 
1.27 ± 0.57 
0.80 ± 0.49 
p=0.616 
5.00 ± 0.23 
4.60 ± 0.25 
p=0.319 
PA-infiltrating CD8+ T cells 
[Mean±SEM] 
< 1% (n=5) 
≥ 1% (n=11) 
0.80 ± 0.80 
1.36 ± 0.59 
p=0.594 
1.60 ± 1.03 
1.45 ± 0.55 
p=0.893 
4.80 ± 0.37 
4.45 ± 0.28 
p=0.492 
1.20 ± 0.80 
1.09 ± 0.51 
p=0.908 
5.00 ± 0.32 
4.82 ± 0.23 
p=0.655 
PA-infiltrating CD4+ T cells 
[Mean±SEM] 
< 1% (n=9) 
≥ 1% (n=7) 
0.78 ± 0.52 
1.71 ± 0.84 
p=0.337 
1.67 ± 0.71 
1.29 ± 0.64 
p=0.705 
4.56 ± 0.38 
4.57 ± 0.20 
p=0.973 
1.00 ± 0.53 
1.29 ± 0.71 
p=0.747 
5.00 ± 0.24 
4.71 ± 0.29 
p=0.449 
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PA-infiltrating B cells 
[Mean±SEM] 
< 0.5% (n=5) 
≥ 0.5% (n=11)  
 
 
0 
1.73 ± 0.62 
p=0.019 
 
 
1.80 ± 1.11 
1.36 ± 0.51 
p=0.685 
 
 
5.20 ± 0.20 
4.27 ± 0.27 
p=0.016 
 
 
1.20 ± 0.80 
1.09 ± 0.51 
p=0.908 
 
 
4.80 ± 0.37 
4.91 ± 0.21 
p=0.789 
PA-infiltrating neutrophils 
[Mean±SEM] 
< 0.5% (n=6) 
≥ 0.5% (n=10)  
 
 
1.00 ± 0.63 
1.30 ± 0.67 
p=0.768 
 
 
0 
2.40 ± 0.60 
p=0.003 
 
 
4.33 ± 0.56 
4.70 ± 0.15 
p=0.550 
 
 
0.67 ± 0.42 
1.40 ± 0.62 
p=0.344 
 
 
5.17 ± 0.31 
4.70 ± 0.21 
p=0.220 
PA-infiltrating FOXP3+ T 
cells [Mean±SEM] 
< 0.3% (n=9) 
≥ 0.3% (n=7)  
 
 
1.00 ± 0.67 
1.43 ± 0.69 
p=0.665 
 
 
1.00 ± 0.53 
2.14 ± 0.83 
p=0.245 
 
 
4.67 ± 0.24 
4.43 ± 0.43 
p=0.614 
 
 
0.67 ± 0.33 
1.71 ± 0.84 
p=0.279 
 
 
4.56 ± 0.18 
5.29 ± 0.29 
p=0.039 
Immune cell ratios 
[Pearson correlation r (p)] 
M2:M1 
CD8:CD4 
CD8:FOXP3 
CD68:FOXP3 
 
 
-0.070 (p=0.796) 
-0.168 (p=0.534) 
0.111 (p=0.683) 
-0.303 (p=0.253) 
 
 
-0.347 (p=0.188) 
-0.176 (p=0.514) 
0.149 (p=0.583) 
0.014 (p=0.958) 
 
 
0.084 (p=0.756) 
-0.099 (p=0.715) 
0.231 (p=0.389) 
0.241 (p=0.369) 
 
 
0.038 (p=0.890) 
-0.171 (p=0.527) 
-0.254 (p=0.343) 
-0.256 (p=0.338) 
 
 
-0.142 (p=0.600) 
-0.007 (p=0.979) 
-0.419 (p=0.106) 
-0.245 (p=0.361) 
 
Correlation between hormonal, cytokine and infiltrating immune cell data and MMP-9, MMP-14, E-
cadherin, ZEB1 and NCAM immunoreactivities among NFPAs (n=16) 
FSH, follicle-stimulating hormone; FT4, free thyroxine; IGF-1, insulin-like growth factor-1; LH, luteinising 
hormone; NFPA, non-functioning pituitary adenoma; MMP, matrix metalloproteinase; NCAM, neural cell 
adhesion molecule; PRL, prolactin; TSH, thyroid-stimulating hormone. 
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Somatotrophinomas 
n = 8 
MVD TMVA Perimeter 
Feret’s 
diameter 
Area per 
vessel 
Roundness 
Hormonal data  
[Pearson correlation r (p)] 
Serum GH 
Serum IGF-1 
IGF-1 index 
Serum PRL 
PRL index 
Serum TSH 
Serum FT4 
Basal plasma cortisol 
Serum LH 
Serum FSH 
Serum testosterone 
 
 
0.209 (p=0.654) 
0.333 (p=0.465) 
0.407 (p=0.317) 
-0.497 (p=0.394) 
-0.420 (p=0.481) 
-0.513 (p=0.239) 
0.875 (p=0.010) 
0.030 (p=0.949) 
0.701 (p=0.079) 
0.734 (p=0.060) 
-0.235 (p=0.655) 
 
 
0.166 (p=0.723) 
0.237 (p=0.610) 
0.196 (p=0.641) 
0.054 (p=0.931) 
0.144 (p=0.817) 
-0.442 (p=0.321) 
0.672 (p=0.098) 
0.050 (p=0.914) 
0.676 (p=0.098) 
0.498 (p=0.255) 
-0.296 (p=0.569) 
 
 
-0.069 (p=0.883) 
-0.210 (p=0.652) 
-0.414 (p=0.308) 
0.627 (p=0.258) 
0.663 (p=0.222) 
-0.153 (p=0.744) 
-0.404 (p=0.369) 
0.192 (p=0.679) 
-0.175 (p=0.708) 
-0.596 (p=0.158) 
-0.594 (p=0.214) 
 
 
-0.142 (p=0.761) 
-0.275 (p=0.550) 
-0.405 (p=0.320) 
0.755 (p=0.140) 
0.785 (p=0.116) 
-0.198 (p=0.671) 
-0.353 (p=0.437) 
0.267 (p=0.563) 
-0.130 (p=0.782) 
-0.579 (p=0.173) 
-0.644 (p=0.167) 
 
 
-0.365 (p=0.421) 
-0.449 (p=0.313) 
-0.554 (p=0.154) 
0.958 (p=0.010) 
0.959 (p=0.010) 
0.226 (p=0.626) 
-0.370 (p=0.414) 
-0.066 (p=0.888) 
0.000 (p=0.999) 
-0.389 (p=0.388) 
-0.410 (p=0.419) 
 
 
0.130 (p=0.781) 
0.242 (p=0.602) 
0.263 (p=0.529) 
0.483 (p=0.409) 
0.479 (p=0.414) 
0.676 (p=0.095) 
0.043 (p=0.927) 
-0.506 (p=0.246) 
0.059 (p=0.900) 
0.442 (p=0.320) 
0.897 (p=0.015) 
PA-derived cytokine data 
[Pearson correlation r (p)] 
IL-8 
CCL2 
CCL3 
CCL4 
CXCL10 
CCL22 
CXCL1 
CX3CL1 
FGF-2 
IL-6 
PDGF-AA 
VEGF-A 
 
 
0.008 (p=0.985) 
-0.222 (p=0.598) 
0.051 (p=0.905) 
-0.484 (p=0.224) 
-0.494 (p=0.214) 
-0.609 (p=0.109) 
-0.571 (p=0.139) 
-0.640 (p=0.087) 
-0.588 (p=0.125) 
-0.596 (p=0.119) 
0.188 (p=0.656) 
0.051 (p=0.904) 
 
 
0.469 (p=0.241) 
0.078 (p=0.855) 
0.210 (p=0.618) 
-0.204 (p=0.628) 
-0.306 (p=0.462) 
-0.507 (p=0.199) 
-0.387 (p=0.344) 
-0.510 (p=0.197) 
-0.269 (p=0.519) 
-0.377 (p=0.357) 
0.322 (p=0.437) 
0.151 (p=0.720) 
 
 
0.679 (p=0.064) 
0.481 (p=0.227) 
0.192 (p=0.649) 
0.330 (p=0.425) 
0.225 (p=0.593) 
0.024 (p=0.954) 
0.185 (p=0.661) 
0.006 (p=0.988) 
0.372 (p=0.364) 
0.243 (p=0.562) 
0.036 (p=0.932) 
0.252 (p=0.548) 
 
 
0.686 (p=0.060) 
0.519 (p=0.188) 
0.155 (p=0.714) 
0.389 (p=0.341) 
0.283 (p=0.498) 
0.039 (p=0.926) 
0.189 (p=0.655) 
-0.005 (p=0.991) 
0.424 (p=0.295) 
0.287 (p=0.490) 
0.008 (p=0.985) 
0.257 (p=0.539) 
 
 
0.725 (p=0.042) 
0.559 (p=0.150) 
0.131 (p=0.758) 
0.670 (p=0.069) 
0.507 (p=0.200) 
0.300 (p=0.471) 
0.403 (p=0.322) 
0.328 (p=0.427) 
0.769 (p=0.026) 
0.564 (p=0.145) 
0.015 (p=0.973) 
0.066 (p=0.877) 
 
 
-0.326 (p=0.430) 
-0.347 (p=0.400) 
0.032 (p=0.939) 
-0.117 (p=0.782) 
-0.114 (p=0.787) 
0.162 (p=0.701) 
0.052 (p=0.902) 
0.323 (p=0.434) 
-0.100 (p=0.813) 
-0.053 (p=0.901) 
0.247 (p=0.556) 
-0.299 (p=0.472) 
TAF cytokine data   n=5 
[Pearson correlation r (p)] 
CCL2 
CCL11 
VEGF-A 
CCL22 
IL-6 
FGF-2 
IL-8 
CXCL1 
CX3CL1 
CCL7 
PDGF-AA 
IFNα2 
 
 
-0.493 (p=0.399) 
-0.459 (p=0.437) 
-0.474 (p=0.420) 
0.937 (p=0.019) 
-0.375 (p=0.534) 
0.532 (p=0.356) 
0.142 (p=0.819) 
0.011 (p=0.986) 
0.585 (p=0.300) 
-0.116 (p=0.852) 
-0.566 (p=0.320) 
0.643 (p=0.242) 
 
 
-0.334 (p=0.582) 
-0.233 (p=0.706) 
-0.258 (p=0.676) 
0.916 (p=0.029) 
-0.138 (p=0.825) 
0.651 (p=0.235) 
0.298 (p=0.626) 
0.138 (p=0.825) 
0.764 (p=0.132) 
0.031 (p=0.960) 
-0.733 (p=0.159) 
0.813 (p=0.095) 
 
 
0.752 (p=0.142) 
0.759 (p=0.137) 
0.769 (p=0.129) 
-0.368 (p=0.542) 
0.812 (p=0.095) 
0.342 (p=0.573) 
0.299 (p=0.625) 
0.215 (p=0.728) 
0.519 (p=0.370) 
0.367 (p=0.544) 
-0.430 (p=0.470) 
0.366 (p=0.545) 
 
 
0.636 (p=0.249) 
0.772 (p=0.127) 
0.800 (p=0.104) 
-0.338 (p=0.578) 
0.830 (p=0.082) 
0.482 (p=0.411) 
0.417 (p=0.485) 
0.336 (p=0.581) 
0.555 (p=0.331) 
0.479 (p=0.414) 
-0.539 (p=0.348) 
0.420 (p=0.481) 
 
 
0.817 (p=0.092) 
0.883 (p=0.047) 
0.836 (p=0.077) 
-0.280 (p=0.648) 
0.912 (p=0.031) 
0.215 (p=0.728) 
0.393 (p=0.513) 
0.301 (p=0.623) 
0.542 (p=0.346) 
0.417 (p=0.485) 
-0.410 (p=0.493) 
0.456 (p=0.440) 
 
 
-0.457 (p=0.439) 
-0.553 (p=0.334) 
-0.610 (p=0.275) 
0.171 (p=0.784) 
-0.640 (p=0.244) 
-0.640 (p=0.245) 
-0.363 (p=0.548) 
-0.264 (p=0.668) 
-0.633 (p=0.251) 
-0.394 (p=0.512) 
0.638 (p=0.246) 
-0.477 (p=0.416) 
PA-infiltrating 
macrophage [Mean±SEM] 
< 6% (n=6) 
≥ 6% (n=2)  
 
 
36.84 ± 7.27 
37.00 ± 18.00 
p=0.992 
 
 
4.87 ± 0.95 
7.49 ± 1.90 
p=0.229 
 
 
78.98 ± 5.14 
101.41 ± 1.93 
p=0.007 
 
 
31.90 ± 2.06 
41.12 ± 1.59 
p=0.019 
 
 
0.13 ± 0.01 
0.23 ± 0.06 
p=0.031 
 
 
0.49 ± 0.02 
0.47 ± 0.01 
p=0.441 
PA-infiltrating CD8+ T cells 
[Mean±SEM] 
< 1% (n=1) 
≥ 1% (n=7)  
 
 
21.67 
39.05 ± 6.85 
p=0.404 
 
 
3.83 
5.77 ± 0.99 
p=0.517 
 
 
98.48 
82.60 ± 5.64 
p=0.358 
 
 
38.51 
33.58 ± 2.39 
p=0.493 
 
 
0.18 
0.16 ± 0.02 
p=0.778 
 
 
0.45 
0.49 ± 0.02 
p=0.358 
PA-infiltrating CD4+ T cells 
[Mean±SEM] 
< 1% (n=6) 
≥ 1% (n=2)  
 
 
40.17 ± 7.84 
27.00 ± 8.00 
p=0.408 
 
 
5.73 ± 1.19 
4.91 ± 0.68 
p=0.723 
 
 
82.34 ± 6.18 
91.34 ± 12.00 
p=0.502 
 
 
33.06 ± 2.43 
37.63 ± 5.08 
p=0.400 
 
 
0.14 ± 0.01 
0.21 ± 0.09 
p=0.210 
 
 
0.49 ± 0.02 
0.47 ± 0.00 
p=0.330 
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PA-infiltrating B cells 
[Mean±SEM] 
< 0.5% (n=3) 
≥ 0.5% (n=5) 
36.45 ± 9.81 
37.13 ± 9.10 
p=0.963 
6.08 ± 1.69 
5.19 ± 1.14 
p=0.666 
95.03 ± 3.96 
78.32 ± 6.85 
p=0.132 
38.13 ± 0.94 
31.84 ± 3.01 
p=0.173 
0.17 ± 0.01 
0.15 ± 0.04 
p=0.793 
0.46 ± 0.00 
0.50 ± 0.02 
p=0.060 
PA-infiltrating neutrophils 
[Mean±SEM] 
< 0.5% (n=7) 
≥ 0.5% (n=1) 
37.86 ± 7.20 
30.00 
p=0.713 
5.85 ± 0.96 
3.23 
p=0.372 
86.54 ± 5.65 
70.89 
p=0.365 
35.21 ± 2.20 
27.16 
p=0.244 
0.17 ± 0.02 
0.11 
p=0.405 
0.48 ± 0.01 
0.53 
p=0.191 
PA-infiltrating FOXP3+ T 
cells [Mean±SEM] 
< 0.3% (n=3) 
≥ 0.3% (n=5) 
49.56 ± 14.78 
29.27 ± 2.74 
p=0.302 
7.56 ± 1.86 
4.30 ± 0.45 
p=0.218 
91.13 ± 7.85 
80.66 ± 7.00 
p=0.376 
36.45 ± 2.59 
32.85 ± 3.13 
p=0.462 
0.16 ± 0.01 
0.16 ± 0.03 
p=0.983 
0.46 ± 0.01 
0.50 ± 0.02 
p=0.164 
Immune cell ratios 
[Pearson correlation r (p)] 
M2:M1 
CD8:CD4 
CD8:FOXP3 
CD68:FOXP3 
0.801 (p=0.017) 
0.621 (p=0.100) 
0.209 (p=0.620) 
-0.097 (p=0.818) 
0.606 (p=0.111) 
0.718 (p=0.045) 
0.122 (p=0.773) 
-0.052 (p=0.903) 
-0.320 (p=0.439) 
0.223 (p=0.595) 
0.038 (p=0.929) 
0.307 (p=0.460) 
-0.259 (p=0.536) 
0.237 (p=0.571) 
0.007 (p=0.986) 
0.237 (p=0.573) 
-0.260 (p=0.534) 
-0.090 (p=0.832) 
-0.139 (p=0.742) 
0.116 (p=0.785) 
0.023 (p=0.957) 
-0.315 (p=0.447) 
-0.232 (p=0.580) 
-0.355 (p=0.389) 
Correlation between hormonal, cytokine and infiltrating immune cell data and PA angiogenesis data 
among somatotrophinomas (n=8) 
Microvessel density (MVD) is expressed in vessels/HPF; total microvessel area (TMVA) is expressed in % of 
the high power field; perimeter and Feret’s diameter are expressed in µm; area per vessel is expressed in % 
of the high power field; vessel roundness correspond to a value comprised between 0 and 1 (1=perfect 
circle). FSH, follicle-stimulating hormone; FT4, free thyroxine; IGF-1, insulin-like growth factor-1; LH, 
luteinising hormone; MVD, microvessel density; NFPA, non-functioning pituitary adenoma; PRL, prolactin; 
TMVA, total microvessel area; TSH, thyroid-stimulating hormone. 
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Somatotrophinomas 
n = 8 
MMP-9 MMP-14 E-cadherin ZEB1 NCAM 
Hormonal data  
[Pearson correlation r (p)] 
Serum GH 
Serum IGF-1 
IGF-1 index 
Serum PRL 
PRL index 
Serum TSH 
Serum FT4 
Basal plasma cortisol 
Serum LH 
Serum FSH 
Serum testosterone 
 
 
0.328 (p=0.472) 
0.325 (p=0.478) 
0.491 (p=0.216) 
-0.963 (p=0.009) 
-0.951 (p=0.013) 
-0.202 (p=0.665) 
-0.014 (p=0.976) 
0.304 (p=0.508) 
-0.159 (p=0.734) 
0.060 (p=0.898) 
0.267 (p=0.609) 
 
 
0.420 (p=0.348) 
0.473 (p=0.284) 
0.644 (p=0.085) 
-0.268 (p=0.663) 
-0.295 (p=0.630) 
0.285 (p=0.536) 
-0.047 (p=0.920) 
-0.232 (p=0.617) 
-0.459 (p=0.301) 
-0.008 (p=0.986) 
0.526 (p=0.284) 
 
 
-0.801 (p=0.031) 
-0.719 (p=0.069) 
-0.450 (p=0.263) 
0.234 (p=0.705) 
0.192 (p=0.757) 
0.034 (p=0.943) 
0.300 (p=0.513) 
0.144 (p=0.759) 
0.649 (p=0.114) 
0.527 (p=0.224) 
0.120 (p=0.820) 
 
 
-0.361 (p=0.426) 
-0.213 (p=0.646) 
-0.216 (p=0.607) 
- 
- 
-0.379 (p=0.402) 
0.910 (p=0.004) 
-0.171 (p=0.714) 
0.933 (p=0.002) 
0.903 (p=0.005) 
-0.299 (p=0.565) 
 
 
0.027 (p=0.954) 
0.147 (p=0.753) 
0.137 (p=0.746) 
-0.989 (p=0.001) 
-0.978 (p=0.004) 
-0.442 (p=0.320) 
0.741 (p=0.057) 
-0.016 (p=0.973) 
0.576 (p=0.176) 
0.746 (p=0.054) 
-0.299 (p=0.565) 
PA-derived cytokine data 
[Pearson correlation r (p)] 
IL-8 
CCL2 
CCL3 
CCL4 
CXCL10 
CCL22 
CXCL1 
CX3CL1 
FGF-2 
IL-6 
PDGF-AA 
VEGF-A 
 
 
-0.597 (p=0.118) 
-0.689 (p=0.059) 
-0.193 (p=0.646) 
-0.864 (p=0.006) 
-0.747 (p=0.033) 
-0.402 (p=0.324) 
-0.456 (p=0.256) 
-0.414 (p=0.308) 
-0.809 (p=0.015) 
-0.738 (p=0.037) 
0.115 (p=0.787) 
-0.184 (p=0.663) 
 
 
-0.252 (p=0.547) 
0.271 (p=0.517) 
0.404 (p=0.320) 
0.315 (p=0.447) 
0.467 (p=0.243) 
0.617 (p=0.103) 
0.546 (p=0.162) 
0.524 (p=0.182) 
0.129 (p=0.761) 
0.447 (p=0.267) 
0.185 (p=0.660) 
0.473 (p=0.237) 
 
 
-0.436 (p=0.280) 
-0.655 (p=0.078) 
-0.817 (p=0.013) 
-0.315 (p=0.448) 
-0.389 (p=0.340) 
-0.373 (p=0.363) 
-0.520 (p=0.186) 
-0.304 (p=0.465) 
-0.074 (p=0.862) 
-0.356 (p=0.387) 
-0.409 (p=0.314) 
-0.886 (p=0.003) 
 
 
-0.360 (p=0.381) 
-0.493 (p=0.214) 
-0.448 (p=0.265) 
-0.438 (p=0.278) 
-0.456 (p=0.256) 
-0.592 (p=0.122) 
-0.662 (p=0.074) 
-0.541 (p=0.167) 
-0.427 (p=0.291) 
-0.520 (p=0.186) 
-0.344 (p=0.405) 
-0.475 (p=0.234) 
 
 
-0.616 (p=0.104) 
-0.692 (p=0.057) 
-0.373 (p=0.363) 
-0.769 (p=0.026) 
-0.697 (p=0.055) 
-0.636 (p=0.090) 
-0.717 (p=0.045) 
-0.607 (p=0.110) 
-0.786 (p=0.021) 
-0.757 (p=0.030) 
-0.210 (p=0.617) 
-0.370 (p=0.367) 
TAF cytokine data   n=5 
[Pearson correlation r (p)] 
CCL2 
CCL11 
VEGF-A 
CCL22 
IL-6 
FGF-2 
IL-8 
CXCL1 
CX3CL1 
CCL7 
PDGF-AA 
IFNα2 
 
 
0.135 (p=0.829) 
0.827 (p=0.084) 
0.822 (p=0.088) 
-0.503 (p=0.388) 
0.758 (p=0.137) 
0.096 (p=0.878) 
0.694 (p=0.194) 
0.770 (p=0.128) 
-0.109 (p=0.861) 
0.800 (p=0.104) 
-0.148 (p=0.812) 
0.023 (p=0.971) 
 
 
-0.390 (p=0.517) 
-0.695 (p=0.192) 
-0.642 (p=0.243) 
-0.314 (p=0.607) 
-0.764 (p=0.132) 
-0.635 (p=0.250) 
-0.681 (p=0.205) 
-0.522 (p=0.367) 
-0.901 (p=0.037) 
-0.536 (p=0.351) 
0.851 (p=0.068) 
-0.911 (p=0.031) 
 
 
-0.368 (p=0.543) 
0.275 (p=0.654) 
0.218 (p=0.724) 
0.565 (p=0.321) 
0.279 (p=0.650) 
0.478 (p=0.416) 
0.751 (p=0.144) 
0.689 (p=0.199) 
0.448 (p=0.449) 
0.556 (p=0.330) 
-0.619 (p=0.266) 
0.669 (p=0.217) 
 
 
-0.274 (p=0.655) 
-0.360 (p=0.552) 
-0.414 (p=0.489) 
0.978 (p=0.004) 
-0.272 (p=0.658) 
0.453 (p=0.444) 
0.107 (p=0.864) 
-0.059 (p=0.926) 
0.705 (p=0.184) 
-0.178 (p=0.775) 
-0.573 (p=0.312) 
0.745 (p=0.149) 
 
 
-0.274 (p=0.655) 
-0.360 (p=0.552) 
-0.414 (p=0.489) 
0.978 (p=0.004) 
-0.272 (p=0.658) 
0.453 (p=0.444) 
0.107 (p=0.864) 
-0.059 (p=0.926) 
0.705 (p=0.184) 
-0.178 (p=0.775) 
-0.573 (p=0.312) 
0.745 (p=0.149) 
PA-infiltrating 
macrophage [Mean±SEM] 
< 6% (n=6) 
≥ 6% (n=2)  
 
 
4.83 ± 0.31 
2.50 ± 2.50 
p=0.521 
 
 
1.00 ± 0.63 
0 
p=0.175 
 
 
5.00 ± 0.516 
4.00 ± 1.00 
p=0.379 
 
 
1.17 ± 0.75 
0 
p=0.180 
 
 
5.33 ± 0.21 
4.50 ± 0.50 
p=0.114 
PA-infiltrating CD8+ T cells 
[Mean±SEM] 
< 1% (n=1) 
≥ 1% (n=7)  
 
 
5.00 
4.14 ± 0.74 
p=0.695 
 
 
0 
0.86 ± 0.55 
p=0.604 
 
 
4.00 
4.86 ± 0.51 
p=0.573 
 
 
0 
1.00 ± 0.66 
p=0.609 
 
 
5.00 
5.14 ± 0.26 
p=0.853 
PA-infiltrating CD4+ T cells 
[Mean±SEM] 
< 1% (n=6) 
≥ 1% (n=2)  
 
 
5.00 ± 0.26 
2.00 ± 2.00 
p=0.371 
 
 
0.50 ± 0.50 
1.50 ± 1.50 
p=0.420 
 
 
5.00 ± 0.52 
4.00 ± 1.00 
p=0.379 
 
 
1.17 ± 0.75 
0 
p=0.426 
 
 
5.33 ± 0.21 
4.50 ± 0.50 
p=0.114 
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PA-infiltrating B cells 
[Mean±SEM] 
< 0.5% (n=3) 
≥ 0.5% (n=5)  
 
 
5.33 ± 0.33 
3.60 ± 0.93 
p=0.218 
 
 
0 
1.20 ± 0.74 
p=0.178 
 
 
4.33 ± 0.88 
5.00 ± 0.55 
p=0.519 
 
 
0 
1.40 ± 0.87 
p=0.274 
 
 
5.00 ± 0.00 
5.20 ± 0.37 
p=0.621 
PA-infiltrating neutrophils 
[Mean±SEM] 
< 0.5% (n=7) 
≥ 0.5% (n=1)  
 
 
4.14 ± 0.74 
5.00 
p=0.695 
 
 
0.86 ± 0.55 
0 
p=0.604 
 
 
4.57 ± 0.48 
6.00 
p=0.334 
 
 
0.57 ± 0.57 
3.00 
p=0.184 
 
 
5.00 ± 0.22 
6.00 
p=0.156 
PA-infiltrating FOXP3+ T 
cells [Mean±SEM] 
< 0.3% (n=3) 
≥ 0.3% (n=5)  
 
 
4.67 ± 0.33 
4.00 ± 1.05 
p=0.655 
 
 
0 
1.20 ± 0.74 
p=0.178 
 
 
4.33 ± 0.88 
5.00 ± 0.55 
p=0.519 
 
 
1.33 ± 1.33 
0.60 ± 0.60 
p=0.582 
 
 
5.33 ± 0.33 
5.00 ± 0.32 
p=0.519 
Immune cell ratios 
[Pearson correlation r (p)] 
M2:M1 
CD8:CD4 
CD8:FOXP3 
CD68:FOXP3 
 
 
0.078 (p=0.853) 
0.445 (p=0.269) 
0.336 (p=0.416) 
0.127 (p=0.764) 
 
 
-0.250 (p=0.550) 
-0.375 (p=0.359) 
-0.262 (p=0.531) 
-0.408 (p=0.994) 
 
 
0.518 (p=0.188) 
-0.061 (p=0.885) 
0.154 (p=0.715) 
0.037 (p=0.930) 
 
 
0.773 (p=0.024) 
-0.019 (p=0.965) 
0.209 (p=0.620) 
0.089 (p=0.833) 
 
 
0.603 (p=0.113) 
0.139 (p=0.742) 
0.296 (p=0.476) 
0.110 (p=0.796) 
 
Correlation between hormonal, cytokine and infiltrating immune cell data and MMP-9, MMP-14, E-
cadherin, ZEB1 and NCAM immunoreactivities among somatotrophinomas (n=8) 
FSH, follicle-stimulating hormone; FT4, free thyroxine; IGF-1, insulin-like growth factor-1; LH, luteinising 
hormone; NFPA, non-functioning pituitary adenoma; MMP, matrix metalloproteinase; NCAM, neural cell 
adhesion molecule; PRL, prolactin; TSH, thyroid-stimulating hormone. 
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Appendix 10: Supplemental tables summarising the pro-tumoural and anti-
tumoural effects of CX3CL1 in different cancers 
 
Pro-tumoural role of CX3CL1-CX3CR1 in different cancer types 
Cancer type 
(and study) 
Main study findings 
B lymphoma 
Andreasson 2008 
Cancer Lett 
Andreasson study: CX3CR1, normally not expressed in B cells, was found expressed in 
several lymphoma subtypes.  
Breast cancer 
Tsang 2003 Breast 
Cancer Res Treat 
 
Andre 2006 Ann Oncol 
 
 
Jamieson-Gladney 
2011 Breast Cancer 
Res 
 
 
Tsang study: High CX3CL1 expression was detected in 33% of invasive breast cancers, and 
CX3CL1 expression was correlated with tumour-infiltrating lymphocytes content, as well as 
with adverse features including lymph node metastasis, high Ki-67 and poorer survival. 
 
Andre study: CX3CR1 expression was associated with breast cancer metastasis to the brain, 
but not with survival or disease-free survival.   
 
Jamieson-Gladney study: Functional interactions between CX3CL1 produced by endothelial 
and stromal cells of the bone marrow and CX3CR1 on breast cancer cells were determinant 
for skeletal dissemination. Breast cancer cells expressing CX3CR1 displayed a higher 
propensity to spread to skeleton. CX3CL1-null transgenic mice indicates that the ablation of 
CX3CL1 impairs skeletal dissemination of circulating breast cancer cells.  
Chronic lymphocytic 
leukaemia 
Ferretti 2011 
Leukemia 
Ferretti study: CX3CL1-CX3CR1 contributes to interactions between chronic lymphocytic 
leukaemia cells and the tumour microenvironment by increasing CXCL12-mediated 
attraction of leukaemic cells. CX3CL1 induced phosphorylation of PI3K, Erk1/2, p38, Akt and 
Src, pathways involved in the leukaemic cells chemotaxis. 
Colon cancer 
Zheng 2013 Mol 
Cancer 
 
Zheng study: CX3CR1 is expressed in human colon carcinomas in a grade- and stage-
dependent manner, and CX3CR1 upregulation in tumour-associated macrophages was 
correlated with poor prognosis. Furthermore, liver metastasis of colon cancer was inhibited 
when the tumour microenvironment was lacking CX3CR1, highlightening its role in the 
macrophage survival in the tumour microenvironment and in metastisation. 
Endometriosis 
Wang 2014 Int J Clin 
Exp Pathol 
 
Hou 2016 Am J Reprod 
Immunol 
 
Wang study: CX3CL1induced M2-macrophage polarisation, and also promoted cell 
invasiveness by activating p38 MAPK and integrin β1 signalling pathways. 
 
Hou study: High CX3CL1 levels in the ectopic milieu promoted proliferation and invasion of 
endometrial stromal cells by activating AKT and p38 signalling pathways. CX3CL1 
concentration was higher in the peritoneal fluid from patients with endometriosis and was 
correlated with endometriosis severity. 
Gastric cancer 
Lv 2014 World J 
Gastroenterol 
 
Wei 2015 Oncol Rep 
Lv study: Expression of CX3CL1 and CX3CR1 in gastric cancer tissues were higher than those 
in adjacent normal tissue. Moreover, CX3CL1 and CX3CR1 expression were higher in gastric 
tumours with perineural invasion. 
 
Wei study: Gastric cancer tissues expressed higher CX3CR1 levels than non-neoplastic 
gastric tissues. Overexpression of CX3CR1 promotes metastasis, proliferation and survival. 
Tumour microenvironment may play a role in the increased CX3CR1 expression in gastric 
cancer cells.   
Glioblastoma 
Erreni 2010 Eur J 
Cancer 
 
Erreni study: CX3CL1 is highly expressed in the most severe forms of gliomas suggesting its 
involvement in the malignant glioblastomas behaviour: 31 out of 36 human glioblastomas 
expressed CX3CL1 and CX3CR1, and uppermost CX3CL1 levels were found in grades III-IV 
tumours and inversely correlated with patients’ survival. 
Kidney cancer 
Yao 2004 Urol Oncol 
 
Yao study: CX3CR1 expression is associated with migration and metastisation of clear cell 
renal cell carcinoma. ERK1/2 and PI3K/Akt were activated upon CX3CL1 stimulation only in 
CX3CR1-tumour cells. Immunohistochemistry data revealed an association between 
CX3CR1 expression, metastisation and poor prognosis.  
Lung cancer 
Zhou 2016 Med Sci 
Monit 
Zhou study: CX3CL1expression in lung cancer was higher than in normal lung tissue, and 
increased in the cases with higher pathological stages. CX3CL1 expression was also higher in 
the lung cancer cases with more metastatic lymph nodes.  
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Melanoma 
Ren 2007 Biochm 
Biophys Res Commun 
Ren study: CX3CL1 was expressed in both mouse and human melanomas, and knockdown 
of CX3CL1 gene inhibited melanoma cells growth which was also correlated to decreased 
angiogenesis in the tumour.  
Multiple myeloma 
Wada 2015 Oncol Rep 
Wada study: CX3CL1 mediates progression of myeloma via CX3CR1. CX3CL1 induced Akt 
and ERK1/2 phosphorylation in CX3CR1-positive myeloma cell lines, but not in CX3CR1-
negative cells. CX3CL1 induced cell adhesion to VCAM-1 and fibronectin in a myeloma cell 
line, and lead to an increased osteoclast differentiation.  
Osteosarcoma 
Liu 2016 Oncotarget 
Liu study: CX3CL1 expression is higher in osteosarcoma cell lines than in normal 
osteoblasts. CX3CL1 promotes cell migration and metastisation by upregulating ICAM-1 
expression via CX3CR1/PI3K/Akt/NF-kB. Knockdown of CX3CL1 inhibited cell migration and 
lung metastasis. Clinical correlation between CX3CL1 and ICAM-1 expression as well as 
tumour stage in human osteosarcoma tissues was noted. 
Ovarian cancer 
Gaudin 2011 PloS One 
 
 
 
 
Kim 2012 Mol Cancer 
Res 
 
 
 
Gurler Main 2017 
Oncogene 
 
 
Gaudin study: CX3CL1 expression was correlated with Ki-67 and with GILZ (glucocorticoid-
induced leucine zipper), previously identified as an activator of cell proliferation in 
malignant epithelial ovarian cancer. In a mouse subcutaneous xenograft model, 
overexpression of GILZ was associated with higher expression of CX3CL1 and faster 
tumoural growth.  
 
Kim study: CX3CR1 is expressed in primary and metastatic ovarian carcinoma. Ovarian 
carcinoma cells migrated towards CX3CL1 in a CX3CR1-dependent manner. Silencing of 
CX3CR1 reduced migration by 70%. Also CX3CL1 induced cellular proliferation in epithelial 
ovarian cancer cells. 
 
Gurler Main study: CX3CL1-CX3CR1 axis is relevant for advanced and relapsed peritoneal 
metastasis in epithelial ovarian carcinoma. CX3CR1 played a role in the initiation of 
peritoneal adhesion important for relapsed peritoneal metastasis, and the CX3CR1 
downregulation reduced the metastatic burden at peritoneal sites. High expression of 
CX3CR1 correlates with shorter survival, specifically in post-menopausal patients with 
advanced ovarian cancer.  
Pancreatic cancer 
Marchesi 2008 Cancer 
Res 
 
 
 
Celesti 2013 Br J 
Cancer 
Marchesi study: Most of pancreatic cancer specimens expressed CX3CR1. Higher CX3CR1 
staining score was associated with more prominent perineural invasion and with earlier 
recurrence. In vivo experiments with transplanted pancreatic cancer showed that CX3CR1-
transfected tumour cells infiltrated peripheral nerves. Thus, CX3CR1 may be involved in 
pancreatic cancer neurotropism and is a risk factor for local relapse in operated patients.  
 
Celesti study: Tumour differentiation, rather than inflammatory signalling, modulates 
CX3CR1 expression in pancreatic cancer. CX3CR1 was upregulated in tumour spheroids, and 
in vivo only in well-differentiated tumours, suggesting its early involvement in pancreatic 
cancer progression. 
Prostate cancer 
Shulby 2004 Cancer 
Res 
 
 
Jamieson 2008 Cancer 
Res 
 
 
 
Xiao 2012 Int J Oncol 
 
 
Tang 2015 Mol Med 
Rep 
 
 
 
Tang 2016 Oncol Rep 
Shulby study: CX3CR1 is expressed by human prostate cancer cells, whereas bone marrow 
endothelial cells and differentiated osteoblasts express CX3CL1. Adhesion of prostate 
cancer cells to bone marrow endothelial cells is reduced by a neutralising CX3CL1 antibody. 
CX3CL1 activates PI3K/Akt pathway in prostate cancer cells. 
 
Jamieson study: CX3CR1 is minimally detectable in normal prostate cells, but it is 
overexpressed upon malignant transformation. Androgens increased CX3CL1 cleavage from 
the cell membrane and its action was reversed by nilutamide (androgen receptor 
antagonist) as well as by a matrix metalloproteinase inhibitor.  
 
Xiao study: HIF-1 and NF-kB are essential for hypoxia-regulated CX3CR1 expression, which 
was associated with increased migratory and invasive potential of prostate cancer cells. 
 
Tang (2015) study: Hypoxia upregulates CX3CL1, which enhanced the prostate cancer cells 
proliferation. Inhibition of fractalkine activity inhibited hypoxia-induced cell proliferation. 
Under normoxemia, cell proliferation increased with exogenous recombinant CX3CL1, and 
this elevation was alleviated by an anti- CX3CL1 treatment. 
 
Tang (2016) study: CX3CL1 increased migration and invasiveness of prostate cancer cells 
DU145 and PC-3 cells, and lead to EMT, via Slug overexpression.  
Pro-tumoural role of CX3CL1-CX3CR1 system in different cancers 
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Anti-tumoural role of CX3CL1-CX3CR1 in different cancer types 
Cancer type 
(and study) 
Main study findings 
Breast cancer 
Park 2005 I Surg Oncol 
Park study: CD8+T cells, intra-tumoural dendritic cells and NK cells were increased in breast 
cancer cases with high CX3CL1 expression. Patients with high CX3CL1 expression had a 
more favorable disease-free progression and survival. 
Colorectal cancer 
Ohta 2005 Int J Oncol 
 
 
 
Vitale 2007 Gut 
 
 
 
 
Erreni 2016 J Immunol 
 
 
 
 
Marelli 2017 Cancer 
Res 
Ohta study: CX3CL1 expression was correlated with tumour-infiltrating lymphocytes 
density. Colorectal cancer cases with stronger CX3CL1 expression had better prognosis than 
those with weak expression, which is likely due to the tumour cell cytotoxicity mediated by 
CX3CR1-positive NK cells and cytotoxic T cells.  
 
Vitale study: Anti-tumoural effects of fractalkine were investigated in its different 
molecular forms. Native CX3CL1 exhibits the strongest anti-tumoural effect. CX3CL1 
expression by tumour cells reduced their metastatic potential, and both molecular forms 
contributed to its anti-tumoural potential. 
 
Erreni study: Tumoural expression of CX3CL1-CX3CR1 acts as a retention factor, increasing 
homotypic cell adhesion and limiting tumour spreading to metastatic sites. Lack or low 
levels of CX3CL1-CX3CR1 by tumour cells identifies patients at increased risk for metastasis. 
Co-expression of CX3CL1-CX3CR1 is associated with longer disease-specific survival. 
 
Marelli study: CX3CR1 in gut macrophages is essential in resolving inflammation, where it 
helps to protect against colitis-associated cancer by regulating hemoxygenase-1 expression 
(anti-oxidant and anti-inflammatory enzyme). 
Gastric cancer 
Hyakudomi 2008 Ann 
Surg Oncol 
Hyakudomi study: CX3CL1 expression by tumour cells enhanced the recruitment of CD8+ T 
and NK cells and induced both innate and adaptive immunity, thereby leading to a more 
favourable disease-free survival in gastric cancer.  
Glioma 
Sciume 2010 Neuro 
Oncol 
 
Sciume study: Both CX3CL1 and CX3CR1 are expressed by human glioma cells. 
Endogenously expressed CX3CL1 negatively regulated cell invasion likely by promoting 
tumour cell aggregation, and TGF-β1 inhibition of CX3CL1 contributed to glioma cell 
invasiveness. 
Hepatocellular 
carcinoma 
Matsubara 2007 J Surg 
Oncol 
Matsubara study: Tumours with high expression of CX3CL1 and CX3CR1 have fewer intra- 
and extra-hepatic recurrences, different histological grades and a better prognosis in terms 
of disease-free and overall survival. 
 
Neuroblastoma 
Zeng 2005 Cancer Lett 
 
Zeng 2007 Cancer Res 
 
Zeng (2005) study: CX3CL1 expression lead to a reduction in primary tumour growth and in 
spontaneous liver metastasis in a syngenic A/J mice.  
 
Zeng (2007) study: Immune mechanisms by which treatment targeted IL-2 of 
neuroblastoma with a CX3CL1-rich tumour microenvironment induced effective anti-
tumoural response. Only CX3CL1- and IL-2-enriched neuroblastoma tumour 
microenvironment resulted in T-cell activation and release of pro-inflammatory cytokines. 
Pancreatic cancer 
Celesti 2013 Br J 
Cancer 
Celesti study: Although CX3CR1 contributed to perineural invasion in pancreas cancer, 
CX3CR1 expression is a feature of more differentiated (G1-G2) tumour cells, and was 
associated with better overall survival in radically resected patients. 
Anti-tumoural role of CX3CL1-CX3CR1 system in different cancers 
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Appendix 11: Abstracts presented in scientific meetings 
 
Abstracts presented in scientific meetings containing the data presented in this thesis: 
 
Marques P, et al. “Adenomas hipofisários associados a mutações dos genes AIP e MEN1: 
diferenças fenotípicas significativas em doentes com formas distintas de adenomas hipofisários 
familiares” [Pituitary adenomas associated with AIP and MEN1 gene mutations: significant 
phenotypic differences in patients with distinct forms of familial pituitary adenomas]. Portuguese 
Congress of Endocrinology, 71st Annual Meeting of Portuguese Society of Endocrinology, Coimbra, 
Portugal, 23-26 January 2020 – Oral presentation. 
 
Marques P, et al. “O papel do microambiente tumoral na angiogénese em adenomas hipofisários” 
[The role of the tumour microenvironment in the angiogenesis of pituitary adenomas]. Portuguese 
Congress of Endocrinology, 71st Annual Meeting of Portuguese Society of Endocrinology, Coimbra, 
Portugal, 23-26 January 2020 – Poster presentation. 
 
Marques P, et al. Pituitary tumour-derived chemokines modulate immune cell infiltrates in the 
tumour microenvironment leading to aggressive phenotype. European Congress of Endocrinology, 
Lyon, France, 18-21 May 2019 – Oral presentation. 
 
Marques P, et al. Cytokine network in pituitary adenomas and its role in the tumor 
microenvironment: focus on macrophages. ENDO2019: The Endocrine Society´s 101st Annual 
Meeting, New Orleans, USA, 23-26 March 2019 – Poster presentation. 
 
Marques P, et al. Pasireotide treatment inhibits cytokine release from pituitary adenoma-
associated fibroblasts – is this mechanism playing a key role in its effect? ENDO2019: The 
Endocrine Society´s 101st Annual Meeting, New Orleans, USA, 23-26 March 2019 – Poster 
presentation 
 
Marques P, et al. AIP mutation-positive patients with somatotropinomas end-up taller and 
requiring more often radiotherapy compared to AIP mutation-negative patients: Data from 784 
familial and young-onset cases. ENDO2019: The Endocrine Society´s 101st Annual Meeting, New 
Orleans, USA, 23-26 March 2019 – Poster presentation. 
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Marques P, et al. Pasireotide treatment inhibits cytokine release from pituitary adenoma-
associated fibroblasts – is this mechanism playing a key role in its effect? Research-in-Progress 
Seminar Series, William Harvey Research Institute, London, UK, 8 March 2019 – Oral presentation. 
 
Marques P, et al. “Papel das citocinas no comportamento biológico e na determinação do 
microambiente tumoral em adenomas hipofisários, com particular foco nos macrófagos” [Role of 
cytokines in the biological behaviour and determination of tumour microenvironment in pituitary 
adenomas, with particular focus on macrophages]. Portuguese Congress of Endocrinology, 70th 
Annual Meeting of Portuguese Society of Endocrinology, Braga, Portugal, 24-27 January 2019 – 
Oral presentation. 
 
Marques P, et al. “Fibroblastos associados a tumores hipofisários: papel no comportamento 
tumoral e promissor alvo de terapêutica farmacológica dirigida com pasireótido?” [Pituitary 
tumour-associated fibroblasts: role in the tumoural behaviour and promising target for 
pharmacological treatment with pasireotide?]. Portuguese Congress of Endocrinology, 70th Annual 
Meeting of Portuguese Society of Endocrinology, Braga, Portugal, 24-27 January 2019 – Oral 
presentation. 
 
Marques P, et al. “Doentes com somatotropinomas associados a mutação do gene AIP apresentam 
estatura final mais elevada e requerem mais frequentemente radioterapia” [Patients with 
somatotropinomas associated with AIP mutations have higher final stature and require more often 
radiotherapy]. Portuguese Congress of Endocrinology, 70th Annual Meeting of Portuguese Society 
of Endocrinology, Braga, Portugal, 24-27 January 2019 – Oral presentation. 
 
Marques P, et al. Significant phenotypic difference between clinically presenting vs prospectively 
diagnosed pituitary adenoma in AIP mutation-positive kindreds. ENDO2018: The Endocrine 
Society´s 100th Annual Meeting, Chicago, USA, 17-20 March 2018 – Poster presentation. 
 
Marques P, et al. “Adenomas hipofisários associados a mutação do gene AIP: fenótipo clínico e 
benefícios do estudo genético” [Pituitary adenomas associated with mutations in the AIP gene: 
clinical phenotype and benefits of genetic study]. Portuguese Congress of Endocrinology, 69th 
Annual Meeting of Portuguese Society of Endocrinology, Vilamoura, Portuga), 1-4 February 2018 
– Oral presentation. 
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Abstracts presented in scientific meetings in other fields during the period of PhD studies: 
Marques P, et al. “Paquidermoperiostose: um diagnóstico diferencial de acromegalia – a propósito 
de 4 casos clínicos” [Pachydermoperiostosis: a differential diagnosis of acromegalia – 4 clinical 
cases]. Portuguese Congress of Endocrinology, 71st Annual Meeting of Portuguese Society of 
Endocrinology, Coimbra, Portugal, 23-26 January 2020 – Poster presentation. 
Marques P, et al. “Síndrome de Marfan como confundidor diagnóstico de gigantismo hipofisário 
em família com adenomas hipofisários familiares associados a mutação do gene AIP” [Marfan 
syndrome as diagnostic confounder of pituitary gigantism in a family with pituitary adenomas 
associated with an AIP gene mutation]. Portuguese Congress of Endocrinology, 70th Annual 
Meeting of Portuguese Society of Endocrinology, Braga, Portugal, 24-27 January 2019 – Oral 
presentation. 
Marques P, et al. “Pseudoacromegalia e síndrome de Cantú: nova mutação no gene ABCC9 em 
família com adenomas hipofisários familiares” [Pseudoacromegaly and Cantú syndrome: new 
mutation in the ABCC9 gene in a family with familial pituitary adenomas]. Portuguese Congress of 
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